[	0	1	O
Histopathologic	1	16	O
examination	17	28	O
of	29	31	O
rectal	32	38	B-Pathological_formation
carcinoma	39	48	I-Pathological_formation
]	48	49	O
.	49	50	O

In	51	53	O
patients	54	62	O
with	63	67	O
rectal	68	74	B-Pathological_formation
carcinoma	75	84	I-Pathological_formation
,	84	85	O
the	86	89	O
histopathological	90	107	O
evaluation	108	118	O
of	119	121	O
the	122	125	O
surgical	126	134	B-Pathological_formation
specimen	135	143	I-Pathological_formation
provides	144	152	O
pivotal	153	160	O
prognostic	161	171	O
and	172	175	O
therapeutic	176	187	O
information	188	199	O
.	199	200	O

Important	201	210	O
parameters	211	221	O
are	222	225	O
tumor	226	231	B-Pathological_formation
site	232	236	O
,	236	237	O
depth	238	243	O
of	244	246	O
invasion	247	255	O
,	255	256	O
histological	257	269	O
type	270	274	O
and	275	278	O
grade	279	284	O
,	284	285	O
pattern	286	293	O
of	294	296	O
invasion	297	305	O
(	306	307	O
diffusely	307	316	O
infiltrating	317	329	O
versus	330	336	O
expanding	337	346	O
margin	347	353	O
)	353	354	O
,	354	355	O
degree	356	362	O
of	363	365	O
peritumoral	366	377	B-Cell
lymphocytic	378	389	I-Cell
infiltration	390	402	O
,	402	403	O
and	404	407	O
tumor	408	413	B-Pathological_formation
involvement	414	425	O
of	426	428	O
surgical	429	437	B-Tissue
margins	438	445	I-Tissue
and	446	449	O
lymph	450	455	B-Multi-tissue_structure
nodes	456	461	I-Multi-tissue_structure
.	461	462	O

Evaluation	463	473	O
of	474	476	O
the	477	480	O
circumferential	481	496	B-Tissue
(	497	498	I-Tissue
deep	498	502	I-Tissue
,	502	503	I-Tissue
lateral	504	511	I-Tissue
)	511	512	I-Tissue
margin	513	519	I-Tissue
is	520	522	O
of	523	525	O
utmost	526	532	O
importance	533	543	O
.	543	544	O

It	545	547	O
should	548	554	O
be	555	557	O
labeled	558	565	O
with	566	570	O
ink	571	574	O
in	575	577	O
the	578	581	O
gross	582	587	O
specimen	588	596	B-Pathological_formation
and	597	600	O
should	601	607	O
be	608	610	O
examined	611	619	O
histologically	620	634	O
using	635	640	O
several	641	648	O
tissue	649	655	B-Tissue
blocks	656	662	O
.	662	663	O

The	664	667	O
number	668	674	O
of	675	677	O
lymph	678	683	B-Pathological_formation
node	684	688	I-Pathological_formation
metastases	689	699	I-Pathological_formation
and	700	703	O
the	704	707	O
total	708	713	O
number	714	720	O
of	721	723	O
lymph	724	729	B-Multi-tissue_structure
nodes	730	735	I-Multi-tissue_structure
examined	736	744	O
should	745	751	O
be	752	754	O
reported	755	763	O
.	763	764	O

A	765	766	O
histological	767	779	O
evaluation	780	790	O
of	791	793	O
the	794	797	O
distal	798	804	B-Multi-tissue_structure
mesorectum	805	815	I-Multi-tissue_structure
in	816	818	O
its	819	822	O
entirety	823	831	O
is	832	834	O
recommended	835	846	O
to	847	849	O
detect	850	856	O
discontinuous	857	870	O
distal	871	877	B-Pathological_formation
mesorectal	878	888	I-Pathological_formation
tumor	889	894	I-Pathological_formation
spread	895	901	O
.	901	902	O

The	903	906	O
histopathological	907	924	O
findings	925	933	O
should	934	940	O
be	941	943	O
summarized	944	954	O
using	955	960	O
the	961	964	O
TNM	965	968	O
-	968	969	O
classification	969	983	O
.	983	984	O

Antisense	0	9	O
technologies	10	22	O
have	23	27	O
a	28	29	O
future	30	36	O
fighting	37	45	O
neurodegenerative	46	63	O
diseases	64	72	O
.	72	73	O

Our	74	77	O
growing	78	85	O
understanding	86	99	O
of	100	102	O
the	103	106	O
role	107	111	O
that	112	116	O
unfavorable	117	128	O
patterns	129	137	O
of	138	140	O
gene	141	145	O
expression	146	156	O
play	157	161	O
in	162	164	O
the	165	168	O
etiology	169	177	O
of	178	180	O
neurodegenerative	181	198	O
disease	199	206	O
emphasizes	207	217	O
the	218	221	O
need	222	226	O
for	227	230	O
strategies	231	241	O
to	242	244	O
selectively	245	256	O
block	257	262	O
the	263	266	O
biosynthesis	267	279	O
of	280	282	O
harmful	283	290	O
proteins	291	299	O
in	300	302	O
the	303	306	O
brain	307	312	B-Organ
.	312	313	O

Antisense	314	323	O
technologies	324	336	O
are	337	340	O
ideally	341	348	O
suited	349	355	O
to	356	358	O
this	359	363	O
purpose	364	371	O
.	371	372	O

Tailor	373	379	O
-	379	380	O
designed	380	388	O
to	389	391	O
target	392	398	O
specific	399	407	O
RNA	408	411	O
,	411	412	O
antisense	413	422	O
oligonucleotides	423	439	O
and	440	443	O
ribozymes	444	453	O
offer	454	459	O
tools	460	465	O
to	466	468	O
suppress	469	477	O
the	478	481	O
production	482	492	O
of	493	495	O
proteins	496	504	O
mediating	505	514	O
neurodegeneration	515	532	O
.	532	533	O

Although	534	542	O
technical	543	552	O
limitations	553	564	O
must	565	569	O
still	570	575	O
be	576	578	O
overcome	579	587	O
,	587	588	O
the	589	592	O
antisense	593	602	O
approach	603	611	O
represents	612	622	O
a	623	624	O
novel	625	630	O
and	631	634	O
exciting	635	643	O
strategy	644	652	O
for	653	656	O
intervention	657	669	O
in	670	672	O
diseases	673	681	O
of	682	684	O
the	685	688	O
central	689	696	B-Anatomical_system
nervous	697	704	I-Anatomical_system
system	705	711	I-Anatomical_system
.	711	712	O

Spacing	0	7	O
effects	8	15	O
on	16	18	O
the	19	22	O
memory	23	29	O
for	30	33	O
faces	34	39	B-Organism_subdivision
.	39	40	O

25	41	43	O
undergraduate	44	57	O
women	58	63	O
studied	64	71	O
12	72	74	O
stimulus	75	83	O
pictures	84	92	O
of	93	95	O
female	96	102	O
faces	103	108	B-Organism_subdivision
successively	109	121	O
presented	122	131	O
in	132	134	O
spaced	135	141	O
or	142	144	O
massed	145	151	O
conditions	152	162	O
and	163	166	O
made	167	171	O
affective	172	181	O
judgments	182	191	O
for	192	195	O
the	196	199	O
pictures	200	208	O
along	209	214	O
a	215	216	O
dimension	217	226	O
of	227	229	O
like	230	234	O
to	235	237	O
dislike	238	245	O
.	245	246	O

One	247	250	O
week	251	255	O
after	256	261	O
the	262	265	O
exposure	266	274	O
(	275	276	O
study	276	281	O
)	281	282	O
period	283	289	O
,	289	290	O
subjects	291	299	O
were	300	304	O
given	305	310	O
an	311	313	O
identification	314	328	O
test	329	333	O
comprised	334	343	O
of	344	346	O
photographs	347	358	O
of	359	361	O
the	362	365	O
same	366	370	O
female	371	377	O
faces	378	383	B-Organism_subdivision
with	384	388	O
different	389	398	O
expressions	399	410	O
.	410	411	O

Analysis	412	420	O
showed	421	427	O
that	428	432	O
the	433	436	O
pictures	437	445	O
presented	446	455	O
in	456	458	O
the	459	462	O
spaced	463	469	O
condition	470	479	O
were	480	484	O
more	485	489	O
frequently	490	500	O
and	501	504	O
accurately	505	515	O
identified	516	526	O
than	527	531	O
those	532	537	O
presented	538	547	O
under	548	553	O
the	554	557	O
massed	558	564	O
condition	565	574	O
and	575	578	O
that	579	583	O
affective	584	593	O
judgment	594	602	O
was	603	606	O
unrelated	607	616	O
to	617	619	O
conditions	620	630	O
of	631	633	O
presentation	634	646	O
.	646	647	O

Abdominal	0	9	B-Organism_subdivision
approach	10	18	O
for	19	22	O
the	23	26	O
ligation	27	35	O
of	36	38	O
bleeding	39	47	O
oesophageal	48	59	B-Multi-tissue_structure
varices	60	67	I-Multi-tissue_structure
.	67	68	O

The	69	72	O
conventional	73	85	O
surgical	86	94	O
treatment	95	104	O
of	105	107	O
bleeding	108	116	O
oesophageal	117	128	B-Multi-tissue_structure
varices	129	136	I-Multi-tissue_structure
in	137	139	O
the	140	143	O
emergency	144	153	O
situation	154	163	O
is	164	166	O
based	167	172	O
upon	173	177	O
the	178	181	O
Boerema	182	189	O
-	189	190	O
Crile	190	195	O
operation	196	205	O
of	206	208	O
transthoracic	209	222	B-Organism_subdivision
oesophagotomy	223	236	O
and	237	240	O
ligation	241	249	O
of	250	252	O
the	253	256	O
varices	257	264	B-Multi-tissue_structure
.	264	265	O

This	266	270	O
and	271	274	O
the	275	278	O
other	279	284	O
methods	285	292	O
of	293	295	O
treatment	296	305	O
of	306	308	O
this	309	313	O
condition	314	323	O
in	324	326	O
current	327	334	O
practice	335	343	O
are	344	347	O
discussed	348	357	O
.	357	358	O

Two	359	362	O
cases	363	368	O
are	369	372	O
reported	373	381	O
in	382	384	O
which	385	390	O
a	391	392	O
transabdominal	393	407	B-Organism_subdivision
oesophagogastrotomy	408	427	O
was	428	431	O
used	432	436	O
to	437	439	O
approach	440	448	O
the	449	452	O
site	453	457	O
of	458	460	O
bleeding	461	469	O
.	469	470	O

This	471	475	O
operation	476	485	O
is	486	488	O
described	489	498	O
and	499	502	O
the	503	506	O
theoretical	507	518	O
and	519	522	O
practical	523	532	O
advantages	533	543	O
it	544	546	O
appears	547	554	O
to	555	557	O
offer	558	563	O
over	564	568	O
the	569	572	O
standard	573	581	O
approach	582	590	O
are	591	594	O
considered	595	605	O
.	605	606	O

Stimulation	0	11	O
of	12	14	O
the	15	18	O
sodium	19	25	O
pump	26	30	O
by	31	33	O
azide	34	39	O
and	40	43	O
high	44	48	O
internal	49	57	O
sodium	58	64	O
:	64	65	O
changes	66	73	O
in	74	76	O
the	77	80	O
number	81	87	O
of	88	90	O
pumping	91	98	O
sites	99	104	O
and	105	108	O
turnover	109	117	O
rate	118	122	O
.	122	123	O

1	124	125	O
.	125	126	O

The	127	130	O
effects	131	138	O
of	139	141	O
5	142	143	O
mM	144	146	O
azide	147	152	O
on	153	155	O
[	156	157	O
3H	157	159	O
]	159	160	O
ouabain	160	167	O
uptake	168	174	O
and	175	178	O
22Na	179	183	O
efflux	184	190	O
were	191	195	O
determined	196	206	O
.	206	207	O

Both	208	212	O
glycoside	213	222	O
uptake	223	229	O
and	230	233	O
22Na	234	238	O
efflux	239	245	O
were	246	250	O
enhanced	251	259	O
by	260	262	O
azide	263	268	O
.	268	269	O

2	270	271	O
.	271	272	O

Azide	273	278	O
stimulated	279	289	O
the	290	293	O
Na	294	296	O
pump	297	301	O
in	302	304	O
muscles	305	312	B-Tissue
whose	313	318	O
pumping	319	326	O
sites	327	332	O
had	333	336	O
been	337	341	O
inhibited	342	351	O
by	352	354	O
ouabain	355	362	O
and	363	366	O
then	367	371	O
transferred	372	383	O
to	384	386	O
a	387	388	O
glycoside	389	398	O
-	398	399	O
free	399	403	O
solution	404	412	O
.	412	413	O

This	414	418	O
stimulation	419	430	O
was	431	434	O
observed	435	443	O
before	444	450	O
detecting	451	460	O
any	461	464	O
recovery	465	473	O
of	474	476	O
the	477	480	O
initial	481	488	O
pumping	489	496	O
activity	497	505	O
.	505	506	O

3	507	508	O
.	508	509	O

When	510	514	O
both	515	519	O
the	520	523	O
resting	524	531	O
and	532	535	O
the	536	539	O
azide	540	545	O
-	545	546	O
stimulated	546	556	O
22Na	557	561	O
efflux	562	568	O
had	569	572	O
been	573	577	O
blocked	578	585	O
by	586	588	O
ouabain	589	596	O
,	596	597	O
an	598	600	O
additional	601	611	O
exposure	612	620	O
to	621	623	O
azide	624	629	O
,	629	630	O
in	631	633	O
a	634	635	O
ouabain	636	643	O
-	643	644	O
free	644	648	O
solution	649	657	O
,	657	658	O
had	659	662	O
no	663	665	O
further	666	673	O
effects	674	681	O
on	682	684	O
22Na	685	689	O
efflux	690	696	O
.	696	697	O

4	698	699	O
.	699	700	O

It	701	703	O
is	704	706	O
concluded	707	716	O
that	717	721	O
the	722	725	O
increase	726	734	O
in	735	737	O
Na	738	740	O
pumping	741	748	O
caused	749	755	O
by	756	758	O
azide	759	764	O
is	765	767	O
due	768	771	O
in	772	774	O
part	775	779	O
to	780	782	O
an	783	785	O
increase	786	794	O
in	795	797	O
the	798	801	O
number	802	808	O
of	809	811	O
pumping	812	819	O
sites	820	825	O
.	825	826	O

5	827	828	O
.	828	829	O

[	830	831	O
3H	831	833	O
]	833	834	O
ouabain	834	841	O
binding	842	849	O
was	850	853	O
measured	854	862	O
in	863	865	O
muscles	866	873	B-Tissue
with	874	878	O
different	879	888	O
intracellular	889	902	B-Immaterial_anatomical_entity
alkali	903	909	O
cation	910	916	O
concentrations	917	931	O
.	931	932	O

Variations	933	943	O
in	944	946	O
[	947	948	O
Na	948	950	O
]	950	951	O
i	951	952	O
from	953	957	O
15	958	960	O
up	961	963	O
to	964	966	O
50	967	969	O
mM	970	972	O
did	973	976	O
not	977	980	O
significantly	981	994	O
affect	995	1001	O
the	1002	1005	O
amount	1006	1012	O
of	1013	1015	O
glycoside	1016	1025	O
bound	1026	1031	O
.	1031	1032	O

A	1033	1034	O
substantial	1035	1046	O
increase	1047	1055	O
in	1056	1058	O
binding	1059	1066	O
occurred	1067	1075	O
when	1076	1080	O
[	1081	1082	O
Na	1082	1084	O
]	1084	1085	O
i	1085	1086	O
reached	1087	1094	O
70	1095	1097	O
mM	1098	1100	O
.	1100	1101	O

6	1102	1103	O
.	1103	1104	O

It	1105	1107	O
is	1108	1110	O
proposed	1111	1119	O
that	1120	1124	O
the	1125	1128	O
increase	1129	1137	O
in	1138	1140	O
Na	1141	1143	O
extrusion	1144	1153	O
that	1154	1158	O
occurs	1159	1165	O
during	1166	1172	O
the	1173	1176	O
recovery	1177	1185	O
of	1186	1188	O
Na	1189	1191	O
loaded	1192	1198	O
muscles	1199	1206	B-Tissue
mostly	1207	1213	O
results	1214	1221	O
from	1222	1226	O
an	1227	1229	O
increased	1230	1239	O
turnover	1240	1248	O
rate	1249	1253	O
of	1254	1256	O
the	1257	1260	O
pump	1261	1265	O
rather	1266	1272	O
than	1273	1277	O
from	1278	1282	O
an	1283	1285	O
increase	1286	1294	O
in	1295	1297	O
number	1298	1304	O
of	1305	1307	O
pumping	1308	1315	O
sites	1316	1321	O
.	1321	1322	O

Focal	0	5	O
congenital	6	16	O
alveolar	17	25	B-Multi-tissue_structure
proteinosis	26	37	O
associated	38	48	O
with	49	53	O
abnormal	54	62	O
surfactant	63	73	O
protein	74	81	O
B	82	83	O
messenger	84	93	O
RNA	94	97	O
.	97	98	O

Two	99	102	O
siblings	103	111	O
presented	112	121	O
with	122	126	O
typical	127	134	O
clinical	135	143	O
features	144	152	O
of	153	155	O
congenital	156	166	O
pulmonary	167	176	B-Multi-tissue_structure
alveolar	177	185	I-Multi-tissue_structure
proteinosis	186	197	O
(	198	199	O
PAP	199	202	O
)	202	203	O
.	203	204	O

Necropsy	205	213	O
of	214	216	O
one	217	220	O
sibling	221	228	O
revealed	229	237	O
scattered	238	247	O
foci	248	252	B-Pathological_formation
of	253	255	O
the	256	259	O
diagnostic	260	270	O
histologic	271	281	O
changes	282	289	O
in	290	292	O
the	293	296	O
lung	297	301	B-Tissue
tissue	302	308	I-Tissue
.	308	309	O

In	310	312	O
contrast	313	321	O
to	322	324	O
infantile	325	334	O
and	335	338	O
adult	339	344	O
PAP	345	348	O
,	348	349	O
focal	350	355	B-Pathological_formation
distribution	356	368	O
is	369	371	O
uncommon	372	380	O
in	381	383	O
congenital	384	394	O
PAP	395	398	O
.	398	399	O

Defective	400	409	O
expression	410	420	O
of	421	423	O
the	424	427	O
granulocyte	428	439	O
-	439	440	O
macrophage	440	450	O
colony	451	457	O
-	457	458	O
stimulating	458	469	O
factor	470	476	O
receptor	477	485	O
was	486	489	O
ruled	490	495	O
out	496	499	O
.	499	500	O

The	501	504	O
surfactant	505	515	O
protein	516	523	O
B	524	525	O
(	526	527	O
SP	527	529	O
-	529	530	O
B	530	531	O
)	531	532	O
content	533	540	O
in	541	543	O
the	544	547	O
lung	548	552	B-Tissue
tissue	553	559	I-Tissue
of	560	562	O
the	563	566	O
autopsied	567	576	O
patient	577	584	O
was	585	588	O
low	589	592	O
,	592	593	O
and	594	597	O
a	598	599	O
deletion	600	608	O
in	609	611	O
the	612	615	O
SP	616	618	O
-	618	619	O
B	619	620	O
messenger	621	630	O
RNA	631	634	O
was	635	638	O
detected	639	647	O
.	647	648	O

We	649	651	O
speculate	652	661	O
that	662	666	O
the	667	670	O
PAP	671	674	O
in	675	677	O
our	678	681	O
patients	682	690	O
was	691	694	O
related	695	702	O
to	703	705	O
the	706	709	O
reduced	710	717	O
quantity	718	726	O
and	727	730	O
/	730	731	O
or	731	733	O
to	734	736	O
the	737	740	O
altered	741	748	O
quality	749	756	O
of	757	759	O
SP	760	762	O
-	762	763	O
B	763	764	O
.	764	765	O

Tonometry	0	9	O
in	10	12	O
normal	13	19	O
and	20	23	O
scarred	24	31	O
corneas	32	39	B-Multi-tissue_structure
,	39	40	O
and	41	44	O
in	45	47	O
postkeratoplasty	48	64	O
eyes	65	69	B-Organ
:	69	70	O
a	71	72	O
comparative	73	84	O
study	85	90	O
of	91	93	O
the	94	97	O
Goldmann	98	106	O
,	106	107	O
the	108	111	O
ProTon	112	118	O
and	119	122	O
the	123	126	O
Schiotz	127	134	O
tonometers	135	145	O
.	145	146	O

PURPOSE	147	154	O
:	154	155	O

Clinical	156	164	O
comparison	165	175	O
of	176	178	O
intraocular	179	190	B-Immaterial_anatomical_entity
pressure	191	199	O
(	200	201	O
IOP	201	204	O
)	204	205	O
measured	206	214	O
with	215	219	O
the	220	223	O
Goldmann	224	232	O
applanation	233	244	O
tonometer	245	254	O
(	255	256	O
GAT	256	259	O
)	259	260	O
,	260	261	O
the	262	265	O
ProTon	266	272	O
tonometer	273	282	O
(	283	284	O
PT	284	286	O
)	286	287	O
,	287	288	O
and	289	292	O
the	293	296	O
Schiotz	297	304	O
tonometer	305	314	O
(	315	316	O
ST	316	318	O
)	318	319	O
,	319	320	O
in	321	323	O
normal	324	330	O
eyes	331	335	B-Organ
,	335	336	O
eyes	337	341	B-Organ
with	342	346	O
scarred	347	354	O
corneas	355	362	B-Multi-tissue_structure
and	363	366	O
postkeratoplasty	367	383	O
eyes	384	388	B-Organ
.	388	389	O

MATERIAL	390	398	O
AND	399	402	O
METHODS	403	410	O
:	410	411	O

The	412	415	O
IOP	416	419	O
readings	420	428	O
with	429	433	O
GAT	434	437	O
,	437	438	O
PT	439	441	O
,	441	442	O
and	443	446	O
ST	447	449	O
were	450	454	O
compared	455	463	O
in	464	466	O
125	467	470	O
eyes	471	475	B-Organ
with	476	480	O
normal	481	487	O
corneas	488	495	B-Multi-tissue_structure
(	496	497	O
Group	497	502	O
A	503	504	O
)	504	505	O
,	505	506	O
17	507	509	O
eyes	510	514	B-Organ
with	515	519	O
scarred	520	527	O
corneas	528	535	B-Multi-tissue_structure
(	536	537	O
Group	537	542	O
B	543	544	O
)	544	545	O
,	545	546	O
and	547	550	O
in	551	553	O
21	554	556	O
postkeratoplasty	557	573	O
eyes	574	578	B-Organ
(	579	580	O
Group	580	585	O
C	586	587	O
)	587	588	O
.	588	589	O

The	590	593	O
data	594	598	O
were	599	603	O
statistically	604	617	O
analysed	618	626	O
at	627	629	O
95	630	632	O
%	632	633	O
confidence	634	644	O
interval	645	653	O
;	653	654	O
linear	655	661	O
regression	662	672	O
analysis	673	681	O
and	682	685	O
paired	686	692	O
t	693	694	O
-	694	695	O
test	695	699	O
were	700	704	O
done	705	709	O
.	709	710	O

RESULTS	711	718	O
:	718	719	O

The	720	723	O
mean	724	728	O
differences	729	740	O
and	741	744	O
their	745	750	O
standard	751	759	O
deviation	760	769	O
[	770	771	O
SD	771	773	O
]	773	774	O
between	775	782	O
GAT	783	786	O
and	787	790	O
PT	791	793	O
readings	794	802	O
,	802	803	O
and	804	807	O
GAT	808	811	O
and	812	815	O
ST	816	818	O
readings	819	827	O
respectively	828	840	O
were	841	845	O
:	845	846	O
[	847	848	O
1	848	849	O
]	849	850	O
in	851	853	O
Group	854	859	O
A	860	861	O
:	861	862	O
-	863	864	O
0	864	865	O
.	865	866	O
23	866	868	O
[	869	870	O
SD	870	872	O
2	873	874	O
.	874	875	O
75	875	877	O
]	877	878	O
mmHg	879	883	O
and	884	887	O
+	888	889	O
0	889	890	O
.	890	891	O
24	891	893	O
[	894	895	O
SD	895	897	O
3	898	899	O
.	899	900	O
18	900	902	O
]	902	903	O
mmHg	904	908	O
respectively	909	921	O
;	921	922	O
[	923	924	O
2	924	925	O
]	925	926	O
in	927	929	O
Group	930	935	O
B	936	937	O
:	937	938	O
-	939	940	O
1	940	941	O
.	941	942	O
8	942	943	O
[	944	945	O
SD	945	947	O
12	948	950	O
.	950	951	O
67	951	953	O
]	953	954	O
mmHg	955	959	O
and	960	963	O
-	964	965	O
4	965	966	O
.	966	967	O
5	967	968	O
[	969	970	O
SD	970	972	O
9	973	974	O
.	974	975	O
95	975	977	O
mmHg	978	982	O
;	982	983	O
and	984	987	O
[	988	989	O
3	989	990	O
]	990	991	O
in	992	994	O
Group	995	1000	O
C	1001	1002	O
:	1002	1003	O
+	1004	1005	O
0	1005	1006	O
.	1006	1007	O
24	1007	1009	O
[	1010	1011	O
SD	1011	1013	O
8	1014	1015	O
.	1015	1016	O
72	1016	1018	O
]	1018	1019	O
mmHg	1020	1024	O
and	1025	1028	O
-	1029	1030	O
0	1030	1031	O
.	1031	1032	O
12	1032	1034	O
[	1035	1036	O
SD	1036	1038	O
8	1039	1040	O
.	1040	1041	O
7	1041	1042	O
]	1042	1043	O
mmHg	1044	1048	O
.	1048	1049	O

They	1050	1054	O
were	1055	1059	O
not	1060	1063	O
statistically	1064	1077	O
significant	1078	1089	O
.	1089	1090	O

In	1091	1093	O
Group	1094	1099	O
A	1100	1101	O
the	1102	1105	O
95	1106	1108	O
%	1108	1109	O
confidence	1110	1120	O
interval	1121	1129	O
between	1130	1137	O
GAT	1138	1141	O
and	1142	1145	O
PT	1146	1148	O
readings	1149	1157	O
was	1158	1161	O
-	1162	1163	O
5	1163	1164	O
.	1164	1165	O
27	1165	1167	O
mmHg	1168	1172	O
to	1173	1175	O
5	1176	1177	O
.	1177	1178	O
73	1178	1180	O
mmHg	1181	1185	O
,	1185	1186	O
and	1187	1190	O
between	1191	1198	O
GAT	1199	1202	O
and	1203	1206	O
ST	1207	1209	O
readings	1210	1218	O
,	1218	1219	O
-	1220	1221	O
6	1221	1222	O
.	1222	1223	O
12	1223	1225	O
mmHg	1226	1230	O
to	1231	1233	O
6	1234	1235	O
.	1235	1236	O
59	1236	1238	O
mmHg	1239	1243	O
.	1243	1244	O

Ninety	1245	1251	O
six	1252	1255	O
[	1256	1257	O
77	1257	1259	O
%	1259	1260	O
]	1260	1261	O
eyes	1262	1266	B-Organ
with	1267	1271	O
the	1272	1275	O
PT	1276	1278	O
and	1279	1282	O
84	1283	1285	O
[	1286	1287	O
69	1287	1289	O
%	1289	1290	O
]	1290	1291	O
eyes	1292	1296	B-Organ
with	1297	1301	O
ST	1302	1304	O
measurements	1305	1317	O
were	1318	1322	O
within	1323	1329	O
3	1330	1331	O
mmHg	1332	1336	O
of	1337	1339	O
GAT	1340	1343	O
pressure	1344	1352	O
.	1352	1353	O

The	1354	1357	O
correlation	1358	1369	O
coefficients	1370	1382	O
[	1383	1384	O
r	1384	1385	O
]	1385	1386	O
for	1387	1390	O
PT	1391	1393	O
and	1394	1397	O
ST	1398	1400	O
were	1401	1405	O
0	1406	1407	O
.	1407	1408	O
93	1408	1410	O
[	1411	1412	O
P	1412	1413	O
=	1414	1415	O
0	1416	1417	O
.	1417	1418	O
0000	1418	1422	O
]	1422	1423	O
and	1424	1427	O
0	1428	1429	O
.	1429	1430	O
88	1430	1432	O
[	1433	1434	O
P	1434	1435	O
=	1436	1437	O
0	1438	1439	O
.	1439	1440	O
0000	1440	1444	O
]	1444	1445	O
respectively	1446	1458	O
.	1458	1459	O

In	1460	1462	O
Group	1463	1468	O
B	1469	1470	O
95	1471	1473	O
%	1473	1474	O
confidence	1475	1485	O
interval	1486	1494	O
between	1495	1502	O
GAT	1503	1506	O
and	1507	1510	O
PT	1511	1513	O
readings	1514	1522	O
was	1523	1526	O
-	1527	1528	O
27	1528	1530	O
.	1530	1531	O
17	1531	1533	O
mmHg	1534	1538	O
to	1539	1541	O
23	1542	1544	O
.	1544	1545	O
51	1545	1547	O
mmHg	1548	1552	O
,	1552	1553	O
and	1554	1557	O
between	1558	1565	O
GAT	1566	1569	O
and	1570	1573	O
ST	1574	1576	O
measurement	1577	1588	O
,	1588	1589	O
-	1590	1591	O
24	1591	1593	O
.	1593	1594	O
37	1594	1596	O
mmHg	1597	1601	O
to	1602	1604	O
15	1605	1607	O
.	1607	1608	O
44	1608	1610	O
mmHg	1611	1615	O
.	1615	1616	O

The	1617	1620	O
correlation	1621	1632	O
coefficients	1633	1645	O
[	1646	1647	O
r	1647	1648	O
]	1648	1649	O
for	1650	1653	O
the	1654	1657	O
PT	1658	1660	O
and	1661	1664	O
ST	1665	1667	O
were	1668	1672	O
0	1673	1674	O
.	1674	1675	O
112	1675	1678	O
[	1679	1680	O
P	1680	1681	O
=	1682	1683	O
0	1684	1685	O
.	1685	1686	O
660	1686	1689	O
]	1689	1690	O
and	1691	1694	O
0	1695	1696	O
.	1696	1697	O
630	1697	1700	O
[	1701	1702	O
P	1702	1703	O
=	1704	1705	O
0	1706	1707	O
.	1707	1708	O
006	1708	1711	O
]	1711	1712	O
respectively	1713	1725	O
.	1725	1726	O

In	1727	1729	O
group	1730	1735	O
C	1736	1737	O
,	1737	1738	O
the	1739	1742	O
95	1743	1745	O
%	1745	1746	O
confidence	1747	1757	O
interval	1758	1766	O
between	1767	1774	O
GAT	1775	1778	O
and	1779	1782	O
PT	1783	1785	O
measurements	1786	1798	O
was	1799	1802	O
-	1803	1804	O
17	1804	1806	O
.	1806	1807	O
20	1807	1809	O
mmHg	1810	1814	O
to	1815	1817	O
17	1818	1820	O
.	1820	1821	O
67	1821	1823	O
mmHg	1824	1828	O
,	1828	1829	O
and	1830	1833	O
between	1834	1841	O
GAT	1842	1845	O
and	1846	1849	O
ST	1850	1852	O
measurements	1853	1865	O
,	1865	1866	O
-	1867	1868	O
17	1868	1870	O
.	1870	1871	O
51	1871	1873	O
mmHg	1874	1878	O
to	1879	1881	O
17	1882	1884	O
.	1884	1885	O
27	1885	1887	O
mmHg	1888	1892	O
.	1892	1893	O

The	1894	1897	O
correlation	1898	1909	O
coefficients	1910	1922	O
[	1923	1924	O
r	1924	1925	O
]	1925	1926	O
for	1927	1930	O
the	1931	1934	O
PT	1935	1937	O
and	1938	1941	O
the	1942	1945	O
ST	1946	1948	O
were	1949	1953	O
0	1954	1955	O
.	1955	1956	O
780	1956	1959	O
[	1960	1961	O
P	1961	1962	O
=	1963	1964	O
0	1965	1966	O
.	1966	1967	O
0000	1967	1971	O
]	1971	1972	O
and	1973	1976	O
0	1977	1978	O
.	1978	1979	O
740	1979	1982	O
[	1983	1984	O
P	1984	1985	O
=	1986	1987	O
0	1988	1989	O
.	1989	1990	O
0001	1990	1994	O
]	1994	1995	O
respectively	1996	2008	O
.	2008	2009	O

CONCLUSIONS	2010	2021	O
:	2021	2022	O

In	2023	2025	O
clinical	2026	2034	O
practice	2035	2043	O
PT	2044	2046	O
appears	2047	2054	O
to	2055	2057	O
have	2058	2062	O
a	2063	2064	O
higher	2065	2071	O
level	2072	2077	O
of	2078	2080	O
accuracy	2081	2089	O
than	2090	2094	O
ST	2095	2097	O
in	2098	2100	O
normal	2101	2107	O
corneas	2108	2115	B-Multi-tissue_structure
.	2115	2116	O

In	2117	2119	O
scarred	2120	2127	O
corneas	2128	2135	B-Multi-tissue_structure
and	2136	2139	O
post	2140	2144	O
-	2144	2145	O
penetrating	2145	2156	O
keratoplasty	2157	2169	O
eyes	2170	2174	B-Organ
,	2174	2175	O
because	2176	2183	O
of	2184	2186	O
high	2187	2191	O
SD	2192	2194	O
for	2195	2198	O
mean	2199	2203	O
differences	2204	2215	O
and	2216	2219	O
wide	2220	2224	O
confidence	2225	2235	O
interval	2236	2244	O
of	2245	2247	O
95	2248	2250	O
%	2250	2251	O
,	2251	2252	O
both	2253	2257	O
PT	2258	2260	O
and	2261	2264	O
ST	2265	2267	O
are	2268	2271	O
inaccurate	2272	2282	O
in	2283	2285	O
measuring	2286	2295	O
IOP	2296	2299	O
as	2300	2302	O
compared	2303	2311	O
to	2312	2314	O
GAT	2315	2318	O
in	2319	2321	O
such	2322	2326	O
eyes	2327	2331	B-Organ
.	2331	2332	O

[	0	1	O
H	1	2	O
.	2	3	O
pylori	4	10	O
infection	11	20	O
.	20	21	O
Our	22	25	O
experience	26	36	O
with	37	41	O
the	42	45	O
quadruple	46	55	O
and	56	59	O
triple	60	66	O
therapy	67	74	O
as	75	77	O
first	78	83	O
pharmacologic	84	97	O
approach	98	106	O
]	106	107	O
.	107	108	O

For	109	112	O
now	113	116	O
the	117	120	O
most	121	125	O
used	126	130	O
pharmacological	131	146	O
treatment	147	156	O
of	157	159	O
first	160	165	O
instance	166	174	O
to	175	177	O
eradication	178	189	O
of	190	192	O
Hp	193	195	O
foresees	196	204	O
utilization	205	216	O
of	217	219	O
triple	220	226	O
therapy	227	234	O
(	235	236	O
PPI	236	239	O
+	240	241	O
two	242	245	O
antibiotics	246	257	O
)	257	258	O
.	258	259	O

In	260	262	O
our	263	266	O
study	267	272	O
we	273	275	O
have	276	280	O
compared	281	289	O
this	290	294	O
kind	295	299	O
of	300	302	O
treatment	303	312	O
with	313	317	O
the	318	321	O
quadruple	322	331	O
therapy	332	339	O
(	340	341	O
PPI	341	344	O
+	345	346	O
three	347	352	O
antibiotics	353	364	O
)	364	365	O
,	365	366	O
that	367	371	O
have	372	376	O
showed	377	383	O
a	384	385	O
taller	386	392	O
percentage	393	403	O
of	404	406	O
eradication	407	418	O
at	419	421	O
the	422	425	O
end	426	429	O
of	430	432	O
first	433	438	O
therapeutical	439	452	O
cycle	453	458	O
with	459	463	O
a	464	465	O
shorter	466	473	O
time	474	478	O
and	479	482	O
lower	483	488	O
price	489	494	O
of	495	497	O
treatment	498	507	O
.	507	508	O

Renormalization	0	15	O
group	16	21	O
analysis	22	30	O
of	31	33	O
autoregressive	34	48	O
processes	49	58	O
and	59	62	O
fractional	63	73	O
noise	74	79	O
.	79	80	O

A	81	82	O
renormalization	83	98	O
group	99	104	O
analysis	105	113	O
is	114	116	O
applied	117	124	O
to	125	127	O
autoregressive	128	142	O
processes	143	152	O
with	153	157	O
an	158	160	O
infinite	161	169	O
series	170	176	O
of	177	179	O
coefficients	180	192	O
.	192	193	O

A	194	195	O
simple	196	202	O
fixed	203	208	O
point	209	214	O
is	215	217	O
given	218	223	O
by	224	226	O
a	227	228	O
random	229	235	O
walk	236	240	O
,	240	241	O
and	242	245	O
a	246	247	O
second	248	254	O
class	255	260	O
is	261	263	O
found	264	269	O
that	270	274	O
is	275	277	O
proportional	278	290	O
to	291	293	O
the	294	297	O
high	298	302	O
order	303	308	O
coefficients	309	321	O
of	322	324	O
fractional	325	335	O
autoregressive	336	350	O
integrated	351	361	O
moving	362	368	O
average	369	376	O
(	377	378	O
ARIMA	378	383	O
)	383	384	O
processes	385	394	O
.	394	395	O

The	396	399	O
approach	400	408	O
might	409	414	O
be	415	417	O
useful	418	424	O
to	425	427	O
detect	428	434	O
nonstationarity	435	450	O
in	451	453	O
autoregressive	454	468	O
processes	469	478	O
.	478	479	O

In	0	2	O
vitro	3	8	O
cytotoxic	9	18	O
potential	19	28	O
and	29	32	O
mechanism	33	42	O
of	43	45	O
action	46	52	O
of	53	55	O
selected	56	64	O
coumarins	65	74	O
,	74	75	O
using	76	81	O
human	82	87	O
renal	88	93	B-Cell
cell	94	98	I-Cell
lines	99	104	I-Cell
.	104	105	O

This	106	110	O
study	111	116	O
determined	117	127	O
the	128	131	O
selective	132	141	O
cytotoxicity	142	154	O
of	155	157	O
eight	158	163	O
coumarin	164	172	O
compounds	173	182	O
to	183	185	O
human	186	191	O
renal	192	197	B-Cell
carcinoma	198	207	I-Cell
cells	208	213	I-Cell
,	213	214	O
relative	215	223	O
to	224	226	O
non	227	230	B-Cell
-	230	231	I-Cell
carcinoma	231	240	I-Cell
proximal	241	249	I-Cell
tubular	250	257	I-Cell
cells	258	263	I-Cell
.	263	264	O

Selectivity	265	276	O
cytotoxicity	277	289	O
was	290	293	O
observed	294	302	O
following	303	312	O
exposure	313	321	O
to	322	324	O
6	325	326	O
-	326	327	O
nitro	327	332	O
-	332	333	O
7	333	334	O
-	334	335	O
hydroxycoumarin	335	350	O
(	351	352	O
6	352	353	O
-	353	354	O
NO	354	356	O
(	356	357	O
2	357	358	O
)	358	359	O
-	359	360	O
7	360	361	O
-	361	362	O
OHC	362	365	O
)	365	366	O
and	367	370	O
7	371	372	O
,	372	373	O
8	373	374	O
-	374	375	O
dihydroxycoumarin	375	392	O
(	393	394	O
7	394	395	O
,	395	396	O
8	396	397	O
-	397	398	O
OHC	398	401	O
)	401	402	O
.	402	403	O

6	404	405	O
-	405	406	O
NO	406	408	O
(	408	409	O
2	409	410	O
)	410	411	O
-	411	412	O
7	412	413	O
-	413	414	O
OHC	414	417	O
induced	418	425	O
cytotoxicity	426	438	O
was	439	442	O
irreversible	443	455	O
in	456	458	O
both	459	463	O
cell	464	468	B-Cell
lines	469	474	I-Cell
,	474	475	O
unlike	476	482	O
7	483	484	O
,	484	485	O
8	485	486	O
-	486	487	O
OHC	487	490	O
,	490	491	O
which	492	497	O
was	498	501	O
reversible	502	512	O
in	513	515	O
the	516	519	O
carcinoma	520	529	B-Cell
cells	530	535	I-Cell
only	536	540	O
.	540	541	O

Mobility	542	550	O
shift	551	556	O
and	557	560	O
BrdU	561	565	O
incorporation	566	579	O
assays	580	586	O
showed	587	593	O
that	594	598	O
both	599	603	O
compounds	604	613	O
did	614	617	O
not	618	621	O
intercalate	622	633	O
DNA	634	637	O
but	638	641	O
had	642	645	O
a	646	647	O
concentration	648	661	O
-	661	662	O
dependent	662	671	O
inhibitory	672	682	O
effect	683	689	O
on	690	692	O
its	693	696	O
synthesis	697	706	O
.	706	707	O

All	708	711	O
coumarins	712	721	O
studied	722	729	O
were	730	734	O
found	735	740	O
to	741	743	O
be	744	746	O
non	747	750	O
-	750	751	O
mutagenic	751	760	O
using	761	766	O
the	767	770	O
standard	771	779	O
Ames	780	784	O
test	785	789	O
.	789	790	O

These	791	796	O
results	797	804	O
would	805	810	O
suggest	811	818	O
that	819	823	O
6	824	825	O
-	825	826	O
NO	826	828	O
(	828	829	O
2	829	830	O
)	830	831	O
-	831	832	O
7	832	833	O
-	833	834	O
OHC	834	837	O
and	838	841	O
7	842	843	O
,	843	844	O
8	844	845	O
-	845	846	O
OHC	846	849	O
might	850	855	O
have	856	860	O
a	861	862	O
therapeutic	863	874	O
role	875	879	O
to	880	882	O
play	883	887	O
in	888	890	O
the	891	894	O
treatment	895	904	O
of	905	907	O
renal	908	913	B-Pathological_formation
cell	914	918	I-Pathological_formation
carcinoma	919	928	I-Pathological_formation
.	928	929	O

On	0	2	O
the	3	6	O
relationship	7	19	O
between	20	27	O
the	28	31	O
population	32	42	O
structure	43	52	O
and	53	56	O
national	57	65	O
economic	66	74	O
development	75	86	O
in	87	89	O
China	90	95	O
.	95	96	O

The	97	100	O
authors	101	108	O
examine	109	116	O
the	117	120	O
relationship	121	133	O
between	134	141	O
population	142	152	O
reproduction	153	165	O
and	166	169	O
the	170	173	O
production	174	184	O
of	185	187	O
material	188	196	O
goods	197	202	O
,	202	203	O
with	204	208	O
particular	209	219	O
reference	220	229	O
to	230	232	O
the	233	236	O
effect	237	243	O
of	244	246	O
changes	247	254	O
in	255	257	O
the	258	261	O
age	262	265	O
composition	266	277	O
of	278	280	O
the	281	284	O
population	285	295	O
on	296	298	O
the	299	302	O
national	303	311	O
economy	312	319	O
and	320	323	O
national	324	332	O
income	333	339	O
.	339	340	O

An	342	344	O
analysis	345	353	O
of	354	356	O
the	357	360	O
population	361	371	O
structure	372	381	O
of	382	384	O
China	385	390	O
is	391	393	O
presented	394	403	O
,	403	404	O
with	405	409	O
consideration	410	423	O
given	424	429	O
to	430	432	O
age	433	436	O
characteristics	437	452	O
,	452	453	O
occupation	454	464	O
,	464	465	O
and	466	469	O
urban	470	475	O
and	476	479	O
rural	480	485	O
population	486	496	O
.	496	497	O

Suggestions	499	510	O
for	511	514	O
improving	515	524	O
the	525	528	O
population	529	539	O
structure	540	549	O
to	550	552	O
achieve	553	560	O
maximum	561	568	O
rates	569	574	O
of	575	577	O
economic	578	586	O
development	587	598	O
are	599	602	O
presented	603	612	O
.	612	613	O

Regional	615	623	O
differences	624	635	O
in	636	638	O
population	639	649	O
structure	650	659	O
are	660	663	O
also	664	668	O
discussed	669	678	O
.	678	679	O

No	0	2	O
evidence	3	11	O
for	12	15	O
an	16	18	O
influence	19	28	O
of	29	31	O
the	32	35	O
human	36	41	O
platelet	42	50	O
antigen	51	58	O
-	58	59	O
1	59	60	O
polymorphism	61	73	O
on	74	76	O
the	77	80	O
antiplatelet	81	93	O
effects	94	101	O
of	102	104	O
glycoprotein	105	117	O
IIb	118	121	O
/	121	122	O
IIIa	122	126	O
inhibitors	127	137	O
.	137	138	O

This	139	143	O
study	144	149	O
investigated	150	162	O
the	163	166	O
hypothesis	167	177	O
that	178	182	O
the	183	186	O
human	187	192	O
platelet	193	201	O
antigen	202	209	O
-	209	210	O
1	210	211	O
(	212	213	O
HPA	213	216	O
-	216	217	O
1	217	218	O
)	218	219	O
polymorphism	220	232	O
may	233	236	O
influence	237	246	O
the	247	250	O
antiplatelet	251	263	O
effects	264	271	O
of	272	274	O
glycoprotein	275	287	O
(	288	289	O
GP	289	291	O
)	291	292	O
IIb	292	295	O
/	295	296	O
IIIa	296	300	O
inhibitors	301	311	O
.	311	312	O

Adenosine	313	322	O
diphosphate	323	334	O
(	335	336	O
30	336	338	O
micro	339	344	O
mol	345	348	O
)	348	349	O
-	349	350	O
induced	350	357	O
fibrinogen	358	368	O
binding	369	376	O
was	377	380	O
measured	381	389	O
by	390	392	O
flow	393	397	O
cytometry	398	407	O
.	407	408	O

Abciximab	409	418	O
(	419	420	O
0	420	421	O
.	421	422	O
03	422	424	O
-	424	425	O
3	425	426	O
micro	427	432	O
g	433	434	O
/	434	435	O
ml	435	437	O
)	437	438	O
,	438	439	O
tirofiban	440	449	O
(	450	451	O
0	451	452	O
.	452	453	O
3	453	454	O
-	454	455	O
30	455	457	O
nmol	458	462	O
/	462	463	O
l	463	464	O
)	464	465	O
or	466	468	O
eptifibatide	469	481	O
(	482	483	O
0	483	484	O
.	484	485	O
01	485	487	O
-	487	488	O
1	488	489	O
micro	490	495	O
g	496	497	O
/	497	498	O
ml	498	500	O
)	500	501	O
were	502	506	O
incubated	507	516	O
for	517	520	O
15	521	523	O
min	524	527	O
with	528	532	O
the	533	536	O
samples	537	544	O
prior	545	550	O
to	551	553	O
stimulation	554	565	O
.	565	566	O

IC	567	569	O
(	569	570	O
50	570	572	O
)	572	573	O
values	574	580	O
for	581	584	O
the	585	588	O
inhibition	589	599	O
of	600	602	O
fibrinogen	603	613	O
binding	614	621	O
were	622	626	O
determined	627	637	O
from	638	642	O
each	643	647	O
experiment	648	658	O
.	658	659	O

All	660	663	O
subjects	664	672	O
were	673	677	O
genotyped	678	687	O
by	688	690	O
GALIOS	691	697	O
and	698	701	O
automated	702	711	O
fluorescence	712	724	O
correlation	725	736	O
spectroscopy	737	749	O
.	749	750	O

Although	751	759	O
a	760	761	O
marked	762	768	O
variability	769	780	O
in	781	783	O
the	784	787	O
inhibitory	788	798	O
effects	799	806	O
of	807	809	O
all	810	813	O
three	814	819	O
GPIIb	820	825	O
/	825	826	O
IIIa	826	830	O
inhibitors	831	841	O
was	842	845	O
confirmed	846	855	O
,	855	856	O
there	857	862	O
were	863	867	O
no	868	870	O
significant	871	882	O
differences	883	894	O
between	895	902	O
the	903	906	O
genotypes	907	916	O
with	917	921	O
respect	922	929	O
to	930	932	O
the	933	936	O
inhibition	937	947	O
of	948	950	O
fibrinogen	951	961	O
binding	962	969	O
.	969	970	O

Thus	971	975	O
,	975	976	O
the	977	980	O
present	981	988	O
study	989	994	O
does	995	999	O
not	1000	1003	O
provide	1004	1011	O
evidence	1012	1020	O
for	1021	1024	O
an	1025	1027	O
effect	1028	1034	O
of	1035	1037	O
HPA	1038	1041	O
-	1041	1042	O
1	1042	1043	O
polymorphism	1044	1056	O
on	1057	1059	O
the	1060	1063	O
inter	1064	1069	O
-	1069	1070	O
individual	1070	1080	O
variability	1081	1092	O
in	1093	1095	O
the	1096	1099	O
platelet	1100	1108	B-Cell
inhibitory	1109	1119	O
effects	1120	1127	O
of	1128	1130	O
the	1131	1134	O
three	1135	1140	O
GPIIb	1141	1146	O
/	1146	1147	O
IIIa	1147	1151	O
inhibitors	1152	1162	O
approved	1163	1171	O
for	1172	1175	O
clinical	1176	1184	O
use	1185	1188	O
.	1188	1189	O

The	0	3	O
Acute	4	9	O
Dialysis	10	18	O
Quality	19	26	O
Initiative	27	37	O
-	37	38	O
-	38	39	O
part	39	43	O
IV	44	46	O
:	46	47	O
membranes	48	57	B-Multi-tissue_structure
for	58	61	O
CRRT	62	66	O
.	66	67	O

The	68	71	O
extracorporeal	72	86	B-Multi-tissue_structure
membrane	87	95	I-Multi-tissue_structure
used	96	100	O
in	101	103	O
a	104	105	O
continuous	106	116	O
renal	117	122	B-Organ
replacement	123	134	O
therapy	135	142	O
(	143	144	O
CRRT	144	148	O
)	148	149	O
for	150	153	O
the	154	157	O
treatment	158	167	O
of	168	170	O
a	171	172	O
critically	173	183	O
ill	184	187	O
patient	188	195	O
with	196	200	O
acute	201	206	O
renal	207	212	B-Organ
failure	213	220	O
(	221	222	O
ARF	222	225	O
)	225	226	O
is	227	229	O
vitally	230	237	O
important	238	247	O
for	248	251	O
several	252	259	O
reasons	260	267	O
,	267	268	O
including	269	278	O
its	279	282	O
influence	283	292	O
on	293	295	O
biocompatibility	296	312	O
and	313	316	O
filter	317	323	O
performance	324	335	O
.	335	336	O

The	337	340	O
clinical	341	349	O
relevance	350	359	O
of	360	362	O
membrane	363	371	B-Multi-tissue_structure
-	371	372	O
related	372	379	O
biocompatibility	380	396	O
markers	397	404	O
traditionally	405	418	O
used	419	423	O
in	424	426	O
chronic	427	434	O
hemodialysis	435	447	O
remains	448	455	O
unclear	456	463	O
in	464	466	O
CRRT	467	471	O
.	471	472	O

Numerous	473	481	O
approaches	482	492	O
may	493	496	O
be	497	499	O
used	500	504	O
to	505	507	O
assess	508	514	O
membrane	515	523	B-Multi-tissue_structure
and	524	527	O
filter	528	534	O
performance	535	546	O
in	547	549	O
CRRT	550	554	O
,	554	555	O
but	556	559	O
no	560	562	O
specific	563	571	O
methodology	572	583	O
is	584	586	O
accepted	587	595	O
widely	596	602	O
at	603	605	O
present	606	613	O
.	613	614	O

Although	615	623	O
a	624	625	O
potential	626	635	O
benefit	636	643	O
of	644	646	O
certain	647	654	O
membranes	655	664	B-Multi-tissue_structure
used	665	669	O
for	670	673	O
CRRT	674	678	O
is	679	681	O
adsorptive	682	692	O
removal	693	700	O
of	701	703	O
inflammatory	704	716	O
mediators	717	726	O
,	726	727	O
this	728	732	O
issue	733	738	O
has	739	742	O
not	743	746	O
been	747	751	O
assessed	752	760	O
carefully	761	770	O
in	771	773	O
well	774	778	O
-	778	779	O
designed	779	787	O
clinical	788	796	O
trials	797	803	O
.	803	804	O

These	805	810	O
and	811	814	O
other	815	820	O
issues	821	827	O
should	828	834	O
be	835	837	O
the	838	841	O
subject	842	849	O
of	850	852	O
future	853	859	O
clinical	860	868	O
research	869	877	O
efforts	878	885	O
.	885	886	O

Sickle	0	6	B-Cell
cell	7	11	I-Cell
disease	12	19	O
:	19	20	O
continuous	21	31	O
arterial	32	40	B-Multi-tissue_structure
spin	41	45	O
-	45	46	O
labeling	46	54	O
perfusion	55	64	O
MR	65	67	O
imaging	68	75	O
in	76	78	O
children	79	87	O
.	87	88	O

Cerebral	89	97	B-Organ
blood	98	103	B-Organism_substance
flow	104	108	O
(	109	110	O
CBF	110	113	O
)	113	114	O
was	115	118	O
measured	119	127	O
with	128	132	O
continuous	133	143	O
arterial	144	152	B-Multi-tissue_structure
spin	153	157	O
-	157	158	O
labeling	158	166	O
perfusion	167	176	O
magnetic	177	185	O
resonance	186	195	O
(	196	197	O
MR	197	199	O
)	199	200	O
imaging	201	208	O
in	209	211	O
14	212	214	O
children	215	223	O
with	224	228	O
sickle	229	235	B-Cell
cell	236	240	I-Cell
disease	241	248	O
and	249	252	O
seven	253	258	O
control	259	266	O
subjects	267	275	O
.	275	276	O

Mean	277	281	O
CBF	282	285	O
values	286	292	O
were	293	297	O
higher	298	304	O
in	305	307	O
patients	308	316	O
(	317	318	O
P	318	319	O
<	320	321	O
.	321	322	O
005	322	325	O
)	325	326	O
than	327	331	O
in	332	334	O
control	335	342	O
subjects	343	351	O
in	352	354	O
all	355	358	O
cerebral	359	367	B-Multi-tissue_structure
artery	368	374	I-Multi-tissue_structure
territories	375	386	O
.	386	387	O

Three	388	393	O
patients	394	402	O
had	403	406	O
decreased	407	416	O
CBF	417	420	O
in	421	423	O
right	424	429	B-Multi-tissue_structure
anterior	430	438	I-Multi-tissue_structure
and	439	442	O
middle	443	449	O
cerebral	450	458	B-Multi-tissue_structure
artery	459	465	I-Multi-tissue_structure
territories	466	477	O
compared	478	486	O
with	487	491	O
CBF	492	495	O
on	496	498	O
the	499	502	O
left	503	507	O
,	507	508	O
and	509	512	O
one	513	516	O
patient	517	524	O
had	525	528	O
a	529	530	O
profound	531	539	O
decrease	540	548	O
in	549	551	O
CBF	552	555	O
in	556	558	O
all	559	562	O
three	563	568	O
territories	569	580	O
in	581	583	O
the	584	587	O
right	588	593	B-Organism_subdivision
hemisphere	594	604	I-Organism_subdivision
.	604	605	O

Baseline	606	614	O
CBF	615	618	O
was	619	622	O
significantly	623	636	O
decreased	637	646	O
in	647	649	O
territories	650	661	O
seen	662	666	O
as	667	669	O
unaffected	670	680	O
on	681	683	O
conventional	684	696	O
MR	697	699	O
images	700	706	O
and	707	710	O
MR	711	713	O
angiograms	714	724	O
in	725	727	O
four	728	732	O
children	733	741	O
with	742	746	O
sickle	747	753	B-Cell
cell	754	758	I-Cell
disease	759	766	O
.	766	767	O

The	0	3	O
septic	4	10	B-Multi-tissue_structure
abscess	11	18	I-Multi-tissue_structure
wall	19	23	I-Multi-tissue_structure
:	23	24	O
a	25	26	O
cytokine	27	35	O
-	35	36	O
generating	36	46	O
organ	47	52	B-Organ
associated	53	63	O
with	64	68	O
portal	69	75	B-Multi-tissue_structure
venous	76	82	I-Multi-tissue_structure
cytokinemia	83	94	O
,	94	95	O
hepatic	96	103	B-Organ
outflow	104	111	O
fibrosis	112	120	O
,	120	121	O
sinusoidal	122	132	B-Tissue
congestion	133	143	O
,	143	144	O
inflammatory	145	157	B-Cell
cell	158	162	I-Cell
sequestration	163	176	O
,	176	177	O
hepatocellular	178	192	B-Cell
lipid	193	198	O
deposition	199	209	O
,	209	210	O
and	211	214	O
focal	215	220	O
cell	221	225	B-Cell
death	226	231	O
.	231	232	O

An	233	235	O
acute	236	241	O
septic	242	248	O
inflammatory	249	261	O
response	262	270	O
with	271	275	O
access	276	282	O
to	283	285	O
the	286	289	O
portal	290	296	O
circulation	297	308	O
was	309	312	O
created	313	320	O
in	321	323	O
a	324	325	O
rat	326	329	O
model	330	335	O
using	336	341	O
an	342	344	O
intra	345	350	O
-	350	351	O
abdominal	351	360	B-Pathological_formation
abscess	361	368	I-Pathological_formation
composed	369	377	O
of	378	380	O
a	381	382	O
sterile	383	390	O
agar	391	395	O
pellet	396	402	O
,	402	403	O
or	404	406	O
one	407	410	O
contaminated	411	423	O
with	424	428	O
102	429	432	O
Escherichia	433	444	O
coli	445	449	O
(	450	451	O
E	451	452	O
.	452	453	O
coli	454	458	O
)	458	459	O
and	460	463	O
109	464	467	O
Bacteriodes	468	479	O
fragilis	480	488	O
(	489	490	O
B	490	491	O
.	491	492	O
fragilis	493	501	O
)	501	502	O
.	502	503	O

After	504	509	O
3	510	511	O
days	512	516	O
postimplantation	517	533	O
,	533	534	O
a	535	536	O
well	537	541	O
-	541	542	O
formed	542	548	O
intra	549	554	O
-	554	555	O
abdominal	555	564	B-Pathological_formation
abscess	565	572	I-Pathological_formation
occurred	573	581	O
whose	582	587	O
wall	588	592	B-Tissue
showed	593	599	O
IL	600	602	O
-	602	603	O
6	603	604	O
DNA	605	608	O
by	609	611	O
PCR	612	615	O
and	616	619	O
IL	620	622	O
-	622	623	O
6	623	624	O
mRNA	625	629	O
by	630	632	O
in	633	635	O
situ	636	640	O
hybridization	641	654	O
.	654	655	O

Portal	656	662	B-Organism_substance
venous	663	669	I-Organism_substance
blood	670	675	I-Organism_substance
draining	676	684	O
into	685	689	O
the	690	693	O
liver	694	699	B-Organ
from	700	704	O
the	705	708	O
intra	709	714	O
-	714	715	O
abdominal	715	724	B-Pathological_formation
abscess	725	732	I-Pathological_formation
had	733	736	O
increased	737	746	O
levels	747	753	O
of	754	756	O
TNF	757	760	O
-	760	761	O
alpha	761	766	O
,	766	767	O
IL	768	770	O
-	770	771	O
1beta	771	776	O
,	776	777	O
and	778	781	O
IL	782	784	O
-	784	785	O
6	785	786	O
in	787	789	O
both	790	794	O
sterile	795	802	O
and	803	806	O
septic	807	813	O
groups	814	820	O
compared	821	829	O
with	830	834	O
a	835	836	O
control	837	844	O
normal	845	851	O
animal	852	858	O
group	859	864	O
.	864	865	O

Increased	866	875	O
levels	876	882	O
of	883	885	O
these	886	891	O
cytokines	892	901	O
were	902	906	O
also	907	911	O
found	912	917	O
in	918	920	O
suprahepatic	921	933	B-Organism_substance
inferior	934	942	I-Organism_substance
vena	943	947	I-Organism_substance
caval	948	953	I-Organism_substance
blood	954	959	I-Organism_substance
,	959	960	O
but	961	964	O
were	965	969	O
correlated	970	980	O
with	981	985	O
the	986	989	O
higher	990	996	O
portal	997	1003	B-Multi-tissue_structure
vein	1004	1008	I-Multi-tissue_structure
levels	1009	1015	O
,	1015	1016	O
suggesting	1017	1027	O
a	1028	1029	O
gradient	1030	1038	O
from	1039	1043	O
abscess	1044	1051	B-Multi-tissue_structure
wall	1052	1056	I-Multi-tissue_structure
to	1057	1059	O
portal	1060	1066	B-Multi-tissue_structure
vein	1067	1071	I-Multi-tissue_structure
into	1072	1076	O
the	1077	1080	O
systemic	1081	1089	O
circulation	1090	1101	O
via	1102	1105	O
the	1106	1109	O
liver	1110	1115	B-Organ
.	1115	1116	O

Liver	1117	1122	B-Organ
histology	1123	1132	O
demonstrated	1133	1145	O
sinusoidal	1146	1156	B-Tissue
congestion	1157	1167	O
centering	1168	1177	O
on	1178	1180	O
the	1181	1184	O
central	1185	1192	B-Multi-tissue_structure
vein	1193	1197	I-Multi-tissue_structure
,	1197	1198	O
growing	1199	1206	O
worse	1207	1212	O
with	1213	1217	O
progression	1218	1229	O
from	1230	1234	O
normal	1235	1241	O
in	1242	1244	O
control	1245	1252	O
,	1252	1253	O
to	1254	1256	O
sterile	1257	1264	O
,	1264	1265	O
to	1266	1268	O
septic	1269	1275	O
.	1275	1276	O

Similarly	1277	1286	O
,	1286	1287	O
the	1288	1291	O
degree	1292	1298	O
of	1299	1301	O
intrahepatic	1302	1314	O
myeloperoxidase	1315	1330	O
-	1330	1331	O
positive	1331	1339	O
inflammatory	1340	1352	B-Cell
cell	1353	1357	I-Cell
infiltration	1358	1370	O
and	1371	1374	O
hepatocellular	1375	1389	B-Cell
lipid	1390	1395	O
deposition	1396	1406	O
and	1407	1410	O
apoptosis	1411	1420	O
also	1421	1425	O
increased	1426	1435	O
from	1436	1440	O
control	1441	1448	O
,	1448	1449	O
to	1450	1452	O
sterile	1453	1460	O
,	1460	1461	O
to	1462	1464	O
septic	1465	1471	O
.	1471	1472	O

Gene	1473	1477	O
expression	1478	1488	O
by	1489	1491	O
in	1492	1494	O
situ	1495	1499	O
hybridization	1500	1513	O
demonstrated	1514	1526	O
a	1527	1528	O
significant	1529	1540	O
increase	1541	1549	O
in	1550	1552	O
IL	1553	1555	O
-	1555	1556	O
6	1556	1557	O
and	1558	1561	O
fibrinogen	1562	1572	O
mRNAs	1573	1578	O
in	1579	1581	O
cells	1582	1587	B-Cell
surrounding	1588	1599	O
the	1600	1603	O
central	1604	1611	B-Multi-tissue_structure
vein	1612	1616	I-Multi-tissue_structure
in	1617	1619	O
sterile	1620	1627	O
and	1628	1631	O
septic	1632	1638	O
animals	1639	1646	O
,	1646	1647	O
being	1648	1653	O
greatest	1654	1662	O
in	1663	1665	O
animals	1666	1673	O
with	1674	1678	O
sepsis	1679	1685	O
,	1685	1686	O
associated	1687	1697	O
with	1698	1702	O
an	1703	1705	O
increased	1706	1715	O
deposition	1716	1726	O
of	1727	1729	O
collagen	1730	1738	O
in	1739	1741	O
the	1742	1745	O
central	1746	1753	B-Multi-tissue_structure
vein	1754	1758	I-Multi-tissue_structure
area	1759	1763	O
,	1763	1764	O
most	1765	1769	O
prominent	1770	1779	O
in	1780	1782	O
the	1783	1786	O
septic	1787	1793	B-Organ
liver	1794	1799	I-Organ
.	1799	1800	O

The	1801	1804	O
pericentral	1805	1816	B-Cell
vein	1817	1821	I-Cell
cells	1822	1827	I-Cell
with	1828	1832	O
IL	1833	1835	O
-	1835	1836	O
6	1836	1837	O
and	1838	1841	O
fibrinogen	1842	1852	O
mRNA	1853	1857	O
increases	1858	1867	O
paralleled	1868	1878	O
the	1879	1882	O
increases	1883	1892	O
in	1893	1895	O
cells	1896	1901	B-Cell
containing	1902	1912	O
IL	1913	1915	O
-	1915	1916	O
6	1916	1917	O
and	1918	1921	O
fibrinogen	1922	1932	O
mRNAs	1933	1938	O
in	1939	1941	O
the	1942	1945	O
abscess	1946	1953	B-Multi-tissue_structure
walls	1954	1959	I-Multi-tissue_structure
of	1960	1962	O
sterile	1963	1970	O
and	1971	1974	O
septic	1975	1981	O
animals	1982	1989	O
,	1989	1990	O
respectively	1991	2003	O
.	2003	2004	O

The	2005	2008	O
data	2009	2013	O
suggest	2014	2021	O
that	2022	2026	O
an	2027	2029	O
intra	2030	2035	O
-	2035	2036	O
abdominal	2036	2045	B-Pathological_formation
abscess	2046	2053	I-Pathological_formation
,	2053	2054	O
especially	2055	2065	O
when	2066	2070	O
contaminated	2071	2083	O
with	2084	2088	O
gram	2089	2093	O
-	2093	2094	O
negative	2094	2102	O
bacteria	2103	2111	O
,	2111	2112	O
induces	2113	2120	O
mRNA	2121	2125	O
-	2125	2126	O
generated	2126	2135	O
cytokine	2136	2144	O
responses	2145	2154	O
in	2155	2157	O
the	2158	2161	O
abscess	2162	2169	B-Multi-tissue_structure
wall	2170	2174	I-Multi-tissue_structure
that	2175	2179	O
are	2180	2183	O
related	2184	2191	O
to	2192	2194	O
increased	2195	2204	O
portal	2205	2211	B-Multi-tissue_structure
venous	2212	2218	I-Multi-tissue_structure
levels	2219	2225	O
of	2226	2228	O
the	2229	2232	O
inflammatory	2233	2245	O
cytokines	2246	2255	O
TNF	2256	2259	O
-	2259	2260	O
alpha	2260	2265	O
,	2265	2266	O
IL	2267	2269	O
-	2269	2270	O
1beta	2270	2275	O
,	2275	2276	O
and	2277	2280	O
IL	2281	2283	O
-	2283	2284	O
6	2284	2285	O
perfusing	2286	2295	O
the	2296	2299	O
liver	2300	2305	B-Organ
.	2305	2306	O

These	2307	2312	O
,	2312	2313	O
in	2314	2316	O
turn	2317	2321	O
,	2321	2322	O
induce	2323	2329	O
localized	2330	2339	O
production	2340	2350	O
of	2351	2353	O
IL	2354	2356	O
-	2356	2357	O
6	2357	2358	O
and	2359	2362	O
fibrinogen	2363	2373	O
mRNAs	2374	2379	O
in	2380	2382	O
cells	2383	2388	B-Cell
at	2389	2391	O
the	2392	2395	O
central	2396	2403	B-Multi-tissue_structure
vein	2404	2408	I-Multi-tissue_structure
area	2409	2413	O
with	2414	2418	O
resultant	2419	2428	O
outflow	2429	2436	O
fibrosis	2437	2445	O
and	2446	2449	O
increased	2450	2459	O
inflammatory	2460	2472	B-Cell
cell	2473	2477	I-Cell
sequestration	2478	2491	O
within	2492	2498	O
the	2499	2502	O
liver	2503	2508	B-Multi-tissue_structure
lobular	2509	2516	I-Multi-tissue_structure
sinuses	2517	2524	I-Multi-tissue_structure
.	2524	2525	O

This	2526	2530	O
is	2531	2533	O
associated	2534	2544	O
with	2545	2549	O
a	2550	2551	O
generalized	2552	2563	O
inflammatory	2564	2576	O
response	2577	2585	O
and	2586	2589	O
intrahepatic	2590	2602	O
portal	2603	2609	O
sinusoid	2610	2618	O
congestion	2619	2629	O
.	2629	2630	O

There	2631	2636	O
is	2637	2639	O
also	2640	2644	O
increased	2645	2654	O
hepatocellular	2655	2669	B-Cell
lipid	2670	2675	O
deposition	2676	2686	O
and	2687	2690	O
apoptosis	2691	2700	O
.	2700	2701	O

Thus	2702	2706	O
,	2706	2707	O
the	2708	2711	O
cytokine	2712	2720	O
production	2721	2731	O
of	2732	2734	O
the	2735	2738	O
abscess	2739	2746	B-Multi-tissue_structure
wall	2747	2751	I-Multi-tissue_structure
itself	2752	2758	O
appears	2759	2766	O
to	2767	2769	O
be	2770	2772	O
a	2773	2774	O
major	2775	2780	O
mediator	2781	2789	O
of	2790	2792	O
the	2793	2796	O
septic	2797	2803	B-Organ
hepatic	2804	2811	I-Organ
response	2812	2820	O
.	2820	2821	O

Treatment	0	9	O
effects	10	17	O
on	18	20	O
nigrostriatal	21	34	B-Multi-tissue_structure
projection	35	45	O
integrity	46	55	O
in	56	58	O
partial	59	66	O
6	67	68	O
-	68	69	O
OHDA	69	73	O
lesions	74	81	B-Pathological_formation
:	81	82	O
comparison	83	93	O
of	94	96	O
L	97	98	O
-	98	99	O
DOPA	99	103	O
and	104	107	O
pramipexole	108	119	O
.	119	120	O

There	121	126	O
is	127	129	O
controversy	130	141	O
over	142	146	O
potential	147	156	O
effects	157	164	O
of	165	167	O
dopaminergic	168	180	O
replacement	181	192	O
therapies	193	202	O
on	203	205	O
the	206	209	O
partially	210	219	O
lesioned	220	228	B-Multi-tissue_structure
nigrostriatal	229	242	I-Multi-tissue_structure
dopaminergic	243	255	O
projection	256	266	O
.	266	267	O

We	268	270	O
evaluated	271	280	O
indirect	281	289	O
(	290	291	O
levodopa	291	299	O
,	299	300	O
L	301	302	O
-	302	303	O
DOPA	303	307	O
)	307	308	O
versus	309	315	O
direct	316	322	O
(	323	324	O
pramipexole	324	335	O
,	335	336	O
PRA	337	340	O
)	340	341	O
dopaminergic	342	354	O
treatment	355	364	O
effects	365	372	O
on	373	375	O
nigrostriatal	376	389	B-Pathological_formation
lesion	390	396	I-Pathological_formation
severity	397	405	O
as	406	408	O
measured	409	417	O
with	418	422	O
vesicular	423	432	O
monoamine	433	442	O
transporter	443	454	O
type	455	459	O
-	459	460	O
2	460	461	O
(	462	463	O
VMAT2	463	468	O
)	468	469	O
binding	470	477	O
.	477	478	O

Prior	479	484	O
studies	485	492	O
have	493	497	O
shown	498	503	O
that	504	508	O
striatal	509	517	B-Multi-tissue_structure
VMAT2	518	523	O
density	524	531	O
provides	532	540	O
an	541	543	O
objective	544	553	O
estimate	554	562	O
of	563	565	O
dopaminergic	566	578	O
neuronal	579	587	B-Cell
integrity	588	597	O
,	597	598	O
without	599	606	O
confounding	607	618	O
effects	619	626	O
of	627	629	O
compensatory	630	642	O
regulation	643	653	O
.	653	654	O

Partial	655	662	O
unilateral	663	673	B-Multi-tissue_structure
median	674	680	I-Multi-tissue_structure
forebrain	681	690	I-Multi-tissue_structure
bundle	691	697	I-Multi-tissue_structure
lesions	698	705	I-Multi-tissue_structure
were	706	710	O
made	711	715	O
by	716	718	O
injection	719	728	O
of	729	731	O
6	732	733	O
-	733	734	O
hydroxydopamine	734	749	O
in	750	752	O
adult	753	758	O
male	759	763	O
Sprague	764	771	O
-	771	772	O
Dawley	772	778	O
rats	779	783	O
.	783	784	O

Lesion	785	791	B-Pathological_formation
severity	792	800	O
was	801	804	O
estimated	805	814	O
using	815	820	O
rotational	821	831	O
behavior	832	840	O
after	841	846	O
injections	847	857	O
of	858	860	O
apomorphine	861	872	O
and	873	876	O
amphetamine	877	888	O
.	888	889	O

Rats	890	894	O
were	895	899	O
ranked	900	906	O
and	907	910	O
matched	911	918	O
in	919	921	O
pairs	922	927	O
by	928	930	O
rotation	931	939	O
and	940	943	O
assigned	944	952	O
to	953	955	O
receive	956	963	O
either	964	970	O
PRA	971	974	O
(	975	976	O
1	976	977	O
mg	978	980	O
/	980	981	O
kg	981	983	O
/	983	984	O
day	984	987	O
)	987	988	O
or	989	991	O
L	992	993	O
-	993	994	O
DOPA	994	998	O
/	998	999	O
benserazide	999	1010	O
(	1011	1012	O
100	1012	1015	O
/	1015	1016	O
25	1016	1018	O
mg	1019	1021	O
/	1021	1022	O
kg	1022	1024	O
/	1024	1025	O
day	1025	1028	O
)	1028	1029	O
ip	1030	1032	O
via	1033	1036	O
osmotic	1037	1044	O
pump	1045	1049	O
.	1049	1050	O

After	1051	1056	O
4	1057	1058	O
weeks	1059	1064	O
of	1065	1067	O
drug	1068	1072	O
treatment	1073	1082	O
,	1082	1083	O
in	1084	1086	O
vitro	1087	1092	O
autoradiography	1093	1108	O
was	1109	1112	O
performed	1113	1122	O
with	1123	1127	O
[	1128	1129	O
(	1129	1130	O
3	1130	1131	O
)	1131	1132	O
H	1132	1133	O
]	1133	1134	O
methoxytetrabenazine	1134	1154	O
to	1155	1157	O
measure	1158	1165	O
striatal	1166	1174	B-Multi-tissue_structure
VMAT2	1175	1180	O
binding	1181	1188	O
density	1189	1196	O
.	1196	1197	O

Lesion	1198	1204	B-Pathological_formation
-	1204	1205	O
to	1205	1207	O
-	1207	1208	O
intact	1208	1214	O
VMAT2	1215	1220	O
density	1221	1228	O
correlated	1229	1239	O
with	1240	1244	O
rotation	1245	1253	O
in	1254	1256	O
both	1257	1261	O
treatment	1262	1271	O
groups	1272	1278	O
.	1278	1279	O

There	1280	1285	O
was	1286	1289	O
no	1290	1292	O
treatment	1293	1302	O
effect	1303	1309	O
on	1310	1312	O
VMAT2	1313	1318	O
expression	1319	1329	O
in	1330	1332	O
the	1333	1336	O
partially	1337	1346	O
lesioned	1347	1355	B-Multi-tissue_structure
striatum	1356	1364	I-Multi-tissue_structure
and	1365	1368	O
thus	1369	1373	O
no	1374	1376	O
differential	1377	1389	O
effect	1390	1396	O
of	1397	1399	O
indirect	1400	1408	O
versus	1409	1415	O
direct	1416	1422	O
dopamimetic	1423	1434	O
treatment	1435	1444	O
on	1445	1447	O
nigrostriatal	1448	1461	B-Multi-tissue_structure
integrity	1462	1471	O
.	1471	1472	O

Neutrophil	0	10	B-Cell
function	11	19	O
in	20	22	O
chronic	23	30	O
neutrophilic	31	43	B-Cell
leukemia	44	52	O
:	52	53	O
defective	54	63	O
respiratory	64	75	B-Anatomical_system
burst	76	81	O
in	82	84	O
response	85	93	O
to	94	96	O
phorbol	97	104	O
esters	105	111	O
.	111	112	O

Functional	113	123	O
analyses	124	132	O
were	133	137	O
performed	138	147	O
on	148	150	O
neutrophils	151	162	B-Cell
isolated	163	171	O
from	172	176	O
6	177	178	O
patients	179	187	O
from	188	192	O
two	193	196	O
institutions	197	209	O
who	210	213	O
displayed	214	223	O
features	224	232	O
of	233	235	O
chronic	236	243	O
neutrophilic	244	256	B-Cell
leukemia	257	265	O
(	266	267	O
CNL	267	270	O
)	270	271	O
.	271	272	O

These	273	278	O
neutrophils	279	290	B-Cell
demonstrated	291	303	O
a	304	305	O
consistent	306	316	O
deficiency	317	327	O
(	328	329	O
44	329	331	O
+	332	333	O
/	333	334	O
-	334	335	O
8	336	337	O
%	337	338	O
of	339	341	O
control	342	349	O
values	350	356	O
)	356	357	O
in	358	360	O
superoxide	361	371	O
anion	372	377	O
(	378	379	O
O2	379	381	O
-	381	382	O
)	382	383	O
production	384	394	O
in	395	397	O
response	398	406	O
to	407	409	O
the	410	413	O
phorbol	414	421	O
ester	422	427	O
,	427	428	O
phorbol	429	436	O
myristate	437	446	O
acetate	447	454	O
(	455	456	O
PMA	456	459	O
)	459	460	O
.	460	461	O

O2	462	464	O
-	464	465	O
production	466	476	O
in	477	479	O
response	480	488	O
to	489	491	O
chemotactic	492	503	O
peptides	504	512	O
was	513	516	O
near	517	521	O
normal	522	528	O
(	529	530	O
82	530	532	O
.	532	533	O
3	533	534	O
+	535	536	O
/	536	537	O
-	537	538	O
10	539	541	O
.	541	542	O
7	542	543	O
%	543	544	O
of	545	547	O
control	548	555	O
values	556	562	O
)	562	563	O
.	563	564	O

Bacterial	565	574	O
killing	575	582	O
was	583	586	O
normal	587	593	O
in	594	596	O
the	597	600	O
two	601	604	O
patients	605	613	O
studied	614	621	O
,	621	622	O
and	623	626	O
chemotaxis	627	637	O
was	638	641	O
diminished	642	652	O
in	653	655	O
response	656	664	O
to	665	667	O
zymosan	668	675	O
-	675	676	O
activated	676	685	O
plasma	686	692	B-Organism_substance
and	693	696	O
to	697	699	O
high	700	704	O
concentrations	705	719	O
of	720	722	O
chemotactic	723	734	O
peptides	735	743	O
in	744	746	O
the	747	750	O
patients	751	759	O
studied	760	767	O
.	767	768	O

Cytosolic	769	778	O
C	779	780	O
kinase	781	787	O
activity	788	796	O
was	797	800	O
decreased	801	810	O
in	811	813	O
one	814	817	O
of	818	820	O
the	821	824	O
two	825	828	O
patients	829	837	O
studied	838	845	O
.	845	846	O

These	847	852	O
results	853	860	O
suggest	861	868	O
that	869	873	O
a	874	875	O
deficient	876	885	O
O2	886	888	O
-	888	889	O
release	890	897	O
in	898	900	O
response	901	909	O
to	910	912	O
PMA	913	916	O
is	917	919	O
a	920	921	O
hallmark	922	930	O
of	931	933	O
neutrophils	934	945	B-Cell
in	946	948	O
CNL	949	952	O
and	953	956	O
may	957	960	O
provide	961	968	O
a	969	970	O
diagnostic	971	981	O
indicator	982	991	O
of	992	994	O
this	995	999	O
condition	1000	1009	O
.	1009	1010	O

In	0	2	O
situ	3	7	O
alkylation	8	18	O
of	19	21	O
cysteine	22	30	O
residues	31	39	O
in	40	42	O
a	43	44	O
hydrophobic	45	56	O
membrane	57	65	B-Cellular_component
protein	66	73	O
immobilized	74	85	O
on	86	88	O
polyvinylidene	89	103	O
difluoride	104	114	O
membranes	115	124	O
by	125	127	O
electroblotting	128	143	O
prior	144	149	O
to	150	152	O
microsequence	153	166	O
and	167	170	O
amino	171	176	O
acid	177	181	O
analysis	182	190	O
.	190	191	O

For	192	195	O
identification	196	210	O
of	211	213	O
cysteine	214	222	O
residues	223	231	O
on	232	234	O
microsequence	235	248	O
analysis	249	257	O
it	258	260	O
is	261	263	O
crucial	264	271	O
to	272	274	O
derivatize	275	285	O
the	286	289	O
sulfhydryl	290	300	O
groups	301	307	O
.	307	308	O

This	309	313	O
reaction	314	322	O
requires	323	331	O
a	332	333	O
desalting	334	343	O
step	344	348	O
which	349	354	O
often	355	360	O
represents	361	371	O
a	372	373	O
major	374	379	O
obstacle	380	388	O
,	388	389	O
especially	390	400	O
if	401	403	O
the	404	407	O
sample	408	414	O
consists	415	423	O
of	424	426	O
limited	427	434	O
amounts	435	442	O
of	443	445	O
a	446	447	O
hydrophobic	448	459	O
membrane	460	468	B-Cellular_component
protein	469	476	O
.	476	477	O

An	478	480	O
alkylation	481	491	O
procedure	492	501	O
is	502	504	O
described	505	514	O
,	514	515	O
allowing	516	524	O
efficient	525	534	O
derivatization	535	549	O
(	550	551	O
greater	551	558	O
than	559	563	O
90	564	566	O
%	566	567	O
)	567	568	O
of	569	571	O
cysteines	572	581	O
and	582	585	O
cystines	586	594	O
even	595	599	O
in	600	602	O
low	603	606	O
microgram	607	616	O
quantities	617	627	O
,	627	628	O
as	629	631	O
revealed	632	640	O
by	641	643	O
test	644	648	O
analyses	649	657	O
with	658	662	O
lysozyme	663	671	O
and	672	675	O
a	676	677	O
hydrophobic	678	689	O
membrane	690	698	B-Cellular_component
protein	699	706	O
.	706	707	O

The	708	711	O
modified	712	720	O
protein	721	728	O
is	729	731	O
recovered	732	741	O
in	742	744	O
high	745	749	O
yields	750	756	O
in	757	759	O
a	760	761	O
form	762	766	O
suitable	767	775	O
for	776	779	O
both	780	784	O
microsequence	785	798	O
analysis	799	807	O
and	808	811	O
amino	812	817	O
acid	818	822	O
analysis	823	831	O
.	831	832	O

The	833	836	O
method	837	843	O
involves	844	852	O
electrophoretic	853	868	O
desalting	869	878	O
by	879	881	O
miniaturized	882	894	O
Tricine	895	902	O
-	902	903	O
sodium	903	909	O
dodecyl	910	917	O
sulfate	918	925	O
-	925	926	O
polyacrylamide	926	940	O
gel	941	944	O
electrophoresis	945	960	O
and	961	964	O
in	965	967	O
situ	968	972	O
alkylation	973	983	O
after	984	989	O
electro	990	997	O
-	997	998	O
transfer	998	1006	O
onto	1007	1011	O
polyvinylidene	1012	1026	O
difluoride	1027	1037	O
membranes	1038	1047	O
.	1047	1048	O

Precautions	1049	1060	O
against	1061	1068	O
NH2	1069	1072	O
-	1072	1073	O
terminal	1073	1081	O
blocking	1082	1090	O
during	1091	1097	O
sample	1098	1104	O
preparations	1105	1117	O
are	1118	1121	O
provided	1122	1130	O
.	1130	1131	O

The	1132	1135	O
general	1136	1143	O
applicability	1144	1157	O
of	1158	1160	O
the	1161	1164	O
method	1165	1171	O
is	1172	1174	O
illustrated	1175	1186	O
by	1187	1189	O
the	1190	1193	O
structural	1194	1204	O
characterization	1205	1221	O
of	1222	1224	O
the	1225	1228	O
low	1229	1232	O
abundance	1233	1242	O
membrane	1243	1251	B-Cellular_component
receptor	1252	1260	O
for	1261	1264	O
human	1265	1270	O
urokinase	1271	1280	O
plasminogen	1281	1292	O
activator	1293	1302	O
.	1302	1303	O

The	0	3	O
effect	4	10	O
of	11	13	O
p	14	15	O
-	15	16	O
chlorophenylalanine	16	35	O
on	36	38	O
the	39	42	O
pethidine	43	52	O
-	52	53	O
or	54	56	O
methadone	57	66	O
-	66	67	O
induced	67	74	O
decrease	75	83	O
in	84	86	O
locomotor	87	96	O
activity	97	105	O
of	106	108	O
rats	109	113	O
.	113	114	O

Either	115	121	O
pethidine	122	131	O
HCl	132	135	O
(	136	137	O
50	137	139	O
mg	140	142	O
/	142	143	O
kg	143	145	O
s	146	147	O
.	147	148	O
c	148	149	O
.	149	150	O
)	150	151	O
or	152	154	O
methadone	155	164	O
HCl	165	168	O
(	169	170	O
8	170	171	O
mg	172	174	O
/	174	175	O
kg	175	177	O
s	178	179	O
.	179	180	O
c	180	181	O
.	181	182	O
)	182	183	O
produced	184	192	O
a	193	194	O
prominent	195	204	O
decrease	205	213	O
in	214	216	O
locomotor	217	226	O
activity	227	235	O
of	236	238	O
rats	239	243	O
.	243	244	O

Pretreatment	245	257	O
of	258	260	O
rats	261	265	O
with	266	270	O
p	271	272	O
-	272	273	O
chlorophenylalanine	273	292	O
(	293	294	O
p	294	295	O
-	295	296	O
CPA	296	299	O
,	299	300	O
320	301	304	O
mg	305	307	O
/	307	308	O
kg	308	310	O
i	311	312	O
.	312	313	O
p	313	314	O
.	314	315	O
)	315	316	O
48	317	319	O
h	320	321	O
before	322	328	O
the	329	332	O
narcotic	333	341	O
injection	342	351	O
significantly	352	365	O
antagonized	366	377	O
the	378	381	O
activity	382	390	O
-	390	391	O
decreasing	391	401	O
effects	402	409	O
of	410	412	O
narcotics	413	422	O
.	422	423	O

When	424	428	O
rats	429	433	O
pretreated	434	444	O
with	445	449	O
p	450	451	O
-	451	452	O
CPA	452	455	O
were	456	460	O
given	461	466	O
5	467	468	O
-	468	469	O
hydroxytryptophan	469	486	O
(	487	488	O
75	488	490	O
mg	491	493	O
/	493	494	O
kg	494	496	O
s	497	498	O
.	498	499	O
c	499	500	O
.	500	501	O
)	501	502	O
30	503	505	O
min	506	509	O
before	510	516	O
narcotic	517	525	O
administration	526	540	O
,	540	541	O
the	542	545	O
activity	546	554	O
-	554	555	O
decreasing	555	565	O
response	566	574	O
to	575	577	O
narcotics	578	587	O
was	588	591	O
restored	592	600	O
.	600	601	O

Thus	602	606	O
,	606	607	O
a	608	609	O
decrease	610	618	O
in	619	621	O
locomotor	622	631	O
activity	632	640	O
induced	641	648	O
in	649	651	O
rats	652	656	O
by	657	659	O
either	660	666	O
pethidine	667	676	O
or	677	679	O
methadone	680	689	O
is	690	692	O
probably	693	701	O
mediated	702	710	O
by	711	713	O
serotonergic	714	726	O
mechanisms	727	737	O
.	737	738	O

The	0	3	O
presence	4	12	O
of	13	15	O
nitrite	16	23	O
during	24	30	O
UVA	31	34	O
irradiation	35	46	O
protects	47	55	O
from	56	60	O
apoptosis	61	70	O
.	70	71	O

Nitrite	72	79	O
occurs	80	86	O
ubiquitously	87	99	O
in	100	102	O
biological	103	113	B-Organism_substance
fluids	114	120	I-Organism_substance
such	121	125	O
as	126	128	O
blood	129	134	B-Organism_substance
and	135	138	O
sweat	139	144	B-Organism_substance
,	144	145	O
representing	146	158	O
an	159	161	O
oxidation	162	171	O
product	172	179	O
of	180	182	O
nitric	183	189	O
oxide	190	195	O
.	195	196	O

Nitrite	197	204	O
has	205	208	O
been	209	213	O
associated	214	224	O
with	225	229	O
a	230	231	O
variety	232	239	O
of	240	242	O
adverse	243	250	O
effects	251	258	O
such	259	263	O
as	264	266	O
mutagenicity	267	279	O
,	279	280	O
carcinogenesis	281	295	O
,	295	296	O
and	297	300	O
toxicity	301	309	O
.	309	310	O

In	311	313	O
contrast	314	322	O
,	322	323	O
here	324	328	O
we	329	331	O
demonstrate	332	343	O
that	344	348	O
the	349	352	O
presence	353	361	O
of	362	364	O
nitrite	365	372	O
,	372	373	O
but	374	377	O
not	378	381	O
nitrate	382	389	O
,	389	390	O
during	391	397	O
irradiation	398	409	O
of	410	412	O
endothelial	413	424	B-Cell
cells	425	430	I-Cell
in	431	433	O
culture	434	441	O
exerts	442	448	O
a	449	450	O
potent	451	457	O
and	458	461	O
concentration	462	475	O
-	475	476	O
dependent	476	485	O
protection	486	496	O
against	497	504	O
UVA	505	508	O
-	508	509	O
induced	509	516	O
apoptotic	517	526	O
cell	527	531	B-Cell
death	532	537	O
.	537	538	O

Protection	539	549	O
is	550	552	O
half	553	557	O
-	557	558	O
maximal	558	565	O
at	566	568	O
a	569	570	O
concentration	571	584	O
of	585	587	O
3	588	589	O
mM	590	592	O
,	592	593	O
and	594	597	O
complete	598	606	O
rescue	607	613	O
is	614	616	O
observed	617	625	O
at	626	628	O
10	629	631	O
mM	632	634	O
.	634	635	O

Nitrite	636	643	O
-	643	644	O
mediated	644	652	O
protection	653	663	O
is	664	666	O
mediated	667	675	O
via	676	679	O
inhibition	680	690	O
of	691	693	O
lipid	694	699	O
peroxidation	700	712	O
in	713	715	O
a	716	717	O
similar	718	725	O
manner	726	732	O
as	733	735	O
seen	736	740	O
with	741	745	O
butylated	746	755	O
hydroxytoluene	756	770	O
,	770	771	O
a	772	773	O
known	774	779	O
inhibitor	780	789	O
of	790	792	O
lipid	793	798	O
peroxidation	799	811	O
.	811	812	O

Interestingly	813	826	O
,	826	827	O
nitrite	828	835	O
-	835	836	O
mediated	836	844	O
protection	845	855	O
is	856	858	O
completely	859	869	O
abolished	870	879	O
by	880	882	O
coincubation	883	895	O
with	896	900	O
the	901	904	O
NO	905	907	O
scavenger	908	917	O
cPTIO	918	923	O
.	923	924	O

Using	925	930	O
electron	931	939	O
paramagnetic	940	952	O
resonance	953	962	O
(	963	964	O
EPR	964	967	O
)	967	968	O
spectroscopy	969	981	O
or	982	984	O
Faraday	985	992	O
modulation	993	1003	O
spectroscopy	1004	1016	O
,	1016	1017	O
we	1018	1020	O
directly	1021	1029	O
prove	1030	1035	O
UVA	1036	1039	O
-	1039	1040	O
induced	1040	1047	O
NO	1048	1050	O
formation	1051	1060	O
in	1061	1063	O
solutions	1064	1073	O
containing	1074	1084	O
nitrite	1085	1092	O
.	1092	1093	O

In	1094	1096	O
conclusion	1097	1107	O
,	1107	1108	O
evidence	1109	1117	O
is	1118	1120	O
presented	1121	1130	O
that	1131	1135	O
nitrite	1136	1143	O
represents	1144	1154	O
a	1155	1156	O
protective	1157	1167	O
agent	1168	1173	O
against	1174	1181	O
UVA	1182	1185	O
-	1185	1186	O
induced	1186	1193	O
apoptosis	1194	1203	O
due	1204	1207	O
to	1208	1210	O
photodecomposition	1211	1229	O
of	1230	1232	O
nitrite	1233	1240	O
and	1241	1244	O
subsequent	1245	1255	O
formation	1256	1265	O
of	1266	1268	O
NO	1269	1271	O
.	1271	1272	O

Induction	0	9	O
of	10	12	O
apoptosis	13	22	O
in	23	25	O
skeletal	26	34	B-Tissue
tissues	35	42	I-Tissue
:	42	43	O
phosphate	44	53	O
-	53	54	O
mediated	54	62	O
chick	63	68	O
chondrocyte	69	80	B-Cell
apoptosis	81	90	O
is	91	93	O
calcium	94	101	O
dependent	102	111	O
.	111	112	O

In	113	115	O
an	116	118	O
earlier	119	126	O
study	127	132	O
,	132	133	O
we	134	136	O
have	137	141	O
shown	142	147	O
that	148	152	O
Pi	153	155	O
induced	156	163	O
apoptosis	164	173	O
of	174	176	O
terminally	177	187	O
differentiated	188	202	O
hypertrophic	203	215	O
chondrocytes	216	228	B-Cell
.	228	229	O

To	230	232	O
ascertain	233	242	O
whether	243	250	O
Ca2	251	254	O
+	254	255	O
modulates	256	265	O
Pi	266	268	O
-	268	269	O
induced	269	276	O
cell	277	281	B-Cell
death	282	287	O
,	287	288	O
we	289	291	O
asked	292	297	O
the	298	301	O
following	302	311	O
two	312	315	O
questions	316	325	O
:	325	326	O
First	327	332	O
,	332	333	O
can	334	337	O
we	338	340	O
prevent	341	348	O
Pi	349	351	O
-	351	352	O
induced	352	359	O
apoptosis	360	369	O
by	370	372	O
removing	373	381	O
Ca2	382	385	O
+	385	386	O
from	387	391	O
the	392	395	O
culture	396	403	O
medium	404	410	O
;	410	411	O
alternatively	412	425	O
,	425	426	O
can	427	430	O
we	431	433	O
potentiate	434	444	O
cell	445	449	B-Cell
death	450	455	O
by	456	458	O
increasing	459	469	O
the	470	473	O
Ca2	474	477	O
+	477	478	O
concentration	479	492	O
?	492	493	O

Second	494	500	O
,	500	501	O
can	502	505	O
we	506	508	O
inhibit	509	516	O
chondrocyte	517	528	B-Cell
apoptosis	529	538	O
by	539	541	O
blocking	542	550	O
Pi	551	553	O
transport	554	563	O
?	563	564	O

We	565	567	O
also	568	572	O
explored	573	581	O
the	582	585	O
mechanism	586	595	O
of	596	598	O
apoptosis	599	608	O
by	609	611	O
evaluating	612	622	O
mitochondrial	623	636	B-Cellular_component
activity	637	645	O
and	646	649	O
reactive	650	658	O
oxygen	659	665	O
species	666	673	O
(	674	675	O
ROS	675	678	O
)	678	679	O
generation	680	690	O
in	691	693	O
cells	694	699	B-Cell
treated	700	707	O
with	708	712	O
the	713	716	O
ion	717	720	O
pair	721	725	O
.	725	726	O

We	727	729	O
noted	730	735	O
that	736	740	O
EDTA	741	745	O
and	746	749	O
EGTA	750	754	O
blocked	755	762	O
Pi	763	765	O
-	765	766	O
induced	766	773	O
apoptosis	774	783	O
in	784	786	O
a	787	788	O
dose	789	793	O
-	793	794	O
dependent	794	803	O
manner	804	810	O
.	810	811	O

While	812	817	O
high	818	822	O
levels	823	829	O
of	830	832	O
Ca2	833	836	O
+	836	837	O
alone	838	843	O
had	844	847	O
little	848	854	O
effect	855	861	O
on	862	864	O
chondrocyte	865	876	B-Cell
viability	877	886	O
,	886	887	O
the	888	891	O
cation	892	898	O
enhanced	899	907	O
Pi	908	910	O
-	910	911	O
dependent	911	920	O
cell	921	925	B-Cell
death	926	931	O
and	932	935	O
greatly	936	943	O
increased	944	953	O
Pi	954	956	O
uptake	957	963	O
.	963	964	O

When	965	969	O
Pi	970	972	O
transport	973	982	O
was	983	986	O
blocked	987	994	O
,	994	995	O
there	996	1001	O
was	1002	1005	O
complete	1006	1014	O
inhibition	1015	1025	O
of	1026	1028	O
cell	1029	1033	B-Cell
killing	1034	1041	O
.	1041	1042	O

The	1043	1046	O
process	1047	1054	O
of	1055	1057	O
cell	1058	1062	B-Cell
death	1063	1068	O
was	1069	1072	O
characterized	1073	1086	O
by	1087	1089	O
mitochondrial	1090	1103	B-Cellular_component
hyperpolarization	1104	1121	O
;	1121	1122	O
two	1123	1126	O
hours	1127	1132	O
following	1133	1142	O
apoptogen	1143	1152	O
treatment	1153	1162	O
,	1162	1163	O
there	1164	1169	O
was	1170	1173	O
a	1174	1175	O
significant	1176	1187	O
decrease	1188	1196	O
in	1197	1199	O
the	1200	1203	O
mitochondrial	1204	1217	B-Cellular_component
membrane	1218	1226	I-Cellular_component
potential	1227	1236	O
.	1236	1237	O

Coincident	1238	1248	O
with	1249	1253	O
the	1254	1257	O
changes	1258	1265	O
in	1266	1268	O
mitochondrial	1269	1282	B-Cellular_component
function	1283	1291	O
,	1291	1292	O
there	1293	1298	O
was	1299	1302	O
an	1303	1305	O
increase	1306	1314	O
in	1315	1317	O
intracellular	1318	1331	B-Immaterial_anatomical_entity
Ca2	1332	1335	O
+	1335	1336	O
that	1337	1341	O
was	1342	1345	O
maintained	1346	1356	O
throughout	1357	1367	O
the	1368	1371	O
experimental	1372	1384	O
period	1385	1391	O
.	1391	1392	O

A	1393	1394	O
raised	1395	1401	O
Ca2	1402	1405	O
+	1405	1406	O
signal	1407	1413	O
was	1414	1417	O
observed	1418	1426	O
in	1427	1429	O
blebs	1430	1435	O
at	1436	1438	O
the	1439	1442	O
cell	1443	1447	B-Cellular_component
membrane	1448	1456	I-Cellular_component
.	1456	1457	O

Finally	1458	1465	O
,	1465	1466	O
we	1467	1469	O
noted	1470	1475	O
that	1476	1480	O
,	1480	1481	O
75	1482	1484	O
minutes	1485	1492	O
after	1493	1498	O
treatment	1499	1508	O
with	1509	1513	O
the	1514	1517	O
ion	1518	1521	O
pair	1522	1526	O
,	1526	1527	O
there	1528	1533	O
was	1534	1537	O
a	1538	1539	O
six	1540	1543	O
-	1543	1544	O
fold	1544	1548	O
elevation	1549	1558	O
in	1559	1561	O
ROS	1562	1565	O
levels	1566	1572	O
.	1572	1573	O

This	1574	1578	O
increase	1579	1587	O
declined	1588	1596	O
to	1597	1599	O
baseline	1600	1608	O
values	1609	1615	O
after	1616	1621	O
three	1622	1627	O
hours	1628	1633	O
.	1633	1634	O

Based	1635	1640	O
on	1641	1643	O
these	1644	1649	O
observations	1650	1662	O
,	1662	1663	O
we	1664	1666	O
suggest	1667	1674	O
that	1675	1679	O
,	1679	1680	O
at	1681	1683	O
the	1684	1687	O
cartilage	1688	1697	B-Tissue
mineralization	1698	1712	O
front	1713	1718	O
,	1718	1719	O
an	1720	1722	O
elevation	1723	1732	O
in	1733	1735	O
local	1736	1741	O
environmental	1742	1755	O
Ca2	1756	1759	O
+	1759	1760	O
and	1761	1764	O
Pi	1765	1767	O
concentrations	1768	1782	O
modulates	1783	1792	O
oxidative	1793	1802	O
metabolism	1803	1813	O
,	1813	1814	O
and	1815	1818	O
triggers	1819	1827	O
apoptosis	1828	1837	O
of	1838	1840	O
terminally	1841	1851	O
differentiated	1852	1866	O
chondrocytes	1867	1879	B-Cell
.	1879	1880	O

Outcomes	0	8	O
of	9	11	O
cefazolin	12	21	O
versus	22	28	O
ceftriaxone	29	40	O
therapy	41	48	O
in	49	51	O
treating	52	60	O
lower	61	66	B-Multi-tissue_structure
respiratory	67	78	I-Multi-tissue_structure
tract	79	84	I-Multi-tissue_structure
infections	85	95	O
in	96	98	O
adults	99	105	O
.	105	106	O

OBJECTIVE	107	116	O
:	116	117	O

To	118	120	O
determine	121	130	O
whether	131	138	O
choice	139	145	O
of	146	148	O
a	149	150	O
first	151	156	O
-	156	157	O
versus	158	164	O
third	165	170	O
-	170	171	O
generation	171	181	O
cephalosporin	182	195	O
as	196	198	O
initial	199	206	O
therapy	207	214	O
for	215	218	O
lower	219	224	B-Multi-tissue_structure
respiratory	225	236	I-Multi-tissue_structure
tract	237	242	I-Multi-tissue_structure
infections	243	253	O
in	254	256	O
hospitalized	257	269	O
adults	270	276	O
affects	277	284	O
the	285	288	O
course	289	295	O
and	296	299	O
duration	300	308	O
of	309	311	O
care	312	316	O
,	316	317	O
both	318	322	O
of	323	325	O
which	326	331	O
may	332	335	O
influence	336	345	O
antimicrobial	346	359	O
treatment	360	369	O
cost	370	374	O
.	374	375	O

DESIGN	376	382	O
:	382	383	O

Retrospective	384	397	O
analysis	398	406	O
of	407	409	O
discharge	410	419	O
abstracts	420	429	O
and	430	433	O
hospital	434	442	O
pharmacy	443	451	O
records	452	459	O
.	459	460	O

SETTING	461	468	O
:	468	469	O

Forty	470	475	O
-	475	476	O
eight	476	481	O
US	482	484	O
acute	485	490	O
-	490	491	O
care	491	495	O
hospitals	496	505	O
.	505	506	O

PATIENTS	507	515	O
:	515	516	O

One	517	520	O
thousand	521	529	O
ninety	530	536	O
-	536	537	O
two	537	540	O
hospitalized	541	553	O
adults	554	560	O
(	561	562	O
aged	562	566	O
>	567	568	O
17	569	571	O
y	572	573	O
)	573	574	O
with	575	579	O
principal	580	589	O
diagnoses	590	599	O
of	600	602	O
lower	603	608	B-Multi-tissue_structure
respiratory	609	620	I-Multi-tissue_structure
tract	621	626	I-Multi-tissue_structure
infections	627	637	O
(	638	639	O
DRGs	639	643	O
79	644	646	O
-	646	647	O
80	647	649	O
,	649	650	O
89	651	653	O
-	653	654	O
90	654	656	O
)	656	657	O
.	657	658	O

INTERVENTIONS	659	672	O
:	672	673	O

Cefazolin	674	683	O
or	684	686	O
ceftriaxone	687	698	O
,	698	699	O
given	700	705	O
as	706	708	O
sole	709	713	O
antimicrobial	714	727	O
therapy	728	735	O
for	736	739	O
at	740	742	O
least	743	748	O
one	749	752	O
day	753	756	O
.	756	757	O

MAIN	758	762	O
OUTCOME	763	770	O
MEASURES	771	779	O
:	779	780	O

(	781	782	O
1	782	783	O
)	783	784	O
The	785	788	O
number	789	795	O
of	796	798	O
patients	799	807	O
who	808	811	O
received	812	820	O
another	821	828	O
parenteral	829	839	O
antibiotic	840	850	O
anytime	851	858	O
prior	859	864	O
to	865	867	O
hospital	868	876	O
discharge	877	886	O
;	886	887	O
(	888	889	O
2	889	890	O
)	890	891	O
the	892	895	O
number	896	902	O
of	903	905	O
days	906	910	O
during	911	917	O
which	918	923	O
patients	924	932	O
received	933	941	O
any	942	945	O
parenteral	946	956	O
antibiotic	957	967	O
while	968	973	O
in	974	976	O
the	977	980	O
hospital	981	989	O
;	989	990	O
and	991	994	O
(	995	996	O
3	996	997	O
)	997	998	O
the	999	1002	O
number	1003	1009	O
of	1010	1012	O
days	1013	1017	O
patients	1018	1026	O
remained	1027	1035	O
hospitalized	1036	1048	O
following	1049	1058	O
the	1059	1062	O
start	1063	1068	O
of	1069	1071	O
antibiotic	1072	1082	O
therapy	1083	1090	O
.	1090	1091	O

RESULTS	1092	1099	O
:	1099	1100	O

Patients	1101	1109	O
treated	1110	1117	O
with	1118	1122	O
cefazolin	1123	1132	O
(	1133	1134	O
n	1134	1135	O
=	1136	1137	O
763	1138	1141	O
)	1141	1142	O
were	1143	1147	O
more	1148	1152	O
likely	1153	1159	O
to	1160	1162	O
receive	1163	1170	O
another	1171	1178	O
parenteral	1179	1189	O
antibiotic	1190	1200	O
while	1201	1206	O
in	1207	1209	O
the	1210	1213	O
hospital	1214	1222	O
(	1223	1224	O
30	1224	1226	O
.	1226	1227	O
3	1227	1228	O
vs	1229	1231	O
.	1231	1232	O
20	1233	1235	O
.	1235	1236	O
7	1236	1237	O
percent	1238	1245	O
;	1245	1246	O
p	1247	1248	O
<	1249	1250	O
0	1251	1252	O
.	1252	1253	O
001	1253	1256	O
)	1256	1257	O
and	1258	1261	O
received	1262	1270	O
more	1271	1275	O
total	1276	1281	O
days	1282	1286	O
of	1287	1289	O
therapy	1290	1297	O
(	1298	1299	O
7	1299	1300	O
.	1300	1301	O
2	1301	1302	O
vs	1303	1305	O
.	1305	1306	O
6	1307	1308	O
.	1308	1309	O
7	1309	1310	O
d	1311	1312	O
;	1312	1313	O
p	1314	1315	O
<	1316	1317	O
0	1318	1319	O
.	1319	1320	O
05	1320	1322	O
)	1322	1323	O
than	1324	1328	O
those	1329	1334	O
treated	1335	1342	O
with	1343	1347	O
ceftriaxone	1348	1359	O
(	1360	1361	O
n	1361	1362	O
=	1363	1364	O
329	1365	1368	O
)	1368	1369	O
.	1369	1370	O

Although	1371	1379	O
the	1380	1383	O
time	1384	1388	O
to	1389	1391	O
hospital	1392	1400	O
discharge	1401	1410	O
did	1411	1414	O
not	1415	1418	O
differ	1419	1425	O
in	1426	1428	O
the	1429	1432	O
full	1433	1437	O
sample	1438	1444	O
(	1445	1446	O
9	1446	1447	O
.	1447	1448	O
2	1448	1449	O
d	1450	1451	O
for	1452	1455	O
both	1456	1460	O
groups	1461	1467	O
)	1467	1468	O
,	1468	1469	O
it	1470	1472	O
was	1473	1476	O
greater	1477	1484	O
among	1485	1490	O
those	1491	1496	O
receiving	1497	1506	O
cefazolin	1507	1516	O
(	1517	1518	O
8	1518	1519	O
.	1519	1520	O
6	1520	1521	O
vs	1522	1524	O
.	1524	1525	O
8	1526	1527	O
.	1527	1528	O
0	1528	1529	O
d	1530	1531	O
;	1531	1532	O
p	1533	1534	O
<	1535	1536	O
0	1537	1538	O
.	1538	1539	O
05	1539	1541	O
)	1541	1542	O
when	1543	1547	O
patients	1548	1556	O
with	1557	1561	O
lengths	1562	1569	O
of	1570	1572	O
stay	1573	1577	O
exceeding	1578	1587	O
24	1588	1590	O
days	1591	1595	O
were	1596	1600	O
excluded	1601	1609	O
from	1610	1614	O
both	1615	1619	O
groups	1620	1626	O
.	1626	1627	O

CONCLUSIONS	1628	1639	O
:	1639	1640	O

In	1641	1643	O
addition	1644	1652	O
to	1653	1655	O
acquisition	1656	1667	O
cost	1668	1672	O
,	1672	1673	O
differences	1674	1685	O
in	1686	1688	O
course	1689	1695	O
and	1696	1699	O
duration	1700	1708	O
of	1709	1711	O
care	1712	1716	O
should	1717	1723	O
be	1724	1726	O
considered	1727	1737	O
when	1738	1742	O
determining	1743	1754	O
the	1755	1758	O
most	1759	1763	O
cost	1764	1768	O
-	1768	1769	O
effective	1769	1778	O
choice	1779	1785	O
for	1786	1789	O
antimicrobial	1790	1803	O
therapy	1804	1811	O
.	1811	1812	O

Is	0	2	O
there	3	8	O
an	9	11	O
upper	12	17	O
limit	18	23	O
of	24	26	O
intracranial	27	39	B-Immaterial_anatomical_entity
pressure	40	48	O
in	49	51	O
patients	52	60	O
with	61	65	O
severe	66	72	O
head	73	77	B-Organism_subdivision
injury	78	84	O
if	85	87	O
cerebral	88	96	B-Organ
perfusion	97	106	O
pressure	107	115	O
is	116	118	O
maintained	119	129	O
?	129	130	O

Authors	131	138	O
of	139	141	O
recent	142	148	O
studies	149	156	O
have	157	161	O
championed	162	172	O
the	173	176	O
importance	177	187	O
of	188	190	O
maintaining	191	202	O
cerebral	203	211	B-Organ
perfusion	212	221	O
pressure	222	230	O
(	231	232	O
CPP	232	235	O
)	235	236	O
to	237	239	O
prevent	240	247	O
secondary	248	257	O
brain	258	263	B-Organ
injury	264	270	O
following	271	280	O
traumatic	281	290	O
head	291	295	B-Organism_subdivision
injury	296	302	O
.	302	303	O

Data	304	308	O
from	309	313	O
these	314	319	O
studies	320	327	O
have	328	332	O
provided	333	341	O
little	342	348	O
information	349	360	O
regarding	361	370	O
outcome	371	378	O
following	379	388	O
severe	389	395	O
head	396	400	B-Organism_subdivision
injury	401	407	O
in	408	410	O
patients	411	419	O
with	420	424	O
an	425	427	O
intracranial	428	440	B-Immaterial_anatomical_entity
pressure	441	449	O
(	450	451	O
ICP	451	454	O
)	454	455	O
greater	456	463	O
than	464	468	O
40	469	471	O
mm	472	474	O
Hg	475	477	O
,	477	478	O
however	479	486	O
,	486	487	O
in	488	490	O
July	491	495	O
1997	496	500	O
the	501	504	O
authors	505	512	O
instituted	513	523	O
a	524	525	O
protocol	526	534	O
for	535	538	O
the	539	542	O
management	543	553	O
of	554	556	O
severe	557	563	O
head	564	568	B-Organism_subdivision
injury	569	575	O
in	576	578	O
patients	579	587	O
with	588	592	O
a	593	594	O
Glasgow	595	602	O
Coma	603	607	O
Scale	608	613	O
score	614	619	O
lower	620	625	O
than	626	630	O
9	631	632	O
.	632	633	O

The	634	637	O
protocol	638	646	O
was	647	650	O
focused	651	658	O
on	659	661	O
resuscitation	662	675	O
from	676	680	O
acidosis	681	689	O
,	689	690	O
maintenance	691	702	O
of	703	705	O
a	706	707	O
CPP	708	711	O
greater	712	719	O
than	720	724	O
60	725	727	O
mm	728	730	O
Hg	731	733	O
through	734	741	O
whatever	742	750	O
means	751	756	O
necessary	757	766	O
as	767	769	O
well	770	774	O
as	775	777	O
elevation	778	787	O
of	788	790	O
the	791	794	O
head	795	799	O
of	800	802	O
the	803	806	O
bed	807	810	O
,	810	811	O
mannitol	812	820	O
infusion	821	829	O
,	829	830	O
and	831	834	O
ventriculostomy	835	850	O
with	851	855	O
cerebrospinal	856	869	B-Organism_substance
fluid	870	875	I-Organism_substance
drainage	876	884	O
for	885	888	O
control	889	896	O
of	897	899	O
ICP	900	903	O
.	903	904	O

Since	905	910	O
the	911	914	O
institution	915	926	O
of	927	929	O
this	930	934	O
protocol	935	943	O
,	943	944	O
nine	945	949	O
patients	950	958	O
had	959	962	O
a	963	964	O
sustained	965	974	O
ICP	975	978	O
greater	979	986	O
than	987	991	O
40	992	994	O
mm	995	997	O
Hg	998	1000	O
for	1001	1004	O
2	1005	1006	O
or	1007	1009	O
more	1010	1014	O
hours	1015	1020	O
,	1020	1021	O
and	1022	1025	O
five	1026	1030	O
of	1031	1033	O
these	1034	1039	O
had	1040	1043	O
an	1044	1046	O
ICP	1047	1050	O
greater	1051	1058	O
than	1059	1063	O
75	1064	1066	O
mm	1067	1069	O
Hg	1070	1072	O
on	1073	1075	O
insertion	1076	1085	O
of	1086	1088	O
the	1089	1092	O
ICP	1093	1096	O
monitor	1097	1104	O
and	1105	1108	O
later	1109	1114	O
experienced	1115	1126	O
herniation	1127	1137	O
and	1138	1141	O
expired	1142	1149	O
within	1150	1156	O
24	1157	1159	O
hours	1160	1165	O
.	1165	1166	O

Because	1167	1174	O
of	1175	1177	O
the	1178	1181	O
severe	1182	1188	O
nature	1189	1195	O
of	1196	1198	O
the	1199	1202	O
injuries	1203	1211	O
demonstrated	1212	1224	O
on	1225	1227	O
computerized	1228	1240	O
tomography	1241	1251	O
scans	1252	1257	O
and	1258	1261	O
their	1262	1267	O
physical	1268	1276	O
examinations	1277	1289	O
,	1289	1290	O
these	1291	1296	O
patients	1297	1305	O
were	1306	1310	O
not	1311	1314	O
aggressively	1315	1327	O
treated	1328	1335	O
under	1336	1341	O
this	1342	1346	O
protocol	1347	1355	O
.	1355	1356	O

The	1357	1360	O
authors	1361	1368	O
vigorously	1369	1379	O
attempted	1380	1389	O
to	1390	1392	O
maintain	1393	1401	O
a	1402	1403	O
CPP	1404	1407	O
greater	1408	1415	O
than	1416	1420	O
60	1421	1423	O
mm	1424	1426	O
Hg	1427	1429	O
with	1430	1434	O
intensive	1435	1444	O
fluid	1445	1450	B-Organism_substance
resuscitation	1451	1464	O
and	1465	1468	O
the	1469	1472	O
administration	1473	1487	O
of	1488	1490	O
pressor	1491	1498	O
agents	1499	1505	O
in	1506	1508	O
the	1509	1512	O
four	1513	1517	O
remaining	1518	1527	O
patients	1528	1536	O
who	1537	1540	O
had	1541	1544	O
developed	1545	1554	O
an	1555	1557	O
ICP	1558	1561	O
higher	1562	1568	O
than	1569	1573	O
40	1574	1576	O
mm	1577	1579	O
Hg	1580	1582	O
after	1583	1588	O
placement	1589	1598	O
of	1599	1601	O
the	1602	1605	O
ICP	1606	1609	O
monitor	1610	1617	O
.	1617	1618	O

Two	1619	1622	O
patients	1623	1631	O
had	1632	1635	O
an	1636	1638	O
episodic	1639	1647	O
ICP	1648	1651	O
greater	1652	1659	O
than	1660	1664	O
40	1665	1667	O
mm	1668	1670	O
Hg	1671	1673	O
for	1674	1677	O
more	1678	1682	O
than	1683	1687	O
36	1688	1690	O
hours	1691	1696	O
,	1696	1697	O
the	1698	1701	O
third	1702	1707	O
patient	1708	1715	O
had	1716	1719	O
an	1720	1722	O
episodic	1723	1731	O
ICP	1732	1735	O
greater	1736	1743	O
than	1744	1748	O
of	1749	1751	O
50	1752	1754	O
mm	1755	1757	O
Hg	1758	1760	O
for	1761	1764	O
more	1765	1769	O
than	1770	1774	O
36	1775	1777	O
hours	1778	1783	O
,	1783	1784	O
and	1785	1788	O
the	1789	1792	O
fourth	1793	1799	O
patient	1800	1807	O
had	1808	1811	O
an	1812	1814	O
episodic	1815	1823	O
ICP	1824	1827	O
greater	1828	1835	O
than	1836	1840	O
50	1841	1843	O
mm	1844	1846	O
Hg	1847	1849	O
for	1850	1853	O
more	1854	1858	O
than	1859	1863	O
48	1864	1866	O
hours	1867	1872	O
.	1872	1873	O

On	1874	1876	O
discharge	1877	1886	O
,	1886	1887	O
all	1888	1891	O
four	1892	1896	O
patients	1897	1905	O
were	1906	1910	O
able	1911	1915	O
to	1916	1918	O
perform	1919	1926	O
normal	1927	1933	O
activities	1934	1944	O
of	1945	1947	O
daily	1948	1953	O
living	1954	1960	O
with	1961	1965	O
minimal	1966	1973	O
assistance	1974	1984	O
and	1985	1988	O
experience	1989	1999	O
ongoing	2000	2007	O
improvement	2008	2019	O
.	2019	2020	O

Data	2021	2025	O
from	2026	2030	O
this	2031	2035	O
preliminary	2036	2047	O
study	2048	2053	O
indicate	2054	2062	O
that	2063	2067	O
intense	2068	2075	O
,	2075	2076	O
aggressive	2077	2087	O
management	2088	2098	O
of	2099	2101	O
CPP	2102	2105	O
can	2106	2109	O
lead	2110	2114	O
to	2115	2117	O
good	2118	2122	O
neurological	2123	2135	B-Anatomical_system
outcomes	2136	2144	O
despite	2145	2152	O
extremely	2153	2162	O
high	2163	2167	O
ICP	2168	2171	O
.	2171	2172	O

Aggressive	2173	2183	O
CPP	2184	2187	O
therapy	2188	2195	O
should	2196	2202	O
be	2203	2205	O
performed	2206	2215	O
and	2216	2219	O
maintained	2220	2230	O
even	2231	2235	O
though	2236	2242	O
apparently	2243	2253	O
lethal	2254	2260	O
ICP	2261	2264	O
levels	2265	2271	O
may	2272	2275	O
be	2276	2278	O
present	2279	2286	O
.	2286	2287	O

Further	2288	2295	O
study	2296	2301	O
is	2302	2304	O
needed	2305	2311	O
to	2312	2314	O
support	2315	2322	O
these	2323	2328	O
encouraging	2329	2340	O
results	2341	2348	O
.	2348	2349	O

Newly	0	5	O
recognized	6	16	O
syndrome	17	25	O
with	26	30	O
heminasal	31	40	O
aplasia	41	48	O
and	49	52	O
ocular	53	59	B-Organ
anomalies	60	69	O
or	70	72	O
wider	73	78	O
spectrum	79	87	O
of	88	90	O
heminasal	91	100	O
aplasia	101	108	O
/	108	109	O
atypical	109	117	O
clefting	118	126	O
syndrome	127	135	O
?	135	136	O

We	137	139	O
report	140	146	O
on	147	149	O
five	150	154	O
unrelated	155	164	O
Brazilian	165	174	O
patients	175	183	O
with	184	188	O
heminasal	189	198	O
aplasia	199	206	O
associated	207	217	O
with	218	222	O
diverses	223	231	O
anomalies	232	241	O
,	241	242	O
including	243	252	O
lateral	253	260	O
proboscis	261	270	O
,	270	271	O
and	272	275	O
anomalies	276	285	O
of	286	288	O
the	289	292	O
eye	293	296	B-Organ
and	297	300	O
first	301	306	O
branchial	307	316	B-Multi-tissue_structure
arch	317	321	I-Multi-tissue_structure
.	321	322	O

We	323	325	O
suggest	326	333	O
that	334	338	O
these	339	344	O
patients	345	353	O
represent	354	363	O
different	364	373	O
conditions	374	384	O
within	385	391	O
the	392	395	O
spectrum	396	404	O
of	405	407	O
the	408	411	O
heminasal	412	421	O
aplasia	422	429	O
malformation	430	442	O
.	442	443	O

Clinical	444	452	O
,	452	453	O
genetic	454	461	O
,	461	462	O
and	463	466	O
differential	467	479	O
diagnosis	480	489	O
are	490	493	O
discussed	494	503	O
.	503	504	O

Neurologic	0	10	O
diagnosis	11	20	O
and	21	24	O
treatment	25	34	O
in	35	37	O
patients	38	46	O
with	47	51	O
computed	52	60	O
tomography	61	71	O
and	72	75	O
nasal	76	81	B-Organism_subdivision
endoscopy	82	91	O
negative	92	100	O
facial	101	107	B-Organism_subdivision
pain	108	112	O
.	112	113	O

OBJECTIVE	114	123	O
:	123	124	O

To	125	127	O
determine	128	137	O
the	138	141	O
helpfulness	142	153	O
of	154	156	O
specialist	157	167	O
neurology	168	177	O
referral	178	186	O
for	187	190	O
patients	191	199	O
with	200	204	O
facial	205	211	B-Organism_subdivision
pain	212	216	O
,	216	217	O
a	218	219	O
normal	220	226	O
sinus	227	232	B-Immaterial_anatomical_entity
computed	233	241	O
tomography	242	252	O
(	253	254	O
CT	254	256	O
)	256	257	O
scan	258	262	O
,	262	263	O
and	264	267	O
normal	268	274	O
nasal	275	280	B-Organism_subdivision
endoscopy	281	290	O
findings	291	299	O
.	299	300	O

STUDY	301	306	O
DESIGN	307	313	O
:	313	314	O

Prospective	315	326	O
identification	327	341	O
of	342	344	O
patients	345	353	O
and	354	357	O
analysis	358	366	O
of	367	369	O
data	370	374	O
approved	375	383	O
by	384	386	O
the	387	390	O
Institutional	391	404	O
Review	405	411	O
Board	412	417	O
.	417	418	O

METHODS	419	426	O
:	426	427	O

The	428	431	O
data	432	436	O
of	437	439	O
104	440	443	O
consecutive	444	455	O
patients	456	464	O
presenting	465	475	O
with	476	480	O
facial	481	487	B-Organism_subdivision
pain	488	492	O
,	492	493	O
a	494	495	O
normal	496	502	O
sinus	503	508	B-Immaterial_anatomical_entity
CT	509	511	O
scan	512	516	O
,	516	517	O
and	518	521	O
normal	522	528	O
nasal	529	534	B-Organism_subdivision
endoscopy	535	544	O
findings	545	553	O
were	554	558	O
reviewed	559	567	O
.	567	568	O

The	569	572	O
patients	573	581	O
presented	582	591	O
to	592	594	O
a	595	596	O
single	597	603	O
rhinologist	604	615	O
in	616	618	O
a	619	620	O
tertiary	621	629	O
care	630	634	O
institution	635	646	O
.	646	647	O

All	648	651	O
patients	652	660	O
were	661	665	O
referred	666	674	O
for	675	678	O
specialist	679	689	O
neurologic	690	700	O
evaluation	701	711	O
and	712	715	O
potential	716	725	O
treatment	726	735	O
.	735	736	O

Further	737	744	O
information	745	756	O
was	757	760	O
obtained	761	769	O
from	770	774	O
a	775	776	O
patient	777	784	O
survey	785	791	O
.	791	792	O

RESULTS	793	800	O
:	800	801	O

Of	802	804	O
the	805	808	O
104	809	812	O
patients	813	821	O
,	821	822	O
81	823	825	O
were	826	830	O
women	831	836	O
and	837	840	O
23	841	843	O
were	844	848	O
men	849	852	O
.	852	853	O

The	854	857	O
average	858	865	O
age	866	869	O
was	870	873	O
46	874	876	O
years	877	882	O
(	883	884	O
range	884	889	O
,	889	890	O
22	891	893	O
-	893	894	O
85	894	896	O
)	896	897	O
.	897	898	O

Fifty	899	904	O
-	904	905	O
six	905	908	O
had	909	912	O
clear	913	918	O
CT	919	921	O
scans	922	927	O
,	927	928	O
48	929	931	O
had	932	935	O
minimal	936	943	O
change	944	950	O
,	950	951	O
and	952	955	O
all	956	959	O
had	960	963	O
negative	964	972	O
endoscopies	973	984	O
.	984	985	O

Twenty	986	992	O
-	992	993	O
nine	993	997	O
had	998	1001	O
previous	1002	1010	O
unsuccessful	1011	1023	O
sinus	1024	1029	B-Immaterial_anatomical_entity
surgery	1030	1037	O
.	1037	1038	O

The	1039	1042	O
average	1043	1050	O
follow	1051	1057	O
-	1057	1058	O
up	1058	1060	O
period	1061	1067	O
was	1068	1071	O
10	1072	1074	O
.	1074	1075	O
5	1075	1076	O
months	1077	1083	O
.	1083	1084	O

Forty	1085	1090	O
of	1091	1093	O
75	1094	1096	O
patients	1097	1105	O
seeing	1106	1112	O
a	1113	1114	O
neurologist	1115	1126	O
were	1127	1131	O
seen	1132	1136	O
on	1137	1139	O
multiple	1140	1148	O
occasions	1149	1158	O
.	1158	1159	O

Four	1160	1164	O
percent	1165	1172	O
of	1173	1175	O
patients	1176	1184	O
seen	1185	1189	O
by	1190	1192	O
a	1193	1194	O
neurologist	1195	1206	O
had	1207	1210	O
an	1211	1213	O
unsuspected	1214	1225	O
serious	1226	1233	O
intracranial	1234	1246	B-Immaterial_anatomical_entity
diagnosis	1247	1256	O
.	1256	1257	O

The	1258	1261	O
most	1262	1266	O
common	1267	1273	O
diagnoses	1274	1283	O
were	1284	1288	O
migraine	1289	1297	O
(	1298	1299	O
37	1299	1301	O
%	1301	1302	O
)	1302	1303	O
,	1303	1304	O
rebound	1305	1312	O
headache	1313	1321	O
(	1322	1323	O
17	1323	1325	O
%	1325	1326	O
)	1326	1327	O
,	1327	1328	O
chronic	1329	1336	O
daily	1337	1342	O
headache	1343	1351	O
(	1352	1353	O
17	1353	1355	O
%	1355	1356	O
)	1356	1357	O
,	1357	1358	O
and	1359	1362	O
obstructive	1363	1374	O
sleep	1375	1380	O
apnea	1381	1386	O
(	1387	1388	O
16	1388	1390	O
%	1390	1391	O
)	1391	1392	O
.	1392	1393	O

Overall	1394	1401	O
,	1401	1402	O
58	1403	1405	O
%	1405	1406	O
improved	1407	1415	O
on	1416	1418	O
medical	1419	1426	O
therapy	1427	1434	O
;	1434	1435	O
60	1436	1438	O
%	1438	1439	O
of	1440	1442	O
those	1443	1448	O
with	1449	1453	O
a	1454	1455	O
clear	1456	1461	O
CT	1462	1464	O
scan	1465	1469	O
improved	1470	1478	O
,	1478	1479	O
and	1480	1483	O
53	1484	1486	O
%	1486	1487	O
of	1488	1490	O
those	1491	1496	O
with	1497	1501	O
minimal	1502	1509	O
change	1510	1516	O
on	1517	1519	O
CT	1520	1522	O
scan	1523	1527	O
improved	1528	1536	O
(	1537	1538	O
P	1538	1539	O
=	1540	1541	O
.	1542	1543	O
749	1543	1546	O
)	1546	1547	O
.	1547	1548	O

CONCLUSIONS	1549	1560	O
:	1560	1561	O

Facial	1562	1568	B-Organism_subdivision
pain	1569	1573	O
remains	1574	1581	O
a	1582	1583	O
difficult	1584	1593	O
symptom	1594	1601	O
to	1602	1604	O
diagnose	1605	1613	O
and	1614	1617	O
treat	1618	1623	O
in	1624	1626	O
rhinologic	1627	1637	O
practice	1638	1646	O
.	1646	1647	O

Patients	1648	1656	O
often	1657	1662	O
undergo	1663	1670	O
surgery	1671	1678	O
without	1679	1686	O
help	1687	1691	O
.	1691	1692	O

Most	1693	1697	O
patients	1698	1706	O
with	1707	1711	O
facial	1712	1718	B-Organism_subdivision
pain	1719	1723	O
,	1723	1724	O
a	1725	1726	O
normal	1727	1733	O
sinus	1734	1739	B-Immaterial_anatomical_entity
CT	1740	1742	O
scan	1743	1747	O
,	1747	1748	O
and	1749	1752	O
normal	1753	1759	O
endoscopy	1760	1769	O
findings	1770	1778	O
benefit	1779	1786	O
from	1787	1791	O
neurologic	1792	1802	O
consultation	1803	1815	O
.	1815	1816	O

Serious	1817	1824	O
intracranial	1825	1837	B-Immaterial_anatomical_entity
pathologic	1838	1848	O
conditions	1849	1859	O
can	1860	1863	O
be	1864	1866	O
excluded	1867	1875	O
and	1876	1879	O
diagnosis	1880	1889	O
-	1889	1890	O
specific	1890	1898	O
pharmacogenetic	1899	1914	O
therapy	1915	1922	O
instituted	1923	1933	O
with	1934	1938	O
improvement	1939	1950	O
in	1951	1953	O
more	1954	1958	O
than	1959	1963	O
50	1964	1966	O
%	1966	1967	O
.	1967	1968	O

TBX21	0	5	O
:	5	6	O
a	7	8	O
functional	9	19	O
variant	20	27	O
predicts	28	36	O
improvement	37	48	O
in	49	51	O
asthma	52	58	O
with	59	63	O
the	64	67	O
use	68	71	O
of	72	74	O
inhaled	75	82	O
corticosteroids	83	98	O
.	98	99	O

TBX21	100	105	O
encodes	106	113	O
for	114	117	O
the	118	121	O
transcription	122	135	O
factor	136	142	O
T	143	144	O
-	144	145	O
bet	145	148	O
(	149	150	O
T	150	151	O
-	151	152	O
box	152	155	O
expressed	156	165	O
in	166	168	O
T	169	170	B-Cell
cells	171	176	I-Cell
)	176	177	O
,	177	178	O
which	179	184	O
influences	185	195	O
naive	196	201	O
T	202	203	B-Cell
lymphocyte	204	214	I-Cell
development	215	226	O
and	227	230	O
has	231	234	O
been	235	239	O
implicated	240	250	O
in	251	253	O
asthma	254	260	O
pathogenesis	261	273	O
.	273	274	O

Specifically	275	287	O
,	287	288	O
the	289	292	O
T	293	294	O
-	294	295	O
bet	295	298	O
knockout	299	307	O
mouse	308	313	O
spontaneously	314	327	O
develops	328	336	O
airway	337	343	B-Multi-tissue_structure
hyperresponsiveness	344	363	O
and	364	367	O
other	368	373	O
changes	374	381	O
consistent	382	392	O
with	393	397	O
asthma	398	404	O
.	404	405	O

Because	406	413	O
airway	414	420	B-Multi-tissue_structure
responsiveness	421	435	O
is	436	438	O
moderated	439	448	O
by	449	451	O
the	452	455	O
use	456	459	O
of	460	462	O
inhaled	463	470	O
corticosteroids	471	486	O
in	487	489	O
asthma	490	496	O
,	496	497	O
it	498	500	O
is	501	503	O
conceivable	504	515	O
that	516	520	O
genetic	521	528	O
variation	529	538	O
in	539	541	O
TBX21	542	547	O
may	548	551	O
alter	552	557	O
asthma	558	564	O
phenotypes	565	575	O
in	576	578	O
a	579	580	O
treatment	581	590	O
-	590	591	O
specific	591	599	O
fashion	600	607	O
.	607	608	O

Here	609	613	O
we	614	616	O
demonstrate	617	628	O
that	629	633	O
the	634	637	O
nonsynonymous	638	651	O
variation	652	661	O
in	662	664	O
TBX21	665	670	O
coding	671	677	O
for	678	681	O
replacement	682	693	O
of	694	696	O
histidine	697	706	O
33	707	709	O
with	710	714	O
glutamine	715	724	O
is	725	727	O
associated	728	738	O
with	739	743	O
significant	744	755	O
improvement	756	767	O
in	768	770	O
the	771	774	O
PC	775	777	O
(	777	778	O
20	778	780	O
)	780	781	O
(	782	783	O
a	783	784	O
measure	785	792	O
of	793	795	O
airway	796	802	B-Multi-tissue_structure
responsiveness	803	817	O
)	817	818	O
of	819	821	O
asthmatic	822	831	O
children	832	840	O
in	841	843	O
a	844	845	O
large	846	851	O
clinical	852	860	O
trial	861	866	O
spanning	867	875	O
4	876	877	O
years	878	883	O
.	883	884	O

We	885	887	O
note	888	892	O
that	893	897	O
this	898	902	O
increase	903	911	O
occurs	912	918	O
only	919	923	O
in	924	926	O
the	927	930	O
children	931	939	O
randomized	940	950	O
to	951	953	O
inhaled	954	961	O
corticosteroids	962	977	O
and	978	981	O
that	982	986	O
it	987	989	O
dramatically	990	1002	O
enhances	1003	1011	O
the	1012	1015	O
overall	1016	1023	O
improvement	1024	1035	O
in	1036	1038	O
PC	1039	1041	O
(	1041	1042	O
20	1042	1044	O
)	1044	1045	O
associated	1046	1056	O
with	1057	1061	O
inhaled	1062	1069	O
corticosteroid	1070	1084	O
usage	1085	1090	O
.	1090	1091	O

The	1092	1095	O
average	1096	1103	O
PC	1104	1106	O
(	1106	1107	O
20	1107	1109	O
)	1109	1110	O
at	1111	1113	O
trial	1114	1119	O
end	1120	1123	O
for	1124	1127	O
subjects	1128	1136	O
on	1137	1139	O
inhaled	1140	1147	O
corticosteroids	1148	1163	O
possessing	1164	1174	O
a	1175	1176	O
variant	1177	1184	O
allele	1185	1191	O
was	1192	1195	O
in	1196	1198	O
the	1199	1202	O
normal	1203	1209	O
range	1210	1215	O
for	1216	1219	O
nonasthmatics	1220	1233	O
.	1233	1234	O

In	1235	1237	O
cellular	1238	1246	O
models	1247	1253	O
,	1253	1254	O
we	1255	1257	O
show	1258	1262	O
that	1263	1267	O
the	1268	1271	O
TBX21	1272	1277	O
variant	1278	1285	O
increases	1286	1295	O
T	1296	1297	B-Cell
helper	1298	1304	I-Cell
1	1305	1306	I-Cell
and	1307	1310	O
decreases	1311	1320	O
T	1321	1322	B-Cell
helper	1323	1329	I-Cell
2	1330	1331	I-Cell
cytokine	1332	1340	O
expression	1341	1351	O
comparably	1352	1362	O
with	1363	1367	O
wild	1368	1372	O
type	1373	1377	O
.	1377	1378	O

TBX21	1379	1384	O
may	1385	1388	O
thus	1389	1393	O
be	1394	1396	O
an	1397	1399	O
important	1400	1409	O
determinant	1410	1421	O
pharmacogenetic	1422	1437	O
response	1438	1446	O
to	1447	1449	O
the	1450	1453	O
therapy	1454	1461	O
of	1462	1464	O
asthma	1465	1471	O
with	1472	1476	O
inhaled	1477	1484	O
corticosteroids	1485	1500	O
.	1500	1501	O

Sox9	0	4	O
neural	5	11	B-Tissue
crest	12	17	I-Tissue
determinant	18	29	O
gene	30	34	O
controls	35	43	O
patterning	44	54	O
and	55	58	O
closure	59	66	O
of	67	69	O
the	70	73	O
posterior	74	83	B-Multi-tissue_structure
frontal	84	91	I-Multi-tissue_structure
cranial	92	99	I-Multi-tissue_structure
suture	100	106	I-Multi-tissue_structure
.	106	107	O

Cranial	108	115	B-Multi-tissue_structure
suture	116	122	I-Multi-tissue_structure
development	123	134	O
involves	135	143	O
a	144	145	O
complex	146	153	O
interaction	154	165	O
of	166	168	O
genes	169	174	O
and	175	178	O
tissues	179	186	B-Tissue
derived	187	194	O
from	195	199	O
neural	200	206	B-Cell
crest	207	212	I-Cell
cells	213	218	I-Cell
(	219	220	O
NCC	220	223	B-Cell
)	223	224	O
and	225	228	O
paraxial	229	237	B-Multi-tissue_structure
mesoderm	238	246	I-Multi-tissue_structure
.	246	247	O

In	248	250	O
mice	251	255	O
,	255	256	O
the	257	260	O
posterior	261	270	B-Multi-tissue_structure
frontal	271	278	I-Multi-tissue_structure
(	279	280	I-Multi-tissue_structure
PF	280	282	I-Multi-tissue_structure
)	282	283	I-Multi-tissue_structure
suture	284	290	I-Multi-tissue_structure
closes	291	297	O
during	298	304	O
the	305	308	O
first	309	314	O
month	315	320	O
of	321	323	O
life	324	328	O
while	329	334	O
other	335	340	O
sutures	341	348	B-Multi-tissue_structure
remain	349	355	O
patent	356	362	O
throughout	363	373	O
the	374	377	O
life	378	382	O
of	383	385	O
the	386	389	O
animal	390	396	O
.	396	397	O

Given	398	403	O
the	404	407	O
unique	408	414	O
NCC	415	418	B-Cell
origin	419	425	O
of	426	428	O
PF	429	431	B-Multi-tissue_structure
suture	432	438	I-Multi-tissue_structure
complex	439	446	O
(	447	448	O
analogous	448	457	O
to	458	460	O
metopic	461	468	B-Multi-tissue_structure
suture	469	475	I-Multi-tissue_structure
in	476	478	O
humans	479	485	O
)	485	486	O
,	486	487	O
we	488	490	O
performed	491	500	O
quantitative	501	513	O
real	514	518	O
-	518	519	O
time	519	523	O
PCR	524	527	O
and	528	531	O
immunohistochemistry	532	552	O
to	553	555	O
study	556	561	O
the	562	565	O
expression	566	576	O
pattern	577	584	O
of	585	587	O
the	588	591	O
NCC	592	595	B-Cell
determinant	596	607	O
gene	608	612	O
Sox9	613	617	O
and	618	621	O
select	622	628	O
markers	629	636	O
of	637	639	O
extracellular	640	653	B-Cellular_component
matrix	654	660	I-Cellular_component
.	660	661	O

Our	662	665	O
results	666	673	O
indicated	674	683	O
a	684	685	O
unique	686	692	O
up	693	695	O
-	695	696	O
regulated	696	705	O
expression	706	716	O
of	717	719	O
Sox9	720	724	O
,	724	725	O
a	726	727	O
regulator	728	737	O
of	738	740	O
chondrogenesis	741	755	O
,	755	756	O
during	757	763	O
initiation	764	774	O
of	775	777	O
PF	778	780	B-Multi-tissue_structure
suture	781	787	I-Multi-tissue_structure
closure	788	795	O
,	795	796	O
along	797	802	O
with	803	807	O
the	808	811	O
expression	812	822	O
of	823	825	O
specific	826	834	O
cartilage	835	844	B-Tissue
markers	845	852	O
(	853	854	O
Type	854	858	O
II	859	861	O
Collagen	862	870	O
and	871	874	O
Type	875	879	O
X	880	881	O
Collagen	882	890	O
)	890	891	O
,	891	892	O
as	893	895	O
well	896	900	O
as	901	903	O
cartilage	904	913	B-Tissue
tissue	914	920	I-Tissue
formation	921	930	O
in	931	933	O
the	934	937	O
PF	938	940	B-Multi-tissue_structure
suture	941	947	I-Multi-tissue_structure
.	947	948	O

This	949	953	O
process	954	961	O
was	962	965	O
followed	966	974	O
by	975	977	O
expression	978	988	O
of	989	991	O
bone	992	996	B-Tissue
markers	997	1004	O
(	1005	1006	O
Type	1006	1010	O
I	1011	1012	O
Collagen	1013	1021	O
and	1022	1025	O
Osteocalcin	1026	1037	O
)	1037	1038	O
,	1038	1039	O
suggesting	1040	1050	O
endochondral	1051	1063	O
ossification	1064	1076	O
.	1076	1077	O

Moreover	1078	1086	O
,	1086	1087	O
we	1088	1090	O
studied	1091	1098	O
the	1099	1102	O
effect	1103	1109	O
of	1110	1112	O
haploinsufficiency	1113	1131	O
of	1132	1134	O
the	1135	1138	O
NCC	1139	1142	B-Cell
determinant	1143	1154	O
gene	1155	1159	O
Sox9	1160	1164	O
in	1165	1167	O
the	1168	1171	O
NCC	1172	1175	B-Cell
derived	1176	1183	O
PF	1184	1186	B-Multi-tissue_structure
suture	1187	1193	I-Multi-tissue_structure
complex	1194	1201	O
.	1201	1202	O

A	1203	1204	O
decrease	1205	1213	O
in	1214	1216	O
dosage	1217	1223	O
of	1224	1226	O
Sox9	1227	1231	O
by	1232	1234	O
haploinsufficiency	1235	1253	O
in	1254	1256	O
NCC	1257	1260	B-Tissue
-	1260	1261	I-Tissue
derived	1261	1268	I-Tissue
tissues	1269	1276	I-Tissue
resulted	1277	1285	O
in	1286	1288	O
delayed	1289	1296	O
PF	1297	1299	B-Multi-tissue_structure
suture	1300	1306	I-Multi-tissue_structure
closure	1307	1314	O
.	1314	1315	O

These	1316	1321	O
results	1322	1329	O
demonstrate	1330	1341	O
a	1342	1343	O
unique	1344	1350	O
development	1351	1362	O
of	1363	1365	O
the	1366	1369	O
PF	1370	1372	B-Multi-tissue_structure
suture	1373	1379	I-Multi-tissue_structure
complex	1380	1387	O
and	1388	1391	O
the	1392	1395	O
role	1396	1400	O
of	1401	1403	O
Sox9	1404	1408	O
as	1409	1411	O
an	1412	1414	O
important	1415	1424	O
contributor	1425	1436	O
to	1437	1439	O
timely	1440	1446	O
and	1447	1450	O
proper	1451	1457	O
closure	1458	1465	O
of	1466	1468	O
the	1469	1472	O
PF	1473	1475	B-Multi-tissue_structure
suture	1476	1482	I-Multi-tissue_structure
through	1483	1490	O
endochondral	1491	1503	O
ossification	1504	1516	O
.	1516	1517	O

Experimental	0	12	O
investigation	13	26	O
of	27	29	O
equibiaxial	30	41	O
extension	42	51	O
and	52	55	O
breakup	56	63	O
of	64	66	O
drops	67	72	O
in	73	75	O
a	76	77	O
molten	78	84	O
two	85	88	O
-	88	89	O
phase	89	94	O
polymer	95	102	O
blend	103	108	O
.	108	109	O

We	110	112	O
experimentally	113	127	O
investigate	128	139	O
the	140	143	O
breakup	144	151	O
of	152	154	O
an	155	157	O
equibiaxially	158	171	O
elongated	172	181	O
polystyrene	182	193	O
(	194	195	O
PS	195	197	O
)	197	198	O
drop	199	203	O
in	204	206	O
a	207	208	O
poly	209	213	O
(	213	214	O
methyl	214	220	O
methacrylate	221	233	O
)	233	234	O
(	235	236	O
PMMA	236	240	O
)	240	241	O
matrix	242	248	O
during	249	255	O
relaxation	256	266	O
after	267	272	O
melt	273	277	O
elongation	278	288	O
.	288	289	O

In	290	292	O
equibiaxial	293	304	O
elongation	305	315	O
,	315	316	O
the	317	320	O
initially	321	330	O
spherical	331	340	O
PS	341	343	O
drop	344	348	O
is	349	351	O
deformed	352	360	O
into	361	365	O
an	366	368	O
ellipsoidal	369	380	O
disclike	381	389	O
shape	390	395	O
for	396	399	O
our	400	403	O
test	404	408	O
parameters	409	419	O
.	419	420	O

Using	421	426	O
a	427	428	O
hotstage	429	437	O
in	438	440	O
combination	441	452	O
with	453	457	O
a	458	459	O
light	460	465	O
microscope	466	476	O
,	476	477	O
we	478	480	O
observe	481	488	O
the	489	492	O
evolution	493	502	O
of	503	505	O
the	506	509	O
drop	510	514	O
shape	515	520	O
during	521	527	O
relaxation	528	538	O
.	538	539	O

In	540	542	O
the	543	546	O
initial	547	554	O
stage	555	560	O
of	561	563	O
relaxation	564	574	O
,	574	575	O
fingers	576	583	O
and	584	587	O
holes	588	593	O
are	594	597	O
formed	598	604	O
.	604	605	O

The	606	609	O
holes	610	615	O
are	616	619	O
located	620	627	O
preferentially	628	642	O
near	643	647	O
the	648	651	O
rim	652	655	O
of	656	658	O
the	659	662	O
drop	663	667	O
.	667	668	O

The	669	672	O
number	673	679	O
and	680	683	O
the	684	687	O
size	688	692	O
of	693	695	O
the	696	699	O
holes	700	705	O
increase	706	714	O
with	715	719	O
time	720	724	O
such	725	729	O
that	730	734	O
the	735	738	O
elongated	739	748	O
PS	749	751	O
drop	752	756	O
attains	757	764	O
a	765	766	O
complex	767	774	O
shape	775	780	O
during	781	787	O
relaxation	788	798	O
.	798	799	O

The	800	803	O
fingers	804	811	O
form	812	816	O
bulbous	817	824	O
ends	825	829	O
which	830	835	O
separate	836	844	O
from	845	849	O
the	850	853	O
fingers	854	861	O
.	861	862	O

We	863	865	O
discuss	866	873	O
the	874	877	O
dynamics	878	886	O
of	887	889	O
this	890	894	O
breakup	895	902	O
process	903	910	O
by	911	913	O
taking	914	920	O
into	921	925	O
account	926	933	O
the	934	937	O
interfacial	938	949	O
energy	950	956	O
between	957	964	O
PS	965	967	O
and	968	971	O
PMMA	972	976	O
.	976	977	O

Our	978	981	O
analysis	982	990	O
shows	991	996	O
that	997	1001	O
a	1002	1003	O
very	1004	1008	O
large	1009	1014	O
number	1015	1021	O
of	1022	1024	O
small	1025	1030	O
PS	1031	1033	O
droplets	1034	1042	O
can	1043	1046	O
be	1047	1049	O
generated	1050	1059	O
by	1060	1062	O
the	1063	1066	O
sequential	1067	1077	O
breakup	1078	1085	O
of	1086	1088	O
the	1089	1092	O
elongated	1093	1102	O
PS	1103	1105	O
drop	1106	1110	O
.	1110	1111	O

Management	0	10	O
of	11	13	O
extremity	14	23	O
trauma	24	30	O
and	31	34	O
related	35	42	O
infections	43	53	O
occurring	54	63	O
in	64	66	O
the	67	70	O
aquatic	71	78	O
environment	79	90	O
.	90	91	O

Wounds	92	98	B-Pathological_formation
sustained	99	108	O
in	109	111	O
oceans	112	118	O
,	118	119	O
lakes	120	125	O
,	125	126	O
and	127	130	O
streams	131	138	O
are	139	142	O
exposed	143	150	O
to	151	153	O
a	154	155	O
milieu	156	162	O
of	163	165	O
bacteria	166	174	O
rarely	175	181	O
encountered	182	193	O
in	194	196	O
typical	197	204	O
land	205	209	O
-	209	210	O
based	210	215	O
injuries	216	224	O
.	224	225	O

These	226	231	O
include	232	239	O
Vibrio	240	246	O
species	247	254	O
,	254	255	O
Aeromonas	256	265	O
hydrophila	266	276	O
,	276	277	O
Pseudomonas	278	289	O
and	290	293	O
Plesiomonas	294	305	O
species	306	313	O
,	313	314	O
Erysipelothrix	315	329	O
rhusiopathiae	330	343	O
,	343	344	O
Mycobacterium	345	358	O
marinum	359	366	O
,	366	367	O
and	368	371	O
other	372	377	O
microbes	378	386	O
.	386	387	O

Failure	388	395	O
to	396	398	O
recognize	399	408	O
and	409	412	O
treat	413	418	O
these	419	424	O
less	425	429	O
common	430	436	O
pathogens	437	446	O
in	447	449	O
a	450	451	O
timely	452	458	O
manner	459	465	O
may	466	469	O
result	470	476	O
in	477	479	O
significant	480	491	O
morbidity	492	501	O
or	502	504	O
death	505	510	O
.	510	511	O

Initial	512	519	O
antibiotic	520	530	O
therapy	531	538	O
should	539	545	O
address	546	553	O
common	554	560	O
gram	561	565	O
-	565	566	O
positive	566	574	O
and	575	578	O
gram	579	583	O
-	583	584	O
negative	584	592	O
aquatic	593	600	O
bacteria	601	609	O
,	609	610	O
depending	611	620	O
on	621	623	O
the	624	627	O
environment	628	639	O
.	639	640	O

Trauma	641	647	O
occurring	648	657	O
in	658	660	O
brackish	661	669	O
or	670	672	O
salt	673	677	O
water	678	683	O
should	684	690	O
be	691	693	O
treated	694	701	O
with	702	706	O
doxycycline	707	718	O
and	719	722	O
ceftazidime	723	734	O
,	734	735	O
or	736	738	O
a	739	740	O
fluoroquinolone	741	756	O
(	757	758	O
eg	758	760	O
,	760	761	O
ciprofloxacin	762	775	O
or	776	778	O
levofloxacin	779	791	O
)	791	792	O
.	792	793	O

Freshwater	794	804	O
wounds	805	811	B-Pathological_formation
should	812	818	O
be	819	821	O
managed	822	829	O
with	830	834	O
ciprofloxacin	835	848	O
,	848	849	O
levofloxacin	850	862	O
,	862	863	O
or	864	866	O
a	867	868	O
third	869	874	O
-	874	875	O
or	876	878	O
fourth	879	885	O
-	885	886	O
generation	886	896	O
cephalosporin	897	910	O
(	911	912	O
eg	912	914	O
,	914	915	O
ceftazidime	916	927	O
)	927	928	O
.	928	929	O

Injuries	930	938	O
sustained	939	948	O
in	949	951	O
a	952	953	O
marine	954	960	O
or	961	963	O
freshwater	964	974	O
environment	975	986	O
may	987	990	O
result	991	997	O
from	998	1002	O
bites	1003	1008	O
or	1009	1011	O
venomous	1012	1020	O
stings	1021	1027	O
of	1028	1030	O
aquatic	1031	1038	O
organisms	1039	1048	O
as	1049	1051	O
well	1052	1056	O
as	1057	1059	O
from	1060	1064	O
accidental	1065	1075	O
trauma	1076	1082	O
.	1082	1083	O

Musculoskeletal	1084	1099	B-Pathological_formation
trauma	1100	1106	I-Pathological_formation
caused	1107	1113	O
by	1114	1116	O
venomous	1117	1125	O
underwater	1126	1136	O
species	1137	1144	O
(	1145	1146	O
eg	1146	1148	O
,	1148	1149	O
stingrays	1150	1159	O
,	1159	1160	O
stinging	1161	1169	O
fish	1170	1174	O
,	1174	1175	O
sea	1176	1179	O
urchins	1180	1187	O
,	1187	1188	O
and	1189	1192	O
coral	1193	1198	O
)	1198	1199	O
requires	1200	1208	O
immediate	1209	1218	O
neutralization	1219	1233	O
of	1234	1236	O
the	1237	1240	O
heat	1241	1245	O
-	1245	1246	O
labile	1246	1252	O
toxin	1253	1258	O
with	1259	1263	O
immersion	1264	1273	O
in	1274	1276	O
nonscalding	1277	1288	O
water	1289	1294	O
for	1295	1298	O
30	1299	1301	O
to	1302	1304	O
90	1305	1307	O
minutes	1308	1315	O
.	1315	1316	O

Appropriate	1317	1328	O
management	1329	1339	O
of	1340	1342	O
aquatic	1343	1350	O
wounds	1351	1357	B-Pathological_formation
requires	1358	1366	O
recognition	1367	1378	O
of	1379	1381	O
the	1382	1385	O
mechanism	1386	1395	O
of	1396	1398	O
injury	1399	1405	O
,	1405	1406	O
neutralization	1407	1421	O
of	1422	1424	O
venom	1425	1430	O
,	1430	1431	O
antibiotic	1432	1442	O
administration	1443	1457	O
,	1457	1458	O
radiographic	1459	1471	O
assessment	1472	1482	O
,	1482	1483	O
surgical	1484	1492	O
debridement	1493	1504	O
with	1505	1509	O
irrigation	1510	1520	O
,	1520	1521	O
wound	1522	1527	B-Pathological_formation
cultures	1528	1536	O
,	1536	1537	O
and	1538	1541	O
structural	1542	1552	O
repair	1553	1559	O
or	1560	1562	O
amputation	1563	1573	O
as	1574	1576	O
indicated	1577	1586	O
by	1587	1589	O
the	1590	1593	O
severity	1594	1602	O
of	1603	1605	O
the	1606	1609	O
injury	1610	1616	O
.	1616	1617	O

Involvement	0	11	O
of	12	14	O
de	15	17	O
novo	18	22	O
ceramide	23	31	O
synthesis	32	41	O
in	42	44	O
radiocontrast	45	58	O
-	58	59	O
induced	59	66	O
renal	67	72	B-Cell
tubular	73	80	I-Cell
cell	81	85	I-Cell
injury	86	92	O
.	92	93	O

We	94	96	O
reported	97	105	O
previously	106	116	O
that	117	121	O
various	122	129	O
radiocontrast	130	143	O
media	144	149	O
cause	150	155	O
apoptosis	156	165	O
in	166	168	O
porcine	169	176	O
proximal	177	185	B-Cell
tubular	186	193	I-Cell
(	194	195	I-Cell
LLC	195	198	I-Cell
-	198	199	I-Cell
PK	199	201	I-Cell
(	201	202	I-Cell
1	202	203	I-Cell
)	203	204	I-Cell
)	204	205	I-Cell
cells	206	211	I-Cell
,	211	212	O
in	213	215	O
which	216	221	O
reduction	222	231	O
in	232	234	O
B	235	236	O
-	236	237	O
cell	237	241	O
lymphoma	242	250	O
(	251	252	O
Bcl	252	255	O
)	255	256	O
-	256	257	O
2	257	258	O
expression	259	269	O
and	270	273	O
caspase	274	281	O
-	281	282	O
3	282	283	O
activation	284	294	O
are	295	298	O
implicated	299	309	O
.	309	310	O

In	311	313	O
the	314	317	O
present	318	325	O
study	326	331	O
,	331	332	O
we	333	335	O
investigated	336	348	O
a	349	350	O
role	351	355	O
for	356	359	O
ceramide	360	368	O
in	369	371	O
radiocontrast	372	385	O
media	386	391	O
-	391	392	O
induced	392	399	O
apoptosis	400	409	O
in	410	412	O
renal	413	418	B-Cell
tubular	419	426	I-Cell
cells	427	432	I-Cell
.	432	433	O

LLC	434	437	B-Cell
-	437	438	I-Cell
PK	438	440	I-Cell
(	440	441	I-Cell
1	441	442	I-Cell
)	442	443	I-Cell
cells	444	449	I-Cell
were	450	454	O
exposed	455	462	O
to	463	465	O
radiocontrast	466	479	O
media	480	485	O
for	486	489	O
30	490	492	O
min	493	496	O
,	496	497	O
followed	498	506	O
by	507	509	O
incubation	510	520	O
for	521	524	O
24	525	527	O
h	528	529	O
in	530	532	O
normal	533	539	O
medium	540	546	O
.	546	547	O

Cell	548	552	B-Cell
viability	553	562	O
was	563	566	O
assessed	567	575	O
by	576	578	O
2	579	580	O
-	580	581	O
(	581	582	O
2	582	583	O
-	583	584	O
methoxy	584	591	O
-	591	592	O
4	592	593	O
-	593	594	O
nitrophenyl	594	605	O
)	605	606	O
-	606	607	O
3	607	608	O
-	608	609	O
(	609	610	O
4	610	611	O
-	611	612	O
nitrophenyl	612	623	O
)	623	624	O
-	624	625	O
5	625	626	O
-	626	627	O
(	627	628	O
2	628	629	O
,	629	630	O
4	630	631	O
-	631	632	O
disulfophenyl	632	645	O
)	645	646	O
-	646	647	O
2H	647	649	O
-	649	650	O
tetrazolium	650	661	O
monosodium	662	672	O
salt	673	677	O
assay	678	683	O
,	683	684	O
while	685	690	O
apoptosis	691	700	O
was	701	704	O
determined	705	715	O
by	716	718	O
terminal	719	727	O
deoxynucleotidyl	728	744	O
transferase	745	756	O
-	756	757	O
mediated	757	765	O
dUTP	766	770	O
nick	771	775	O
end	776	779	O
labeling	780	788	O
stain	789	794	O
.	794	795	O

Immunofluorescent	796	813	O
stains	814	820	O
were	821	825	O
performed	826	835	O
using	836	841	O
antibodies	842	852	O
against	853	860	O
phosphorylated	861	875	O
Akt	876	879	O
(	880	881	O
pAkt	881	885	O
)	885	886	O
and	887	890	O
cAMP	891	895	O
response	896	904	O
element	905	912	O
binding	913	920	O
protein	921	928	O
(	929	930	O
CREB	930	934	O
)	934	935	O
(	936	937	O
pCREB	937	942	O
)	942	943	O
,	943	944	O
and	945	948	O
ceramide	949	957	O
.	957	958	O

The	959	962	O
mRNA	963	967	O
expression	968	978	O
and	979	982	O
protein	983	990	O
content	991	998	O
of	999	1001	O
Bcl	1002	1005	O
-	1005	1006	O
2	1006	1007	O
were	1008	1012	O
determined	1013	1023	O
by	1024	1026	O
reverse	1027	1034	O
transcriptase	1035	1048	O
-	1048	1049	O
polymerase	1049	1059	O
chain	1060	1065	O
reaction	1066	1074	O
and	1075	1078	O
enzyme	1079	1085	O
immunoassay	1086	1097	O
,	1097	1098	O
respectively	1099	1111	O
.	1111	1112	O

In	1113	1115	O
vivo	1116	1120	O
model	1121	1126	O
of	1127	1129	O
contrast	1130	1138	O
-	1138	1139	O
induced	1139	1146	O
renal	1147	1152	B-Organ
injury	1153	1159	O
was	1160	1163	O
induced	1164	1171	O
in	1172	1174	O
mice	1175	1179	O
with	1180	1184	O
unilateral	1185	1195	O
renal	1196	1201	B-Organ
occlusion	1202	1211	O
.	1211	1212	O

The	1213	1216	O
cell	1217	1221	B-Cell
injury	1222	1228	O
induced	1229	1236	O
by	1237	1239	O
the	1240	1243	O
nonionic	1244	1252	O
radiocontrast	1253	1266	O
medium	1267	1273	O
ioversol	1274	1282	O
was	1283	1286	O
reversed	1287	1295	O
by	1296	1298	O
inhibiting	1299	1309	O
de	1310	1312	O
novo	1313	1317	O
ceramide	1318	1326	O
synthesis	1327	1336	O
with	1337	1341	O
fumonisin	1342	1351	O
B	1352	1353	O
(	1353	1354	O
1	1354	1355	O
)	1355	1356	O
(	1357	1358	O
FB	1358	1360	O
(	1360	1361	O
1	1361	1362	O
)	1362	1363	O
)	1363	1364	O
and	1365	1368	O
L	1369	1370	O
-	1370	1371	O
cycloserine	1371	1382	O
,	1382	1383	O
but	1384	1387	O
not	1388	1391	O
by	1392	1394	O
suppressing	1395	1406	O
sphingomyelin	1407	1420	O
breakdown	1421	1430	O
with	1431	1435	O
D609	1436	1440	O
.	1440	1441	O

FB	1442	1444	O
(	1444	1445	O
1	1445	1446	O
)	1446	1447	O
reversed	1448	1456	O
ioversol	1457	1465	O
-	1465	1466	O
induced	1466	1473	O
decrease	1474	1482	O
in	1483	1485	O
the	1486	1489	O
immunoreactivities	1490	1508	O
of	1509	1511	O
pAkt	1512	1516	O
and	1517	1520	O
pCREB	1521	1526	O
,	1526	1527	O
reduction	1528	1537	O
in	1538	1540	O
Bcl	1541	1544	O
-	1544	1545	O
2	1545	1546	O
expression	1547	1557	O
and	1558	1561	O
caspase	1562	1569	O
-	1569	1570	O
3	1570	1571	O
activation	1572	1582	O
.	1582	1583	O

Like	1584	1588	O
ioversol	1589	1597	O
,	1597	1598	O
C2	1599	1601	O
ceramide	1602	1610	O
and	1611	1614	O
the	1615	1618	O
Akt	1619	1622	O
inhibitor	1623	1632	O
Src	1633	1636	O
homology	1637	1645	O
-	1645	1646	O
6	1646	1647	O
induced	1648	1655	O
apoptosis	1656	1665	O
by	1666	1668	O
reducing	1669	1677	O
pAkt	1678	1682	O
and	1683	1686	O
pCREB	1687	1692	O
-	1692	1693	O
like	1693	1697	O
immunoreactivities	1698	1716	O
,	1716	1717	O
lowering	1718	1726	O
Bcl	1727	1730	O
-	1730	1731	O
2	1731	1732	O
expression	1733	1743	O
and	1744	1747	O
enhancing	1748	1757	O
caspase	1758	1765	O
-	1765	1766	O
3	1766	1767	O
activity	1768	1776	O
.	1776	1777	O

Indeed	1778	1784	O
,	1784	1785	O
various	1786	1793	O
radiocontrast	1794	1807	O
media	1808	1813	O
,	1813	1814	O
excluding	1815	1824	O
iodixanol	1825	1834	O
which	1835	1840	O
showed	1841	1847	O
the	1848	1851	O
least	1852	1857	O
nephrotoxicity	1858	1872	O
,	1872	1873	O
enhanced	1874	1882	O
ceramide	1883	1891	O
-	1891	1892	O
like	1892	1896	O
immunoreactivity	1897	1913	O
.	1913	1914	O

The	1915	1918	O
role	1919	1923	O
for	1924	1927	O
de	1928	1930	O
novo	1931	1935	O
ceramide	1936	1944	O
synthesis	1945	1954	O
was	1955	1958	O
also	1959	1963	O
shown	1964	1969	O
in	1970	1972	O
the	1973	1976	O
in	1977	1979	O
vivo	1980	1984	O
model	1985	1990	O
of	1991	1993	O
radiocontrast	1994	2007	O
nephropathy	2008	2019	O
.	2019	2020	O

We	2021	2023	O
demonstrated	2024	2036	O
here	2037	2041	O
for	2042	2045	O
the	2046	2049	O
first	2050	2055	O
time	2056	2060	O
that	2061	2065	O
the	2066	2069	O
enhancement	2070	2081	O
of	2082	2084	O
de	2085	2087	O
novo	2088	2092	O
ceramide	2093	2101	O
synthesis	2102	2111	O
contributes	2112	2123	O
to	2124	2126	O
radiocontrast	2127	2140	O
nephropathy	2141	2152	O
.	2152	2153	O

A	0	1	O
potential	2	11	O
role	12	16	O
for	17	20	O
the	21	24	O
Src	25	28	O
-	28	29	O
like	29	33	O
adapter	34	41	O
protein	42	49	O
SLAP	50	54	O
-	54	55	O
2	55	56	O
in	57	59	O
signaling	60	69	O
by	70	72	O
the	73	76	O
colony	77	83	O
stimulating	84	95	O
factor	96	102	O
-	102	103	O
1	103	104	O
receptor	105	113	O
.	113	114	O

The	115	118	O
development	119	130	O
of	131	133	O
macrophages	134	145	B-Cell
from	146	150	O
myeloid	151	158	B-Cell
progenitor	159	169	I-Cell
cells	170	175	I-Cell
is	176	178	O
primarily	179	188	O
controlled	189	199	O
by	200	202	O
the	203	206	O
growth	207	213	O
factor	214	220	O
colony	221	227	O
stimulating	228	239	O
factor	240	246	O
-	246	247	O
1	247	248	O
(	249	250	O
CSF	250	253	O
-	253	254	O
1	254	255	O
)	255	256	O
and	257	260	O
its	261	264	O
cognate	265	272	O
receptor	273	281	O
,	281	282	O
a	283	284	O
transmembrane	285	298	B-Cellular_component
tyrosine	299	307	O
kinase	308	314	O
encoded	315	322	O
by	323	325	O
the	326	329	O
c	330	331	O
-	331	332	O
Fms	332	335	O
proto	336	341	O
-	341	342	O
oncogene	342	350	O
.	350	351	O

The	352	355	O
CSF	356	359	O
-	359	360	O
1	360	361	O
receptor	362	370	O
exerts	371	377	O
its	378	381	O
biological	382	392	O
effects	393	400	O
on	401	403	O
cells	404	409	B-Cell
via	410	413	O
a	414	415	O
range	416	421	O
of	422	424	O
signaling	425	434	O
proteins	435	443	O
including	444	453	O
Erk1	454	458	O
/	458	459	O
2	459	460	O
and	461	464	O
Akt	465	468	O
.	468	469	O

Here	470	474	O
we	475	477	O
have	478	482	O
investigated	483	495	O
the	496	499	O
potential	500	509	O
involvement	510	521	O
of	522	524	O
the	525	528	O
Src	529	532	O
-	532	533	O
like	533	537	O
adapter	538	545	O
protein	546	553	O
(	554	555	O
SLAP	555	559	O
-	559	560	O
2	560	561	O
)	561	562	O
in	563	565	O
signaling	566	575	O
by	576	578	O
the	579	582	O
CSF	583	586	O
-	586	587	O
1	587	588	O
receptor	589	597	O
in	598	600	O
mouse	601	606	O
bone	607	611	B-Multi-tissue_structure
marrow	612	618	I-Multi-tissue_structure
-	618	619	O
derived	619	626	O
macrophages	627	638	B-Cell
.	638	639	O

RT	640	642	O
-	642	643	O
PCR	643	646	O
analysis	647	655	O
revealed	656	664	O
constitutive	665	677	O
expression	678	688	O
of	689	691	O
the	692	695	O
SLAP	696	700	O
-	700	701	O
2	701	702	O
gene	703	707	O
in	708	710	O
bone	711	715	B-Cell
marrow	716	722	I-Cell
macrophages	723	734	I-Cell
.	734	735	O

Surprisingly	736	748	O
,	748	749	O
co	750	752	O
-	752	753	O
immunoprecipitation	753	772	O
and	773	776	O
GST	777	780	O
binding	781	788	O
experiments	789	800	O
demonstrated	801	813	O
that	814	818	O
the	819	822	O
CSF	823	826	O
-	826	827	O
1	827	828	O
receptor	829	837	O
could	838	843	O
bind	844	848	O
to	849	851	O
SLAP	852	856	O
-	856	857	O
2	857	858	O
in	859	861	O
a	862	863	O
ligand	864	870	O
-	870	871	O
independent	871	882	O
manner	883	889	O
.	889	890	O

Furthermore	891	902	O
,	902	903	O
the	904	907	O
binding	908	915	O
of	916	918	O
SLAP	919	923	O
-	923	924	O
2	924	925	O
to	926	928	O
the	929	932	O
CSF	933	936	O
-	936	937	O
1	937	938	O
receptor	939	947	O
involved	948	956	O
multiple	957	965	O
domains	966	973	O
of	974	976	O
SLAP	977	981	O
-	981	982	O
2	982	983	O
.	983	984	O

SLAP	985	989	O
-	989	990	O
2	990	991	O
also	992	996	O
bound	997	1002	O
c	1003	1004	O
-	1004	1005	O
Cbl	1005	1008	O
,	1008	1009	O
with	1010	1014	O
the	1015	1018	O
interaction	1019	1030	O
being	1031	1036	O
mediated	1037	1045	O
,	1045	1046	O
at	1047	1049	O
least	1050	1055	O
in	1056	1058	O
part	1059	1063	O
,	1063	1064	O
by	1065	1067	O
the	1068	1071	O
unique	1072	1078	O
C	1079	1080	O
-	1080	1081	O
terminal	1081	1089	O
domain	1090	1096	O
of	1097	1099	O
SLAP	1100	1104	O
-	1104	1105	O
2	1105	1106	O
.	1106	1107	O

Overexpression	1108	1122	O
of	1123	1125	O
SLAP	1126	1130	O
-	1130	1131	O
2	1131	1132	O
in	1133	1135	O
bone	1136	1140	B-Cell
marrow	1141	1147	I-Cell
macrophages	1148	1159	I-Cell
partially	1160	1169	O
suppressed	1170	1180	O
the	1181	1184	O
CSF	1185	1188	O
-	1188	1189	O
1	1189	1190	O
-	1190	1191	O
induced	1191	1198	O
tyrosine	1199	1207	O
phosphorylation	1208	1223	O
and	1224	1227	O
/	1227	1228	O
or	1228	1230	O
expression	1231	1241	O
level	1242	1247	O
of	1248	1250	O
a	1251	1252	O
approximately	1253	1266	O
80	1267	1269	O
kDa	1270	1273	O
protein	1274	1281	O
without	1282	1289	O
affecting	1290	1299	O
CSF	1300	1303	O
-	1303	1304	O
1	1304	1305	O
-	1305	1306	O
induced	1306	1313	O
global	1314	1320	O
tyrosine	1321	1329	O
phosphorylation	1330	1345	O
,	1345	1346	O
or	1347	1349	O
activation	1350	1360	O
of	1361	1363	O
Akt	1364	1367	O
or	1368	1370	O
Erk1	1371	1375	O
/	1375	1376	O
2	1376	1377	O
.	1377	1378	O

Significantly	1379	1392	O
,	1392	1393	O
CSF	1394	1397	O
-	1397	1398	O
1	1398	1399	O
stimulation	1400	1411	O
induced	1412	1419	O
serine	1420	1426	O
phosphorylation	1427	1442	O
of	1443	1445	O
SLAP	1446	1450	O
-	1450	1451	O
2	1451	1452	O
.	1452	1453	O

Pharmacologic	1454	1467	O
inhibition	1468	1478	O
of	1479	1481	O
specific	1482	1490	O
protein	1491	1498	O
kinases	1499	1506	O
revealed	1507	1515	O
that	1516	1520	O
CSF	1521	1524	O
-	1524	1525	O
1	1525	1526	O
-	1526	1527	O
induced	1527	1534	O
phosphorylation	1535	1550	O
of	1551	1553	O
SLAP	1554	1558	O
-	1558	1559	O
2	1559	1560	O
was	1561	1564	O
dependent	1565	1574	O
on	1575	1577	O
JNK	1578	1581	O
activity	1582	1590	O
.	1590	1591	O

Taken	1592	1597	O
together	1598	1606	O
,	1606	1607	O
our	1608	1611	O
results	1612	1619	O
suggest	1620	1627	O
that	1628	1632	O
SLAP	1633	1637	O
-	1637	1638	O
2	1638	1639	O
could	1640	1645	O
potentially	1646	1657	O
be	1658	1660	O
involved	1661	1669	O
in	1670	1672	O
signaling	1673	1682	O
by	1683	1685	O
the	1686	1689	O
CSF	1690	1693	O
-	1693	1694	O
1	1694	1695	O
receptor	1696	1704	O
.	1704	1705	O

Structure	0	9	O
of	10	12	O
the	13	16	O
genetic	17	24	O
code	25	29	O
suggested	30	39	O
by	40	42	O
the	43	46	O
hydropathy	47	57	O
correlation	58	69	O
between	70	77	O
anticodons	78	88	O
and	89	92	O
amino	93	98	O
acid	99	103	O
residues	104	112	O
.	112	113	O

The	114	117	O
correlation	118	129	O
between	130	137	O
hydropathies	138	150	O
of	151	153	O
anticodons	154	164	O
and	165	168	O
amino	169	174	O
acids	175	180	O
,	180	181	O
detected	182	190	O
by	191	193	O
other	194	199	O
authors	200	207	O
utilizing	208	217	O
scales	218	224	O
of	225	227	O
amino	228	233	O
acid	234	238	O
molecules	239	248	O
in	249	251	O
solution	252	260	O
,	260	261	O
was	262	265	O
improved	266	274	O
with	275	279	O
the	280	283	O
utilization	284	295	O
of	296	298	O
scales	299	305	O
of	306	308	O
amino	309	314	O
acid	315	319	O
residues	320	328	O
in	329	331	O
proteins	332	340	O
.	340	341	O

Three	342	347	O
partitions	348	358	O
were	359	363	O
discerned	364	373	O
in	374	376	O
the	377	380	O
correlation	381	392	O
plot	393	397	O
with	398	402	O
the	403	406	O
principal	407	416	O
dinucleotides	417	430	O
of	431	433	O
anticodons	434	444	O
(	445	446	O
pDiN	446	450	O
,	450	451	O
excluding	452	461	O
the	462	465	O
wobble	466	472	O
position	473	481	O
)	481	482	O
.	482	483	O

(	484	485	O
a	485	486	O
)	486	487	O
The	488	491	O
set	492	495	O
of	496	498	O
outliers	499	507	O
of	508	510	O
the	511	514	O
correlation	515	526	O
:	526	527	O
Gly	528	531	O
-	531	532	O
CC	532	534	O
,	534	535	O
Pro	536	539	O
-	539	540	O
GG	540	542	O
,	542	543	O
Ser	544	547	O
-	547	548	O
GA	548	550	O
and	551	554	O
Ser	555	558	O
-	558	559	O
CU	559	561	O
.	561	562	O

The	563	566	O
amino	567	572	O
acids	573	578	O
are	579	582	O
consistently	583	595	O
small	596	601	O
,	601	602	O
hydro	603	608	O
-	608	609	O
apathetic	609	618	O
,	618	619	O
stabilizers	620	631	O
of	632	634	O
protein	635	642	O
N	643	644	O
-	644	645	O
ends	645	649	O
,	649	650	O
preferred	651	660	O
in	661	663	O
aperiodic	664	673	O
protein	674	681	O
conformations	682	695	O
and	696	699	O
belong	700	706	O
to	707	709	O
synthetases	710	721	O
class	722	727	O
II	728	730	O
.	730	731	O

The	732	735	O
pDiN	736	740	O
sequences	741	750	O
are	751	754	O
representative	755	769	O
of	770	772	O
the	773	776	O
homogeneous	777	788	O
sector	789	795	O
(	796	797	O
triplets	797	805	O
NRR	806	809	O
and	810	813	O
NYY	814	817	O
)	817	818	O
,	818	819	O
distinguished	820	833	O
from	834	838	O
the	839	842	O
mixed	843	848	O
sector	849	855	O
(	856	857	O
triplets	857	865	O
NRY	866	869	O
and	870	873	O
NYR	874	877	O
)	877	878	O
,	878	879	O
that	880	884	O
depict	885	891	O
a	892	893	O
70	894	896	O
%	896	897	O
correspondence	898	912	O
to	913	915	O
the	916	919	O
synthetases	920	931	O
class	932	937	O
II	938	940	O
and	941	944	O
I	945	946	O
,	946	947	O
respectively	948	960	O
.	960	961	O

The	962	965	O
triplet	966	973	O
pairs	974	979	O
proposed	980	988	O
to	989	991	O
be	992	994	O
responsible	995	1006	O
for	1007	1010	O
the	1011	1014	O
coherence	1015	1024	O
in	1025	1027	O
the	1028	1031	O
set	1032	1035	O
of	1036	1038	O
outliers	1039	1047	O
are	1048	1051	O
of	1052	1054	O
the	1055	1058	O
palindromic	1059	1070	O
kind	1071	1075	O
,	1075	1076	O
where	1077	1082	O
the	1083	1086	O
lateral	1087	1094	O
bases	1095	1100	O
are	1101	1104	O
the	1105	1108	O
same	1109	1113	O
,	1113	1114	O
CCC	1115	1118	O
:	1118	1119	O
GGG	1120	1123	O
and	1124	1127	O
AGA	1128	1131	O
:	1131	1132	O
UCU	1133	1136	O
.	1136	1137	O

This	1138	1142	O
suggests	1143	1151	O
that	1152	1156	O
UCU	1157	1160	O
previously	1161	1171	O
belonged	1172	1180	O
to	1181	1183	O
Ser	1184	1187	O
,	1187	1188	O
adding	1189	1195	O
to	1196	1198	O
other	1199	1204	O
indications	1205	1216	O
that	1217	1221	O
the	1222	1225	O
attribution	1226	1237	O
of	1238	1240	O
Arg	1241	1244	O
to	1245	1247	O
YCU	1248	1251	O
was	1252	1255	O
due	1256	1259	O
to	1260	1262	O
an	1263	1265	O
expansion	1266	1275	O
of	1276	1278	O
the	1279	1282	O
Arg	1283	1286	O
-	1286	1287	O
tRNA	1287	1291	O
synthetase	1292	1302	O
specificity	1303	1314	O
.	1314	1315	O

The	1316	1319	O
other	1320	1325	O
attributions	1326	1338	O
produced	1339	1347	O
two	1348	1351	O
correlation	1352	1363	O
sets	1364	1368	O
.	1368	1369	O

(	1370	1371	O
b	1371	1372	O
)	1372	1373	O
One	1374	1377	O
corresponds	1378	1389	O
to	1390	1392	O
the	1393	1396	O
remaining	1397	1406	O
pDiN	1407	1411	O
of	1412	1414	O
the	1415	1418	O
homogeneous	1419	1430	O
sector	1431	1437	O
,	1437	1438	O
containing	1439	1449	O
both	1450	1454	O
synthetase	1455	1465	O
classes	1466	1473	O
;	1473	1474	O
its	1475	1478	O
regression	1479	1489	O
line	1490	1494	O
overlapped	1495	1505	O
the	1506	1509	O
one	1510	1513	O
formed	1514	1520	O
by	1521	1523	O
the	1524	1527	O
remaining	1528	1537	O
attributions	1538	1550	O
to	1551	1553	O
class	1554	1559	O
II	1560	1562	O
.	1562	1563	O

(	1564	1565	O
c	1565	1566	O
)	1566	1567	O
The	1568	1571	O
other	1572	1577	O
contains	1578	1586	O
the	1587	1590	O
pDiN	1591	1595	O
of	1596	1598	O
the	1599	1602	O
mixed	1603	1608	O
sector	1609	1615	O
and	1616	1619	O
produced	1620	1628	O
steeper	1629	1636	O
slopes	1637	1643	O
,	1643	1644	O
especially	1645	1655	O
with	1656	1660	O
the	1661	1664	O
class	1665	1670	O
I	1671	1672	O
attributions	1673	1685	O
.	1685	1686	O

It	1687	1689	O
is	1690	1692	O
suggested	1693	1702	O
that	1703	1707	O
the	1708	1711	O
correlation	1712	1723	O
was	1724	1727	O
established	1728	1739	O
when	1740	1744	O
the	1745	1748	O
amino	1749	1754	O
acid	1755	1759	O
composition	1760	1771	O
of	1772	1774	O
the	1775	1778	O
protein	1779	1786	O
synthetases	1787	1798	O
became	1799	1805	O
progressively	1806	1819	O
enriched	1820	1828	O
and	1829	1832	O
that	1833	1837	O
the	1838	1841	O
set	1842	1845	O
of	1846	1848	O
outliers	1849	1857	O
were	1858	1862	O
the	1863	1866	O
earliest	1867	1875	O
to	1876	1878	O
have	1879	1883	O
been	1884	1888	O
fixed	1889	1894	O
.	1894	1895	O

Hypocholesterolaemic	0	20	O
and	21	24	O
antioxidant	25	36	O
effects	37	44	O
of	45	47	O
Glycyrrhiza	48	59	O
glabra	60	66	O
(	67	68	O
Linn	68	72	O
)	72	73	O
in	74	76	O
rats	77	81	O
.	81	82	O

The	83	86	O
hypocholesterolaemic	87	107	O
and	108	111	O
antioxidant	112	123	O
effects	124	131	O
of	132	134	O
Glycyrrhiza	135	146	O
glabra	147	153	O
(	154	155	O
GG	155	157	O
)	157	158	O
root	159	163	B-Organ
powder	164	170	O
were	171	175	O
examined	176	184	O
in	185	187	O
hypercholesterolaemic	188	209	O
male	210	214	O
albino	215	221	O
rats	222	226	O
.	226	227	O

A	228	229	O
4	230	231	O
-	231	232	O
week	232	236	O
administration	237	251	O
of	252	254	O
GG	255	257	O
root	258	262	B-Organ
powder	263	269	O
(	270	271	O
5	271	272	O
and	273	276	O
10	277	279	O
gm	280	282	O
%	282	283	O
in	284	286	O
diet	287	291	O
)	291	292	O
to	293	295	O
hypercholesterolaemic	296	317	O
rats	318	322	O
resulted	323	331	O
in	332	334	O
significant	335	346	O
reduction	347	356	O
in	357	359	O
plasma	360	366	B-Organism_substance
,	366	367	O
hepatic	368	375	B-Organ
total	376	381	O
lipids	382	388	O
,	388	389	O
cholesterol	390	401	O
,	401	402	O
triglycerides	403	416	O
and	417	420	O
plasma	421	427	B-Organism_substance
low	428	431	O
-	431	432	O
density	432	439	O
lipoprotein	440	451	O
and	452	455	O
VLDL	456	460	O
-	460	461	O
cholesterol	461	472	O
accompanied	473	484	O
by	485	487	O
significant	488	499	O
increases	500	509	O
in	510	512	O
HDL	513	516	O
-	516	517	O
cholesterol	517	528	O
levels	529	535	O
.	535	536	O

Furthermore	537	548	O
,	548	549	O
significant	550	561	O
increases	562	571	O
in	572	574	O
fecal	575	580	B-Organism_substance
cholesterol	581	592	O
,	592	593	O
neutral	594	601	O
sterols	602	609	O
and	610	613	O
bile	614	618	O
acid	619	623	O
excretion	624	633	O
along	634	639	O
with	640	644	O
an	645	647	O
increase	648	656	O
in	657	659	O
hepatic	660	667	B-Organ
HMG	668	671	O
-	671	672	O
CoA	672	675	O
reductase	676	685	O
activity	686	694	O
and	695	698	O
bile	699	703	O
acid	704	708	O
production	709	719	O
were	720	724	O
observed	725	733	O
in	734	736	O
these	737	742	O
animals	743	750	O
.	750	751	O

The	752	755	O
root	756	760	B-Organ
powder	761	767	O
administration	768	782	O
to	783	785	O
hypercholesterolaemic	786	807	O
rats	808	812	O
also	813	817	O
decreased	818	827	O
hepatic	828	835	B-Organ
lipid	836	841	O
peroxidation	842	854	O
with	855	859	O
a	860	861	O
concomitant	862	873	O
increase	874	882	O
in	883	885	O
superoxide	886	896	O
dismutase	897	906	O
(	907	908	O
SOD	908	911	O
)	911	912	O
and	913	916	O
catalase	917	925	O
activities	926	936	O
and	937	940	O
total	941	946	O
ascorbic	947	955	O
acid	956	960	O
content	961	968	O
.	968	969	O

Thus	970	974	O
,	974	975	O
the	976	979	O
hypocholesterolaemic	980	1000	O
and	1001	1004	O
antioxidant	1005	1016	O
effects	1017	1024	O
of	1025	1027	O
GG	1028	1030	O
root	1031	1035	B-Organ
appeared	1036	1044	O
to	1045	1047	O
be	1048	1050	O
mediated	1051	1059	O
via	1060	1063	O
(	1064	1065	O
i	1065	1066	O
)	1066	1067	O
accelerated	1068	1079	O
cholesterol	1080	1091	O
,	1091	1092	O
neutral	1093	1100	O
sterol	1101	1107	O
and	1108	1111	O
bile	1112	1116	O
acid	1117	1121	O
elimination	1122	1133	O
through	1134	1141	O
fecal	1142	1147	B-Organism_substance
matter	1148	1154	I-Organism_substance
with	1155	1159	O
an	1160	1162	O
increased	1163	1172	O
hepatic	1173	1180	B-Organ
bile	1181	1185	O
acid	1186	1190	O
production	1191	1201	O
and	1202	1205	O
(	1206	1207	O
ii	1207	1209	O
)	1209	1210	O
improving	1211	1220	O
the	1221	1224	O
activities	1225	1235	O
of	1236	1238	O
hepatic	1239	1246	B-Organ
SOD	1247	1250	O
,	1250	1251	O
catalase	1252	1260	O
and	1261	1264	O
increasing	1265	1275	O
the	1276	1279	O
ascorbic	1280	1288	O
acid	1289	1293	O
content	1294	1301	O
.	1301	1302	O

The	1303	1306	O
normo	1307	1312	O
-	1312	1313	O
cholesterolaemic	1313	1329	O
animals	1330	1337	O
when	1338	1342	O
fed	1343	1346	O
with	1347	1351	O
GG	1352	1354	O
root	1355	1359	B-Organ
powder	1360	1366	O
at	1367	1369	O
10	1370	1372	O
gm	1373	1375	O
%	1375	1376	O
level	1377	1382	O
,	1382	1383	O
registered	1384	1394	O
a	1395	1396	O
significant	1397	1408	O
decline	1409	1416	O
in	1417	1419	O
plasma	1420	1426	B-Organism_substance
lipid	1427	1432	O
profiles	1433	1441	O
and	1442	1445	O
an	1446	1448	O
increase	1449	1457	O
in	1458	1460	O
HDL	1461	1464	O
-	1464	1465	O
cholesterol	1465	1476	O
content	1477	1484	O
.	1484	1485	O

The	1486	1489	O
antioxidant	1490	1501	O
status	1502	1508	O
of	1509	1511	O
these	1512	1517	O
animals	1518	1525	O
also	1526	1530	O
was	1531	1534	O
improved	1535	1543	O
upon	1544	1548	O
treatment	1549	1558	O
.	1558	1559	O

Multicentre	0	11	O
study	12	17	O
on	18	20	O
peri	21	25	O
-	25	26	O
and	27	30	O
postoperative	31	44	O
central	45	52	B-Multi-tissue_structure
venous	53	59	I-Multi-tissue_structure
oxygen	60	66	O
saturation	67	77	O
in	78	80	O
high	81	85	O
-	85	86	O
risk	86	90	O
surgical	91	99	O
patients	100	108	O
.	108	109	O

INTRODUCTION	110	122	O
:	122	123	O

Low	124	127	O
central	128	135	B-Multi-tissue_structure
venous	136	142	I-Multi-tissue_structure
oxygen	143	149	O
saturation	150	160	O
(	161	162	O
ScvO2	162	167	O
)	167	168	O
has	169	172	O
been	173	177	O
associated	178	188	O
with	189	193	O
increased	194	203	O
risk	204	208	O
of	209	211	O
postoperative	212	225	O
complications	226	239	O
in	240	242	O
high	243	247	O
-	247	248	O
risk	248	252	O
surgery	253	260	O
.	260	261	O

Whether	262	269	O
this	270	274	O
association	275	286	O
is	287	289	O
centre	290	296	O
-	296	297	O
specific	297	305	O
or	306	308	O
more	309	313	O
generalisable	314	327	O
is	328	330	O
not	331	334	O
known	335	340	O
.	340	341	O

The	342	345	O
aim	346	349	O
of	350	352	O
this	353	357	O
study	358	363	O
was	364	367	O
to	368	370	O
assess	371	377	O
the	378	381	O
association	382	393	O
between	394	401	O
peri	402	406	O
-	406	407	O
and	408	411	O
postoperative	412	425	O
ScvO2	426	431	O
and	432	435	O
outcome	436	443	O
in	444	446	O
high	447	451	O
-	451	452	O
risk	452	456	O
surgical	457	465	O
patients	466	474	O
in	475	477	O
a	478	479	O
multicentre	480	491	O
setting	492	499	O
.	499	500	O

METHODS	501	508	O
:	508	509	O

Three	510	515	O
large	516	521	O
European	522	530	O
university	531	541	O
hospitals	542	551	O
(	552	553	O
two	553	556	O
in	557	559	O
Finland	560	567	O
,	567	568	O
one	569	572	O
in	573	575	O
Switzerland	576	587	O
)	587	588	O
participated	589	601	O
.	601	602	O

In	603	605	O
60	606	608	O
patients	609	617	O
with	618	622	O
intra	623	628	O
-	628	629	O
abdominal	629	638	B-Organism_subdivision
surgery	639	646	O
lasting	647	654	O
more	655	659	O
than	660	664	O
90	665	667	O
minutes	668	675	O
,	675	676	O
the	677	680	O
presence	681	689	O
of	690	692	O
at	693	695	O
least	696	701	O
two	702	705	O
of	706	708	O
Shoemaker	709	718	O
'	718	719	O
s	719	720	O
criteria	721	729	O
,	729	730	O
and	731	734	O
ASA	735	738	O
(	739	740	O
American	740	748	O
Society	749	756	O
of	757	759	O
Anesthesiologists	760	777	O
)	777	778	O
class	779	784	O
greater	785	792	O
than	793	797	O
2	798	799	O
,	799	800	O
ScvO2	801	806	O
was	807	810	O
determined	811	821	O
preoperatively	822	836	O
and	837	840	O
at	841	843	O
two	844	847	O
hour	848	852	O
intervals	853	862	O
during	863	869	O
the	870	873	O
operation	874	883	O
until	884	889	O
12	890	892	O
hours	893	898	O
postoperatively	899	914	O
.	914	915	O

Hospital	916	924	O
length	925	931	O
of	932	934	O
stay	935	939	O
(	940	941	O
LOS	941	944	O
)	944	945	O
mortality	946	955	O
,	955	956	O
and	957	960	O
predefined	961	971	O
postoperative	972	985	O
complications	986	999	O
were	1000	1004	O
recorded	1005	1013	O
.	1013	1014	O

RESULTS	1015	1022	O
:	1022	1023	O

The	1024	1027	O
age	1028	1031	O
of	1032	1034	O
the	1035	1038	O
patients	1039	1047	O
was	1048	1051	O
72	1052	1054	O
+	1055	1056	O
/	1056	1057	O
-	1057	1058	O
10	1059	1061	O
years	1062	1067	O
(	1068	1069	O
mean	1069	1073	O
+	1074	1075	O
/	1075	1076	O
-	1076	1077	O
standard	1078	1086	O
deviation	1087	1096	O
)	1096	1097	O
,	1097	1098	O
and	1099	1102	O
simplified	1103	1113	O
acute	1114	1119	O
physiology	1120	1130	O
score	1131	1136	O
(	1137	1138	O
SAPS	1138	1142	O
II	1143	1145	O
)	1145	1146	O
was	1147	1150	O
32	1151	1153	O
+	1154	1155	O
/	1155	1156	O
-	1156	1157	O
12	1158	1160	O
.	1160	1161	O

Hospital	1162	1170	O
LOS	1171	1174	O
was	1175	1178	O
10	1179	1181	O
.	1181	1182	O
5	1182	1183	O
(	1184	1185	O
8	1185	1186	O
to	1187	1189	O
14	1190	1192	O
)	1192	1193	O
days	1194	1198	O
,	1198	1199	O
and	1200	1203	O
28	1204	1206	O
-	1206	1207	O
day	1207	1210	O
hospital	1211	1219	O
mortality	1220	1229	O
was	1230	1233	O
10	1234	1236	O
.	1236	1237	O
0	1237	1238	O
%	1238	1239	O
.	1239	1240	O

Preoperative	1241	1253	O
ScvO2	1254	1259	O
decreased	1260	1269	O
from	1270	1274	O
77	1275	1277	O
%	1277	1278	O
+	1279	1280	O
/	1280	1281	O
-	1281	1282	O
10	1283	1285	O
%	1285	1286	O
to	1287	1289	O
70	1290	1292	O
%	1292	1293	O
+	1294	1295	O
/	1295	1296	O
-	1296	1297	O
11	1298	1300	O
%	1300	1301	O
(	1302	1303	O
p	1303	1304	O
<	1305	1306	O
0	1307	1308	O
.	1308	1309	O
001	1309	1312	O
)	1312	1313	O
immediately	1314	1325	O
after	1326	1331	O
surgery	1332	1339	O
and	1340	1343	O
remained	1344	1352	O
unchanged	1353	1362	O
12	1363	1365	O
hours	1366	1371	O
later	1372	1377	O
.	1377	1378	O

A	1379	1380	O
total	1381	1386	O
of	1387	1389	O
67	1390	1392	O
postoperative	1393	1406	O
complications	1407	1420	O
were	1421	1425	O
recorded	1426	1434	O
in	1435	1437	O
32	1438	1440	O
patients	1441	1449	O
.	1449	1450	O

After	1451	1456	O
multivariate	1457	1469	O
analysis	1470	1478	O
,	1478	1479	O
mean	1480	1484	O
ScvO2	1485	1490	O
value	1491	1496	O
(	1497	1498	O
odds	1498	1502	O
ratio	1503	1508	O
[	1509	1510	O
OR	1510	1512	O
]	1512	1513	O
1	1514	1515	O
.	1515	1516	O
23	1516	1518	O
[	1519	1520	O
95	1520	1522	O
%	1522	1523	O
confidence	1524	1534	O
interval	1535	1543	O
(	1544	1545	O
CI	1545	1547	O
)	1547	1548	O
1	1549	1550	O
.	1550	1551	O
01	1551	1553	O
to	1554	1556	O
1	1557	1558	O
.	1558	1559	O
50	1559	1561	O
]	1561	1562	O
,	1562	1563	O
p	1564	1565	O
=	1566	1567	O
0	1568	1569	O
.	1569	1570	O
037	1570	1573	O
)	1573	1574	O
,	1574	1575	O
hospital	1576	1584	O
LOS	1585	1588	O
(	1589	1590	O
OR	1590	1592	O
0	1593	1594	O
.	1594	1595	O
75	1595	1597	O
[	1598	1599	O
95	1599	1601	O
%	1601	1602	O
CI	1603	1605	O
0	1606	1607	O
.	1607	1608	O
59	1608	1610	O
to	1611	1613	O
0	1614	1615	O
.	1615	1616	O
94	1616	1618	O
]	1618	1619	O
,	1619	1620	O
p	1621	1622	O
=	1623	1624	O
0	1625	1626	O
.	1626	1627	O
012	1627	1630	O
)	1630	1631	O
,	1631	1632	O
and	1633	1636	O
SAPS	1637	1641	O
II	1642	1644	O
(	1645	1646	O
OR	1646	1648	O
0	1649	1650	O
.	1650	1651	O
90	1651	1653	O
[	1654	1655	O
95	1655	1657	O
%	1657	1658	O
CI	1659	1661	O
0	1662	1663	O
.	1663	1664	O
82	1664	1666	O
to	1667	1669	O
0	1670	1671	O
.	1671	1672	O
99	1672	1674	O
]	1674	1675	O
,	1675	1676	O
p	1677	1678	O
=	1679	1680	O
0	1681	1682	O
.	1682	1683	O
029	1683	1686	O
)	1686	1687	O
were	1688	1692	O
independently	1693	1706	O
associated	1707	1717	O
with	1718	1722	O
postoperative	1723	1736	O
complications	1737	1750	O
.	1750	1751	O

The	1752	1755	O
optimal	1756	1763	O
value	1764	1769	O
of	1770	1772	O
mean	1773	1777	O
ScvO2	1778	1783	O
to	1784	1786	O
discriminate	1787	1799	O
between	1800	1807	O
patients	1808	1816	O
who	1817	1820	O
did	1821	1824	O
or	1825	1827	O
did	1828	1831	O
not	1832	1835	O
develop	1836	1843	O
complications	1844	1857	O
was	1858	1861	O
73	1862	1864	O
%	1864	1865	O
(	1866	1867	O
sensitivity	1867	1878	O
72	1879	1881	O
%	1881	1882	O
,	1882	1883	O
specificity	1884	1895	O
61	1896	1898	O
%	1898	1899	O
)	1899	1900	O
.	1900	1901	O

CONCLUSION	1902	1912	O
:	1912	1913	O

Low	1914	1917	O
ScvO2	1918	1923	O
perioperatively	1924	1939	O
is	1940	1942	O
related	1943	1950	O
to	1951	1953	O
increased	1954	1963	O
risk	1964	1968	O
of	1969	1971	O
postoperative	1972	1985	O
complications	1986	1999	O
in	2000	2002	O
high	2003	2007	O
-	2007	2008	O
risk	2008	2012	O
surgery	2013	2020	O
.	2020	2021	O

This	2022	2026	O
warrants	2027	2035	O
trials	2036	2042	O
with	2043	2047	O
goal	2048	2052	O
-	2052	2053	O
directed	2053	2061	O
therapy	2062	2069	O
using	2070	2075	O
ScvO2	2076	2081	O
as	2082	2084	O
a	2085	2086	O
target	2087	2093	O
in	2094	2096	O
high	2097	2101	O
-	2101	2102	O
risk	2102	2106	O
surgery	2107	2114	O
patients	2115	2123	O
.	2123	2124	O

[	0	1	O
Treatment	1	10	O
of	11	13	O
squamous	14	22	B-Pathological_formation
intraepithelial	23	38	I-Pathological_formation
lesion	39	45	I-Pathological_formation
of	46	48	O
type	49	53	O
CIN2	54	58	O
et	59	61	O
CIN3	62	66	O
with	67	71	O
laser	72	77	O
CO2	78	81	O
vaporization	82	94	O
:	94	95	O
retrospective	96	109	O
study	110	115	O
of	116	118	O
52	119	121	O
cases	122	127	O
]	127	128	O
.	128	129	O

OBJECTIVES	130	140	O
:	140	141	O

This	142	146	O
study	147	152	O
was	153	156	O
carried	157	164	O
out	165	168	O
over	169	173	O
an	174	176	O
8	177	178	O
-	178	179	O
year	179	183	O
period	184	190	O
in	191	193	O
order	194	199	O
to	200	202	O
evaluate	203	211	O
the	212	215	O
long	216	220	O
-	220	221	O
term	221	225	O
effectiveness	226	239	O
of	240	242	O
laser	243	248	O
CO2	249	252	O
vaporization	253	265	O
in	266	268	O
the	269	272	O
treatment	273	282	O
of	283	285	O
squamous	286	294	B-Pathological_formation
intraepithelial	295	310	I-Pathological_formation
lesion	311	317	I-Pathological_formation
of	318	320	O
type	321	325	O
CIN2	326	330	O
and	331	334	O
CIN3	335	339	O
.	339	340	O

MATERIALS	341	350	O
AND	351	354	O
METHODS	355	362	O
:	362	363	O

A	364	365	O
retrospective	366	379	O
study	380	385	O
of	386	388	O
52	389	391	O
cases	392	397	O
of	398	400	O
cervical	401	409	B-Pathological_formation
lesions	410	417	I-Pathological_formation
of	418	420	O
type	421	425	O
CIN2	426	430	O
and	431	434	O
CIN3	435	439	O
treated	440	447	O
in	448	450	O
first	451	456	O
intention	457	466	O
by	467	469	O
laser	470	475	O
CO2	476	479	O
vaporization	480	492	O
was	493	496	O
carried	497	504	O
out	505	508	O
at	509	511	O
the	512	515	O
hospital	516	524	O
Jeanne	525	531	O
-	531	532	O
de	532	534	O
-	534	535	O
Flandre	535	542	O
in	543	545	O
CHRU	546	550	O
of	551	553	O
Lille	554	559	O
from	560	564	O
1996	565	569	O
to	570	572	O
2003	573	577	O
.	577	578	O

This	579	583	O
treatment	584	593	O
was	594	597	O
performed	598	607	O
on	608	610	O
only	611	615	O
high	616	620	O
-	620	621	O
grade	621	626	O
exo	627	630	B-Pathological_formation
-	630	631	I-Pathological_formation
cervical	631	639	I-Pathological_formation
lesions	640	647	I-Pathological_formation
,	647	648	O
of	649	651	O
small	652	657	O
size	658	662	O
(	663	664	O
<	664	665	O
2cm2	665	669	O
)	669	670	O
,	670	671	O
after	672	677	O
a	678	679	O
complete	680	688	O
colposcopic	689	700	O
examination	701	712	O
.	712	713	O

RESULTS	714	721	O
:	721	722	O

Fifty	723	728	O
-	728	729	O
two	729	732	O
patients	733	741	O
were	742	746	O
treated	747	754	O
by	755	757	O
first	758	763	O
-	763	764	O
intention	764	773	O
laser	774	779	O
vaporization	780	792	O
only	793	797	O
.	797	798	O

Mean	799	803	O
age	804	807	O
was	808	811	O
29	812	814	O
.	814	815	O
4	815	816	O
years	817	822	O
and	823	826	O
51	827	829	O
.	829	830	O
9	830	831	O
%	831	832	O
were	833	837	O
nulliparous	838	849	O
.	849	850	O

At	851	853	O
the	854	857	O
first	858	863	O
cyto	864	868	O
-	868	869	O
colposcopic	869	880	O
control	881	888	O
,	888	889	O
there	890	895	O
were	896	900	O
17	901	903	O
persistent	904	914	O
lesions	915	922	B-Pathological_formation
(	923	924	O
32	924	926	O
.	926	927	O
7	927	928	O
%	928	929	O
)	929	930	O
.	930	931	O

Among	932	937	O
the	938	941	O
35	942	944	O
patients	945	953	O
without	954	961	O
persistent	962	972	O
lesion	973	979	B-Pathological_formation
,	979	980	O
29	981	983	O
achieved	984	992	O
cure	993	997	O
(	998	999	O
absence	999	1006	O
of	1007	1009	O
recurrence	1010	1020	O
)	1020	1021	O
,	1021	1022	O
4	1023	1024	O
presented	1025	1034	O
a	1035	1036	O
recurrence	1037	1047	O
and	1048	1051	O
2	1052	1053	O
were	1054	1058	O
lost	1059	1063	O
to	1064	1066	O
follow	1067	1073	O
-	1073	1074	O
up	1074	1076	O
.	1076	1077	O

CONCLUSION	1078	1088	O
:	1088	1089	O

The	1090	1093	O
current	1094	1101	O
data	1102	1106	O
of	1107	1109	O
the	1110	1113	O
literature	1114	1124	O
concerning	1125	1135	O
the	1136	1139	O
treatment	1140	1149	O
by	1150	1152	O
laser	1153	1158	O
CO2	1159	1162	O
vaporization	1163	1175	O
authorize	1176	1185	O
application	1186	1197	O
of	1198	1200	O
this	1201	1205	O
method	1206	1212	O
for	1213	1216	O
certain	1217	1224	O
high	1225	1229	O
-	1229	1230	O
grade	1230	1235	O
exocervical	1236	1247	B-Pathological_formation
lesions	1248	1255	I-Pathological_formation
after	1256	1261	O
a	1262	1263	O
complete	1264	1272	O
colposcopic	1273	1284	O
examination	1285	1296	O
.	1296	1297	O

This	1298	1302	O
type	1303	1307	O
of	1308	1310	O
treatment	1311	1320	O
remains	1321	1328	O
less	1329	1333	O
aggressive	1334	1344	O
than	1345	1349	O
a	1350	1351	O
surgical	1352	1360	O
treatment	1361	1370	O
.	1370	1371	O

The	1372	1375	O
high	1376	1380	O
rate	1381	1385	O
of	1386	1388	O
residual	1389	1397	O
lesions	1398	1405	B-Pathological_formation
in	1406	1408	O
particular	1409	1419	O
in	1420	1422	O
the	1423	1426	O
event	1427	1432	O
of	1433	1435	O
CIN3	1436	1440	O
can	1441	1444	O
be	1445	1447	O
due	1448	1451	O
to	1452	1454	O
an	1455	1457	O
incomplete	1458	1468	O
destruction	1469	1480	O
of	1481	1483	O
the	1484	1487	O
lesion	1488	1494	B-Pathological_formation
.	1494	1495	O

Patients	1496	1504	O
should	1505	1511	O
thus	1512	1516	O
be	1517	1519	O
advised	1520	1527	O
that	1528	1532	O
monitoring	1533	1543	O
is	1544	1546	O
an	1547	1549	O
integral	1550	1558	O
part	1559	1563	O
of	1564	1566	O
the	1567	1570	O
treatment	1571	1580	O
.	1580	1581	O

Laser	1582	1587	O
vaporization	1588	1600	O
could	1601	1606	O
be	1607	1609	O
limited	1610	1617	O
to	1618	1620	O
CIN1	1621	1625	O
and	1626	1629	O
CIN2	1630	1634	O
lesions	1635	1642	B-Pathological_formation
.	1642	1643	O

Segmental	0	9	O
atrial	10	16	B-Multi-tissue_structure
contraction	17	28	O
in	29	31	O
patients	32	40	O
restored	41	49	O
to	50	52	O
sinus	53	58	B-Immaterial_anatomical_entity
rhythm	59	65	O
after	66	71	O
cardioversion	72	85	O
for	86	89	O
chronic	90	97	O
atrial	98	104	B-Multi-tissue_structure
fibrillation	105	117	O
:	117	118	O
a	119	120	O
colour	121	127	O
Doppler	128	135	O
tissue	136	142	B-Tissue
imaging	143	150	O
study	151	156	O
.	156	157	O

AIMS	158	162	O
:	162	163	O

There	164	169	O
is	170	172	O
little	173	179	O
known	180	185	O
about	186	191	O
segmental	192	201	O
atrial	202	208	B-Multi-tissue_structure
function	209	217	O
in	218	220	O
patients	221	229	O
with	230	234	O
atrial	235	241	B-Multi-tissue_structure
arrhythmias	242	253	O
.	253	254	O

We	255	257	O
evaluated	258	267	O
segmental	268	277	O
atrial	278	284	B-Multi-tissue_structure
contractility	285	298	O
using	299	304	O
colour	305	311	O
Doppler	312	319	O
tissue	320	326	B-Tissue
imaging	327	334	O
(	335	336	O
CDTI	336	340	O
)	340	341	O
in	342	344	O
patients	345	353	O
with	354	358	O
chronic	359	366	O
atrial	367	373	B-Multi-tissue_structure
fibrillation	374	386	O
(	387	388	O
CAF	388	391	O
)	391	392	O
who	393	396	O
were	397	401	O
successfully	402	414	O
restored	415	423	O
and	424	427	O
maintained	428	438	O
in	439	441	O
sinus	442	447	B-Immaterial_anatomical_entity
rhythm	448	454	O
(	455	456	O
SR	456	458	O
)	458	459	O
.	459	460	O

METHODS	461	468	O
AND	469	472	O
RESULTS	473	480	O
:	480	481	O

We	482	484	O
compared	485	493	O
the	494	497	O
segmental	498	507	O
atrial	508	514	B-Multi-tissue_structure
contractility	515	528	O
in	529	531	O
39	532	534	O
CAF	535	538	O
patients	539	547	O
who	548	551	O
were	552	556	O
successfully	557	569	O
cardioverted	570	582	O
and	583	586	O
maintained	587	597	O
in	598	600	O
SR	601	603	O
for	604	607	O
6	608	609	O
months	610	616	O
.	616	617	O

Follow	618	624	O
up	625	627	O
echocardiograms	628	643	O
were	644	648	O
performed	649	658	O
at	659	661	O
baseline	662	670	O
,	670	671	O
1	672	673	O
week	674	678	O
,	678	679	O
1	680	681	O
month	682	687	O
and	688	691	O
6	692	693	O
months	694	700	O
and	701	704	O
compared	705	713	O
to	714	716	O
a	717	718	O
normal	719	725	O
age	726	729	O
matched	730	737	O
cohort	738	744	O
(	745	746	O
n	746	747	O
=	748	749	O
34	750	752	O
)	752	753	O
.	753	754	O

Using	755	760	O
CDTI	761	765	O
,	765	766	O
mean	767	771	O
peak	772	776	O
velocities	777	787	O
of	788	790	O
atrial	791	797	B-Multi-tissue_structure
contraction	798	809	O
were	810	814	O
measured	815	823	O
from	824	828	O
annular	829	836	O
,	836	837	O
mid	838	841	O
and	842	845	O
superior	846	854	O
segments	855	863	O
of	864	866	O
lateral	867	874	B-Multi-tissue_structure
and	875	878	O
septal	879	885	B-Multi-tissue_structure
walls	886	891	I-Multi-tissue_structure
of	892	894	O
the	895	898	O
left	899	903	B-Multi-tissue_structure
atrium	904	910	I-Multi-tissue_structure
and	911	914	O
right	915	920	B-Multi-tissue_structure
atrium	921	927	I-Multi-tissue_structure
in	928	930	O
the	931	934	O
apical	935	941	O
four	942	946	O
-	946	947	O
chamber	947	954	O
view	955	959	O
.	959	960	O

Segmental	961	970	O
velocities	971	981	O
from	982	986	O
the	987	990	O
posterior	991	1000	O
and	1001	1004	O
anterior	1005	1013	O
walls	1014	1019	O
of	1020	1022	O
the	1023	1026	O
left	1027	1031	B-Multi-tissue_structure
atrium	1032	1038	I-Multi-tissue_structure
were	1039	1043	O
measured	1044	1052	O
from	1053	1057	O
the	1058	1061	O
apical	1062	1068	O
two	1069	1072	O
-	1072	1073	O
chamber	1073	1080	O
view	1081	1085	O
.	1085	1086	O

Segmental	1087	1096	O
left	1097	1101	B-Multi-tissue_structure
atrial	1102	1108	I-Multi-tissue_structure
velocities	1109	1119	O
improved	1120	1128	O
over	1129	1133	O
time	1134	1138	O
in	1139	1141	O
the	1142	1145	O
CAF	1146	1149	O
group	1150	1155	O
,	1155	1156	O
with	1157	1161	O
the	1162	1165	O
majority	1166	1174	O
of	1175	1177	O
the	1178	1181	O
recovery	1182	1190	O
occurring	1191	1200	O
in	1201	1203	O
the	1204	1207	O
first	1208	1213	O
month	1214	1219	O
,	1219	1220	O
but	1221	1224	O
failed	1225	1231	O
to	1232	1234	O
normalise	1235	1244	O
even	1245	1249	O
at	1250	1252	O
6	1253	1254	O
months	1255	1261	O
.	1261	1262	O

In	1263	1265	O
comparison	1266	1276	O
,	1276	1277	O
the	1278	1281	O
right	1282	1287	B-Multi-tissue_structure
atrial	1288	1294	I-Multi-tissue_structure
velocities	1295	1305	O
in	1306	1308	O
the	1309	1312	O
AF	1313	1315	O
group	1316	1321	O
had	1322	1325	O
normalised	1326	1336	O
at	1337	1339	O
1	1340	1341	O
month	1342	1347	O
.	1347	1348	O

CONCLUSION	1349	1359	O
:	1359	1360	O

Patients	1361	1369	O
with	1370	1374	O
CAF	1375	1378	O
have	1379	1383	O
persistent	1384	1394	O
segmental	1395	1404	O
left	1405	1409	B-Multi-tissue_structure
atrial	1410	1416	I-Multi-tissue_structure
dysfunction	1417	1428	O
even	1429	1433	O
6	1434	1435	O
months	1436	1442	O
after	1443	1448	O
restoration	1449	1460	O
and	1461	1464	O
maintenance	1465	1476	O
of	1477	1479	O
SR	1480	1482	O
,	1482	1483	O
though	1484	1490	O
right	1491	1496	B-Multi-tissue_structure
atrial	1497	1503	I-Multi-tissue_structure
velocities	1504	1514	O
appear	1515	1521	O
to	1522	1524	O
normalise	1525	1534	O
.	1534	1535	O

This	1536	1540	O
differential	1541	1553	O
recovery	1554	1562	O
indicates	1563	1572	O
that	1573	1577	O
left	1578	1582	B-Multi-tissue_structure
atrial	1583	1589	I-Multi-tissue_structure
function	1590	1598	O
remains	1599	1606	O
subnormal	1607	1616	O
in	1617	1619	O
patients	1620	1628	O
with	1629	1633	O
CAF	1634	1637	O
despite	1638	1645	O
maintenance	1646	1657	O
of	1658	1660	O
SR	1661	1663	O
,	1663	1664	O
suggesting	1665	1675	O
underlying	1676	1686	O
atrial	1687	1693	B-Multi-tissue_structure
myopathy	1694	1702	O
or	1703	1705	O
fibrosis	1706	1714	O
as	1715	1717	O
a	1718	1719	O
consequence	1720	1731	O
of	1732	1734	O
CAF	1735	1738	O
.	1738	1739	O

[	0	1	O
Anomalous	1	10	O
origin	11	17	O
of	18	20	O
the	21	24	O
right	25	30	B-Multi-tissue_structure
coronary	31	39	I-Multi-tissue_structure
artery	40	46	I-Multi-tissue_structure
from	47	51	O
the	52	55	O
left	56	60	O
sinus	61	66	B-Immaterial_anatomical_entity
of	67	69	O
Valsalva	70	78	O
:	78	79	O
case	80	84	O
report	85	91	O
and	92	95	O
literature	96	106	O
review	107	113	O
]	113	114	O
.	114	115	O

We	116	118	O
describe	119	127	O
the	128	131	O
case	132	136	O
of	137	139	O
a	140	141	O
patient	142	149	O
in	150	152	O
whom	153	157	O
evaluation	158	168	O
of	169	171	O
effort	172	178	O
angina	179	185	O
revealed	186	194	O
a	195	196	O
tight	197	202	O
stenosis	203	211	O
of	212	214	O
a	215	216	O
right	217	222	B-Multi-tissue_structure
coronary	223	231	I-Multi-tissue_structure
artery	232	238	I-Multi-tissue_structure
anomalously	239	250	O
arising	251	258	O
from	259	263	O
the	264	267	O
left	268	272	O
sinus	273	278	B-Immaterial_anatomical_entity
of	279	281	O
Valsalva	282	290	O
,	290	291	O
which	292	297	O
was	298	301	O
successfully	302	314	O
treated	315	322	O
by	323	325	O
stent	326	331	O
implantation	332	344	O
.	344	345	O

The	346	349	O
abnormal	350	358	O
origin	359	365	O
of	366	368	O
the	369	372	O
right	373	378	B-Multi-tissue_structure
coronary	379	387	I-Multi-tissue_structure
artery	388	394	I-Multi-tissue_structure
from	395	399	O
the	400	403	O
left	404	408	O
aortic	409	415	B-Immaterial_anatomical_entity
sinus	416	421	I-Immaterial_anatomical_entity
coursing	422	430	O
between	431	438	O
the	439	442	O
aorta	443	448	B-Multi-tissue_structure
and	449	452	O
the	453	456	O
pulmonary	457	466	B-Multi-tissue_structure
trunk	467	472	I-Multi-tissue_structure
is	473	475	O
a	476	477	O
rare	478	482	O
congenital	483	493	O
anomaly	494	501	O
.	501	502	O

It	503	505	O
may	506	509	O
remain	510	516	O
asymptomatic	517	529	O
,	529	530	O
but	531	534	O
can	535	538	O
also	539	543	O
cause	544	549	O
major	550	555	O
cardiac	556	563	B-Organ
events	564	570	O
,	570	571	O
even	572	576	O
in	577	579	O
the	580	583	O
absence	584	591	O
of	592	594	O
coronary	595	603	B-Multi-tissue_structure
atherosclerosis	604	619	O
.	619	620	O

We	621	623	O
discuss	624	631	O
the	632	635	O
clinical	636	644	O
importance	645	655	O
of	656	658	O
this	659	663	O
anomaly	664	671	O
and	672	675	O
review	676	682	O
the	683	686	O
literature	687	697	O
concerning	698	708	O
current	709	716	O
views	717	722	O
and	723	726	O
therapy	727	734	O
.	734	735	O

Determination	0	13	O
of	14	16	O
eprosartan	17	27	O
in	28	30	O
human	31	36	O
plasma	37	43	B-Organism_substance
and	44	47	O
urine	48	53	B-Organism_substance
by	54	56	O
LC	57	59	O
/	59	60	O
MS	60	62	O
/	62	63	O
MS	63	65	O
.	65	66	O

A	67	68	O
protein	69	76	O
precipitation	77	90	O
,	90	91	O
liquid	92	98	O
chromatography	99	113	O
/	113	114	O
tandem	114	120	O
mass	121	125	O
spectrometry	126	138	O
(	139	140	O
LC	140	142	O
/	142	143	O
MS	143	145	O
/	145	146	O
MS	146	148	O
)	148	149	O
method	150	156	O
has	157	160	O
been	161	165	O
developed	166	175	O
and	176	179	O
validated	180	189	O
for	190	193	O
the	194	197	O
determination	198	211	O
of	212	214	O
eprosartan	215	225	O
in	226	228	O
human	229	234	O
plasma	235	241	B-Organism_substance
and	242	245	O
urine	246	251	B-Organism_substance
.	251	252	O

The	253	256	O
solvent	257	264	O
system	265	271	O
also	272	276	O
served	277	283	O
as	284	286	O
a	287	288	O
protein	289	296	O
precipitation	297	310	O
reagent	311	318	O
.	318	319	O

The	320	323	O
chromatographic	324	339	O
separation	340	350	O
was	351	354	O
achieved	355	363	O
on	364	366	O
a	367	368	O
CAPCELL	369	376	O
PAK	377	380	O
C18	381	384	O
column	385	391	O
(	392	393	O
50	393	395	O
mmx2	396	400	O
.	400	401	O
0	401	402	O
mm	403	405	O
,	405	406	O
5	407	408	O
microm	409	415	O
,	415	416	O
Shiseido	417	425	O
)	425	426	O
.	426	427	O

A	428	429	O
mobile	430	436	O
phase	437	442	O
was	443	446	O
consisted	447	456	O
of	457	459	O
0	460	461	O
.	461	462	O
5	462	463	O
%	463	464	O
formic	465	471	O
acid	472	476	O
in	477	479	O
water	480	485	O
and	486	489	O
0	490	491	O
.	491	492	O
5	492	493	O
%	493	494	O
formic	495	501	O
acid	502	506	O
in	507	509	O
acetonitrile	510	522	O
(	523	524	O
72	524	526	O
:	526	527	O
28	527	529	O
)	529	530	O
.	530	531	O

Detection	532	541	O
was	542	545	O
by	546	548	O
positive	549	557	O
ion	558	561	O
electrospray	562	574	O
tandem	575	581	O
mass	582	586	O
spectrometry	587	599	O
on	600	602	O
a	603	604	O
Sciex	605	610	O
API3000	611	618	O
.	618	619	O

The	620	623	O
standard	624	632	O
curves	633	639	O
,	639	640	O
which	641	646	O
ranged	647	653	O
from	654	658	O
5	659	660	O
to	661	663	O
2000	664	668	O
ng	669	671	O
/	671	672	O
mL	672	674	O
in	675	677	O
human	678	683	O
plasma	684	690	B-Organism_substance
and	691	694	O
from	695	699	O
0	700	701	O
.	701	702	O
25	702	704	O
to	705	707	O
50	708	710	O
microg	711	717	O
/	717	718	O
mL	718	720	O
in	721	723	O
urine	724	729	B-Organism_substance
,	729	730	O
were	731	735	O
fitted	736	742	O
to	743	745	O
a	746	747	O
1	748	749	O
/	749	750	O
x	750	751	O
weighted	752	760	O
quadratic	761	770	O
regression	771	781	O
model	782	787	O
.	787	788	O

The	789	792	O
method	793	799	O
proved	800	806	O
to	807	809	O
be	810	812	O
accurate	813	821	O
,	821	822	O
specific	823	831	O
and	832	835	O
sensitive	836	845	O
enough	846	852	O
to	853	855	O
be	856	858	O
successfully	859	871	O
applied	872	879	O
to	880	882	O
a	883	884	O
pharmacokinetic	885	900	O
study	901	906	O
.	906	907	O

[	0	1	O
Synthetic	1	10	O
fragments	11	20	O
of	21	23	O
the	24	27	O
NS1	28	31	O
protein	32	39	O
of	40	42	O
the	43	46	O
tick	47	51	O
-	51	52	O
borne	52	57	O
encephalitis	58	70	O
virus	71	76	O
exhibiting	77	87	O
a	88	89	O
protective	90	100	O
effect	101	107	O
]	107	108	O
.	108	109	O

Potentially	110	121	O
immunoactive	122	134	O
regions	135	142	O
of	143	145	O
the	146	149	O
NS1	150	153	O
nonstructural	154	167	O
protein	168	175	O
of	176	178	O
the	179	182	O
tick	183	187	O
-	187	188	O
borne	188	193	O
encephalitis	194	206	O
virus	207	212	O
that	213	217	O
can	218	221	O
stimulate	222	231	O
the	232	235	O
antibody	236	244	O
formation	245	254	O
in	255	257	O
vivo	258	262	O
and	263	266	O
protect	267	274	O
animals	275	282	O
from	283	287	O
this	288	292	O
disease	293	300	O
were	301	305	O
chosen	306	312	O
on	313	315	O
the	316	319	O
basis	320	325	O
of	326	328	O
theoretical	329	340	O
calculations	341	353	O
.	353	354	O

Eleven	355	361	O
16	362	364	O
-	364	365	O
to	366	368	O
27	369	371	O
-	371	372	O
aa	372	374	O
peptides	375	383	O
containing	384	394	O
the	395	398	O
chosen	399	405	O
regions	406	413	O
were	414	418	O
synthesized	419	430	O
.	430	431	O

The	432	435	O
ability	436	443	O
of	444	446	O
the	447	450	O
free	451	455	O
peptides	456	464	O
(	465	466	O
without	466	473	O
any	474	477	O
high	478	482	O
-	482	483	O
molecular	483	492	O
-	492	493	O
mass	493	497	O
carrier	498	505	O
)	505	506	O
to	507	509	O
stimulate	510	519	O
the	520	523	O
production	524	534	O
of	535	537	O
antipeptide	538	549	O
antibodies	550	560	O
in	561	563	O
mice	564	568	O
of	569	571	O
three	572	577	O
lines	578	583	O
and	584	587	O
ensure	588	594	O
the	595	598	O
formation	599	608	O
of	609	611	O
protective	612	622	O
immunity	623	631	O
was	632	635	O
studied	636	643	O
.	643	644	O

Most	645	649	O
of	650	652	O
these	653	658	O
peptides	659	667	O
were	668	672	O
shown	673	678	O
to	679	681	O
exhibit	682	689	O
the	690	693	O
immunogenic	694	705	O
activity	706	714	O
in	715	717	O
a	718	719	O
free	720	724	O
state	725	730	O
.	730	731	O

Five	732	736	O
fragments	737	746	O
that	747	751	O
can	752	755	O
protect	756	763	O
mice	764	768	O
from	769	773	O
the	774	777	O
infection	778	787	O
by	788	790	O
a	791	792	O
lethal	793	799	O
dose	800	804	O
of	805	807	O
tick	808	812	O
-	812	813	O
borne	813	818	O
encephalitis	819	831	O
virus	832	837	O
were	838	842	O
found	843	848	O
.	848	849	O

Long	0	4	O
-	4	5	O
term	5	9	O
immunosuppression	10	27	O
in	28	30	O
burned	31	37	O
patients	38	46	O
assessed	47	55	O
by	56	58	O
in	59	61	O
vitro	62	67	O
neutrophil	68	78	B-Cell
oxidative	79	88	O
burst	89	94	O
(	95	96	O
Phagoburst	96	106	O
)	106	107	O
.	107	108	O

OBJECTIVE	109	118	O
:	118	119	O

To	120	122	O
assess	123	129	O
the	130	133	O
duration	134	142	O
and	143	146	O
magnitude	147	156	O
of	157	159	O
immunosuppression	160	177	O
induced	178	185	O
by	186	188	O
burns	189	194	O
as	195	197	O
measured	198	206	O
by	207	209	O
the	210	213	O
neutrophil	214	224	B-Cell
oxidative	225	234	O
burst	235	240	O
in	241	243	O
vitro	244	249	O
.	249	250	O

DESIGN	251	257	O
:	257	258	O

Prospective	259	270	O
exploratory	271	282	O
cohort	283	289	O
study	290	295	O
.	295	296	O

SETTING	297	304	O
:	304	305	O

Tertiary	306	314	O
referral	315	323	O
unit	324	328	O
,	328	329	O
University	330	340	O
Hospital	341	349	O
,	349	350	O
Linkoping	351	360	O
,	360	361	O
Sweden	362	368	O
(	369	370	O
National	370	378	O
Burn	379	383	O
Unit	384	388	O
)	388	389	O
.	389	390	O

PATIENTS	391	399	O
AND	400	403	O
HEALTHY	404	411	O
VOLUNTEERS	412	422	O
(	423	424	O
CONTROLS	424	432	O
)	432	433	O
:	433	434	O
Twenty	435	441	O
-	441	442	O
eight	442	447	O
subjects	448	456	O
consecutively	457	470	O
admitted	471	479	O
to	480	482	O
the	483	486	O
Burn	487	491	O
Unit	492	496	O
.	496	497	O

The	498	501	O
mean	502	506	O
total	507	512	O
burn	513	517	O
surface	518	525	O
area	526	530	O
(	531	532	O
TBSA	532	536	O
%	536	537	O
)	537	538	O
was	539	542	O
36	543	545	O
(	546	547	O
range	547	552	O
13	553	555	O
-	555	556	O
87	556	558	O
)	558	559	O
and	560	563	O
mean	564	568	O
age	569	572	O
44	573	575	O
years	576	581	O
(	582	583	O
range	583	588	O
14	589	591	O
-	591	592	O
89	592	594	O
)	594	595	O
.	595	596	O

Patients	597	605	O
'	605	606	O
data	607	611	O
were	612	616	O
collected	617	626	O
prospectively	627	640	O
in	641	643	O
the	644	647	O
burn	648	652	O
unit	653	657	O
,	657	658	O
which	659	664	O
also	665	669	O
included	670	678	O
sequential	679	689	O
organ	690	695	B-Organ
failure	696	703	O
assessment	704	714	O
(	715	716	O
SOFA	716	720	O
)	720	721	O
score	722	727	O
.	727	728	O

INTERVENTIONS	729	742	O
:	742	743	O

None	744	748	O
.	748	749	O

MEASUREMENTS	750	762	O
AND	763	766	O
RESULTS	767	774	O
:	774	775	O

To	776	778	O
assess	779	785	O
the	786	789	O
changes	790	797	O
in	798	800	O
the	801	804	O
oxidative	805	814	O
capacity	815	823	O
of	824	826	O
neutrophils	827	838	B-Cell
after	839	844	O
the	845	848	O
burn	849	853	O
,	853	854	O
blood	855	860	B-Organism_substance
samples	861	868	I-Organism_substance
for	869	872	O
the	873	876	O
Phagoburst	877	887	O
analysis	888	896	O
were	897	901	O
taken	902	907	O
on	908	910	O
admission	911	920	O
and	921	924	O
at	925	927	O
least	928	933	O
once	934	938	O
every	939	944	O
second	945	951	O
week	952	956	O
for	957	960	O
the	961	964	O
duration	965	973	O
of	974	976	O
stay	977	981	O
in	982	984	O
hospital	985	993	O
and	994	997	O
thereafter	998	1008	O
monthly	1009	1016	O
up	1017	1019	O
to	1020	1022	O
12	1023	1025	O
months	1026	1032	O
after	1033	1038	O
the	1039	1042	O
burn	1043	1047	O
.	1047	1048	O

Neutrophils	1049	1060	B-Cell
were	1061	1065	O
stimulated	1066	1076	O
in	1077	1079	O
vitro	1080	1085	O
by	1086	1088	O
Escherichia	1089	1100	O
coli	1101	1105	O
,	1105	1106	O
phorbol	1107	1114	O
12	1115	1117	O
-	1117	1118	O
phorbol	1118	1125	O
myristate	1126	1135	O
13	1136	1138	O
-	1138	1139	O
acetate	1139	1146	O
(	1147	1148	O
PMA	1148	1151	O
)	1151	1152	O
,	1152	1153	O
and	1154	1157	O
peptide	1158	1165	O
N	1166	1167	O
-	1167	1168	O
formyl	1168	1174	O
-	1174	1175	O
Met	1175	1178	O
-	1178	1179	O
Leu	1179	1182	O
-	1182	1183	O
Phe	1183	1186	O
(	1187	1188	O
fMLP	1188	1192	O
)	1192	1193	O
.	1193	1194	O

Oxidative	1195	1204	O
burst	1205	1210	O
was	1211	1214	O
measured	1215	1223	O
by	1224	1226	O
flow	1227	1231	O
cytometry	1232	1241	O
.	1241	1242	O

Oxidative	1243	1252	O
capacity	1253	1261	O
of	1262	1264	O
the	1265	1268	O
neutrophils	1269	1280	B-Cell
decreased	1281	1290	O
similarly	1291	1300	O
for	1301	1304	O
all	1305	1308	O
three	1309	1314	O
stimulants	1315	1325	O
:	1325	1326	O
there	1327	1332	O
was	1333	1336	O
a	1337	1338	O
pathological	1339	1351	O
decrease	1352	1360	O
shortly	1361	1368	O
after	1369	1374	O
admission	1375	1384	O
,	1384	1385	O
with	1386	1390	O
the	1391	1394	O
lowest	1395	1401	O
value	1402	1407	O
occurring	1408	1417	O
between	1418	1425	O
days	1426	1430	O
7	1431	1432	O
and	1433	1436	O
10	1437	1439	O
,	1439	1440	O
followed	1441	1449	O
by	1450	1452	O
a	1453	1454	O
gradual	1455	1462	O
recovery	1463	1471	O
during	1472	1478	O
the	1479	1482	O
ensuing	1483	1490	O
months	1491	1497	O
.	1497	1498	O

Full	1499	1503	O
recovery	1504	1512	O
(	1513	1514	O
to	1514	1516	O
the	1517	1520	O
values	1521	1527	O
of	1528	1530	O
the	1531	1534	O
controls	1535	1543	O
)	1543	1544	O
was	1545	1548	O
seen	1549	1553	O
first	1554	1559	O
3	1560	1561	O
.	1561	1562	O
5	1562	1563	O
months	1564	1570	O
after	1571	1576	O
the	1577	1580	O
burn	1581	1585	O
.	1585	1586	O

Using	1587	1592	O
multiple	1593	1601	O
regression	1602	1612	O
,	1612	1613	O
we	1614	1616	O
found	1617	1622	O
that	1623	1627	O
only	1628	1632	O
age	1633	1636	O
and	1637	1640	O
time	1641	1645	O
since	1646	1651	O
the	1652	1655	O
burn	1656	1660	O
significantly	1661	1674	O
(	1675	1676	O
p	1676	1677	O
<	1677	1678	O
0	1678	1679	O
.	1679	1680	O
05	1680	1682	O
)	1682	1683	O
affected	1684	1692	O
the	1693	1696	O
oxidative	1697	1706	O
burst	1707	1712	O
.	1712	1713	O

White	1714	1719	B-Cell
cell	1720	1724	I-Cell
count	1725	1730	O
(	1731	1732	O
WCC	1732	1735	O
)	1735	1736	O
and	1737	1740	O
C	1741	1742	O
-	1742	1743	O
reactive	1743	1751	O
protein	1752	1759	O
(	1760	1761	O
CRP	1761	1764	O
)	1764	1765	O
values	1766	1772	O
returned	1773	1781	O
to	1782	1784	O
reference	1785	1794	O
ranges	1795	1801	O
long	1802	1806	O
before	1807	1813	O
the	1814	1817	O
oxidative	1818	1827	O
burst	1828	1833	O
.	1833	1834	O

CONCLUSIONS	1835	1846	O
:	1846	1847	O

This	1848	1852	O
study	1853	1858	O
provides	1859	1867	O
evidence	1868	1876	O
that	1877	1881	O
immunosuppression	1882	1899	O
in	1900	1902	O
those	1903	1908	O
injured	1909	1916	O
by	1917	1919	O
burns	1920	1925	O
,	1925	1926	O
as	1927	1929	O
assessed	1930	1938	O
by	1939	1941	O
the	1942	1945	O
in	1946	1948	O
vitro	1949	1954	O
oxidative	1955	1964	O
burst	1965	1970	O
of	1971	1973	O
neutrophils	1974	1985	B-Cell
,	1985	1986	O
remains	1987	1994	O
long	1995	1999	O
after	2000	2005	O
the	2006	2009	O
event	2010	2015	O
of	2016	2018	O
the	2019	2022	O
burn	2023	2027	O
(	2028	2029	O
up	2029	2031	O
to	2032	2034	O
3	2035	2036	O
.	2036	2037	O
5	2037	2038	O
months	2039	2045	O
after	2046	2051	O
burn	2052	2056	O
)	2056	2057	O
.	2057	2058	O

Absence	2059	2066	O
of	2067	2069	O
correlations	2070	2082	O
to	2083	2085	O
TBSA	2086	2090	O
%	2090	2091	O
,	2091	2092	O
FTB	2093	2096	O
%	2096	2097	O
,	2097	2098	O
blood	2099	2104	B-Organism_substance
transfusion	2105	2116	O
,	2116	2117	O
opiates	2118	2125	O
provided	2126	2134	O
,	2134	2135	O
and	2136	2139	O
multiple	2140	2148	O
organ	2149	2154	B-Organ
failure	2155	2162	O
score	2163	2168	O
and	2169	2172	O
laboratory	2173	2183	O
infection	2184	2193	O
variables	2194	2203	O
together	2204	2212	O
with	2213	2217	O
the	2218	2221	O
finding	2222	2229	O
that	2230	2234	O
decreased	2235	2244	O
oxidative	2245	2254	O
burst	2255	2260	O
was	2261	2264	O
uniform	2265	2272	O
after	2273	2278	O
the	2279	2282	O
injury	2283	2289	O
,	2289	2290	O
suggesting	2291	2301	O
that	2302	2306	O
this	2307	2311	O
immunosuppression	2312	2329	O
is	2330	2332	O
primarily	2333	2342	O
due	2343	2346	O
to	2347	2349	O
the	2350	2353	O
general	2354	2361	O
metabolic	2362	2371	O
response	2372	2380	O
rather	2381	2387	O
than	2388	2392	O
recurring	2393	2402	O
infections	2403	2413	O
.	2413	2414	O

Neurohypophyseal	0	16	B-Pathological_formation
granulomatous	17	30	I-Pathological_formation
germinoma	31	40	I-Pathological_formation
invading	41	49	O
the	50	53	O
right	54	59	B-Immaterial_anatomical_entity
cavernous	60	69	I-Immaterial_anatomical_entity
sinus	70	75	I-Immaterial_anatomical_entity
:	75	76	O
case	77	81	O
report	82	88	O
and	89	92	O
review	93	99	O
of	100	102	O
the	103	106	O
literature	107	117	O
.	117	118	O

We	119	121	O
encountered	122	133	O
a	134	135	O
rare	136	140	O
case	141	145	O
of	146	148	O
neurohypophyseal	149	165	B-Pathological_formation
germinoma	166	175	I-Pathological_formation
with	176	180	O
a	181	182	O
prominent	183	192	O
granulomatous	193	206	O
reaction	207	215	O
,	215	216	O
which	217	222	O
invaded	223	230	O
the	231	234	O
right	235	240	B-Immaterial_anatomical_entity
cavernous	241	250	I-Immaterial_anatomical_entity
sinus	251	256	I-Immaterial_anatomical_entity
.	256	257	O

The	258	261	O
neuroimaging	262	274	O
and	275	278	O
histopathology	279	293	O
features	294	302	O
in	303	305	O
this	306	310	O
case	311	315	O
were	316	320	O
unique	321	327	O
,	327	328	O
distinguishing	329	343	O
it	344	346	O
from	347	351	O
other	352	357	O
types	358	363	O
of	364	366	O
suprasellar	367	378	B-Pathological_formation
lesions	379	386	I-Pathological_formation
.	386	387	O

A	388	389	O
13	390	392	O
-	392	393	O
year	393	397	O
-	397	398	O
old	398	401	O
boy	402	405	O
presented	406	415	O
with	416	420	O
loss	421	425	O
of	426	428	O
appetite	429	437	O
and	438	441	O
polyuria	442	450	O
;	450	451	O
both	452	456	O
symptoms	457	465	O
were	466	470	O
present	471	478	O
for	479	482	O
1	483	484	O
year	485	489	O
,	489	490	O
and	491	494	O
headache	495	503	O
,	503	504	O
general	505	512	O
fatigue	513	520	O
and	521	524	O
blurred	525	532	O
vision	533	539	O
present	540	547	O
for	548	551	O
the	552	555	O
prior	556	561	O
2	562	563	O
months	564	570	O
.	570	571	O

On	572	574	O
admission	575	584	O
,	584	585	O
neurological	586	598	O
examination	599	610	O
indicated	611	620	O
bitemporal	621	631	O
hemianopsia	632	643	O
and	644	647	O
optic	648	653	O
atrophy	654	661	O
.	661	662	O

Endocrinological	663	679	O
exam	680	684	O
showed	685	691	O
panhypopituitarism	692	710	O
.	710	711	O

Tumor	712	717	B-Pathological_formation
markers	718	725	O
such	726	730	O
as	731	733	O
alpha	734	739	O
-	739	740	O
fetoprotein	740	751	O
,	751	752	O
human	753	758	O
growth	759	765	O
hormone	766	773	O
,	773	774	O
carcinoembryonic	775	791	O
antigen	792	799	O
,	799	800	O
and	801	804	O
placental	805	814	B-Organ
alkaline	815	823	O
phosphatase	824	835	O
were	836	840	O
negative	841	849	O
.	849	850	O

Brain	851	856	B-Organ
CT	857	859	O
revealed	860	868	O
a	869	870	O
suprasellar	871	882	B-Pathological_formation
tumor	883	888	I-Pathological_formation
with	889	893	O
calcification	894	907	O
.	907	908	O

MR	909	911	O
T	912	913	O
(	913	914	O
1	914	915	O
)	915	916	O
-	916	917	O
weighted	917	925	O
and	926	929	O
T	930	931	O
(	931	932	O
2	932	933	O
)	933	934	O
-	934	935	O
weighted	935	943	O
images	944	950	O
showed	951	957	O
the	958	961	O
tumor	962	967	B-Pathological_formation
to	968	970	O
be	971	973	O
isointense	974	984	O
to	985	987	O
normal	988	994	O
brain	995	1000	B-Organ
parenchyma	1001	1011	O
and	1012	1015	O
to	1016	1018	O
be	1019	1021	O
enhanced	1022	1030	O
densely	1031	1038	O
.	1038	1039	O

The	1040	1043	O
tumor	1044	1049	B-Pathological_formation
also	1050	1054	O
involved	1055	1063	O
the	1064	1067	O
right	1068	1073	B-Immaterial_anatomical_entity
cavernous	1074	1083	I-Immaterial_anatomical_entity
sinus	1084	1089	I-Immaterial_anatomical_entity
,	1089	1090	O
so	1091	1093	O
that	1094	1098	O
a	1099	1100	O
biopsy	1101	1107	O
was	1108	1111	O
performed	1112	1121	O
by	1122	1124	O
the	1125	1128	O
transsphenoidal	1129	1144	B-Multi-tissue_structure
approach	1145	1153	O
.	1153	1154	O

On	1155	1157	O
pathologic	1158	1168	O
examination	1169	1180	O
of	1181	1183	O
the	1184	1187	O
specimen	1188	1196	O
,	1196	1197	O
typical	1198	1205	O
large	1206	1211	O
tumor	1212	1217	B-Cell
cells	1218	1223	I-Cell
with	1224	1228	O
lymphocytic	1229	1240	B-Cell
cell	1241	1245	I-Cell
infiltration	1246	1258	O
and	1259	1262	O
prominent	1263	1272	O
granulomatous	1273	1286	O
reaction	1287	1295	O
were	1296	1300	O
observed	1301	1309	O
.	1309	1310	O

Neurohypophyseal	1311	1327	B-Pathological_formation
granulomatous	1328	1341	I-Pathological_formation
germinoma	1342	1351	I-Pathological_formation
was	1352	1355	O
diagnosed	1356	1365	O
.	1365	1366	O

Radiotherapy	1367	1379	O
was	1380	1383	O
performed	1384	1393	O
with	1394	1398	O
a	1399	1400	O
total	1401	1406	O
dose	1407	1411	O
of	1412	1414	O
51	1415	1417	O
Gy	1418	1420	O
and	1421	1424	O
the	1425	1428	O
tumor	1429	1434	B-Pathological_formation
shrank	1435	1441	O
remarkably	1442	1452	O
.	1452	1453	O

The	1454	1457	O
patient	1458	1465	O
returned	1466	1474	O
to	1475	1477	O
school	1478	1484	O
under	1485	1490	O
hormone	1491	1498	O
replacement	1499	1510	O
therapy	1511	1518	O
.	1518	1519	O

Melanoma	0	8	B-Pathological_formation
/	8	9	O
skin	9	13	B-Pathological_formation
cancer	14	20	I-Pathological_formation
screening	21	30	O
clinics	31	38	O
:	38	39	O
experiences	40	51	O
in	52	54	O
The	55	58	O
Netherlands	59	70	O
.	70	71	O

In	72	74	O
1989	75	79	O
and	80	83	O
1990	84	88	O
we	89	91	O
conducted	92	101	O
two	102	105	O
free	106	110	O
melanoma	111	119	B-Pathological_formation
/	119	120	O
skin	120	124	B-Organ
screening	125	134	O
clinics	135	142	O
in	143	145	O
Oss	146	149	O
and	150	153	O
Arnhem	154	160	O
in	161	163	O
the	164	167	O
Netherlands	168	179	O
.	179	180	O

The	181	184	O
study	185	190	O
was	191	194	O
carried	195	202	O
out	203	206	O
along	207	212	O
the	213	216	O
lines	217	222	O
of	223	225	O
the	226	229	O
recent	230	236	O
campaigns	237	246	O
supported	247	256	O
by	257	259	O
the	260	263	O
American	264	272	O
Academy	273	280	O
of	281	283	O
Dermatology	284	295	O
.	295	296	O

Of	297	299	O
2564	300	304	O
persons	305	312	O
screened	313	321	O
,	321	322	O
53	323	325	O
had	326	329	O
melanoma	330	338	B-Pathological_formation
or	339	341	O
nonmelanoma	342	353	B-Pathological_formation
skin	354	358	I-Pathological_formation
cancer	359	365	I-Pathological_formation
(	366	367	O
2	367	368	O
.	368	369	O
1	369	370	O
%	370	371	O
)	371	372	O
.	372	373	O

Compliance	374	384	O
with	385	389	O
follow	390	396	O
-	396	397	O
up	397	399	O
for	400	403	O
persons	404	411	O
with	412	416	O
suspected	417	426	O
melanoma	427	435	B-Pathological_formation
/	435	436	O
skin	436	440	B-Pathological_formation
cancer	441	447	I-Pathological_formation
was	448	451	O
adequate	452	460	O
(	461	462	O
93	462	464	O
of	465	467	O
103	468	471	O
;	471	472	O
90	473	475	O
.	475	476	O
3	476	477	O
%	477	478	O
)	478	479	O
.	479	480	O

Impact	0	6	O
of	7	9	O
dexamethasone	10	23	O
-	23	24	O
induced	24	31	O
immunosuppression	32	49	O
on	50	52	O
the	53	56	O
duration	57	65	O
and	66	69	O
level	70	75	O
of	76	78	O
shedding	79	87	O
of	88	90	O
Escherichia	91	102	O
coli	103	107	O
O157	108	112	O
:	112	113	O
H7	113	115	O
in	116	118	O
calves	119	125	O
.	125	126	O

The	127	130	O
goal	131	135	O
of	136	138	O
this	139	143	O
study	144	149	O
was	150	153	O
to	154	156	O
determine	157	166	O
whether	167	174	O
immunosuppression	175	192	O
plays	193	198	O
a	199	200	O
role	201	205	O
in	206	208	O
the	209	212	O
level	213	218	O
and	219	222	O
duration	223	231	O
of	232	234	O
fecal	235	240	B-Organism_substance
shedding	241	249	O
of	250	252	O
Escherichia	253	264	O
coli	265	269	O
O157	270	274	O
.	274	275	O

Immunosuppression	276	293	O
was	294	297	O
induced	298	305	O
in	306	308	O
calves	309	315	O
by	316	318	O
administering	319	332	O
dexamethasone	333	346	O
.	346	347	O

Six	348	351	O
1	352	353	O
-	353	354	O
week	354	358	O
-	358	359	O
old	359	362	O
Holstein	363	371	O
bull	372	376	O
calves	377	383	O
were	384	388	O
injected	389	397	O
intramuscularly	398	413	B-Tissue
with	414	418	O
dexamethasone	419	432	O
and	433	436	O
orally	437	443	O
inoculated	444	454	O
with	455	459	O
10	460	462	O
(	462	463	O
9	463	464	O
)	464	465	O
CFU	466	469	O
of	470	472	O
a	473	474	O
mixture	475	482	O
of	483	485	O
three	486	491	O
nalidixic	492	501	O
-	501	502	O
acid	502	506	O
resistant	507	516	O
strains	517	524	O
of	525	527	O
E	528	529	O
.	529	530	O
coli	531	535	O
O157	536	540	O
:	540	541	O
H7	541	543	O
.	543	544	O

Five	545	549	O
1	550	551	O
-	551	552	O
week	552	556	O
-	556	557	O
old	557	560	O
Holstein	561	569	O
bull	570	574	O
calves	575	581	O
that	582	586	O
were	587	591	O
given	592	597	O
the	598	601	O
same	602	606	O
oral	607	611	O
inoculation	612	623	O
of	624	626	O
E	627	628	O
.	628	629	O
coli	630	634	O
O157	635	639	O
:	639	640	O
H7	640	642	O
,	642	643	O
but	644	647	O
not	648	651	O
the	652	655	O
dexamethasone	656	669	O
injections	670	680	O
,	680	681	O
served	682	688	O
as	689	691	O
controls	692	700	O
.	700	701	O

All	702	705	O
calves	706	712	O
were	713	717	O
examined	718	726	O
daily	727	732	O
and	733	736	O
fecal	737	742	B-Organism_substance
samples	743	750	O
were	751	755	O
collected	756	765	O
three	766	771	O
times	772	777	O
a	778	779	O
week	780	784	O
for	785	788	O
detection	789	798	O
and	799	802	O
enumeration	803	814	O
of	815	817	O
the	818	821	O
nalidixic	822	831	O
-	831	832	O
acid	832	836	O
resistant	837	846	O
E	847	848	O
.	848	849	O
coli	850	854	O
O157	855	859	O
.	859	860	O

Four	861	865	O
weeks	866	871	O
after	872	877	O
the	878	881	O
last	882	886	O
calf	887	891	O
stopped	892	899	O
shedding	900	908	O
,	908	909	O
all	910	913	O
calves	914	920	O
were	921	925	O
necropsied	926	936	O
and	937	940	O
samples	941	948	O
from	949	953	O
the	954	957	O
gastrointestinal	958	974	B-Organism_subdivision
tract	975	980	I-Organism_subdivision
were	981	985	O
taken	986	991	O
for	992	995	O
the	996	999	O
detection	1000	1009	O
of	1010	1012	O
the	1013	1016	O
nalidixic	1017	1026	O
-	1026	1027	O
acid	1027	1031	O
resistant	1032	1041	O
E	1042	1043	O
.	1043	1044	O
coli	1045	1049	O
O157	1050	1054	O
.	1054	1055	O

Dexamethasone	1056	1069	O
-	1069	1070	O
injected	1070	1078	O
calves	1079	1085	O
shed	1086	1090	O
at	1091	1093	O
higher	1094	1100	O
levels	1101	1107	O
(	1108	1109	O
P	1109	1110	O
=	1111	1112	O
0	1113	1114	O
.	1114	1115	O
04	1115	1117	O
)	1117	1118	O
on	1119	1121	O
days	1122	1126	O
4	1127	1128	O
and	1129	1132	O
7	1133	1134	O
postinoculation	1135	1150	O
,	1150	1151	O
but	1152	1155	O
not	1156	1159	O
thereafter	1160	1170	O
.	1170	1171	O

None	1172	1176	O
of	1177	1179	O
the	1180	1183	O
samples	1184	1191	O
collected	1192	1201	O
at	1202	1204	O
necropsy	1205	1213	O
were	1214	1218	O
positive	1219	1227	O
for	1228	1231	O
E	1232	1233	O
.	1233	1234	O
coli	1235	1239	O
O157	1240	1244	O
.	1244	1245	O

Data	1246	1250	O
from	1251	1255	O
this	1256	1260	O
study	1261	1266	O
suggest	1267	1274	O
that	1275	1279	O
there	1280	1285	O
may	1286	1289	O
be	1290	1292	O
a	1293	1294	O
time	1295	1299	O
-	1299	1300	O
dependent	1300	1309	O
relationship	1310	1322	O
between	1323	1330	O
dexamethasone	1331	1344	O
immunosuppression	1345	1362	O
and	1363	1366	O
the	1367	1370	O
fecal	1371	1376	B-Organism_substance
concentration	1377	1390	O
of	1391	1393	O
E	1394	1395	O
.	1395	1396	O
coli	1397	1401	O
O157	1402	1406	O
but	1407	1410	O
that	1411	1415	O
transient	1416	1425	O
immunosuppression	1426	1443	O
does	1444	1448	O
not	1449	1452	O
appear	1453	1459	O
to	1460	1462	O
prolong	1463	1470	O
shedding	1471	1479	O
of	1480	1482	O
E	1483	1484	O
.	1484	1485	O
coli	1486	1490	O
O157	1491	1495	O
.	1495	1496	O

Analysis	0	8	O
of	9	11	O
processivity	12	24	O
of	25	27	O
mungbean	28	36	O
dideoxynucleotide	37	54	O
-	54	55	O
sensitive	55	64	O
DNA	65	68	O
polymerase	69	79	O
and	80	83	O
detection	84	93	O
of	94	96	O
the	97	100	O
activity	101	109	O
and	110	113	O
expression	114	124	O
of	125	127	O
the	128	131	O
enzyme	132	138	O
in	139	141	O
the	142	145	O
meristematic	146	158	B-Tissue
and	159	162	O
meiotic	163	170	B-Tissue
tissues	171	178	I-Tissue
and	179	182	O
following	183	192	O
DNA	193	196	O
damaging	197	205	O
agent	206	211	O
.	211	212	O

Analysis	213	221	O
of	222	224	O
the	225	228	O
processivity	229	241	O
of	242	244	O
mungbean	245	253	O
ddNTP	254	259	O
-	259	260	O
sensitive	260	269	O
DNA	270	273	O
polymerase	274	284	O
showed	285	291	O
the	292	295	O
incorporation	296	309	O
of	310	312	O
approximately	313	326	O
35	327	329	O
-	329	330	O
40	330	332	O
nucleotides	333	344	O
per	345	348	O
binding	349	356	O
event	357	362	O
in	363	365	O
the	366	369	O
replication	370	381	O
assays	382	388	O
involving	389	398	O
M13	399	402	O
ss	403	405	O
DNA	406	409	O
template	410	418	O
with	419	423	O
5	424	425	O
'	425	426	O
-	426	427	O
labeled	427	434	O
17	435	437	O
-	437	438	O
mer	438	441	O
primer	442	448	O
.	448	449	O

Optimal	450	457	O
processivity	458	470	O
was	471	474	O
obtained	475	483	O
with	484	488	O
100	489	492	O
-	492	493	O
150	493	496	O
mM	497	499	O
KCl	500	503	O
and	504	507	O
6	508	509	O
-	509	510	O
8	510	511	O
mM	512	514	O
Mg2	515	518	O
+	518	519	O
at	520	522	O
pH	523	525	O
7	526	527	O
.	527	528	O
5	528	529	O
.	529	530	O

The	531	534	O
enzyme	535	541	O
showed	542	548	O
preference	549	559	O
for	560	563	O
Mg2	564	567	O
+	567	568	O
over	569	573	O
Mn2	574	577	O
+	577	578	O
as	579	581	O
the	582	585	O
metal	586	591	O
activator	592	601	O
for	602	605	O
processivity	606	618	O
.	618	619	O

2	620	621	O
'	621	622	O
,	622	623	O
3	624	625	O
'	625	626	O
dideoxythymidine	627	643	O
5	644	645	O
'	645	646	O
triphosphate	647	659	O
(	660	661	O
ddTTP	661	666	O
)	666	667	O
and	668	671	O
rat	672	675	O
DNA	676	679	O
pol	680	683	O
beta	684	688	O
antibody	689	697	O
strongly	698	706	O
influenced	707	717	O
distributive	718	730	O
synthesis	731	740	O
.	740	741	O

Considerable	742	754	O
enhancement	755	766	O
in	767	769	O
processivity	770	782	O
was	783	786	O
noticed	787	794	O
at	795	797	O
1mM	798	801	O
ATP	802	805	O
and	806	809	O
2	810	811	O
-	811	812	O
4	812	813	O
mM	814	816	O
spermidine	817	827	O
while	828	833	O
higher	834	840	O
concentrations	841	855	O
of	856	858	O
spermidine	859	869	O
caused	870	876	O
distributive	877	889	O
synthesis	890	899	O
.	899	900	O

The	901	904	O
enzyme	905	911	O
was	912	915	O
found	916	921	O
to	922	924	O
be	925	927	O
active	928	934	O
in	935	937	O
both	938	942	O
meristematic	943	955	B-Tissue
and	956	959	O
meiotic	960	967	B-Tissue
tissues	968	975	I-Tissue
and	976	979	O
distinctly	980	990	O
induced	991	998	O
by	999	1001	O
EMS	1002	1005	O
treatment	1006	1015	O
.	1015	1016	O

DNA	1017	1020	O
-	1020	1021	O
binding	1021	1028	O
assays	1029	1035	O
revealed	1036	1044	O
distinct	1045	1053	O
binding	1054	1061	O
ability	1062	1069	O
of	1070	1072	O
the	1073	1076	O
enzyme	1077	1083	O
to	1084	1086	O
template	1087	1095	O
/	1095	1096	O
primer	1096	1102	O
and	1103	1106	O
damaged	1107	1114	O
DNA	1115	1118	O
substrate	1119	1128	O
.	1128	1129	O

Together	1130	1138	O
these	1139	1144	O
observations	1145	1157	O
illustrate	1158	1168	O
the	1169	1172	O
probable	1173	1181	O
involvement	1182	1193	O
of	1194	1196	O
the	1197	1200	O
enzyme	1201	1207	O
in	1208	1210	O
replication	1211	1222	O
and	1223	1226	O
repair	1227	1233	O
machinery	1234	1243	O
in	1244	1246	O
higher	1247	1253	O
plants	1254	1260	O
.	1260	1261	O

The	0	3	O
detection	4	13	O
of	14	16	O
macrosomia	17	27	O
at	28	30	O
a	31	32	O
teaching	33	41	O
hospital	42	50	O
.	50	51	O

We	52	54	O
sought	55	61	O
to	62	64	O
determine	65	74	O
the	75	78	O
detection	79	88	O
(	89	90	O
clinical	90	98	O
or	99	101	O
sonographic	102	113	O
)	113	114	O
rate	115	119	O
of	120	122	O
macrosomic	123	133	O
newborns	134	142	O
(	143	144	O
at	144	146	O
least	147	152	O
4000	153	157	O
g	158	159	O
)	159	160	O
and	161	164	O
the	165	168	O
peripartum	169	179	O
factors	180	187	O
among	188	193	O
those	194	199	O
who	200	203	O
were	204	208	O
or	209	211	O
were	212	216	O
not	217	220	O
identified	221	231	O
accurately	232	242	O
.	242	243	O

We	244	246	O
retrospectively	247	262	O
reviewed	263	271	O
all	272	275	O
deliveries	276	286	O
over	287	291	O
1	292	293	O
year	294	298	O
and	299	302	O
all	303	306	O
maternal	307	315	O
and	316	319	O
neonatal	320	328	O
charts	329	335	O
of	336	338	O
macrosomic	339	349	O
newborns	350	358	O
delivered	359	368	O
during	369	375	O
that	376	380	O
year	381	385	O
.	385	386	O

Odds	387	391	O
ratio	392	397	O
(	398	399	O
ORs	399	402	O
)	402	403	O
and	404	407	O
95	408	410	O
%	410	411	O
confidence	412	422	O
intervals	423	432	O
(	433	434	O
CIs	434	437	O
)	437	438	O
were	439	443	O
calculated	444	454	O
.	454	455	O

Over	456	460	O
a	461	462	O
12	463	465	O
-	465	466	O
month	466	471	O
period	472	478	O
,	478	479	O
the	480	483	O
rate	484	488	O
of	489	491	O
macrosomia	492	502	O
was	503	506	O
10	507	509	O
%	509	510	O
(	511	512	O
421	512	515	O
/	515	516	O
4194	516	520	O
)	520	521	O
and	522	525	O
of	526	528	O
those	529	534	O
,	534	535	O
only	536	540	O
11	541	543	O
%	543	544	O
(	545	546	O
95	546	548	O
%	548	549	O
CI	550	552	O
8	553	554	O
to	555	557	O
14	558	560	O
%	560	561	O
)	561	562	O
were	563	567	O
suspected	568	577	O
clinically	578	588	O
or	589	591	O
sonographically	592	607	O
.	607	608	O

None	609	613	O
of	614	616	O
the	617	620	O
newborns	621	629	O
weighing	630	638	O
4500	639	643	O
g	644	645	O
or	646	648	O
more	649	653	O
were	654	658	O
recognized	659	669	O
before	670	676	O
birth	677	682	O
(	683	684	O
0	684	685	O
/	685	686	O
57	686	688	O
;	688	689	O
95	690	692	O
%	692	693	O
CI	694	696	O
0	697	698	O
to	699	701	O
6	702	703	O
%	703	704	O
)	704	705	O
.	705	706	O

The	707	710	O
rate	711	715	O
of	716	718	O
cesarean	719	727	O
delivery	728	736	O
was	737	740	O
significantly	741	754	O
higher	755	761	O
among	762	767	O
newborns	768	776	O
correctly	777	786	O
identified	787	797	O
as	798	800	O
macrosomic	801	811	O
(	812	813	O
58	813	815	O
%	815	816	O
)	816	817	O
versus	818	824	O
those	825	830	O
missed	831	837	O
(	838	839	O
36	839	841	O
%	841	842	O
;	842	843	O
OR	844	846	O
2	847	848	O
.	848	849	O
76	849	851	O
,	851	852	O
95	853	855	O
%	855	856	O
CI	857	859	O
1	860	861	O
.	861	862	O
46	862	864	O
,	864	865	O
5	866	867	O
.	867	868	O
16	868	870	O
)	870	871	O
.	871	872	O

The	873	876	O
incidence	877	886	O
of	887	889	O
newborns	890	898	O
weighing	899	907	O
in	908	910	O
excess	911	917	O
of	918	920	O
4000	921	925	O
g	926	927	O
is	928	930	O
10	931	933	O
%	933	934	O
,	934	935	O
and	936	939	O
approximately	940	953	O
90	954	956	O
%	956	957	O
of	958	960	O
these	961	966	O
macrosomic	967	977	O
newborns	978	986	O
were	987	991	O
unsuspected	992	1003	O
before	1004	1010	O
birth	1011	1016	O
.	1016	1017	O

Heart	0	5	B-Organ
sound	6	11	O
and	12	15	O
electrocardiogram	16	33	O
recording	34	43	O
devices	44	51	O
for	52	55	O
telemedicine	56	68	O
environments	69	81	O
.	81	82	O

There	83	88	O
is	89	91	O
currently	92	101	O
a	102	103	O
worldwide	104	113	O
trend	114	119	O
to	120	122	O
bring	123	128	O
healthcare	129	139	O
services	140	148	O
as	149	151	O
close	152	157	O
as	158	160	O
possible	161	169	O
to	170	172	O
the	173	176	O
patient	177	184	O
,	184	185	O
either	186	192	O
through	193	200	O
home	201	205	O
healthcare	206	216	O
systems	217	224	O
,	224	225	O
or	226	228	O
telemedicine	229	241	O
.	241	242	O

There	243	248	O
is	249	251	O
thus	252	256	O
a	257	258	O
general	259	266	O
need	267	271	O
for	272	275	O
equipment	276	285	O
that	286	290	O
can	291	294	O
capture	295	302	O
patient	303	310	O
data	311	315	O
electronically	316	330	O
for	331	334	O
automated	335	344	O
review	345	351	O
or	352	354	O
analysis	355	363	O
by	364	366	O
a	367	368	O
medical	369	376	O
practitioner	377	389	O
.	389	390	O

This	391	395	O
paper	396	401	O
presents	402	410	O
prototype	411	420	O
systems	421	428	O
that	429	433	O
were	434	438	O
developed	439	448	O
with	449	453	O
the	454	457	O
ultimate	458	466	O
aim	467	470	O
for	471	474	O
use	475	478	O
in	479	481	O
telemedicine	482	494	O
settings	495	503	O
in	504	506	O
rural	507	512	O
Africa	513	519	O
.	519	520	O

These	521	526	O
devices	527	534	O
can	535	538	O
be	539	541	O
used	542	546	O
to	547	549	O
electronically	550	564	O
capture	565	572	O
data	573	577	O
on	578	580	O
patients	581	589	O
from	590	594	O
several	595	602	O
sensors	603	610	O
in	611	613	O
a	614	615	O
quick	616	621	O
an	622	624	O
easy	625	629	O
manner	630	636	O
.	636	637	O

In	638	640	O
our	641	644	O
presented	645	654	O
cases	655	660	O
we	661	663	O
focus	664	669	O
on	670	672	O
cardiovascular	673	687	B-Anatomical_system
information	688	699	O
.	699	700	O

One	701	704	O
of	705	707	O
the	708	711	O
main	712	716	O
advantages	717	727	O
of	728	730	O
the	731	734	O
proposed	735	743	O
systems	744	751	O
is	752	754	O
that	755	759	O
the	760	763	O
data	764	768	O
are	769	772	O
captured	773	781	O
simultaneously	782	796	O
from	797	801	O
multiple	802	810	O
sensors	811	818	O
.	818	819	O

The	820	823	O
data	824	828	O
can	829	832	O
be	833	835	O
stored	836	842	O
and	843	846	O
sent	847	851	O
electronically	852	866	O
for	867	870	O
review	871	877	O
and	878	881	O
analysis	882	890	O
,	890	891	O
and	892	895	O
knowledge	896	905	O
-	905	906	O
based	906	911	O
systems	912	919	O
or	920	922	O
neural	923	929	O
network	930	937	O
type	938	942	O
models	943	949	O
can	950	953	O
be	954	956	O
used	957	961	O
in	962	964	O
the	965	968	O
future	969	975	O
for	976	979	O
semi	980	984	O
-	984	985	O
autonomous	985	995	O
screening	996	1005	O
of	1006	1008	O
the	1009	1012	O
recordings	1013	1023	O
,	1023	1024	O
before	1025	1031	O
a	1032	1033	O
patient	1034	1041	O
is	1042	1044	O
referred	1045	1053	O
to	1054	1056	O
a	1057	1058	O
specialist	1059	1069	O
.	1069	1070	O

An	0	2	O
introduction	3	15	O
to	16	18	O
evidence	19	27	O
-	27	28	O
based	28	33	O
practice	34	42	O
for	43	46	O
hand	47	51	B-Organism_subdivision
surgeons	52	60	O
and	61	64	O
therapists	65	75	O
.	75	76	O

Evidence	77	85	O
-	85	86	O
based	86	91	O
practice	92	100	O
is	101	103	O
a	104	105	O
methodical	106	116	O
approach	117	125	O
to	126	128	O
clinical	129	137	O
practice	138	146	O
where	147	152	O
experience	153	163	O
,	163	164	O
best	165	169	O
research	170	178	O
evidence	179	187	O
,	187	188	O
and	189	192	O
patient	193	200	O
goals	201	206	O
and	207	210	O
values	211	217	O
are	218	221	O
integrated	222	232	O
to	233	235	O
make	236	240	O
optimal	241	248	O
decisions	249	258	O
when	259	263	O
making	264	270	O
a	271	272	O
diagnosis	273	282	O
,	282	283	O
selecting	284	293	O
a	294	295	O
diagnostic	296	306	O
test	307	311	O
,	311	312	O
picking	313	320	O
an	321	323	O
intervention	324	336	O
or	337	339	O
determining	340	351	O
prognosis	352	361	O
.	361	362	O

There	363	368	O
are	369	372	O
five	373	377	O
steps	378	383	O
in	384	386	O
this	387	391	O
process	392	399	O
.	399	400	O

Hand	401	405	B-Organism_subdivision
surgeons	406	414	O
and	415	418	O
therapists	419	429	O
can	430	433	O
use	434	437	O
the	438	441	O
evidence	442	450	O
-	450	451	O
based	451	456	O
process	457	464	O
to	465	467	O
attain	468	474	O
optimal	475	482	O
management	483	493	O
of	494	496	O
individual	497	507	O
patients	508	516	O
,	516	517	O
manage	518	524	O
their	525	530	O
overall	531	538	O
practice	539	547	O
,	547	548	O
guide	549	554	O
the	555	558	O
ongoing	559	566	O
professional	567	579	O
development	580	591	O
,	591	592	O
and	593	596	O
deal	597	601	O
with	602	606	O
funding	607	614	O
and	615	618	O
policy	619	625	O
makers	626	632	O
.	632	633	O

Prolonged	0	9	O
control	10	17	O
of	18	20	O
patterned	21	30	O
biofilm	31	38	B-Cell
formation	39	48	O
by	49	51	O
bio	52	55	O
-	55	56	O
inert	56	61	O
surface	62	69	O
chemistry	70	79	O
.	79	80	O

A	81	82	O
bio	83	86	O
-	86	87	O
inert	87	92	O
surface	93	100	O
chemistry	101	110	O
was	111	114	O
developed	115	124	O
that	125	129	O
can	130	133	O
confine	134	141	O
biofilm	142	149	B-Cell
formation	150	159	O
in	160	162	O
designed	163	171	O
patterns	172	180	O
for	181	184	O
at	185	187	O
least	188	193	O
26	194	196	O
days	197	201	O
.	201	202	O

Women	0	5	O
'	5	6	O
s	6	7	O
attitudes	8	17	O
,	17	18	O
preferences	19	30	O
,	30	31	O
and	32	35	O
perceived	36	45	O
barriers	46	54	O
to	55	57	O
treatment	58	67	O
for	68	71	O
perinatal	72	81	O
depression	82	92	O
.	92	93	O

BACKGROUND	94	104	O
:	104	105	O

Perinatal	106	115	O
depression	116	126	O
is	127	129	O
associated	130	140	O
with	141	145	O
potential	146	155	O
negative	156	164	O
consequences	165	177	O
for	178	181	O
the	182	185	O
mother	186	192	O
and	193	196	O
infant	197	203	O
,	203	204	O
and	205	208	O
therefore	209	218	O
efforts	219	226	O
to	227	229	O
improve	230	237	O
treatment	238	247	O
access	248	254	O
and	255	258	O
efficacy	259	267	O
are	268	271	O
warranted	272	281	O
.	281	282	O

The	283	286	O
purpose	287	294	O
of	295	297	O
this	298	302	O
study	303	308	O
was	309	312	O
to	313	315	O
examine	316	323	O
pregnant	324	332	O
women	333	338	O
'	338	339	O
s	339	340	O
preferences	341	352	O
and	353	356	O
attitudes	357	366	O
about	367	372	O
treatment	373	382	O
for	383	386	O
depression	387	397	O
,	397	398	O
and	399	402	O
perceived	403	412	O
potential	413	422	O
barriers	423	431	O
to	432	434	O
accessing	435	444	O
treatment	445	454	O
.	454	455	O

METHODS	456	463	O
:	463	464	O

Data	465	469	O
were	470	474	O
collected	475	484	O
by	485	487	O
means	488	493	O
of	494	496	O
a	497	498	O
questionnaire	499	512	O
from	513	517	O
a	518	519	O
convenience	520	531	O
sample	532	538	O
of	539	541	O
509	542	545	O
predominantly	546	559	O
well	560	564	O
-	564	565	O
educated	565	573	O
,	573	574	O
high	575	579	O
-	579	580	O
income	580	586	O
,	586	587	O
married	588	595	O
women	596	601	O
in	602	604	O
the	605	608	O
northeastern	609	621	O
United	622	628	O
States	629	635	O
during	636	642	O
the	643	646	O
last	647	651	O
trimester	652	661	O
of	662	664	O
pregnancy	665	674	O
.	674	675	O

Participants	676	688	O
were	689	693	O
queried	694	701	O
as	702	704	O
to	705	707	O
treatment	708	717	O
modalities	718	728	O
in	729	731	O
which	732	737	O
they	738	742	O
would	743	748	O
most	749	753	O
likely	754	760	O
participate	761	772	O
if	773	775	O
they	776	780	O
wanted	781	787	O
help	788	792	O
for	793	796	O
depression	797	807	O
,	807	808	O
their	809	814	O
attitudes	815	824	O
toward	825	831	O
psychotherapeutic	832	849	O
and	850	853	O
pharmacological	854	869	O
treatments	870	880	O
,	880	881	O
and	882	885	O
perceived	886	895	O
barriers	896	904	O
to	905	907	O
receiving	908	917	O
help	918	922	O
.	922	923	O

RESULTS	924	931	O
:	931	932	O

Most	933	937	O
women	938	943	O
(	944	945	O
92	945	947	O
%	947	948	O
)	948	949	O
indicated	950	959	O
that	960	964	O
would	965	970	O
likely	971	977	O
participate	978	989	O
in	990	992	O
individual	993	1003	O
therapy	1004	1011	O
if	1012	1014	O
help	1015	1019	O
was	1020	1023	O
needed	1024	1030	O
.	1030	1031	O

Only	1032	1036	O
35	1037	1039	O
percent	1040	1047	O
stated	1048	1054	O
that	1055	1059	O
they	1060	1064	O
would	1065	1070	O
likely	1071	1077	O
take	1078	1082	O
medication	1083	1093	O
if	1094	1096	O
recommended	1097	1108	O
,	1108	1109	O
and	1110	1113	O
14	1114	1116	O
percent	1117	1124	O
indicated	1125	1134	O
that	1135	1139	O
they	1140	1144	O
would	1145	1150	O
participate	1151	1162	O
in	1163	1165	O
group	1166	1171	O
therapy	1172	1179	O
.	1179	1180	O

The	1181	1184	O
greatest	1185	1193	O
perceived	1194	1203	O
potential	1204	1213	O
barriers	1214	1222	O
to	1223	1225	O
treatment	1226	1235	O
were	1236	1240	O
lack	1241	1245	O
of	1246	1248	O
time	1249	1253	O
(	1254	1255	O
65	1255	1257	O
%	1257	1258	O
)	1258	1259	O
,	1259	1260	O
stigma	1261	1267	O
(	1268	1269	O
43	1269	1271	O
%	1271	1272	O
)	1272	1273	O
,	1273	1274	O
and	1275	1278	O
childcare	1279	1288	O
issues	1289	1295	O
(	1296	1297	O
33	1297	1299	O
%	1299	1300	O
)	1300	1301	O
.	1301	1302	O

Most	1303	1307	O
women	1308	1313	O
indicated	1314	1323	O
a	1324	1325	O
preference	1326	1336	O
to	1337	1339	O
receive	1340	1347	O
mental	1348	1354	O
health	1355	1361	O
care	1362	1366	O
at	1367	1369	O
the	1370	1373	O
obstetrics	1374	1384	O
clinic	1385	1391	O
,	1391	1392	O
either	1393	1399	O
from	1400	1404	O
their	1405	1410	O
obstetrics	1411	1421	O
practitioner	1422	1434	O
or	1435	1437	O
from	1438	1442	O
a	1443	1444	O
mental	1445	1451	O
health	1452	1458	O
practitioner	1459	1471	O
located	1472	1479	O
at	1480	1482	O
the	1483	1486	O
clinic	1487	1493	O
.	1493	1494	O

Factors	1495	1502	O
associated	1503	1513	O
with	1514	1518	O
acceptability	1519	1532	O
of	1533	1535	O
various	1536	1543	O
depression	1544	1554	O
treatments	1555	1565	O
are	1566	1569	O
presented	1570	1579	O
.	1579	1580	O

CONCLUSIONS	1581	1592	O
:	1592	1593	O

Understanding	1594	1607	O
what	1608	1612	O
prevents	1613	1621	O
women	1622	1627	O
from	1628	1632	O
seeking	1633	1640	O
or	1641	1643	O
obtaining	1644	1653	O
help	1654	1658	O
for	1659	1662	O
depression	1663	1673	O
and	1674	1677	O
determining	1678	1689	O
what	1690	1694	O
they	1695	1699	O
prefer	1700	1706	O
in	1707	1709	O
the	1710	1713	O
way	1714	1717	O
of	1718	1720	O
treatment	1721	1730	O
may	1731	1734	O
lead	1735	1739	O
to	1740	1742	O
improved	1743	1751	O
depression	1752	1762	O
treatment	1763	1772	O
rates	1773	1778	O
and	1779	1782	O
hold	1783	1787	O
promise	1788	1795	O
for	1796	1799	O
improving	1800	1809	O
the	1810	1813	O
overall	1814	1821	O
health	1822	1828	O
of	1829	1831	O
childbearing	1832	1844	O
women	1845	1850	O
.	1850	1851	O

The	0	3	O
impact	4	10	O
of	11	13	O
tracheal	14	22	B-Multi-tissue_structure
intubation	23	33	O
on	34	36	O
host	37	41	O
defenses	42	50	O
and	51	54	O
risks	55	60	O
for	61	64	O
nosocomial	65	75	O
pneumonia	76	85	O
.	85	86	O

Nosocomial	87	97	O
pneumonia	98	107	O
remains	108	115	O
a	116	117	O
common	118	124	O
complication	125	137	O
in	138	140	O
patients	141	149	O
treated	150	157	O
with	158	162	O
endotracheal	163	175	O
intubation	176	186	O
and	187	190	O
mechanical	191	201	O
ventilation	202	213	O
and	214	217	O
continues	218	227	O
to	228	230	O
have	231	235	O
a	236	237	O
significant	238	249	O
impact	250	256	O
on	257	259	O
the	260	263	O
mortality	264	273	O
rate	274	278	O
of	279	281	O
these	282	287	O
patients	288	296	O
.	296	297	O

Epidemiologic	298	311	O
studies	312	319	O
have	320	324	O
shown	325	330	O
that	331	335	O
the	336	339	O
risk	340	344	O
of	345	347	O
pneumonia	348	357	O
increases	358	367	O
with	368	372	O
the	373	376	O
duration	377	385	O
of	386	388	O
intubation	389	399	O
but	400	403	O
that	404	408	O
the	409	412	O
period	413	419	O
of	420	422	O
highest	423	430	O
risk	431	435	O
is	436	438	O
the	439	442	O
first	443	448	O
2	449	450	O
weeks	451	456	O
of	457	459	O
therapy	460	467	O
.	467	468	O

Gram	469	473	O
-	473	474	O
negative	474	482	O
bacteria	483	491	O
account	492	499	O
for	500	503	O
most	504	508	O
nosocomial	509	519	O
pneumonias	520	530	O
in	531	533	O
intubated	534	543	O
patients	544	552	O
,	552	553	O
but	554	557	O
Staphylococcus	558	572	O
aureus	573	579	O
may	580	583	O
also	584	588	O
play	589	593	O
a	594	595	O
role	596	600	O
in	601	603	O
what	604	608	O
may	609	612	O
be	613	615	O
a	616	617	O
polymicrobial	618	631	O
infection	632	641	O
.	641	642	O

In	643	645	O
the	646	649	O
most	650	654	O
seriously	655	664	O
ill	665	668	O
individuals	669	680	O
,	680	681	O
and	682	685	O
in	686	688	O
those	689	694	O
treated	695	702	O
with	703	707	O
long	708	712	O
-	712	713	O
term	713	717	O
mechanical	718	728	O
ventilation	729	740	O
,	740	741	O
Pseudomonas	742	753	O
aeruginosa	754	764	O
is	765	767	O
a	768	769	O
common	770	776	O
pathogen	777	785	O
.	785	786	O

Endotracheal	787	799	O
intubation	800	810	O
and	811	814	O
mechanical	815	825	O
ventilation	826	837	O
predispose	838	848	O
to	849	851	O
pneumonia	852	861	O
for	862	865	O
a	866	867	O
variety	868	875	O
of	876	878	O
reasons	879	886	O
(	887	888	O
see	888	891	O
Fig	892	895	O
.	895	896	O
1	897	898	O
)	898	899	O
.	899	900	O

The	901	904	O
endotracheal	905	917	B-Multi-tissue_structure
tube	918	922	I-Multi-tissue_structure
can	923	926	O
have	927	931	O
direct	932	938	O
effects	939	946	O
on	947	949	O
the	950	953	O
airway	954	960	B-Multi-tissue_structure
that	961	965	O
result	966	972	O
in	973	975	O
a	976	977	O
reduction	978	987	O
in	988	990	O
local	991	996	O
host	997	1001	O
defenses	1002	1010	O
.	1010	1011	O

Thus	1012	1016	O
,	1016	1017	O
mucosal	1018	1025	B-Multi-tissue_structure
injury	1026	1032	O
can	1033	1036	O
reduce	1037	1043	O
mucociliary	1044	1055	B-Tissue
function	1056	1064	O
,	1064	1065	O
while	1066	1071	O
upper	1072	1077	O
airway	1078	1084	B-Multi-tissue_structure
defenses	1085	1093	O
are	1094	1097	O
bypassed	1098	1106	O
and	1107	1110	O
the	1111	1114	O
effectiveness	1115	1128	O
of	1129	1131	O
cough	1132	1137	O
is	1138	1140	O
reduced	1141	1148	O
.	1148	1149	O

Indirectly	1150	1160	O
,	1160	1161	O
intubation	1162	1172	O
can	1173	1176	O
result	1177	1183	O
in	1184	1186	O
an	1187	1189	O
enhanced	1190	1198	O
capacity	1199	1207	O
of	1208	1210	O
tracheobronchial	1211	1227	B-Cell
cells	1228	1233	I-Cell
to	1234	1236	O
bind	1237	1241	O
gram	1242	1246	O
-	1246	1247	O
negative	1247	1255	O
bacteria	1256	1264	O
,	1264	1265	O
an	1266	1268	O
effect	1269	1275	O
that	1276	1280	O
favors	1281	1287	O
airway	1288	1294	B-Multi-tissue_structure
colonization	1295	1307	O
and	1308	1311	O
pneumonia	1312	1321	O
.	1321	1322	O

The	1323	1326	O
injury	1327	1333	O
to	1334	1336	O
the	1337	1340	O
airway	1341	1347	B-Multi-tissue_structure
can	1348	1351	O
create	1352	1358	O
binding	1359	1366	O
sites	1367	1372	O
for	1373	1376	O
bacteria	1377	1385	O
in	1386	1388	O
the	1389	1392	O
basement	1393	1401	B-Multi-tissue_structure
membrane	1402	1410	I-Multi-tissue_structure
of	1411	1413	O
the	1414	1417	O
bronchial	1418	1427	B-Multi-tissue_structure
tree	1428	1432	I-Multi-tissue_structure
and	1433	1436	O
the	1437	1440	O
stimulation	1441	1452	O
of	1453	1455	O
the	1456	1459	O
secretion	1460	1469	O
of	1470	1472	O
mucus	1473	1478	B-Organism_substance
,	1478	1479	O
which	1480	1485	O
then	1486	1490	O
stagnates	1491	1500	O
and	1501	1504	O
can	1505	1508	O
create	1509	1515	O
potential	1516	1525	O
sites	1526	1531	O
for	1532	1535	O
bacterial	1536	1545	O
adherence	1546	1555	O
.	1555	1556	O

The	1557	1560	O
endotracheal	1561	1573	B-Multi-tissue_structure
tube	1574	1578	I-Multi-tissue_structure
also	1579	1583	O
enhances	1584	1592	O
bacterial	1593	1602	O
entry	1603	1608	O
to	1609	1611	O
the	1612	1615	O
lung	1616	1620	B-Organ
by	1621	1623	O
serving	1624	1631	O
as	1632	1634	O
a	1635	1636	O
reservoir	1637	1646	O
for	1647	1650	O
bacteria	1651	1659	O
to	1660	1662	O
remain	1663	1669	O
sequestered	1670	1681	O
,	1681	1682	O
safe	1683	1687	O
from	1688	1692	O
host	1693	1697	O
defenses	1698	1706	O
.	1706	1707	O

Respiratory	1708	1719	O
therapy	1720	1727	O
devices	1728	1735	O
can	1736	1739	O
allow	1740	1745	O
bacteria	1746	1754	O
to	1755	1757	O
proliferate	1758	1769	O
and	1770	1773	O
can	1774	1777	O
then	1778	1782	O
introduce	1783	1792	O
them	1793	1797	O
into	1798	1802	O
the	1803	1806	O
patient	1807	1814	O
if	1815	1817	O
not	1818	1821	O
handled	1822	1829	O
properly	1830	1838	O
.	1838	1839	O

Finally	1840	1847	O
,	1847	1848	O
patients	1849	1857	O
who	1858	1861	O
are	1862	1865	O
ill	1866	1869	O
enough	1870	1876	O
to	1877	1879	O
require	1880	1887	O
intubation	1888	1898	O
also	1899	1903	O
have	1904	1908	O
disease	1909	1916	O
-	1916	1917	O
associated	1917	1927	O
impairments	1928	1939	O
in	1940	1942	O
systemic	1943	1951	O
host	1952	1956	O
defense	1957	1964	O
,	1964	1965	O
which	1966	1971	O
add	1972	1975	O
to	1976	1978	O
the	1979	1982	O
impairments	1983	1994	O
caused	1995	2001	O
by	2002	2004	O
the	2005	2008	O
use	2009	2012	O
of	2013	2015	O
an	2016	2018	O
artificial	2019	2029	O
airway	2030	2036	B-Multi-tissue_structure
.	2036	2037	O

The	2038	2041	O
host	2042	2046	O
defense	2047	2054	O
impairments	2055	2066	O
that	2067	2071	O
occur	2072	2077	O
in	2078	2080	O
mechanically	2081	2093	O
ventilated	2094	2104	O
patients	2105	2113	O
can	2114	2117	O
lead	2118	2122	O
to	2123	2125	O
respiratory	2126	2137	B-Multi-tissue_structure
tract	2138	2143	I-Multi-tissue_structure
infection	2144	2153	O
in	2154	2156	O
the	2157	2160	O
form	2161	2165	O
of	2166	2168	O
either	2169	2175	O
febrile	2176	2183	O
tracheobronchitis	2184	2201	O
or	2202	2204	O
pneumonia	2205	2214	O
.	2214	2215	O

The	2216	2219	O
diagnosis	2220	2229	O
of	2230	2232	O
pneumonia	2233	2242	O
in	2243	2245	O
intubated	2246	2255	O
patients	2256	2264	O
is	2265	2267	O
difficult	2268	2277	O
and	2278	2281	O
controversial	2282	2295	O
.	2295	2296	O

It	2297	2299	O
can	2300	2303	O
be	2304	2306	O
made	2307	2311	O
by	2312	2314	O
either	2315	2321	O
clinical	2322	2330	O
criteria	2331	2339	O
or	2340	2342	O
microbiologic	2343	2356	O
criteria	2357	2365	O
,	2365	2366	O
the	2367	2370	O
latter	2371	2377	O
by	2378	2380	O
using	2381	2386	O
a	2387	2388	O
bronchoscopically	2389	2406	O
directed	2407	2415	O
protected	2416	2425	O
specimen	2426	2434	O
brush	2435	2440	O
.	2440	2441	O

Therapy	2442	2449	O
of	2450	2452	O
pneumonia	2453	2462	O
in	2463	2465	O
mechanically	2466	2478	O
ventilated	2479	2489	O
patients	2490	2498	O
is	2499	2501	O
not	2502	2505	O
always	2506	2512	O
successful	2513	2523	O
,	2523	2524	O
and	2525	2528	O
systemic	2529	2537	O
antibiotics	2538	2549	O
may	2550	2553	O
need	2554	2558	O
to	2559	2561	O
be	2562	2564	O
supplemented	2565	2577	O
by	2578	2580	O
topical	2581	2588	O
antimicrobials	2589	2603	O
.	2603	2604	O

No	2605	2607	O
clearly	2608	2615	O
effective	2616	2625	O
prophylactic	2626	2638	O
strategy	2639	2647	O
currently	2648	2657	O
exists	2658	2664	O
,	2664	2665	O
but	2666	2669	O
our	2670	2673	O
understanding	2674	2687	O
of	2688	2690	O
pneumonia	2691	2700	O
pathogenesis	2701	2713	O
has	2714	2717	O
led	2718	2721	O
to	2722	2724	O
some	2725	2729	O
promising	2730	2739	O
directions	2740	2750	O
.	2750	2751	O

As	2752	2754	O
more	2755	2759	O
data	2760	2764	O
are	2765	2768	O
collected	2769	2778	O
,	2778	2779	O
inhaled	2780	2787	O
antibiotics	2788	2799	O
,	2799	2800	O
selective	2801	2810	O
digestive	2811	2820	O
decontamination	2821	2836	O
,	2836	2837	O
and	2838	2841	O
enhancement	2842	2853	O
of	2854	2856	O
host	2857	2861	O
defenses	2862	2870	O
by	2871	2873	O
cytokines	2874	2883	O
and	2884	2887	O
pre	2888	2891	O
-	2891	2892	O
formed	2892	2898	O
antibodies	2899	2909	O
may	2910	2913	O
emerge	2914	2920	O
as	2921	2923	O
useful	2924	2930	O
approaches	2931	2941	O
.	2941	2942	O

Mapping	0	7	O
of	8	10	O
the	11	14	O
L	15	16	O
-	16	17	O
methylmalonyl	17	30	O
-	30	31	O
CoA	31	34	O
mutase	35	41	O
gene	42	46	O
to	47	49	O
mouse	50	55	O
chromosome	56	66	B-Cellular_component
17	67	69	I-Cellular_component
.	69	70	O

In	71	73	O
humans	74	80	O
,	80	81	O
methylmalonyl	82	95	O
acidemia	96	104	O
is	105	107	O
caused	108	114	O
by	115	117	O
a	118	119	O
deficiency	120	130	O
of	131	133	O
L	134	135	O
-	135	136	O
methylmalonyl	136	149	O
-	149	150	O
CoA	150	153	O
mutase	154	160	O
(	161	162	O
MUT	162	165	O
)	165	166	O
controlled	167	177	O
by	178	180	O
a	181	182	O
gene	183	187	O
that	188	192	O
has	193	196	O
been	197	201	O
mapped	202	208	O
to	209	211	O
chromosome	212	222	B-Cellular_component
6	223	224	I-Cellular_component
.	224	225	O

The	226	229	O
mouse	230	235	O
homolog	236	243	O
of	244	246	O
this	247	251	O
gene	252	256	O
has	257	260	O
now	261	264	O
been	265	269	O
mapped	270	276	O
to	277	279	O
mouse	280	285	O
chromosome	286	296	B-Cellular_component
17	297	299	I-Cellular_component
.	299	300	O

Recombinant	301	312	O
inbred	313	319	O
and	320	323	O
congenic	324	332	O
strains	333	340	O
place	341	346	O
the	347	350	O
mouse	351	356	O
Mut	357	360	O
locus	361	366	O
1	367	368	O
.	368	369	O
06	369	371	O
cM	372	374	O
distal	375	381	O
to	382	384	O
H	385	386	O
-	386	387	O
2	387	388	O
,	388	389	O
between	390	397	O
Pgk	398	401	O
-	401	402	O
2	402	403	O
and	404	407	O
Ce	408	410	O
-	410	411	O
2	411	412	O
.	412	413	O

The	414	417	O
relative	418	426	O
order	427	432	O
of	433	435	O
syntenic	436	444	O
probes	445	451	O
flanking	452	460	O
H	461	462	O
-	462	463	O
2	463	464	O
on	465	467	O
mouse	468	473	O
chromosome	474	484	B-Cellular_component
17	485	487	I-Cellular_component
and	488	491	O
HLA	492	495	O
on	496	498	O
human	499	504	O
chromosome	505	515	B-Cellular_component
6	516	517	I-Cellular_component
is	518	520	O
shown	521	526	O
to	527	529	O
be	530	532	O
different	533	542	O
.	542	543	O

Range	0	5	O
of	6	8	O
motion	9	15	O
limitation	16	26	O
after	27	32	O
rotator	33	40	B-Organ
cuff	41	45	I-Organ
repair	46	52	O
.	52	53	O

HYPOTHESIS	54	64	O
:	64	65	O

This	66	70	O
study	71	76	O
was	77	80	O
conducted	81	90	O
to	91	93	O
identify	94	102	O
preoperative	103	115	O
factors	116	123	O
correlating	124	135	O
with	136	140	O
limited	141	148	O
motion	149	155	O
after	156	161	O
rotator	162	169	B-Organ
cuff	170	174	I-Organ
repair	175	181	O
(	182	183	O
RCR	183	186	O
)	186	187	O
and	188	191	O
to	192	194	O
evaluate	195	203	O
the	204	207	O
affect	208	214	O
of	215	217	O
loss	218	222	O
of	223	225	O
motion	226	232	O
on	233	235	O
outcome	236	243	O
.	243	244	O

We	245	247	O
hypothesized	248	260	O
that	261	265	O
patients	266	274	O
with	275	279	O
preoperative	280	292	O
ROM	293	296	O
loss	297	301	O
,	301	302	O
diabetes	303	311	O
,	311	312	O
and	313	316	O
workman	317	324	O
'	324	325	O
s	325	326	O
compensation	327	339	O
claims	340	346	O
would	347	352	O
exhibit	353	360	O
postoperative	361	374	O
ROM	375	378	O
loss	379	383	O
at	384	386	O
3	387	388	O
months	389	395	O
.	395	396	O

MATERIAL	397	405	O
AND	406	409	O
METHODS	410	417	O
:	417	418	O

Preoperative	419	431	O
and	432	435	O
postoperative	436	449	O
evaluations	450	461	O
,	461	462	O
including	463	472	O
outcomes	473	481	O
assessment	482	492	O
and	493	496	O
physical	497	505	O
examination	506	517	O
parameters	518	528	O
,	528	529	O
were	530	534	O
reviewed	535	543	O
for	544	547	O
345	548	551	O
patients	552	560	O
who	561	564	O
underwent	565	574	O
RCR	575	578	O
.	578	579	O

Correlations	580	592	O
between	593	600	O
demographic	601	612	O
,	612	613	O
physical	614	622	O
examination	623	634	O
,	634	635	O
and	636	639	O
surgical	640	648	O
variables	649	658	O
and	659	662	O
postoperative	663	676	O
limitation	677	687	O
of	688	690	O
motion	691	697	O
and	698	701	O
need	702	706	O
for	707	710	O
capsular	711	719	O
release	720	727	O
were	728	732	O
determined	733	743	O
.	743	744	O

RESULTS	745	752	O
:	752	753	O

At	754	756	O
3	757	758	O
-	758	759	O
month	759	764	O
follow	765	771	O
-	771	772	O
up	772	774	O
,	774	775	O
mean	776	780	O
active	781	787	O
forward	788	795	O
elevation	796	805	O
(	806	807	O
AFE	807	810	O
)	810	811	O
,	811	812	O
active	813	819	O
external	820	828	O
rotation	829	837	O
(	838	839	O
AER	839	842	O
)	842	843	O
,	843	844	O
and	845	848	O
passive	849	856	O
internal	857	865	O
rotation	866	874	O
(	875	876	O
PIR	876	879	O
)	879	880	O
were	881	885	O
90	886	888	O
%	888	889	O
,	889	890	O
78	891	893	O
%	893	894	O
,	894	895	O
and	896	899	O
80	900	902	O
%	902	903	O
of	904	906	O
the	907	910	O
contralateral	911	924	O
side	925	929	O
.	929	930	O

Limitation	931	941	O
of	942	944	O
preoperative	945	957	O
motion	958	964	O
correlated	965	975	O
with	976	980	O
limitation	981	991	O
of	992	994	O
postoperative	995	1008	O
AFE	1009	1012	O
,	1012	1013	O
AER	1014	1017	O
,	1017	1018	O
and	1019	1022	O
PIR	1023	1026	O
(	1027	1028	O
P	1028	1029	O
<	1030	1031	O
.	1032	1033	O
001	1033	1036	O
)	1036	1037	O
.	1037	1038	O

Forty	1039	1044	O
-	1044	1045	O
seven	1045	1050	O
patients	1051	1059	O
considered	1060	1070	O
clinically	1071	1081	O
stiff	1082	1087	O
were	1088	1092	O
followed	1093	1101	O
at	1102	1104	O
1	1105	1106	O
year	1107	1111	O
postoperatively	1112	1127	O
.	1127	1128	O

Three	1129	1134	O
patients	1135	1143	O
required	1144	1152	O
arthroscopic	1153	1165	O
capsular	1166	1174	O
release	1175	1182	O
for	1183	1186	O
persistent	1187	1197	O
range	1198	1203	O
of	1204	1206	O
motion	1207	1213	O
loss	1214	1218	O
.	1218	1219	O

CONCLUSION	1220	1230	O
:	1230	1231	O

Early	1232	1237	O
postoperative	1238	1251	O
limitation	1252	1262	O
of	1263	1265	O
motion	1266	1272	O
after	1273	1278	O
RCR	1279	1282	O
is	1283	1285	O
associated	1286	1296	O
with	1297	1301	O
restricted	1302	1312	O
preoperative	1313	1325	O
motion	1326	1332	O
.	1332	1333	O

Other	1334	1339	O
factors	1340	1347	O
,	1347	1348	O
including	1349	1358	O
diabetes	1359	1367	O
mellitus	1368	1376	O
and	1377	1380	O
worker	1381	1387	O
'	1387	1388	O
s	1388	1389	O
compensation	1390	1402	O
claim	1403	1408	O
,	1408	1409	O
are	1410	1413	O
also	1414	1418	O
associated	1419	1429	O
with	1430	1434	O
range	1435	1440	O
of	1441	1443	O
motion	1444	1450	O
loss	1451	1455	O
.	1455	1456	O

Most	1457	1461	O
shoulders	1462	1471	B-Organism_subdivision
with	1472	1476	O
early	1477	1482	O
motion	1483	1489	O
loss	1490	1494	O
recover	1495	1502	O
motion	1503	1509	O
and	1510	1513	O
rarely	1514	1520	O
require	1521	1528	O
capsular	1529	1537	O
release	1538	1545	O
.	1545	1546	O

Neural	0	6	O
network	7	14	O
analysis	15	23	O
of	24	26	O
spectroscopic	27	40	O
data	41	45	O
of	46	48	O
lycopene	49	57	O
and	58	61	O
beta	62	66	O
-	66	67	O
carotene	67	75	O
content	76	83	O
in	84	86	O
food	87	91	O
samples	92	99	O
compared	100	108	O
to	109	111	O
HPLC	112	116	O
-	116	117	O
UV	117	119	O
-	119	120	O
vis	120	123	O
.	123	124	O

In	125	127	O
this	128	132	O
study	133	138	O
a	139	140	O
neural	141	147	O
network	148	155	O
(	156	157	O
NN	157	159	O
)	159	160	O
model	161	166	O
was	167	170	O
designed	171	179	O
to	180	182	O
predict	183	190	O
lycopene	191	199	O
and	200	203	O
beta	204	208	O
-	208	209	O
carotene	209	217	O
concentrations	218	232	O
in	233	235	O
food	236	240	O
samples	241	248	O
,	248	249	O
combined	250	258	O
with	259	263	O
a	264	265	O
simple	266	272	O
and	273	276	O
fast	277	281	O
technique	282	291	O
,	291	292	O
such	293	297	O
as	298	300	O
UV	301	303	O
-	303	304	O
vis	304	307	O
spectroscopy	308	320	O
.	320	321	O

The	322	325	O
measurement	326	337	O
of	338	340	O
the	341	344	O
absorbance	345	355	O
at	356	358	O
446	359	362	O
and	363	366	O
502	367	370	O
nm	371	373	O
of	374	376	O
different	377	386	O
beta	387	391	O
-	391	392	O
carotene	392	400	O
and	401	404	O
lycopene	405	413	O
standard	414	422	O
mixtures	423	431	O
was	432	435	O
used	436	440	O
to	441	443	O
optimize	444	452	O
a	453	454	O
neural	455	461	O
network	462	469	O
based	470	475	O
on	476	478	O
a	479	480	O
multilayer	481	491	O
perceptron	492	502	O
(	503	504	O
MLP	504	507	O
)	507	508	O
(	509	510	O
learning	510	518	O
and	519	522	O
verification	523	535	O
process	536	543	O
)	543	544	O
.	544	545	O

Then	546	550	O
,	550	551	O
for	552	555	O
validation	556	566	O
purposes	567	575	O
,	575	576	O
the	577	580	O
optimized	581	590	O
NN	591	593	O
has	594	597	O
been	598	602	O
applied	603	610	O
to	611	613	O
determine	614	623	O
the	624	627	O
concentration	628	641	O
of	642	644	O
both	645	649	O
compounds	650	659	O
in	660	662	O
food	663	667	O
samples	668	675	O
(	676	677	O
fresh	677	682	O
tomato	683	689	O
,	689	690	O
tomato	691	697	O
concentrate	698	709	B-Organism_substance
,	709	710	O
tomato	711	717	O
sauce	718	723	O
,	723	724	O
ketchup	725	732	O
,	732	733	O
tomato	734	740	O
juice	741	746	B-Organism_substance
,	746	747	O
watermelon	748	758	O
,	758	759	O
medlar	760	766	O
,	766	767	O
green	768	773	O
pepper	774	780	O
,	780	781	O
and	782	785	O
carrots	786	793	O
)	793	794	O
,	794	795	O
comparing	796	805	O
the	806	809	O
NN	810	812	O
results	813	820	O
with	821	825	O
the	826	829	O
known	830	835	O
values	836	842	O
of	843	845	O
these	846	851	O
compounds	852	861	O
obtained	862	870	O
by	871	873	O
analytical	874	884	O
techniques	885	895	O
(	896	897	O
UV	897	899	O
-	899	900	O
vis	900	903	O
and	904	907	O
HPLC	908	912	O
)	912	913	O
.	913	914	O

It	915	917	O
was	918	921	O
concluded	922	931	O
that	932	936	O
when	937	941	O
the	942	945	O
MLP	946	949	O
-	949	950	O
NN	950	952	O
is	953	955	O
used	956	960	O
within	961	967	O
the	968	971	O
range	972	977	O
studied	978	985	O
,	985	986	O
the	987	990	O
optimized	991	1000	O
NN	1001	1003	O
is	1004	1006	O
able	1007	1011	O
to	1012	1014	O
estimate	1015	1023	O
the	1024	1027	O
beta	1028	1032	O
-	1032	1033	O
carotene	1033	1041	O
and	1042	1045	O
lycopene	1046	1054	O
concentrations	1055	1069	O
in	1070	1072	O
food	1073	1077	O
samples	1078	1085	O
with	1086	1090	O
an	1091	1093	O
adequate	1094	1102	O
accuracy	1103	1111	O
,	1111	1112	O
solving	1113	1120	O
the	1121	1124	O
UV	1125	1127	O
-	1127	1128	O
vis	1128	1131	O
interference	1132	1144	O
of	1145	1147	O
beta	1148	1152	O
-	1152	1153	O
carotene	1153	1161	O
and	1162	1165	O
lycopene	1166	1174	O
.	1174	1175	O

Costs	0	5	O
of	6	8	O
hip	9	12	B-Organism_subdivision
fracture	13	21	O
.	21	22	O

Rehabilitation	23	37	O
of	38	40	O
180	41	44	O
patients	45	53	O
in	54	56	O
primary	57	64	O
health	65	71	O
care	72	76	O
.	76	77	O

Costs	78	83	O
related	84	91	O
to	92	94	O
functional	95	105	O
status	106	112	O
were	113	117	O
calculated	118	128	O
for	129	132	O
180	133	136	O
consecutive	137	148	O
hip	149	152	B-Organism_subdivision
fracture	153	161	O
patients	162	170	O
(	171	172	O
mean	172	176	O
age	177	180	O
78	181	183	O
years	184	189	O
)	189	190	O
who	191	194	O
were	195	199	O
admitted	200	208	O
from	209	213	O
their	214	219	O
own	220	223	O
home	224	228	O
and	229	232	O
rehabilitated	233	246	O
in	247	249	O
primary	250	257	O
health	258	264	O
care	265	269	O
.	269	270	O

Within	271	277	O
4	278	279	O
months	280	286	O
after	287	292	O
the	293	296	O
fracture	297	305	O
,	305	306	O
75	307	309	O
percent	310	317	O
of	318	320	O
the	321	324	O
patients	325	333	O
had	334	337	O
been	338	342	O
discharged	343	353	O
to	354	356	O
their	357	362	O
own	363	366	O
home	367	371	O
,	371	372	O
9	373	374	O
percent	375	382	O
were	383	387	O
dead	388	392	O
,	392	393	O
and	394	397	O
the	398	401	O
short	402	407	O
-	407	408	O
term	408	412	O
medical	413	420	O
treatment	421	430	O
costs	431	436	O
per	437	440	O
patient	441	448	O
were	449	453	O
SEK	454	457	O
43	458	460	O
,	460	461	O
000	461	464	O
,	464	465	O
whereas	466	473	O
the	474	477	O
total	478	483	O
costs	484	489	O
including	490	499	O
communal	500	508	O
help	509	513	O
and	514	517	O
costs	518	523	O
for	524	527	O
living	528	534	O
accommodations	535	549	O
after	550	555	O
discharge	556	565	O
were	566	570	O
twice	571	576	O
as	577	579	O
high	580	584	O
.	584	585	O

The	586	589	O
total	590	595	O
costs	596	601	O
per	602	605	O
patient	606	613	O
for	614	617	O
long	618	622	O
-	622	623	O
term	623	627	O
medical	628	635	O
treatment	636	645	O
(	646	647	O
from	647	651	O
4	652	653	O
months	654	660	O
up	661	663	O
to	664	666	O
3	667	668	O
years	669	674	O
after	675	680	O
fracture	681	689	O
)	689	690	O
were	691	695	O
7	696	697	O
percent	698	705	O
of	706	708	O
the	709	712	O
short	713	718	O
-	718	719	O
term	719	723	O
medical	724	731	O
treatment	732	741	O
costs	742	747	O
.	747	748	O

Patients	749	757	O
with	758	762	O
a	763	764	O
cervical	765	773	B-Organism_subdivision
fracture	774	782	O
discharged	783	793	O
to	794	796	O
their	797	802	O
own	803	806	O
home	807	811	O
and	812	815	O
with	816	820	O
good	821	825	O
functional	826	836	O
status	837	843	O
consumed	844	852	O
only	853	857	O
one	858	861	O
fifth	862	867	O
of	868	870	O
the	871	874	O
resources	875	884	O
that	885	889	O
patients	890	898	O
with	899	903	O
a	904	905	O
trochanteric	906	918	B-Multi-tissue_structure
fracture	919	927	O
discharged	928	938	O
to	939	941	O
institutional	942	955	O
care	956	960	O
and	961	964	O
who	965	968	O
had	969	972	O
reduced	973	980	O
functional	981	991	O
status	992	998	O
consumed	999	1007	O
.	1007	1008	O

A	1009	1010	O
substantial	1011	1022	O
part	1023	1027	O
of	1028	1030	O
the	1031	1034	O
costs	1035	1040	O
can	1041	1044	O
be	1045	1047	O
saved	1048	1053	O
by	1054	1056	O
improved	1057	1065	O
organization	1066	1078	O
of	1079	1081	O
rehabilitation	1082	1096	O
after	1097	1102	O
discharge	1103	1112	O
from	1113	1117	O
the	1118	1121	O
hospital	1122	1130	O
.	1130	1131	O

A	1132	1133	O
further	1134	1141	O
cost	1142	1146	O
reduction	1147	1156	O
would	1157	1162	O
require	1163	1170	O
a	1171	1172	O
combination	1173	1184	O
of	1185	1187	O
technologic	1188	1199	O
,	1199	1200	O
social	1201	1207	O
,	1207	1208	O
and	1209	1212	O
organizational	1213	1227	O
changes	1228	1235	O
aimed	1236	1241	O
at	1242	1244	O
early	1245	1250	O
discharge	1251	1260	O
and	1261	1264	O
continued	1265	1274	O
follow	1275	1281	O
-	1281	1282	O
up	1282	1284	O
in	1285	1287	O
primary	1288	1295	O
health	1296	1302	O
care	1303	1307	O
.	1307	1308	O

A	0	1	O
randomized	2	12	O
pilot	13	18	O
study	19	24	O
of	25	27	O
the	28	31	O
Engaging	32	40	O
Moms	41	45	O
Program	46	53	O
for	54	57	O
family	58	64	O
drug	65	69	O
court	70	75	O
.	75	76	O

In	77	79	O
response	80	88	O
to	89	91	O
the	92	95	O
need	96	100	O
for	101	104	O
effective	105	114	O
drug	115	119	O
court	120	125	O
interventions	126	139	O
,	139	140	O
the	141	144	O
effectiveness	145	158	O
of	159	161	O
the	162	165	O
Engaging	166	174	O
Moms	175	179	O
Program	180	187	O
(	188	189	O
EMP	189	192	O
)	192	193	O
versus	194	200	O
Intensive	201	210	O
Case	211	215	O
Management	216	226	O
Services	227	235	O
(	236	237	O
ICMS	237	241	O
)	241	242	O
on	243	245	O
multiple	246	254	O
outcomes	255	263	O
for	264	267	O
mothers	268	275	O
enrolled	276	284	O
in	285	287	O
family	288	294	O
drug	295	299	O
court	300	305	O
was	306	309	O
investigated	310	322	O
.	322	323	O

In	324	326	O
this	327	331	O
intent	332	338	O
-	338	339	O
to	339	341	O
-	341	342	O
treat	342	347	O
study	348	353	O
,	353	354	O
mothers	355	362	O
(	363	364	O
N	364	365	O
=	366	367	O
62	368	370	O
)	370	371	O
were	372	376	O
randomly	377	385	O
assigned	386	394	O
to	395	397	O
either	398	404	O
usual	405	410	O
drug	411	415	O
court	416	421	O
care	422	426	O
or	427	429	O
the	430	433	O
Engaging	434	442	O
Moms	443	447	O
drug	448	452	O
court	453	458	O
program	459	466	O
.	466	467	O

Mothers	468	475	O
were	476	480	O
assessed	481	489	O
at	490	492	O
intake	493	499	O
and	500	503	O
3	504	505	O
,	505	506	O
6	507	508	O
,	508	509	O
12	510	512	O
,	512	513	O
and	514	517	O
18	518	520	O
months	521	527	O
following	528	537	O
intake	538	544	O
.	544	545	O

Results	546	553	O
indicated	554	563	O
that	564	568	O
at	569	571	O
18	572	574	O
months	575	581	O
post	582	586	O
drug	587	591	O
court	592	597	O
enrollment	598	608	O
,	608	609	O
77	610	612	O
%	612	613	O
of	614	616	O
mothers	617	624	O
assigned	625	633	O
to	634	636	O
EMP	637	640	O
versus	641	647	O
55	648	650	O
%	650	651	O
of	652	654	O
mothers	655	662	O
assigned	663	671	O
to	672	674	O
ICMS	675	679	O
had	680	683	O
positive	684	692	O
child	693	698	O
welfare	699	706	O
dispositions	707	719	O
.	719	720	O

There	721	726	O
were	727	731	O
statistically	732	745	O
significant	746	757	O
time	758	762	O
effects	763	770	O
for	771	774	O
both	775	779	O
intervention	780	792	O
groups	793	799	O
on	800	802	O
multiple	803	811	O
outcomes	812	820	O
including	821	830	O
substance	831	840	O
use	841	844	O
,	844	845	O
mental	846	852	O
health	853	859	O
,	859	860	O
parenting	861	870	O
practices	871	880	O
,	880	881	O
and	882	885	O
family	886	892	O
functioning	893	904	O
.	904	905	O

EMP	906	909	O
showed	910	916	O
equal	917	922	O
or	923	925	O
better	926	932	O
improvement	933	944	O
than	945	949	O
ICMS	950	954	O
on	955	957	O
all	958	961	O
outcomes	962	970	O
.	970	971	O

The	972	975	O
results	976	983	O
suggest	984	991	O
that	992	996	O
EMP	997	1000	O
in	1001	1003	O
family	1004	1010	O
drug	1011	1015	O
court	1016	1021	O
is	1022	1024	O
a	1025	1026	O
viable	1027	1033	O
and	1034	1037	O
promising	1038	1047	O
intervention	1048	1060	O
approach	1061	1069	O
to	1070	1072	O
reduce	1073	1079	O
maternal	1080	1088	O
addiction	1089	1098	O
and	1099	1102	O
child	1103	1108	O
maltreatment	1109	1121	O
.	1121	1122	O

Absence	0	7	O
of	8	10	O
microbiota	11	21	O
(	22	23	O
germ	23	27	O
-	27	28	O
free	28	32	O
conditions	33	43	O
)	43	44	O
accelerates	45	56	O
the	57	60	O
atherosclerosis	61	76	O
in	77	79	O
ApoE	80	84	O
-	84	85	O
deficient	85	94	O
mice	95	99	O
fed	100	103	O
standard	104	112	O
low	113	116	O
cholesterol	117	128	O
diet	129	133	O
.	133	134	O

AIM	135	138	O
:	138	139	O

The	140	143	O
aim	144	147	O
of	148	150	O
our	151	154	O
work	155	159	O
was	160	163	O
to	164	166	O
determine	167	176	O
the	177	180	O
influence	181	190	O
of	191	193	O
intestinal	194	204	B-Multi-tissue_structure
bacteria	205	213	O
on	214	216	O
the	217	220	O
development	221	232	O
of	233	235	O
atherosclerotic	236	251	B-Pathological_formation
lesions	252	259	I-Pathological_formation
using	260	265	O
apolipoprotein	266	280	O
E	281	282	O
(	283	284	O
ApoE	284	288	O
)	288	289	O
-	289	290	O
deficient	290	299	O
knockout	300	308	O
mice	309	313	O
.	313	314	O

METHODS	315	322	O
:	322	323	O

The	324	327	O
experiments	328	339	O
were	340	344	O
performed	345	354	O
on	355	357	O
ApoE	358	362	O
-	362	363	O
/	363	364	O
-	364	365	O
-	365	366	O
deficient	366	375	O
mouse	376	381	O
strain	382	388	O
C57BL	389	394	O
/	394	395	O
6	395	396	O
,	396	397	O
bred	398	402	O
under	403	408	O
germ	409	413	O
-	413	414	O
free	414	418	O
(	419	420	O
GF	420	422	O
)	422	423	O
conditions	424	434	O
for	435	438	O
two	439	442	O
generations	443	454	O
or	455	457	O
under	458	463	O
conventional	464	476	O
conditions	477	487	O
with	488	492	O
defined	493	500	O
microflora	501	511	O
(	512	513	O
CV	513	515	O
)	515	516	O
.	516	517	O

The	518	521	O
mice	522	526	O
were	527	531	O
fed	532	535	O
a	536	537	O
standard	538	546	O
low	547	550	O
cholesterol	551	562	O
diet	563	567	O
or	568	570	O
cholesterol	571	582	O
-	582	583	O
rich	583	587	O
diet	588	592	O
for	593	596	O
3	597	598	O
-	598	599	O
4	599	600	O
months	601	607	O
.	607	608	O

We	609	611	O
studied	612	619	O
the	620	623	O
development	624	635	O
of	636	638	O
advanced	639	647	O
lesions	648	655	B-Pathological_formation
in	656	658	O
the	659	662	O
thoracic	663	671	B-Multi-tissue_structure
and	672	675	O
abdominal	676	685	B-Multi-tissue_structure
aorta	686	691	I-Multi-tissue_structure
by	692	694	O
histological	695	707	O
,	707	708	O
morphometric	709	721	O
and	722	725	O
immunohistological	726	744	O
methods	745	752	O
.	752	753	O

RESULTS	754	761	O
:	761	762	O

Conventionally	763	777	O
reared	778	784	O
ApoE	785	789	O
-	789	790	O
/	790	791	O
-	791	792	O
mice	793	797	O
(	798	799	O
containing	799	809	O
no	810	812	O
pathogenic	813	823	O
intestinal	824	834	B-Multi-tissue_structure
microbiota	835	845	O
)	845	846	O
and	847	850	O
fed	851	854	O
a	855	856	O
standard	857	865	O
low	866	869	O
cholesterol	870	881	O
diet	882	886	O
in	887	889	O
contrast	890	898	O
to	899	901	O
a	902	903	O
high	904	908	O
cholesterol	909	920	O
diet	921	925	O
did	926	929	O
not	930	933	O
develop	934	941	O
atherosclerotic	942	957	B-Pathological_formation
aortic	958	964	I-Pathological_formation
plaques	965	972	I-Pathological_formation
.	972	973	O

In	974	976	O
contrast	977	985	O
,	985	986	O
ApoE	987	991	O
-	991	992	O
/	992	993	O
-	993	994	O
mice	995	999	O
reared	1000	1006	O
under	1007	1012	O
germfree	1013	1021	O
conditions	1022	1032	O
for	1033	1036	O
2	1037	1038	O
generations	1039	1050	O
and	1051	1054	O
fed	1055	1058	O
a	1059	1060	O
low	1061	1064	O
cholesterol	1065	1076	O
diet	1077	1081	O
exhibited	1082	1091	O
atherosclerotic	1092	1107	B-Pathological_formation
plaques	1108	1115	I-Pathological_formation
in	1116	1118	O
the	1119	1122	O
aorta	1123	1128	B-Multi-tissue_structure
.	1128	1129	O

Characteristic	1130	1144	O
lipid	1145	1150	O
deposition	1151	1161	O
with	1162	1166	O
foam	1167	1171	O
cells	1172	1177	B-Cell
and	1178	1181	O
macrophages	1182	1193	B-Cell
was	1194	1197	O
found	1198	1203	O
in	1204	1206	O
their	1207	1212	O
arterial	1213	1221	B-Multi-tissue_structure
walls	1222	1227	I-Multi-tissue_structure
.	1227	1228	O

CONCLUSION	1229	1239	O
:	1239	1240	O

In	1241	1243	O
contrast	1244	1252	O
to	1253	1255	O
the	1256	1259	O
absence	1260	1267	O
of	1268	1270	O
atherosclerotic	1271	1286	B-Pathological_formation
plaques	1287	1294	I-Pathological_formation
in	1295	1297	O
conventionally	1298	1312	O
reared	1313	1319	O
ApoE	1320	1324	O
-	1324	1325	O
deficient	1325	1334	O
mice	1335	1339	O
,	1339	1340	O
germ	1341	1345	O
-	1345	1346	O
free	1346	1350	O
ApoE	1351	1355	O
-	1355	1356	O
/	1356	1357	O
-	1357	1358	O
mice	1359	1363	O
consuming	1364	1373	O
the	1374	1377	O
same	1378	1382	O
low	1383	1386	O
cholesterol	1387	1398	O
standard	1399	1407	O
diet	1408	1412	O
developed	1413	1422	O
atherosclerotic	1423	1438	B-Pathological_formation
plaques	1439	1446	I-Pathological_formation
in	1447	1449	O
the	1450	1453	O
aorta	1454	1459	B-Multi-tissue_structure
.	1459	1460	O

Differences	1461	1472	O
in	1473	1475	O
atherosclerotic	1476	1491	B-Pathological_formation
plaques	1492	1499	I-Pathological_formation
between	1500	1507	O
GF	1508	1510	O
and	1511	1514	O
CV	1515	1517	O
ApoE	1518	1522	O
-	1522	1523	O
/	1523	1524	O
-	1524	1525	O
mice	1526	1530	O
are	1531	1534	O
not	1535	1538	O
so	1539	1541	O
apparent	1542	1550	O
when	1551	1555	O
mice	1556	1560	O
are	1561	1564	O
fed	1565	1568	O
a	1569	1570	O
high	1571	1575	O
cholesterol	1576	1587	O
diet	1588	1592	O
.	1592	1593	O

Our	1594	1597	O
findings	1598	1606	O
thus	1607	1611	O
document	1612	1620	O
the	1621	1624	O
protective	1625	1635	O
effect	1636	1642	O
of	1643	1645	O
microbiota	1646	1656	O
(	1657	1658	O
commensal	1658	1667	O
bacteria	1668	1676	O
)	1676	1677	O
on	1678	1680	O
atherosclerosis	1681	1696	O
development	1697	1708	O
.	1708	1709	O

A	0	1	O
generative	2	12	O
model	13	18	O
for	19	22	O
image	23	28	O
segmentation	29	41	O
based	42	47	O
on	48	50	O
label	51	56	O
fusion	57	63	O
.	63	64	O

We	65	67	O
propose	68	75	O
a	76	77	O
nonparametric	78	91	O
,	91	92	O
probabilistic	93	106	O
model	107	112	O
for	113	116	O
the	117	120	O
automatic	121	130	O
segmentation	131	143	O
of	144	146	O
medical	147	154	O
images	155	161	O
,	161	162	O
given	163	168	O
a	169	170	O
training	171	179	O
set	180	183	O
of	184	186	O
images	187	193	O
and	194	197	O
corresponding	198	211	O
label	212	217	O
maps	218	222	O
.	222	223	O

The	224	227	O
resulting	228	237	O
inference	238	247	O
algorithms	248	258	O
rely	259	263	O
on	264	266	O
pairwise	267	275	O
registrations	276	289	O
between	290	297	O
the	298	301	O
test	302	306	O
image	307	312	O
and	313	316	O
individual	317	327	O
training	328	336	O
images	337	343	O
.	343	344	O

The	345	348	O
training	349	357	O
labels	358	364	O
are	365	368	O
then	369	373	O
transferred	374	385	O
to	386	388	O
the	389	392	O
test	393	397	O
image	398	403	O
and	404	407	O
fused	408	413	O
to	414	416	O
compute	417	424	O
the	425	428	O
final	429	434	O
segmentation	435	447	O
of	448	450	O
the	451	454	O
test	455	459	O
subject	460	467	O
.	467	468	O

Such	469	473	O
label	474	479	O
fusion	480	486	O
methods	487	494	O
have	495	499	O
been	500	504	O
shown	505	510	O
to	511	513	O
yield	514	519	O
accurate	520	528	O
segmentation	529	541	O
,	541	542	O
since	543	548	O
the	549	552	O
use	553	556	O
of	557	559	O
multiple	560	568	O
registrations	569	582	O
captures	583	591	O
greater	592	599	O
inter	600	605	O
-	605	606	O
subject	606	613	O
anatomical	614	624	O
variability	625	636	O
and	637	640	O
improves	641	649	O
robustness	650	660	O
against	661	668	O
occasional	669	679	O
registration	680	692	O
failures	693	701	O
.	701	702	O

To	703	705	O
the	706	709	O
best	710	714	O
of	715	717	O
our	718	721	O
knowledge	722	731	O
,	731	732	O
this	733	737	O
manuscript	738	748	O
presents	749	757	O
the	758	761	O
first	762	767	O
comprehensive	768	781	O
probabilistic	782	795	O
framework	796	805	O
that	806	810	O
rigorously	811	821	O
motivates	822	831	O
label	832	837	O
fusion	838	844	O
as	845	847	O
a	848	849	O
segmentation	850	862	O
approach	863	871	O
.	871	872	O

The	873	876	O
proposed	877	885	O
framework	886	895	O
allows	896	902	O
us	903	905	O
to	906	908	O
compare	909	916	O
different	917	926	O
label	927	932	O
fusion	933	939	O
algorithms	940	950	O
theoretically	951	964	O
and	965	968	O
practically	969	980	O
.	980	981	O

In	982	984	O
particular	985	995	O
,	995	996	O
recent	997	1003	O
label	1004	1009	O
fusion	1010	1016	O
or	1017	1019	O
multiatlas	1020	1030	O
segmentation	1031	1043	O
algorithms	1044	1054	O
are	1055	1058	O
interpreted	1059	1070	O
as	1071	1073	O
special	1074	1081	O
cases	1082	1087	O
of	1088	1090	O
our	1091	1094	O
framework	1095	1104	O
.	1104	1105	O

We	1106	1108	O
conduct	1109	1116	O
two	1117	1120	O
sets	1121	1125	O
of	1126	1128	O
experiments	1129	1140	O
to	1141	1143	O
validate	1144	1152	O
the	1153	1156	O
proposed	1157	1165	O
methods	1166	1173	O
.	1173	1174	O

In	1175	1177	O
the	1178	1181	O
first	1182	1187	O
set	1188	1191	O
of	1192	1194	O
experiments	1195	1206	O
,	1206	1207	O
we	1208	1210	O
use	1211	1214	O
39	1215	1217	O
brain	1218	1223	B-Organ
MRI	1224	1227	O
scans	1228	1233	O
-	1233	1234	O
with	1234	1238	O
manually	1239	1247	O
segmented	1248	1257	O
white	1258	1263	B-Multi-tissue_structure
matter	1264	1270	I-Multi-tissue_structure
,	1270	1271	O
cerebral	1272	1280	B-Multi-tissue_structure
cortex	1281	1287	I-Multi-tissue_structure
,	1287	1288	O
ventricles	1289	1299	B-Multi-tissue_structure
and	1300	1303	O
subcortical	1304	1315	B-Multi-tissue_structure
structures	1316	1326	I-Multi-tissue_structure
-	1326	1327	O
to	1327	1329	O
compare	1330	1337	O
different	1338	1347	O
label	1348	1353	O
fusion	1354	1360	O
algorithms	1361	1371	O
and	1372	1375	O
the	1376	1379	O
widely	1380	1386	O
-	1386	1387	O
used	1387	1391	O
FreeSurfer	1392	1402	O
whole	1403	1408	O
-	1408	1409	O
brain	1409	1414	B-Organ
segmentation	1415	1427	O
tool	1428	1432	O
.	1432	1433	O

Our	1434	1437	O
results	1438	1445	O
indicate	1446	1454	O
that	1455	1459	O
the	1460	1463	O
proposed	1464	1472	O
framework	1473	1482	O
yields	1483	1489	O
more	1490	1494	O
accurate	1495	1503	O
segmentation	1504	1516	O
than	1517	1521	O
FreeSurfer	1522	1532	O
and	1533	1536	O
previous	1537	1545	O
label	1546	1551	O
fusion	1552	1558	O
algorithms	1559	1569	O
.	1569	1570	O

In	1571	1573	O
a	1574	1575	O
second	1576	1582	O
experiment	1583	1593	O
,	1593	1594	O
we	1595	1597	O
use	1598	1601	O
brain	1602	1607	B-Organ
MRI	1608	1611	O
scans	1612	1617	O
of	1618	1620	O
282	1621	1624	O
subjects	1625	1633	O
to	1634	1636	O
demonstrate	1637	1648	O
that	1649	1653	O
the	1654	1657	O
proposed	1658	1666	O
segmentation	1667	1679	O
tool	1680	1684	O
is	1685	1687	O
sufficiently	1688	1700	O
sensitive	1701	1710	O
to	1711	1713	O
robustly	1714	1722	O
detect	1723	1729	O
hippocampal	1730	1741	B-Multi-tissue_structure
volume	1742	1748	O
changes	1749	1756	O
in	1757	1759	O
a	1760	1761	O
study	1762	1767	O
of	1768	1770	O
aging	1771	1776	O
and	1777	1780	O
Alzheimer	1781	1790	O
'	1790	1791	O
s	1791	1792	O
Disease	1793	1800	O
.	1800	1801	O

Listerine	0	9	O
:	9	10	O
past	11	15	O
,	15	16	O
present	17	24	O
and	25	28	O
future	29	35	O
-	35	36	O
-	36	37	O
a	37	38	O
test	39	43	O
of	44	46	O
thyme	47	52	O
.	52	53	O

Listerine	54	63	O
,	63	64	O
a	65	66	O
mouthrinse	67	77	O
composed	78	86	O
of	87	89	O
a	90	91	O
mixture	92	99	O
of	100	102	O
essential	103	112	O
oils	113	117	O
,	117	118	O
was	119	122	O
created	123	130	O
in	131	133	O
1879	134	138	O
and	139	142	O
was	143	146	O
originally	147	157	O
formulated	158	168	O
as	169	171	O
a	172	173	O
surgical	174	182	O
antiseptic	183	193	O
.	193	194	O

In	195	197	O
spite	198	203	O
of	204	206	O
its	207	210	O
known	211	216	O
antimicrobial	217	230	O
properties	231	241	O
it	242	244	O
was	245	248	O
thought	249	256	O
of	257	259	O
as	260	262	O
a	263	264	O
product	265	272	O
in	273	275	O
search	276	282	O
of	283	285	O
a	286	287	O
use	288	291	O
and	292	295	O
promoted	296	304	O
as	305	307	O
a	308	309	O
deterrent	310	319	O
for	320	323	O
halitosis	324	333	O
and	334	337	O
as	338	340	O
a	341	342	O
floor	343	348	O
cleaner	349	356	O
.	356	357	O

In	358	360	O
the	361	364	O
last	365	369	O
several	370	377	O
years	378	383	O
Listerine	384	393	O
has	394	397	O
emerged	398	405	O
as	406	408	O
a	409	410	O
bona	411	415	O
fide	416	420	O
therapeutic	421	432	O
agent	433	438	O
for	439	442	O
reduction	443	452	O
of	453	455	O
plaque	456	462	B-Organism_substance
induced	463	470	O
oral	471	475	B-Organism_subdivision
diseases	476	484	O
.	484	485	O

In	486	488	O
contrast	489	497	O
to	498	500	O
the	501	504	O
inconsistent	505	517	O
history	518	525	O
of	526	528	O
Listerine	529	538	O
,	538	539	O
systemic	540	548	O
antibiotics	549	560	O
discovered	561	571	O
in	572	574	O
the	575	578	O
1940	579	583	O
'	583	584	O
s	584	585	O
were	586	590	O
heralded	591	599	O
as	600	602	O
miracle	603	610	O
drugs	611	616	O
.	616	617	O

However	618	625	O
,	625	626	O
the	627	630	O
value	631	636	O
of	637	639	O
prophylactic	640	652	O
usage	653	658	O
of	659	661	O
antibiotics	662	673	O
has	674	677	O
come	678	682	O
under	683	688	O
scrutiny	689	697	O
as	698	700	O
a	701	702	O
result	703	709	O
of	710	712	O
increasing	713	723	O
resistance	724	734	O
and	735	738	O
adverse	739	746	O
reactions	747	756	O
.	756	757	O

Moreover	758	766	O
,	766	767	O
reports	768	775	O
by	776	778	O
both	779	783	O
American	784	792	O
and	793	796	O
British	797	804	O
professional	805	817	O
societies	818	827	O
have	828	832	O
led	833	836	O
to	837	839	O
a	840	841	O
re	842	844	O
-	844	845	O
evaluation	845	855	O
of	856	858	O
the	859	862	O
relative	863	871	O
risks	872	877	O
associated	878	888	O
with	889	893	O
plaque	894	900	B-Organism_substance
induced	901	908	O
bacteremia	909	919	O
when	920	924	O
twice	925	930	O
-	930	931	O
yearly	931	937	O
visits	938	944	O
to	945	947	O
dental	948	954	O
professionals	955	968	O
are	969	972	O
compared	973	981	O
to	982	984	O
daily	985	990	O
activities	991	1001	O
.	1001	1002	O

These	1003	1008	O
new	1009	1012	O
recommendations	1013	1028	O
and	1029	1032	O
revelations	1033	1044	O
open	1045	1049	O
the	1050	1053	O
door	1054	1058	O
for	1059	1062	O
local	1063	1068	O
antimicrobial	1069	1082	O
approaches	1083	1093	O
to	1094	1096	O
reduce	1097	1103	O
the	1104	1107	O
challenge	1108	1117	O
of	1118	1120	O
plaque	1121	1127	B-Organism_substance
-	1127	1128	O
induced	1128	1135	O
bacteremias	1136	1147	O
.	1147	1148	O

These	1149	1154	O
issues	1155	1161	O
will	1162	1166	O
be	1167	1169	O
discussed	1170	1179	O
in	1180	1182	O
the	1183	1186	O
context	1187	1194	O
of	1195	1197	O
Listerine	1198	1207	O
,	1207	1208	O
its	1209	1212	O
intricate	1213	1222	O
and	1223	1226	O
complicated	1227	1238	O
past	1239	1243	O
,	1243	1244	O
and	1245	1248	O
its	1249	1252	O
connection	1253	1263	O
to	1264	1266	O
current	1267	1274	O
uses	1275	1279	O
in	1280	1282	O
oral	1283	1287	B-Organism_subdivision
health	1288	1294	O
and	1295	1298	O
beyond	1299	1305	O
.	1305	1306	O

Acute	0	5	O
ablation	6	14	O
of	15	17	O
Langerhans	18	28	B-Cell
cells	29	34	I-Cell
enhances	35	43	O
skin	44	48	B-Organ
immune	49	55	O
responses	56	65	O
.	65	66	O

Understanding	67	80	O
the	81	84	O
function	85	93	O
of	94	96	O
Langerhans	97	107	B-Cell
cells	108	113	I-Cell
(	114	115	O
LCs	115	118	B-Cell
)	118	119	O
in	120	122	O
vivo	123	127	O
has	128	131	O
been	132	136	O
complicated	137	148	O
by	149	151	O
conflicting	152	163	O
results	164	171	O
from	172	176	O
LC	177	179	B-Cell
-	179	180	O
deficient	180	189	O
mice	190	194	O
.	194	195	O

Human	196	201	O
Langerin	202	210	O
-	210	211	O
DTA	211	214	O
mice	215	219	O
constitutively	220	234	O
lack	235	239	O
LCs	240	243	B-Cell
and	244	247	O
develop	248	255	O
exaggerated	256	267	O
contact	268	275	O
hypersensitivity	276	292	O
(	293	294	O
CHS	294	297	O
)	297	298	O
responses	299	308	O
.	308	309	O

Murine	310	316	O
Langerin	317	325	O
-	325	326	O
diphtheria	326	336	O
toxin	337	342	O
receptor	343	351	O
(	352	353	O
DTR	353	356	O
)	356	357	O
mice	358	362	O
allow	363	368	O
for	369	372	O
the	373	376	O
inducible	377	386	O
elimination	387	398	O
of	399	401	O
LCs	402	405	B-Cell
and	406	409	O
Langerin	410	418	B-Cell
(	418	419	I-Cell
+	419	420	I-Cell
)	420	421	I-Cell
dermal	422	428	I-Cell
dendritic	429	438	I-Cell
cells	439	444	I-Cell
(	445	446	O
dDCs	446	450	B-Cell
)	450	451	O
after	452	457	O
administration	458	472	O
of	473	475	O
diphtheria	476	486	O
toxin	487	492	O
,	492	493	O
which	494	499	O
results	500	507	O
in	508	510	O
reduced	511	518	O
CHS	519	522	O
.	522	523	O

When	524	528	O
Langerin	529	537	B-Cell
(	537	538	I-Cell
+	538	539	I-Cell
)	539	540	I-Cell
dDCs	541	545	I-Cell
have	546	550	O
partially	551	560	O
repopulated	561	572	O
the	573	576	O
skin	577	581	B-Organ
but	582	585	O
LCs	586	589	B-Cell
are	590	593	O
still	594	599	O
absent	600	606	O
,	606	607	O
CHS	608	611	O
returns	612	619	O
to	620	622	O
normal	623	629	O
.	629	630	O

Thus	631	635	O
,	635	636	O
LCs	637	640	B-Cell
appear	641	647	O
to	648	650	O
be	651	653	O
suppressive	654	665	O
in	666	668	O
human	669	674	O
Langerin	675	683	O
-	683	684	O
DTA	684	687	O
mice	688	692	O
and	693	696	O
redundant	697	706	O
in	707	709	O
murine	710	716	O
Langerin	717	725	O
-	725	726	O
DTR	726	729	O
mice	730	734	O
.	734	735	O

To	736	738	O
determine	739	748	O
whether	749	756	O
inducible	757	766	O
versus	767	773	O
constitutive	774	786	O
LC	787	789	B-Cell
ablation	790	798	O
explains	799	807	O
these	808	813	O
results	814	821	O
,	821	822	O
we	823	825	O
engineered	826	836	O
human	837	842	O
Langerin	843	851	O
-	851	852	O
DTR	852	855	O
mice	856	860	O
in	861	863	O
which	864	869	O
diphtheria	870	880	O
toxin	881	886	O
ablates	887	894	O
LCs	895	898	B-Cell
without	899	906	O
affecting	907	916	O
Langerin	917	925	B-Cell
(	925	926	I-Cell
+	926	927	I-Cell
)	927	928	I-Cell
dDCs	929	933	I-Cell
.	933	934	O

The	935	938	O
inducible	939	948	O
ablation	949	957	O
of	958	960	O
LCs	961	964	B-Cell
in	965	967	O
human	968	973	O
Langerin	974	982	O
-	982	983	O
DTR	983	986	O
mice	987	991	O
resulted	992	1000	O
in	1001	1003	O
increased	1004	1013	O
CHS	1014	1017	O
.	1017	1018	O

Thus	1019	1023	O
,	1023	1024	O
LC	1025	1027	B-Cell
-	1027	1028	O
mediated	1028	1036	O
suppression	1037	1048	O
does	1049	1053	O
not	1054	1057	O
require	1058	1065	O
their	1066	1071	O
absence	1072	1079	O
during	1080	1086	O
ontogeny	1087	1095	O
or	1096	1098	O
during	1099	1105	O
the	1106	1109	O
steady	1110	1116	O
-	1116	1117	O
state	1117	1122	O
and	1123	1126	O
is	1127	1129	O
consistent	1130	1140	O
with	1141	1145	O
a	1146	1147	O
model	1148	1153	O
in	1154	1156	O
which	1157	1162	O
LCs	1163	1166	B-Cell
actively	1167	1175	O
suppress	1176	1184	O
Ag	1185	1187	O
-	1187	1188	O
specific	1188	1196	O
CHS	1197	1200	O
responses	1201	1210	O
.	1210	1211	O

The	0	3	O
proenkephalin	4	17	O
-	17	18	O
A	18	19	O
-	19	20	O
derivative	20	30	O
Met	31	34	O
-	34	35	O
enkephalin	35	45	O
-	45	46	O
Arg	46	49	O
-	49	50	O
Gly	50	53	O
-	53	54	O
Leu	54	57	O
is	58	60	O
not	61	64	O
present	65	72	O
in	73	75	O
the	76	79	O
feline	80	86	O
species	87	94	O
.	94	95	O

No	96	98	O
opioid	99	105	O
octapeptide	106	117	O
Met	118	121	O
-	121	122	O
enkephalin	122	132	O
-	132	133	O
Arg	133	136	O
-	136	137	O
Gly	137	140	O
-	140	141	O
Leu	141	144	O
was	145	148	O
detected	149	157	O
either	158	164	O
in	165	167	O
the	168	171	O
brain	172	177	B-Organ
or	178	180	O
in	181	183	O
the	184	187	O
adrenal	188	195	B-Organ
gland	196	201	I-Organ
of	202	204	O
the	205	208	O
cat	209	212	O
using	213	218	O
a	219	220	O
specific	221	229	O
radioimmunoassay	230	246	O
.	246	247	O

Whereas	248	255	O
it	256	258	O
was	259	262	O
possible	263	271	O
to	272	274	O
determine	275	284	O
the	285	288	O
Met	289	292	O
-	292	293	O
enkephalin	293	303	O
and	304	307	O
Leu	308	311	O
-	311	312	O
enkephalin	312	322	O
contents	323	331	O
.	331	332	O

The	333	336	O
Met	337	340	O
-	340	341	O
enkephalin	341	351	O
versus	352	358	O
Leu	359	362	O
-	362	363	O
enkephalin	363	373	O
concentration	374	387	O
ratio	388	393	O
was	394	397	O
around	398	404	O
five	405	409	O
in	410	412	O
each	413	417	O
area	418	422	O
of	423	425	O
the	426	429	O
brain	430	435	B-Organ
assayed	436	443	O
.	443	444	O

The	445	448	O
presence	449	457	O
of	458	460	O
authentic	461	470	O
Met	471	474	O
-	474	475	O
enkephalin	475	485	O
and	486	489	O
Leu	490	493	O
-	493	494	O
enkephalin	494	504	O
was	505	508	O
confirmed	509	518	O
by	519	521	O
high	522	526	O
performance	527	538	O
liquid	539	545	O
chromatography	546	560	O
analysis	561	569	O
.	569	570	O

All	571	574	O
in	575	577	O
all	578	581	O
,	581	582	O
these	583	588	O
data	589	593	O
seem	594	598	O
to	599	601	O
indicate	602	610	O
that	611	615	O
the	616	619	O
cat	620	623	O
proenkephalin	624	637	O
is	638	640	O
partly	641	647	O
different	648	657	O
from	658	662	O
that	663	667	O
previously	668	678	O
analysed	679	687	O
in	688	690	O
mammalian	691	700	O
species	701	708	O
including	709	718	O
humans	719	725	O
,	725	726	O
rats	727	731	O
and	732	735	O
cows	736	740	O
.	740	741	O

Dissecting	0	10	O
genetic	11	18	O
networks	19	27	O
underlying	28	38	O
complex	39	46	O
phenotypes	47	57	O
:	57	58	O
the	59	62	O
theoretical	63	74	O
framework	75	84	O
.	84	85	O

Great	86	91	O
progress	92	100	O
has	101	104	O
been	105	109	O
made	110	114	O
in	115	117	O
genetic	118	125	O
dissection	126	136	O
of	137	139	O
quantitative	140	152	O
trait	153	158	O
variation	159	168	O
during	169	175	O
the	176	179	O
past	180	184	O
two	185	188	O
decades	189	196	O
,	196	197	O
but	198	201	O
many	202	206	O
studies	207	214	O
still	215	220	O
reveal	221	227	O
only	228	232	O
a	233	234	O
small	235	240	O
fraction	241	249	O
of	250	252	O
quantitative	253	265	O
trait	266	271	O
loci	272	276	O
(	277	278	O
QTLs	278	282	O
)	282	283	O
,	283	284	O
and	285	288	O
epistasis	289	298	O
remains	299	306	O
elusive	307	314	O
.	314	315	O

We	316	318	O
integrate	319	328	O
contemporary	329	341	O
knowledge	342	351	O
of	352	354	O
signal	355	361	O
transduction	362	374	O
pathways	375	383	O
with	384	388	O
principles	389	399	O
of	400	402	O
quantitative	403	415	O
and	416	419	O
population	420	430	O
genetics	431	439	O
to	440	442	O
characterize	443	455	O
genetic	456	463	O
networks	464	472	O
underlying	473	483	O
complex	484	491	O
traits	492	498	O
,	498	499	O
using	500	505	O
a	506	507	O
model	508	513	O
founded	514	521	O
upon	522	526	O
one	527	530	O
-	530	531	O
way	531	534	O
functional	535	545	O
dependency	546	556	O
of	557	559	O
downstream	560	570	O
genes	571	576	O
on	577	579	O
upstream	580	588	O
regulators	589	599	O
(	600	601	O
the	601	604	O
principle	605	614	O
of	615	617	O
hierarchy	618	627	O
)	627	628	O
and	629	632	O
mutual	633	639	O
functional	640	650	O
dependency	651	661	O
among	662	667	O
related	668	675	O
genes	676	681	O
(	682	683	O
functional	683	693	O
genetic	694	701	O
units	702	707	O
,	707	708	O
FGU	709	712	O
)	712	713	O
.	713	714	O

Both	715	719	O
simulated	720	729	O
and	730	733	O
real	734	738	O
data	739	743	O
suggest	744	751	O
that	752	756	O
complementary	757	770	O
epistasis	771	780	O
contributes	781	792	O
greatly	793	800	O
to	801	803	O
quantitative	804	816	O
trait	817	822	O
variation	823	832	O
,	832	833	O
and	834	837	O
obscures	838	846	O
the	847	850	O
phenotypic	851	861	O
effects	862	869	O
of	870	872	O
many	873	877	O
'	878	879	O
downstream	879	889	O
'	889	890	O
loci	891	895	O
in	896	898	O
pathways	899	907	O
.	907	908	O

The	909	912	O
mathematical	913	925	O
relationships	926	939	O
between	940	947	O
the	948	951	O
main	952	956	O
effects	957	964	O
and	965	968	O
epistatic	969	978	O
effects	979	986	O
of	987	989	O
genes	990	995	O
acting	996	1002	O
at	1003	1005	O
different	1006	1015	O
levels	1016	1022	O
of	1023	1025	O
signaling	1026	1035	O
pathways	1036	1044	O
were	1045	1049	O
established	1050	1061	O
using	1062	1067	O
the	1068	1071	O
quantitative	1072	1084	O
and	1085	1088	O
population	1089	1099	O
genetic	1100	1107	O
parameters	1108	1118	O
.	1118	1119	O

Both	1120	1124	O
loss	1125	1129	O
of	1130	1132	O
function	1133	1141	O
and	1142	1145	O
"	1146	1147	O
co	1147	1149	O
-	1149	1150	O
adapted	1150	1157	O
"	1157	1158	O
gene	1159	1163	O
complexes	1164	1173	O
formed	1174	1180	O
by	1181	1183	O
multiple	1184	1192	O
alleles	1193	1200	O
with	1201	1205	O
differentiated	1206	1220	O
functions	1221	1230	O
(	1231	1232	O
effects	1232	1239	O
)	1239	1240	O
are	1241	1244	O
predicted	1245	1254	O
to	1255	1257	O
be	1258	1260	O
frequent	1261	1269	O
types	1270	1275	O
of	1276	1278	O
allelic	1279	1286	O
diversity	1287	1296	O
at	1297	1299	O
loci	1300	1304	O
that	1305	1309	O
contribute	1310	1320	O
to	1321	1323	O
the	1324	1327	O
genetic	1328	1335	O
variation	1336	1345	O
of	1346	1348	O
complex	1349	1356	O
traits	1357	1363	O
in	1364	1366	O
populations	1367	1378	O
.	1378	1379	O

Downstream	1380	1390	O
FGUs	1391	1395	O
appear	1396	1402	O
to	1403	1405	O
be	1406	1408	O
more	1409	1413	O
vulnerable	1414	1424	O
to	1425	1427	O
loss	1428	1432	O
of	1433	1435	O
function	1436	1444	O
than	1445	1449	O
their	1450	1455	O
upstream	1456	1464	O
regulators	1465	1475	O
,	1475	1476	O
but	1477	1480	O
this	1481	1485	O
vulnerability	1486	1499	O
is	1500	1502	O
apparently	1503	1513	O
compensated	1514	1525	O
by	1526	1528	O
different	1529	1538	O
FGUs	1539	1543	O
of	1544	1546	O
similar	1547	1554	O
functions	1555	1564	O
.	1564	1565	O

Other	1566	1571	O
predictions	1572	1583	O
from	1584	1588	O
the	1589	1592	O
model	1593	1598	O
may	1599	1602	O
account	1603	1610	O
for	1611	1614	O
puzzling	1615	1623	O
results	1624	1631	O
regarding	1632	1641	O
responses	1642	1651	O
to	1652	1654	O
selection	1655	1664	O
,	1664	1665	O
genotype	1666	1674	O
by	1675	1677	O
environment	1678	1689	O
interaction	1690	1701	O
,	1701	1702	O
and	1703	1706	O
the	1707	1710	O
genetic	1711	1718	O
basis	1719	1724	O
of	1725	1727	O
heterosis	1728	1737	O
.	1737	1738	O

3	0	1	O
-	1	2	O
[	2	3	O
(	3	4	O
Methyl	4	10	O
-	10	11	O
carbamo	11	18	O
-	18	19	O
yl	19	21	O
)	21	22	O
amino	22	27	O
]	27	28	O
-	28	29	O
1H	29	31	O
-	31	32	O
isoindolium	32	43	O
chloride	44	52	O
.	52	53	O

The	54	57	O
title	58	63	O
compound	64	72	O
,	72	73	O
C	74	75	O
(	75	76	O
10	76	78	O
)	78	79	O
H	79	80	O
(	80	81	O
12	81	83	O
)	83	84	O
N	84	85	O
(	85	86	O
3	86	87	O
)	87	88	O
O	88	89	O
(	89	90	O
+	90	91	O
)	91	92	O
.	92	93	O
Cl	93	95	O
(	95	96	O
-	96	97	O
)	97	98	O
,	98	99	O
is	100	102	O
a	103	104	O
derivative	105	115	O
of	116	118	O
o	119	120	O
-	120	121	O
phthaldehyde	121	133	O
and	134	137	O
methyl	138	144	O
-	144	145	O
thio	145	149	O
-	149	150	O
urea	150	154	O
.	154	155	O

The	156	159	O
mol	160	163	O
-	163	164	O
ecules	164	170	O
form	171	175	O
dimers	176	182	O
through	183	190	O
intra	191	196	O
-	196	197	O
and	198	201	O
inter	202	207	O
-	207	208	O
molecular	208	217	O
N	218	219	O
-	219	220	O
H	220	221	O
.	221	222	O
.	222	223	O
.	223	224	O
O	224	225	O
hydrogen	226	234	O
bonds	235	240	O
.	240	241	O

The	242	245	O
dimers	246	252	O
are	253	256	O
further	257	264	O
linked	265	271	O
into	272	276	O
chains	277	283	O
through	284	291	O
one	292	295	O
C	296	297	O
-	297	298	O
H	298	299	O
.	299	300	O
.	300	301	O
.	301	302	O
Cl	302	304	O
and	305	308	O
two	309	312	O
N	313	314	O
-	314	315	O
H	315	316	O
.	316	317	O
.	317	318	O
.	318	319	O
Cl	319	321	O
hydrogen	322	330	O
bonds	331	336	O
.	336	337	O

Oscillatory	0	11	O
alpha	12	17	O
-	17	18	O
band	18	22	O
mechanisms	23	33	O
and	34	37	O
the	38	41	O
deployment	42	52	O
of	53	55	O
spatial	56	63	O
attention	64	73	O
to	74	76	O
anticipated	77	88	O
auditory	89	97	O
and	98	101	O
visual	102	108	O
target	109	115	O
locations	116	125	O
:	125	126	O
supramodal	127	137	O
or	138	140	O
sensory	141	148	O
-	148	149	O
specific	149	157	O
control	158	165	O
mechanisms	166	176	O
?	176	177	O

Oscillatory	178	189	O
alpha	190	195	O
-	195	196	O
band	196	200	O
activity	201	209	O
(	210	211	O
8	211	212	O
-	212	213	O
15	213	215	O
Hz	216	218	O
)	218	219	O
over	220	224	O
parieto	225	232	B-Multi-tissue_structure
-	232	233	I-Multi-tissue_structure
occipital	233	242	I-Multi-tissue_structure
cortex	243	249	I-Multi-tissue_structure
in	250	252	O
humans	253	259	O
plays	260	265	O
an	266	268	O
important	269	278	O
role	279	283	O
in	284	286	O
suppression	287	298	O
of	299	301	O
processing	302	312	O
for	313	316	O
inputs	317	323	O
at	324	326	O
to	327	329	O
-	329	330	O
be	330	332	O
-	332	333	O
ignored	333	340	O
regions	341	348	O
of	349	351	O
space	352	357	O
,	357	358	O
with	359	363	O
increased	364	373	O
alpha	374	379	O
-	379	380	O
band	380	384	O
power	385	390	O
observed	391	399	O
over	400	404	O
cortex	405	411	B-Multi-tissue_structure
contralateral	412	425	O
to	426	428	O
locations	429	438	O
expected	439	447	O
to	448	450	O
contain	451	458	O
distractors	459	470	O
.	470	471	O

It	472	474	O
is	475	477	O
unclear	478	485	O
whether	486	493	O
similar	494	501	O
processes	502	511	O
operate	512	519	O
during	520	526	O
deployment	527	537	O
of	538	540	O
spatial	541	548	O
attention	549	558	O
in	559	561	O
other	562	567	O
sensory	568	575	O
modalities	576	586	O
.	586	587	O

Evidence	588	596	O
from	597	601	O
lesion	602	608	B-Pathological_formation
patients	609	617	O
suggests	618	626	O
that	627	631	O
parietal	632	640	B-Organism_subdivision
regions	641	648	I-Organism_subdivision
house	649	654	O
supramodal	655	665	O
representations	666	681	O
of	682	684	O
space	685	690	O
.	690	691	O

The	692	695	O
parietal	696	704	B-Multi-tissue_structure
lobes	705	710	I-Multi-tissue_structure
are	711	714	O
prominent	715	724	O
generators	725	735	O
of	736	738	O
alpha	739	744	O
oscillations	745	757	O
,	757	758	O
raising	759	766	O
the	767	770	O
possibility	771	782	O
that	783	787	O
alpha	788	793	O
is	794	796	O
a	797	798	O
neural	799	805	B-Multi-tissue_structure
signature	806	815	O
of	816	818	O
supramodal	819	829	O
spatial	830	837	O
attention	838	847	O
.	847	848	O

Furthermore	849	860	O
,	860	861	O
when	862	866	O
spatial	867	874	O
attention	875	884	O
is	885	887	O
deployed	888	896	O
within	897	903	O
vision	904	910	O
,	910	911	O
processing	912	922	O
of	923	925	O
task	926	930	O
-	930	931	O
irrelevant	931	941	O
auditory	942	950	O
inputs	951	957	O
at	958	960	O
attended	961	969	O
locations	970	979	O
is	980	982	O
also	983	987	O
enhanced	988	996	O
,	996	997	O
pointing	998	1006	O
to	1007	1009	O
automatic	1010	1019	O
links	1020	1025	O
between	1026	1033	O
spatial	1034	1041	O
deployments	1042	1053	O
across	1054	1060	O
senses	1061	1067	O
.	1067	1068	O

Here	1069	1073	O
,	1073	1074	O
we	1075	1077	O
asked	1078	1083	O
whether	1084	1091	O
lateralized	1092	1103	O
alpha	1104	1109	O
-	1109	1110	O
band	1110	1114	O
activity	1115	1123	O
is	1124	1126	O
also	1127	1131	O
evident	1132	1139	O
in	1140	1142	O
a	1143	1144	O
purely	1145	1151	O
auditory	1152	1160	O
spatial	1161	1168	O
-	1168	1169	O
cueing	1169	1175	O
task	1176	1180	O
and	1181	1184	O
whether	1185	1192	O
it	1193	1195	O
had	1196	1199	O
the	1200	1203	O
same	1204	1208	O
underlying	1209	1219	O
generator	1220	1229	O
configuration	1230	1243	O
as	1244	1246	O
in	1247	1249	O
a	1250	1251	O
purely	1252	1258	O
visuospatial	1259	1271	O
task	1272	1276	O
.	1276	1277	O

If	1278	1280	O
common	1281	1287	O
to	1288	1290	O
both	1291	1295	O
sensory	1296	1303	O
systems	1304	1311	O
,	1311	1312	O
this	1313	1317	O
would	1318	1323	O
provide	1324	1331	O
strong	1332	1338	O
support	1339	1346	O
for	1347	1350	O
"	1351	1352	O
supramodal	1352	1362	O
"	1362	1363	O
attention	1364	1373	O
theory	1374	1380	O
.	1380	1381	O

Alternately	1382	1393	O
,	1393	1394	O
alpha	1395	1400	O
-	1400	1401	O
band	1401	1405	O
differences	1406	1417	O
between	1418	1425	O
auditory	1426	1434	O
and	1435	1438	O
visual	1439	1445	O
tasks	1446	1451	O
would	1452	1457	O
support	1458	1465	O
a	1466	1467	O
sensory	1468	1475	O
-	1475	1476	O
specific	1476	1484	O
account	1485	1492	O
.	1492	1493	O

Lateralized	1494	1505	O
shifts	1506	1512	O
in	1513	1515	O
alpha	1516	1521	O
-	1521	1522	O
band	1522	1526	O
activity	1527	1535	O
were	1536	1540	O
indeed	1541	1547	O
observed	1548	1556	O
during	1557	1563	O
a	1564	1565	O
purely	1566	1572	O
auditory	1573	1581	O
spatial	1582	1589	O
task	1590	1594	O
.	1594	1595	O

Crucially	1596	1605	O
,	1605	1606	O
there	1607	1612	O
were	1613	1617	O
clear	1618	1623	O
differences	1624	1635	O
in	1636	1638	O
scalp	1639	1644	B-Multi-tissue_structure
topographies	1645	1657	O
of	1658	1660	O
this	1661	1665	O
alpha	1666	1671	O
activity	1672	1680	O
depending	1681	1690	O
on	1691	1693	O
the	1694	1697	O
sensory	1698	1705	O
system	1706	1712	O
within	1713	1719	O
which	1720	1725	O
spatial	1726	1733	O
attention	1734	1743	O
was	1744	1747	O
deployed	1748	1756	O
.	1756	1757	O

Findings	1758	1766	O
suggest	1767	1774	O
that	1775	1779	O
parietally	1780	1790	O
generated	1791	1800	O
alpha	1801	1806	O
-	1806	1807	O
band	1807	1811	O
mechanisms	1812	1822	O
are	1823	1826	O
central	1827	1834	O
to	1835	1837	O
attentional	1838	1849	O
deployments	1850	1861	O
across	1862	1868	O
modalities	1869	1879	O
but	1880	1883	O
that	1884	1888	O
they	1889	1893	O
are	1894	1897	O
invoked	1898	1905	O
in	1906	1908	O
a	1909	1910	O
sensory	1911	1918	O
-	1918	1919	O
specific	1919	1927	O
manner	1928	1934	O
.	1934	1935	O

The	1936	1939	O
data	1940	1944	O
support	1945	1952	O
an	1953	1955	O
"	1956	1957	O
interactivity	1957	1970	O
account	1971	1978	O
,	1978	1979	O
"	1979	1980	O
whereby	1981	1988	O
a	1989	1990	O
supramodal	1991	2001	O
system	2002	2008	O
interacts	2009	2018	O
with	2019	2023	O
sensory	2024	2031	O
-	2031	2032	O
specific	2032	2040	O
control	2041	2048	O
systems	2049	2056	O
during	2057	2063	O
deployment	2064	2074	O
of	2075	2077	O
spatial	2078	2085	O
attention	2086	2095	O
.	2095	2096	O

Absence	0	7	O
of	8	10	O
antisperm	11	20	O
antibodies	21	31	O
in	32	34	O
anejaculatory	35	48	O
men	49	52	O
.	52	53	O

Antisperm	54	63	O
antibodies	64	74	O
were	75	79	O
assessed	80	88	O
in	89	91	O
the	92	95	O
serum	96	101	B-Organism_substance
samples	102	109	I-Organism_substance
of	110	112	O
73	113	115	O
men	116	119	O
unable	120	126	O
to	127	129	O
ejaculate	130	139	O
naturally	140	149	O
and	150	153	O
on	154	156	O
the	157	160	O
sperm	161	166	B-Cell
cells	167	172	I-Cell
of	173	175	O
13	176	178	O
of	179	181	O
these	182	187	O
men	188	191	O
.	191	192	O

None	193	197	O
of	198	200	O
the	201	204	O
serum	205	210	B-Organism_substance
samples	211	218	I-Organism_substance
were	219	223	O
found	224	229	O
to	230	232	O
be	233	235	O
positive	236	244	O
by	245	247	O
sperm	248	253	B-Cell
agglutination	254	267	O
or	268	270	O
sperm	271	276	B-Cell
immobilization	277	291	O
methods	292	299	O
and	300	303	O
antibodies	304	314	O
were	315	319	O
detected	320	328	O
by	329	331	O
an	332	334	O
immunobead	335	345	O
assay	346	351	O
on	352	354	O
the	355	358	O
sperm	359	364	B-Cell
cells	365	370	I-Cell
of	371	373	O
one	374	377	O
of	378	380	O
the	381	384	O
13	385	387	O
men	388	391	O
examined	392	400	O
.	400	401	O

[	0	1	O
Biotechnological	1	17	O
and	18	21	O
biomedical	22	32	O
aspects	33	40	O
of	41	43	O
production	44	54	O
and	55	58	O
study	59	64	O
of	65	67	O
metal	68	73	O
cation	74	80	O
-	80	81	O
phospholipid	81	93	O
complexes	94	103	O
]	103	104	O
.	104	105	O

Problems	106	114	O
relating	115	123	O
to	124	126	O
the	127	130	O
technology	131	141	O
of	142	144	O
a	145	146	O
phospholipid	147	159	O
preparation	160	171	O
from	172	176	O
natural	177	184	O
materials	185	194	O
,	194	195	O
liposome	196	204	O
production	205	215	O
,	215	216	O
and	217	220	O
studies	221	228	O
into	229	233	O
the	234	237	O
mechanisms	238	248	O
of	249	251	O
interaction	252	263	O
between	264	271	O
metal	272	277	O
(	278	279	O
trace	279	284	O
elements	285	293	O
)	293	294	O
cations	295	302	O
and	303	306	O
model	307	312	O
bilayer	313	320	B-Cellular_component
lipid	321	326	I-Cellular_component
membranes	327	336	I-Cellular_component
are	337	340	O
discussed	341	350	O
.	350	351	O

The	352	355	O
proposed	356	364	O
technology	365	375	O
of	376	378	O
extraction	379	389	O
allows	390	396	O
for	397	400	O
preparation	401	412	O
of	413	415	O
phospholipids	416	429	O
utilizable	430	440	O
for	441	444	O
liposome	445	453	O
formation	454	463	O
.	463	464	O

The	465	468	O
cation	469	475	O
specificity	476	487	O
of	488	490	O
lipid	491	496	O
bilayers	497	505	O
is	506	508	O
found	509	514	O
to	515	517	O
be	518	520	O
determined	521	531	O
by	532	534	O
the	535	538	O
presence	539	547	O
of	548	550	O
anionic	551	558	O
phosphate	559	568	O
adsorption	569	579	O
sites	580	585	O
on	586	588	O
their	589	594	O
surface	595	602	O
.	602	603	O

Endoscopic	0	10	O
injection	11	20	O
therapy	21	28	O
for	29	32	O
acute	33	38	O
upper	39	44	B-Organism_subdivision
GI	45	47	I-Organism_subdivision
bleeding	48	56	O
.	56	57	O

In	58	60	O
summary	61	68	O
,	68	69	O
we	70	72	O
have	73	77	O
found	78	83	O
this	84	88	O
technique	89	98	O
to	99	101	O
be	102	104	O
useful	105	111	O
in	112	114	O
patients	115	123	O
in	124	126	O
whom	127	131	O
coagulation	132	143	O
therapy	144	151	O
is	152	154	O
not	155	158	O
possible	159	167	O
or	168	170	O
effective	171	180	O
.	180	181	O

It	182	184	O
must	185	189	O
still	190	195	O
be	196	198	O
considered	199	209	O
a	210	211	O
technique	212	221	O
which	222	227	O
is	228	230	O
undergoing	231	241	O
evaluation	242	252	O
.	252	253	O

Prospective	254	265	O
randomized	266	276	O
trials	277	283	O
comparing	284	293	O
this	294	298	O
therapy	299	306	O
with	307	311	O
other	312	317	O
currently	318	327	O
available	328	337	O
therapies	338	347	O
such	348	352	O
a	353	354	O
electrocoagulation	355	373	O
,	373	374	O
laser	375	380	O
and	381	384	O
conservative	385	397	O
management	398	408	O
must	409	413	O
be	414	416	O
completed	417	426	O
to	427	429	O
firmly	430	436	O
define	437	443	O
its	444	447	O
place	448	453	O
in	454	456	O
treatment	457	466	O
strategy	467	475	O
for	476	479	O
acute	480	485	O
upper	486	491	B-Organism_subdivision
GI	492	494	I-Organism_subdivision
bleeding	495	503	O
.	503	504	O

Effects	0	7	O
of	8	10	O
hypertension	11	23	O
and	24	27	O
sympathetic	28	39	O
denervation	40	51	O
on	52	54	O
cerebral	55	63	B-Organ
blood	64	69	B-Organism_substance
flow	70	74	O
in	75	77	O
newborn	78	85	O
pigs	86	90	O
.	90	91	O

To	92	94	O
investigate	95	106	O
the	107	110	O
potential	111	120	O
role	121	125	O
of	126	128	O
sympathetic	129	140	O
nerves	141	147	B-Multi-tissue_structure
in	148	150	O
preventing	151	161	O
pronounced	162	172	O
increases	173	182	O
in	183	185	O
cerebral	186	194	B-Organ
blood	195	200	B-Organism_substance
flow	201	205	O
,	205	206	O
we	207	209	O
evaluated	210	219	O
the	220	223	O
effects	224	231	O
of	232	234	O
abrupt	235	241	O
hypertension	242	254	O
on	255	257	O
the	258	261	O
cerebral	262	270	B-Organ
circulation	271	282	O
of	283	285	O
newborn	286	293	O
pigs	294	298	O
with	299	303	O
intact	304	310	O
cerebral	311	319	B-Organ
sympathetic	320	331	O
innervation	332	343	O
and	344	347	O
after	348	353	O
cerebral	354	362	B-Organ
sympathetic	363	374	O
denervation	375	386	O
.	386	387	O

Epinephrine	388	399	O
infusion	400	408	O
was	409	412	O
used	413	417	O
to	418	420	O
induce	421	427	O
abrupt	428	434	O
increases	435	444	O
in	445	447	O
mean	448	452	O
(	453	454	O
+	454	455	O
/	455	456	O
-	456	457	O
SEM	458	461	O
)	461	462	O
arterial	463	471	B-Multi-tissue_structure
pressure	472	480	O
(	481	482	O
innervated	482	492	O
pigs	493	497	O
,	497	498	O
62	499	501	O
+	502	503	O
/	503	504	O
-	504	505	O
3	506	507	O
mm	508	510	O
of	511	513	O
Hg	514	516	O
to	517	519	O
115	520	523	O
+	524	525	O
/	525	526	O
-	526	527	O
3	528	529	O
mm	530	532	O
of	533	535	O
Hg	536	538	O
;	538	539	O
denervated	540	550	O
pigs	551	555	O
,	555	556	O
71	557	559	O
+	560	561	O
/	561	562	O
-	562	563	O
4	564	565	O
mm	566	568	O
of	569	571	O
Hg	572	574	O
to	575	577	O
132	578	581	O
+	582	583	O
/	583	584	O
-	584	585	O
4	586	587	O
mm	588	590	O
of	591	593	O
Hg	594	596	O
)	596	597	O
that	598	602	O
remained	603	611	O
increased	612	621	O
for	622	625	O
the	626	629	O
3	630	631	O
minutes	632	639	O
of	640	642	O
the	643	646	O
study	647	652	O
.	652	653	O

Abrupt	654	660	O
hypertension	661	673	O
increased	674	683	O
blood	684	689	B-Organism_substance
flow	690	694	O
to	695	697	O
all	698	701	O
brain	702	707	B-Organ
regions	708	715	O
.	715	716	O

In	717	719	O
denervated	720	730	O
pigs	731	735	O
,	735	736	O
the	737	740	O
increased	741	750	O
flow	751	755	O
to	756	758	O
the	759	762	O
cerebrum	763	771	B-Multi-tissue_structure
was	772	775	O
prolonged	776	785	O
,	785	786	O
compared	787	795	O
with	796	800	O
that	801	805	O
in	806	808	O
pigs	809	813	O
with	814	818	O
intact	819	825	O
sympathetic	826	837	O
innervation	838	849	O
.	849	850	O

Differences	851	862	O
between	863	870	O
pigs	871	875	O
of	876	878	O
the	879	882	O
innervated	883	893	O
and	894	897	O
denervated	898	908	O
groups	909	915	O
were	916	920	O
not	921	924	O
apparent	925	933	O
,	933	934	O
with	935	939	O
respect	940	947	O
to	948	950	O
blood	951	956	B-Organism_substance
flow	957	961	O
to	962	964	O
any	965	968	O
other	969	974	O
region	975	981	O
(	982	983	O
caudate	983	990	O
region	991	997	O
,	997	998	O
brain	999	1004	B-Multi-tissue_structure
stem	1005	1009	I-Multi-tissue_structure
,	1009	1010	O
cerebellum	1011	1021	B-Multi-tissue_structure
)	1021	1022	O
.	1022	1023	O

In	1024	1026	O
newborn	1027	1034	O
pigs	1035	1039	O
,	1039	1040	O
sympathetic	1041	1052	O
nerves	1053	1059	B-Multi-tissue_structure
may	1060	1063	O
attenuate	1064	1073	O
hypertension	1074	1086	O
-	1086	1087	O
induced	1087	1094	O
increases	1095	1104	O
in	1105	1107	O
blood	1108	1113	B-Organism_substance
flow	1114	1118	O
to	1119	1121	O
the	1122	1125	O
cerebrum	1126	1134	B-Multi-tissue_structure
,	1134	1135	O
but	1136	1139	O
do	1140	1142	O
not	1143	1146	O
appear	1147	1153	O
to	1154	1156	O
affect	1157	1163	O
flow	1164	1168	O
to	1169	1171	O
the	1172	1175	O
rest	1176	1180	O
of	1181	1183	O
the	1184	1187	O
brain	1188	1193	B-Organ
.	1193	1194	O

Sensitivity	0	11	O
analysis	12	20	O
of	21	23	O
the	24	27	O
influence	28	37	O
of	38	40	O
source	41	47	O
-	47	48	O
term	48	52	O
and	53	56	O
environmental	57	70	O
parameters	71	81	O
on	82	84	O
the	85	88	O
radiological	89	101	O
risk	102	106	O
of	107	109	O
coal	110	114	O
-	114	115	O
fired	115	120	O
plants	121	127	O
.	127	128	O

A	129	130	O
sensitivity	131	142	O
analysis	143	151	O
was	152	155	O
undertaken	156	166	O
to	167	169	O
determine	170	179	O
the	180	183	O
influence	184	193	O
of	194	196	O
different	197	206	O
source	207	213	O
-	213	214	O
term	214	218	O
and	219	222	O
environmental	223	236	O
parameters	237	247	O
on	248	250	O
the	251	254	O
radiological	255	267	O
risks	268	273	O
from	274	278	O
a	279	280	O
coal	281	285	O
-	285	286	O
fired	286	291	O
plant	292	297	O
(	298	299	O
CFP	299	302	O
)	302	303	O
.	303	304	O

It	305	307	O
was	308	311	O
found	312	317	O
that	318	322	O
the	323	326	O
release	327	334	O
rate	335	339	O
of	340	342	O
radionuclides	343	356	O
and	357	360	O
the	361	364	O
effective	365	374	O
release	375	382	O
height	383	389	O
most	390	394	O
significantly	395	408	O
influence	409	418	O
radiological	419	431	O
risk	432	436	O
.	436	437	O

Site	438	442	O
characteristics	443	458	O
,	458	459	O
such	460	464	O
as	465	467	O
rain	468	472	O
scavenging	473	483	O
coefficients	484	496	O
and	497	500	O
food	501	505	O
acquirement	506	517	O
habits	518	524	O
,	524	525	O
have	526	530	O
a	531	532	O
lesser	533	539	O
influence	540	549	O
,	549	550	O
and	551	554	O
some	555	559	O
parameters	560	570	O
,	570	571	O
such	572	576	O
as	577	579	O
time	580	584	O
delay	585	590	O
before	591	597	O
ingestion	598	607	O
of	608	610	O
contaminated	611	623	O
food	624	628	O
,	628	629	O
have	630	634	O
practically	635	646	O
no	647	649	O
influence	650	659	O
on	660	662	O
the	663	666	O
radiological	667	679	O
impact	680	686	O
of	687	689	O
a	690	691	O
CFP	692	695	O
.	695	696	O

The	697	700	O
contribution	701	713	O
to	714	716	O
radiation	717	726	O
risks	727	732	O
of	733	735	O
different	736	745	O
exposure	746	754	O
modes	755	760	O
(	761	762	O
i	762	763	O
.	763	764	O
e	764	765	O
.	765	766	O
inhalation	767	777	O
,	777	778	O
ingestion	779	788	O
and	789	792	O
contact	793	800	O
with	801	805	O
ground	806	812	O
surface	813	820	O
)	820	821	O
were	822	826	O
also	827	831	O
analyzed	832	840	O
,	840	841	O
as	842	844	O
well	845	849	O
as	850	852	O
of	853	855	O
specific	856	864	O
radionuclides	865	878	O
and	879	882	O
human	883	888	O
body	889	893	B-Organ
organs	894	900	I-Organ
.	900	901	O

Results	902	909	O
of	910	912	O
the	913	916	O
sensitivity	917	928	O
analysis	929	937	O
were	938	942	O
interpreted	943	954	O
in	955	957	O
terms	958	963	O
of	964	966	O
the	967	970	O
characteristics	971	986	O
of	987	989	O
the	990	993	O
fuel	994	998	O
,	998	999	O
facilities	1000	1010	O
and	1011	1014	O
site	1015	1019	O
of	1020	1022	O
a	1023	1024	O
CFP	1025	1028	O
.	1028	1029	O

It	1030	1032	O
is	1033	1035	O
concluded	1036	1045	O
that	1046	1050	O
by	1051	1053	O
proper	1054	1060	O
choice	1061	1067	O
of	1068	1070	O
coal	1071	1075	O
,	1075	1076	O
furnace	1077	1084	O
,	1084	1085	O
ash	1086	1089	O
filtration	1090	1100	O
and	1101	1104	O
stack	1105	1110	O
height	1111	1117	O
,	1117	1118	O
as	1119	1121	O
well	1122	1126	O
as	1127	1129	O
by	1130	1132	O
proper	1133	1139	O
siting	1140	1146	O
,	1146	1147	O
the	1148	1151	O
radiological	1152	1164	O
impact	1165	1171	O
of	1172	1174	O
a	1175	1176	O
CFP	1177	1180	O
can	1181	1184	O
be	1185	1187	O
drastically	1188	1199	O
reduced	1200	1207	O
.	1207	1208	O

Antishock	0	9	O
trousers	10	18	O
:	18	19	O
a	20	21	O
collective	22	32	O
review	33	39	O
.	39	40	O

Antishock	41	50	O
trousers	51	59	O
have	60	64	O
become	65	71	O
an	72	74	O
integral	75	83	O
part	84	88	O
of	89	91	O
emergency	92	101	O
medical	102	109	O
care	110	114	O
for	115	118	O
many	119	123	O
traumatic	124	133	O
and	134	137	O
life	138	142	O
-	142	143	O
threatening	143	154	O
emergencies	155	166	O
.	166	167	O

This	168	172	O
article	173	180	O
represents	181	191	O
a	192	193	O
summary	194	201	O
of	202	204	O
the	205	208	O
current	209	216	O
state	217	222	O
of	223	225	O
knowledge	226	235	O
concerning	236	246	O
the	247	250	O
use	251	254	O
of	255	257	O
this	258	262	O
device	263	269	O
.	269	270	O

A	271	272	O
brief	273	278	O
history	279	286	O
of	287	289	O
the	290	293	O
development	294	305	O
of	306	308	O
antishock	309	318	O
garments	319	327	O
is	328	330	O
discussed	331	340	O
.	340	341	O

This	342	346	O
is	347	349	O
followed	350	358	O
by	359	361	O
a	362	363	O
discussion	364	374	O
of	375	377	O
human	378	383	O
clinical	384	392	O
studies	393	400	O
and	401	404	O
results	405	412	O
of	413	415	O
clinical	416	424	O
research	425	433	O
on	434	436	O
hemodynamics	437	449	O
,	449	450	O
respiration	451	462	O
,	462	463	O
use	464	467	O
in	468	470	O
head	471	475	B-Organism_subdivision
injury	476	482	O
,	482	483	O
and	484	487	O
effects	488	495	O
on	496	498	O
vascular	499	507	B-Multi-tissue_structure
hemostasis	508	518	O
.	518	519	O

Indications	520	531	O
,	531	532	O
contraindications	533	550	O
,	550	551	O
complications	552	565	O
,	565	566	O
and	567	570	O
recommended	571	582	O
procedure	583	592	O
for	593	596	O
use	597	600	O
are	601	604	O
discussed	605	614	O
.	614	615	O

Based	616	621	O
on	622	624	O
randomized	625	635	O
prospective	636	647	O
studies	648	655	O
,	655	656	O
antishock	657	666	O
garments	667	675	O
have	676	680	O
not	681	684	O
,	684	685	O
as	686	688	O
yet	689	692	O
,	692	693	O
been	694	698	O
shown	699	704	O
to	705	707	O
improve	708	715	O
patient	716	723	O
morbidity	724	733	O
or	734	736	O
mortality	737	746	O
.	746	747	O

Proper	748	754	O
use	755	758	O
of	759	761	O
antishock	762	771	O
garments	772	780	O
requires	781	789	O
an	790	792	O
understanding	793	806	O
of	807	809	O
both	810	814	O
their	815	820	O
function	821	829	O
and	830	833	O
their	834	839	O
limitations	840	851	O
.	851	852	O

Measurement	0	11	O
of	12	14	O
serum	15	20	B-Organism_substance
glycosylated	21	33	O
proteins	34	42	O
and	43	46	O
glycosylated	47	59	O
low	60	63	O
density	64	71	O
lipoprotein	72	83	O
fraction	84	92	O
in	93	95	O
diabetes	96	104	O
mellitus	105	113	O
.	113	114	O

A	115	116	O
simple	117	123	O
method	124	130	O
was	131	134	O
developed	135	144	O
for	145	148	O
estimating	149	159	O
serum	160	165	B-Organism_substance
glycosylated	166	178	O
protein	179	186	O
levels	187	193	O
using	194	199	O
gel	200	203	O
filtration	204	214	O
with	215	219	O
Bio	220	223	O
-	223	224	O
Gel	224	227	O
P6	228	230	O
by	231	233	O
determining	234	245	O
the	246	249	O
protein	250	257	O
and	258	261	O
sugar	262	267	O
content	268	275	O
in	276	278	O
the	279	282	O
void	283	287	O
volume	288	294	O
fraction	295	303	O
.	303	304	O

The	305	308	O
glycosylated	309	321	O
protein	322	329	O
levels	330	336	O
(	337	338	O
GSP	338	341	O
)	341	342	O
correlated	343	353	O
well	354	358	O
with	359	363	O
fasting	364	371	O
blood	372	377	B-Organism_substance
sugar	378	383	O
levels	384	390	O
and	391	394	O
glycosylated	395	407	O
albumin	408	415	O
level	416	421	O
(	422	423	O
G	423	424	O
-	424	425	O
ALB	425	428	O
)	428	429	O
determined	430	440	O
by	441	443	O
affinity	444	452	O
chromatography	453	467	O
with	468	472	O
Blue	473	477	O
Sepharose	478	487	O
CL6B	488	492	O
.	492	493	O

The	494	497	O
glycosylation	498	511	O
level	512	517	O
of	518	520	O
heparin	521	528	O
-	528	529	O
citrate	529	536	O
precipitable	537	549	O
fraction	550	558	O
of	559	561	O
serum	562	567	B-Organism_substance
which	568	573	O
predominantly	574	587	O
contained	588	597	O
low	598	601	O
density	602	609	O
lipoprotein	610	621	O
(	622	623	O
G	623	624	O
-	624	625	O
LDL	625	628	O
)	628	629	O
also	630	634	O
correlated	635	645	O
well	646	650	O
with	651	655	O
GSP	656	659	O
and	660	663	O
LDL	664	667	O
-	667	668	O
cholesterol	668	679	O
levels	680	686	O
.	686	687	O

Significantly	688	701	O
different	702	711	O
values	712	718	O
were	719	723	O
obtained	724	732	O
for	733	736	O
GSP	737	740	O
,	740	741	O
G	742	743	O
-	743	744	O
ALB	744	747	O
,	747	748	O
and	749	752	O
G	753	754	O
-	754	755	O
LDL	755	758	O
between	759	766	O
normals	767	774	O
and	775	778	O
diabetics	779	788	O
.	788	789	O

The	0	3	O
origin	4	10	O
of	11	13	O
yolk	14	18	B-Developing_anatomical_structure
-	18	19	O
DNA	19	22	O
in	23	25	O
Xenopus	26	33	O
laevis	34	40	O
.	40	41	O

Xenopus	42	49	O
laevis	50	56	O
serum	57	62	B-Organism_substance
and	63	66	O
plasma	67	73	B-Organism_substance
was	74	77	O
found	78	83	O
to	84	86	O
contain	87	94	O
an	95	97	O
average	98	105	O
of	106	108	O
25	109	111	O
microgram	112	121	O
DNA	122	125	O
/	125	126	O
ml	126	128	O
.	128	129	O

Isolated	130	138	O
X	139	140	O
.	140	141	O
laevis	142	148	O
oocytes	149	156	B-Cell
incubated	157	166	O
in	167	169	O
medium	170	176	O
containing	177	187	O
25	188	190	O
microgram	191	200	O
DNA	201	204	O
/	204	205	O
ml	205	207	O
labeled	208	215	O
with	216	220	O
either	221	227	O
125I	228	232	O
,	232	233	O
32P	234	237	O
or	238	240	O
14C	241	244	O
and	245	248	O
from	249	253	O
three	254	259	O
different	260	269	O
sources	270	277	O
(	278	279	O
bovine	279	285	O
,	285	286	O
E	287	288	O
.	288	289	O
coli	290	294	O
and	295	298	O
X	299	300	O
.	300	301	O
laevis	302	308	O
)	308	309	O
,	309	310	O
incorporated	311	323	O
the	324	327	O
label	328	333	O
at	334	336	O
an	337	339	O
average	340	347	O
rate	348	352	O
of	353	355	O
0	356	357	O
.	357	358	O
11	358	360	O
ng	361	363	O
.	363	364	O
mm	364	366	O
-	366	367	O
2	367	368	O
.	368	369	O
hr	369	371	O
-	371	372	O
1	372	373	O
.	373	374	O

Sucrose	375	382	O
gradient	383	391	O
fractionation	392	405	O
of	406	408	O
oocytes	409	416	B-Cell
revealed	417	425	O
that	426	430	O
40	431	433	O
-	433	434	O
75	434	436	O
%	436	437	O
of	438	440	O
the	441	444	O
acid	445	449	O
-	449	450	O
precipitable	450	462	O
label	463	468	O
incorporated	469	481	O
was	482	485	O
associated	486	496	O
with	497	501	O
the	502	505	O
yolk	506	510	B-Cell
platelets	511	520	I-Cell
.	520	521	O

Additional	522	532	O
incubations	533	544	O
of	545	547	O
oocytes	548	555	B-Cell
in	556	558	O
unlabeled	559	568	O
medium	569	575	O
demonstrated	576	588	O
that	589	593	O
the	594	597	O
DNA	598	601	O
incorporated	602	614	O
into	615	619	O
the	620	623	O
yolk	624	628	B-Cell
platelets	629	638	I-Cell
was	639	642	O
undergoing	643	653	O
turnover	654	662	O
;	662	663	O
only	664	668	O
20	669	671	O
%	671	672	O
of	673	675	O
the	676	679	O
yolk	680	684	B-Developing_anatomical_structure
-	684	685	O
associated	685	695	O
DNA	696	699	O
was	700	703	O
still	704	709	O
present	710	717	O
after	718	723	O
a	724	725	O
one	726	729	O
-	729	730	O
week	730	734	O
incubation	735	745	O
.	745	746	O

Our	747	750	O
data	751	755	O
suggest	756	763	O
that	764	768	O
yolk	769	773	B-Developing_anatomical_structure
-	773	774	O
DNA	774	777	O
arises	778	784	O
by	785	787	O
the	788	791	O
adventitious	792	804	O
uptake	805	811	O
of	812	814	O
DNA	815	818	O
present	819	826	O
in	827	829	O
the	830	833	O
maternal	834	842	O
serum	843	848	B-Organism_substance
by	849	851	O
vitellogenic	852	864	O
oocytes	865	872	B-Cell
.	872	873	O

Immunoglobulins	0	15	O
associated	16	26	O
with	27	31	O
elevated	32	40	O
riboflavin	41	51	O
binding	52	59	O
by	60	62	O
plasma	63	69	B-Organism_substance
from	70	74	O
cancer	75	81	B-Pathological_formation
patients	82	90	O
.	90	91	O

Plasma	92	98	B-Organism_substance
from	99	103	O
182	104	107	O
patients	108	116	O
with	117	121	O
different	122	131	O
malignant	132	141	O
diseases	142	150	O
was	151	154	O
tested	155	161	O
for	162	165	O
riboflavin	166	176	O
binding	177	184	O
by	185	187	O
immunoglobulins	188	203	O
,	203	204	O
which	205	210	O
have	211	215	O
been	216	220	O
recently	221	229	O
identified	230	240	O
as	241	243	O
major	244	249	O
carriers	250	258	O
of	259	261	O
this	262	266	O
micronutrient	267	280	O
.	280	281	O

A	282	283	O
wide	284	288	O
range	289	294	O
of	295	297	O
binding	298	305	O
(	306	307	O
5	307	308	O
.	308	309	O
9	309	310	O
to	311	313	O
130	314	317	O
pmole	318	323	O
/	323	324	O
ml	324	326	O
plasma	327	333	O
)	333	334	O
was	335	338	O
observed	339	347	O
,	347	348	O
and	349	352	O
significant	353	364	O
elevations	365	375	O
were	376	380	O
found	381	386	O
for	387	390	O
patients	391	399	O
having	400	406	O
breast	407	413	B-Pathological_formation
cancer	414	420	I-Pathological_formation
(	421	422	O
21	422	424	O
.	424	425	O
2	425	426	O
+	427	428	O
/	428	429	O
-	429	430	O
1	431	432	O
.	432	433	O
9	433	434	O
,	434	435	O
P	436	437	O
less	438	442	O
than	443	447	O
0	448	449	O
.	449	450	O
05	450	452	O
)	452	453	O
and	454	457	O
melanoma	458	466	B-Pathological_formation
(	467	468	O
25	468	470	O
.	470	471	O
7	471	472	O
+	473	474	O
/	474	475	O
-	475	476	O
1	477	478	O
.	478	479	O
9	479	480	O
,	480	481	O
P	482	483	O
less	484	488	O
than	489	493	O
0	494	495	O
.	495	496	O
001	496	499	O
)	499	500	O
compared	501	509	O
to	510	512	O
controls	513	521	O
(	522	523	O
15	523	525	O
.	525	526	O
5	526	527	O
+	528	529	O
/	529	530	O
-	530	531	O
1	532	533	O
.	533	534	O
9	534	535	O
)	535	536	O
.	536	537	O

The	538	541	O
proteins	542	550	O
responsible	551	562	O
for	563	566	O
a	567	568	O
majority	569	577	O
of	578	580	O
the	581	584	O
higher	585	591	O
binding	592	599	O
were	600	604	O
identified	605	615	O
as	616	618	O
immunoglobulins	619	634	O
,	634	635	O
based	636	641	O
on	642	644	O
their	645	650	O
elution	651	658	O
from	659	663	O
gel	664	667	O
filtration	668	678	O
columns	679	686	O
and	687	690	O
the	691	694	O
removal	695	702	O
of	703	705	O
57	706	708	O
-	708	709	O
88	709	711	O
%	711	712	O
of	713	715	O
the	716	719	O
non	720	723	O
-	723	724	O
albumin	724	731	O
binding	732	739	O
by	740	742	O
treating	743	751	O
of	752	754	O
plasma	755	761	B-Organism_substance
with	762	766	O
Protein	767	774	O
A	775	776	O
-	776	777	O
agarose	777	784	O
.	784	785	O

The	786	789	O
binding	790	797	O
was	798	801	O
only	802	806	O
weakly	807	813	O
related	814	821	O
to	822	824	O
the	825	828	O
total	829	834	O
concentration	835	848	O
of	849	851	O
immunoglobulins	852	867	O
(	868	869	O
r	869	870	O
=	871	872	O
0	873	874	O
.	874	875	O
11	875	877	O
by	878	880	O
linear	881	887	O
regression	888	898	O
analysis	899	907	O
)	907	908	O
,	908	909	O
however	910	917	O
,	917	918	O
and	919	922	O
is	923	925	O
apparently	926	936	O
due	937	940	O
to	941	943	O
a	944	945	O
subclass	946	954	O
that	955	959	O
is	960	962	O
elevated	963	971	O
in	972	974	O
some	975	979	O
types	980	985	O
of	986	988	O
cancer	989	995	O
.	995	996	O

Elevated	997	1005	O
levels	1006	1012	O
of	1013	1015	O
these	1016	1021	O
immunoglobulins	1022	1037	O
may	1038	1041	O
contribute	1042	1052	O
to	1053	1055	O
the	1056	1059	O
lower	1060	1065	O
urinary	1066	1073	B-Organism_substance
levels	1074	1080	O
and	1081	1084	O
clearance	1085	1094	O
of	1095	1097	O
riboflavin	1098	1108	O
in	1109	1111	O
cancer	1112	1118	B-Pathological_formation
.	1118	1119	O

Postpartum	0	10	O
rubella	11	18	O
immunization	19	31	O
:	31	32	O
association	33	44	O
with	45	49	O
development	50	61	O
of	62	64	O
prolonged	65	74	O
arthritis	75	84	O
,	84	85	O
neurological	86	98	B-Anatomical_system
sequelae	99	107	O
,	107	108	O
and	109	112	O
chronic	113	120	O
rubella	121	128	O
viremia	129	136	O
.	136	137	O

Six	138	141	O
women	142	147	O
developed	148	157	O
chronic	158	165	O
long	166	170	O
-	170	171	O
term	171	175	O
arthropathy	176	187	O
after	188	193	O
postpartum	194	204	O
immunization	205	217	O
against	218	225	O
rubella	226	233	O
.	233	234	O

All	235	238	O
individuals	239	250	O
developed	251	260	O
acute	261	266	O
polyarticular	267	280	O
arthritis	281	290	O
within	291	297	O
12	298	300	O
days	301	305	O
to	306	308	O
three	309	314	O
weeks	315	320	O
postimmunization	321	337	O
and	338	341	O
have	342	346	O
had	347	350	O
continuing	351	361	O
chronic	362	369	O
or	370	372	O
recurrent	373	382	O
arthralgia	383	393	O
or	394	396	O
arthritis	397	406	O
for	407	410	O
two	411	414	O
to	415	417	O
seven	418	423	O
years	424	429	O
after	430	435	O
vaccination	436	447	O
.	447	448	O

Acute	449	454	O
neurological	455	467	B-Anatomical_system
manifestations	468	482	O
,	482	483	O
consisting	484	494	O
of	495	497	O
carpal	498	504	O
tunnel	505	511	O
syndrome	512	520	O
or	521	523	O
multiple	524	532	O
paresthesiae	533	545	O
,	545	546	O
developed	547	556	O
postvaccination	557	572	O
in	573	575	O
three	576	581	O
women	582	587	O
.	587	588	O

Two	589	592	O
have	593	597	O
developed	598	607	O
continuing	608	618	O
active	619	625	O
or	626	628	O
chronic	629	636	O
recurrent	637	646	O
episodes	647	655	O
of	656	658	O
blurred	659	666	O
vision	667	673	O
,	673	674	O
paresthesiae	675	687	O
,	687	688	O
and	689	692	O
painful	693	700	O
limb	701	705	B-Organism_subdivision
syndromes	706	715	O
together	716	724	O
with	725	729	O
recurrent	730	739	O
joint	740	745	O
symptoms	746	754	O
.	754	755	O

Chronic	756	763	O
rubella	764	771	O
viremia	772	779	O
has	780	783	O
been	784	788	O
detected	789	797	O
in	798	800	O
peripheral	801	811	B-Cell
blood	812	817	I-Cell
mononuclear	818	829	I-Cell
cell	830	834	I-Cell
(	835	836	O
MNC	836	839	B-Cell
)	839	840	O
populations	841	852	O
in	853	855	O
five	856	860	O
of	861	863	O
the	864	867	O
six	868	871	O
women	872	877	O
up	878	880	O
to	881	883	O
six	884	887	O
years	888	893	O
after	894	899	O
vaccination	900	911	O
.	911	912	O

In	913	915	O
addition	916	924	O
rubella	925	932	O
virus	933	938	O
was	939	942	O
isolated	943	951	O
from	952	956	O
breast	957	963	B-Cell
milk	964	968	I-Cell
MNCs	969	973	I-Cell
in	974	976	O
one	977	980	O
individual	981	991	O
at	992	994	O
nine	995	999	O
months	1000	1006	O
postvaccination	1007	1022	O
and	1023	1026	O
from	1027	1031	O
peripheral	1032	1042	B-Cell
blood	1043	1048	I-Cell
MNCs	1049	1053	I-Cell
in	1054	1056	O
two	1057	1060	O
of	1061	1063	O
four	1064	1068	O
breast	1069	1075	B-Organism_subdivision
-	1075	1076	O
fed	1076	1079	O
infants	1080	1087	O
studied	1088	1095	O
at	1096	1098	O
12	1099	1101	O
-	1101	1102	O
18	1102	1104	O
months	1105	1111	O
of	1112	1114	O
age	1115	1118	O
.	1118	1119	O

Immune	1120	1126	O
responses	1127	1136	O
to	1137	1139	O
rubella	1140	1147	O
virus	1148	1153	O
studied	1154	1161	O
at	1162	1164	O
sequential	1165	1175	O
intervals	1176	1185	O
after	1186	1191	O
vaccination	1192	1203	O
correlated	1204	1214	O
with	1215	1219	O
development	1220	1231	O
of	1232	1234	O
rheumatologic	1235	1248	O
and	1249	1252	O
neurological	1253	1265	B-Anatomical_system
manifestations	1266	1280	O
.	1280	1281	O

Cardiac	0	7	B-Organ
gap	8	11	O
junction	12	20	O
configuration	21	34	O
after	35	40	O
an	41	43	O
uncoupling	44	54	O
treatment	55	64	O
as	65	67	O
a	68	69	O
function	70	78	O
of	79	81	O
time	82	86	O
.	86	87	O

Rabbit	88	94	O
ventricle	95	104	B-Multi-tissue_structure
either	105	111	O
was	112	115	O
fixed	116	121	O
in	122	124	O
glutaraldehyde	125	139	O
without	140	147	O
injury	148	154	O
(	155	156	O
control	156	163	O
)	163	164	O
or	165	167	O
was	168	171	O
injured	172	179	O
before	180	186	O
fixation	187	195	O
,	195	196	O
presumably	197	207	O
causing	208	215	O
electrical	216	226	O
uncoupling	227	237	O
of	238	240	O
the	241	244	O
gap	245	248	O
junctions	249	258	O
.	258	259	O

All	260	263	O
tissue	264	270	B-Tissue
was	271	274	O
then	275	279	O
processed	280	289	O
for	290	293	O
freeze	294	300	O
-	300	301	O
fracture	301	309	O
.	309	310	O

Replicas	311	319	O
of	320	322	O
control	323	330	O
gap	331	334	O
junctions	335	344	O
exhibited	345	354	O
irregular	355	364	O
packing	365	372	O
of	373	375	O
the	376	379	O
P	380	381	O
-	381	382	O
face	382	386	O
particles	387	396	O
and	397	400	O
E	401	402	O
-	402	403	O
face	403	407	O
pits	408	412	O
.	412	413	O

Average	414	421	O
center	422	428	O
-	428	429	O
to	429	431	O
-	431	432	O
center	432	438	O
spacing	439	446	O
of	447	449	O
the	450	453	O
particles	454	463	O
was	464	467	O
10	468	470	O
.	470	471	O
5	471	472	O
nm	473	475	O
.	475	476	O

Tissue	477	483	B-Tissue
fixed	484	489	O
1	490	491	O
-	491	492	O
5	492	493	O
min	494	497	O
after	498	503	O
injury	504	510	O
showed	511	517	O
clumping	518	526	O
of	527	529	O
gap	530	533	O
junctional	534	544	O
particles	545	554	O
and	555	558	O
pits	559	563	O
.	563	564	O

Within	565	571	O
the	572	575	O
clumps	576	582	O
,	582	583	O
the	584	587	O
particles	588	597	O
and	598	601	O
pits	602	606	O
were	607	611	O
hexagonally	612	623	O
packed	624	630	O
and	631	634	O
the	635	638	O
center	639	645	O
-	645	646	O
to	646	648	O
-	648	649	O
center	649	655	O
spacing	656	663	O
of	664	666	O
the	667	670	O
particles	671	680	O
averaged	681	689	O
9	690	691	O
.	691	692	O
5	692	693	O
nm	694	696	O
.	696	697	O

In	698	700	O
tissue	701	707	B-Tissue
fixed	708	713	O
15	714	716	O
-	716	717	O
30	717	719	O
min	720	723	O
after	724	729	O
injury	730	736	O
,	736	737	O
the	738	741	O
clumps	742	748	O
of	749	751	O
gap	752	755	O
junctional	756	766	O
particles	767	776	O
had	777	780	O
coalesced	781	790	O
into	791	795	O
a	796	797	O
homogeneous	798	809	O
structure	810	819	O
in	820	822	O
most	823	827	O
junctions	828	837	O
.	837	838	O

The	839	842	O
packing	843	850	O
of	851	853	O
the	854	857	O
particles	858	867	O
and	868	871	O
pits	872	876	O
was	877	880	O
hexagonal	881	890	O
and	891	894	O
the	895	898	O
spacing	899	906	O
of	907	909	O
the	910	913	O
particles	914	923	O
averaged	924	932	O
9	933	934	O
.	934	935	O
5	935	936	O
nm	937	939	O
.	939	940	O

A	941	942	O
few	943	946	O
pieces	947	953	O
of	954	956	O
rabbit	957	963	O
atrium	964	970	B-Multi-tissue_structure
were	971	975	O
frozen	976	982	O
without	983	990	O
prior	991	996	O
fixation	997	1005	O
or	1006	1008	O
cryoprotection	1009	1023	O
to	1024	1026	O
try	1027	1030	O
to	1031	1033	O
assess	1034	1040	O
the	1041	1044	O
effect	1045	1051	O
of	1052	1054	O
glutarldehyde	1055	1068	O
fixation	1069	1077	O
on	1078	1080	O
gap	1081	1084	O
junction	1085	1093	O
structure	1094	1103	O
.	1103	1104	O

In	1105	1107	O
this	1108	1112	O
tissue	1113	1119	B-Tissue
the	1120	1123	O
gap	1124	1127	O
junctional	1128	1138	O
particles	1139	1148	O
were	1149	1153	O
irregularly	1154	1165	O
packed	1166	1172	O
and	1173	1176	O
their	1177	1182	O
spacing	1183	1190	O
averaged	1191	1199	O
10	1200	1202	O
.	1202	1203	O
0	1203	1204	O
nm	1205	1207	O
.	1207	1208	O

Absence	0	7	O
of	8	10	O
effect	11	17	O
of	18	20	O
prenatal	21	29	O
ethanol	30	37	O
on	38	40	O
adult	41	46	O
emotionality	47	59	O
and	60	63	O
ethanol	64	71	O
consumption	72	83	O
in	84	86	O
rats	87	91	O
.	91	92	O

Lower	93	98	O
peak	99	103	O
blood	104	109	B-Organism_substance
ethanol	110	117	O
concentrations	118	132	O
after	133	138	O
1	139	140	O
and	141	144	O
2	145	146	O
g	147	148	O
of	149	151	O
ethanol	152	159	O
per	160	163	O
kg	164	166	O
were	167	171	O
found	172	177	O
in	178	180	O
pregnant	181	189	O
rats	190	194	O
than	195	199	O
in	200	202	O
virgin	203	209	O
females	210	217	O
.	217	218	O

No	219	221	O
significant	222	233	O
differences	234	245	O
in	246	248	O
adult	249	254	O
"	255	256	O
emotionality	256	268	O
"	268	269	O
or	270	272	O
ethanol	273	280	O
consumption	281	292	O
were	293	297	O
found	298	303	O
in	304	306	O
rats	307	311	O
exposed	312	319	O
to	320	322	O
prenatal	323	331	O
alcohol	332	339	O
and	340	343	O
in	344	346	O
pair	347	351	O
-	351	352	O
fed	352	355	O
and	356	359	O
untreated	360	369	O
controls	370	378	O
.	378	379	O

Tropical	0	8	O
splenomegaly	9	21	O
syndrome	22	30	O
in	31	33	O
Zambia	34	40	O
:	40	41	O
further	42	49	O
observations	50	62	O
and	63	66	O
effects	67	74	O
of	75	77	O
cycloguanil	78	89	O
and	90	93	O
proguanil	94	103	O
.	103	104	O

Nineteen	105	113	O
Zambian	114	121	O
patients	122	130	O
with	131	135	O
the	136	139	O
tropical	140	148	O
splenomegaly	149	161	O
syndrome	162	170	O
and	171	174	O
sinusoidal	175	185	B-Tissue
lymphocytosis	186	199	O
on	200	202	O
liver	203	208	B-Organ
biopsy	209	215	O
were	216	220	O
studied	221	228	O
.	228	229	O

The	230	233	O
association	234	245	O
of	246	248	O
macrobulinaemia	249	264	O
with	265	269	O
the	270	273	O
tropical	274	282	O
splenomegaly	283	295	O
syndrome	296	304	O
has	305	308	O
again	309	314	O
been	315	319	O
confirmed	320	329	O
.	329	330	O

Sixteen	331	338	O
patients	339	347	O
were	348	352	O
treated	353	360	O
with	361	365	O
antimalarials	366	379	O
-	379	380	O
12	380	382	O
with	383	387	O
cycloguanil	388	399	O
pamoate	400	407	O
alone	408	413	O
,	413	414	O
3	415	416	O
with	417	421	O
cycloguanil	422	433	O
and	434	437	O
proguanil	438	447	O
,	447	448	O
and	449	452	O
1	453	454	O
with	455	459	O
proguanil	460	469	O
alone	470	475	O
.	475	476	O

Twelve	477	483	O
patients	484	492	O
were	493	497	O
observed	498	506	O
for	507	510	O
periods	511	518	O
of	519	521	O
sufficient	522	532	O
length	533	539	O
for	540	543	O
the	544	547	O
drug	548	552	O
effect	553	559	O
to	560	562	O
be	563	565	O
assessed	566	574	O
,	574	575	O
and	576	579	O
in	580	582	O
11	583	585	O
there	586	591	O
was	592	595	O
a	596	597	O
good	598	602	O
response	603	611	O
in	612	614	O
terms	615	620	O
of	621	623	O
decrease	624	632	O
in	633	635	O
spleen	636	642	B-Organ
size	643	647	O
.	647	648	O
Cycloguanil	648	659	O
pamoate	660	667	O
may	668	671	O
be	672	674	O
of	675	677	O
value	678	683	O
both	684	688	O
for	689	692	O
prophylaxis	693	704	O
and	705	708	O
treatment	709	718	O
in	719	721	O
areas	722	727	O
where	728	733	O
tropical	734	742	O
splenomegaly	743	755	O
syndrome	756	764	O
is	765	767	O
endemic	768	775	O
.	775	776	O

Regulation	0	10	O
of	11	13	O
glucosyl	14	22	O
-	22	23	O
and	24	27	O
fructosyltransferase	28	48	O
synthesis	49	58	O
by	59	61	O
continuous	62	72	O
cultures	73	81	O
of	82	84	O
Streptococcus	85	98	O
mutans	99	105	O
.	105	106	O

Streptococcus	107	120	O
mutans	121	127	O
strains	128	135	O
Ingbritt	136	144	O
,	144	145	O
and	146	149	O
its	150	153	O
derivative	154	164	O
B7	165	167	O
which	168	173	O
had	174	177	O
been	178	182	O
passaged	183	191	O
through	192	199	O
monkeys	200	207	O
,	207	208	O
have	209	213	O
been	214	218	O
used	219	223	O
to	224	226	O
investigate	227	238	O
how	239	242	O
the	243	246	O
synthesis	247	256	O
of	257	259	O
extracellular	260	273	B-Immaterial_anatomical_entity
glucosyl	274	282	O
-	282	283	O
and	284	287	O
fructosyltransferases	288	309	O
is	310	312	O
regulated	313	322	O
.	322	323	O

The	324	327	O
most	328	332	O
active	333	339	O
enzyme	340	346	O
from	347	351	O
carbon	352	358	O
-	358	359	O
limited	359	366	O
continuous	367	377	O
cultures	378	386	O
was	387	390	O
a	391	392	O
fructosyltransferase	393	413	O
;	413	414	O
enzymes	415	422	O
catalysing	423	433	O
the	434	437	O
formation	438	447	O
of	448	450	O
water	451	456	O
-	456	457	O
insoluble	457	466	O
glucans	467	474	O
from	475	479	O
sucrose	480	487	O
were	488	492	O
relatively	493	503	O
inactive	504	512	O
.	512	513	O

Dextransucrase	514	528	O
(	529	530	O
EC	530	532	O
2	533	534	O
.	534	535	O
4	535	536	O
.	536	537	O
1	537	538	O
.	538	539	O
5	539	540	O
)	540	541	O
,	541	542	O
which	543	548	O
catalyses	549	558	O
soluble	559	566	O
glucan	567	573	O
synthesis	574	583	O
,	583	584	O
was	585	588	O
most	589	593	O
active	594	600	O
in	601	603	O
the	604	607	O
supernatant	608	619	O
fluid	620	625	O
from	626	630	O
cultures	631	639	O
grown	640	645	O
with	646	650	O
excess	651	657	O
glucose	658	665	O
,	665	666	O
fructose	667	675	O
or	676	678	O
sucrose	679	686	O
,	686	687	O
but	688	691	O
full	692	696	O
activity	697	705	O
was	706	709	O
detected	710	718	O
only	719	723	O
when	724	728	O
the	729	732	O
enzyme	733	739	O
was	740	743	O
incubated	744	753	O
with	754	758	O
both	759	763	O
sucrose	764	771	O
and	772	775	O
dextran	776	783	O
.	783	784	O

Little	785	791	O
dextransucrase	792	806	O
activity	807	815	O
was	816	819	O
detected	820	828	O
in	829	831	O
carbon	832	838	O
-	838	839	O
limited	839	846	O
cultures	847	855	O
.	855	856	O

It	857	859	O
is	860	862	O
concluded	863	872	O
that	873	877	O
glucosyl	878	886	O
-	886	887	O
and	888	891	O
fructosyltransferases	892	913	O
are	914	917	O
constitutive	918	930	O
enzymes	931	938	O
in	939	941	O
that	942	946	O
they	947	951	O
are	952	955	O
synthesized	956	967	O
at	968	970	O
similar	971	978	O
rates	979	984	O
during	985	991	O
growth	992	998	O
with	999	1003	O
an	1004	1006	O
excess	1007	1013	O
of	1014	1016	O
the	1017	1020	O
substrate	1021	1030	O
or	1031	1033	O
of	1034	1036	O
the	1037	1040	O
products	1041	1049	O
of	1050	1052	O
the	1053	1056	O
reactions	1057	1066	O
which	1067	1072	O
they	1073	1077	O
catalyse	1078	1086	O
.	1086	1087	O

Although	1088	1096	O
the	1097	1100	O
Ingbritt	1101	1109	O
strain	1110	1116	O
was	1117	1120	O
originally	1121	1131	O
isolated	1132	1140	O
from	1141	1145	O
a	1146	1147	O
carious	1148	1155	B-Pathological_formation
lesion	1156	1162	I-Pathological_formation
,	1162	1163	O
it	1164	1166	O
is	1167	1169	O
now	1170	1173	O
a	1174	1175	O
poor	1176	1180	O
source	1181	1187	O
of	1188	1190	O
glucosyltransferase	1191	1210	O
activity	1211	1219	O
.	1219	1220	O

Glucosyltransferases	1221	1241	O
were	1242	1246	O
extremely	1247	1256	O
active	1257	1263	O
in	1264	1266	O
cultures	1267	1275	O
of	1276	1278	O
a	1279	1280	O
recent	1281	1287	O
clinical	1288	1296	O
isolate	1297	1304	O
,	1304	1305	O
strain	1306	1312	O
3209	1313	1317	O
,	1317	1318	O
and	1319	1322	O
were	1323	1327	O
apparently	1328	1338	O
induced	1339	1346	O
during	1347	1353	O
growth	1354	1360	O
with	1361	1365	O
excess	1366	1372	O
glucose	1373	1380	O
.	1380	1381	O

Role	0	4	O
of	5	7	O
interleukin	8	19	O
1	20	21	O
in	22	24	O
antigen	25	32	O
-	32	33	O
specific	33	41	O
T	42	43	B-Cell
cell	44	48	I-Cell
proliferation	49	62	O
.	62	63	O

The	64	67	O
role	68	72	O
of	73	75	O
interleukin	76	87	O
1	88	89	O
(	90	91	O
IL	91	93	O
1	94	95	O
)	95	96	O
in	97	99	O
human	100	105	O
antigen	106	113	O
-	113	114	O
specific	114	122	O
T	123	124	B-Cell
cell	125	129	I-Cell
proliferation	130	143	O
was	144	147	O
examined	148	156	O
.	156	157	O

Nylon	158	163	O
wool	164	168	O
-	168	169	O
purified	169	177	O
T	178	179	B-Cell
cells	180	185	I-Cell
proliferated	186	198	O
in	199	201	O
the	202	205	O
presence	206	214	O
of	215	217	O
autologous	218	228	B-Cell
monocytes	229	238	I-Cell
(	239	240	O
Mo	240	242	B-Cell
.	242	243	O
)	243	244	O
pulsed	245	251	O
for	252	255	O
18	256	258	O
h	259	260	O
with	261	265	O
tetanus	266	273	O
toxoid	274	280	O
(	281	282	O
TT	282	284	O
)	284	285	O
antigen	286	293	O
(	294	295	O
Mo	295	297	B-Cell
.	297	298	O
TT	298	300	O
)	300	301	O
.	301	302	O

Irradiation	303	314	O
of	315	317	O
Mo	318	320	B-Cell
.	320	321	O
TT	321	323	O
with	324	328	O
ultraviolet	329	340	O
(	341	342	O
UV	342	344	O
)	344	345	O
light	346	351	O
(	352	353	O
72	353	355	O
J	356	357	O
/	357	358	O
m2	358	360	O
)	360	361	O
abolished	362	371	O
their	372	377	O
capacity	378	386	O
to	387	389	O
support	390	397	O
T	398	399	B-Cell
cell	400	404	I-Cell
proliferation	405	418	O
and	419	422	O
drastically	423	434	O
reduced	435	442	O
their	443	448	O
capacity	449	457	O
to	458	460	O
secrete	461	468	O
IL	469	471	O
1	472	473	O
after	474	479	O
stimulation	480	491	O
with	492	496	O
Staphylococcus	497	511	O
albus	512	517	O
.	517	518	O

The	519	522	O
defect	523	529	O
in	530	532	O
antigen	533	540	O
presentation	541	553	O
induced	554	561	O
by	562	564	O
UV	565	567	O
irradiation	568	579	O
of	580	582	O
Mo	583	585	B-Cell
.	585	586	O
TT	586	588	O
was	589	592	O
reversed	593	601	O
in	602	604	O
a	605	606	O
dose	607	611	O
-	611	612	O
dependent	612	621	O
manner	622	628	O
by	629	631	O
the	632	635	O
addition	636	644	O
of	645	647	O
two	648	651	O
different	652	661	O
preparations	662	674	O
containing	675	685	O
human	686	691	O
interleukin	692	703	O
1	704	705	O
(	706	707	O
IL	707	709	O
1	710	711	O
)	711	712	O
.	712	713	O

The	714	717	O
first	718	723	O
preparation	724	735	O
consisted	736	745	O
of	746	748	O
supernatants	749	761	O
of	762	764	O
Mo	765	767	B-Cell
.	767	768	O
stimulated	769	779	O
with	780	784	O
Con	785	788	O
A	789	790	O
for	791	794	O
18	795	797	O
hr	798	800	O
and	801	804	O
in	805	807	O
which	808	813	O
Con	814	817	O
A	818	819	O
activity	820	828	O
was	829	832	O
blocked	833	840	O
by	841	843	O
alpha	844	849	O
-	849	850	O
D	850	851	O
-	851	852	O
methyl	852	858	O
-	858	859	O
mannoside	859	868	O
(	869	870	O
Mo	870	872	B-Cell
.	872	873	O
-	873	874	O
Con	874	877	O
A	878	879	O
-	879	880	O
Sup	880	883	O
)	883	884	O
.	884	885	O

The	886	889	O
second	890	896	O
preparation	897	908	O
consisted	909	918	O
of	919	921	O
human	922	927	O
IL	928	930	O
1	931	932	O
partially	933	942	O
purified	943	951	O
from	952	956	O
supernatants	957	969	O
of	970	972	O
human	973	978	O
peripheral	979	989	B-Cell
blood	990	995	I-Cell
mononuclear	996	1007	I-Cell
cells	1008	1013	I-Cell
stimulated	1014	1024	O
with	1025	1029	O
S	1030	1031	O
.	1031	1032	O
albus	1033	1038	O
.	1038	1039	O

This	1040	1044	O
IL	1045	1047	O
1	1048	1049	O
copurified	1050	1060	O
with	1061	1065	O
human	1066	1071	O
leukocyte	1072	1081	B-Cell
pyrogen	1082	1089	O
(	1090	1091	O
LP	1091	1093	O
)	1093	1094	O
and	1095	1098	O
was	1099	1102	O
termed	1103	1109	O
IL	1110	1112	O
1	1113	1114	O
/	1114	1115	O
LP	1115	1117	O
.	1117	1118	O

Both	1119	1123	O
IL	1124	1126	O
1	1127	1128	O
-	1128	1129	O
containing	1129	1139	O
preparations	1140	1152	O
enhanced	1153	1161	O
the	1162	1165	O
response	1166	1174	O
of	1175	1177	O
C57BL	1178	1183	O
/	1183	1184	O
6	1184	1185	O
mouse	1186	1191	O
thymocytes	1192	1202	B-Cell
to	1203	1205	O
phytohemagglutinin	1206	1224	O
.	1224	1225	O

A	1226	1227	O
rabbit	1228	1234	O
antibody	1235	1243	O
to	1244	1246	O
human	1247	1252	O
IL	1253	1255	O
1	1256	1257	O
/	1257	1258	O
LP	1258	1260	O
inhibited	1261	1270	O
the	1271	1274	O
capacity	1275	1283	O
of	1284	1286	O
T	1287	1288	B-Cell
cells	1289	1294	I-Cell
to	1295	1297	O
proliferate	1298	1309	O
in	1310	1312	O
response	1313	1321	O
to	1322	1324	O
Mo	1325	1327	B-Cell
.	1327	1328	O
TT	1328	1330	O
and	1331	1334	O
inhibited	1335	1344	O
the	1345	1348	O
capacity	1349	1357	O
of	1358	1360	O
Mo	1361	1363	B-Cell
.	1363	1364	O
-	1364	1365	O
Con	1365	1368	O
A	1369	1370	O
-	1370	1371	O
Sup	1371	1374	O
to	1375	1377	O
reconstitute	1378	1390	O
the	1391	1394	O
T	1395	1396	B-Cell
cell	1397	1401	I-Cell
response	1402	1410	O
to	1411	1413	O
UV	1414	1416	O
-	1416	1417	O
irradiated	1417	1427	O
Mo	1428	1430	B-Cell
.	1430	1431	O
TT	1431	1433	O
.	1433	1434	O

IL	1435	1437	O
1	1438	1439	O
/	1439	1440	O
LP	1440	1442	O
was	1443	1446	O
not	1447	1450	O
necessary	1451	1460	O
for	1461	1464	O
T	1465	1466	B-Cell
cells	1467	1472	I-Cell
to	1473	1475	O
recognize	1476	1485	O
the	1486	1489	O
immunogenic	1490	1501	O
moiety	1502	1508	O
presented	1509	1518	O
by	1519	1521	O
Mo	1522	1524	B-Cell
.	1524	1525	O
,	1525	1526	O
because	1527	1534	O
monolayers	1535	1545	O
of	1546	1548	O
UV	1549	1551	O
-	1551	1552	O
irradiated	1552	1562	O
Mo	1563	1565	B-Cell
.	1565	1566	O
TT	1566	1568	O
were	1569	1573	O
equivalent	1574	1584	O
to	1585	1587	O
monolayers	1588	1598	O
of	1599	1601	O
unirradiated	1602	1614	O
MO	1615	1617	B-Cell
.	1617	1618	O
TT	1618	1620	O
in	1621	1623	O
their	1624	1629	O
capacity	1630	1638	O
to	1639	1641	O
adsorb	1642	1648	O
TT	1649	1651	O
-	1651	1652	O
reactive	1652	1660	O
T	1661	1662	B-Cell
cells	1663	1668	I-Cell
specifically	1669	1681	O
.	1681	1682	O

Furthermore	1683	1694	O
,	1694	1695	O
the	1696	1699	O
addition	1700	1708	O
of	1709	1711	O
rabbit	1712	1718	O
antibody	1719	1727	O
to	1728	1730	O
IL	1731	1733	O
1	1734	1735	O
/	1735	1736	O
LP	1736	1738	O
did	1739	1742	O
not	1743	1746	O
interfere	1747	1756	O
with	1757	1761	O
the	1762	1765	O
capacity	1766	1774	O
of	1775	1777	O
UV	1778	1780	O
-	1780	1781	O
irradiated	1781	1791	O
Mo	1792	1794	B-Cell
.	1794	1795	O
TT	1795	1797	O
to	1798	1800	O
adsorb	1801	1807	O
TT	1808	1810	O
-	1810	1811	O
reactive	1811	1819	O
T	1820	1821	B-Cell
cells	1822	1827	I-Cell
.	1827	1828	O

The	1829	1832	O
results	1833	1840	O
obtained	1841	1849	O
in	1850	1852	O
this	1853	1857	O
study	1858	1863	O
indicate	1864	1872	O
that	1873	1877	O
IL	1878	1880	O
1	1881	1882	O
is	1883	1885	O
involved	1886	1894	O
in	1895	1897	O
optimal	1898	1905	O
antigen	1906	1913	O
-	1913	1914	O
driven	1914	1920	O
proliferation	1921	1934	O
of	1935	1937	O
human	1938	1943	O
T	1944	1945	B-Cell
lymphocytes	1946	1957	I-Cell
.	1957	1958	O

Ca	0	2	O
+	2	3	O
+	3	4	O
distribution	5	17	O
after	18	23	O
Na	24	26	O
+	26	27	O
pump	28	32	O
inhibition	33	43	O
in	44	46	O
cultured	47	55	O
neonatal	56	64	O
rat	65	68	O
myocardial	69	79	B-Cell
cells	80	85	I-Cell
.	85	86	O

The	87	90	O
influence	91	100	O
of	101	103	O
inhibition	104	114	O
of	115	117	O
the	118	121	O
Na	122	124	O
+	124	125	O
pump	126	130	O
,	130	131	O
with	132	136	O
secondary	137	146	O
stimulation	147	158	O
of	159	161	O
Na	162	164	O
+	164	165	O
-	165	166	O
Ca	166	168	O
+	168	169	O
+	169	170	O
exchange	171	179	O
,	179	180	O
on	181	183	O
cellular	184	192	B-Cell
Ca	193	195	O
+	195	196	O
+	196	197	O
distribution	198	210	O
is	211	213	O
examined	214	222	O
using	223	228	O
the	229	232	O
on	233	235	O
-	235	236	O
line	236	240	O
scintillation	241	254	O
disk	255	259	O
technique	260	269	O
and	270	273	O
cultured	274	282	O
neonatal	283	291	O
rat	292	295	O
myocardial	296	306	B-Cell
cells	307	312	I-Cell
.	312	313	O

Under	314	319	O
control	320	327	O
conditions	328	338	O
,	338	339	O
La	340	342	O
+	342	343	O
+	343	344	O
+	344	345	O
displaced	346	355	O
78	356	358	O
.	358	359	O
1	359	360	O
+	361	362	O
/	362	363	O
-	363	364	O
1	365	366	O
.	366	367	O
13	367	369	O
%	369	370	O
(	371	372	O
SEM	372	375	O
)	375	376	O
of	377	379	O
the	380	383	O
total	384	389	O
cell	390	394	B-Cell
associated	395	405	O
45Ca	406	410	O
.	410	411	O

Application	412	423	O
of	424	426	O
1	427	428	O
mm	429	431	O
ouabain	432	439	O
or	440	442	O
reduction	443	452	O
of	453	455	O
[	456	457	O
K	457	458	O
+	458	459	O
]	459	460	O
o	460	461	O
to	462	464	O
0	465	466	O
.	466	467	O
5	467	468	O
mM	469	471	O
resulted	472	480	O
in	481	483	O
a	484	485	O
net	486	489	O
increase	490	498	O
of	499	501	O
10	502	504	O
.	504	505	O
6	505	506	O
+	507	508	O
/	508	509	O
-	509	510	O
1	511	512	O
.	512	513	O
3	513	514	O
%	514	515	O
and	516	519	O
13	520	522	O
.	522	523	O
8	523	524	O
+	525	526	O
/	526	527	O
-	527	528	O
2	529	530	O
%	530	531	O
,	531	532	O
respectively	533	545	O
,	545	546	O
in	547	549	O
total	550	555	O
cell	556	560	B-Cell
-	560	561	O
associated	561	571	O
Ca	572	574	O
+	574	575	O
+	575	576	O
.	576	577	O

Of	578	580	O
this	581	585	O
added	586	591	O
45Ca	592	596	O
,	596	597	O
75	598	600	O
.	600	601	O
9	601	602	O
+	603	604	O
/	604	605	O
-	605	606	O
2	607	608	O
.	608	609	O
7	609	610	O
%	610	611	O
and	612	615	O
78	616	618	O
.	618	619	O
4	619	620	O
+	621	622	O
/	622	623	O
-	623	624	O
2	625	626	O
.	626	627	O
1	627	628	O
%	628	629	O
,	629	630	O
respectively	631	643	O
remained	644	652	O
La	653	655	O
+	655	656	O
+	656	657	O
+	657	658	O
-	658	659	O
displaceable	659	671	O
.	671	672	O

The	673	676	O
45Ca	677	681	O
-	681	682	O
binding	682	689	O
characteristics	690	705	O
of	706	708	O
isolated	709	717	O
sarcolemma	718	728	B-Cellular_component
,	728	729	O
prepared	730	738	O
from	739	743	O
the	744	747	O
cultured	748	756	O
neonatal	757	765	O
rat	766	769	O
myocardial	770	780	B-Cell
cells	781	786	I-Cell
using	787	792	O
the	793	796	O
gas	797	800	O
dissection	801	811	O
technique	812	821	O
,	821	822	O
were	823	827	O
examined	828	836	O
.	836	837	O

When	838	842	O
treated	843	850	O
with	851	855	O
either	856	862	O
ouabain	863	870	O
or	871	873	O
low	874	877	O
[	878	879	O
K	879	880	O
+	880	881	O
]	881	882	O
o	882	883	O
solutions	884	893	O
,	893	894	O
sarcolemmal	895	906	B-Cellular_component
45Ca	907	911	O
binding	912	919	O
did	920	923	O
not	924	927	O
change	928	934	O
.	934	935	O

This	936	940	O
result	941	947	O
indicates	948	957	O
that	958	962	O
functional	963	973	O
,	973	974	O
intact	975	981	O
tissue	982	988	B-Tissue
is	989	991	O
necessary	992	1001	O
to	1002	1004	O
observe	1005	1012	O
the	1013	1016	O
Ca	1017	1019	O
+	1019	1020	O
+	1020	1021	O
increase	1022	1030	O
.	1030	1031	O

Treatment	1032	1041	O
of	1042	1044	O
the	1045	1048	O
cells	1049	1054	B-Cell
with	1055	1059	O
verapamil	1060	1069	O
before	1070	1076	O
and	1077	1080	O
during	1081	1087	O
ouabain	1088	1095	O
exposure	1096	1104	O
failed	1105	1111	O
to	1112	1114	O
inhibit	1115	1122	O
the	1123	1126	O
ouabain	1127	1134	O
-	1134	1135	O
induced	1135	1142	O
increase	1143	1151	O
in	1152	1154	O
cell	1155	1159	B-Cell
-	1159	1160	O
associated	1160	1170	O
45Ca	1171	1175	O
.	1175	1176	O

The	1177	1180	O
evidence	1181	1189	O
indicates	1190	1199	O
that	1200	1204	O
inhibition	1205	1215	O
of	1216	1218	O
the	1219	1222	O
Na	1223	1225	O
+	1225	1226	O
-	1226	1227	O
pump	1227	1231	O
,	1231	1232	O
and	1233	1236	O
secondary	1237	1246	O
stimulation	1247	1258	O
of	1259	1261	O
Na	1262	1264	O
+	1264	1265	O
-	1265	1266	O
Ca	1266	1268	O
+	1268	1269	O
+	1269	1270	O
exchange	1271	1279	O
,	1279	1280	O
result	1281	1287	O
in	1288	1290	O
a	1291	1292	O
net	1293	1296	O
increase	1297	1305	O
of	1306	1308	O
11	1309	1311	O
-	1311	1312	O
15	1312	1314	O
%	1314	1315	O
in	1316	1318	O
cell	1319	1323	O
-	1323	1324	O
associated	1324	1334	O
Ca	1335	1337	O
+	1337	1338	O
+	1338	1339	O
,	1339	1340	O
78	1341	1343	O
%	1343	1344	O
of	1345	1347	O
which	1348	1353	O
remains	1354	1361	O
La	1362	1364	O
+	1364	1365	O
+	1365	1366	O
+	1366	1367	O
-	1367	1368	O
displaceable	1368	1380	O
and	1381	1384	O
is	1385	1387	O
,	1387	1388	O
therefore	1389	1398	O
,	1398	1399	O
localized	1400	1409	O
to	1410	1412	O
the	1413	1416	O
sarcolemma	1417	1427	B-Cellular_component
-	1427	1428	O
glycocalyx	1428	1438	B-Cellular_component
complex	1439	1446	O
.	1446	1447	O

Oesophageal	0	11	B-Organ
candidiasis	12	23	O
and	24	27	O
croup	28	33	O
in	34	36	O
a	37	38	O
child	39	44	O
with	45	49	O
defective	50	59	O
neutrophil	60	70	B-Cell
motility	71	79	O
.	79	80	O

Severe	81	87	O
oesophageal	88	99	B-Organ
candidiasis	100	111	O
and	112	115	O
croup	116	121	O
due	122	125	O
to	126	128	O
involvement	129	140	O
of	141	143	O
the	144	147	O
larynx	148	154	B-Multi-tissue_structure
developed	155	164	O
insidiously	165	176	O
in	177	179	O
a	180	181	O
girl	182	186	O
aged	187	191	O
20	192	194	O
months	195	201	O
.	201	202	O

There	203	208	O
had	209	212	O
been	213	217	O
delayed	218	225	O
separation	226	236	O
of	237	239	O
the	240	243	O
umbilical	244	253	O
cord	254	258	O
and	259	262	O
repeated	263	271	O
infections	272	282	O
associated	283	293	O
with	294	298	O
a	299	300	O
defect	301	307	O
of	308	310	O
neutrophil	311	321	B-Cell
motility	322	330	O
.	330	331	O

The	332	335	O
significance	336	348	O
of	349	351	O
the	352	355	O
early	356	361	O
clinical	362	370	O
features	371	379	O
was	380	383	O
not	384	387	O
fully	388	393	O
appreciated	394	405	O
and	406	409	O
the	410	413	O
diagnosis	414	423	O
considered	424	434	O
only	435	439	O
when	440	444	O
stricture	445	454	O
of	455	457	O
the	458	461	O
oesophagus	462	472	B-Organ
became	473	479	O
evident	480	487	O
.	487	488	O

She	489	492	O
was	493	496	O
treated	497	504	O
with	505	509	O
oral	510	514	O
ketoconazole	515	527	O
100	528	531	O
mg	532	534	O
daily	535	540	O
.	540	541	O

After	542	547	O
one	548	551	O
month	552	557	O
'	557	558	O
s	558	559	O
treatment	560	569	O
there	570	575	O
was	576	579	O
striking	580	588	O
radiological	589	601	O
improvement	602	613	O
apart	614	619	O
from	620	624	O
the	625	628	O
persistence	629	640	O
of	641	643	O
the	644	647	O
oesophageal	648	659	B-Organ
stricture	660	669	O
.	669	670	O

The	671	674	O
croup	675	680	O
resolved	681	689	O
completely	690	700	O
but	701	704	O
there	705	710	O
was	711	714	O
only	715	719	O
partial	720	727	O
relief	728	734	O
of	735	737	O
dysphagia	738	747	O
because	748	755	O
of	756	758	O
the	759	762	O
residual	763	771	O
stricture	772	781	O
.	781	782	O

We	783	785	O
would	786	791	O
emphasis	792	800	O
that	801	805	O
candidiasis	806	817	O
should	818	824	O
be	825	827	O
anticipated	828	839	O
and	840	843	O
treated	844	851	O
vigorously	852	862	O
in	863	865	O
children	866	874	O
with	875	879	O
such	880	884	O
a	885	886	O
defect	887	893	O
of	894	896	O
neutrophil	897	907	B-Cell
motility	908	916	O
.	916	917	O

[	0	1	O
Suppurated	1	11	O
acute	12	17	O
obstructive	18	29	O
cholangitis	30	41	O
.	41	42	O
Anatomoclinical	43	58	O
and	59	62	O
therapeutic	63	74	O
aspects	75	82	O
]	82	83	O
.	83	84	O

A	85	86	O
total	87	92	O
of	93	95	O
134	96	99	O
cases	100	105	O
are	106	109	O
discussed	110	119	O
,	119	120	O
with	121	125	O
suppurated	126	136	O
acute	137	142	O
obstructive	143	154	O
angiocholitis	155	168	O
,	168	169	O
that	170	174	O
underwent	175	184	O
surgical	185	193	O
treatment	194	203	O
over	204	208	O
a	209	210	O
period	211	217	O
of	218	220	O
10	221	223	O
years	224	229	O
,	229	230	O
representing	231	243	O
12	244	246	O
,	246	247	O
8	247	248	O
%	248	249	O
of	250	252	O
the	253	256	O
total	257	262	O
number	263	269	O
of	270	272	O
organic	273	280	O
obstructions	281	293	O
of	294	296	O
the	297	300	O
hepato	301	307	B-Multi-tissue_structure
-	307	308	I-Multi-tissue_structure
choledocus	308	318	I-Multi-tissue_structure
.	318	319	O

From	320	324	O
the	325	328	O
standpoint	329	339	O
of	340	342	O
the	343	346	O
etiopathogenic	347	361	O
mechanisms	362	372	O
the	373	376	O
angiocholitis	377	390	O
was	391	394	O
determined	395	405	O
by	406	408	O
biliary	409	416	O
lithiasis	417	426	O
in	427	429	O
59	430	432	O
cases	433	438	O
,	438	439	O
by	440	442	O
sclerosis	443	452	O
of	453	455	O
the	456	459	O
Oddi	460	464	B-Tissue
sphincter	465	474	I-Tissue
in	475	477	O
5	478	479	O
cases	480	485	O
,	485	486	O
by	487	489	O
postoperative	490	503	O
cicatriceal	504	515	O
stenosis	516	524	O
of	525	527	O
the	528	531	O
main	532	536	O
biliary	537	544	O
pathway	545	552	O
in	553	555	O
2	556	557	O
cases	558	563	O
,	563	564	O
by	565	567	O
hepatic	568	575	B-Organ
hydatitosis	576	587	O
in	588	590	O
16	591	593	O
cases	594	599	O
,	599	600	O
by	601	603	O
Vater	604	609	O
ampuloma	610	618	O
in	619	621	O
10	622	624	O
cases	625	630	O
by	631	633	O
cancers	634	641	B-Pathological_formation
of	642	644	O
the	645	648	O
main	649	653	O
biliary	654	661	O
pathway	662	669	O
in	670	672	O
40	673	675	O
cases	676	681	O
and	682	685	O
by	686	688	O
the	689	692	O
congenital	693	703	O
cyst	704	708	B-Pathological_formation
of	709	711	O
the	712	715	O
choledocus	716	726	B-Multi-tissue_structure
in	727	729	O
one	730	733	O
case	734	738	O
.	738	739	O

The	740	743	O
high	744	748	O
frequency	749	758	O
was	759	762	O
noted	763	768	O
,	768	769	O
of	770	772	O
the	773	776	O
severe	777	783	O
forms	784	789	O
of	790	792	O
ictero	793	799	O
-	799	800	O
uremigenic	800	810	O
angiocholitis	811	824	O
(	825	826	O
representing	826	838	O
68	839	841	O
cases	842	847	O
,	847	848	O
or	849	851	O
50	852	854	O
,	854	855	O
7	855	856	O
%	856	857	O
of	858	860	O
the	861	864	O
total	865	870	O
,	870	871	O
with	872	876	O
a	877	878	O
death	879	884	O
rate	885	889	O
of	890	892	O
34	893	895	O
%	895	896	O
)	896	897	O
.	897	898	O

Medico	899	905	O
-	905	906	O
surgical	906	914	O
treatment	915	924	O
should	925	931	O
be	932	934	O
performed	935	944	O
as	945	947	O
early	948	953	O
as	954	956	O
possible	957	965	O
,	965	966	O
and	967	970	O
it	971	973	O
must	974	978	O
be	979	981	O
intensive	982	991	O
,	991	992	O
complex	993	1000	O
,	1000	1001	O
and	1002	1005	O
adapted	1006	1013	O
to	1014	1016	O
the	1017	1020	O
anatomo	1021	1028	O
-	1028	1029	O
clinical	1029	1037	O
forms	1038	1043	O
.	1043	1044	O

The	1045	1048	O
authors	1049	1056	O
performed	1057	1066	O
evacuation	1067	1077	O
choledocotomy	1078	1091	O
with	1092	1096	O
external	1097	1105	O
draining	1106	1114	O
in	1115	1117	O
22	1118	1120	O
cases	1121	1126	O
(	1127	1128	O
3	1128	1129	O
deaths	1130	1136	O
)	1136	1137	O
,	1137	1138	O
and	1139	1142	O
choledoco	1143	1152	O
-	1152	1153	O
duodenal	1153	1161	O
anastomosis	1162	1173	O
in	1174	1176	O
46	1177	1179	O
cases	1180	1185	O
(	1186	1187	O
10	1187	1189	O
deaths	1190	1196	O
)	1196	1197	O
,	1197	1198	O
choledoco	1199	1208	O
-	1208	1209	O
jejunostomia	1209	1221	O
in	1222	1224	O
3	1225	1226	O
cases	1227	1232	O
,	1232	1233	O
Oddi	1234	1238	O
sphincterotomia	1239	1254	O
in	1255	1257	O
12	1258	1260	O
cases	1261	1266	O
(	1267	1268	O
2	1268	1269	O
deaths	1270	1276	O
)	1276	1277	O
ampulectomia	1278	1290	O
in	1291	1293	O
5	1294	1295	O
cases	1296	1301	O
(	1302	1303	O
2	1303	1304	O
deaths	1305	1311	O
)	1311	1312	O
.	1312	1313	O

Peripheral	1314	1324	O
bilio	1325	1330	O
-	1330	1331	O
hepatodigestive	1331	1346	O
anastomoses	1347	1358	O
were	1359	1363	O
performed	1364	1373	O
in	1374	1376	O
40	1377	1379	O
cases	1380	1385	O
with	1386	1390	O
5	1391	1392	O
deaths	1393	1399	O
.	1399	1400	O

[	0	1	O
Reactive	1	9	O
states	10	16	O
among	17	22	O
psychopathic	23	35	O
personalities	36	49	O
of	50	52	O
different	53	62	O
clinical	63	71	O
groups	72	78	O
]	78	79	O
.	79	80	O

On	81	83	O
the	84	87	O
basis	88	93	O
of	94	96	O
a	97	98	O
clinical	99	107	O
follow	108	114	O
-	114	115	O
up	115	117	O
of	118	120	O
71	121	123	O
psychopaths	124	135	O
with	136	140	O
manifestations	141	155	O
of	156	158	O
reactive	159	167	O
psychosis	168	177	O
,	177	178	O
the	179	182	O
authors	183	190	O
established	191	202	O
the	203	206	O
clinico	207	214	O
-	214	215	O
typological	215	226	O
characteristics	227	242	O
of	243	245	O
both	246	250	O
groups	251	257	O
of	258	260	O
pathology	261	270	O
and	271	274	O
the	275	278	O
system	279	285	O
of	286	288	O
correlations	289	301	O
between	302	309	O
them	310	314	O
.	314	315	O

They	316	320	O
also	321	325	O
described	326	335	O
the	336	339	O
structure	340	349	O
of	350	352	O
the	353	356	O
psychopathic	357	369	O
and	370	373	O
psychogenic	374	385	O
syndromes	386	395	O
,	395	396	O
the	397	400	O
type	401	405	O
of	406	408	O
psychopathic	409	421	O
personality	422	433	O
reaction	434	442	O
and	443	446	O
the	447	450	O
form	451	455	O
of	456	458	O
psychogenic	459	470	O
responses	471	480	O
and	481	484	O
proved	485	491	O
statistically	492	505	O
their	506	511	O
close	512	517	O
interrelationship	518	535	O
.	535	536	O

Data	537	541	O
were	542	546	O
obtained	547	555	O
on	556	558	O
some	559	563	O
general	564	571	O
regularities	572	584	O
of	585	587	O
interrelations	588	602	O
of	603	605	O
reactive	606	614	O
psychoses	615	624	O
with	625	629	O
a	630	631	O
psychopathic	632	644	O
background	645	655	O
which	656	661	O
are	662	665	O
important	666	675	O
for	676	679	O
the	680	683	O
prognosis	684	693	O
,	693	694	O
prophylaxis	695	706	O
and	707	710	O
therapy	711	718	O
of	719	721	O
reactive	722	730	O
states	731	737	O
.	737	738	O

An	0	2	O
unusual	3	10	O
case	11	15	O
of	16	18	O
benign	19	25	O
mucous	26	32	B-Multi-tissue_structure
membrane	33	41	I-Multi-tissue_structure
pemphigoid	42	52	O
.	52	53	O

This	54	58	O
case	59	63	O
of	64	66	O
benign	67	73	O
mucous	74	80	B-Multi-tissue_structure
membrane	81	89	I-Multi-tissue_structure
pemphigoid	90	100	O
(	101	102	O
BMMP	102	106	O
)	106	107	O
is	108	110	O
unusual	111	118	O
in	119	121	O
that	122	126	O
blistering	127	137	O
,	137	138	O
scarring	139	147	O
lesions	148	155	B-Pathological_formation
were	156	160	O
confined	161	169	O
to	170	172	O
the	173	176	O
skin	177	181	B-Organ
for	182	185	O
15	186	188	O
years	189	194	O
before	195	201	O
mucous	202	208	B-Multi-tissue_structure
membranes	209	218	I-Multi-tissue_structure
were	219	223	O
involved	224	232	O
.	232	233	O

The	234	237	O
onset	238	243	O
of	244	246	O
this	247	251	O
disorder	252	260	O
at	261	263	O
the	264	267	O
age	268	271	O
of	272	274	O
38	275	277	O
is	278	280	O
also	281	285	O
unusual	286	293	O
.	293	294	O

Detailed	295	303	O
immunological	304	317	O
investigation	318	331	O
was	332	335	O
performed	336	345	O
on	346	348	O
this	349	353	O
patient	354	361	O
but	362	365	O
the	366	369	O
results	370	377	O
in	378	380	O
no	381	383	O
way	384	387	O
clarify	388	395	O
the	396	399	O
present	400	407	O
confusion	408	417	O
regarding	418	427	O
the	428	431	O
immunopathological	432	450	O
processes	451	460	O
in	461	463	O
BMMP	464	468	O
related	469	476	O
to	477	479	O
those	480	485	O
operative	486	495	O
in	496	498	O
bullous	499	506	O
pemphigoid	507	517	O
.	517	518	O

The	0	3	O
LHRH	4	8	O
pulse	9	14	O
generator	15	24	O
:	24	25	O
a	26	27	O
mediobasal	28	38	B-Multi-tissue_structure
hypothalamic	39	51	I-Multi-tissue_structure
location	52	60	O
.	60	61	O

The	62	65	O
location	66	74	O
and	75	78	O
mechanism	79	88	O
of	89	91	O
LHRH	92	96	O
pulse	97	102	O
generator	103	112	O
are	113	116	O
discussed	117	126	O
based	127	132	O
on	133	135	O
our	136	139	O
series	140	146	O
of	147	149	O
experiments	150	161	O
.	161	162	O

Suckling	163	171	O
stimulus	172	180	O
is	181	183	O
a	184	185	O
novel	186	191	O
stimulus	192	200	O
that	201	205	O
inhibits	206	214	O
LH	215	217	O
pulses	218	224	O
without	225	232	O
any	233	236	O
cooperation	237	248	O
from	249	253	O
ovarian	254	261	B-Organ
steroids	262	270	O
,	270	271	O
unlike	272	278	O
other	279	284	O
stimuli	285	292	O
such	293	297	O
as	298	300	O
stress	301	307	O
,	307	308	O
photoperiod	309	320	O
etc	321	324	O
.	324	325	O

It	326	328	O
is	329	331	O
directly	332	340	O
involved	341	349	O
in	350	352	O
suppressing	353	364	O
the	365	368	O
activity	369	377	O
of	378	380	O
the	381	384	O
LHRH	385	389	O
pulse	390	395	O
generator	396	405	O
.	405	406	O

The	407	410	O
information	411	422	O
from	423	427	O
teats	428	433	O
suckled	434	441	O
by	442	444	O
pups	445	449	O
or	450	452	O
babies	453	459	O
is	460	462	O
conveyed	463	471	O
dorsally	472	480	O
to	481	483	O
the	484	487	O
mediobasal	488	498	B-Multi-tissue_structure
hypothalamus	499	511	I-Multi-tissue_structure
(	512	513	O
MBH	513	516	O
)	516	517	O
,	517	518	O
where	519	524	O
the	525	528	O
LHRH	529	533	O
pulse	534	539	O
generator	540	549	O
may	550	553	O
be	554	556	O
located	557	564	O
.	564	565	O

Experiments	566	577	O
using	578	583	O
various	584	591	O
types	592	597	O
of	598	600	O
deafferentation	601	616	O
and	617	620	O
fetal	621	626	B-Tissue
brain	627	632	I-Tissue
tissue	633	639	I-Tissue
transplantation	640	655	O
confirmed	656	665	O
that	666	670	O
the	671	674	O
LHRH	675	679	O
pulse	680	685	O
generator	686	695	O
is	696	698	O
located	699	706	O
in	707	709	O
the	710	713	O
MBH	714	717	O
and	718	721	O
suggested	722	731	O
that	732	736	O
LHRH	737	741	O
pulse	742	747	O
generator	748	757	O
consists	758	766	O
of	767	769	O
nonLHRH	770	777	O
neurons	778	785	O
.	785	786	O

Endogenous	787	797	O
excitatory	798	808	O
amino	809	814	O
acid	815	819	O
is	820	822	O
one	823	826	O
of	827	829	O
the	830	833	O
possible	834	842	O
neurotransmitters	843	860	O
that	861	865	O
regulate	866	874	O
LHRH	875	879	O
release	880	887	O
at	888	890	O
the	891	894	O
nerve	895	900	B-Multi-tissue_structure
terminal	901	909	I-Multi-tissue_structure
in	910	912	O
ME	913	915	O
.	915	916	O

Colorimetrical	0	14	O
rate	15	19	O
assay	20	25	O
for	26	29	O
urinary	30	37	B-Organism_substance
dipeptidyl	38	48	O
peptidase	49	58	O
IV	59	61	O
(	62	63	O
DPPIV	63	68	O
)	68	69	O
activity	70	78	O
using	79	84	O
a	85	86	O
new	87	90	O
substrate	91	100	O
.	100	101	O

We	102	104	O
synthesized	105	116	O
a	117	118	O
new	119	122	O
substrate	123	132	O
glycyl	133	139	O
-	139	140	O
L	140	141	O
-	141	142	O
proline	142	149	O
3	150	151	O
,	151	152	O
5	152	153	O
-	153	154	O
dibromo	154	161	O
-	161	162	O
4	162	163	O
-	163	164	O
hydroxyanilide	164	178	O
(	179	180	O
Gly	180	183	O
-	183	184	O
Pro	184	187	O
-	187	188	O
DBAP	188	192	O
)	192	193	O
,	193	194	O
for	195	198	O
dipeptidyl	199	209	O
peptidase	210	219	O
IV	220	222	O
(	223	224	O
DPPIV	224	229	O
)	229	230	O
.	230	231	O

Its	232	235	O
hydrolysis	236	246	O
by	247	249	O
DPPIV	250	255	O
resulted	256	264	O
in	265	267	O
the	268	271	O
formation	272	281	O
of	282	284	O
a	285	286	O
chromophore	287	298	O
,	298	299	O
2	300	301	O
,	301	302	O
6	302	303	O
-	303	304	O
dibromophenol	304	317	O
-	317	318	O
indo	318	322	O
-	322	323	O
p	323	324	O
-	324	325	O
xylenol	325	332	O
,	332	333	O
and	334	337	O
its	338	341	O
maximal	342	349	O
absorption	350	360	O
wavelength	361	371	O
(	372	373	O
600	373	376	O
nm	377	379	O
)	379	380	O
was	381	384	O
longer	385	391	O
than	392	396	O
that	397	401	O
of	402	404	O
p	405	406	O
-	406	407	O
nitroaniline	407	419	O
(	420	421	O
415	421	424	O
nm	425	427	O
)	427	428	O
released	429	437	O
from	438	442	O
conventional	443	455	O
substrate	456	465	O
,	465	466	O
glycyl	467	473	O
-	473	474	O
L	474	475	O
-	475	476	O
proline	476	483	O
p	484	485	O
-	485	486	O
nitroanilide	486	498	O
(	499	500	O
Gly	500	503	O
-	503	504	O
Pro	504	507	O
-	507	508	O
pNA	508	511	O
)	511	512	O
.	512	513	O

We	514	516	O
also	517	521	O
established	522	533	O
the	534	537	O
rate	538	542	O
assay	543	548	O
for	549	552	O
urinary	553	560	B-Organism_substance
DPPIV	561	566	O
activity	567	575	O
using	576	581	O
Gly	582	585	O
-	585	586	O
Pro	586	589	O
-	589	590	O
DBAP	590	594	O
.	594	595	O

The	596	599	O
optimum	600	607	O
pH	608	610	O
was	611	614	O
between	615	622	O
8	623	624	O
.	624	625	O
5	625	626	O
and	627	630	O
9	631	632	O
.	632	633	O
0	633	634	O
.	634	635	O

The	636	639	O
apparent	640	648	O
Km	649	651	O
was	652	655	O
1	656	657	O
.	657	658	O
1	658	659	O
mmol	660	664	O
/	664	665	O
1	665	666	O
.	666	667	O

The	668	671	O
detectable	672	682	O
range	683	688	O
was	689	692	O
2	693	694	O
.	694	695	O
5	695	696	O
-	696	697	O
350	697	700	O
U	701	702	O
/	702	703	O
l	703	704	O
.	704	705	O

No	706	708	O
changes	709	716	O
in	717	719	O
blank	720	725	O
values	726	732	O
occurred	733	741	O
throughout	742	752	O
the	753	756	O
enzyme	757	763	O
reaction	764	772	O
in	773	775	O
the	776	779	O
optimum	780	787	O
pH	788	790	O
.	790	791	O

Its	792	795	O
value	796	801	O
was	802	805	O
also	806	810	O
much	811	815	O
lower	816	821	O
than	822	826	O
Gly	827	830	O
-	830	831	O
Pro	831	834	O
-	834	835	O
pNA	835	838	O
.	838	839	O

CVs	840	843	O
for	844	847	O
within	848	854	O
-	854	855	O
run	855	858	O
and	859	862	O
between	863	870	O
-	870	871	O
run	871	874	O
were	875	879	O
1	880	881	O
.	881	882	O
1	882	883	O
%	883	884	O
(	885	886	O
n	886	887	O
=	888	889	O
10	890	892	O
)	892	893	O
and	894	897	O
3	898	899	O
.	899	900	O
0	900	901	O
%	901	902	O
(	903	904	O
n	904	905	O
=	906	907	O
10	908	910	O
)	910	911	O
,	911	912	O
respectively	913	925	O
.	925	926	O

Among	927	932	O
tested	933	939	O
peptidases	940	950	O
,	950	951	O
only	952	956	O
DPPIV	957	962	O
could	963	968	O
hydrolyze	969	978	O
Gly	979	982	O
-	982	983	O
Pro	983	986	O
-	986	987	O
DBAP	987	991	O
.	991	992	O

Among	993	998	O
the	999	1002	O
protease	1003	1011	O
inhibitors	1012	1022	O
,	1022	1023	O
only	1024	1028	O
two	1029	1032	O
,	1032	1033	O
diprotin	1034	1042	O
-	1042	1043	O
A	1043	1044	O
and	1045	1048	O
phenylmethylsulfonyl	1049	1069	O
fluoride	1070	1078	O
(	1079	1080	O
PMSA	1080	1084	O
)	1084	1085	O
,	1085	1086	O
could	1087	1092	O
inhibit	1093	1100	O
DPPIV	1101	1106	O
activity	1107	1115	O
.	1115	1116	O

The	1117	1120	O
present	1121	1128	O
method	1129	1135	O
did	1136	1139	O
not	1140	1143	O
interfere	1144	1153	O
with	1154	1158	O
urinary	1159	1166	B-Organism_substance
ingredients	1167	1178	O
such	1179	1183	O
as	1184	1186	O
hemoglobin	1187	1197	O
.	1197	1198	O

The	1199	1202	O
correlation	1203	1214	O
between	1215	1222	O
the	1223	1226	O
present	1227	1234	O
(	1235	1236	O
y	1236	1237	O
)	1237	1238	O
and	1239	1242	O
conventional	1243	1255	O
(	1256	1257	O
x	1257	1258	O
)	1258	1259	O
methods	1260	1267	O
is	1268	1270	O
presented	1271	1280	O
by	1281	1283	O
the	1284	1287	O
equation	1288	1296	O
y	1297	1298	O
=	1299	1300	O
1	1301	1302	O
.	1302	1303	O
121x	1303	1307	O
+	1308	1309	O
0	1310	1311	O
.	1311	1312	O
096	1312	1315	O
(	1316	1317	O
r	1317	1318	O
=	1319	1320	O
0	1321	1322	O
.	1322	1323	O
993	1323	1326	O
)	1326	1327	O
.	1327	1328	O

Thus	1329	1333	O
the	1334	1337	O
present	1338	1345	O
method	1346	1352	O
provides	1353	1361	O
practical	1362	1371	O
advantages	1372	1382	O
over	1383	1387	O
the	1388	1391	O
conventional	1392	1404	O
method	1405	1411	O
for	1412	1415	O
routine	1416	1423	O
laboratory	1424	1434	O
use	1435	1438	O
.	1438	1439	O

Primary	0	7	O
hyperparathyroidism	8	27	O
and	28	31	O
the	32	35	O
heart	36	41	B-Organ
:	41	42	O
cardiac	43	50	B-Organ
abnormalities	51	64	O
correlated	65	75	O
to	76	78	O
clinical	79	87	O
and	88	91	O
biochemical	92	103	O
data	104	108	O
.	108	109	O

Comparing	110	119	O
patients	120	128	O
with	129	133	O
primary	134	141	O
hyperparathyroidism	142	161	O
(	162	163	O
PHP	163	166	O
)	166	167	O
to	168	170	O
a	171	172	O
normocalcemic	173	186	O
control	187	194	O
population	195	205	O
,	205	206	O
those	207	212	O
with	213	217	O
PHP	218	221	O
have	222	226	O
a	227	228	O
higher	229	235	O
incidence	236	245	O
of	246	248	O
cardiovascular	249	263	B-Multi-tissue_structure
disease	264	271	O
and	272	275	O
cardiac	276	283	B-Organ
abnormalities	284	297	O
.	297	298	O

This	299	303	O
study	304	309	O
aimed	310	315	O
at	316	318	O
correlating	319	330	O
cardiac	331	338	B-Organ
findings	339	347	O
(	348	349	O
valvular	349	357	B-Multi-tissue_structure
and	358	361	O
myocardial	362	372	B-Multi-tissue_structure
calcification	373	386	O
,	386	387	O
myocardial	388	398	B-Multi-tissue_structure
hypertrophy	399	410	O
)	410	411	O
with	412	416	O
clinical	417	425	O
data	426	430	O
(	431	432	O
age	432	435	O
,	435	436	O
sex	437	440	O
,	440	441	O
clinical	442	450	O
manifestation	451	464	O
,	464	465	O
nephrolithiasis	466	481	O
,	481	482	O
nephrocalcinosis	483	499	O
,	499	500	O
hypertension	501	513	O
,	513	514	O
skeletal	515	523	B-Anatomical_system
abnormalities	524	537	O
,	537	538	O
hypercalcemic	539	552	O
syndrome	553	561	O
)	561	562	O
and	563	566	O
biochemical	567	578	O
data	579	583	O
(	584	585	O
serum	585	590	B-Organism_substance
calcium	591	598	O
,	598	599	O
serum	600	605	B-Organism_substance
phosphate	606	615	O
,	615	616	O
serum	617	622	B-Organism_substance
iPTH	623	627	O
level	628	633	O
,	633	634	O
serum	635	640	B-Organism_substance
creatinine	641	651	O
)	651	652	O
.	652	653	O

A	654	655	O
group	656	661	O
of	662	664	O
132	665	668	O
consecutive	669	680	O
patients	681	689	O
with	690	694	O
surgically	695	705	O
verified	706	714	O
PHP	715	718	O
(	719	720	O
94	720	722	O
women	723	728	O
,	728	729	O
38	730	732	O
men	733	736	O
;	736	737	O
ages	738	742	O
15	743	745	O
-	745	746	O
86	746	748	O
,	748	749	O
mean	750	754	O
age	755	758	O
57	759	761	O
+	762	763	O
/	763	764	O
-	764	765	O
16	766	768	O
years	769	774	O
)	774	775	O
were	776	780	O
included	781	789	O
in	790	792	O
this	793	797	O
study	798	803	O
.	803	804	O

Blood	805	810	B-Organism_substance
chemistry	811	820	O
,	820	821	O
clinical	822	830	O
presentation	831	843	O
,	843	844	O
radiography	845	856	O
,	856	857	O
and	858	861	O
echocardiography	862	878	O
were	879	883	O
carried	884	891	O
out	892	895	O
in	896	898	O
all	899	902	O
patients	903	911	O
for	912	915	O
univariate	916	926	O
and	927	930	O
multivariate	931	943	O
analyses	944	952	O
of	953	955	O
all	956	959	O
parameters	960	970	O
.	970	971	O

There	972	977	O
was	978	981	O
no	982	984	O
statistical	985	996	O
correlation	997	1008	O
between	1009	1016	O
clinical	1017	1025	O
symptoms	1026	1034	O
,	1034	1035	O
biochemical	1036	1047	O
data	1048	1052	O
,	1052	1053	O
and	1054	1057	O
cardiac	1058	1065	B-Organ
calcific	1066	1074	O
alterations	1075	1086	O
.	1086	1087	O

Typical	1088	1095	O
skeletal	1096	1104	B-Anatomical_system
manifestations	1105	1119	O
(	1120	1121	O
osteolysis	1121	1131	O
/	1131	1132	O
subperiostal	1132	1144	O
resorption	1145	1155	O
)	1155	1156	O
and	1157	1160	O
valvular	1161	1169	B-Multi-tissue_structure
calcifications	1170	1184	O
were	1185	1189	O
significantly	1190	1203	O
correlated	1204	1214	O
to	1215	1217	O
left	1218	1222	B-Multi-tissue_structure
ventricular	1223	1234	I-Multi-tissue_structure
hypertrophy	1235	1246	O
(	1247	1248	O
p	1248	1249	O
=	1250	1251	O
0	1252	1253	O
.	1253	1254	O
005	1254	1257	O
)	1257	1258	O
.	1258	1259	O

Cardiac	1260	1267	B-Organ
abnormalities	1268	1281	O
such	1282	1286	O
as	1287	1289	O
calcific	1290	1298	O
myocardial	1299	1309	B-Multi-tissue_structure
deposits	1310	1318	O
or	1319	1321	O
mitral	1322	1328	B-Multi-tissue_structure
and	1329	1332	O
aortic	1333	1339	B-Multi-tissue_structure
valvular	1340	1348	I-Multi-tissue_structure
calcifications	1349	1363	O
do	1364	1366	O
not	1367	1370	O
correlate	1371	1380	O
with	1381	1385	O
laboratory	1386	1396	O
findings	1397	1405	O
and	1406	1409	O
clinical	1410	1418	O
presentation	1419	1431	O
at	1432	1434	O
the	1435	1438	O
time	1439	1443	O
of	1444	1446	O
diagnosis	1447	1456	O
.	1456	1457	O

There	1458	1463	O
was	1464	1467	O
no	1468	1470	O
biochemical	1471	1482	O
or	1483	1485	O
clinical	1486	1494	O
variable	1495	1503	O
that	1504	1508	O
could	1509	1514	O
predict	1515	1522	O
the	1523	1526	O
frequency	1527	1536	O
or	1537	1539	O
severity	1540	1548	O
of	1549	1551	O
valvular	1552	1560	B-Multi-tissue_structure
sclerosis	1561	1570	O
or	1571	1573	O
calcific	1574	1582	O
deposits	1583	1591	O
in	1592	1594	O
the	1595	1598	O
myocardium	1599	1609	B-Multi-tissue_structure
.	1609	1610	O

However	1611	1618	O
,	1618	1619	O
PHP	1620	1623	O
-	1623	1624	O
related	1624	1631	O
skeletal	1632	1640	B-Anatomical_system
abnormalities	1641	1654	O
and	1655	1658	O
valvular	1659	1667	B-Multi-tissue_structure
calcification	1668	1681	O
were	1682	1686	O
predicting	1687	1697	O
factors	1698	1705	O
for	1706	1709	O
left	1710	1714	B-Multi-tissue_structure
ventricular	1715	1726	I-Multi-tissue_structure
hypertrophy	1727	1738	O
,	1738	1739	O
a	1740	1741	O
reversible	1742	1752	O
cardiac	1753	1760	B-Organ
manifestation	1761	1774	O
of	1775	1777	O
PHP	1778	1781	O
.	1781	1782	O

Myocardial	1783	1793	B-Multi-tissue_structure
hypertrophy	1794	1805	O
is	1806	1808	O
more	1809	1813	O
often	1814	1819	O
found	1820	1825	O
with	1826	1830	O
classic	1831	1838	O
symptomatic	1839	1850	O
PHP	1851	1854	O
with	1855	1859	O
osseous	1860	1867	B-Organ
abnormalities	1868	1881	O
.	1881	1882	O

Image	0	5	O
-	5	6	O
directed	6	14	O
and	15	18	O
color	19	24	O
Doppler	25	32	O
studies	33	40	O
of	41	43	O
gallbladder	44	55	B-Pathological_formation
tumors	56	62	I-Pathological_formation
.	62	63	O

Thirteen	64	72	O
cases	73	78	O
of	79	81	O
primary	82	89	O
adenocarcinoma	90	104	B-Pathological_formation
of	105	107	O
the	108	111	O
gallbladder	112	123	B-Organ
(	124	125	O
GB	125	127	B-Organ
)	127	128	O
,	128	129	O
1	130	131	O
of	132	134	O
malignant	135	144	B-Pathological_formation
fibrous	145	152	I-Pathological_formation
histocytoma	153	164	I-Pathological_formation
,	164	165	O
3	166	167	O
of	168	170	O
metastatic	171	181	B-Pathological_formation
adenocarcinoma	182	196	I-Pathological_formation
,	196	197	O
5	198	199	O
of	200	202	O
adenoma	203	210	B-Pathological_formation
,	210	211	O
5	212	213	O
of	214	216	O
polypus	217	224	B-Pathological_formation
,	224	225	O
2	226	227	O
of	228	230	O
xanthogranuloma	231	246	B-Pathological_formation
,	246	247	O
6	248	249	O
of	250	252	O
chronic	253	260	O
cholecystitis	261	274	O
,	274	275	O
4	276	277	O
of	278	280	O
acute	281	286	O
cholecystitis	287	300	O
,	300	301	O
and	302	305	O
8	306	307	O
of	308	310	O
subacute	311	319	O
cholecystitis	320	333	O
were	334	338	O
studied	339	346	O
by	347	349	O
image	350	355	O
-	355	356	O
directed	356	364	O
and	365	368	O
color	369	374	O
Doppler	375	382	O
ultrasonography	383	398	O
(	399	400	O
CDUS	400	404	O
)	404	405	O
.	405	406	O

All	407	410	O
of	411	413	O
the	414	417	O
14	418	420	O
cases	421	426	O
of	427	429	O
primary	430	437	O
GB	438	440	B-Pathological_formation
cancer	441	447	I-Pathological_formation
(	448	449	O
10	449	451	O
masses	452	458	O
,	458	459	O
4	460	461	O
thickening	462	472	O
wall	473	477	B-Multi-tissue_structure
)	477	478	O
were	479	483	O
found	484	489	O
to	490	492	O
have	493	497	O
a	498	499	O
high	500	504	O
velocity	505	513	O
arterial	514	522	B-Organism_substance
blood	523	528	I-Organism_substance
flow	529	533	O
signal	534	540	O
in	541	543	O
the	544	547	O
wall	548	552	B-Multi-tissue_structure
of	553	555	O
the	556	559	O
GB	560	562	B-Organ
.	562	563	O

In	564	566	O
contrast	567	575	O
,	575	576	O
the	577	580	O
3	581	582	O
cases	583	588	O
of	589	591	O
metastatic	592	602	B-Pathological_formation
cancer	603	609	I-Pathological_formation
of	610	612	O
the	613	616	O
GB	617	619	B-Organ
had	620	623	O
no	624	626	O
blood	627	632	B-Organism_substance
flow	633	637	O
signal	638	644	O
in	645	647	O
the	648	651	O
wall	652	656	B-Multi-tissue_structure
of	657	659	O
the	660	663	O
GB	664	666	B-Organ
.	666	667	O

For	668	671	O
the	672	675	O
30	676	678	O
cases	679	684	O
of	685	687	O
benign	688	694	B-Pathological_formation
lesions	695	702	I-Pathological_formation
of	703	705	O
the	706	709	O
GB	710	712	B-Organ
,	712	713	O
only	714	718	O
in	719	721	O
12	722	724	O
cases	725	730	O
was	731	734	O
a	735	736	O
low	737	740	O
velocity	741	749	O
blood	750	755	B-Organism_substance
flow	756	760	O
signal	761	767	O
found	768	773	O
.	773	774	O

Nine	775	779	O
of	780	782	O
10	783	785	O
cases	786	791	O
of	792	794	O
primary	795	802	O
GB	803	805	B-Pathological_formation
malignancy	806	816	I-Pathological_formation
were	817	821	O
found	822	827	O
to	828	830	O
have	831	835	O
high	836	840	O
velocity	841	849	O
arterial	850	858	B-Organism_substance
blood	859	864	I-Organism_substance
flow	865	869	O
signals	870	877	O
in	878	880	O
the	881	884	O
tumor	885	890	B-Pathological_formation
masses	891	897	O
.	897	898	O

No	899	901	O
blood	902	907	B-Organism_substance
flow	908	912	O
signal	913	919	O
was	920	923	O
observed	924	932	O
in	933	935	O
the	936	939	O
masses	940	946	O
of	947	949	O
13	950	952	O
cases	953	958	O
(	959	960	O
3	960	961	O
of	962	964	O
metastatic	965	975	B-Pathological_formation
adenocarcinoma	976	990	I-Pathological_formation
,	990	991	O
5	992	993	O
of	994	996	O
adenoma	997	1004	B-Pathological_formation
,	1004	1005	O
5	1006	1007	O
of	1008	1010	O
polypus	1011	1018	B-Pathological_formation
)	1018	1019	O
.	1019	1020	O

An	1021	1023	O
abnormal	1024	1032	O
high	1033	1037	O
velocity	1038	1046	O
arterial	1047	1055	B-Organism_substance
blood	1056	1061	I-Organism_substance
flow	1062	1066	O
signal	1067	1073	O
observed	1074	1082	O
within	1083	1089	O
masses	1090	1096	O
in	1097	1099	O
the	1100	1103	O
GB	1104	1106	B-Organ
or	1107	1109	O
in	1110	1112	O
the	1113	1116	O
GB	1117	1119	B-Multi-tissue_structure
wall	1120	1124	I-Multi-tissue_structure
is	1125	1127	O
a	1128	1129	O
significant	1130	1141	O
feature	1142	1149	O
of	1150	1152	O
primary	1153	1160	O
GB	1161	1163	B-Pathological_formation
cancer	1164	1170	I-Pathological_formation
and	1171	1174	O
thus	1175	1179	O
helps	1180	1185	O
to	1186	1188	O
differentiate	1189	1202	O
primary	1203	1210	O
GB	1211	1213	B-Pathological_formation
cancer	1214	1220	I-Pathological_formation
from	1221	1225	O
metastatic	1226	1236	B-Pathological_formation
and	1237	1240	O
benign	1241	1247	B-Pathological_formation
lesions	1248	1255	I-Pathological_formation
of	1256	1258	O
the	1259	1262	O
GB	1263	1265	B-Organ
.	1265	1266	O

Inhibition	0	10	O
of	11	13	O
calmodulin	14	24	O
-	24	25	O
dependent	25	34	O
myosin	35	41	O
light	42	47	O
-	47	48	O
chain	48	53	O
kinase	54	60	O
by	61	63	O
growth	64	70	O
-	70	71	O
hormone	71	78	O
-	78	79	O
releasing	79	88	O
factor	89	95	O
and	96	99	O
vasoactive	100	110	O
intestinal	111	121	B-Multi-tissue_structure
peptide	122	129	O
.	129	130	O

In	131	133	O
view	134	138	O
of	139	141	O
the	142	145	O
ability	146	153	O
of	154	156	O
calmodulin	157	167	O
to	168	170	O
bind	171	175	O
vasoactive	176	186	O
intestinal	187	197	B-Multi-tissue_structure
peptide	198	205	O
(	206	207	O
VIP	207	210	O
)	210	211	O
and	212	215	O
growth	216	222	O
-	222	223	O
hormone	223	230	O
-	230	231	O
releasing	231	240	O
factor	241	247	O
(	248	249	O
GRF	249	252	O
)	252	253	O
with	254	258	O
high	259	263	O
affinity	264	272	O
[	273	274	O
Stallwood	274	283	O
,	283	284	O
Brugger	285	292	O
,	292	293	O
Baggenstoss	294	305	O
,	305	306	O
Stemmer	307	314	O
,	314	315	O
Shiraga	316	323	O
,	323	324	O
Landers	325	332	O
and	333	336	O
Paul	337	341	O
(	342	343	O
1992	343	347	O
)	347	348	O
J	349	350	O
.	350	351	O
Biol	352	356	O
.	356	357	O
Chem	358	362	O
.	362	363	O
267	364	367	O
,	367	368	O
19617	369	374	O
-	374	375	O
19621	375	380	O
]	380	381	O
,	381	382	O
the	383	386	O
effects	387	394	O
of	395	397	O
these	398	403	O
neuropeptides	404	417	O
on	418	420	O
a	421	422	O
model	423	428	O
calmodulin	429	439	O
-	439	440	O
dependent	440	449	O
enzyme	450	456	O
,	456	457	O
myosin	458	464	O
light	465	470	O
-	470	471	O
chain	471	476	O
kinase	477	483	O
(	484	485	O
MLCK	485	489	O
)	489	490	O
,	490	491	O
were	492	496	O
studied	497	504	O
.	504	505	O

Both	506	510	O
peptides	511	519	O
were	520	524	O
potent	525	531	O
inhibitors	532	542	O
of	543	545	O
MLCK	546	550	O
activity	551	559	O
.	559	560	O

The	561	564	O
inhibition	565	575	O
of	576	578	O
enzyme	579	585	O
activity	586	594	O
by	595	597	O
VIP	598	601	O
and	602	605	O
GRF	606	609	O
was	610	613	O
progressively	614	627	O
overcome	628	636	O
with	637	641	O
increasing	642	652	O
calmodulin	653	663	O
concentrations	664	678	O
,	678	679	O
with	680	684	O
no	685	687	O
inhibition	688	698	O
observed	699	707	O
at	708	710	O
a	711	712	O
saturating	713	723	O
calmodulin	724	734	O
concentration	735	748	O
.	748	749	O

Nanomolar	750	759	O
concentrations	760	774	O
of	775	777	O
MLCK	778	782	O
blocked	783	790	O
the	791	794	O
formation	795	804	O
of	805	807	O
calmodulin	808	818	O
-	818	819	O
[	819	820	O
125I	820	824	O
-	824	825	O
Tyr10	825	830	O
]	830	831	O
VIP	831	834	O
complexes	835	844	O
.	844	845	O

These	846	851	O
data	852	856	O
provide	857	864	O
support	865	872	O
for	873	876	O
a	877	878	O
functional	879	889	O
role	890	894	O
of	895	897	O
VIP	898	901	O
and	902	905	O
GRF	906	909	O
binding	910	917	O
by	918	920	O
calmodulin	921	931	O
.	931	932	O

Methotrexate	0	12	O
osteopathy	13	23	O
in	24	26	O
rheumatic	27	36	O
disease	37	44	O
.	44	45	O

OBJECTIVE	46	55	O
:	55	56	O

To	57	59	O
determine	60	69	O
whether	70	77	O
two	78	81	O
adults	82	88	O
with	89	93	O
stress	94	100	O
fractures	101	110	O
receiving	111	120	O
low	121	124	O
weekly	125	131	O
doses	132	137	O
of	138	140	O
methotrexate	141	153	O
had	154	157	O
methotrexate	158	170	O
osteopathy	171	181	O
.	181	182	O

CASE	183	187	O
REPORTS	188	195	O
:	195	196	O

Two	197	200	O
adult	201	206	O
patients	207	215	O
developed	216	225	O
features	226	234	O
consistent	235	245	O
with	246	250	O
methotrexate	251	263	O
osteopathy	264	274	O
while	275	280	O
receiving	281	290	O
low	291	294	O
weekly	295	301	O
doses	302	307	O
of	308	310	O
methotrexate	311	323	O
.	323	324	O

METHODS	325	332	O
:	332	333	O

Iliac	334	339	B-Multi-tissue_structure
crest	340	345	I-Multi-tissue_structure
biopsy	346	352	I-Multi-tissue_structure
samples	353	360	I-Multi-tissue_structure
were	361	365	O
taken	366	371	O
and	372	375	O
bone	376	380	B-Tissue
histomorphometry	381	397	O
carried	398	405	O
out	406	409	O
.	409	410	O

RESULTS	411	418	O
:	418	419	O

Symptoms	420	428	O
resolved	429	437	O
when	438	442	O
the	443	446	O
methotrexate	447	459	O
was	460	463	O
discontinued	464	476	O
.	476	477	O

Bone	478	482	B-Tissue
histology	483	492	O
showed	493	499	O
changes	500	507	O
consistent	508	518	O
with	519	523	O
osteoblast	524	534	B-Cell
inhibition	535	545	O
by	546	548	O
methotrexate	549	561	O
.	561	562	O

CONCLUSIONS	563	574	O
:	574	575	O

When	576	580	O
given	581	586	O
in	587	589	O
low	590	593	O
doses	594	599	O
for	600	603	O
prolonged	604	613	O
periods	614	621	O
,	621	622	O
methotrexate	623	635	O
may	636	639	O
have	640	644	O
adverse	645	652	O
effects	653	660	O
on	661	663	O
bone	664	668	B-Organ
,	668	669	O
particularly	670	682	O
in	683	685	O
post	686	690	O
-	690	691	O
menopausal	691	701	O
women	702	707	O
.	707	708	O

Methodologies	0	13	O
for	14	17	O
measuring	18	27	O
carcinogen	28	38	O
adducts	39	46	O
in	47	49	O
humans	50	56	O
.	56	57	O

In	58	60	O
summary	61	68	O
,	68	69	O
although	70	78	O
some	79	83	O
of	84	86	O
the	87	90	O
more	91	95	O
optimistic	96	106	O
aspirations	107	118	O
for	119	122	O
human	123	128	O
biomonitoring	129	142	O
studies	143	150	O
envisaged	151	160	O
a	161	162	O
decade	163	169	O
ago	170	173	O
have	174	178	O
not	179	182	O
been	183	187	O
realized	188	196	O
thus	197	201	O
far	202	205	O
,	205	206	O
some	207	211	O
considerable	212	224	O
advances	225	233	O
have	234	238	O
been	239	243	O
made	244	248	O
.	248	249	O

The	250	253	O
examples	254	262	O
cited	263	268	O
above	269	274	O
indicate	275	283	O
that	284	288	O
the	289	292	O
feasibility	293	304	O
of	305	307	O
biomonitoring	308	321	O
has	322	325	O
been	326	330	O
clearly	331	338	O
established	339	350	O
.	350	351	O

In	352	354	O
addition	355	363	O
,	363	364	O
they	365	369	O
demonstrate	370	381	O
the	382	385	O
need	386	390	O
for	391	394	O
preliminary	395	406	O
biomarker	407	416	O
testing	417	424	O
and	425	428	O
validation	429	439	O
through	440	447	O
transitional	448	460	O
studies	461	468	O
prior	469	474	O
to	475	477	O
their	478	483	O
field	484	489	O
application	490	501	O
.	501	502	O

In	503	505	O
the	506	509	O
next	510	514	O
decade	515	521	O
of	522	524	O
research	525	533	O
into	534	538	O
carcinogen	539	549	O
adducts	550	557	O
in	558	560	O
humans	561	567	O
,	567	568	O
continued	569	578	O
improvements	579	591	O
in	592	594	O
the	595	598	O
reproducibility	599	614	O
and	615	618	O
specificity	619	630	O
of	631	633	O
assays	634	640	O
for	641	644	O
DNA	645	648	O
adducts	649	656	O
will	657	661	O
be	662	664	O
needed	665	671	O
.	671	672	O

Perhaps	673	680	O
the	681	684	O
increasing	685	695	O
use	696	699	O
of	700	702	O
hybrid	703	709	O
methodologies	710	723	O
to	724	726	O
concentrate	727	738	O
adducts	739	746	O
followed	747	755	O
by	756	758	O
specific	759	767	O
chemical	768	776	O
analyses	777	785	O
will	786	790	O
allow	791	796	O
such	797	801	O
adducts	802	809	O
to	810	812	O
be	813	815	O
monitored	816	825	O
more	826	830	O
precisely	831	840	O
.	840	841	O

Of	842	844	O
course	845	851	O
,	851	852	O
further	853	860	O
basic	861	866	O
research	867	875	O
into	876	880	O
the	881	884	O
mechanisms	885	895	O
of	896	898	O
carcinogenesis	899	913	O
will	914	918	O
allow	919	924	O
the	925	928	O
measurement	929	940	O
of	941	943	O
specific	944	952	O
novel	953	958	O
markers	959	966	O
which	967	972	O
are	973	976	O
more	977	981	O
closely	982	989	O
tied	990	994	O
to	995	997	O
the	998	1001	O
disease	1002	1009	O
endpoint	1010	1018	O
than	1019	1023	O
adducts	1024	1031	O
.	1031	1032	O

The	1033	1036	O
development	1037	1048	O
of	1049	1051	O
new	1052	1055	O
assays	1056	1062	O
for	1063	1066	O
determining	1067	1078	O
metabolic	1079	1088	O
phenotypes	1089	1099	O
and	1100	1103	O
genotypes	1104	1113	O
relevant	1114	1122	O
to	1123	1125	O
carcinogenesis	1126	1140	O
should	1141	1147	O
improve	1148	1155	O
our	1156	1159	O
estimates	1160	1169	O
of	1170	1172	O
susceptibility	1173	1187	O
(	1188	1189	O
46	1189	1191	O
-	1191	1192	O
48	1192	1194	O
)	1194	1195	O
.	1195	1196	O

Such	1197	1201	O
new	1202	1205	O
approaches	1206	1216	O
along	1217	1222	O
with	1223	1227	O
the	1228	1231	O
sustained	1232	1241	O
improvement	1242	1253	O
of	1254	1256	O
current	1257	1264	O
assays	1265	1271	O
will	1272	1276	O
allow	1277	1282	O
molecular	1283	1292	O
approaches	1293	1303	O
to	1304	1306	O
continue	1307	1315	O
to	1316	1318	O
enrich	1319	1325	O
cancer	1326	1332	B-Pathological_formation
epidemiology	1333	1345	O
in	1346	1348	O
the	1349	1352	O
future	1353	1359	O
.	1359	1360	O

Lactotransferrin	0	16	O
binding	17	24	O
to	25	27	O
its	28	31	O
platelet	32	40	B-Cell
receptor	41	49	O
inhibits	50	58	O
platelet	59	67	B-Cell
aggregation	68	79	O
.	79	80	O

A	81	82	O
fluorescent	83	94	O
lactotransferrin	95	111	O
probe	112	117	O
was	118	121	O
prepared	122	130	O
by	131	133	O
coupling	134	142	O
5	143	144	O
-	144	145	O
(	145	146	O
(	146	147	O
[	147	148	O
2	148	149	O
-	149	150	O
(	150	151	O
carbhydrazino	151	164	O
)	164	165	O
methyl	165	171	O
]	171	172	O
-	172	173	O
thio	173	177	O
)	177	178	O
acetyl	178	184	O
)	184	185	O
amino	185	190	O
fluorescein	191	202	O
to	203	205	O
aldehyde	206	214	O
groups	215	221	O
that	222	226	O
were	227	231	O
produced	232	240	O
by	241	243	O
a	244	245	O
mild	246	250	O
periodic	251	259	O
-	259	260	O
acid	260	264	O
oxidation	265	274	O
of	275	277	O
the	278	281	O
glycan	282	288	O
moieties	289	297	O
of	298	300	O
lactotransferrin	301	317	O
.	317	318	O

In	319	321	O
this	322	326	O
manner	327	333	O
,	333	334	O
the	335	338	O
receptor	339	347	O
-	347	348	O
binding	348	355	O
site	356	360	O
of	361	363	O
the	364	367	O
lactotransferrin	368	384	O
remains	385	392	O
active	393	399	O
in	400	402	O
contrast	403	411	O
to	412	414	O
the	415	418	O
binding	419	426	O
site	427	431	O
of	432	434	O
the	435	438	O
lactotransferrin	439	455	O
derivatized	456	467	O
with	468	472	O
fluorescein	473	484	O
isothiocyanate	485	499	O
.	499	500	O

The	501	504	O
fluorescent	505	516	O
probe	517	522	O
allowed	523	530	O
us	531	533	O
to	534	536	O
characterize	537	549	O
,	549	550	O
by	551	553	O
flow	554	558	O
cytometry	559	568	O
,	568	569	O
the	570	573	O
binding	574	581	O
of	582	584	O
lactotransferrin	585	601	O
to	602	604	O
non	605	608	O
-	608	609	O
activated	609	618	O
human	619	624	O
platelets	625	634	B-Cell
.	634	635	O

The	636	639	O
putative	640	648	O
lactotransferrin	649	665	O
platelet	666	674	B-Cell
receptor	675	683	O
was	684	687	O
purified	688	696	O
and	697	700	O
its	701	704	O
immunological	705	718	O
and	719	722	O
physico	723	730	O
-	730	731	O
chemical	731	739	O
properties	740	750	O
were	751	755	O
found	756	761	O
to	762	764	O
be	765	767	O
very	768	772	O
similar	773	780	O
to	781	783	O
those	784	789	O
of	790	792	O
the	793	796	O
receptor	797	805	O
previously	806	816	O
isolated	817	825	O
from	826	830	O
activated	831	840	O
human	841	846	O
lymphocytes	847	858	B-Cell
.	858	859	O

Lactotransferrin	860	876	O
inhibits	877	885	O
ADP	886	889	O
-	889	890	O
induced	890	897	O
platelet	898	906	B-Cell
aggregation	907	918	O
at	919	921	O
concentrations	922	936	O
down	937	941	O
to	942	944	O
5	945	946	O
nM	947	949	O
,	949	950	O
which	951	956	O
can	957	960	O
be	961	963	O
reached	964	971	O
in	972	974	O
the	975	978	O
plasma	979	985	B-Organism_substance
after	986	991	O
leukocyte	992	1001	B-Cell
degranulation	1002	1015	O
.	1015	1016	O

Inhibition	1017	1027	O
of	1028	1030	O
platelet	1031	1039	B-Cell
aggregation	1040	1051	O
was	1052	1055	O
also	1056	1060	O
observed	1061	1069	O
with	1070	1074	O
the	1075	1078	O
N	1079	1080	O
-	1080	1081	O
terminal	1081	1089	O
fragment	1090	1098	O
of	1099	1101	O
lactotransferrin	1102	1118	O
(	1119	1120	O
residues	1120	1128	O
3	1129	1130	O
-	1130	1131	O
281	1131	1134	O
;	1134	1135	O
50	1136	1138	O
%	1138	1139	O
inhibition	1140	1150	O
=	1151	1152	O
2	1153	1154	O
microM	1155	1161	O
)	1161	1162	O
and	1163	1166	O
with	1167	1171	O
CFQWQRNMRKVRGPPVSC	1172	1190	O
synthetic	1191	1200	O
octodecapeptide	1201	1216	O
(	1217	1218	O
residues	1218	1226	O
20	1227	1229	O
-	1229	1230	O
37	1230	1232	O
;	1232	1233	O
50	1234	1236	O
%	1236	1237	O
inhibition	1238	1248	O
=	1249	1250	O
20	1251	1253	O
microM	1254	1260	O
)	1260	1261	O
corresponding	1262	1275	O
to	1276	1278	O
one	1279	1282	O
of	1283	1285	O
the	1286	1289	O
two	1290	1293	O
external	1294	1302	O
loops	1303	1308	O
(	1309	1310	O
residues	1310	1318	O
28	1319	1321	O
-	1321	1322	O
34	1322	1324	O
and	1325	1328	O
39	1329	1331	O
-	1331	1332	O
42	1332	1334	O
)	1334	1335	O
where	1336	1341	O
we	1342	1344	O
recently	1345	1353	O
located	1354	1361	O
the	1362	1365	O
receptor	1366	1374	O
-	1374	1375	O
binding	1375	1382	O
site	1383	1387	O
.	1387	1388	O

The	1389	1392	O
activity	1393	1401	O
(	1402	1403	O
50	1403	1405	O
%	1405	1406	O
inhibition	1407	1417	O
=	1418	1419	O
500	1420	1423	O
microM	1424	1430	O
)	1430	1431	O
of	1432	1434	O
the	1435	1438	O
tetrapeptide	1439	1451	O
KRDS	1452	1456	O
(	1457	1458	O
residues	1458	1466	O
39	1467	1469	O
-	1469	1470	O
42	1470	1472	O
)	1472	1473	O
,	1473	1474	O
which	1475	1480	O
has	1481	1484	O
already	1485	1492	O
been	1493	1497	O
described	1498	1507	O
,	1507	1508	O
was	1509	1512	O
at	1513	1515	O
least	1516	1521	O
25	1522	1524	O
-	1524	1525	O
times	1525	1530	O
and	1531	1534	O
16000	1535	1540	O
-	1540	1541	O
times	1541	1546	O
lower	1547	1552	O
than	1553	1557	O
the	1558	1561	O
activity	1562	1570	O
of	1571	1573	O
the	1574	1577	O
octodecapeptide	1578	1593	O
and	1594	1597	O
of	1598	1600	O
the	1601	1604	O
lactotransferrin	1605	1621	O
molecules	1622	1631	O
,	1631	1632	O
respectively	1633	1645	O
.	1645	1646	O

Finally	1647	1654	O
,	1654	1655	O
the	1656	1659	O
inhibition	1660	1670	O
was	1671	1674	O
demonstrated	1675	1687	O
to	1688	1690	O
be	1691	1693	O
mediated	1694	1702	O
by	1703	1705	O
a	1706	1707	O
mechanism	1708	1717	O
which	1718	1723	O
requires	1724	1732	O
the	1733	1736	O
binding	1737	1744	O
of	1745	1747	O
lactotransferrin	1748	1764	O
to	1765	1767	O
its	1768	1771	O
putative	1772	1780	O
receptor	1781	1789	O
and	1790	1793	O
not	1794	1797	O
to	1798	1800	O
platelet	1801	1809	B-Cell
glycoprotein	1810	1822	O
IIb	1823	1826	O
-	1826	1827	O
IIIa	1827	1831	O
.	1831	1832	O

Do	0	2	O
we	3	5	O
know	6	10	O
how	11	14	O
much	15	19	O
people	20	26	O
like	27	31	O
one	32	35	O
another	36	43	O
?	43	44	O

Metaperception	45	59	O
is	60	62	O
a	63	64	O
person	65	71	O
'	71	72	O
s	72	73	O
perception	74	84	O
about	85	90	O
a	91	92	O
second	93	99	O
person	100	106	O
'	106	107	O
s	107	108	O
perception	109	119	O
of	120	122	O
a	123	124	O
third	125	130	O
person	131	137	O
.	137	138	O

The	139	142	O
purpose	143	150	O
of	151	153	O
this	154	158	O
article	159	166	O
is	167	169	O
to	170	172	O
examine	173	180	O
the	181	184	O
accuracy	185	193	O
of	194	196	O
metaperceptions	197	212	O
of	213	215	O
liking	216	222	O
.	222	223	O

A	224	225	O
related	226	233	O
question	234	242	O
concerns	243	251	O
whether	252	259	O
the	260	263	O
heuristics	264	274	O
of	275	277	O
balance	278	285	O
,	285	286	O
reciprocity	287	298	O
,	298	299	O
and	300	303	O
agreement	304	313	O
are	314	317	O
used	318	322	O
by	323	325	O
perceivers	326	336	O
when	337	341	O
forming	342	349	O
such	350	354	O
judgments	355	364	O
.	364	365	O

The	366	369	O
authors	370	377	O
present	378	385	O
analyses	386	394	O
from	395	399	O
5	400	401	O
diverse	402	409	O
research	410	418	O
studies	419	426	O
that	427	431	O
used	432	436	O
an	437	439	O
adaptation	440	450	O
of	451	453	O
the	454	457	O
social	458	464	O
relations	465	474	O
model	475	480	O
for	481	484	O
triads	485	491	O
(	492	493	O
C	493	494	O
.	494	495	O
F	495	496	O
.	496	497	O
Bond	498	502	O
,	502	503	O
E	504	505	O
.	505	506	O
M	506	507	O
.	507	508	O
Horn	509	513	O
,	513	514	O
&	515	516	O
D	517	518	O
.	518	519	O
A	519	520	O
.	520	521	O
Kenny	522	527	O
,	527	528	O
in	529	531	O
press	532	537	O
)	537	538	O
.	538	539	O

The	540	543	O
results	544	551	O
indicate	552	560	O
that	561	565	O
people	566	572	O
know	573	577	O
how	578	581	O
much	582	586	O
people	587	593	O
like	594	598	O
one	599	602	O
another	603	610	O
,	610	611	O
even	612	616	O
with	617	621	O
small	622	627	O
amounts	628	635	O
of	636	638	O
information	639	650	O
.	650	651	O

Although	652	660	O
there	661	666	O
is	667	669	O
evidence	670	678	O
for	679	682	O
the	683	686	O
use	687	690	O
of	691	693	O
heuristics	694	704	O
,	704	705	O
particularly	706	718	O
reciprocity	719	730	O
and	731	734	O
agreement	735	744	O
,	744	745	O
accuracy	746	754	O
is	755	757	O
sometimes	758	767	O
enhanced	768	776	O
by	777	779	O
using	780	785	O
these	786	791	O
heuristics	792	802	O
.	802	803	O

Genetic	0	7	O
heterogeneity	8	21	O
evidenced	22	31	O
by	32	34	O
low	35	38	O
incidence	39	48	O
of	49	51	O
KAL	52	55	O
-	55	56	O
1	56	57	O
gene	58	62	O
mutations	63	72	O
in	73	75	O
sporadic	76	84	O
cases	85	90	O
of	91	93	O
gonadotropin	94	106	O
-	106	107	O
releasing	107	116	O
hormone	117	124	O
deficiency	125	135	O
.	135	136	O

Isolated	137	145	O
GnRH	146	150	O
deficiency	151	161	O
is	162	164	O
a	165	166	O
heritable	167	176	O
condition	177	186	O
characterized	187	200	O
by	201	203	O
a	204	205	O
functional	206	216	O
deficit	217	224	O
in	225	227	O
GnRH	228	232	O
secretion	233	242	O
.	242	243	O

Familial	244	252	O
cases	253	258	O
with	259	263	O
different	264	273	O
modes	274	279	O
of	280	282	O
inheritance	283	294	O
have	295	299	O
been	300	304	O
described	305	314	O
,	314	315	O
and	316	319	O
the	320	323	O
gene	324	328	O
responsible	329	340	O
for	341	344	O
the	345	348	O
X	349	350	O
-	350	351	O
linked	351	357	O
form	358	362	O
(	363	364	O
KAL	364	367	O
-	367	368	O
1	368	369	O
)	369	370	O
has	371	374	O
been	375	379	O
identified	380	390	O
.	390	391	O

However	392	399	O
,	399	400	O
sporadic	401	409	O
cases	410	415	O
with	416	420	O
no	421	423	O
documented	424	434	O
family	435	441	O
history	442	449	O
of	450	452	O
GnRH	453	457	O
deficiency	458	468	O
account	469	476	O
for	477	480	O
the	481	484	O
majority	485	493	O
of	494	496	O
the	497	500	O
affected	501	509	O
patients	510	518	O
.	518	519	O

For	520	523	O
this	524	528	O
reason	529	535	O
,	535	536	O
we	537	539	O
sought	540	546	O
to	547	549	O
determine	550	559	O
the	560	563	O
frequency	564	573	O
with	574	578	O
which	579	584	O
KAL	585	588	O
-	588	589	O
1	589	590	O
gene	591	595	O
mutations	596	605	O
occur	606	611	O
in	612	614	O
patients	615	623	O
with	624	628	O
sporadic	629	637	O
GnRH	638	642	O
deficiency	643	653	O
.	653	654	O

Only	655	659	O
1	660	661	O
of	662	664	O
21	665	667	O
patients	668	676	O
with	677	681	O
sporadic	682	690	O
GnRH	691	695	O
deficiency	696	706	O
was	707	710	O
found	711	716	O
to	717	719	O
bear	720	724	O
a	725	726	O
defect	727	733	O
in	734	736	O
the	737	740	O
KAL	741	744	O
-	744	745	O
1	745	746	O
gene	747	751	O
(	752	753	O
a	753	754	O
deletion	755	763	O
of	764	766	O
14	767	769	O
bases	770	775	O
starting	776	784	O
at	785	787	O
codon	788	793	O
464	794	797	O
)	797	798	O
.	798	799	O

Three	800	805	O
types	806	811	O
of	812	814	O
polymorphic	815	826	O
single	827	833	O
base	834	838	O
substitutions	839	852	O
with	853	857	O
no	858	860	O
apparent	861	869	O
correlation	870	881	O
with	882	886	O
GnRH	887	891	O
deficiency	892	902	O
were	903	907	O
also	908	912	O
detected	913	921	O
in	922	924	O
several	925	932	O
patients	933	941	O
.	941	942	O

In	943	945	O
each	946	950	O
of	951	953	O
3	954	955	O
different	956	965	O
patients	966	974	O
with	975	979	O
an	980	982	O
X	983	984	O
-	984	985	O
linked	985	991	O
mode	992	996	O
of	997	999	O
inheritance	1000	1011	O
,	1011	1012	O
3	1013	1014	O
genetic	1015	1022	O
defects	1023	1030	O
,	1030	1031	O
2	1032	1033	O
point	1034	1039	O
mutations	1040	1049	O
and	1050	1053	O
a	1054	1055	O
small	1056	1061	O
intragenic	1062	1072	O
deletion	1073	1081	O
,	1081	1082	O
were	1083	1087	O
detected	1088	1096	O
.	1096	1097	O

These	1098	1103	O
defects	1104	1111	O
consist	1112	1119	O
of	1120	1122	O
a	1123	1124	O
single	1125	1131	O
base	1132	1136	O
mutation	1137	1145	O
introducing	1146	1157	O
a	1158	1159	O
stop	1160	1164	O
codon	1165	1170	O
at	1171	1173	O
position	1174	1182	O
328	1183	1186	O
,	1186	1187	O
a	1188	1189	O
single	1190	1196	O
base	1197	1201	O
mutation	1202	1210	O
resulting	1211	1220	O
in	1221	1223	O
a	1224	1225	O
phenylalanine	1226	1239	O
to	1240	1242	O
leucine	1243	1250	O
substitution	1251	1263	O
at	1264	1266	O
position	1267	1275	O
517	1276	1279	O
,	1279	1280	O
and	1281	1284	O
a	1285	1286	O
9	1287	1288	O
-	1288	1289	O
base	1289	1293	O
deletion	1294	1302	O
at	1303	1305	O
the	1306	1309	O
3	1310	1311	O
'	1311	1312	O
-	1312	1313	O
exon	1313	1317	O
-	1317	1318	O
intron	1318	1324	O
splice	1325	1331	O
site	1332	1336	O
of	1337	1339	O
exon	1340	1344	O
8	1345	1346	O
,	1346	1347	O
respectively	1348	1360	O
.	1360	1361	O

All	1362	1365	O
identified	1366	1376	O
genetic	1377	1384	O
defects	1385	1392	O
occur	1393	1398	O
within	1399	1405	O
the	1406	1409	O
fibronectin	1410	1421	O
type	1422	1426	O
III	1427	1430	O
repeats	1431	1438	O
of	1439	1441	O
the	1442	1445	O
predicted	1446	1455	O
protein	1456	1463	O
encoded	1464	1471	O
by	1472	1474	O
the	1475	1478	O
KAL	1479	1482	O
-	1482	1483	O
1	1483	1484	O
gene	1485	1489	O
.	1489	1490	O

In	1491	1493	O
conclusion	1494	1504	O
,	1504	1505	O
our	1506	1509	O
study	1510	1515	O
indicates	1516	1525	O
that	1526	1530	O
the	1531	1534	O
incidence	1535	1544	O
of	1545	1547	O
genetic	1548	1555	O
defects	1556	1563	O
within	1564	1570	O
the	1571	1574	O
coding	1575	1581	O
region	1582	1588	O
of	1589	1591	O
the	1592	1595	O
KAL	1596	1599	O
-	1599	1600	O
1	1600	1601	O
gene	1602	1606	O
in	1607	1609	O
patients	1610	1618	O
with	1619	1623	O
sporadic	1624	1632	O
GnRH	1633	1637	O
deficiency	1638	1648	O
is	1649	1651	O
low	1652	1655	O
(	1656	1657	O
5	1657	1658	O
-	1658	1659	O
8	1659	1660	O
%	1660	1661	O
)	1661	1662	O
,	1662	1663	O
thus	1664	1668	O
supporting	1669	1679	O
the	1680	1683	O
idea	1684	1688	O
that	1689	1693	O
the	1694	1697	O
X	1698	1699	O
-	1699	1700	O
linked	1700	1706	O
form	1707	1711	O
of	1712	1714	O
inheritance	1715	1726	O
represents	1727	1737	O
the	1738	1741	O
least	1742	1747	O
common	1748	1754	O
form	1755	1759	O
of	1760	1762	O
the	1763	1766	O
disease	1767	1774	O
.	1774	1775	O

The	0	3	O
effect	4	10	O
of	11	13	O
early	14	19	O
diagnosis	20	29	O
and	30	33	O
treatment	34	43	O
in	44	46	O
cystic	47	53	O
fibrosis	54	62	O
:	62	63	O
a	64	65	O
seven	66	71	O
-	71	72	O
year	72	76	O
study	77	82	O
of	83	85	O
16	86	88	O
sibling	89	96	O
pairs	97	102	O
.	102	103	O

Data	104	108	O
on	109	111	O
16	112	114	O
sibling	115	122	O
pairs	123	128	O
with	129	133	O
cystic	134	140	O
fibrosis	141	149	O
were	150	154	O
analyzed	155	163	O
to	164	166	O
test	167	171	O
the	172	175	O
hypothesis	176	186	O
that	187	191	O
early	192	197	O
treatment	198	207	O
of	208	210	O
this	211	215	O
condition	216	225	O
improves	226	234	O
prognosis	235	244	O
.	244	245	O

Younger	246	253	O
siblings	254	262	O
'	262	263	O
conditions	264	274	O
were	275	279	O
diagnosed	280	289	O
before	290	296	O
1	297	298	O
year	299	303	O
of	304	306	O
age	307	310	O
,	310	311	O
usually	312	319	O
before	320	326	O
the	327	330	O
onset	331	336	O
of	337	339	O
pulmonary	340	349	B-Organ
disease	350	357	O
.	357	358	O

Older	359	364	O
siblings	365	373	O
'	373	374	O
conditions	375	385	O
were	386	390	O
diagnosed	391	400	O
after	401	406	O
1	407	408	O
year	409	413	O
of	414	416	O
age	417	420	O
and	421	424	O
after	425	430	O
the	431	434	O
onset	435	440	O
of	441	443	O
pulmonary	444	453	B-Organ
disease	454	461	O
.	461	462	O

Although	463	471	O
the	472	475	O
sibling	476	483	O
pairs	484	489	O
received	490	498	O
similar	499	506	O
treatment	507	516	O
,	516	517	O
comparison	518	528	O
at	529	531	O
7	532	533	O
years	534	539	O
of	540	542	O
age	543	546	O
showed	547	553	O
that	554	558	O
the	559	562	O
younger	563	570	O
siblings	571	579	O
had	580	583	O
significantly	584	597	O
better	598	604	O
chest	605	610	B-Organism_subdivision
roentgenogram	611	624	O
scores	625	631	O
,	631	632	O
total	633	638	O
clinical	639	647	O
scores	648	654	O
,	654	655	O
residual	656	664	O
lung	665	669	B-Organ
volumes	670	677	O
,	677	678	O
and	679	682	O
ratios	683	689	O
of	690	692	O
residual	693	701	O
volume	702	708	O
to	709	711	O
total	712	717	O
lung	718	722	B-Organ
volume	723	729	O
.	729	730	O

Younger	731	738	O
siblings	739	747	O
also	748	752	O
required	753	761	O
fewer	762	767	O
hospital	768	776	O
admissions	777	787	O
to	788	790	O
control	791	798	O
their	799	804	O
lung	805	809	B-Organ
disease	810	817	O
.	817	818	O

The	819	822	O
results	823	830	O
suggest	831	838	O
that	839	843	O
,	843	844	O
in	845	847	O
general	848	855	O
,	855	856	O
early	857	862	O
initiation	863	873	O
of	874	876	O
therapy	877	884	O
is	885	887	O
beneficial	888	898	O
for	899	902	O
patients	903	911	O
with	912	916	O
cystic	917	923	O
fibrosis	924	932	O
.	932	933	O

The	0	3	O
effects	4	11	O
of	12	14	O
oxidative	15	24	O
stress	25	31	O
on	32	34	O
in	35	37	O
vivo	38	42	O
brain	43	48	B-Organ
GSH	49	52	O
turnover	53	61	O
in	62	64	O
young	65	70	O
and	71	74	O
mature	75	81	O
mice	82	86	O
.	86	87	O

Glutathione	88	99	O
(	100	101	O
GSH	101	104	O
)	104	105	O
synthetase	106	116	O
activities	117	127	O
and	128	131	O
GSH	132	135	O
turnover	136	144	O
rates	145	150	O
were	151	155	O
examined	156	164	O
during	165	171	O
severe	172	178	O
oxidative	179	188	O
stress	189	195	O
in	196	198	O
the	199	202	O
mouse	203	208	O
brain	209	214	B-Organ
as	215	217	O
induced	218	225	O
by	226	228	O
t	229	230	O
-	230	231	O
butylhydroperoxide	231	249	O
(	250	251	O
t	251	252	O
-	252	253	O
BuOOH	253	258	O
)	258	259	O
.	259	260	O

Brain	261	266	B-Organ
GSH	267	270	O
synthetase	271	281	O
activities	282	292	O
in	293	295	O
8	296	297	O
-	297	298	O
mo	298	300	O
-	300	301	O
old	301	304	O
mice	305	309	O
in	310	312	O
the	313	316	O
cortex	317	323	B-Multi-tissue_structure
,	323	324	O
striatum	325	333	B-Multi-tissue_structure
,	333	334	O
thalamus	335	343	B-Multi-tissue_structure
,	343	344	O
hippocampus	345	356	B-Multi-tissue_structure
,	356	357	O
midbrain	358	366	B-Multi-tissue_structure
,	366	367	O
and	368	371	O
cerebellum	372	382	B-Multi-tissue_structure
were	383	387	O
found	388	393	O
to	394	396	O
increase	397	405	O
following	406	415	O
t	416	417	O
-	417	418	O
BuOOH	418	423	O
treatment	424	433	O
.	433	434	O

The	435	438	O
effect	439	445	O
of	446	448	O
GSH	449	452	O
synthesis	453	462	O
on	463	465	O
brain	466	471	B-Organ
GSH	472	475	O
turnover	476	484	O
rates	485	490	O
for	491	494	O
2	495	496	O
-	496	497	O
and	498	501	O
8	502	503	O
-	503	504	O
mo	504	506	O
-	506	507	O
old	507	510	O
mice	511	515	O
were	516	520	O
determined	521	531	O
after	532	537	O
intracerebroventricular	538	561	O
(	562	563	O
icv	563	566	O
)	566	567	O
injection	568	577	O
of	578	580	O
[	581	582	O
35S	582	585	O
]	585	586	O
cysteine	586	594	O
.	594	595	O

Rate	596	600	O
constants	601	610	O
for	611	614	O
GSH	615	618	O
turnover	619	627	O
were	628	632	O
determined	633	643	O
by	644	646	O
least	647	652	O
-	652	653	O
squares	653	660	O
iterative	661	670	O
minimization	671	683	O
from	684	688	O
the	689	692	O
specific	693	701	O
activity	702	710	O
data	711	715	O
from	716	720	O
20	721	723	O
min	724	727	O
to	728	730	O
108	731	734	O
h	735	736	O
after	737	742	O
[	743	744	O
35S	744	747	O
]	747	748	O
cysteine	748	756	O
administration	757	771	O
.	771	772	O

GSH	773	776	O
and	777	780	O
glutathione	781	792	O
disulfide	793	802	O
(	803	804	O
GSSG	804	808	O
)	808	809	O
specific	810	818	O
activities	819	829	O
were	830	834	O
determined	835	845	O
after	846	851	O
separation	852	862	O
by	863	865	O
high	866	870	O
-	870	871	O
pressure	871	879	O
liquid	880	886	O
chromatography	887	901	O
(	902	903	O
HPLC	903	907	O
)	907	908	O
.	908	909	O

The	910	913	O
half	914	918	O
-	918	919	O
life	919	923	O
of	924	926	O
GSH	927	930	O
in	931	933	O
the	934	937	O
2	938	939	O
-	939	940	O
mo	940	942	O
-	942	943	O
old	943	946	O
mouse	947	952	O
was	953	956	O
59	957	959	O
.	959	960	O
5	960	961	O
h	962	963	O
and	964	967	O
in	968	970	O
the	971	974	O
8	975	976	O
-	976	977	O
mo	977	979	O
-	979	980	O
old	980	983	O
mouse	984	989	O
was	990	993	O
79	994	996	O
.	996	997	O
1	997	998	O
h	999	1000	O
.	1000	1001	O

In	1002	1004	O
summary	1005	1012	O
,	1012	1013	O
defense	1014	1021	O
mechanisms	1022	1032	O
against	1033	1040	O
oxidative	1041	1050	O
stress	1051	1057	O
in	1058	1060	O
the	1061	1064	O
brain	1065	1070	B-Organ
differ	1071	1077	O
with	1078	1082	O
age	1083	1086	O
.	1086	1087	O

Young	1088	1093	O
mice	1094	1098	O
can	1099	1102	O
increase	1103	1111	O
the	1112	1115	O
cellular	1116	1124	B-Cell
availability	1125	1137	O
of	1138	1140	O
GSH	1141	1144	O
,	1144	1145	O
whereas	1146	1153	O
mature	1154	1160	O
mice	1161	1165	O
can	1166	1169	O
increase	1170	1178	O
GSH	1179	1182	O
synthetase	1183	1193	O
activity	1194	1202	O
during	1203	1209	O
oxidative	1210	1219	O
stress	1220	1226	O
.	1226	1227	O

These	1228	1233	O
differences	1234	1245	O
make	1246	1250	O
mature	1251	1257	O
mice	1258	1262	O
more	1263	1267	O
susceptible	1268	1279	O
to	1280	1282	O
brain	1283	1288	B-Organ
oxidative	1289	1298	O
damage	1299	1305	O
.	1305	1306	O

Multiple	0	8	O
phosphotyrosine	9	24	O
phosphatase	25	36	O
mRNAs	37	42	O
are	43	46	O
expressed	47	56	O
in	57	59	O
the	60	63	O
human	64	69	O
lung	70	74	B-Cell
fibroblast	75	85	I-Cell
cell	86	90	I-Cell
line	91	95	I-Cell
WI	96	98	I-Cell
-	98	99	I-Cell
38	99	101	I-Cell
.	101	102	O

Protein	103	110	O
tyrosine	111	119	O
phosphatases	120	132	O
are	133	136	O
important	137	146	O
components	147	157	O
of	158	160	O
signal	161	167	O
transduction	168	180	O
pathways	181	189	O
.	189	190	O

The	191	194	O
authors	195	202	O
have	203	207	O
used	208	212	O
reverse	213	220	O
transcription	221	234	O
/	234	235	O
polymerase	235	245	O
chain	246	251	O
reactions	252	261	O
to	262	264	O
accomplish	265	275	O
a	276	277	O
comprehensive	278	291	O
examination	292	303	O
of	304	306	O
the	307	310	O
RNA	311	314	O
expression	315	325	O
for	326	329	O
58	330	332	O
distinct	333	341	O
mammalian	342	351	O
protein	352	359	O
tyrosine	360	368	O
and	369	372	O
dual	373	377	O
specificity	378	389	O
phosphatase	390	401	O
(	402	403	O
PTPase	403	409	O
)	409	410	O
and	411	414	O
PTPase	415	421	O
-	421	422	O
like	422	426	O
genes	427	432	O
in	433	435	O
the	436	439	O
normal	440	446	O
human	447	452	O
diploid	453	460	B-Cell
fibroblast	461	471	I-Cell
cell	472	476	I-Cell
line	477	481	I-Cell
WI	482	484	I-Cell
-	484	485	I-Cell
38	485	487	I-Cell
.	487	488	O

Thirty	489	495	O
-	495	496	O
seven	496	501	O
of	502	504	O
these	505	510	O
PTPase	511	517	O
genes	518	523	O
express	524	531	O
easily	532	538	O
measurable	539	549	O
RNA	550	553	O
,	553	554	O
and	555	558	O
four	559	563	O
simultaneously	564	578	O
express	579	586	O
the	587	590	O
RNA	591	594	O
for	595	598	O
two	599	602	O
or	603	605	O
more	606	610	O
isoforms	611	619	O
.	619	620	O

Messages	621	629	O
for	630	633	O
an	634	636	O
additional	637	647	O
eight	648	653	O
PTPase	654	660	O
genes	661	666	O
are	667	670	O
detectable	671	681	O
at	682	684	O
low	685	688	O
levels	689	695	O
.	695	696	O

Only	697	701	O
14	702	704	O
known	705	710	O
PTPase	711	717	O
genes	718	723	O
do	724	726	O
not	727	730	O
express	731	738	O
measurable	739	749	O
RNA	750	753	O
under	754	759	O
our	760	763	O
conditions	764	774	O
.	774	775	O

For	776	779	O
purposes	780	788	O
of	789	791	O
comparison	792	802	O
,	802	803	O
the	804	807	O
authors	808	815	O
also	816	820	O
assessed	821	829	O
the	830	833	O
PTPases	834	841	O
expressed	842	851	O
in	852	854	O
the	855	858	O
WI	859	861	B-Cell
-	861	862	I-Cell
38	862	864	I-Cell
cell	865	869	I-Cell
line	870	874	I-Cell
using	875	880	O
highly	881	887	O
degenerate	888	898	O
primers	899	906	O
to	907	909	O
conserved	910	919	O
motifs	920	926	O
found	927	932	O
in	933	935	O
the	936	939	O
classical	940	949	O
tyrosine	950	958	O
-	958	959	O
specific	959	967	O
PTPases	968	975	O
.	975	976	O

Only	977	981	O
eight	982	987	O
of	988	990	O
the	991	994	O
22	995	997	O
classic	998	1005	O
tyrosine	1006	1014	O
-	1014	1015	O
specific	1015	1023	O
PTPases	1024	1031	O
detected	1032	1040	O
using	1041	1046	O
the	1047	1050	O
specific	1051	1059	O
primers	1060	1067	O
were	1068	1072	O
detected	1073	1081	O
using	1082	1087	O
these	1088	1093	O
degenerate	1094	1104	O
primers	1105	1112	O
.	1112	1113	O

Our	1114	1117	O
panel	1118	1123	O
of	1124	1126	O
specific	1127	1135	O
PTPase	1136	1142	O
primers	1143	1150	O
should	1151	1157	O
be	1158	1160	O
very	1161	1165	O
useful	1166	1172	O
for	1173	1176	O
semiquantitatively	1177	1195	O
assessing	1196	1205	O
the	1206	1209	O
repertoire	1210	1220	O
of	1221	1223	O
PTPases	1224	1231	O
expressed	1232	1241	O
by	1242	1244	O
cells	1245	1250	B-Cell
.	1250	1251	O

Epstein	0	7	O
-	7	8	O
Barr	8	12	O
virus	13	18	O
-	18	19	O
associated	19	29	O
nonsmall	30	38	B-Pathological_formation
cell	39	43	I-Pathological_formation
lung	44	48	I-Pathological_formation
carcinoma	49	58	I-Pathological_formation
:	58	59	O
undifferentiated	60	76	O
"	77	78	B-Pathological_formation
lymphoepithelioma	78	95	I-Pathological_formation
-	95	96	I-Pathological_formation
like	96	100	I-Pathological_formation
"	100	101	I-Pathological_formation
carcinoma	102	111	I-Pathological_formation
as	112	114	O
a	115	116	O
distinct	117	125	O
entity	126	132	O
with	133	137	O
better	138	144	O
prognosis	145	154	O
.	154	155	O

BACKGROUND	156	166	O
:	166	167	O

Epstein	168	175	O
-	175	176	O
Barr	176	180	O
virus	181	186	O
(	187	188	O
EBV	188	191	O
)	191	192	O
infection	193	202	O
in	203	205	O
nonsmall	206	214	B-Pathological_formation
cell	215	219	I-Pathological_formation
lung	220	224	I-Pathological_formation
carcinoma	225	234	I-Pathological_formation
(	235	236	O
NSCLC	236	241	B-Pathological_formation
)	241	242	O
has	243	246	O
been	247	251	O
demonstrated	252	264	O
in	265	267	O
some	268	272	O
ethnic	273	279	O
groups	280	286	O
.	286	287	O

The	288	291	O
pathobiology	292	304	O
and	305	308	O
the	309	312	O
role	313	317	O
of	318	320	O
EBV	321	324	O
and	325	328	O
oncoprotein	329	340	O
expression	341	351	O
in	352	354	O
these	355	360	O
tumors	361	367	B-Pathological_formation
have	368	372	O
not	373	376	O
been	377	381	O
studied	382	389	O
extensively	390	401	O
.	401	402	O

In	403	405	O
this	406	410	O
study	411	416	O
,	416	417	O
the	418	421	O
authors	422	429	O
investigated	430	442	O
EBV	443	446	O
-	446	447	O
encoded	447	454	O
RNA	455	458	O
-	458	459	O
1	459	460	O
(	461	462	O
EBER1	462	467	O
)	467	468	O
transcripts	469	480	O
by	481	483	O
in	484	486	O
situ	487	491	O
hybridization	492	505	O
and	506	509	O
the	510	513	O
expression	514	524	O
of	525	527	O
latent	528	534	O
membrane	535	543	O
protein	544	551	O
-	551	552	O
1	552	553	O
(	554	555	O
LMP	555	558	O
-	558	559	O
1	559	560	O
)	560	561	O
and	562	565	O
bcl	566	569	O
-	569	570	O
2	570	571	O
protein	572	579	O
by	580	582	O
immunohistochemistry	583	603	O
in	604	606	O
NSCLC	607	612	B-Pathological_formation
patients	613	621	O
from	622	626	O
Taiwan	627	633	O
,	633	634	O
where	635	640	O
nasopharyngeal	641	655	B-Pathological_formation
carcinoma	656	665	I-Pathological_formation
is	666	668	O
endemic	669	676	O
.	676	677	O

METHODS	678	685	O
:	685	686	O

A	687	688	O
total	689	694	O
of	695	697	O
127	698	701	O
cases	702	707	O
of	708	710	O
NSCLC	711	716	B-Pathological_formation
(	717	718	O
43	718	720	O
cases	721	726	O
of	727	729	O
squamous	730	738	B-Pathological_formation
cell	739	743	I-Pathological_formation
carcinoma	744	753	I-Pathological_formation
[	754	755	O
SCC	755	758	B-Pathological_formation
]	758	759	O
,	759	760	O
67	761	763	O
cases	764	769	O
of	770	772	O
adenocarcinoma	773	787	B-Pathological_formation
[	788	789	O
AD	789	791	B-Pathological_formation
]	791	792	O
,	792	793	O
12	794	796	O
cases	797	802	O
of	803	805	O
large	806	811	B-Pathological_formation
cell	812	816	I-Pathological_formation
carcinoma	817	826	I-Pathological_formation
[	827	828	O
LCC	828	831	B-Pathological_formation
]	831	832	O
,	832	833	O
and	834	837	O
5	838	839	O
cases	840	845	O
of	846	848	O
lymphoepithelioma	849	866	B-Pathological_formation
-	866	867	I-Pathological_formation
like	867	871	I-Pathological_formation
carcinoma	872	881	I-Pathological_formation
[	882	883	O
LE	883	885	B-Pathological_formation
]	885	886	O
)	886	887	O
were	888	892	O
included	893	901	O
.	901	902	O

A	903	904	O
sensitive	905	914	O
polymerase	915	925	O
chain	926	931	O
reaction	932	940	O
-	940	941	O
derived	941	948	O
,	948	949	O
digoxigenin	950	961	O
-	961	962	O
labeled	962	969	O
DNA	970	973	O
probe	974	979	O
for	980	983	O
in	984	986	O
situ	987	991	O
detection	992	1001	O
of	1002	1004	O
EBER1	1005	1010	O
transcripts	1011	1022	O
was	1023	1026	O
performed	1027	1036	O
for	1037	1040	O
the	1041	1044	O
detection	1045	1054	O
of	1055	1057	O
EBV	1058	1061	O
.	1061	1062	O

Immunohistochemistry	1063	1083	O
using	1084	1089	O
the	1090	1093	O
avidin	1094	1100	O
-	1100	1101	O
biotin	1101	1107	O
-	1107	1108	O
immunoperoxidase	1108	1124	O
method	1125	1131	O
was	1132	1135	O
also	1136	1140	O
performed	1141	1150	O
to	1151	1153	O
evaluate	1154	1162	O
the	1163	1166	O
expression	1167	1177	O
of	1178	1180	O
bcl	1181	1184	O
-	1184	1185	O
2	1185	1186	O
and	1187	1190	O
LMP	1191	1194	O
-	1194	1195	O
1	1195	1196	O
.	1196	1197	O

RESULTS	1198	1205	O
:	1205	1206	O

EBER1	1207	1212	O
was	1213	1216	O
detected	1217	1225	O
in	1226	1228	O
11	1229	1231	O
of	1232	1234	O
the	1235	1238	O
127	1239	1242	O
NSCLC	1243	1248	B-Pathological_formation
cases	1249	1254	O
(	1255	1256	O
8	1256	1257	O
.	1257	1258	O
7	1258	1259	O
%	1259	1260	O
;	1260	1261	O
6	1262	1263	O
SCC	1264	1267	B-Pathological_formation
cases	1268	1273	O
and	1274	1277	O
5	1278	1279	O
LE	1280	1282	B-Pathological_formation
cases	1283	1288	O
)	1288	1289	O
.	1289	1290	O

All	1291	1294	O
5	1295	1296	O
LE	1297	1299	B-Pathological_formation
cases	1300	1305	O
were	1306	1310	O
EBV	1311	1314	O
-	1314	1315	O
positive	1315	1323	O
,	1323	1324	O
whereas	1325	1332	O
only	1333	1337	O
6	1338	1339	O
of	1340	1342	O
the	1343	1346	O
43	1347	1349	O
SCC	1350	1353	B-Pathological_formation
cases	1354	1359	O
(	1360	1361	O
14	1361	1363	O
%	1363	1364	O
)	1364	1365	O
,	1365	1366	O
0	1367	1368	O
of	1369	1371	O
67	1372	1374	O
AD	1375	1377	B-Pathological_formation
cases	1378	1383	O
,	1383	1384	O
and	1385	1388	O
12	1389	1391	O
LCC	1392	1395	B-Pathological_formation
cases	1396	1401	O
were	1402	1406	O
EBV	1407	1410	O
-	1410	1411	O
positive	1411	1419	O
(	1420	1421	O
P	1421	1422	O
<	1423	1424	O
0	1425	1426	O
.	1426	1427	O
05	1427	1429	O
)	1429	1430	O
.	1430	1431	O

All	1432	1435	O
five	1436	1440	O
LE	1441	1443	B-Pathological_formation
cases	1444	1449	O
showed	1450	1456	O
diffuse	1457	1464	O
,	1464	1465	O
strong	1466	1472	O
,	1472	1473	O
positive	1474	1482	O
staining	1483	1491	O
of	1492	1494	O
tumor	1495	1500	B-Cell
cells	1501	1506	I-Cell
;	1506	1507	O
five	1508	1512	O
of	1513	1515	O
the	1516	1519	O
six	1520	1523	O
SCC	1524	1527	B-Pathological_formation
cases	1528	1533	O
showed	1534	1540	O
diffuse	1541	1548	O
but	1549	1552	O
weak	1553	1557	O
staining	1558	1566	O
.	1566	1567	O

Among	1568	1573	O
the	1574	1577	O
nontumor	1578	1586	B-Cell
epithelial	1587	1597	I-Cell
cells	1598	1603	I-Cell
,	1603	1604	O
there	1605	1610	O
was	1611	1614	O
no	1615	1617	O
EBER1	1618	1623	O
staining	1624	1632	O
of	1633	1635	O
any	1636	1639	O
of	1640	1642	O
the	1643	1646	O
11	1647	1649	O
EBER1	1650	1655	O
-	1655	1656	O
positive	1656	1664	O
cases	1665	1670	O
.	1670	1671	O

The	1672	1675	O
mean	1676	1680	O
age	1681	1684	O
of	1685	1687	O
the	1688	1691	O
LE	1692	1694	B-Pathological_formation
patients	1695	1703	O
was	1704	1707	O
10	1708	1710	O
years	1711	1716	O
younger	1717	1724	O
than	1725	1729	O
that	1730	1734	O
of	1735	1737	O
the	1738	1741	O
patients	1742	1750	O
with	1751	1755	O
other	1756	1761	O
histological	1762	1774	O
types	1775	1780	O
.	1780	1781	O

All	1782	1785	O
5	1786	1787	O
LE	1788	1790	B-Pathological_formation
patients	1791	1799	O
were	1800	1804	O
nonsmokers	1805	1815	O
,	1815	1816	O
whereas	1817	1824	O
3	1825	1826	O
of	1827	1829	O
the	1830	1833	O
6	1834	1835	O
patients	1836	1844	O
with	1845	1849	O
EBER1	1850	1855	O
-	1855	1856	O
positive	1856	1864	O
SCC	1865	1868	B-Pathological_formation
(	1869	1870	O
50	1870	1872	O
%	1872	1873	O
)	1873	1874	O
were	1875	1879	O
smokers	1880	1887	O
.	1887	1888	O

EBER1	1889	1894	O
expression	1895	1905	O
did	1906	1909	O
not	1910	1913	O
correlate	1914	1923	O
with	1924	1928	O
the	1929	1932	O
2	1933	1934	O
-	1934	1935	O
year	1935	1939	O
survival	1940	1948	O
rate	1949	1953	O
of	1954	1956	O
overall	1957	1964	O
cases	1965	1970	O
,	1970	1971	O
but	1972	1975	O
all	1976	1979	O
5	1980	1981	O
LE	1982	1984	B-Pathological_formation
patients	1985	1993	O
were	1994	1998	O
alive	1999	2004	O
without	2005	2012	O
clinical	2013	2021	O
evidence	2022	2030	O
of	2031	2033	O
disease	2034	2041	O
at	2042	2044	O
last	2045	2049	O
follow	2050	2056	O
-	2056	2057	O
up	2057	2059	O
.	2059	2060	O

Gender	2061	2067	O
,	2067	2068	O
lymph	2069	2074	B-Multi-tissue_structure
node	2075	2079	I-Multi-tissue_structure
or	2080	2082	O
distant	2083	2090	O
metastasis	2091	2101	O
,	2101	2102	O
and	2103	2106	O
clinical	2107	2115	O
stage	2116	2121	O
were	2122	2126	O
not	2127	2130	O
found	2131	2136	O
to	2137	2139	O
have	2140	2144	O
any	2145	2148	O
correlation	2149	2160	O
with	2161	2165	O
EBER1	2166	2171	O
expression	2172	2182	O
(	2183	2184	O
P	2184	2185	O
>	2186	2187	O
0	2188	2189	O
.	2189	2190	O
05	2190	2192	O
)	2192	2193	O
.	2193	2194	O

All	2195	2198	O
LE	2199	2201	B-Pathological_formation
cases	2202	2207	O
had	2208	2211	O
bcl	2212	2215	O
-	2215	2216	O
2	2216	2217	O
oncoprotein	2218	2229	O
expression	2230	2240	O
(	2241	2242	O
100	2242	2245	O
%	2245	2246	O
)	2246	2247	O
.	2247	2248	O

This	2249	2253	O
frequency	2254	2263	O
was	2264	2267	O
significantly	2268	2281	O
different	2282	2291	O
from	2292	2296	O
other	2297	2302	O
histologic	2303	2313	O
types	2314	2319	O
(	2320	2321	O
P	2321	2322	O
<	2323	2324	O
0	2325	2326	O
.	2326	2327	O
05	2327	2329	O
)	2329	2330	O
.	2330	2331	O

The	2332	2335	O
LMP	2336	2339	O
-	2339	2340	O
1	2340	2341	O
detection	2342	2351	O
rate	2352	2356	O
was	2357	2360	O
low	2361	2364	O
and	2365	2368	O
demonstrated	2369	2381	O
no	2382	2384	O
correlation	2385	2396	O
with	2397	2401	O
bcl	2402	2405	O
-	2405	2406	O
2	2406	2407	O
expression	2408	2418	O
.	2418	2419	O

CONCLUSIONS	2420	2431	O
:	2431	2432	O

In	2433	2435	O
this	2436	2440	O
study	2441	2446	O
,	2446	2447	O
the	2448	2451	O
authors	2452	2459	O
found	2460	2465	O
that	2466	2470	O
the	2471	2474	O
primary	2475	2482	O
LE	2483	2485	B-Pathological_formation
of	2486	2488	O
the	2489	2492	O
lung	2493	2497	B-Organ
is	2498	2500	O
associated	2501	2511	O
with	2512	2516	O
young	2517	2522	O
age	2523	2526	O
,	2526	2527	O
a	2528	2529	O
history	2530	2537	O
of	2538	2540	O
not	2541	2544	O
smoking	2545	2552	O
,	2552	2553	O
high	2554	2558	O
bcl	2559	2562	O
-	2562	2563	O
2	2563	2564	O
immunoreactivity	2565	2581	O
,	2581	2582	O
and	2583	2586	O
better	2587	2593	O
survival	2594	2602	O
rate	2603	2607	O
.	2607	2608	O

These	2609	2614	O
characteristics	2615	2630	O
demonstrate	2631	2642	O
that	2643	2647	O
EBV	2648	2651	O
-	2651	2652	O
associated	2652	2662	O
LE	2663	2665	B-Pathological_formation
of	2666	2668	O
the	2669	2672	O
lung	2673	2677	B-Organ
is	2678	2680	O
a	2681	2682	O
unique	2683	2689	O
entity	2690	2696	O
.	2696	2697	O

The	2698	2701	O
findings	2702	2710	O
of	2711	2713	O
the	2714	2717	O
current	2718	2725	O
study	2726	2731	O
suggest	2732	2739	O
that	2740	2744	O
EBV	2745	2748	O
infection	2749	2758	O
may	2759	2762	O
play	2763	2767	O
a	2768	2769	O
different	2770	2779	O
role	2780	2784	O
in	2785	2787	O
the	2788	2791	O
tumorigenesis	2792	2805	O
of	2806	2808	O
primary	2809	2816	O
LE	2817	2819	B-Pathological_formation
of	2820	2822	O
the	2823	2826	O
lung	2827	2831	B-Organ
than	2832	2836	O
it	2837	2839	O
does	2840	2844	O
in	2845	2847	O
other	2848	2853	O
EBER1	2854	2859	B-Pathological_formation
-	2859	2860	I-Pathological_formation
positive	2860	2868	I-Pathological_formation
NSCLCs	2869	2875	I-Pathological_formation
.	2875	2876	O

Antisocial	0	10	O
patients	11	19	O
:	19	20	O
a	21	22	O
comparison	23	33	O
of	34	36	O
those	37	42	O
with	43	47	O
and	48	51	O
those	52	57	O
without	58	65	O
childhood	66	75	O
conduct	76	83	O
disorder	84	92	O
.	92	93	O

The	94	97	O
purpose	98	105	O
of	106	108	O
this	109	113	O
study	114	119	O
was	120	123	O
to	124	126	O
compare	127	134	O
persons	135	142	O
with	143	147	O
antisocial	148	158	O
personality	159	170	O
disorder	171	179	O
(	180	181	O
ASP	181	184	O
)	184	185	O
with	186	190	O
those	191	196	O
who	197	200	O
meet	201	205	O
the	206	209	O
adult	210	215	O
criteria	216	224	O
for	225	228	O
ASP	229	232	O
but	233	236	O
fail	237	241	O
to	242	244	O
meet	245	249	O
the	250	253	O
criteria	254	262	O
for	263	266	O
childhood	267	276	O
conduct	277	284	O
disorder	285	293	O
.	293	294	O

Sociodemographic	295	311	O
data	312	316	O
,	316	317	O
medical	318	325	O
history	326	333	O
,	333	334	O
and	335	338	O
psychiatric	339	350	O
symptoms	351	359	O
exhibited	360	369	O
during	370	376	O
a	377	378	O
recent	379	385	O
hospital	386	394	O
admission	395	404	O
were	405	409	O
compared	410	418	O
in	419	421	O
the	422	425	O
two	426	429	O
groups	430	436	O
by	437	439	O
chart	440	445	O
review	446	452	O
.	452	453	O

The	454	457	O
two	458	461	O
groups	462	468	O
were	469	473	O
virtually	474	483	O
indistinguishable	484	501	O
,	501	502	O
except	503	509	O
that	510	514	O
patients	515	523	O
without	524	531	O
childhood	532	541	O
conduct	542	549	O
disorder	550	558	O
were	559	563	O
less	564	568	O
likely	569	575	O
to	576	578	O
smoke	579	584	O
or	585	587	O
consume	588	595	O
alcohol	596	603	O
,	603	604	O
were	605	609	O
less	610	614	O
likely	615	621	O
to	622	624	O
have	625	629	O
spent	630	635	O
time	636	640	O
in	641	643	O
a	644	645	O
training	646	654	O
school	655	661	O
/	661	662	O
boot	662	666	O
camp	667	671	O
as	672	674	O
a	675	676	O
child	677	682	O
or	683	685	O
adolescent	686	696	O
,	696	697	O
were	698	702	O
less	703	707	O
likely	708	714	O
to	715	717	O
have	718	722	O
been	723	727	O
admitted	728	736	O
for	737	740	O
a	741	742	O
recent	743	749	O
suicide	750	757	O
attempt	758	765	O
,	765	766	O
and	767	770	O
were	771	775	O
less	776	780	O
likely	781	787	O
to	788	790	O
have	791	795	O
conned	796	802	O
others	803	809	O
.	809	810	O

We	811	813	O
conclude	814	822	O
that	823	827	O
persons	828	835	O
meeting	836	843	O
the	844	847	O
adult	848	853	O
criteria	854	862	O
for	863	866	O
ASP	867	870	O
but	871	874	O
not	875	878	O
the	879	882	O
childhood	883	892	O
conduct	893	900	O
disorder	901	909	O
criteria	910	918	O
essentially	919	930	O
suffer	931	937	O
the	938	941	O
same	942	946	O
disorder	947	955	O
as	956	958	O
those	959	964	O
who	965	968	O
meet	969	973	O
full	974	978	O
ASP	979	982	O
criteria	983	991	O
but	992	995	O
are	996	999	O
less	1000	1004	O
severely	1005	1013	O
affected	1014	1022	O
.	1022	1023	O

Brainstem	0	9	B-Multi-tissue_structure
auditory	10	18	O
-	18	19	O
evoked	19	25	O
potential	26	35	O
evaluation	36	46	O
in	47	49	O
children	50	58	O
with	59	63	O
meningitis	64	74	O
.	74	75	O

Brainstem	76	85	B-Multi-tissue_structure
auditory	86	94	O
-	94	95	O
evoked	95	101	O
potential	102	111	O
(	112	113	O
BAEP	113	117	O
)	117	118	O
was	119	122	O
performed	123	132	O
on	133	135	O
101	136	139	O
children	140	148	O
with	149	153	O
meningitis	154	164	O
to	165	167	O
assess	168	174	O
the	175	178	O
incidence	179	188	O
of	189	191	O
hearing	192	199	O
impairment	200	210	O
.	210	211	O

Fifty	212	217	O
-	217	218	O
two	218	221	O
(	222	223	O
51	223	225	O
.	225	226	O
5	226	227	O
%	227	228	O
)	228	229	O
children	230	238	O
had	239	242	O
bacterial	243	252	O
meningitis	253	263	O
,	263	264	O
six	265	268	O
(	269	270	O
5	270	271	O
.	271	272	O
9	272	273	O
%	273	274	O
)	274	275	O
had	276	279	O
viral	280	285	O
meningitis	286	296	O
,	296	297	O
and	298	301	O
43	302	304	O
(	305	306	O
42	306	308	O
.	308	309	O
6	309	310	O
%	310	311	O
)	311	312	O
had	313	316	O
aseptic	317	324	O
meningitis	325	335	O
.	335	336	O

Fifty	337	342	O
-	342	343	O
one	343	346	O
(	347	348	O
50	348	350	O
.	350	351	O
5	351	352	O
%	352	353	O
)	353	354	O
patients	355	363	O
were	364	368	O
assessed	369	377	O
before	378	384	O
discharge	385	394	O
and	395	398	O
50	399	401	O
(	402	403	O
49	403	405	O
.	405	406	O
5	406	407	O
%	407	408	O
)	408	409	O
9	410	411	O
days	412	416	O
to	417	419	O
17	420	422	O
months	423	429	O
later	430	435	O
(	436	437	O
mean	437	441	O
=	442	443	O
4	444	445	O
months	446	452	O
)	452	453	O
.	453	454	O

BAEP	455	459	O
impairment	460	470	O
was	471	474	O
found	475	480	O
in	481	483	O
28	484	486	O
(	487	488	O
27	488	490	O
.	490	491	O
7	491	492	O
%	492	493	O
)	493	494	O
of	495	497	O
101	498	501	O
patients	502	510	O
;	510	511	O
24	512	514	O
had	515	518	O
sensorineural	519	532	O
and	533	536	O
four	537	541	O
had	542	545	O
conductive	546	556	O
type	557	561	O
of	562	564	O
hearing	565	572	O
loss	573	577	O
,	577	578	O
and	579	582	O
17	583	585	O
(	586	587	O
60	587	589	O
.	589	590	O
7	590	591	O
%	591	592	O
)	592	593	O
had	594	597	O
unilateral	598	608	O
and	609	612	O
11	613	615	O
(	616	617	O
39	617	619	O
.	619	620	O
3	620	621	O
%	621	622	O
)	622	623	O
had	624	627	O
bilateral	628	637	O
impairment	638	648	O
.	648	649	O

Hearing	650	657	O
threshold	658	667	O
was	668	671	O
elevated	672	680	O
in	681	683	O
22	684	686	O
(	687	688	O
21	688	690	O
.	690	691	O
8	691	692	O
%	692	693	O
)	693	694	O
patients	695	703	O
,	703	704	O
and	705	708	O
the	709	712	O
other	713	718	O
six	719	722	O
had	723	726	O
increased	727	736	O
latency	737	744	O
and	745	748	O
interpeak	749	758	O
latencies	759	768	O
with	769	773	O
normal	774	780	O
threshold	781	790	O
.	790	791	O

Frequency	792	801	O
of	802	804	O
BAEP	805	809	O
impairment	810	820	O
or	821	823	O
hearing	824	831	O
loss	832	836	O
associated	837	847	O
with	848	852	O
bacterial	853	862	O
meningitis	863	873	O
was	874	877	O
34	878	880	O
.	880	881	O
6	881	882	O
%	882	883	O
and	884	887	O
30	888	890	O
.	890	891	O
8	891	892	O
%	892	893	O
,	893	894	O
respectively	895	907	O
;	907	908	O
frequency	909	918	O
associated	919	929	O
with	930	934	O
aseptic	935	942	O
meningitis	943	953	O
was	954	957	O
20	958	960	O
.	960	961	O
9	961	962	O
%	962	963	O
and	964	967	O
13	968	970	O
.	970	971	O
9	971	972	O
%	972	973	O
,	973	974	O
respectively	975	987	O
.	987	988	O

One	989	992	O
child	993	998	O
with	999	1003	O
viral	1004	1009	O
meningitis	1010	1020	O
(	1021	1022	O
coxsackie	1022	1031	O
virus	1032	1037	O
)	1037	1038	O
had	1039	1042	O
mild	1043	1047	O
BAEP	1048	1052	O
impairment	1053	1063	O
.	1063	1064	O

Most	1065	1069	O
of	1070	1072	O
the	1073	1076	O
BAEP	1077	1081	O
impairment	1082	1092	O
in	1093	1095	O
the	1096	1099	O
bacterial	1100	1109	O
meningitis	1110	1120	O
group	1121	1126	O
was	1127	1130	O
associated	1131	1141	O
with	1142	1146	O
H	1147	1148	O
.	1148	1149	O
influenzae	1150	1160	O
.	1160	1161	O

Prospective	1162	1173	O
BAEP	1174	1178	O
study	1179	1184	O
was	1185	1188	O
performed	1189	1198	O
in	1199	1201	O
20	1202	1204	O
patients	1205	1213	O
randomly	1214	1222	O
at	1223	1225	O
0	1226	1227	O
.	1227	1228	O
3	1228	1229	O
to	1230	1232	O
18	1233	1235	O
months	1236	1242	O
to	1243	1245	O
assess	1246	1252	O
hearing	1253	1260	O
status	1261	1267	O
after	1268	1273	O
antibiotic	1274	1284	O
treatment	1285	1294	O
,	1294	1295	O
10	1296	1298	O
with	1299	1303	O
normal	1304	1310	O
and	1311	1314	O
10	1315	1317	O
with	1318	1322	O
abnormal	1323	1331	O
BAEP	1332	1336	O
.	1336	1337	O

All	1338	1341	O
the	1342	1345	O
initially	1346	1355	O
normal	1356	1362	O
BAEP	1363	1367	O
patients	1368	1376	O
remained	1377	1385	O
normal	1386	1392	O
.	1392	1393	O

Of	1394	1396	O
the	1397	1400	O
10	1401	1403	O
patients	1404	1412	O
with	1413	1417	O
abnormal	1418	1426	O
BAEP	1427	1431	O
results	1432	1439	O
initially	1440	1449	O
,	1449	1450	O
four	1451	1455	O
returned	1456	1464	O
to	1465	1467	O
normal	1468	1474	O
,	1474	1475	O
two	1476	1479	O
improved	1480	1488	O
,	1488	1489	O
three	1490	1495	O
remained	1496	1504	O
unchanged	1505	1514	O
,	1514	1515	O
and	1516	1519	O
one	1520	1523	O
deteriorated	1524	1536	O
.	1536	1537	O

The	1538	1541	O
incidence	1542	1551	O
of	1552	1554	O
hearing	1555	1562	O
loss	1563	1567	O
after	1568	1573	O
bacterial	1574	1583	O
and	1584	1587	O
aseptic	1588	1595	O
meningitis	1596	1606	O
is	1607	1609	O
high	1610	1614	O
.	1614	1615	O

BAEP	1616	1620	O
is	1621	1623	O
useful	1624	1630	O
to	1631	1633	O
screen	1634	1640	O
for	1641	1644	O
possible	1645	1653	O
hearing	1654	1661	O
loss	1662	1666	O
in	1667	1669	O
children	1670	1678	O
with	1679	1683	O
meningitis	1684	1694	O
,	1694	1695	O
and	1696	1699	O
follow	1700	1706	O
-	1706	1707	O
up	1707	1709	O
BAEP	1710	1714	O
is	1715	1717	O
necessary	1718	1727	O
for	1728	1731	O
those	1732	1737	O
patients	1738	1746	O
with	1747	1751	O
initially	1752	1761	O
abnormal	1762	1770	O
BAEP	1771	1775	O
.	1775	1776	O

[	0	1	O
The	1	4	O
assessment	5	15	O
of	16	18	O
flow	19	23	O
velocity	24	32	O
in	33	35	O
carotid	36	43	B-Multi-tissue_structure
and	44	47	O
intracranial	48	60	B-Multi-tissue_structure
arteries	61	69	I-Multi-tissue_structure
in	70	72	O
three	73	78	O
different	79	88	O
age	89	92	O
groups	93	99	O
]	99	100	O
.	100	101	O

In	102	104	O
this	105	109	O
report	110	116	O
we	117	119	O
assess	120	126	O
the	127	130	O
systolic	131	139	O
maximal	140	147	O
flow	148	152	O
velocity	153	161	O
in	162	164	O
carotid	165	172	B-Multi-tissue_structure
and	173	176	O
intracranial	177	189	B-Multi-tissue_structure
arteries	190	198	I-Multi-tissue_structure
in	199	201	O
191	202	205	O
subjects	206	214	O
with	215	219	O
no	220	222	O
history	223	230	O
of	231	233	O
cerebral	234	242	B-Multi-tissue_structure
vascular	243	251	I-Multi-tissue_structure
disease	252	259	O
in	260	262	O
3	263	264	O
age	265	268	O
groups	269	275	O
:	275	276	O
20	277	279	O
-	279	280	O
40	280	282	O
years	283	288	O
(	289	290	O
1	290	291	O
group	292	297	O
)	297	298	O
,	298	299	O
41	300	302	O
-	302	303	O
60	303	305	O
years	306	311	O
(	312	313	O
2	313	314	O
group	315	320	O
)	320	321	O
,	321	322	O
and	323	326	O
above	327	332	O
60	333	335	O
years	336	341	O
(	342	343	O
3	343	344	O
group	345	350	O
)	350	351	O
.	351	352	O

The	353	356	O
subjects	357	365	O
were	366	370	O
assessed	371	379	O
using	380	385	O
Sonomed	386	393	O
Transcranial	394	406	O
Doppler	407	414	O
Spectrograph	415	427	O
according	428	437	O
to	438	440	O
generally	441	450	O
accepted	451	459	O
principles	460	470	O
.	470	471	O

The	472	475	O
purpose	476	483	O
of	484	486	O
the	487	490	O
study	491	496	O
was	497	500	O
to	501	503	O
establish	504	513	O
the	514	517	O
mean	518	522	O
value	523	528	O
of	529	531	O
maximal	532	539	O
flow	540	544	O
velocity	545	553	O
in	554	556	O
each	557	561	O
particular	562	572	O
artery	573	579	B-Multi-tissue_structure
in	580	582	O
three	583	588	O
age	589	592	O
groups	593	599	O
,	599	600	O
and	601	604	O
to	605	607	O
observe	608	615	O
the	616	619	O
changes	620	627	O
in	628	630	O
this	631	635	O
parameter	636	645	O
with	646	650	O
age	651	654	O
.	654	655	O

The	656	659	O
results	660	667	O
were	668	672	O
analyzed	673	681	O
using	682	687	O
statistical	688	699	O
methods	700	707	O
and	708	711	O
a	712	713	O
significant	714	725	O
decrease	726	734	O
in	735	737	O
blood	738	743	B-Organism_substance
flow	744	748	O
,	748	749	O
Vmax	750	754	O
,	754	755	O
was	756	759	O
found	760	765	O
in	766	768	O
all	769	772	O
investigated	773	785	O
arteries	786	794	B-Multi-tissue_structure
.	794	795	O

A	796	797	O
mean	798	802	O
decrease	803	811	O
of	812	814	O
8	815	816	O
.	816	817	O
02	817	819	O
%	819	820	O
in	821	823	O
flow	824	828	O
velocity	829	837	O
Vmax	838	842	O
was	843	846	O
found	847	852	O
,	852	853	O
when	854	858	O
comparing	859	868	O
groups	869	875	O
2	876	877	O
and	878	881	O
1	882	883	O
,	883	884	O
and	885	888	O
difference	889	899	O
15	900	902	O
.	902	903	O
99	903	905	O
%	905	906	O
comparing	907	916	O
3	917	918	O
and	919	922	O
1	923	924	O
.	924	925	O

(	0	1	O
a	1	2	O
)	2	3	O
Schematic	4	13	O
drawing	14	21	O
of	22	24	O
the	25	28	O
magnetic	29	37	O
tweezers	38	46	O
.	46	47	O

A	48	49	O
DNA	50	53	O
molecule	54	62	O
is	63	65	O
attached	66	74	O
at	75	77	O
one	78	81	O
end	82	85	O
to	86	88	O
the	89	92	O
bottom	93	99	O
of	100	102	O
the	103	106	O
flow	107	111	O
cell	112	116	B-Cell
and	117	120	O
at	121	123	O
the	124	127	O
other	128	133	O
end	134	137	O
to	138	140	O
a	141	142	O
magnetic	143	151	O
bead	152	156	O
.	156	157	O

This	158	162	O
molecule	163	171	O
can	172	175	O
be	176	178	O
pulled	179	185	O
and	186	189	O
twisted	190	197	O
using	198	203	O
small	204	209	O
magnets	210	217	O
placed	218	224	O
above	225	230	O
the	231	234	O
flow	235	239	O
cell	240	244	B-Cell
.	244	245	O

The	246	249	O
position	250	258	O
of	259	261	O
the	262	265	O
magnetic	266	274	O
bead	275	279	O
is	280	282	O
measured	283	291	O
using	292	297	O
an	298	300	O
inverted	301	309	O
microscope	310	320	O
placed	321	327	O
beneath	328	335	O
the	336	339	O
flow	340	344	O
cell	345	349	B-Cell
.	349	350	O

The	351	354	O
bead	355	359	O
position	360	368	O
and	369	372	O
thus	373	377	O
the	378	381	O
end	382	385	O
-	385	386	O
to	386	388	O
-	388	389	O
end	389	392	O
distance	393	401	O
of	402	404	O
the	405	408	O
DNA	409	412	O
molecule	413	421	O
is	422	424	O
determined	425	435	O
using	436	441	O
video	442	447	O
microscopy	448	458	O
and	459	462	O
image	463	468	O
analysis	469	477	O
.	477	478	O

(	479	480	O
b	480	481	O
)	481	482	O
Extension	483	492	O
of	493	495	O
a	496	497	O
DNA	498	501	O
molecule	502	510	O
versus	511	517	O
the	518	521	O
number	522	528	O
of	529	531	O
turns	532	537	O
applied	538	545	O
by	546	548	O
the	549	552	O
magnets	553	560	O
for	561	564	O
various	565	572	O
stretching	573	583	O
forces	584	590	O
.	590	591	O

At	592	594	O
low	595	598	O
force	599	604	O
,	604	605	O
contraction	606	617	O
of	618	620	O
the	621	624	O
molecule	625	633	O
is	634	636	O
symmetrical	637	648	O
under	649	654	O
positive	655	663	O
and	664	667	O
negative	668	676	O
applied	677	684	O
turns	685	690	O
.	690	691	O

At	692	694	O
higher	695	701	O
force	702	707	O
,	707	708	O
the	709	712	O
molecule	713	721	O
'	721	722	O
s	722	723	O
extension	724	733	O
initially	734	743	O
remains	744	751	O
constant	752	760	O
for	761	764	O
positive	765	773	O
applied	774	781	O
turns	782	787	O
.	787	788	O

The	789	792	O
induced	793	800	O
torque	801	807	O
increases	808	817	O
linearly	818	826	O
with	827	831	O
the	832	835	O
number	836	842	O
of	843	845	O
applied	846	853	O
turns	854	859	O
,	859	860	O
as	861	863	O
depicted	864	872	O
in	873	875	O
the	876	879	O
top	880	883	O
graph	884	889	O
until	890	895	O
a	896	897	O
buckling	898	906	O
transition	907	917	O
allows	918	924	O
the	925	928	O
system	929	935	O
to	936	938	O
saturate	939	947	O
its	948	951	O
torsional	952	961	O
constraint	962	972	O
through	973	980	O
the	981	984	O
formation	985	994	O
of	995	997	O
plectonemes	998	1009	B-Cellular_component
.	1009	1010	O

Effect	0	6	O
of	7	9	O
Trail	10	15	O
on	16	18	O
the	19	22	O
expression	23	33	O
of	34	36	O
endogenous	37	47	O
M2	48	50	O
.	50	51	O

(	52	53	O
A	53	54	O
)	54	55	O
Effect	56	62	O
of	63	65	O
Trail	66	71	O
on	72	74	O
the	75	78	O
level	79	84	O
of	85	87	O
endogenous	88	98	O
M2	99	101	O
protein	102	109	O
.	109	110	O

The	111	114	O
expression	115	125	O
level	126	131	O
of	132	134	O
endogenous	135	145	O
M2	146	148	O
protein	149	156	O
in	157	159	O
HeLa	160	164	B-Cell
cells	165	170	I-Cell
was	171	174	O
determined	175	185	O
using	186	191	O
western	192	199	O
blot	200	204	O
4	205	206	O
h	207	208	O
following	209	218	O
Trail	219	224	O
(	225	226	O
250	226	229	O
mug	230	233	O
/	233	234	O
ml	234	236	O
)	236	237	O
treatment	238	247	O
.	247	248	O

(	249	250	O
B	250	251	O
)	251	252	O
Effect	253	259	O
of	260	262	O
Trail	263	268	O
on	269	271	O
the	272	275	O
endogenous	276	286	O
M2	287	289	O
mRNA	290	294	O
.	294	295	O

The	296	299	O
expression	300	310	O
level	311	316	O
of	317	319	O
endogenous	320	330	O
M2	331	333	O
mRNA	334	338	O
in	339	341	O
HeLa	342	346	B-Cell
cells	347	352	I-Cell
was	353	356	O
detected	357	365	O
using	366	371	O
RNase	372	377	O
protection	378	388	O
assay	389	394	O
4	395	396	O
h	397	398	O
following	399	408	O
Trail	409	414	O
(	415	416	O
250	416	419	O
mug	420	423	O
/	423	424	O
ml	424	426	O
)	426	427	O
treatment	428	437	O
.	437	438	O

(	439	440	O
C	440	441	O
)	441	442	O
Effect	443	449	O
of	450	452	O
Trail	453	458	O
on	459	461	O
the	462	465	O
synthesis	466	475	O
of	476	478	O
endogenous	479	489	O
M2	490	492	O
protein	493	500	O
.	500	501	O

HeLa	502	506	B-Cell
cells	507	512	I-Cell
were	513	517	O
first	518	523	O
treated	524	531	O
with	532	536	O
250	537	540	O
mug	541	544	O
/	544	545	O
ml	545	547	O
Trail	548	553	O
followed	554	562	O
by	563	565	O
pulse	566	571	O
labeling	572	580	O
of	581	583	O
newly	584	589	O
synthesized	590	601	O
proteins	602	610	O
with	611	615	O
[	616	617	O
35S	617	620	O
]	620	621	O
methionine	621	631	O
.	631	632	O

M2	633	635	O
protein	636	643	O
was	644	647	O
then	648	652	O
immunoprecipitated	653	671	O
and	672	675	O
separated	676	685	O
by	686	688	O
SDS	689	692	O
-	692	693	O
PAGE	693	697	O
for	698	701	O
autoradiography	702	717	O
as	718	720	O
described	721	730	O
in	731	733	O
Materials	734	743	O
and	744	747	O
Methods	748	755	O
.	755	756	O

The	0	3	O
most	4	8	O
highly	9	15	O
represented	16	27	O
gene	28	32	O
ontology	33	41	O
themes	42	48	O
in	49	51	O
the	52	55	O
neurosphere	56	67	B-Cell
vs	68	70	O
.	70	71	O
differentiated	72	86	B-Cell
cells	87	92	I-Cell
comparison	93	103	O
(	104	105	O
F	105	106	O
-	106	107	O
G	107	108	O
)	108	109	O
.	109	110	O

Planning	0	8	O
for	9	12	O
the	13	16	O
Future	17	23	O
:	23	24	O
Disaster	25	33	O
Preparedness	34	46	O
and	47	50	O
Mitigation	51	61	O

It	62	64	O
is	65	67	O
often	68	73	O
believed	74	82	O
that	83	87	O
casualties	88	98	O
from	99	103	O
natural	104	111	O
disasters	112	121	O
are	122	125	O
unavoidable	126	137	O
,	137	138	O
but	139	142	O
this	143	147	O
belief	148	154	O
is	155	157	O
false	158	163	O
[	164	165	O
8	165	166	O
]	166	167	O
.	167	168	O

There	169	174	O
are	175	178	O
many	179	183	O
measures	184	192	O
that	193	197	O
can	198	201	O
reduce	202	208	O
morbidity	209	218	O
and	219	222	O
mortality	223	232	O
following	233	242	O
large	243	248	O
and	249	252	O
potentially	253	264	O
catastrophic	265	277	O
flooding	278	286	O
events	287	293	O
[	294	295	O
19	295	297	O
]	297	298	O
.	298	299	O

Early	300	305	O
warning	306	313	O
of	314	316	O
impending	317	326	O
floods	327	333	O
and	334	337	O
natural	338	345	O
events	346	352	O
such	353	357	O
as	358	360	O
hurricanes	361	371	O
allows	372	378	O
sufficient	379	389	O
time	390	394	O
for	395	398	O
communities	399	410	O
to	411	413	O
be	414	416	O
evacuated	417	426	O
to	427	429	O
safe	430	434	O
areas	435	440	O
.	440	441	O

Although	442	450	O
Florida	451	458	O
experienced	459	470	O
one	471	474	O
of	475	477	O
the	478	481	O
worst	482	487	O
hurricane	488	497	O
seasons	498	505	O
on	506	508	O
record	509	515	O
in	516	518	O
2004	519	523	O
,	523	524	O
the	525	528	O
number	529	535	O
of	536	538	O
fatalities	539	549	O
was	550	553	O
lower	554	559	O
than	560	564	O
expected	565	573	O
because	574	581	O
of	582	584	O
early	585	590	O
warning	591	598	O
and	599	602	O
evacuation	603	613	O
.	613	614	O

Early	615	620	O
warning	621	628	O
also	629	633	O
provides	634	642	O
sufficient	643	653	O
time	654	658	O
to	659	661	O
prepare	662	669	O
when	670	674	O
evacuation	675	685	O
is	686	688	O
not	689	692	O
possible	693	701	O
.	701	702	O

Hurricane	703	712	O
George	713	719	O
in	720	722	O
1998	723	727	O
caused	728	734	O
widespread	735	745	O
damage	746	752	O
and	753	756	O
several	757	764	O
fatalities	765	775	O
in	776	778	O
the	779	782	O
Dominican	783	792	O
Republic	793	801	O
,	801	802	O
where	803	808	O
residents	809	818	O
were	819	823	O
not	824	827	O
warned	828	834	O
.	834	835	O

In	836	838	O
contrast	839	847	O
,	847	848	O
Cuba	849	853	O
and	854	857	O
Puerto	858	864	O
Rico	865	869	O
experienced	870	881	O
relatively	882	892	O
limited	893	900	O
damage	901	907	O
and	908	911	O
loss	912	916	O
of	917	919	O
life	920	924	O
,	924	925	O
because	926	933	O
preparations	934	946	O
were	947	951	O
made	952	956	O
in	957	959	O
the	960	963	O
hours	964	969	O
before	970	976	O
the	977	980	O
storm	981	986	O
.	986	987	O

Disaster	988	996	O
preparedness	997	1009	O
can	1010	1013	O
also	1014	1018	O
be	1019	1021	O
developed	1022	1031	O
for	1032	1035	O
communities	1036	1047	O
that	1048	1052	O
are	1053	1056	O
regularly	1057	1066	O
exposed	1067	1074	O
to	1075	1077	O
flooding	1078	1086	O
disasters	1087	1096	O
.	1096	1097	O

Cyclone	1098	1105	O
shelters	1106	1114	O
built	1115	1120	O
by	1121	1123	O
the	1124	1127	O
Red	1128	1131	O
Cross	1132	1137	O
in	1138	1140	O
Orissa	1141	1147	O
,	1147	1148	O
India	1149	1154	O
,	1154	1155	O
saved	1156	1161	O
many	1162	1166	O
thousands	1167	1176	O
of	1177	1179	O
lives	1180	1185	O
in	1186	1188	O
1999	1189	1193	O
when	1194	1198	O
two	1199	1202	O
cyclones	1203	1211	O
struck	1212	1218	O
.	1218	1219	O

In	1220	1222	O
the	1223	1226	O
region	1227	1233	O
of	1234	1236	O
the	1237	1240	O
Americas	1241	1249	O
,	1249	1250	O
the	1251	1254	O
Pan	1255	1258	O
American	1259	1267	O
Health	1268	1274	O
Organization	1275	1287	O
has	1288	1291	O
spent	1292	1297	O
many	1298	1302	O
years	1303	1308	O
promoting	1309	1318	O
and	1319	1322	O
integrating	1323	1334	O
disaster	1335	1343	O
preparedness	1344	1356	O
into	1357	1361	O
building	1362	1370	O
health	1371	1377	O
facilities	1378	1388	O
to	1389	1391	O
ensure	1392	1398	O
that	1399	1403	O
medical	1404	1411	O
services	1412	1420	O
needed	1421	1427	O
to	1428	1430	O
treat	1431	1436	O
victims	1437	1444	O
and	1445	1448	O
maintain	1449	1457	O
ongoing	1458	1465	O
care	1466	1470	O
for	1471	1474	O
patients	1475	1483	O
with	1484	1488	O
chronic	1489	1496	O
conditions	1497	1507	O
will	1508	1512	O
not	1513	1516	O
be	1517	1519	O
disrupted	1520	1529	O
by	1530	1532	O
disasters	1533	1542	O
.	1542	1543	O

A	1544	1545	O
recent	1546	1552	O
global	1553	1559	O
-	1559	1560	O
scale	1560	1565	O
review	1566	1572	O
of	1573	1575	O
health	1576	1582	O
risks	1583	1588	O
from	1589	1593	O
flooding	1594	1602	O
highlights	1603	1613	O
that	1614	1618	O
in	1619	1621	O
flood	1622	1627	O
-	1627	1628	O
prone	1628	1633	O
areas	1634	1639	O
,	1639	1640	O
disaster	1641	1649	O
preparedness	1650	1662	O
within	1663	1669	O
the	1670	1673	O
health	1674	1680	O
system	1681	1687	O
as	1688	1690	O
a	1691	1692	O
whole	1693	1698	O
is	1699	1701	O
particularly	1702	1714	O
important	1715	1724	O
[	1725	1726	O
20	1726	1728	O
]	1728	1729	O
.	1729	1730	O

In	1731	1733	O
addition	1734	1742	O
to	1743	1745	O
infrastructure	1746	1760	O
and	1761	1764	O
early	1765	1770	O
-	1770	1771	O
warning	1771	1778	O
systems	1779	1786	O
,	1786	1787	O
another	1788	1795	O
key	1796	1799	O
element	1800	1807	O
in	1808	1810	O
disaster	1811	1819	O
preparedness	1820	1832	O
is	1833	1835	O
education	1836	1845	O
and	1846	1849	O
raising	1850	1857	O
awareness	1858	1867	O
about	1868	1873	O
disaster	1874	1882	O
risks	1883	1888	O
and	1889	1892	O
response	1893	1901	O
plans	1902	1907	O
.	1907	1908	O

Had	1909	1912	O
there	1913	1918	O
been	1919	1923	O
greater	1924	1931	O
awareness	1932	1941	O
about	1942	1947	O
the	1948	1951	O
risk	1952	1956	O
of	1957	1959	O
tsunamis	1960	1968	O
,	1968	1969	O
perhaps	1970	1977	O
many	1978	1982	O
lives	1983	1988	O
could	1989	1994	O
have	1995	1999	O
been	2000	2004	O
saved	2005	2010	O
in	2011	2013	O
the	2014	2017	O
South	2018	2023	O
Asian	2024	2029	O
disaster	2030	2038	O
in	2039	2041	O
December	2042	2050	O
2004	2051	2055	O
.	2055	2056	O

Discussion	0	10	O

Among	11	16	O
adolescent	17	27	O
boys	28	32	O
in	33	35	O
Chapaevsk	36	45	O
,	45	46	O
Russia	47	53	O
,	53	54	O
higher	55	61	O
serum	62	67	B-Organism_substance
levels	68	74	O
of	75	77	O
sum	78	81	O
of	82	84	O
dioxin	85	91	O
-	91	92	O
like	92	96	O
compounds	97	106	O
and	107	110	O
sum	111	114	O
of	115	117	O
dioxin	118	124	O
TEQs	125	129	O
were	130	134	O
positively	135	145	O
associated	146	156	O
with	157	161	O
increased	162	171	O
age	172	175	O
,	175	176	O
consumption	177	188	O
of	189	191	O
fish	192	196	O
,	196	197	O
local	198	203	O
meats	204	209	B-Organism_subdivision
other	210	215	O
than	216	220	O
chicken	221	228	O
,	228	229	O
and	230	233	O
inversely	234	243	O
with	244	248	O
weeks	249	254	O
of	255	257	O
gestation	258	267	O
.	267	268	O

The	269	272	O
age	273	276	O
association	277	288	O
was	289	292	O
found	293	298	O
despite	299	306	O
a	307	308	O
narrow	309	315	O
age	316	319	O
range	320	325	O
of	326	328	O
slightly	329	337	O
over	338	342	O
two	343	346	O
years	347	352	O
in	353	355	O
our	356	359	O
study	360	365	O
.	365	366	O

Although	367	375	O
not	376	379	O
statistically	380	393	O
significant	394	405	O
,	405	406	O
the	407	410	O
distance	411	419	O
the	420	423	O
boy	424	427	O
lived	428	433	O
from	434	438	O
the	439	442	O
Khimprom	443	451	O
factory	452	459	O
at	460	462	O
the	463	466	O
time	467	471	O
of	472	474	O
blood	475	480	B-Organism_substance
draw	481	485	O
was	486	489	O
inversely	490	499	O
associated	500	510	O
with	511	515	O
serum	516	521	B-Organism_substance
levels	522	528	O
of	529	531	O
sum	532	535	O
of	536	538	O
dioxin	539	545	O
-	545	546	O
like	546	550	O
compounds	551	560	O
and	561	564	O
sum	565	568	O
of	569	571	O
dioxin	572	578	O
TEQs	579	583	O
.	583	584	O

As	585	587	O
expected	588	596	O
,	596	597	O
serum	598	603	B-Organism_substance
PCBs	604	608	O
,	608	609	O
specifically	610	622	O
PCB	623	626	O
118	627	630	O
,	630	631	O
were	632	636	O
strongly	637	645	O
associated	646	656	O
with	657	661	O
both	662	666	O
sum	667	670	O
of	671	673	O
dioxin	674	680	O
-	680	681	O
like	681	685	O
compounds	686	695	O
and	696	699	O
sum	700	703	O
of	704	706	O
dioxin	707	713	O
TEQs	714	718	O
.	718	719	O

There	720	725	O
was	726	729	O
no	730	732	O
association	733	744	O
between	745	752	O
the	753	756	O
distance	757	765	O
of	766	768	O
the	769	772	O
residence	773	782	O
from	783	787	O
the	788	791	O
Khimprom	792	800	O
plant	801	806	O
during	807	813	O
the	814	817	O
pregnancy	818	827	O
and	828	831	O
subsequent	832	842	O
serum	843	848	B-Organism_substance
dioxin	849	855	O
levels	856	862	O
.	862	863	O

One	864	867	O
potential	868	877	O
explanation	878	889	O
for	890	893	O
the	894	897	O
lack	898	902	O
of	903	905	O
association	906	917	O
may	918	921	O
include	922	929	O
misclassification	930	947	O
of	948	950	O
distance	951	959	O
since	960	965	O
the	966	969	O
mother	970	976	O
was	977	980	O
asked	981	986	O
to	987	989	O
recall	990	996	O
a	997	998	O
time	999	1003	O
period	1004	1010	O
more	1011	1015	O
than	1016	1020	O
14	1021	1023	O
years	1024	1029	O
prior	1030	1035	O
to	1036	1038	O
the	1039	1042	O
study	1043	1048	O
.	1048	1049	O

However	1050	1057	O
,	1057	1058	O
we	1059	1061	O
would	1062	1067	O
expect	1068	1074	O
that	1075	1079	O
the	1080	1083	O
mother	1084	1090	O
would	1091	1096	O
be	1097	1099	O
able	1100	1104	O
to	1105	1107	O
recall	1108	1114	O
residential	1115	1126	O
history	1127	1134	O
at	1135	1137	O
the	1138	1141	O
time	1142	1146	O
of	1147	1149	O
the	1150	1153	O
birth	1154	1159	O
of	1160	1162	O
their	1163	1168	O
son	1169	1172	O
.	1172	1173	O

Mother	1174	1180	O
'	1180	1181	O
s	1181	1182	O
self	1183	1187	O
-	1187	1188	O
reported	1188	1196	O
estimates	1197	1206	O
of	1207	1209	O
current	1210	1217	O
residential	1218	1229	O
distance	1230	1238	O
from	1239	1243	O
Khimprom	1244	1252	O
was	1253	1256	O
generally	1257	1266	O
accurate	1267	1275	O
;	1275	1276	O
twenty	1277	1283	O
-	1283	1284	O
one	1284	1287	O
of	1288	1290	O
twenty	1291	1297	O
-	1297	1298	O
nine	1298	1302	O
mothers	1303	1310	O
correctly	1311	1320	O
categorized	1321	1332	O
their	1333	1338	O
current	1339	1346	O
residential	1347	1358	O
distance	1359	1367	O
from	1368	1372	O
the	1373	1376	O
Khimprom	1377	1385	O
plants	1386	1392	O
based	1393	1398	O
on	1399	1401	O
cross	1402	1407	O
-	1407	1408	O
referencing	1408	1419	O
using	1420	1425	O
GIS	1426	1429	O
mapping	1430	1437	O
.	1437	1438	O

Other	1439	1444	O
explanations	1445	1457	O
include	1458	1465	O
that	1466	1470	O
prenatal	1471	1479	O
exposure	1480	1488	O
14	1489	1491	O
or	1492	1494	O
more	1495	1499	O
years	1500	1505	O
prior	1506	1511	O
to	1512	1514	O
the	1515	1518	O
current	1519	1526	O
serum	1527	1532	B-Organism_substance
sample	1533	1539	I-Organism_substance
is	1540	1542	O
not	1543	1546	O
as	1547	1549	O
strong	1550	1556	O
a	1557	1558	O
predictor	1559	1568	O
as	1569	1571	O
are	1572	1575	O
exposures	1576	1585	O
resulting	1586	1595	O
from	1596	1600	O
present	1601	1608	O
residential	1609	1620	O
location	1621	1629	O
.	1629	1630	O

Although	1631	1639	O
there	1640	1645	O
was	1646	1649	O
no	1650	1652	O
association	1653	1664	O
of	1665	1667	O
case	1668	1672	O
status	1673	1679	O
(	1680	1681	O
cryptorchidism	1681	1695	O
or	1696	1698	O
hypospadias	1699	1710	O
)	1710	1711	O
with	1712	1716	O
dioxin	1717	1723	O
levels	1724	1730	O
,	1730	1731	O
we	1732	1734	O
did	1735	1738	O
not	1739	1742	O
have	1743	1747	O
sufficient	1748	1758	O
power	1759	1764	O
to	1765	1767	O
definitively	1768	1780	O
assess	1781	1787	O
this	1788	1792	O
relationship	1793	1805	O
.	1805	1806	O

Perinatal	1807	1816	O
history	1817	1824	O
(	1825	1826	O
e	1826	1827	O
.	1827	1828	O
g	1828	1829	O
.	1829	1830	O
weeks	1831	1836	O
of	1837	1839	O
breastfeeding	1840	1853	O
)	1853	1854	O
was	1855	1858	O
generally	1859	1868	O
not	1869	1872	O
associated	1873	1883	O
with	1884	1888	O
exposure	1889	1897	O
measures	1898	1906	O
in	1907	1909	O
this	1910	1914	O
population	1915	1925	O
;	1925	1926	O
this	1927	1931	O
may	1932	1935	O
be	1936	1938	O
a	1939	1940	O
function	1941	1949	O
of	1950	1952	O
older	1953	1958	O
age	1959	1962	O
of	1963	1965	O
the	1966	1969	O
children	1970	1978	O
.	1978	1979	O

However	1980	1987	O
,	1987	1988	O
there	1989	1994	O
are	1995	1998	O
limited	1999	2006	O
data	2007	2011	O
on	2012	2014	O
the	2015	2018	O
relationship	2019	2031	O
of	2032	2034	O
perinatal	2035	2044	O
factors	2045	2052	O
with	2053	2057	O
organochlorine	2058	2072	O
exposures	2073	2082	O
in	2083	2085	O
this	2086	2090	O
age	2091	2094	O
group	2095	2100	O
so	2101	2103	O
a	2104	2105	O
null	2106	2110	O
finding	2111	2118	O
is	2119	2121	O
of	2122	2124	O
interest	2125	2133	O
given	2134	2139	O
reports	2140	2147	O
that	2148	2152	O
differences	2153	2164	O
in	2165	2167	O
organochlorine	2168	2182	O
levels	2183	2189	O
among	2190	2195	O
breastfed	2196	2205	O
and	2206	2209	O
non	2210	2213	O
-	2213	2214	O
breastfed	2214	2223	O
are	2224	2227	O
generally	2228	2237	O
no	2238	2240	O
longer	2241	2247	O
discernable	2248	2259	O
by	2260	2262	O
early	2263	2268	O
school	2269	2275	O
age	2276	2279	O
[	2280	2281	O
24	2281	2283	O
,	2283	2284	O
25	2284	2286	O
]	2286	2287	O
and	2288	2291	O
,	2291	2292	O
furthermore	2293	2304	O
,	2304	2305	O
that	2306	2310	O
dietary	2311	2318	O
intake	2319	2325	O
after	2326	2331	O
this	2332	2336	O
age	2337	2340	O
contributes	2341	2352	O
significantly	2353	2366	O
to	2367	2369	O
total	2370	2375	O
dioxin	2376	2382	O
intake	2383	2389	O
[	2390	2391	O
26	2391	2393	O
]	2393	2394	O
.	2394	2395	O

In	2396	2398	O
prior	2399	2404	O
studies	2405	2412	O
,	2412	2413	O
substantial	2414	2425	O
emphasis	2426	2434	O
has	2435	2438	O
been	2439	2443	O
placed	2444	2450	O
on	2451	2453	O
pre	2454	2457	O
-	2457	2458	O
and	2459	2462	O
early	2463	2468	O
postnatal	2469	2478	O
(	2479	2480	O
via	2480	2483	O
breastfeeding	2484	2497	O
)	2497	2498	O
exposures	2499	2508	O
because	2509	2516	O
of	2517	2519	O
particular	2520	2530	O
vulnerability	2531	2544	O
during	2545	2551	O
fetal	2552	2557	B-Developing_anatomical_structure
and	2558	2561	O
early	2562	2567	O
infant	2568	2574	O
development	2575	2586	O
.	2586	2587	O

The	2588	2591	O
exposure	2592	2600	O
risk	2601	2605	O
factors	2606	2613	O
during	2614	2620	O
peri	2621	2625	O
-	2625	2626	O
adolescence	2626	2637	O
,	2637	2638	O
another	2639	2646	O
period	2647	2653	O
of	2654	2656	O
potential	2657	2666	O
developmental	2667	2680	O
vulnerability	2681	2694	O
,	2694	2695	O
has	2696	2699	O
not	2700	2703	O
been	2704	2708	O
studied	2709	2716	O
in	2717	2719	O
-	2719	2720	O
detail	2720	2726	O
,	2726	2727	O
therefore	2728	2737	O
,	2737	2738	O
the	2739	2742	O
identification	2743	2757	O
of	2758	2760	O
exposure	2761	2769	O
risk	2770	2774	O
factors	2775	2782	O
specific	2783	2791	O
to	2792	2794	O
this	2795	2799	O
period	2800	2806	O
will	2807	2811	O
enhance	2812	2819	O
our	2820	2823	O
understanding	2824	2837	O
of	2838	2840	O
this	2841	2845	O
critical	2846	2854	O
period	2855	2861	O
.	2861	2862	O

Although	2863	2871	O
data	2872	2876	O
on	2877	2879	O
levels	2880	2886	O
of	2887	2889	O
PCDD	2890	2894	O
/	2894	2895	O
PCDFs	2895	2900	O
in	2901	2903	O
children	2904	2912	O
is	2913	2915	O
limited	2916	2923	O
,	2923	2924	O
our	2925	2928	O
results	2929	2936	O
suggest	2937	2944	O
that	2945	2949	O
the	2950	2953	O
mean	2954	2958	O
total	2959	2964	O
TEQs	2965	2969	O
among	2970	2975	O
Chapaevsk	2976	2985	O
adolescents	2986	2997	O
were	2998	3002	O
higher	3003	3009	O
than	3010	3014	O
most	3015	3019	O
values	3020	3026	O
previously	3027	3037	O
reported	3038	3046	O
in	3047	3049	O
non	3050	3053	O
-	3053	3054	O
occupationally	3054	3068	O
exposed	3069	3076	O
populations	3077	3088	O
of	3089	3091	O
comparable	3092	3102	O
or	3103	3105	O
even	3106	3110	O
older	3111	3116	O
ages	3117	3121	O
.	3121	3122	O

Figure	3123	3129	O
2	3130	3131	O
shows	3132	3137	O
a	3138	3139	O
comparison	3140	3150	O
of	3151	3153	O
the	3154	3157	O
mean	3158	3162	O
PCDD	3163	3167	O
/	3167	3168	O
PCDFs	3168	3173	O
TEQ	3174	3177	O
levels	3178	3184	O
in	3185	3187	O
Chapaevsk	3188	3197	O
boys	3198	3202	O
with	3203	3207	O
other	3208	3213	O
populations	3214	3225	O
(	3226	3227	O
TEQ	3227	3230	O
from	3231	3235	O
dioxin	3236	3242	O
-	3242	3243	O
like	3243	3247	O
PCBs	3248	3252	O
was	3253	3256	O
not	3257	3260	O
included	3261	3269	O
,	3269	3270	O
since	3271	3276	O
some	3277	3281	O
of	3282	3284	O
these	3285	3290	O
studies	3291	3298	O
did	3299	3302	O
not	3303	3306	O
report	3307	3313	O
them	3314	3318	O
)	3318	3319	O
.	3319	3320	O

The	3321	3324	O
mean	3325	3329	O
TEQs	3330	3334	O
of	3335	3337	O
pooled	3338	3344	O
blood	3345	3350	B-Organism_substance
samples	3351	3358	I-Organism_substance
from	3359	3363	O
10	3364	3366	O
year	3367	3371	O
-	3371	3372	O
old	3372	3375	O
German	3376	3382	O
boys	3383	3387	O
in	3388	3390	O
rural	3391	3396	O
and	3397	3400	O
urban	3401	3406	O
settings	3407	3415	O
was	3416	3419	O
8	3420	3421	O
.	3421	3422	O
2	3422	3423	O
pg	3424	3426	O
TEQ	3427	3430	O
/	3430	3431	O
g	3431	3432	O
lipid	3433	3438	O
for	3439	3442	O
an	3443	3445	O
urban	3446	3451	O
industrial	3452	3462	O
area	3463	3467	O
,	3467	3468	O
9	3469	3470	O
.	3470	3471	O
0	3471	3472	O
pg	3473	3475	O
TEQ	3476	3479	O
/	3479	3480	O
g	3480	3481	O
lipid	3482	3487	O
for	3488	3491	O
an	3492	3494	O
industrial	3495	3505	O
area	3506	3510	O
within	3511	3517	O
a	3518	3519	O
rural	3520	3525	O
setting	3526	3533	O
,	3533	3534	O
and	3535	3538	O
10	3539	3541	O
.	3541	3542	O
1	3542	3543	O
pg	3544	3546	O
TEQ	3547	3550	O
/	3550	3551	O
g	3551	3552	O
lipid	3553	3558	O
for	3559	3562	O
a	3563	3564	O
rural	3565	3570	O
area	3571	3575	O
[	3576	3577	O
27	3577	3579	O
]	3579	3580	O
.	3580	3581	O

In	3582	3584	O
comparison	3585	3595	O
,	3595	3596	O
the	3597	3600	O
mean	3601	3605	O
TEQ	3606	3609	O
in	3610	3612	O
the	3613	3616	O
Chapevsk	3617	3625	O
boys	3626	3630	O
was	3631	3634	O
19	3635	3637	O
.	3637	3638	O
3	3638	3639	O
pg	3640	3642	O
TEQ	3643	3646	O
/	3646	3647	O
g	3647	3648	O
lipid	3649	3654	O
.	3654	3655	O

With	3656	3660	O
the	3661	3664	O
exception	3665	3674	O
of	3675	3677	O
children	3678	3686	O
described	3687	3696	O
by	3697	3699	O
Wuthe	3700	3705	O
et	3706	3708	O
al	3709	3711	O
.	3711	3712	O

[	3713	3714	O
27	3714	3716	O
]	3716	3717	O
,	3717	3718	O
subjects	3719	3727	O
in	3728	3730	O
the	3731	3734	O
other	3735	3740	O
studies	3741	3748	O
in	3749	3751	O
Figure	3752	3758	O
2	3759	3760	O
were	3761	3765	O
significantly	3766	3779	O
older	3780	3785	O
than	3786	3790	O
the	3791	3794	O
Chapaevsk	3795	3804	O
boys	3805	3809	O
.	3809	3810	O

Despite	3811	3818	O
age	3819	3822	O
differences	3823	3834	O
,	3834	3835	O
the	3836	3839	O
mean	3840	3844	O
TEQ	3845	3848	O
in	3849	3851	O
Chapaevsk	3852	3861	O
boys	3862	3866	O
was	3867	3870	O
comparable	3871	3881	O
to	3882	3884	O
or	3885	3887	O
even	3888	3892	O
higher	3893	3899	O
than	3900	3904	O
the	3905	3908	O
mean	3909	3913	O
TEQ	3914	3917	O
in	3918	3920	O
older	3921	3926	O
populations	3927	3938	O
from	3939	3943	O
other	3944	3949	O
countries	3950	3959	O
.	3959	3960	O

For	3961	3964	O
example	3965	3972	O
,	3972	3973	O
they	3974	3978	O
were	3979	3983	O
higher	3984	3990	O
than	3991	3995	O
mean	3996	4000	O
TEQs	4001	4005	O
of	4006	4008	O
18	4009	4011	O
.	4011	4012	O
4	4012	4013	O
pg	4014	4016	O
TEQ	4017	4020	O
/	4020	4021	O
g	4021	4022	O
lipid	4023	4028	O
in	4029	4031	O
adults	4032	4038	O
(	4039	4040	O
40	4040	4042	O
.	4042	4043	O
6	4043	4044	O
years	4045	4050	O
old	4051	4054	O
average	4055	4062	O
)	4062	4063	O
from	4064	4068	O
South	4069	4074	O
Germany	4075	4082	O
[	4083	4084	O
27	4084	4086	O
]	4086	4087	O
or	4088	4090	O
16	4091	4093	O
.	4093	4094	O
4	4094	4095	O
pg	4096	4098	O
TEQ	4099	4102	O
/	4102	4103	O
g	4103	4104	O
lipid	4105	4110	O
from	4111	4115	O
20	4116	4118	O
year	4119	4123	O
old	4124	4127	O
Japanese	4128	4136	O
women	4137	4142	O
[	4143	4144	O
28	4144	4146	O
]	4146	4147	O
or	4148	4150	O
pooled	4151	4157	O
samples	4158	4165	B-Organism_substance
from	4166	4170	O
randomly	4171	4179	O
selected	4180	4188	O
males	4189	4194	O
and	4195	4198	O
females	4199	4206	O
18	4207	4209	O
-	4209	4210	O
69	4210	4212	O
years	4213	4218	O
of	4219	4221	O
age	4222	4225	O
from	4226	4230	O
the	4231	4234	O
Spanish	4235	4242	O
city	4243	4247	O
of	4248	4250	O
Mataro	4251	4257	O
[	4258	4259	O
29	4259	4261	O
]	4261	4262	O
,	4262	4263	O
which	4264	4269	O
were	4270	4274	O
12	4275	4277	O
.	4277	4278	O
5	4278	4279	O
and	4280	4283	O
14	4284	4286	O
.	4286	4287	O
7	4287	4288	O
pg	4289	4291	O
TEQ	4292	4295	O
/	4295	4296	O
g	4296	4297	O
lipid	4298	4303	O
respectively	4304	4316	O
.	4316	4317	O

The	4318	4321	O
mean	4322	4326	O
levels	4327	4333	O
in	4334	4336	O
adult	4337	4342	O
female	4343	4349	O
(	4350	4351	O
mean	4351	4355	O
age	4356	4359	O
41	4360	4362	O
years	4363	4368	O
)	4368	4369	O
non	4370	4373	O
-	4373	4374	O
factory	4374	4381	O
workers	4382	4389	O
in	4390	4392	O
the	4393	4396	O
Russian	4397	4404	O
city	4405	4409	O
of	4410	4412	O
Shelekhovo	4413	4423	O
were	4424	4428	O
also	4429	4433	O
lower	4434	4439	O
at	4440	4442	O
14	4443	4445	O
.	4445	4446	O
5	4446	4447	O
pg	4448	4450	O
TEQ	4451	4454	O
/	4454	4455	O
g	4455	4456	O
lipid	4457	4462	O
[	4463	4464	O
30	4464	4466	O
]	4466	4467	O
.	4467	4468	O

Mean	4469	4473	O
TEQs	4474	4478	O
for	4479	4482	O
the	4483	4486	O
general	4487	4494	O
population	4495	4505	O
(	4506	4507	O
mean	4507	4511	O
age	4512	4515	O
44	4516	4518	O
.	4518	4519	O
2	4519	4520	O
years	4521	4526	O
)	4526	4527	O
in	4528	4530	O
Germany	4531	4538	O
,	4538	4539	O
collected	4540	4549	O
in	4550	4552	O
1997	4553	4557	O
-	4557	4558	O
98	4558	4560	O
[	4561	4562	O
31	4562	4564	O
]	4564	4565	O
,	4565	4566	O
and	4567	4570	O
median	4571	4577	O
TEQs	4578	4582	O
for	4583	4586	O
long	4587	4591	O
-	4591	4592	O
term	4592	4596	O
workers	4597	4604	O
of	4605	4607	O
pulp	4608	4612	O
and	4613	4616	O
paper	4617	4622	O
mill	4623	4627	O
and	4628	4631	O
non	4632	4635	O
-	4635	4636	O
workers	4636	4643	O
in	4644	4646	O
the	4647	4650	O
U	4651	4652	O
.	4652	4653	O
S	4653	4654	O
.	4654	4655	O
in	4656	4658	O
1996	4659	4663	O
[	4664	4665	O
32	4665	4667	O
]	4667	4668	O
were	4669	4673	O
similar	4674	4681	O
to	4682	4684	O
levels	4685	4691	O
found	4692	4697	O
in	4698	4700	O
the	4701	4704	O
Chapaevsk	4705	4714	O
boys	4715	4719	O
.	4719	4720	O

The	4721	4724	O
mean	4725	4729	O
levels	4730	4736	O
in	4737	4739	O
the	4740	4743	O
study	4744	4749	O
in	4750	4752	O
Germany	4753	4760	O
were	4761	4765	O
20	4766	4768	O
.	4768	4769	O
71	4769	4771	O
pg	4772	4774	O
TEQ	4775	4778	O
/	4778	4779	O
g	4779	4780	O
lipid	4781	4786	O
and	4787	4790	O
in	4791	4793	O
the	4794	4797	O
U	4798	4799	O
.	4799	4800	O
S	4800	4801	O
.	4801	4802	O
the	4803	4806	O
median	4807	4813	O
levels	4814	4820	O
were	4821	4825	O
19	4826	4828	O
.	4828	4829	O
1	4829	4830	O
pg	4831	4833	O
TEQ	4834	4837	O
/	4837	4838	O
g	4838	4839	O
lipid	4840	4845	O
for	4846	4849	O
community	4850	4859	O
residents	4860	4869	O
and	4870	4873	O
21	4874	4876	O
.	4876	4877	O
2	4877	4878	O
pg	4879	4881	O
TEQ	4882	4885	O
/	4885	4886	O
g	4886	4887	O
lipid	4888	4893	O
for	4894	4897	O
low	4898	4901	O
exposure	4902	4910	O
workers	4911	4918	O
.	4918	4919	O

Figure	4920	4926	O
2	4927	4928	O

Mean	4929	4933	O
PCDD	4934	4938	O
/	4938	4939	O
PCDFs	4939	4944	O
TEQ	4945	4948	O
levels	4949	4955	O
in	4956	4958	O
Chapaevsk	4959	4968	O
boys	4969	4973	O
in	4974	4976	O
comparison	4977	4987	O
with	4988	4992	O
other	4993	4998	O
populations	4999	5010	O
.	5010	5011	O

Although	5012	5020	O
TCDD	5021	5025	O
was	5026	5029	O
largely	5030	5037	O
below	5038	5043	O
the	5044	5047	O
detection	5048	5057	O
limits	5058	5064	O
in	5065	5067	O
this	5068	5072	O
small	5073	5078	O
pilot	5079	5084	O
sample	5085	5091	B-Organism_substance
,	5091	5092	O
the	5093	5096	O
two	5097	5100	O
boys	5101	5105	O
with	5106	5110	O
detectable	5111	5121	O
values	5122	5128	O
had	5129	5132	O
high	5133	5137	O
TCDD	5138	5142	O
levels	5143	5149	O
(	5150	5151	O
17	5151	5153	O
.	5153	5154	O
9	5154	5155	O
and	5156	5159	O
21	5160	5162	O
.	5162	5163	O
7	5163	5164	O
pg	5165	5167	O
/	5167	5168	O
g	5168	5169	O
lipid	5170	5175	O
)	5175	5176	O
,	5176	5177	O
suggesting	5178	5188	O
that	5189	5193	O
exposure	5194	5202	O
for	5203	5206	O
at	5207	5209	O
least	5210	5215	O
some	5216	5220	O
portion	5221	5228	O
of	5229	5231	O
this	5232	5236	O
population	5237	5247	O
is	5248	5250	O
substantially	5251	5264	O
higher	5265	5271	O
than	5272	5276	O
typical	5277	5284	O
of	5285	5287	O
this	5288	5292	O
age	5293	5296	O
group	5297	5302	O
.	5302	5303	O

In	5304	5306	O
comparison	5307	5317	O
,	5317	5318	O
in	5319	5321	O
a	5322	5323	O
cohort	5324	5330	O
of	5331	5333	O
adult	5334	5339	O
(	5340	5341	O
mean	5341	5345	O
age	5346	5349	O
of	5350	5352	O
58	5353	5355	O
years	5356	5361	O
)	5361	5362	O
fishermen	5363	5372	O
from	5373	5377	O
a	5378	5379	O
polluted	5380	5388	O
region	5389	5395	O
of	5396	5398	O
Finland	5399	5406	O
,	5406	5407	O
the	5408	5411	O
mean	5412	5416	O
TCDD	5417	5421	O
concentration	5422	5435	O
was	5436	5439	O
19	5440	5442	O
pg	5443	5445	O
/	5445	5446	O
g	5446	5447	O
lipid	5448	5453	O
[	5454	5455	O
33	5455	5457	O
]	5457	5458	O
.	5458	5459	O

In	5460	5462	O
adult	5463	5468	O
(	5469	5470	O
mean	5470	5474	O
age	5475	5478	O
of	5479	5481	O
53	5482	5484	O
years	5485	5490	O
)	5490	5491	O
residents	5492	5501	O
from	5502	5506	O
Calcasieu	5507	5516	O
Parish	5517	5523	O
,	5523	5524	O
Louisiana	5525	5534	O
,	5534	5535	O
which	5536	5541	O
is	5542	5544	O
near	5545	5549	O
a	5550	5551	O
chemical	5552	5560	O
industrial	5561	5571	O
complex	5572	5579	O
,	5579	5580	O
the	5581	5584	O
mean	5585	5589	O
TCDD	5590	5594	O
level	5595	5600	O
was	5601	5604	O
7	5605	5606	O
.	5606	5607	O
6	5607	5608	O
pg	5609	5611	O
/	5611	5612	O
g	5612	5613	O
lipid	5614	5619	O
[	5620	5621	O
34	5621	5623	O
]	5623	5624	O
.	5624	5625	O

Not	5626	5629	O
only	5630	5634	O
were	5635	5639	O
the	5640	5643	O
dioxin	5644	5650	O
levels	5651	5657	O
in	5658	5660	O
these	5661	5666	O
two	5667	5670	O
children	5671	5679	O
higher	5680	5686	O
than	5687	5691	O
those	5692	5697	O
found	5698	5703	O
in	5704	5706	O
these	5707	5712	O
studies	5713	5720	O
,	5720	5721	O
but	5722	5725	O
the	5726	5729	O
adults	5730	5736	O
in	5737	5739	O
the	5740	5743	O
previous	5744	5752	O
studies	5753	5760	O
were	5761	5765	O
several	5766	5773	O
decades	5774	5781	O
older	5782	5787	O
and	5788	5791	O
therefore	5792	5801	O
would	5802	5807	O
be	5808	5810	O
expected	5811	5819	O
to	5820	5822	O
have	5823	5827	O
higher	5828	5834	O
dioxin	5835	5841	O
body	5842	5846	B-Organism_subdivision
burdens	5847	5854	O
than	5855	5859	O
younger	5860	5867	O
children	5868	5876	O
[	5877	5878	O
35	5878	5880	O
]	5880	5881	O
.	5881	5882	O

Potential	5883	5892	O
explanations	5893	5905	O
for	5906	5909	O
the	5910	5913	O
large	5914	5919	O
number	5920	5926	O
of	5927	5929	O
non	5930	5933	O
-	5933	5934	O
detectable	5934	5944	O
samples	5945	5952	B-Organism_substance
for	5953	5956	O
TCDD	5957	5961	O
include	5962	5969	O
the	5970	5973	O
small	5974	5979	O
sample	5980	5986	B-Organism_substance
volume	5987	5993	O
and	5994	5997	O
young	5998	6003	O
age	6004	6007	O
of	6008	6010	O
the	6011	6014	O
subjects	6015	6023	O
.	6023	6024	O

In	6025	6027	O
our	6028	6031	O
future	6032	6038	O
studies	6039	6046	O
in	6047	6049	O
this	6050	6054	O
population	6055	6065	O
,	6065	6066	O
we	6067	6069	O
will	6070	6074	O
collect	6075	6082	O
larger	6083	6089	O
volumes	6090	6097	O
of	6098	6100	O
serum	6101	6106	B-Organism_substance
for	6107	6110	O
dioxin	6111	6117	O
analysis	6118	6126	O
.	6126	6127	O

In	6128	6130	O
one	6131	6134	O
of	6135	6137	O
the	6138	6141	O
few	6142	6145	O
studies	6146	6153	O
on	6154	6156	O
dioxin	6157	6163	O
-	6163	6164	O
like	6164	6168	O
compounds	6169	6178	O
in	6179	6181	O
which	6182	6187	O
children	6188	6196	O
were	6197	6201	O
included	6202	6210	O
,	6210	6211	O
Eskenazi	6212	6220	O
and	6221	6224	O
coworkers	6225	6234	O
[	6235	6236	O
36	6236	6238	O
]	6238	6239	O
evaluated	6240	6249	O
the	6250	6253	O
relationship	6254	6266	O
between	6267	6274	O
serum	6275	6280	B-Organism_substance
TCDD	6281	6285	O
concentrations	6286	6300	O
and	6301	6304	O
age	6305	6308	O
at	6309	6311	O
exposure	6312	6320	O
of	6321	6323	O
female	6324	6330	O
residents	6331	6340	O
of	6341	6343	O
Seveso	6344	6350	O
,	6350	6351	O
Italy	6352	6357	O
.	6357	6358	O

Residents	6359	6368	O
near	6369	6373	O
the	6374	6377	O
ICMESA	6378	6384	O
chemical	6385	6393	O
plant	6394	6399	O
in	6400	6402	O
Seveso	6403	6409	O
were	6410	6414	O
exposed	6415	6422	O
to	6423	6425	O
some	6426	6430	O
of	6431	6433	O
the	6434	6437	O
highest	6438	6445	O
known	6446	6451	O
residential	6452	6463	O
levels	6464	6470	O
of	6471	6473	O
2	6474	6475	O
,	6475	6476	O
3	6476	6477	O
,	6477	6478	O
7	6478	6479	O
,	6479	6480	O
8	6480	6481	O
-	6481	6482	O
TCDD	6482	6486	O
as	6487	6489	O
a	6490	6491	O
result	6492	6498	O
of	6499	6501	O
an	6502	6504	O
explosion	6505	6514	O
at	6515	6517	O
the	6518	6521	O
plant	6522	6527	O
.	6527	6528	O

Archived	6529	6537	O
serum	6538	6543	B-Organism_substance
collected	6544	6553	O
near	6554	6558	O
the	6559	6562	O
time	6563	6567	O
of	6568	6570	O
the	6571	6574	O
accident	6575	6583	O
was	6584	6587	O
used	6588	6592	O
to	6593	6595	O
measure	6596	6603	O
exposures	6604	6613	O
.	6613	6614	O

Residents	6615	6624	O
closest	6625	6632	O
to	6633	6635	O
the	6636	6639	O
plant	6640	6645	O
had	6646	6649	O
a	6650	6651	O
median	6652	6658	O
2	6659	6660	O
,	6660	6661	O
3	6661	6662	O
,	6662	6663	O
7	6663	6664	O
,	6664	6665	O
8	6665	6666	O
-	6666	6667	O
TCDD	6667	6671	O
level	6672	6677	O
of	6678	6680	O
272	6681	6684	O
ppt	6685	6688	O
(	6689	6690	O
IQR	6690	6693	O
92	6694	6696	O
-	6697	6698	O
883	6699	6702	O
ppt	6703	6706	O
)	6706	6707	O
.	6707	6708	O

Residential	6709	6720	O
proximity	6721	6730	O
to	6731	6733	O
the	6734	6737	O
plant	6738	6743	O
and	6744	6747	O
younger	6748	6755	O
age	6756	6759	O
(	6760	6761	O
up	6761	6763	O
to	6764	6766	O
13	6767	6769	O
years	6770	6775	O
old	6776	6779	O
)	6779	6780	O
were	6781	6785	O
the	6786	6789	O
strongest	6790	6799	O
predictors	6800	6810	O
of	6811	6813	O
an	6814	6816	O
individual	6817	6827	O
'	6827	6828	O
s	6828	6829	O
serum	6830	6835	B-Organism_substance
2	6836	6837	O
,	6837	6838	O
3	6838	6839	O
,	6839	6840	O
7	6840	6841	O
,	6841	6842	O
8	6842	6843	O
-	6843	6844	O
TCDD	6844	6848	O
level	6849	6854	O
.	6854	6855	O

Other	6856	6861	O
predictors	6862	6872	O
included	6873	6881	O
being	6882	6887	O
outdoors	6888	6896	O
at	6897	6899	O
the	6900	6903	O
time	6904	6908	O
of	6909	6911	O
explosion	6912	6921	O
and	6922	6925	O
consumption	6926	6937	O
of	6938	6940	O
homegrown	6941	6950	O
food	6951	6955	O
.	6955	6956	O

The	6957	6960	O
higher	6961	6967	O
levels	6968	6974	O
found	6975	6980	O
in	6981	6983	O
children	6984	6992	O
were	6993	6997	O
most	6998	7002	O
likely	7003	7009	O
a	7010	7011	O
result	7012	7018	O
of	7019	7021	O
increased	7022	7031	O
exposure	7032	7040	O
as	7041	7043	O
a	7044	7045	O
result	7046	7052	O
of	7053	7055	O
activity	7056	7064	O
patterns	7065	7073	O
and	7074	7077	O
a	7078	7079	O
greater	7080	7087	O
proportionate	7088	7101	O
consumption	7102	7113	O
of	7114	7116	O
food	7117	7121	O
,	7121	7122	O
water	7123	7128	O
and	7129	7132	O
air	7133	7136	O
than	7137	7141	O
adults	7142	7148	O
[	7149	7150	O
37	7150	7152	O
]	7152	7153	O
.	7153	7154	O

Although	7155	7163	O
the	7164	7167	O
exposure	7168	7176	O
scenario	7177	7185	O
(	7186	7187	O
an	7187	7189	O
acute	7190	7195	O
high	7196	7200	O
exposure	7201	7209	O
event	7210	7215	O
)	7215	7216	O
is	7217	7219	O
different	7220	7229	O
than	7230	7234	O
the	7235	7238	O
chronic	7239	7246	O
low	7247	7250	O
/	7250	7251	O
moderate	7251	7259	O
exposure	7260	7268	O
occurring	7269	7278	O
in	7279	7281	O
Chapaevsk	7282	7291	O
,	7291	7292	O
the	7293	7296	O
results	7297	7304	O
from	7305	7309	O
Seveso	7310	7316	O
suggest	7317	7324	O
that	7325	7329	O
children	7330	7338	O
may	7339	7342	O
be	7343	7345	O
at	7346	7348	O
increased	7349	7358	O
risk	7359	7363	O
for	7364	7367	O
high	7368	7372	O
dioxin	7373	7379	O
exposure	7380	7388	O
from	7389	7393	O
environmental	7394	7407	O
contamination	7408	7421	O
.	7421	7422	O

In	7423	7425	O
our	7426	7429	O
study	7430	7435	O
,	7435	7436	O
although	7437	7445	O
distance	7446	7454	O
from	7455	7459	O
the	7460	7463	O
Khimprom	7464	7472	O
plants	7473	7479	O
was	7480	7483	O
a	7484	7485	O
weak	7486	7490	O
predictor	7491	7500	O
of	7501	7503	O
serum	7504	7509	B-Organism_substance
dioxin	7510	7516	O
-	7516	7517	O
like	7517	7521	O
compounds	7522	7531	O
,	7531	7532	O
consumption	7533	7544	O
of	7545	7547	O
local	7548	7553	O
foods	7554	7559	O
(	7560	7561	O
specifically	7561	7573	O
meat	7574	7578	B-Organism_subdivision
and	7579	7582	O
fish	7583	7587	O
)	7587	7588	O
,	7588	7589	O
as	7590	7592	O
in	7593	7595	O
the	7596	7599	O
Seveso	7600	7606	O
study	7607	7612	O
,	7612	7613	O
was	7614	7617	O
a	7618	7619	O
strong	7620	7626	O
predictor	7627	7636	O
of	7637	7639	O
sum	7640	7643	O
of	7644	7646	O
dioxin	7647	7653	O
-	7653	7654	O
like	7654	7658	O
compounds	7659	7668	O
and	7669	7672	O
dioxin	7673	7679	O
TEQs	7680	7684	O
.	7684	7685	O

This	7686	7690	O
finding	7691	7698	O
is	7699	7701	O
notable	7702	7709	O
given	7710	7715	O
concerns	7716	7724	O
regarding	7725	7734	O
environmental	7735	7748	O
dioxin	7749	7755	O
contamination	7756	7769	O
in	7770	7772	O
the	7773	7776	O
community	7777	7786	O
and	7787	7790	O
suggests	7791	7799	O
that	7800	7804	O
food	7805	7809	O
may	7810	7813	O
be	7814	7816	O
one	7817	7820	O
of	7821	7823	O
the	7824	7827	O
more	7828	7832	O
,	7832	7833	O
if	7834	7836	O
not	7837	7840	O
most	7841	7845	O
,	7845	7846	O
important	7847	7856	O
routes	7857	7863	O
of	7864	7866	O
environmental	7867	7880	O
contaminant	7881	7892	O
exposure	7893	7901	O
for	7902	7905	O
residents	7906	7915	O
in	7916	7918	O
this	7919	7923	O
setting	7924	7931	O
.	7931	7932	O

In	7933	7935	O
other	7936	7941	O
settings	7942	7950	O
,	7950	7951	O
contaminated	7952	7964	O
food	7965	7969	O
generally	7970	7979	O
contributes	7980	7991	O
much	7992	7996	O
more	7997	8001	O
substantially	8002	8015	O
to	8016	8018	O
human	8019	8024	O
organochlorine	8025	8039	O
burden	8040	8046	O
than	8047	8051	O
air	8052	8055	O
or	8056	8058	O
soil	8059	8063	O
(	8064	8065	O
which	8065	8070	O
may	8071	8074	O
be	8075	8077	O
related	8078	8085	O
to	8086	8088	O
residential	8089	8100	O
proximity	8101	8110	O
to	8111	8113	O
pollutant	8114	8123	O
sources	8124	8131	O
)	8131	8132	O
[	8133	8134	O
6	8134	8135	O
]	8135	8136	O
.	8136	8137	O

We	8138	8140	O
will	8141	8145	O
investigate	8146	8157	O
this	8158	8162	O
issue	8163	8168	O
in	8169	8171	O
more	8172	8176	O
detail	8177	8183	O
in	8184	8186	O
our	8187	8190	O
ongoing	8191	8198	O
study	8199	8204	O
.	8204	8205	O

Figures	0	7	O
and	8	11	O
Tables	12	18	O

Figure	19	25	O
1	26	27	O

Allergen	28	36	O
and	37	40	O
particle	41	49	O
dose	50	54	O
-	54	55	O
response	55	63	O
experiments	64	75	O
in	76	78	O
BALB	79	83	O
/	83	84	O
cA	84	86	O
and	87	90	O
NIH	91	94	O
mice	95	99	O
Levels	100	106	O
of	107	109	O
serum	110	115	B-Organism_substance
OVA	116	119	O
-	119	120	O
specific	120	128	O
IgE	129	132	O
(	133	134	O
A	134	135	O
,	135	136	O
D	137	138	O
)	138	139	O
,	139	140	O
IgG1	141	145	O
(	146	147	O
B	147	148	O
,	148	149	O
E	150	151	O
)	151	152	O
and	153	156	O
IgG2a	157	162	O
(	163	164	O
C	164	165	O
,	165	166	O
F	167	168	O
)	168	169	O
on	170	172	O
day	173	176	O
26	177	179	O
after	180	185	O
injection	186	195	O
into	196	200	O
one	201	204	O
hind	205	209	B-Organism_subdivision
footpad	210	217	I-Organism_subdivision
of	218	220	O
100	221	224	O
(	225	226	O
open	226	230	O
columns	231	238	O
)	238	239	O
,	239	240	O
50	241	243	O
(	244	245	O
gray	245	249	O
)	249	250	O
or	251	253	O
10	254	256	O
(	257	258	O
black	258	263	O
)	263	264	O
mug	265	268	O
OVA	269	272	O
combined	273	281	O
with	282	286	O
100	287	290	O
,	290	291	O
40	292	294	O
,	294	295	O
10	296	298	O
or	299	301	O
0	302	303	O
mug	304	307	O
PSP	308	311	O
,	311	312	O
or	313	315	O
buffer	316	322	O
(	323	324	O
HBSS	324	328	O
(	329	330	O
hatched	330	337	O
)	337	338	O
)	338	339	O
,	339	340	O
in	341	343	O
BALB	344	348	O
/	348	349	O
cA	349	351	O
(	352	353	O
A	353	354	O
,	354	355	O
B	356	357	O
,	357	358	O
C	359	360	O
)	360	361	O
and	362	365	O
NIH	366	369	O
(	370	371	O
D	371	372	O
,	372	373	O
E	374	375	O
,	375	376	O
F	377	378	O
)	378	379	O
mice	380	384	O
.	384	385	O

On	386	388	O
day	389	392	O
21	393	395	O
the	396	399	O
mice	400	404	O
were	405	409	O
boostered	410	419	O
with	420	424	O
the	425	428	O
same	429	433	O
OVA	434	437	O
dose	438	442	O
in	443	445	O
the	446	449	O
footpad	450	457	B-Organism_subdivision
.	457	458	O

The	459	462	O
PSP	463	466	O
-	466	467	O
control	467	474	O
(	475	476	O
"	476	477	O
PSP	477	480	O
ctr	481	484	O
"	484	485	O
)	485	486	O
group	487	492	O
was	493	496	O
given	497	502	O
100	503	506	O
mug	507	510	O
PSP	511	514	O
on	515	517	O
day	518	521	O
0	522	523	O
,	523	524	O
followed	525	533	O
by	534	536	O
HBSS	537	541	O
injection	542	551	O
on	552	554	O
day	555	558	O
21	559	561	O
(	562	563	O
diamonds	563	571	O
)	571	572	O
.	572	573	O

Values	574	580	O
(	581	582	O
arbitrary	582	591	O
units	592	597	O
,	597	598	O
AU	599	601	O
)	601	602	O
for	603	606	O
individual	607	617	O
mice	618	622	O
(	623	624	O
circles	624	631	O
)	631	632	O
and	633	636	O
median	637	643	O
values	644	650	O
(	651	652	O
columns	652	659	O
)	659	660	O
for	661	664	O
groups	665	671	O
of	672	674	O
eight	675	680	O
mice	681	685	O
are	686	689	O
shown	690	695	O
.	695	696	O

Dotted	697	703	O
lines	704	709	O
indicate	710	718	O
the	719	722	O
lower	723	728	O
or	729	731	O
higher	732	738	O
detection	739	748	O
limits	749	755	O
for	756	759	O
the	760	763	O
ELISA	764	769	O
assays	770	776	O
.	776	777	O

Note	778	782	O
different	783	792	O
scales	793	799	O
for	800	803	O
the	804	807	O
two	808	811	O
strains	812	819	O
of	820	822	O
mice	823	827	O
.	827	828	O

Figure	829	835	O
2	836	837	O

The	838	841	O
adjuvant	842	850	O
effect	851	857	O
of	858	860	O
PSP	861	864	O
on	865	867	O
OVA	868	871	O
-	871	872	O
specific	872	880	O
IgE	881	884	O
and	885	888	O
IgG2a	889	894	O
responses	895	904	O
in	905	907	O
different	908	917	O
strains	918	925	O
of	926	928	O
mice	929	933	O
Levels	934	940	O
of	941	943	O
serum	944	949	B-Organism_substance
OVA	950	953	O
-	953	954	O
specific	954	962	O
IgE	963	966	O
(	967	968	O
A	968	969	O
)	969	970	O
and	971	974	O
IgG2a	975	980	O
(	981	982	O
B	982	983	O
)	983	984	O
on	985	987	O
day	988	991	O
26	992	994	O
after	995	1000	O
injection	1001	1010	O
into	1011	1015	O
one	1016	1019	O
hind	1020	1024	B-Organism_subdivision
footpad	1025	1032	I-Organism_subdivision
of	1033	1035	O
HBSS	1036	1040	O
(	1041	1042	O
open	1042	1046	O
columns	1047	1054	O
)	1054	1055	O
,	1055	1056	O
10	1057	1059	O
mug	1060	1063	O
OVA	1064	1067	O
(	1068	1069	O
gray	1069	1073	O
)	1073	1074	O
,	1074	1075	O
40	1076	1078	O
mug	1079	1082	O
PSP	1083	1086	O
(	1087	1088	O
hatched	1088	1095	O
)	1095	1096	O
or	1097	1099	O
10	1100	1102	O
mug	1103	1106	O
OVA	1107	1110	O
+	1111	1112	O
40	1113	1115	O
mug	1116	1119	O
PSP	1120	1123	O
(	1124	1125	O
black	1125	1130	O
)	1130	1131	O
in	1132	1134	O
different	1135	1144	O
mouse	1145	1150	O
strains	1151	1158	O
.	1158	1159	O

On	1160	1162	O
day	1163	1166	O
21	1167	1169	O
all	1170	1173	O
mice	1174	1178	O
were	1179	1183	O
boostered	1184	1193	O
with	1194	1198	O
10	1199	1201	O
mug	1202	1205	O
OVA	1206	1209	O
in	1210	1212	O
the	1213	1216	O
footpad	1217	1224	B-Organism_subdivision
.	1224	1225	O

Vertical	1226	1234	O
straight	1235	1243	O
lines	1244	1249	O
indicate	1250	1258	O
separate	1259	1267	O
experiments	1268	1279	O
.	1279	1280	O

Values	1281	1287	O
(	1288	1289	O
arbitrary	1289	1298	O
units	1299	1304	O
,	1304	1305	O
AU	1306	1308	O
)	1308	1309	O
for	1310	1313	O
individual	1314	1324	O
mice	1325	1329	O
(	1330	1331	O
circles	1331	1338	O
)	1338	1339	O
and	1340	1343	O
median	1344	1350	O
values	1351	1357	O
(	1358	1359	O
columns	1359	1366	O
)	1366	1367	O
for	1368	1371	O
groups	1372	1378	O
of	1379	1381	O
mice	1382	1386	O
are	1387	1390	O
shown	1391	1396	O
.	1396	1397	O

Dotted	1398	1404	O
lines	1405	1410	O
indicate	1411	1419	O
the	1420	1423	O
lower	1424	1429	O
detection	1430	1439	O
limits	1440	1446	O
for	1447	1450	O
the	1451	1454	O
ELISA	1455	1460	O
assays	1461	1467	O
.	1467	1468	O

Brackets	1469	1477	O
indicate	1478	1486	O
statistically	1487	1500	O
significant	1501	1512	O
differences	1513	1524	O
between	1525	1532	O
groups	1533	1539	O
(	1540	1541	O
p	1541	1542	O
<	1543	1544	O
0	1545	1546	O
.	1546	1547	O
05	1547	1549	O
)	1549	1550	O
.	1550	1551	O

All	1552	1555	O
experiments	1556	1567	O
were	1568	1572	O
performed	1573	1582	O
twice	1583	1588	O
with	1589	1593	O
similar	1594	1601	O
results	1602	1609	O
,	1609	1610	O
with	1611	1615	O
eight	1616	1621	O
mice	1622	1626	O
per	1627	1630	O
group	1631	1636	O
.	1636	1637	O

Figure	1638	1644	O
3	1645	1646	O

The	1647	1650	O
primary	1651	1658	O
cellular	1659	1667	B-Cell
response	1668	1676	O
in	1677	1679	O
the	1680	1683	O
draining	1684	1692	O
lymph	1693	1698	B-Multi-tissue_structure
node	1699	1703	I-Multi-tissue_structure
The	1704	1707	O
primary	1708	1715	O
cellular	1716	1724	B-Cell
response	1725	1733	O
in	1734	1736	O
the	1737	1740	O
draining	1741	1749	O
PLN	1750	1753	B-Multi-tissue_structure
was	1754	1757	O
determined	1758	1768	O
five	1769	1773	O
days	1774	1778	O
after	1779	1784	O
a	1785	1786	O
single	1787	1793	O
injection	1794	1803	O
of	1804	1806	O
HBSS	1807	1811	O
(	1812	1813	O
open	1813	1817	O
columns	1818	1825	O
)	1825	1826	O
,	1826	1827	O
10	1828	1830	O
mug	1831	1834	O
OVA	1835	1838	O
(	1839	1840	O
gray	1840	1844	O
)	1844	1845	O
,	1845	1846	O
40	1847	1849	O
mug	1850	1853	O
PSP	1854	1857	O
(	1858	1859	O
hatched	1859	1866	O
)	1866	1867	O
or	1868	1870	O
10	1871	1873	O
mug	1874	1877	O
OVA	1878	1881	O
+	1882	1883	O
40	1884	1886	O
mug	1887	1890	O
PSP	1891	1894	O
(	1895	1896	O
black	1896	1901	O
)	1901	1902	O
into	1903	1907	O
both	1908	1912	O
hind	1913	1917	O
footpads	1918	1926	O
of	1927	1929	O
BALB	1930	1934	O
/	1934	1935	O
cA	1935	1937	O
,	1937	1938	O
NIH	1939	1942	O
and	1943	1946	O
C3H	1947	1950	O
/	1950	1951	O
HeN	1951	1954	O
mice	1955	1959	O
.	1959	1960	O

The	1961	1964	O
total	1965	1970	O
lymph	1971	1976	B-Cell
node	1977	1981	I-Cell
cell	1982	1986	I-Cell
numbers	1987	1994	O
(	1995	1996	O
A	1996	1997	O
)	1997	1998	O
and	1999	2002	O
IL	2003	2005	O
-	2005	2006	O
4	2006	2007	O
(	2008	2009	O
B	2009	2010	O
)	2010	2011	O
,	2011	2012	O
IFN	2013	2016	O
-	2016	2017	O
gamma	2017	2022	O
(	2023	2024	O
C	2024	2025	O
)	2025	2026	O
and	2027	2030	O
IL	2031	2033	O
-	2033	2034	O
10	2034	2036	O
(	2037	2038	O
D	2038	2039	O
)	2039	2040	O
secreted	2041	2049	O
from	2050	2054	O
the	2055	2058	O
PLN	2059	2062	B-Cell
cells	2063	2068	I-Cell
after	2069	2074	O
ex	2075	2077	O
vivo	2078	2082	O
stimulation	2083	2094	O
with	2095	2099	O
Con	2100	2103	O
A	2104	2105	O
were	2106	2110	O
determined	2111	2121	O
.	2121	2122	O

Values	2123	2129	O
for	2130	2133	O
individual	2134	2144	O
samples	2145	2152	B-Cell
(	2153	2154	O
circles	2154	2161	O
)	2161	2162	O
and	2163	2166	O
group	2167	2172	O
median	2173	2179	O
values	2180	2186	O
(	2187	2188	O
columns	2188	2195	O
)	2195	2196	O
are	2197	2200	O
shown	2201	2206	O
.	2206	2207	O

Dotted	2208	2214	O
lines	2215	2220	O
indicate	2221	2229	O
the	2230	2233	O
lower	2234	2239	O
detection	2240	2249	O
limits	2250	2256	O
for	2257	2260	O
the	2261	2264	O
cytokine	2265	2273	O
ELISA	2274	2279	O
assays	2280	2286	O
,	2286	2287	O
and	2288	2291	O
brackets	2292	2300	O
indicate	2301	2309	O
statistically	2310	2323	O
significant	2324	2335	O
differences	2336	2347	O
between	2348	2355	O
groups	2356	2362	O
(	2363	2364	O
p	2364	2365	O
<	2366	2367	O
0	2368	2369	O
.	2369	2370	O
05	2370	2372	O
)	2372	2373	O
.	2373	2374	O

Figures	0	7	O
and	8	11	O
Tables	12	18	O

Stages	19	25	O
in	26	28	O
the	29	32	O
life	33	37	O
cycle	38	43	O
of	44	46	O
Plasmodium	47	57	O
falciparum	58	68	O

(	69	70	O
Illustration	70	82	O
:	82	83	O
Coatney	84	91	O
GR	92	94	O
,	94	95	O
Collins	96	103	O
WE	104	106	O
,	106	107	O
Warren	108	114	O
M	115	116	O
,	116	117	O
Contacos	118	126	O
PG	127	129	O
(	130	131	O
1971	131	135	O
)	135	136	O

The	137	140	O
primate	141	148	O
malarias	149	157	O
.	157	158	O

(	159	160	O
Bethesda	160	168	O
)	168	169	O
:	169	170	O
U	171	172	O
.	172	173	O
S	173	174	O
.	174	175	O

Department	176	186	O
of	187	189	O
Health	190	196	O
,	196	197	O
Education	198	207	O
and	208	211	O
Welfare	212	219	O
.	219	220	O
)	220	221	O

Images	0	6	O

FIGURE	7	13	O
2	14	15	O
.	15	16	O

A	17	18	O

FIGURE	19	25	O
2	26	27	O
.	27	28	O

B	29	30	O

FIGURE	31	37	O
3	38	39	O
.	39	40	O

Supporting	0	10	O
Information	11	22	O

Table	23	28	O
S1	29	31	O

Supplementary	32	45	O
Information	46	57	O
on	58	60	O
Genes	61	66	O
in	67	69	O
the	70	73	O
Three	74	79	O
Gene	80	84	O
Sets	85	89	O

(	90	91	O
219	91	94	O
KB	95	97	O
PDF	98	101	O
)	101	102	O

Click	103	108	O
here	109	113	O
for	114	117	O
additional	118	128	O
data	129	133	O
file	134	138	O
.	138	139	O

Table	140	145	O
S2	146	148	O

UFW	149	152	O
Primers	153	160	O
for	161	164	O
Gene	165	169	O
Set	170	173	O
I	174	175	O

(	176	177	O
36	177	179	O
KB	180	182	O
PDF	183	186	O
)	186	187	O

Click	188	193	O
here	194	198	O
for	199	202	O
additional	203	213	O
data	214	218	O
file	219	223	O
.	223	224	O

Table	225	230	O
S3	231	233	O

UFW	234	237	O
Primers	238	245	O
for	246	249	O
Gene	250	254	O
Set	255	258	O
II	259	261	O

(	262	263	O
44	263	265	O
KB	266	268	O
PDF	269	272	O
)	272	273	O

Click	274	279	O
here	280	284	O
for	285	288	O
additional	289	299	O
data	300	304	O
file	305	309	O
.	309	310	O

Table	311	316	O
S4	317	319	O

UFW	320	323	O
Primers	324	331	O
for	332	335	O
Gene	336	340	O
Set	341	344	O
III	345	348	O

(	349	350	O
31	350	352	O
KB	353	355	O
PDF	356	359	O
)	359	360	O

Click	361	366	O
here	367	371	O
for	372	375	O
additional	376	386	O
data	387	391	O
file	392	396	O
.	396	397	O

Table	398	403	O
S5	404	406	O

Transposable	407	419	O
Element	420	427	O
-	427	428	O
Specific	428	436	O
Primers	437	444	O
for	445	448	O
Additional	449	459	O
Screens	460	467	O

(	468	469	O
80	469	471	O
KB	472	474	O
PDF	475	478	O
)	478	479	O

Click	480	485	O
here	486	490	O
for	491	494	O
additional	495	505	O
data	506	510	O
file	511	515	O
.	515	516	O

Table	517	522	O
S6	523	525	O

Primers	526	533	O
for	534	537	O
Intergenic	538	548	O
Regions	549	556	O

(	557	558	O
58	558	560	O
KB	561	563	O
PDF	564	567	O
)	567	568	O

Click	569	574	O
here	575	579	O
for	580	583	O
additional	584	594	O
data	595	599	O
file	600	604	O
.	604	605	O

Table	606	611	O
S7	612	614	O

P	615	616	O
Element	617	624	O
-	624	625	O
Specific	625	633	O
Primers	634	641	O
for	642	645	O
Orientation	646	657	O
and	658	661	O
Length	662	668	O
Determination	669	682	O

(	683	684	O
299	684	687	O
KB	688	690	O
PDF	691	694	O
)	694	695	O

Click	696	701	O
here	702	706	O
for	707	710	O
additional	711	721	O
data	722	726	O
file	727	731	O
.	731	732	O

Background	0	10	O

HIV	11	14	O
-	14	15	O
1	15	16	O
infectivity	17	28	O
depends	29	36	O
on	37	39	O
free	40	44	O
cholesterol	45	56	O
incorporated	57	69	O
into	70	74	O
the	75	78	O
viral	79	84	O
envelope	85	93	B-Cellular_component
.	93	94	O

Here	95	99	O
,	99	100	O
we	101	103	O
analyze	104	111	O
HIV	112	115	O
infectivity	116	127	O
in	128	130	O
the	131	134	O
presence	135	143	O
of	144	146	O
drugs	147	152	O
that	153	157	O
stimulate	158	167	O
cholesterol	168	179	O
efflux	180	186	O
.	186	187	O

Additional	0	10	O
File	11	15	O
1	16	17	O

Appendix	18	26	O
1	27	28	O
.	28	29	O

Indications	30	41	O
for	42	45	O
liver	46	51	B-Organ
function	52	60	O
tests	61	66	O
with	67	71	O
no	72	74	O
obvious	75	82	O
liver	83	88	B-Organ
disease	89	96	O
,	96	97	O
and	98	101	O
consequent	102	112	O
investigations	113	127	O

Representative	0	14	O
PCR	15	18	O
/	18	19	O
LDR	19	22	O
results	23	30	O
for	31	34	O
HPTs	35	39	O
in	40	42	O
fimX	43	47	O
,	47	48	O
BP0059	49	55	O
,	55	56	O
BP0880	57	63	O
,	63	64	O
sphB2	65	70	O
,	70	71	O
ptxA	72	76	O
,	76	77	O
and	78	81	O
bhuR	82	86	O
.	86	87	O

Raw	88	91	O
capillary	92	101	O
electrophoresis	102	117	O
data	118	122	O
for	123	126	O
ligation	127	135	O
products	136	144	O
(	145	146	O
green	146	151	O
)	151	152	O
and	153	156	O
molecular	157	166	O
weight	167	173	O
standards	174	183	O
(	184	185	O
red	185	188	O
)	188	189	O
displayed	190	199	O
as	200	202	O
if	203	205	O
an	206	208	O
electrophoretic	209	224	O
gel	225	228	O
image	229	234	O
.	234	235	O

Assayed	236	243	O
locus	244	249	O
is	250	252	O
indicated	253	262	O
at	263	265	O
the	266	269	O
top	270	273	O
of	274	276	O
each	277	281	O
panel	282	287	O
;	287	288	O
strain	289	295	O
and	296	299	O
length	300	306	O
of	307	309	O
its	310	313	O
HPT	314	317	O
allele	318	324	O
are	325	328	O
noted	329	334	O
above	335	340	O
each	341	345	O
lane	346	350	O
.	350	351	O

Representative	352	366	O
LDR	367	370	O
results	371	378	O
are	379	382	O
depicted	383	391	O
here	392	396	O
;	396	397	O
for	398	401	O
complete	402	410	O
data	411	415	O
from	416	420	O
all	421	424	O
strains	425	432	O
see	433	436	O
Additional	437	447	O
files	448	453	O
8	454	455	O
,	455	456	O
9	457	458	O
,	458	459	O
10	460	462	O
,	462	463	O
11	464	466	O
,	466	467	O
12	468	470	O
,	470	471	O
and	472	475	O
13	476	478	O
.	478	479	O

BP0880	480	486	O
,	486	487	O
BP0059	488	494	O
,	494	495	O
fimX	496	500	O
,	500	501	O
and	502	505	O
sphB2	506	511	O
HPTs	512	516	O
were	517	521	O
screened	522	530	O
by	531	533	O
uniplex	534	541	O
LDR	542	545	O
reactions	546	555	O
containing	556	566	O
only	567	571	O
the	572	575	O
discriminating	576	590	O
oligonucleotide	591	606	O
that	607	611	O
targets	612	619	O
the	620	623	O
Tohama	624	630	O
I	631	632	O
sequence	633	641	O
.	641	642	O

The	643	646	O
ptxA	647	651	O
and	652	655	O
bhuR	656	660	O
HPTs	661	665	O
were	666	670	O
screened	671	679	O
by	680	682	O
multiplex	683	692	O
reactions	693	702	O
that	703	707	O
contain	708	715	O
all	716	719	O
three	720	725	O
discriminating	726	740	O
oligonucleotides	741	757	O
.	757	758	O

Letters	759	766	O
in	767	769	O
teal	770	774	O
indicate	775	783	O
molecular	784	793	O
weight	794	800	O
standards	801	810	O
as	811	813	O
labeled	814	821	O
in	822	824	O
the	825	828	O
corresponding	829	842	O
supplementary	843	856	O
figures	857	864	O
.	864	865	O

Ligation	866	874	O
products	875	883	O
(	884	885	O
arrows	885	891	O
)	891	892	O
are	893	896	O
labeled	897	904	O
using	905	910	O
the	911	914	O
notation	915	923	O
described	924	933	O
in	934	936	O
the	937	940	O
legend	941	947	O
to	948	950	O
Figure	951	957	O
1	958	959	O
.	959	960	O

The	961	964	O
open	965	969	O
arrowhead	970	979	O
indicates	980	989	O
a	990	991	O
synthesis	992	1001	O
artifact	1002	1010	O
in	1011	1013	O
the	1014	1017	O
BP0059	1018	1024	O
common	1025	1031	O
oligonucleotide	1032	1047	O
preparation	1048	1059	O
.	1059	1060	O

INTRODUCTION	0	12	O

Comparing	13	22	O
genomic	23	30	O
sequences	31	40	O
across	41	47	O
related	48	55	O
species	56	63	O
is	64	66	O
a	67	68	O
fruitful	69	77	O
source	78	84	O
of	85	87	O
biological	88	98	O
insight	99	106	O
.	106	107	O

Functional	108	118	O
elements	119	127	O
such	128	132	O
as	133	135	O
exons	136	141	O
tend	142	146	O
to	147	149	O
exhibit	150	157	O
significant	158	169	O
sequence	170	178	O
similarity	179	189	O
due	190	193	O
to	194	196	O
purifying	197	206	O
selection	207	216	O
,	216	217	O
whereas	218	225	O
regions	226	233	O
that	234	238	O
are	239	242	O
not	243	246	O
functional	247	257	O
tend	258	262	O
to	263	265	O
be	266	268	O
neutrally	269	278	O
evolving	279	287	O
and	288	291	O
thus	292	296	O
less	297	301	O
conserved	302	311	O
.	311	312	O

The	313	316	O
first	317	322	O
step	323	327	O
in	328	330	O
comparing	331	340	O
genomic	341	348	O
sequences	349	358	O
is	359	361	O
to	362	364	O
align	365	370	O
them	371	375	O
-	375	376	O
-	376	377	O
to	377	379	O
map	380	383	O
the	384	387	O
letters	388	395	O
of	396	398	O
the	399	402	O
sequences	403	412	O
to	413	415	O
each	416	420	O
other	421	426	O
.	426	427	O

After	428	433	O
an	434	436	O
alignment	437	446	O
is	447	449	O
computed	450	458	O
,	458	459	O
visualization	460	473	O
frameworks	474	484	O
become	485	491	O
essential	492	501	O
to	502	504	O
enable	505	511	O
users	512	517	O
to	518	520	O
interact	521	529	O
with	530	534	O
the	535	538	O
sequence	539	547	O
and	548	551	O
conservation	552	564	O
data	565	569	O
,	569	570	O
especially	571	581	O
in	582	584	O
the	585	588	O
context	589	596	O
of	597	599	O
longer	600	606	O
DNA	607	610	O
sequences	611	620	O
or	621	623	O
whole	624	629	O
genomes	630	637	O
.	637	638	O

Visualization	639	652	O
frameworks	653	663	O
should	664	670	O
be	671	673	O
easy	674	678	O
to	679	681	O
understand	682	692	O
by	693	695	O
a	696	697	O
biologist	698	707	O
and	708	711	O
provide	712	719	O
insight	720	727	O
into	728	732	O
the	733	736	O
mutations	737	746	O
that	747	751	O
a	752	753	O
particular	754	764	O
genomic	765	772	O
locus	773	778	O
has	779	782	O
undergone	783	792	O
.	792	793	O

The	794	797	O
VISTA	798	803	O
portal	804	810	O
is	811	813	O
a	814	815	O
comprehensive	816	829	O
comparative	830	841	O
genomics	842	850	O
resource	851	859	O
that	860	864	O
provides	865	873	O
biomedical	874	884	O
scientists	885	895	O
with	896	900	O
a	901	902	O
single	903	909	O
unified	910	917	O
framework	918	927	O
to	928	930	O
generate	931	939	O
and	940	943	O
download	944	952	O
multiple	953	961	O
sequence	962	970	O
alignments	971	981	O
,	981	982	O
visualize	983	992	O
the	993	996	O
results	997	1004	O
in	1005	1007	O
the	1008	1011	O
context	1012	1019	O
of	1020	1022	O
existing	1023	1031	O
annotations	1032	1043	O
and	1044	1047	O
analyze	1048	1055	O
comparative	1056	1067	O
results	1068	1075	O
in	1076	1078	O
search	1079	1085	O
for	1086	1089	O
important	1090	1099	O
sequence	1100	1108	O
signals	1109	1116	O
in	1117	1119	O
alignments	1120	1130	O
.	1130	1131	O

The	1132	1135	O
VISTA	1136	1141	O
suite	1142	1147	O
of	1148	1150	O
programs	1151	1159	O
has	1160	1163	O
been	1164	1168	O
in	1169	1171	O
development	1172	1183	O
and	1184	1187	O
continued	1188	1197	O
use	1198	1201	O
since	1202	1207	O
2000	1208	1212	O
(	1213	1214	O
1	1214	1215	O
-	1215	1216	O
4	1216	1217	O
)	1217	1218	O
.	1218	1219	O

It	1220	1222	O
was	1223	1226	O
originally	1227	1237	O
developed	1238	1247	O
for	1248	1251	O
the	1252	1255	O
alignment	1256	1265	O
and	1266	1269	O
comparative	1270	1281	O
analysis	1282	1290	O
of	1291	1293	O
long	1294	1298	O
genomic	1299	1306	O
sequences	1307	1316	O
and	1317	1320	O
later	1321	1326	O
was	1327	1330	O
expanded	1331	1339	O
to	1340	1342	O
pair	1343	1347	O
-	1347	1348	O
wise	1348	1352	O
and	1353	1356	O
multiple	1357	1365	O
alignment	1366	1375	O
of	1376	1378	O
vertebrate	1379	1389	O
genomes	1390	1397	O
.	1397	1398	O

VISTA	1399	1404	O
has	1405	1408	O
popularized	1409	1420	O
the	1421	1424	O
visualization	1425	1438	O
of	1439	1441	O
the	1442	1445	O
level	1446	1451	O
of	1452	1454	O
conservation	1455	1467	O
in	1468	1470	O
the	1471	1474	O
format	1475	1481	O
of	1482	1484	O
a	1485	1486	O
continuous	1487	1497	O
curve	1498	1503	O
based	1504	1509	O
on	1510	1512	O
the	1513	1516	O
conservation	1517	1529	O
in	1530	1532	O
a	1533	1534	O
sliding	1535	1542	O
window	1543	1549	O
.	1549	1550	O

This	1551	1555	O
concept	1556	1563	O
proved	1564	1570	O
to	1571	1573	O
be	1574	1576	O
extremely	1577	1586	O
successful	1587	1597	O
due	1598	1601	O
to	1602	1604	O
the	1605	1608	O
easy	1609	1613	O
interpretation	1614	1628	O
of	1629	1631	O
the	1632	1635	O
resulting	1636	1645	O
plots	1646	1651	O
.	1651	1652	O

VISTA	1653	1658	O
was	1659	1662	O
built	1663	1668	O
through	1669	1676	O
a	1677	1678	O
close	1679	1684	O
collaboration	1685	1698	O
between	1699	1706	O
computational	1707	1720	O
and	1721	1724	O
biological	1725	1735	O
scientists	1736	1746	O
,	1746	1747	O
resulting	1748	1757	O
in	1758	1760	O
a	1761	1762	O
product	1763	1770	O
that	1771	1775	O
is	1776	1778	O
robust	1779	1785	O
,	1785	1786	O
efficient	1787	1796	O
and	1797	1800	O
powerful	1801	1809	O
,	1809	1810	O
yet	1811	1814	O
simple	1815	1821	O
to	1822	1824	O
use	1825	1828	O
for	1829	1832	O
a	1833	1834	O
person	1835	1841	O
without	1842	1849	O
extensive	1850	1859	O
computer	1860	1868	O
experience	1869	1879	O
,	1879	1880	O
as	1881	1883	O
is	1884	1886	O
illustrated	1887	1898	O
by	1899	1901	O
more	1902	1906	O
than	1907	1911	O
1000	1912	1916	O
citations	1917	1926	O
to	1927	1929	O
the	1930	1933	O
various	1934	1941	O
VISTA	1942	1947	O
-	1947	1948	O
associated	1948	1958	O
tools	1959	1964	O
(	1965	1966	O
according	1966	1975	O
to	1976	1978	O
http	1979	1983	O
:	1983	1984	O
/	1984	1985	O
/	1985	1986	O
scholar	1986	1993	O
.	1993	1994	O
google	1994	2000	O
.	2000	2001	O
com	2001	2004	O
)	2004	2005	O
.	2005	2006	O

In	2007	2009	O
the	2010	2013	O
last	2014	2018	O
2	2019	2020	O
years	2021	2026	O
the	2027	2030	O
VISTA	2031	2036	O
portal	2037	2043	O
has	2044	2047	O
seen	2048	2052	O
many	2053	2057	O
significant	2058	2069	O
improvements	2070	2082	O
.	2082	2083	O

In	2084	2086	O
addition	2087	2095	O
to	2096	2098	O
updating	2099	2107	O
the	2108	2111	O
whole	2112	2117	O
genome	2118	2124	O
alignments	2125	2135	O
,	2135	2136	O
computed	2137	2145	O
using	2146	2151	O
recent	2152	2158	O
assemblies	2159	2169	O
of	2170	2172	O
vertebrate	2173	2183	O
,	2183	2184	O
insect	2185	2191	O
,	2191	2192	O
plant	2193	2198	O
and	2199	2202	O
microbial	2203	2212	O
genomes	2213	2220	O
,	2220	2221	O
we	2222	2224	O
have	2225	2229	O
added	2230	2235	O
significant	2236	2247	O
new	2248	2251	O
functionality	2252	2265	O
and	2266	2269	O
resources	2270	2279	O
to	2280	2282	O
the	2283	2286	O
Genome	2287	2293	O
Browser	2294	2301	O
and	2302	2305	O
other	2306	2311	O
tools	2312	2317	O
,	2317	2318	O
including	2319	2328	O
:	2328	2329	O

A	2331	2332	O
novel	2333	2338	O
multiple	2339	2347	O
whole	2348	2353	O
genome	2354	2360	O
alignment	2361	2370	O
algorithm	2371	2380	O
.	2380	2381	O

A	2382	2383	O
new	2384	2387	O
server	2388	2394	O
for	2395	2398	O
whole	2399	2404	O
-	2404	2405	O
genome	2405	2411	O
alignment	2412	2421	O
of	2422	2424	O
bacterial	2425	2434	O
genomes	2435	2442	O
.	2442	2443	O

Base	2444	2448	O
-	2448	2449	O
pair	2449	2453	O
level	2454	2459	O
visualization	2460	2473	O
ability	2474	2481	O
within	2482	2488	O
the	2489	2492	O
VISTA	2493	2498	O
browser	2499	2506	O
.	2506	2507	O

Visual	2508	2514	O
access	2515	2521	O
to	2522	2524	O
the	2525	2528	O
results	2529	2536	O
of	2537	2539	O
the	2540	2543	O
prediction	2544	2554	O
of	2555	2557	O
potential	2558	2567	O
deleteriousness	2568	2583	O
of	2584	2586	O
non	2587	2590	O
-	2590	2591	O
synonymous	2591	2601	O
Single	2602	2608	O
Nucleotide	2609	2619	O
Polymorphisms	2620	2633	O
(	2634	2635	O
SNPs	2635	2639	O
)	2639	2640	O
by	2641	2643	O
the	2644	2647	O
algorithm	2648	2657	O
PolyPhen	2658	2666	O
(	2667	2668	O
5	2668	2669	O
)	2669	2670	O
.	2670	2671	O

A	2672	2673	O
novel	2674	2679	O
conservation	2680	2692	O
track	2693	2698	O
,	2698	2699	O
Rank	2700	2704	O
-	2704	2705	O
VISTA	2705	2710	O
,	2710	2711	O
to	2712	2714	O
show	2715	2719	O
the	2720	2723	O
statistical	2724	2735	O
significance	2736	2748	O
of	2749	2751	O
conserved	2752	2761	O
regions	2762	2769	O
computed	2770	2778	O
by	2779	2781	O
the	2782	2785	O
Gumby	2786	2791	O
algorithm	2792	2801	O
(	2802	2803	O
6	2803	2804	O
)	2804	2805	O
.	2805	2806	O

Whole	2807	2812	O
-	2812	2813	O
genome	2813	2819	O
rVISTA	2820	2826	O
,	2826	2827	O
that	2828	2832	O
allows	2833	2839	O
for	2840	2843	O
evaluation	2844	2854	O
of	2855	2857	O
which	2858	2863	O
conserved	2864	2873	O
transcription	2874	2887	O
factor	2888	2894	O
binding	2895	2902	O
sites	2903	2908	O
(	2909	2910	O
TFBS	2910	2914	O
)	2914	2915	O
are	2916	2919	O
over	2920	2924	O
-	2924	2925	O
represented	2925	2936	O
in	2937	2939	O
a	2940	2941	O
group	2942	2947	O
of	2948	2950	O
genes	2951	2956	O
.	2956	2957	O

Images	0	6	O

Figure	7	13	O
5	14	15	O

Miscellaneous	0	13	O
Proteins	14	22	O

Apart	23	28	O
from	29	33	O
the	34	37	O
above	38	43	O
-	43	44	O
described	44	53	O
proteins	54	62	O
,	62	63	O
several	64	71	O
other	72	77	O
molecules	78	87	O
are	88	91	O
also	92	96	O
associated	97	107	O
with	108	112	O
the	113	116	O
pathological	117	129	B-Pathological_formation
lesions	130	137	I-Pathological_formation
of	138	140	O
AD	141	143	O
,	143	144	O
and	145	148	O
some	149	153	O
of	154	156	O
these	157	162	O
can	163	166	O
be	167	169	O
regarded	170	178	O
as	179	181	O
amateur	182	189	O
chaperones	190	200	O
.	200	201	O

Acute	202	207	O
phase	208	213	O
proteins	214	222	O
,	222	223	O
such	224	228	O
as	229	231	O
alpha1	232	238	O
-	238	239	O
antichymotrypsin	239	255	O
(	256	257	O
ACT	257	260	O
)	260	261	O
,	261	262	O
alpha2	263	269	O
-	269	270	O
macroglobulin	270	283	O
(	284	285	O
alpha2M	285	292	O
)	292	293	O
,	293	294	O
and	295	298	O
SAP	299	302	O
,	302	303	O
are	304	307	O
all	308	311	O
associated	312	322	O
with	323	327	O
Abeta	328	333	O
deposition	334	344	O
[	345	346	O
129	346	349	O
-	349	350	O
132	350	353	O
]	353	354	O
.	354	355	O

ACT	356	359	O
is	360	362	O
a	363	364	O
serine	365	371	O
protease	372	380	O
inhibitor	381	390	O
of	391	393	O
the	394	397	O
serpin	398	404	O
family	405	411	O
,	411	412	O
and	413	416	O
in	417	419	O
AD	420	422	O
,	422	423	O
ACT	424	427	O
levels	428	434	O
are	435	438	O
upregulated	439	450	O
,	450	451	O
and	452	455	O
binding	456	463	O
of	464	466	O
ACT	467	470	O
with	471	475	O
Abeta	476	481	O
induces	482	489	O
Abeta	490	495	O
fibrillogenesis	496	511	O
[	512	513	O
133	513	516	O
-	516	517	O
135	517	520	O
]	520	521	O
.	521	522	O

Furthermore	523	534	O
,	534	535	O
when	536	540	O
ACT	541	544	O
is	545	547	O
overexpressed	548	561	O
in	562	564	O
transgenic	565	575	O
mice	576	580	O
,	580	581	O
an	582	584	O
increased	585	594	O
plaque	595	601	B-Cell
load	602	606	O
in	607	609	O
the	610	613	O
brains	614	620	B-Organ
of	621	623	O
these	624	629	O
mice	630	634	O
and	635	638	O
impaired	639	647	O
spatial	648	655	O
learning	656	664	O
is	665	667	O
observed	668	676	O
[	677	678	O
134	678	681	O
,	681	682	O
135	683	686	O
]	686	687	O
.	687	688	O

alpha2M	689	696	O
also	697	701	O
binds	702	707	O
Abeta	708	713	O
,	713	714	O
although	715	723	O
in	724	726	O
contrast	727	735	O
to	736	738	O
ACT	739	742	O
,	742	743	O
this	744	748	O
binding	749	756	O
prevents	757	765	O
Abeta	766	771	O
fibril	772	778	B-Pathological_formation
formation	779	788	O
and	789	792	O
fibril	793	799	O
-	799	800	O
associated	800	810	O
neurotoxicity	811	824	O
[	825	826	O
136	826	829	O
,	829	830	O
137	831	834	O
]	834	835	O
.	835	836	O

alpha2M	837	844	O
promotes	845	853	O
the	854	857	O
protease	858	866	O
-	866	867	O
mediated	867	875	O
degradation	876	887	O
of	888	890	O
alpha2M	891	898	O
/	898	899	O
Abeta	899	904	O
complexes	905	914	O
and	915	918	O
contributes	919	930	O
to	931	933	O
clearance	934	943	O
of	944	946	O
Abeta	947	952	O
from	953	957	O
the	958	961	O
brain	962	967	B-Organ
(	968	969	O
discussed	969	978	O
in	979	981	O
paragraph	982	991	O
4	992	993	O
)	993	994	O
[	995	996	O
138	996	999	O
,	999	1000	O
139	1001	1004	O
]	1004	1005	O
.	1005	1006	O

The	1007	1010	O
glycoprotein	1011	1023	O
SAP	1024	1027	O
belongs	1028	1035	O
to	1036	1038	O
the	1039	1042	O
pentraxin	1043	1052	O
family	1053	1059	O
and	1060	1063	O
is	1064	1066	O
a	1067	1068	O
common	1069	1075	O
component	1076	1085	O
of	1086	1088	O
all	1089	1092	O
known	1093	1098	O
types	1099	1104	O
of	1105	1107	O
amyloid	1108	1115	B-Pathological_formation
fibrils	1116	1123	I-Pathological_formation
.	1123	1124	O

SAP	1125	1128	O
is	1129	1131	O
upregulated	1132	1143	O
in	1144	1146	O
AD	1147	1149	O
and	1150	1153	O
protects	1154	1162	O
amyloid	1163	1170	B-Pathological_formation
fibrils	1171	1178	I-Pathological_formation
from	1179	1183	O
proteolysis	1184	1195	O
in	1196	1198	O
vitro	1199	1204	O
[	1205	1206	O
140	1206	1209	O
,	1209	1210	O
141	1211	1214	O
]	1214	1215	O
.	1215	1216	O

SAP	1217	1220	O
not	1221	1224	O
only	1225	1229	O
colocalizes	1230	1241	O
with	1242	1246	O
SPs	1247	1250	O
and	1251	1254	O
interacts	1255	1264	O
with	1265	1269	O
aggregated	1270	1280	O
Abeta	1281	1286	O
;	1286	1287	O
SAP	1288	1291	O
oligomers	1292	1301	O
also	1302	1306	O
bind	1307	1311	O
and	1312	1315	O
activate	1316	1324	O
C1	1325	1327	O
[	1328	1329	O
142	1329	1332	O
]	1332	1333	O
.	1333	1334	O

Both	1335	1339	O
C1	1340	1342	O
and	1343	1346	O
SAP	1347	1350	O
may	1351	1354	O
bind	1355	1359	O
to	1360	1362	O
fibrillar	1363	1372	B-Pathological_formation
Abeta	1373	1378	O
deposits	1379	1387	O
in	1388	1390	O
vivo	1391	1395	O
and	1396	1399	O
induce	1400	1406	O
microglial	1407	1417	B-Cell
activation	1418	1428	O
,	1428	1429	O
as	1430	1432	O
cultured	1433	1441	O
human	1442	1447	O
microglial	1448	1458	B-Cell
cells	1459	1464	I-Cell
show	1465	1469	O
an	1470	1472	O
increase	1473	1481	O
in	1482	1484	O
cytokine	1485	1493	O
production	1494	1504	O
after	1505	1510	O
co	1511	1513	O
-	1513	1514	O
stimulation	1514	1525	O
of	1526	1528	O
Abeta	1529	1534	O
with	1535	1539	O
C1q	1540	1543	O
and	1544	1547	O
SAP	1548	1551	O
[	1552	1553	O
104	1553	1556	O
]	1556	1557	O
.	1557	1558	O

These	1559	1564	O
observations	1565	1577	O
further	1578	1585	O
strengthen	1586	1596	O
the	1597	1600	O
above	1601	1606	O
-	1606	1607	O
noted	1607	1612	O
suggestion	1613	1623	O
that	1624	1628	O
not	1629	1632	O
only	1633	1637	O
Abeta	1638	1643	O
,	1643	1644	O
but	1645	1648	O
also	1649	1653	O
several	1654	1661	O
Abeta	1662	1667	O
-	1667	1668	O
binding	1668	1675	O
proteins	1676	1684	O
,	1684	1685	O
are	1686	1689	O
capable	1690	1697	O
of	1698	1700	O
activating	1701	1711	O
the	1712	1715	O
complement	1716	1726	O
system	1727	1733	O
,	1733	1734	O
and	1735	1738	O
thus	1739	1743	O
,	1743	1744	O
contribute	1745	1755	O
to	1756	1758	O
neuroinflammation	1759	1776	O
in	1777	1779	O
AD	1780	1782	O
.	1782	1783	O

In	1784	1786	O
addition	1787	1795	O
,	1795	1796	O
both	1797	1801	O
alpha2M	1802	1809	O
and	1810	1813	O
ACT	1814	1817	O
,	1817	1818	O
in	1819	1821	O
contrast	1822	1830	O
to	1831	1833	O
SAP	1834	1837	O
,	1837	1838	O
can	1839	1842	O
be	1843	1845	O
regarded	1846	1854	O
as	1855	1857	O
amateur	1858	1865	O
chaperones	1866	1876	O
,	1876	1877	O
as	1878	1880	O
they	1881	1885	O
regulate	1886	1894	O
conformational	1895	1909	O
changes	1910	1917	O
of	1918	1920	O
Abeta	1921	1926	O
.	1926	1927	O

Tissue	1928	1934	O
-	1934	1935	O
type	1935	1939	O
plasminogen	1940	1951	O
activator	1952	1961	O
(	1962	1963	O
tPA	1963	1966	O
)	1966	1967	O
regulates	1968	1977	O
activation	1978	1988	O
of	1989	1991	O
plasminogen	1992	2003	O
into	2004	2008	O
plasmin	2009	2016	O
and	2017	2020	O
is	2021	2023	O
expressed	2024	2033	O
in	2034	2036	O
various	2037	2044	O
regions	2045	2052	O
of	2053	2055	O
the	2056	2059	O
brain	2060	2065	B-Organ
especially	2066	2076	O
in	2077	2079	O
the	2080	2083	O
hippocampus	2084	2095	B-Multi-tissue_structure
[	2096	2097	O
143	2097	2100	O
]	2100	2101	O
.	2101	2102	O

Several	2103	2110	O
reports	2111	2118	O
suggested	2119	2128	O
an	2129	2131	O
important	2132	2141	O
role	2142	2146	O
for	2147	2150	O
tPA	2151	2154	O
in	2155	2157	O
AD	2158	2160	O
,	2160	2161	O
as	2162	2164	O
the	2165	2168	O
tPA	2169	2172	O
system	2173	2179	O
is	2180	2182	O
involved	2183	2191	O
in	2192	2194	O
Abeta	2195	2200	O
turnover	2201	2209	O
[	2210	2211	O
144	2211	2214	O
,	2214	2215	O
145	2216	2219	O
]	2219	2220	O
.	2220	2221	O

Fibrillar	2222	2231	B-Pathological_formation
forms	2232	2237	O
of	2238	2240	O
Abeta	2241	2246	O
stimulate	2247	2256	O
tPA	2257	2260	O
activity	2261	2269	O
in	2270	2272	O
vitro	2273	2278	O
,	2278	2279	O
whereas	2280	2287	O
in	2288	2290	O
AD	2291	2293	O
patients	2294	2302	O
,	2302	2303	O
a	2304	2305	O
reduction	2306	2315	O
of	2316	2318	O
tPA	2319	2322	O
activity	2323	2331	O
is	2332	2334	O
observed	2335	2343	O
in	2344	2346	O
the	2347	2350	O
affected	2351	2359	O
areas	2360	2365	O
[	2366	2367	O
144	2367	2370	O
,	2370	2371	O
146	2372	2375	O
]	2375	2376	O
.	2376	2377	O

Although	2378	2386	O
tPA	2387	2390	O
has	2391	2394	O
no	2395	2397	O
effect	2398	2404	O
on	2405	2407	O
conformational	2408	2422	O
changes	2423	2430	O
of	2431	2433	O
Abeta	2434	2439	O
,	2439	2440	O
it	2441	2443	O
might	2444	2449	O
play	2450	2454	O
a	2455	2456	O
role	2457	2461	O
in	2462	2464	O
the	2465	2468	O
clearance	2469	2478	O
of	2479	2481	O
Abeta	2482	2487	O
from	2488	2492	O
the	2493	2496	O
brain	2497	2502	B-Organ
(	2503	2504	O
paragraph	2504	2513	O
4	2514	2515	O
]	2515	2516	O
.	2516	2517	O

The	2518	2521	O
actin	2522	2527	O
-	2527	2528	O
regulatory	2528	2538	O
protein	2539	2546	O
gelsolin	2547	2555	O
is	2556	2558	O
found	2559	2564	O
both	2565	2569	O
intracellularly	2570	2585	B-Cell
and	2586	2589	O
in	2590	2592	O
plasma	2593	2599	B-Organism_substance
[	2600	2601	O
147	2601	2604	O
,	2604	2605	O
148	2606	2609	O
]	2609	2610	O
.	2610	2611	O

Plasma	2612	2618	B-Organism_substance
gelsolin	2619	2627	O
can	2628	2631	O
be	2632	2634	O
considered	2635	2645	O
an	2646	2648	O
amateur	2649	2656	O
chaperone	2657	2666	O
,	2666	2667	O
as	2668	2670	O
it	2671	2673	O
binds	2674	2679	O
Abeta	2680	2685	O
and	2686	2689	O
not	2690	2693	O
only	2694	2698	O
inhibits	2699	2707	O
its	2708	2711	O
Abeta	2712	2717	O
fibrillization	2718	2732	O
but	2733	2736	O
is	2737	2739	O
also	2740	2744	O
capable	2745	2752	O
of	2753	2755	O
degrading	2756	2765	O
preformed	2766	2775	O
Abeta	2776	2781	O
fibrils	2782	2789	B-Pathological_formation
[	2790	2791	O
149	2791	2794	O
,	2794	2795	O
150	2796	2799	O
]	2799	2800	O
.	2800	2801	O

Furthermore	2802	2813	O
,	2813	2814	O
gelsolin	2815	2823	O
inhibits	2824	2832	O
Abeta	2833	2838	O
-	2838	2839	O
mediated	2839	2847	O
neurotoxicity	2848	2861	O
[	2862	2863	O
151	2863	2866	O
]	2866	2867	O
.	2867	2868	O

One	2869	2872	O
of	2873	2875	O
the	2876	2879	O
major	2880	2885	O
gangliosides	2886	2898	O
in	2899	2901	O
the	2902	2905	O
brain	2906	2911	B-Organ
is	2912	2914	O
GM1	2915	2918	O
.	2918	2919	O

Soluble	2920	2927	O
Abeta	2928	2933	O
binds	2934	2939	O
GM1	2940	2943	O
and	2944	2947	O
the	2948	2951	O
formed	2952	2958	O
complexes	2959	2968	O
accelerate	2969	2979	O
Abeta	2980	2985	O
fibrillogenesis	2986	3001	O
by	3002	3004	O
acting	3005	3011	O
as	3012	3014	O
a	3015	3016	O
seed	3017	3021	O
for	3022	3025	O
Abeta	3026	3031	O
[	3032	3033	O
152	3033	3036	O
]	3036	3037	O
.	3037	3038	O

In	3039	3041	O
the	3042	3045	O
presence	3046	3054	O
of	3055	3057	O
GM1	3058	3061	O
,	3061	3062	O
Abeta	3063	3068	O
is	3069	3071	O
more	3072	3076	O
neurotoxic	3077	3087	O
than	3088	3092	O
Abeta	3093	3098	O
alone	3099	3104	O
,	3104	3105	O
and	3106	3109	O
cholesterol	3110	3121	O
-	3121	3122	O
rich	3122	3126	O
membranes	3127	3136	B-Cellular_component
demonstrate	3137	3148	O
accelerated	3149	3160	O
Abeta	3161	3166	O
binding	3167	3174	O
due	3175	3178	O
to	3179	3181	O
the	3182	3185	O
formation	3186	3195	O
of	3196	3198	O
GM1	3199	3202	O
clusters	3203	3211	O
[	3212	3213	O
153	3213	3216	O
,	3216	3217	O
154	3218	3221	O
]	3221	3222	O
.	3222	3223	O

As	3224	3226	O
GM1	3227	3230	O
is	3231	3233	O
a	3234	3235	O
major	3236	3241	O
component	3242	3251	O
of	3252	3254	O
lipid	3255	3260	B-Organism_substance
rafts	3261	3266	I-Organism_substance
and	3267	3270	O
recent	3271	3277	O
studies	3278	3285	O
suggest	3286	3293	O
that	3294	3298	O
Abeta	3299	3304	O
accumulation	3305	3317	O
in	3318	3320	O
these	3321	3326	O
lipid	3327	3332	B-Organism_substance
rafts	3333	3338	I-Organism_substance
is	3339	3341	O
an	3342	3344	O
early	3345	3350	O
event	3351	3356	O
in	3357	3359	O
AD	3360	3362	O
development	3363	3374	O
,	3374	3375	O
GM1	3376	3379	O
might	3380	3385	O
play	3386	3390	O
an	3391	3393	O
important	3394	3403	O
role	3404	3408	O
in	3409	3411	O
the	3412	3415	O
early	3416	3421	O
steps	3422	3427	O
in	3428	3430	O
AD	3431	3433	O
pathogenesis	3434	3446	O
[	3447	3448	O
155	3448	3451	O
,	3451	3452	O
156	3453	3456	O
]	3456	3457	O
.	3457	3458	O

In	3459	3461	O
summary	3462	3469	O
,	3469	3470	O
several	3471	3478	O
proteins	3479	3487	O
are	3488	3491	O
associated	3492	3502	O
with	3503	3507	O
Abeta	3508	3513	O
aggregates	3514	3524	O
in	3525	3527	O
the	3528	3531	O
AD	3532	3534	B-Organ
brain	3535	3540	I-Organ
and	3541	3544	O
contribute	3545	3555	O
to	3556	3558	O
the	3559	3562	O
aggregation	3563	3574	O
of	3575	3577	O
Abeta	3578	3583	O
and	3584	3587	O
should	3588	3594	O
,	3594	3595	O
therefore	3596	3605	O
,	3605	3606	O
be	3607	3609	O
considered	3610	3620	O
as	3621	3623	O
amateur	3624	3631	O
chaperones	3632	3642	O
.	3642	3643	O

In	3644	3646	O
addition	3647	3655	O
,	3655	3656	O
they	3657	3661	O
might	3662	3667	O
play	3668	3672	O
a	3673	3674	O
role	3675	3679	O
in	3680	3682	O
triggering	3683	3693	O
inflammation	3694	3706	O
.	3706	3707	O

Mineralization	0	14	O
(	15	16	O
red	16	19	O
)	19	20	O
of	21	23	O
the	24	27	O
aorta	28	33	B-Multi-tissue_structure
is	34	36	O
prevented	37	46	O
by	47	49	O
local	50	55	O
(	56	57	O
left	57	61	O
)	61	62	O
,	62	63	O
but	64	67	O
not	68	71	O
global	72	78	O
(	79	80	O
right	80	85	O
)	85	86	O
,	86	87	O
Mgp	88	91	O
expression	92	102	O
.	102	103	O

Basilar	0	7	B-Multi-tissue_structure
papilla	8	15	I-Multi-tissue_structure

The	16	19	O
basilar	20	27	B-Multi-tissue_structure
papilla	28	35	I-Multi-tissue_structure
is	36	38	O
found	39	44	O
in	45	47	O
a	48	49	O
recess	50	56	O
that	57	61	O
opens	62	67	O
into	68	72	O
the	73	76	O
saccular	77	85	B-Immaterial_anatomical_entity
space	86	91	I-Immaterial_anatomical_entity
at	92	94	O
one	95	98	O
end	99	102	O
,	102	103	O
and	104	107	O
is	108	110	O
limited	111	118	O
by	119	121	O
a	122	123	O
thin	124	128	O
contact	129	136	B-Multi-tissue_structure
membrane	137	145	I-Multi-tissue_structure
at	146	148	O
the	149	152	O
other	153	158	O
.	158	159	O

The	160	163	O
contact	164	171	B-Multi-tissue_structure
membrane	172	180	I-Multi-tissue_structure
separates	181	190	O
the	191	194	O
endolymphatic	195	208	B-Organism_substance
fluid	209	214	I-Organism_substance
in	215	217	O
the	218	221	O
papillar	222	230	B-Multi-tissue_structure
recess	231	237	O
from	238	242	O
the	243	246	O
perilymphatic	247	260	B-Organism_substance
fluid	261	266	I-Organism_substance
at	267	269	O
the	270	273	O
round	274	279	O
window	280	286	O
(	287	288	O
Lewis	288	293	O
and	294	297	O
Narins	298	304	O
1999	305	309	O
;	309	310	O
Wever	311	316	O
1985	317	321	O
)	321	322	O
.	322	323	O

The	324	327	O
recess	328	334	O
perimeter	335	344	O
is	345	347	O
roughly	348	355	O
oval	356	360	O
in	361	363	O
shape	364	369	O
;	369	370	O
in	371	373	O
the	374	377	O
bullfrog	378	386	O
,	386	387	O
Rana	388	392	O
catesbeiana	393	404	O
,	404	405	O
its	406	409	O
major	410	415	O
axis	416	420	O
is	421	423	O
approximately	424	437	O
200	438	441	O
mum	442	445	O
long	446	450	O
,	450	451	O
while	452	457	O
the	458	461	O
minor	462	467	O
axis	468	472	O
measures	473	481	O
approximately	482	495	O
150	496	499	O
mum	500	503	O
(	504	505	O
Van	505	508	O
Bergeijk	509	517	O
1957	518	522	O
)	522	523	O
.	523	524	O

In	525	527	O
the	528	531	O
leopard	532	539	O
frog	540	544	O
,	544	545	O
Rana	546	550	O
pipiens	551	558	O
pipiens	559	566	O
,	566	567	O
it	568	570	O
is	571	573	O
of	574	576	O
similar	577	584	O
size	585	589	O
(	590	591	O
personal	591	599	O
observation	600	611	O
,	611	612	O
RLMS	613	617	O
&	618	619	O
JMS	620	623	O
)	623	624	O
.	624	625	O

The	626	629	O
oval	630	634	O
perimeter	635	644	O
of	645	647	O
the	648	651	O
lumen	652	657	B-Immaterial_anatomical_entity
is	658	660	O
formed	661	667	O
from	668	672	O
limbic	673	679	B-Tissue
tissue	680	686	I-Tissue
;	686	687	O
a	688	689	O
substance	690	699	O
unique	700	706	O
to	707	709	O
the	710	713	O
inner	714	719	B-Multi-tissue_structure
ear	720	723	I-Multi-tissue_structure
,	723	724	O
and	725	728	O
similar	729	736	O
to	737	739	O
cartilage	740	749	B-Tissue
(	750	751	O
Wever	751	756	O
1985	757	761	O
)	761	762	O
.	762	763	O

The	764	767	O
sensory	768	775	B-Tissue
epithelium	776	786	I-Tissue
is	787	789	O
approximately	790	803	O
100	804	807	O
mum	808	811	O
long	812	816	O
.	816	817	O

It	818	820	O
occupies	821	829	O
a	830	831	O
curved	832	838	O
area	839	843	O
that	844	848	O
is	849	851	O
symmetrical	852	863	O
in	864	866	O
the	867	870	O
major	871	876	O
axis	877	881	O
of	882	884	O
the	885	888	O
elliptical	889	899	B-Immaterial_anatomical_entity
lumen	900	905	I-Immaterial_anatomical_entity
.	905	906	O

It	907	909	O
contains	910	918	O
approximately	919	932	O
60	933	935	O
hair	936	940	B-Cell
cells	941	946	I-Cell
(	947	948	O
measured	948	956	O
in	957	959	O
Rana	960	964	O
catesbeiana	965	976	O
)	976	977	O
,	977	978	O
from	979	983	O
which	984	989	O
the	990	993	O
stereovilli	994	1005	B-Cellular_component
protrude	1006	1014	O
into	1015	1019	O
the	1020	1023	O
lumen	1024	1029	B-Immaterial_anatomical_entity
and	1030	1033	O
connect	1034	1041	O
to	1042	1044	O
the	1045	1048	O
tectorial	1049	1058	B-Multi-tissue_structure
membrane	1059	1067	I-Multi-tissue_structure
(	1068	1069	O
Frishkopf	1069	1078	O
and	1079	1082	O
Flock	1083	1088	O
1974	1089	1093	O
)	1093	1094	O
.	1094	1095	O

Typically	1096	1105	O
the	1106	1109	O
orientation	1110	1121	O
of	1122	1124	O
the	1125	1128	O
hair	1129	1133	B-Cell
cells	1134	1139	I-Cell
,	1139	1140	O
as	1141	1143	O
defined	1144	1151	O
by	1152	1154	O
the	1155	1158	O
direction	1159	1168	O
to	1169	1171	O
which	1172	1177	O
the	1178	1181	O
v	1182	1183	O
-	1183	1184	O
shape	1184	1189	O
of	1190	1192	O
the	1193	1196	O
stereovilli	1197	1208	B-Cellular_component
bundle	1209	1215	O
points	1216	1222	O
(	1223	1224	O
Lewis	1224	1229	O
et	1230	1232	O
al	1233	1235	O
.	1235	1236	O
1985	1237	1241	O
)	1241	1242	O
,	1242	1243	O
is	1244	1246	O
away	1247	1251	O
from	1252	1256	O
the	1257	1260	O
sacculus	1261	1269	B-Multi-tissue_structure
in	1270	1272	O
Ranidae	1273	1280	O
.	1280	1281	O

The	1282	1285	O
tectorial	1286	1295	B-Multi-tissue_structure
membrane	1296	1304	I-Multi-tissue_structure
spans	1305	1310	O
the	1311	1314	O
lumen	1315	1320	B-Immaterial_anatomical_entity
of	1321	1323	O
the	1324	1327	O
papillar	1328	1336	B-Multi-tissue_structure
recess	1337	1343	O
.	1343	1344	O

It	1345	1347	O
occludes	1348	1356	O
about	1357	1362	O
half	1363	1367	O
the	1368	1371	O
lumen	1372	1377	B-Immaterial_anatomical_entity
,	1377	1378	O
and	1379	1382	O
consequently	1383	1395	O
takes	1396	1401	O
an	1402	1404	O
approximately	1405	1418	O
semi	1419	1423	O
-	1423	1424	O
circular	1424	1432	O
shape	1433	1438	O
when	1439	1443	O
viewed	1444	1450	O
from	1451	1455	O
the	1456	1459	O
saccular	1460	1468	B-Multi-tissue_structure
side	1469	1473	O
(	1474	1475	O
Frishkopf	1475	1484	O
and	1485	1488	O
Flock	1489	1494	O
1974	1495	1499	O
;	1499	1500	O
Wever	1501	1506	O
1985	1507	1511	O
)	1511	1512	O
.	1512	1513	O

The	1514	1517	O
membrane	1518	1526	B-Multi-tissue_structure
has	1527	1530	O
pores	1531	1536	O
at	1537	1539	O
the	1540	1543	O
surface	1544	1551	O
closest	1552	1559	O
to	1560	1562	O
the	1563	1566	O
epithelium	1567	1577	B-Tissue
,	1577	1578	O
into	1579	1583	O
which	1584	1589	O
the	1590	1593	O
tips	1594	1598	O
of	1599	1601	O
the	1602	1605	O
hair	1606	1610	B-Multi-tissue_structure
bundles	1611	1618	O
project	1619	1626	O
(	1627	1628	O
Lewis	1628	1633	O
and	1634	1637	O
Narins	1638	1644	O
1999	1645	1649	O
)	1649	1650	O
.	1650	1651	O
4	1651	1652	O

Haplotype	0	9	O
block	10	15	O
structure	16	25	O
from	26	30	O
one	31	34	O
replicate	35	44	O
generated	45	54	O
by	55	57	O
the	58	61	O
block	62	67	O
method	68	74	O
(	75	76	O
ALS	76	79	O
)	79	80	O
.	80	81	O

Competing	0	9	O
interests	10	19	O

The	20	23	O
authors	24	31	O
declare	32	39	O
that	40	44	O
they	45	49	O
have	50	54	O
no	55	57	O
competing	58	67	O
interests	68	77	O
.	77	78	O

Background	0	10	O

Previous	11	19	O
publications	20	32	O
indicate	33	41	O
that	42	46	O
acupuncture	47	58	O
is	59	61	O
efficient	62	71	O
for	72	75	O
the	76	79	O
treatment	80	89	O
of	90	92	O
pelvic	93	99	B-Multi-tissue_structure
girdle	100	106	I-Multi-tissue_structure
pain	107	111	O
,	111	112	O
PGP	113	116	O
,	116	117	O
in	118	120	O
pregnant	121	129	O
women	130	135	O
.	135	136	O

However	137	144	O
,	144	145	O
the	146	149	O
use	150	153	O
of	154	156	O
acupuncture	157	168	O
for	169	172	O
PGP	173	176	O
is	177	179	O
rare	180	184	O
due	185	188	O
to	189	191	O
insufficient	192	204	O
documentation	205	218	O
of	219	221	O
adverse	222	229	O
effects	230	237	O
of	238	240	O
this	241	245	O
treatment	246	255	O
in	256	258	O
this	259	263	O
specific	264	272	O
condition	273	282	O
.	282	283	O

The	284	287	O
aim	288	291	O
of	292	294	O
the	295	298	O
present	299	306	O
work	307	311	O
was	312	315	O
to	316	318	O
assess	319	325	O
adverse	326	333	O
effects	334	341	O
of	342	344	O
acupuncture	345	356	O
on	357	359	O
the	360	363	O
pregnancy	364	373	O
,	373	374	O
mother	375	381	O
,	381	382	O
delivery	383	391	O
and	392	395	O
the	396	399	O
fetus	400	405	B-Developing_anatomical_structure
/	405	406	O
neonate	406	413	O
in	414	416	O
comparison	417	427	O
with	428	432	O
women	433	438	O
that	439	443	O
received	444	452	O
stabilising	453	464	O
exercises	465	474	O
as	475	477	O
adjunct	478	485	O
to	486	488	O
standard	489	497	O
treatment	498	507	O
or	508	510	O
standard	511	519	O
treatment	520	529	O
alone	530	535	O
.	535	536	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

MP	23	25	O
prepared	26	34	O
the	35	38	O
first	39	44	O
draft	45	50	O
with	51	55	O
the	56	59	O
assistance	60	70	O
of	71	73	O
JLdR	74	78	O
.	78	79	O

Other	80	85	O
authors	86	93	O
reviewed	94	102	O
the	103	106	O
manuscript	107	117	O
,	117	118	O
provided	119	127	O
further	128	135	O
contributions	136	149	O
and	150	153	O
suggestions	154	165	O
.	165	166	O

All	167	170	O
of	171	173	O
the	174	177	O
authors	178	185	O
worked	186	192	O
collectively	193	205	O
to	206	208	O
develop	209	216	O
the	217	220	O
algorithms	221	231	O
and	232	235	O
methods	236	243	O
described	244	253	O
in	254	256	O
this	257	261	O
paper	262	267	O
.	267	268	O

Study	0	5	O
of	6	8	O
freeze	9	15	O
-	15	16	O
thaw	16	20	O
effects	21	28	O
and	29	32	O
CSF	33	36	O
pH	37	39	O
on	40	42	O
tissue	43	49	B-Tissue
RNA	50	53	O
integrity	54	63	O

We	64	66	O
have	67	71	O
long	72	76	O
suspected	77	86	O
,	86	87	O
on	88	90	O
the	91	94	O
basis	95	100	O
of	101	103	O
our	104	107	O
tissue	108	114	B-Tissue
banking	115	122	O
experience	123	133	O
,	133	134	O
that	135	139	O
most	140	144	O
of	145	147	O
the	148	151	O
molecular	152	161	O
degradation	162	173	O
that	174	178	O
occurs	179	185	O
in	186	188	O
banked	189	195	O
tissue	196	202	B-Tissue
is	203	205	O
due	206	209	O
to	210	212	O
repeated	213	221	O
freeze	222	228	O
-	228	229	O
thaw	229	233	O
cycles	234	240	O
,	240	241	O
which	242	247	O
occur	248	253	O
due	254	257	O
to	258	260	O
improper	261	269	O
handling	270	278	O
during	279	285	O
dissection	286	296	O
for	297	300	O
tissue	301	307	B-Tissue
retrieval	308	317	O
or	318	320	O
due	321	324	O
to	325	327	O
freezer	328	335	O
malfunctions	336	348	O
.	348	349	O

Our	350	353	O
freezers	354	362	O
are	363	366	O
currently	367	376	O
protected	377	386	O
by	387	389	O
temperature	390	401	O
-	401	402	O
sensitive	402	411	O
alarms	412	418	O
that	419	423	O
automatically	424	437	O
telephone	438	447	O
maintenance	448	459	O
and	460	463	O
tissue	464	470	B-Tissue
banking	471	478	O
personnel	479	488	O
when	489	493	O
the	494	497	O
temperature	498	509	O
reaches	510	517	O
a	518	519	O
certain	520	527	O
level	528	533	O
.	533	534	O

More	535	539	O
protection	540	550	O
is	551	553	O
preferable	554	564	O
,	564	565	O
with	566	570	O
CO2	571	574	O
tanks	575	580	O
for	581	584	O
backup	585	591	O
cooling	592	599	O
the	600	603	O
optimum	604	611	O
(	612	613	O
but	613	616	O
expensive	617	626	O
)	626	627	O
approach	628	636	O
.	636	637	O

We	638	640	O
plan	641	645	O
to	646	648	O
systematically	649	663	O
investigate	664	675	O
the	676	679	O
effects	680	687	O
of	688	690	O
thawing	691	698	O
and	699	702	O
refreezing	703	713	O
on	714	716	O
RNA	717	720	O
integrity	721	730	O
,	730	731	O
by	732	734	O
deliberately	735	747	O
thawing	748	755	O
and	756	759	O
freezing	760	768	O
small	769	774	O
samples	775	782	B-Tissue
of	783	785	O
brain	786	791	B-Tissue
tissue	792	798	I-Tissue
over	799	803	O
varying	804	811	O
time	812	816	O
intervals	817	826	O
and	827	830	O
temperatures	831	843	O
.	843	844	O

Printing	0	8	O
solution	9	17	O

Several	18	25	O
transfection	26	38	O
reagents	39	47	O
were	48	52	O
tested	53	59	O
(	60	61	O
data	61	65	O
not	66	69	O
shown	70	75	O
)	75	76	O
,	76	77	O
and	78	81	O
we	82	84	O
found	85	90	O
that	91	95	O
the	96	99	O
X	100	101	O
-	101	102	O
tremeGENE	102	111	O
siRNA	112	117	O
transfection	118	130	O
reagent	131	138	O
(	139	140	O
Roche	140	145	O
)	145	146	O
gave	147	151	O
good	152	156	O
transfection	157	169	O
efficiencies	170	182	O
both	183	187	O
for	188	191	O
plasmids	192	200	B-Cellular_component
and	201	204	O
siRNAs	205	211	O
,	211	212	O
and	213	216	O
chose	217	222	O
to	223	225	O
use	226	229	O
this	230	234	O
reagent	235	242	O
for	243	246	O
all	247	250	O
transfected	251	262	O
cell	263	267	B-Cell
microarray	268	278	O
experiments	279	290	O
in	291	293	O
the	294	297	O
present	298	305	O
study	306	311	O
.	311	312	O

For	313	316	O
printing	317	325	O
the	326	329	O
arrays	330	336	O
,	336	337	O
one	338	341	O
major	342	347	O
challenge	348	357	O
is	358	360	O
to	361	363	O
find	364	368	O
a	369	370	O
good	371	375	O
balance	376	383	O
between	384	391	O
high	392	396	O
transfection	397	409	O
efficiency	410	420	O
and	421	424	O
spatially	425	434	O
confined	435	443	O
spots	444	449	O
to	450	452	O
avoid	453	458	O
cross	459	464	O
-	464	465	O
contamination	465	478	O
between	479	486	O
the	487	490	O
spots	491	496	O
.	496	497	O

In	498	500	O
order	501	506	O
to	507	509	O
optimize	510	518	O
the	519	522	O
reverse	523	530	O
transfection	531	543	O
protocol	544	552	O
for	553	556	O
HEK	557	560	B-Cell
293ind	561	567	I-Cell
-	567	568	I-Cell
ICER	568	572	I-Cell
IIgamma	573	580	I-Cell
cells	581	586	I-Cell
(	587	588	O
see	588	591	O
below	592	597	O
)	597	598	O
and	599	602	O
X	603	604	O
-	604	605	O
tremeGENE	605	614	O
transfection	615	627	O
reagent	628	635	O
,	635	636	O
we	637	639	O
investigated	640	652	O
the	653	656	O
effect	657	663	O
of	664	666	O
varying	667	674	O
the	675	678	O
concentrations	679	693	O
of	694	696	O
gelatine	697	705	O
and	706	709	O
sucrose	710	717	O
in	718	720	O
the	721	724	O
printing	725	733	O
solution	734	742	O
.	742	743	O

These	744	749	O
reagents	750	758	O
have	759	763	O
been	764	768	O
reported	769	777	O
to	778	780	O
influence	781	790	O
both	791	795	O
the	796	799	O
transfection	800	812	O
efficiency	813	823	O
and	824	827	O
spot	828	832	O
integrity	833	842	O
(	843	844	O
6	844	845	O
,	845	846	O
27	846	848	O
)	848	849	O
.	849	850	O

Sucrose	851	858	O
was	859	862	O
observed	863	871	O
to	872	874	O
be	875	877	O
specifically	878	890	O
beneficial	891	901	O
for	902	905	O
obtaining	906	915	O
high	916	920	O
transfection	921	933	O
efficiency	934	944	O
when	945	949	O
storing	950	957	O
the	958	961	O
arrays	962	968	O
for	969	972	O
several	973	980	O
weeks	981	986	O
before	987	993	O
use	994	997	O
(	998	999	O
data	999	1003	O
not	1004	1007	O
shown	1008	1013	O
)	1013	1014	O
.	1014	1015	O

Figure	1016	1022	O
1A	1023	1025	O
and	1026	1029	O
B	1030	1031	O
show	1032	1036	O
representative	1037	1051	O
images	1052	1058	O
of	1059	1061	O
the	1062	1065	O
observed	1066	1074	O
effects	1075	1082	O
of	1083	1085	O
varying	1086	1093	O
the	1094	1097	O
concentrations	1098	1112	O
of	1113	1115	O
gelatine	1116	1124	O
and	1125	1128	O
sucrose	1129	1136	O
.	1136	1137	O

We	1138	1140	O
observed	1141	1149	O
that	1150	1154	O
the	1155	1158	O
transfection	1159	1171	O
efficiency	1172	1182	O
increased	1183	1192	O
with	1193	1197	O
increasing	1198	1208	O
gelatine	1209	1217	O
concentration	1218	1231	O
(	1232	1233	O
tested	1233	1239	O
in	1240	1242	O
the	1243	1246	O
range	1247	1252	O
0	1253	1254	O
.	1254	1255	O
01	1255	1257	O
-	1257	1258	O
0	1258	1259	O
.	1259	1260	O
40	1260	1262	O
%	1262	1263	O
)	1263	1264	O
.	1264	1265	O

However	1266	1273	O
,	1273	1274	O
an	1275	1277	O
increased	1278	1287	O
disturbance	1288	1299	O
of	1300	1302	O
the	1303	1306	O
spatial	1307	1314	O
definition	1315	1325	O
of	1326	1328	O
the	1329	1332	O
spots	1333	1338	O
was	1339	1342	O
observed	1343	1351	O
with	1352	1356	O
increasing	1357	1367	O
concentrations	1368	1382	O
of	1383	1385	O
gelatine	1386	1394	O
or	1395	1397	O
sucrose	1398	1405	O
(	1406	1407	O
tested	1407	1413	O
in	1414	1416	O
the	1417	1420	O
range	1421	1426	O
0	1427	1428	O
-	1428	1429	O
100	1429	1432	O
mM	1433	1435	O
)	1435	1436	O
.	1436	1437	O

A	1438	1439	O
combined	1440	1448	O
effect	1449	1455	O
of	1456	1458	O
the	1459	1462	O
concentrations	1463	1477	O
of	1478	1480	O
gelatine	1481	1489	O
and	1490	1493	O
sucrose	1494	1501	O
was	1502	1505	O
also	1506	1510	O
observed	1511	1519	O
,	1519	1520	O
as	1521	1523	O
low	1524	1527	O
concentrations	1528	1542	O
of	1543	1545	O
gelatine	1546	1554	O
allowed	1555	1562	O
us	1563	1565	O
to	1566	1568	O
use	1569	1572	O
higher	1573	1579	O
concentrations	1580	1594	O
of	1595	1597	O
sucrose	1598	1605	O
than	1606	1610	O
with	1611	1615	O
higher	1616	1622	O
concentrations	1623	1637	O
of	1638	1640	O
gelatine	1641	1649	O
before	1650	1656	O
cells	1657	1662	B-Cell
spread	1663	1669	O
outside	1670	1677	O
the	1678	1681	O
spots	1682	1687	O
.	1687	1688	O

Based	1689	1694	O
on	1695	1697	O
several	1698	1705	O
optimizing	1706	1716	O
experiments	1717	1728	O
,	1728	1729	O
we	1730	1732	O
found	1733	1738	O
that	1739	1743	O
3	1744	1745	O
microl	1746	1752	O
X	1753	1754	O
-	1754	1755	O
tremeGENE	1755	1764	O
solution	1765	1773	O
per	1774	1777	O
microgram	1778	1787	O
nucleic	1788	1795	O
acid	1796	1800	O
,	1800	1801	O
25	1802	1804	O
mM	1805	1807	O
sucrose	1808	1815	O
and	1816	1819	O
0	1820	1821	O
.	1821	1822	O
1	1822	1823	O
%	1823	1824	O
gelatine	1825	1833	O
in	1834	1836	O
the	1837	1840	O
final	1841	1846	O
printing	1847	1855	O
solution	1856	1864	O
reproducibly	1865	1877	O
gave	1878	1882	O
spatial	1883	1890	O
restricted	1891	1901	O
transfection	1902	1914	O
with	1915	1919	O
high	1920	1924	O
transfection	1925	1937	O
efficiency	1938	1948	O
printing	1949	1957	O
the	1958	1961	O
arrays	1962	1968	O
with	1969	1973	O
both	1974	1978	O
a	1979	1980	O
pipette	1981	1988	O
tip	1989	1992	O
and	1993	1996	O
a	1997	1998	O
hand	1999	2003	O
-	2003	2004	O
held	2004	2008	O
arrayer	2009	2016	O
(	2017	2018	O
see	2018	2021	O
below	2022	2027	O
)	2027	2028	O
.	2028	2029	O

Figure	2031	2037	O
1	2038	2039	O
.	2039	2040	O

Effects	2041	2048	O
of	2049	2051	O
sucrose	2052	2059	O
and	2060	2063	O
gelatine	2064	2072	O
concentrations	2073	2087	O
on	2088	2090	O
spot	2091	2095	O
integrity	2096	2105	O
and	2106	2109	O
transfection	2110	2122	O
efficiency	2123	2133	O
.	2133	2134	O

(	2135	2136	O
A	2136	2137	O
)	2137	2138	O
Array	2139	2144	O
printed	2145	2152	O
with	2153	2157	O
pDsRed	2158	2164	O
(	2165	2166	O
50	2166	2168	O
ng	2169	2171	O
/	2171	2172	O
microl	2172	2178	O
)	2178	2179	O
in	2180	2182	O
a	2183	2184	O
printing	2185	2193	O
solution	2194	2202	O
with	2203	2207	O
different	2208	2217	O
gelatine	2218	2226	O
and	2227	2230	O
sucrose	2231	2238	O
concentrations	2239	2253	O
.	2253	2254	O

Scanning	2255	2263	O
image	2264	2269	O
of	2270	2272	O
the	2273	2276	O
whole	2277	2282	O
array	2283	2288	O
and	2289	2292	O
magnifications	2293	2307	O
of	2308	2310	O
specific	2311	2319	O
spots	2320	2325	O
.	2325	2326	O

(	2327	2328	O
B	2328	2329	O
)	2329	2330	O
Array	2331	2336	O
printed	2337	2344	O
with	2345	2349	O
pEGFP	2350	2355	O
(	2356	2357	O
50	2357	2359	O
ng	2360	2362	O
/	2362	2363	O
microl	2363	2369	O
)	2369	2370	O
in	2371	2373	O
a	2374	2375	O
printing	2376	2384	O
solution	2385	2393	O
with	2394	2398	O
25	2399	2401	O
mM	2402	2404	O
sucrose	2405	2412	O
and	2413	2416	O
four	2417	2421	O
different	2422	2431	O
concentrations	2432	2446	O
of	2447	2449	O
gelatine	2450	2458	O
.	2458	2459	O

Top	2460	2463	O
:	2463	2464	O
Box	2465	2468	O
plot	2469	2473	O
of	2474	2476	O
the	2477	2480	O
fluorescence	2481	2493	O
intensities	2494	2505	O
in	2506	2508	O
each	2509	2513	O
spot	2514	2518	O
(	2519	2520	O
n	2520	2521	O
=	2522	2523	O
32	2524	2526	O
-	2526	2527	O
34	2527	2529	O
)	2529	2530	O
.	2530	2531	O

Bottom	2532	2538	O
:	2538	2539	O
Scanning	2540	2548	O
image	2549	2554	O
showing	2555	2562	O
squares	2563	2570	O
of	2571	2573	O
seven	2574	2579	O
times	2580	2585	O
five	2586	2590	O
spots	2591	2596	O
for	2597	2600	O
the	2601	2604	O
four	2605	2609	O
gelatine	2610	2618	O
concentrations	2619	2633	O
.	2633	2634	O

From	2635	2639	O
left	2640	2644	O
to	2645	2647	O
right	2648	2653	O
:	2653	2654	O
0	2655	2656	O
.	2656	2657	O
01	2657	2659	O
,	2659	2660	O
0	2661	2662	O
.	2662	2663	O
05	2663	2665	O
,	2665	2666	O
0	2667	2668	O
.	2668	2669	O
1	2669	2670	O
and	2671	2674	O
0	2675	2676	O
.	2676	2677	O
2	2677	2678	O
%	2678	2679	O
gelatine	2680	2688	O
.	2688	2689	O

The	2690	2693	O
DNA	2694	2697	O
-	2697	2698	O
lipid	2698	2703	O
-	2703	2704	O
gelatine	2704	2712	O
-	2712	2713	O
sucrose	2713	2720	O
solutions	2721	2730	O
were	2731	2735	O
printed	2736	2743	O
manually	2744	2752	O
with	2753	2757	O
a	2758	2759	O
10	2760	2762	O
microl	2763	2769	O
pipette	2770	2777	O
tip	2778	2781	O
(	2782	2783	O
A	2783	2784	O
)	2784	2785	O
or	2786	2788	O
by	2789	2791	O
MicroCasterTM	2792	2805	O
manual	2806	2812	O
arrayer	2813	2820	O
system	2821	2827	O
(	2828	2829	O
B	2829	2830	O
)	2830	2831	O
.	2831	2832	O

In	2833	2835	O
a	2836	2837	O
1	2838	2839	O
.	2839	2840	O
5	2840	2841	O
ml	2842	2844	O
microcentrifuge	2845	2860	O
tube	2861	2865	O
,	2865	2866	O
plasmid	2867	2874	O
(	2875	2876	O
1	2876	2877	O
microg	2878	2884	O
/	2884	2885	O
microl	2885	2891	O
)	2891	2892	O
and	2893	2896	O
siRNA	2897	2902	O
were	2903	2907	O
mixed	2908	2913	O
with	2914	2918	O
growth	2919	2925	O
medium	2926	2932	O
without	2933	2940	O
fetal	2941	2946	B-Developing_anatomical_structure
calf	2947	2951	O
serum	2952	2957	B-Organism_substance
(	2958	2959	O
FCS	2959	2962	O
)	2962	2963	O
,	2963	2964	O
0	2965	2966	O
.	2966	2967	O
5	2967	2968	O
microl	2969	2975	O
1	2976	2977	O
.	2977	2978	O
5	2978	2979	O
M	2980	2981	O
sucrose	2982	2989	O
and	2990	2993	O
3	2994	2995	O
microl	2996	3002	O
X	3003	3004	O
-	3004	3005	O
tremeGENE	3005	3014	O
per	3015	3018	O
microgram	3019	3028	O
nucleic	3029	3036	O
acid	3037	3041	O
to	3042	3044	O
a	3045	3046	O
final	3047	3052	O
volume	3053	3059	O
of	3060	3062	O
22	3063	3065	O
.	3065	3066	O
5	3066	3067	O
microl	3068	3074	O
.	3074	3075	O

After	3076	3081	O
15	3082	3084	O
-	3084	3085	O
20	3085	3087	O
min	3088	3091	O
of	3092	3094	O
incubation	3095	3105	O
,	3105	3106	O
7	3107	3108	O
.	3108	3109	O
5	3109	3110	O
microl	3111	3117	O
0	3118	3119	O
.	3119	3120	O
4	3120	3121	O
%	3121	3122	O
gelatine	3123	3131	O
(	3132	3133	O
Type	3133	3137	O
B	3138	3139	O
,	3139	3140	O
G9391	3141	3146	O
,	3146	3147	O
Sigma	3148	3153	O
)	3153	3154	O
was	3155	3158	O
added	3159	3164	O
to	3165	3167	O
give	3168	3172	O
30	3173	3175	O
microl	3176	3182	O
printing	3183	3191	O
solution	3192	3200	O
.	3200	3201	O

The	3202	3205	O
gelatine	3206	3214	O
solution	3215	3223	O
was	3224	3227	O
prepared	3228	3236	O
as	3237	3239	O
described	3240	3249	O
by	3250	3252	O
Ziauddin	3253	3261	O
and	3262	3265	O
Sabatini	3266	3274	O
(	3275	3276	O
1	3276	3277	O
)	3277	3278	O
.	3278	3279	O

To	3280	3282	O
achieve	3283	3290	O
sufficient	3291	3301	O
level	3302	3307	O
of	3308	3310	O
expression	3311	3321	O
from	3322	3326	O
the	3327	3330	O
transfected	3331	3342	O
plasmids	3343	3351	O
,	3351	3352	O
25	3353	3355	O
-	3355	3356	O
50	3356	3358	O
ng	3359	3361	O
/	3361	3362	O
microl	3362	3368	O
pEGFP	3369	3374	O
-	3374	3375	O
N1	3375	3377	O
or	3378	3380	O
pDsRed	3381	3387	O
-	3387	3388	O
express	3388	3395	O
-	3395	3396	O
N1	3396	3398	O
and	3399	3402	O
50	3403	3405	O
-	3405	3406	O
75	3406	3408	O
ng	3409	3411	O
/	3411	3412	O
microl	3412	3418	O
of	3419	3421	O
CRE	3422	3425	O
or	3426	3428	O
NFkappaB	3429	3437	O
reporter	3438	3446	O
plasmids	3447	3455	B-Cellular_component
was	3456	3459	O
used	3460	3464	O
.	3464	3465	O

For	3466	3469	O
siRNA	3470	3475	O
studies	3476	3483	O
,	3483	3484	O
2	3485	3486	O
-	3486	3487	O
30	3487	3489	O
ng	3490	3492	O
/	3492	3493	O
microl	3493	3499	O
siRNA	3500	3505	O
in	3506	3508	O
the	3509	3512	O
final	3513	3518	O
printing	3519	3527	O
solution	3528	3536	O
was	3537	3540	O
used	3541	3545	O
.	3545	3546	O

Candle	0	6	O
wicks	7	12	O

Candles	13	20	O
with	21	25	O
a	26	27	O
lead	28	32	O
metal	33	38	O
core	39	43	O
contribute	44	54	O
to	55	57	O
lead	58	62	O
in	63	65	O
the	66	69	O
home	70	74	O
(	75	76	O
Nriagu	76	82	O
and	83	86	O
Kim	87	90	O
2000	91	95	O
;	95	96	O
van	97	100	O
Alphen	101	107	O
1999	108	112	O
)	112	113	O
.	113	114	O

Exposure	115	123	O
occurs	124	130	O
both	131	135	O
from	136	140	O
air	141	144	O
and	145	148	O
from	149	153	O
hand	154	158	O
-	158	159	O
to	159	161	O
-	161	162	O
mouth	162	167	O
activity	168	176	O
.	176	177	O

However	178	185	O
,	185	186	O
to	187	189	O
date	190	194	O
,	194	195	O
no	196	198	O
children	199	207	O
'	207	208	O
s	208	209	O
EBLs	210	214	O
traceable	215	224	O
to	225	227	O
candles	228	235	O
have	236	240	O
been	241	245	O
reported	246	254	O
.	254	255	O

In	256	258	O
2002	259	263	O
,	263	264	O
the	265	268	O
CPSC	269	273	O
banned	274	280	O
candlewicks	281	292	O
containing	293	303	O
>	304	305	O
0	306	307	O
.	307	308	O
06	308	310	O
%	310	311	O
lead	312	316	O
(	317	318	O
CPSC	318	322	O
2003	323	327	O
)	327	328	O
.	328	329	O

Variables	0	9	O

Our	10	13	O
study	14	19	O
used	20	24	O
the	25	28	O
following	29	38	O
9	39	40	O
HRQOL	41	46	O
questions	47	56	O
from	57	61	O
the	62	65	O
2004	66	70	O
Rhode	71	76	O
Island	77	83	O
BRFSS	84	89	O
:	89	90	O
1	91	92	O
)	92	93	O
self	94	98	O
-	98	99	O
rated	99	104	O
general	105	112	O
health	113	119	O
status	120	126	O
;	126	127	O
and	128	131	O
self	132	136	O
-	136	137	O
reported	137	145	O
number	146	152	O
of	153	155	O
healthy	156	163	O
and	164	167	O
unhealthy	168	177	O
days	178	182	O
in	183	185	O
the	186	189	O
previous	190	198	O
30	199	201	O
days	202	206	O
for	207	210	O
2	211	212	O
)	212	213	O
physical	214	222	O
health	223	229	O
,	229	230	O
3	231	232	O
)	232	233	O
mental	234	240	O
health	241	247	O
,	247	248	O
4	249	250	O
)	250	251	O
physical	252	260	O
or	261	263	O
mental	264	270	O
health	271	277	O
-	277	278	O
related	278	285	O
activity	286	294	O
limitation	295	305	O
,	305	306	O
5	307	308	O
)	308	309	O
pain	310	314	O
-	314	315	O
related	315	322	O
activity	323	331	O
limitation	332	342	O
,	342	343	O
6	344	345	O
)	345	346	O
sad	347	350	O
,	350	351	O
blue	352	356	O
,	356	357	O
or	358	360	O
depressed	361	370	O
,	370	371	O
7	372	373	O
)	373	374	O
worried	375	382	O
,	382	383	O
tense	384	389	O
,	389	390	O
or	391	393	O
anxious	394	401	O
,	401	402	O
8	403	404	O
)	404	405	O
lack	406	410	O
of	411	413	O
rest	414	418	O
or	419	421	O
sleep	422	427	O
,	427	428	O
and	429	432	O
9	433	434	O
)	434	435	O
lack	436	440	O
of	441	443	O
energy	444	450	O
(	451	452	O
1	452	453	O
,	453	454	O
2	454	455	O
,	455	456	O
15	456	458	O
)	458	459	O
.	459	460	O

We	461	463	O
created	464	471	O
9	472	473	O
dichotomous	474	485	O
indicator	486	495	O
variables	496	505	O
.	505	506	O

The	507	510	O
responses	511	520	O
to	521	523	O
the	524	527	O
self	528	532	O
-	532	533	O
rated	533	538	O
general	539	546	O
health	547	553	O
status	554	560	O
question	561	569	O
were	570	574	O
dichotomized	575	587	O
into	588	592	O
"	593	594	O
poor	594	598	O
"	598	599	O
(	600	601	O
poor	601	605	O
or	606	608	O
fair	609	613	O
)	613	614	O
health	615	621	O
or	622	624	O
"	625	626	O
good	626	630	O
"	630	631	O
(	632	633	O
good	633	637	O
,	637	638	O
very	639	643	O
good	644	648	O
,	648	649	O
or	650	652	O
excellent	653	662	O
)	662	663	O
health	664	670	O
.	670	671	O

The	672	675	O
indicators	676	686	O
measured	687	695	O
in	696	698	O
days	699	703	O
were	704	708	O
dichotomized	709	721	O
at	722	724	O
a	725	726	O
cutoff	727	733	O
value	734	739	O
of	740	742	O
14	743	745	O
or	746	748	O
more	749	753	O
days	754	758	O
of	759	761	O
poor	762	766	O
health	767	773	O
in	774	776	O
the	777	780	O
previous	781	789	O
month	790	795	O
compared	796	804	O
to	805	807	O
less	808	812	O
than	813	817	O
14	818	820	O
days	821	825	O
(	826	827	O
3	827	828	O
)	828	829	O
.	829	830	O

We	831	833	O
selected	834	842	O
the	843	846	O
14	847	849	O
-	849	850	O
day	850	853	O
minimum	854	861	O
period	862	868	O
because	869	876	O
most	877	881	O
of	882	884	O
the	885	888	O
publications	889	901	O
we	902	904	O
reviewed	905	913	O
that	914	918	O
use	919	922	O
the	923	926	O
BRFSS	927	932	O
HRQOL	933	938	O
indicators	939	949	O
(	950	951	O
outcomes	951	959	O
)	959	960	O
use	961	964	O
the	965	968	O
cutoff	969	975	O
of	976	978	O
14	979	981	O
or	982	984	O
more	985	989	O
days	990	994	O
compared	995	1003	O
to	1004	1006	O
13	1007	1009	O
or	1010	1012	O
fewer	1013	1018	O
days	1019	1023	O
(	1024	1025	O
3	1025	1026	O
-	1026	1027	O
5	1027	1028	O
,	1028	1029	O
7	1029	1030	O
-	1030	1031	O
11	1031	1033	O
,	1033	1034	O
16	1034	1036	O
,	1036	1037	O
17	1037	1039	O
)	1039	1040	O
.	1040	1041	O

Adopting	1042	1050	O
this	1051	1055	O
precedent	1056	1065	O
ensured	1066	1073	O
comparability	1074	1087	O
.	1087	1088	O

In	1089	1091	O
addition	1092	1100	O
,	1100	1101	O
clinicians	1102	1112	O
and	1113	1116	O
clinical	1117	1125	O
researchers	1126	1137	O
often	1138	1143	O
use	1144	1147	O
this	1148	1152	O
period	1153	1159	O
as	1160	1162	O
a	1163	1164	O
marker	1165	1171	O
for	1172	1175	O
clinical	1176	1184	O
depression	1185	1195	O
and	1196	1199	O
anxiety	1200	1207	O
disorders	1208	1217	O
,	1217	1218	O
and	1219	1222	O
long	1223	1227	O
symptomatic	1228	1239	O
durations	1240	1249	O
are	1250	1253	O
associated	1254	1264	O
with	1265	1269	O
high	1270	1274	O
levels	1275	1281	O
of	1282	1284	O
activity	1285	1293	O
limitation	1294	1304	O
(	1305	1306	O
2	1306	1307	O
,	1307	1308	O
18	1308	1310	O
)	1310	1311	O
.	1311	1312	O

Detailed	1313	1321	O
definitions	1322	1333	O
of	1334	1336	O
the	1337	1340	O
9	1341	1342	O
indicators	1343	1353	O
are	1354	1357	O
available	1358	1367	O
in	1368	1370	O
our	1371	1374	O
previous	1375	1383	O
article	1384	1391	O
(	1392	1393	O
1	1393	1394	O
)	1394	1395	O
or	1396	1398	O
are	1399	1402	O
accessible	1403	1413	O
through	1414	1421	O
the	1422	1425	O
Centers	1426	1433	O
for	1434	1437	O
Disease	1438	1445	O
Control	1446	1453	O
and	1454	1457	O
Prevention	1458	1468	O
'	1468	1469	O
s	1469	1470	O
HRQOL	1471	1476	O
Web	1477	1480	O
site	1481	1485	O
(	1486	1487	O
2	1487	1488	O
)	1488	1489	O
.	1489	1490	O

We	1491	1493	O
chose	1494	1499	O
12	1500	1502	O
predictors	1503	1513	O
for	1514	1517	O
the	1518	1521	O
analysis	1522	1530	O
:	1530	1531	O
5	1532	1533	O
standard	1534	1542	O
demographic	1543	1554	O
measures	1555	1563	O
(	1564	1565	O
age	1565	1568	O
,	1568	1569	O
sex	1570	1573	O
,	1573	1574	O
race	1575	1579	O
/	1579	1580	O
Hispanic	1580	1588	O
ethnicity	1589	1598	O
,	1598	1599	O
annual	1600	1606	O
income	1607	1613	O
,	1613	1614	O
and	1615	1618	O
employment	1619	1629	O
status	1630	1636	O
)	1636	1637	O
;	1637	1638	O
4	1639	1640	O
health	1641	1647	O
conditions	1648	1658	O
(	1659	1660	O
asthma	1660	1666	O
,	1666	1667	O
diabetes	1668	1676	O
,	1676	1677	O
obesity	1678	1685	O
,	1685	1686	O
and	1687	1690	O
physical	1691	1699	O
disability	1700	1710	O
)	1710	1711	O
;	1711	1712	O
and	1713	1716	O
3	1717	1718	O
health	1719	1725	O
risk	1726	1730	O
behaviors	1731	1740	O
(	1741	1742	O
smoking	1742	1749	O
,	1749	1750	O
chronic	1751	1758	O
alcohol	1759	1766	O
use	1767	1770	O
,	1770	1771	O
and	1772	1775	O
no	1776	1778	O
leisure	1779	1786	O
-	1786	1787	O
time	1787	1791	O
physical	1792	1800	O
activity	1801	1809	O
)	1809	1810	O
.	1810	1811	O

These	1812	1817	O
predictors	1818	1828	O
paralleled	1829	1839	O
the	1840	1843	O
results	1844	1851	O
of	1852	1854	O
other	1855	1860	O
studies	1861	1868	O
that	1869	1873	O
have	1874	1878	O
examined	1879	1887	O
relationships	1888	1901	O
between	1902	1909	O
a	1910	1911	O
specific	1912	1920	O
HRQOL	1921	1926	O
indicator	1927	1936	O
and	1937	1940	O
various	1941	1948	O
predictors	1949	1959	O
(	1960	1961	O
17	1961	1963	O
,	1963	1964	O
19	1964	1966	O
)	1966	1967	O
,	1967	1968	O
or	1969	1971	O
that	1972	1976	O
have	1977	1981	O
examined	1982	1990	O
multiple	1991	1999	O
HRQOL	2000	2005	O
indicators	2006	2016	O
in	2017	2019	O
relation	2020	2028	O
to	2029	2031	O
demographics	2032	2044	O
(	2045	2046	O
4	2046	2047	O
,	2047	2048	O
20	2048	2050	O
)	2050	2051	O
,	2051	2052	O
health	2053	2059	O
risks	2060	2065	O
(	2066	2067	O
5	2067	2068	O
,	2068	2069	O
10	2069	2071	O
,	2071	2072	O
21	2072	2074	O
)	2074	2075	O
,	2075	2076	O
or	2077	2079	O
specific	2080	2088	O
health	2089	2095	O
conditions	2096	2106	O
(	2107	2108	O
6	2108	2109	O
-	2109	2110	O
9	2110	2111	O
,	2111	2112	O
12	2112	2114	O
,	2114	2115	O
22	2115	2117	O
)	2117	2118	O
.	2118	2119	O

We	2120	2122	O
dichotomized	2123	2135	O
some	2136	2140	O
predictors	2141	2151	O
for	2152	2155	O
the	2156	2159	O
analysis	2160	2168	O
(	2169	2170	O
ie	2170	2172	O
,	2172	2173	O
sex	2174	2177	O
,	2177	2178	O
current	2179	2186	O
smoking	2187	2194	O
,	2194	2195	O
alcohol	2196	2203	O
use	2204	2207	O
,	2207	2208	O
physical	2209	2217	O
activity	2218	2226	O
,	2226	2227	O
asthma	2228	2234	O
,	2234	2235	O
diabetes	2236	2244	O
,	2244	2245	O
obesity	2246	2253	O
,	2253	2254	O
and	2255	2258	O
disability	2259	2269	O
)	2269	2270	O
,	2270	2271	O
whereas	2272	2279	O
other	2280	2285	O
predictors	2286	2296	O
had	2297	2300	O
multiple	2301	2309	O
categories	2310	2320	O
(	2321	2322	O
ie	2322	2324	O
,	2324	2325	O
age	2326	2329	O
,	2329	2330	O
race	2331	2335	O
/	2335	2336	O
Hispanic	2336	2344	O
ethnicity	2345	2354	O
,	2354	2355	O
income	2356	2362	O
,	2362	2363	O
and	2364	2367	O
employment	2368	2378	O
status	2379	2385	O
)	2385	2386	O
.	2386	2387	O

The	2388	2391	O
definitions	2392	2403	O
of	2404	2406	O
the	2407	2410	O
12	2411	2413	O
predictors	2414	2424	O
are	2425	2428	O
available	2429	2438	O
in	2439	2441	O
our	2442	2445	O
previous	2446	2454	O
article	2455	2462	O
(	2463	2464	O
1	2464	2465	O
)	2465	2466	O
.	2466	2467	O

Reference	2468	2477	O
groups	2478	2484	O
chosen	2485	2491	O
for	2492	2495	O
the	2496	2499	O
IRT	2500	2503	O
model	2504	2509	O
were	2510	2514	O
those	2515	2520	O
having	2521	2527	O
the	2528	2531	O
lowest	2532	2538	O
risk	2539	2543	O
for	2544	2547	O
poor	2548	2552	O
or	2553	2555	O
fair	2556	2560	O
general	2561	2568	O
health	2569	2575	O
and	2576	2579	O
usually	2580	2587	O
the	2588	2591	O
lowest	2592	2598	O
risk	2599	2603	O
for	2604	2607	O
the	2608	2611	O
other	2612	2617	O
HRQOL	2618	2623	O
variables	2624	2633	O
as	2634	2636	O
well	2637	2641	O
.	2641	2642	O

Results	0	7	O

1	0	1	O
.	1	2	O

Introduction	3	15	O

Phase	16	21	O
I	22	23	O
clinical	24	32	O
trials	33	39	O
of	40	42	O
new	43	46	O
anticancer	47	57	O
agents	58	64	O
have	65	69	O
been	70	74	O
commonly	75	83	O
conducted	84	93	O
using	94	99	O
the	100	103	O
method	104	110	O
of	111	113	O
modified	114	122	O
Fibonacci	123	132	O
[	133	134	O
1	134	135	O
]	135	136	O
.	136	137	O

In	138	140	O
brief	141	146	O
,	146	147	O
3	148	149	O
patients	150	158	O
are	159	162	O
treated	163	170	O
at	171	173	O
a	174	175	O
starting	176	184	O
dose	185	189	O
which	190	195	O
is	196	198	O
typically	199	208	O
one	209	212	O
tenth	213	218	O
of	219	221	O
the	222	225	O
dose	226	230	O
that	231	235	O
is	236	238	O
lethal	239	245	O
to	246	248	O
10	249	251	O
%	251	252	O
of	253	255	O
animals	256	263	O
defined	264	271	O
in	272	274	O
preclinical	275	286	O
studies	287	294	O
.	294	295	O

If	296	298	O
none	299	303	O
of	304	306	O
the	307	310	O
3	311	312	O
patients	313	321	O
experiences	322	333	O
DLT	334	337	O
,	337	338	O
then	339	343	O
the	344	347	O
next	348	352	O
3	353	354	O
patients	355	363	O
will	364	368	O
be	369	371	O
treated	372	379	O
at	380	382	O
the	383	386	O
next	387	391	O
higher	392	398	O
dose	399	403	O
.	403	404	O

If	405	407	O
DLT	408	411	O
is	412	414	O
observed	415	423	O
,	423	424	O
additional	425	435	O
patients	436	444	O
will	445	449	O
be	450	452	O
treated	453	460	O
at	461	463	O
the	464	467	O
same	468	472	O
or	473	475	O
lower	476	481	O
dose	482	486	O
level	487	492	O
to	493	495	O
determine	496	505	O
MTD	506	509	O
according	510	519	O
to	520	522	O
a	523	524	O
predetermined	525	538	O
schema	539	545	O
.	545	546	O

The	547	550	O
MTD	551	554	O
is	555	557	O
defined	558	565	O
as	566	568	O
the	569	572	O
highest	573	580	O
dose	581	585	O
reached	586	593	O
for	594	597	O
which	598	603	O
the	604	607	O
incidence	608	617	O
of	618	620	O
DLT	621	624	O
occurs	625	631	O
in	632	634	O
less	635	639	O
than	640	644	O
33	645	647	O
%	647	648	O
of	649	651	O
the	652	655	O
subjects	656	664	O
.	664	665	O

Typically	666	675	O
,	675	676	O
intrapatient	677	689	O
dose	690	694	O
escalation	695	705	O
is	706	708	O
not	709	712	O
allowed	713	720	O
.	720	721	O

There	722	727	O
are	728	731	O
several	732	739	O
shortcomings	740	752	O
associated	753	763	O
with	764	768	O
the	769	772	O
modified	773	781	O
-	781	782	O
Fibonacci	782	791	O
design	792	798	O
.	798	799	O

It	800	802	O
has	803	806	O
long	807	811	O
been	812	816	O
recognized	817	827	O
that	828	832	O
a	833	834	O
substantial	835	846	O
number	847	853	O
of	854	856	O
patients	857	865	O
are	866	869	O
likely	870	876	O
to	877	879	O
be	880	882	O
treated	883	890	O
at	891	893	O
subtherapeutic	894	908	O
doses	909	914	O
[	915	916	O
2	916	917	O
,	917	918	O
3	919	920	O
]	920	921	O
.	921	922	O

This	923	927	O
is	928	930	O
particularly	931	943	O
true	944	948	O
for	949	952	O
drugs	953	958	O
with	959	963	O
potential	964	973	O
anticancer	974	984	O
activity	985	993	O
.	993	994	O

Since	995	1000	O
the	1001	1004	O
primary	1005	1012	O
purpose	1013	1020	O
of	1021	1023	O
phase	1024	1029	O
I	1030	1031	O
trials	1032	1038	O
is	1039	1041	O
to	1042	1044	O
determine	1045	1054	O
DLT	1055	1058	O
and	1059	1062	O
MTD	1063	1066	O
,	1066	1067	O
the	1068	1071	O
efficacy	1072	1080	O
of	1081	1083	O
the	1084	1087	O
drug	1088	1092	O
may	1093	1096	O
not	1097	1100	O
be	1101	1103	O
evident	1104	1111	O
for	1112	1115	O
certain	1116	1123	O
tumor	1124	1129	B-Pathological_formation
types	1130	1135	O
as	1136	1138	O
there	1139	1144	O
are	1145	1148	O
only	1149	1153	O
a	1154	1155	O
small	1156	1161	O
number	1162	1168	O
of	1169	1171	O
patients	1172	1180	O
enrolled	1181	1189	O
into	1190	1194	O
the	1195	1198	O
trial	1199	1204	O
.	1204	1205	O

Furthermore	1206	1217	O
,	1217	1218	O
the	1219	1222	O
modified	1223	1231	O
-	1231	1232	O
Fibonacci	1232	1241	O
design	1242	1248	O
does	1249	1253	O
not	1254	1257	O
take	1258	1262	O
into	1263	1267	O
account	1268	1275	O
individual	1276	1286	O
variations	1287	1297	O
in	1298	1300	O
therapeutic	1301	1312	O
and	1313	1316	O
toxicologic	1317	1328	O
responses	1329	1338	O
due	1339	1342	O
to	1343	1345	O
genomic	1346	1353	O
polymorphisms	1354	1367	O
[	1368	1369	O
4	1369	1370	O
,	1370	1371	O
5	1372	1373	O
]	1373	1374	O
.	1374	1375	O

In	1376	1378	O
addition	1379	1387	O
,	1387	1388	O
since	1389	1394	O
there	1395	1400	O
is	1401	1403	O
a	1404	1405	O
limit	1406	1411	O
of	1412	1414	O
3	1415	1416	O
subjects	1417	1425	O
allowed	1426	1433	O
for	1434	1437	O
each	1438	1442	O
cohort	1443	1449	O
,	1449	1450	O
a	1451	1452	O
waiting	1453	1460	O
period	1461	1467	O
of	1468	1470	O
up	1471	1473	O
to	1474	1476	O
four	1477	1481	O
weeks	1482	1487	O
is	1488	1490	O
commonly	1491	1499	O
required	1500	1508	O
before	1509	1515	O
enrollment	1516	1526	O
of	1527	1529	O
the	1530	1533	O
next	1534	1538	O
cohort	1539	1545	O
of	1546	1548	O
subjects	1549	1557	O
.	1557	1558	O

This	1559	1563	O
latter	1564	1570	O
requirement	1571	1582	O
creates	1583	1590	O
anxiety	1591	1598	O
of	1599	1601	O
waiting	1602	1609	O
for	1610	1613	O
eligible	1614	1622	O
patients	1623	1631	O
.	1631	1632	O

Several	1633	1640	O
alternative	1641	1652	O
phase	1653	1658	O
I	1659	1660	O
designs	1661	1668	O
have	1669	1673	O
been	1674	1678	O
proposed	1679	1687	O
which	1688	1693	O
limit	1694	1699	O
the	1700	1703	O
number	1704	1710	O
of	1711	1713	O
patients	1714	1722	O
accrued	1723	1730	O
at	1731	1733	O
each	1734	1738	O
dose	1739	1743	O
level	1744	1749	O
and	1750	1753	O
accelerate	1754	1764	O
the	1765	1768	O
dose	1769	1773	O
escalation	1774	1784	O
process	1785	1792	O
[	1793	1794	O
1	1794	1795	O
,	1795	1796	O
6	1797	1798	O
]	1798	1799	O
.	1799	1800	O

There	1801	1806	O
has	1807	1810	O
also	1811	1815	O
been	1816	1820	O
an	1821	1823	O
increase	1824	1832	O
in	1833	1835	O
the	1836	1839	O
number	1840	1846	O
of	1847	1849	O
clinical	1850	1858	O
trials	1859	1865	O
that	1866	1870	O
include	1871	1878	O
a	1879	1880	O
component	1881	1890	O
of	1891	1893	O
intrapatient	1894	1906	O
dose	1907	1911	O
escalation	1912	1922	O
although	1923	1931	O
no	1932	1934	O
formal	1935	1941	O
validation	1942	1952	O
with	1953	1957	O
the	1958	1961	O
modified	1962	1970	O
-	1970	1971	O
Fibonacci	1971	1980	O
approach	1981	1989	O
has	1990	1993	O
been	1994	1998	O
reported	1999	2007	O
[	2008	2009	O
7	2009	2010	O
-	2010	2011	O
9	2011	2012	O
]	2012	2013	O
.	2013	2014	O

We	2015	2017	O
have	2018	2022	O
pioneered	2023	2032	O
a	2033	2034	O
population	2035	2045	O
-	2045	2046	O
based	2046	2051	O
design	2052	2058	O
to	2059	2061	O
maximize	2062	2070	O
therapeutic	2071	2082	O
efficacy	2083	2091	O
,	2091	2092	O
to	2093	2095	O
provide	2096	2103	O
preliminary	2104	2115	O
efficacy	2116	2124	O
information	2125	2136	O
and	2137	2140	O
to	2141	2143	O
allow	2144	2149	O
derivation	2150	2160	O
of	2161	2163	O
a	2164	2165	O
pMTD	2166	2170	O
for	2171	2174	O
subsequent	2175	2185	O
phase	2186	2191	O
II	2192	2194	O
trials	2195	2201	O
.	2201	2202	O

Irinotecan	2203	2213	O
and	2214	2217	O
cisplatin	2218	2227	O
have	2228	2232	O
been	2233	2237	O
shown	2238	2243	O
to	2244	2246	O
have	2247	2251	O
promising	2252	2261	O
efficacy	2262	2270	O
in	2271	2273	O
patients	2274	2282	O
with	2283	2287	O
small	2288	2293	B-Pathological_formation
-	2293	2294	I-Pathological_formation
cell	2294	2298	I-Pathological_formation
lung	2299	2303	I-Pathological_formation
cancer	2304	2310	I-Pathological_formation
in	2311	2313	O
phase	2314	2319	O
III	2320	2323	O
trial	2324	2329	O
where	2330	2335	O
irinotecan	2336	2346	O
was	2347	2350	O
given	2351	2356	O
on	2357	2359	O
a	2360	2361	O
weekly	2362	2368	O
schedule	2369	2377	O
[	2378	2379	O
10	2379	2381	O
]	2381	2382	O
.	2382	2383	O

We	2384	2386	O
wished	2387	2393	O
to	2394	2396	O
perform	2397	2404	O
a	2405	2406	O
population	2407	2417	O
-	2417	2418	O
based	2418	2423	O
phase	2424	2429	O
I	2430	2431	O
trial	2432	2437	O
of	2438	2440	O
irinotecan	2441	2451	O
,	2451	2452	O
given	2453	2458	O
every	2459	2464	O
3	2465	2466	O
weeks	2467	2472	O
,	2472	2473	O
and	2474	2477	O
carboplatin	2478	2489	O
,	2489	2490	O
a	2491	2492	O
platinated	2493	2503	O
anticancer	2504	2514	O
drug	2515	2519	O
which	2520	2525	O
is	2526	2528	O
generally	2529	2538	O
better	2539	2545	O
tolerated	2546	2555	O
than	2556	2560	O
its	2561	2564	O
cisplatin	2565	2574	O
analog	2575	2581	O
.	2581	2582	O

2	0	1	O
.	1	2	O
2	2	3	O
.	3	4	O

Iris	5	9	B-Multi-tissue_structure
and	10	13	O
Ciliary	14	21	B-Multi-tissue_structure
Body	22	26	I-Multi-tissue_structure

Serotonin	27	36	O
is	37	39	O
present	40	47	O
in	48	50	O
mammalian	51	60	O
iris	61	65	B-Multi-tissue_structure
-	65	66	I-Multi-tissue_structure
ciliary	66	73	I-Multi-tissue_structure
body	74	78	I-Multi-tissue_structure
complex	79	86	I-Multi-tissue_structure
(	87	88	O
ICB	88	91	B-Multi-tissue_structure
)	91	92	O
at	93	95	O
higher	96	102	O
concentration	103	116	O
that	117	121	O
in	122	124	O
non	125	128	O
-	128	129	O
mammalian	129	138	O
species	139	146	O
[	147	148	O
5	148	149	O
,	149	150	O
45	151	153	O
,	153	154	O
73	155	157	O
,	157	158	O
129	159	162	O
,	162	163	O
137	164	167	O
]	167	168	O
.	168	169	O

Moreover	170	178	O
,	178	179	O
the	180	183	O
presence	184	192	O
of	193	195	O
serotonergic	196	208	O
nerves	209	215	B-Multi-tissue_structure
has	216	219	O
been	220	224	O
demonstrated	225	237	O
in	238	240	O
studies	241	248	O
conducted	249	258	O
on	259	261	O
the	262	265	O
ICB	266	269	B-Multi-tissue_structure
of	270	272	O
various	273	280	O
species	281	288	O
[	289	290	O
102	290	293	O
,	293	294	O
137	295	298	O
,	298	299	O
138	300	303	O
]	303	304	O
.	304	305	O

Experimental	306	318	O
evidence	319	327	O
and	328	331	O
radioligand	332	343	O
analyses	344	352	O
have	353	357	O
defined	358	365	O
the	366	369	O
presence	370	378	O
at	379	381	O
this	382	386	O
level	387	392	O
of	393	395	O
three	396	401	O
different	402	411	O
types	412	417	O
of	418	420	O
serotonin	421	430	O
receptors	431	440	O
[	441	442	O
10	442	444	O
,	444	445	O
28	446	448	O
,	448	449	O
85	450	452	O
,	452	453	O
136	454	457	O
,	457	458	O
137	459	462	O
]	462	463	O
,	463	464	O
i	465	466	O
.	466	467	O
e	467	468	O
.	468	469	O
5	470	471	O
-	471	472	O
HT1A	472	476	O
,	476	477	O
5	478	479	O
-	479	480	O
HT2A	480	484	O
/	484	485	O
2C	485	487	O
and	488	491	O
5	492	493	O
-	493	494	O
HT7	494	497	O
[	498	499	O
98	499	501	O
]	501	502	O
,	502	503	O
one	504	507	O
linked	508	514	O
to	515	517	O
a	518	519	O
stimulation	520	531	O
of	532	534	O
inositol	535	543	O
phosphates	544	554	O
(	555	556	O
5	556	557	O
-	557	558	O
HT2	558	561	O
subtype	562	569	O
)	569	570	O
,	570	571	O
while	572	577	O
the	578	581	O
others	582	588	O
two	589	592	O
are	593	596	O
linked	597	603	O
to	604	606	O
cAMP	607	611	O
activity	612	620	O
.	620	621	O

The	622	625	O
plausibility	626	638	O
of	639	641	O
the	642	645	O
existence	646	655	O
of	656	658	O
more	659	663	O
than	664	668	O
one	669	672	O
5	673	674	O
-	674	675	O
HT	675	677	O
receptor	678	686	O
type	687	691	O
in	692	694	O
the	695	698	O
ciliary	699	706	B-Multi-tissue_structure
body	707	711	I-Multi-tissue_structure
is	712	714	O
confirmed	715	724	O
by	725	727	O
intraocular	728	739	B-Immaterial_anatomical_entity
pressure	740	748	O
(	749	750	O
IOP	750	753	O
)	753	754	O
experiments	755	766	O
.	766	767	O

Topical	768	775	O
application	776	787	O
of	788	790	O
serotonin	791	800	O
has	801	804	O
been	805	809	O
reported	810	818	O
to	819	821	O
both	822	826	O
elevate	827	834	O
[	835	836	O
84	836	838	O
]	838	839	O
and	840	843	O
lower	844	849	O
[	850	851	O
88	851	853	O
]	853	854	O
IOP	855	858	O
in	859	861	O
rabbit	862	868	O
.	868	869	O

A	870	871	O
large	872	877	O
number	878	884	O
of	885	887	O
reports	888	895	O
have	896	900	O
shown	901	906	O
that	907	911	O
serotonin	912	921	O
agonists	922	930	O
and	931	934	O
antagonists	935	946	O
can	947	950	O
produce	951	958	O
increases	959	968	O
and	969	972	O
decreases	973	982	O
in	983	985	O
IOP	986	989	O
when	990	994	O
given	995	1000	O
orally	1001	1007	O
,	1007	1008	O
topically	1009	1018	O
to	1019	1021	O
the	1022	1025	O
eye	1026	1029	B-Organ
or	1030	1032	O
when	1033	1037	O
they	1038	1042	O
are	1043	1046	O
directly	1047	1055	O
injected	1056	1064	O
in	1065	1067	O
the	1068	1071	O
anterior	1072	1080	B-Multi-tissue_structure
chamber	1081	1088	I-Multi-tissue_structure
[	1089	1090	O
10	1090	1092	O
,	1092	1093	O
26	1094	1096	O
,	1096	1097	O
34	1098	1100	O
,	1100	1101	O
35	1102	1104	O
,	1104	1105	O
64	1106	1108	O
,	1108	1109	O
75	1110	1112	O
,	1112	1113	O
84	1114	1116	O
,	1116	1117	O
87	1118	1120	O
,	1120	1121	O
88	1122	1124	O
,	1124	1125	O
112	1126	1129	O
,	1129	1130	O
113	1131	1134	O
,	1134	1135	O
126	1136	1139	O
,	1139	1140	O
136	1141	1144	O
,	1144	1145	O
137	1146	1149	O
]	1149	1150	O
.	1150	1151	O

A	1152	1153	O
rationale	1154	1163	O
for	1164	1167	O
such	1168	1172	O
apparently	1173	1183	O
contradictory	1184	1197	O
results	1198	1205	O
may	1206	1209	O
be	1210	1212	O
due	1213	1216	O
to	1217	1219	O
the	1220	1223	O
different	1224	1233	O
sites	1234	1239	O
of	1240	1242	O
action	1243	1249	O
,	1249	1250	O
i	1251	1252	O
.	1252	1253	O
e	1253	1254	O
.	1254	1255	O
which	1256	1261	O
class	1262	1267	O
of	1268	1270	O
serotonin	1271	1280	O
receptor	1281	1289	O
is	1290	1292	O
activated	1293	1302	O
.	1302	1303	O

In	1304	1306	O
fact	1307	1311	O
,	1311	1312	O
in	1313	1315	O
rabbit	1316	1322	O
the	1323	1326	O
administration	1327	1341	O
of	1342	1344	O
5	1345	1346	O
-	1346	1347	O
methyl	1347	1353	O
-	1353	1354	O
urapidil	1354	1362	O
(	1363	1364	O
a	1364	1365	O
combined	1366	1374	O
5	1375	1376	O
-	1376	1377	O
HT1A	1377	1381	O
agonist	1382	1389	O
/	1389	1390	O
alpha1	1390	1396	O
adrenoreceptor	1397	1411	O
antagonist	1412	1422	O
)	1422	1423	O
and	1424	1427	O
8	1428	1429	O
-	1429	1430	O
OH	1430	1432	O
-	1432	1433	O
DPAT	1433	1437	O
(	1438	1439	O
8	1439	1440	O
-	1440	1441	O
hydroxydypropylaminotetralin	1441	1469	O
,	1469	1470	O
a	1471	1472	O
5HT1A	1473	1478	O
agonist	1479	1486	O
)	1486	1487	O
reduces	1488	1495	O
IOP	1496	1499	O
,	1499	1500	O
while	1501	1506	O
the	1507	1510	O
administration	1511	1525	O
of	1526	1528	O
5	1529	1530	O
-	1530	1531	O
CT	1531	1533	O
(	1534	1535	O
5	1535	1536	O
-	1536	1537	O
carboxamidotryptamine	1537	1558	O
,	1558	1559	O
a	1560	1561	O
5	1562	1563	O
-	1563	1564	O
HT1A	1564	1568	O
and	1569	1572	O
5	1573	1574	O
-	1574	1575	O
HT7	1575	1578	O
agonist	1579	1586	O
)	1586	1587	O
increases	1588	1597	O
IOP	1598	1601	O
[	1602	1603	O
36	1603	1605	O
,	1605	1606	O
84	1607	1609	O
,	1609	1610	O
99	1611	1613	O
]	1613	1614	O
.	1614	1615	O

Chidlow	1616	1623	O
,	1623	1624	O
Le	1625	1627	O
Corre	1628	1633	O
and	1634	1637	O
Osborne	1638	1645	O
[	1646	1647	O
28	1647	1649	O
]	1649	1650	O
have	1651	1655	O
recently	1656	1664	O
demonstrated	1665	1677	O
that	1678	1682	O
,	1682	1683	O
in	1684	1686	O
section	1687	1694	O
taken	1695	1700	O
through	1701	1708	O
the	1709	1712	O
whole	1713	1718	O
eye	1719	1722	B-Organ
and	1723	1726	O
ciliary	1727	1734	B-Multi-tissue_structure
body	1735	1739	I-Multi-tissue_structure
,	1739	1740	O
prominent	1741	1750	O
5	1751	1752	O
-	1752	1753	O
HT1A	1753	1757	O
and	1758	1761	O
5	1762	1763	O
-	1763	1764	O
HT7	1764	1767	O
receptor	1768	1776	O
messenger	1777	1786	O
ribonucleic	1787	1798	O
acid	1799	1803	O
signals	1804	1811	O
were	1812	1816	O
obtained	1817	1825	O
.	1825	1826	O

These	1827	1832	O
signals	1833	1840	O
were	1841	1845	O
evident	1846	1853	O
in	1854	1856	O
both	1857	1861	O
the	1862	1865	O
pigmented	1866	1875	O
and	1876	1879	O
non	1880	1883	O
-	1883	1884	O
pigmented	1884	1893	O
epithelial	1894	1904	B-Cell
cell	1905	1909	I-Cell
layers	1910	1916	O
of	1917	1919	O
the	1920	1923	O
pars	1924	1928	B-Multi-tissue_structure
plicata	1929	1936	I-Multi-tissue_structure
region	1937	1943	O
of	1944	1946	O
the	1947	1950	O
ciliary	1951	1958	B-Multi-tissue_structure
processes	1959	1968	O
,	1968	1969	O
but	1970	1973	O
not	1974	1977	O
in	1978	1980	O
the	1981	1984	O
pars	1985	1989	B-Multi-tissue_structure
plana	1990	1995	I-Multi-tissue_structure
or	1996	1998	O
in	1999	2001	O
the	2002	2005	O
ciliary	2006	2013	B-Multi-tissue_structure
musculature	2014	2025	I-Multi-tissue_structure
.	2025	2026	O

5	2027	2028	O
-	2028	2029	O
HT1A	2029	2033	O
and	2034	2037	O
5	2038	2039	O
-	2039	2040	O
HT7	2040	2043	O
signals	2044	2051	O
were	2052	2056	O
apparent	2057	2065	O
in	2066	2068	O
the	2069	2072	O
posterior	2073	2082	O
processes	2083	2092	O
but	2093	2096	O
not	2097	2100	O
in	2101	2103	O
the	2104	2107	O
iris	2108	2112	B-Multi-tissue_structure
processes	2113	2122	O
.	2122	2123	O

The	2124	2127	O
presence	2128	2136	O
of	2137	2139	O
both	2140	2144	O
receptors	2145	2154	O
in	2155	2157	O
the	2158	2161	O
ciliary	2162	2169	B-Multi-tissue_structure
body	2170	2174	I-Multi-tissue_structure
would	2175	2180	O
certainly	2181	2190	O
provide	2191	2198	O
an	2199	2201	O
explanation	2202	2213	O
for	2214	2217	O
the	2218	2221	O
shallow	2222	2229	O
displacement	2230	2242	O
curves	2243	2249	O
observed	2250	2258	O
in	2259	2261	O
[	2262	2263	O
3H	2263	2265	O
]	2265	2266	O
5	2266	2267	O
-	2267	2268	O
HT	2268	2270	O
binding	2271	2278	O
studies	2279	2286	O
with	2287	2291	O
the	2292	2295	O
tissue	2296	2302	B-Tissue
[	2303	2304	O
110	2304	2307	O
]	2307	2308	O
,	2308	2309	O
since	2310	2315	O
this	2316	2320	O
ligand	2321	2327	O
can	2328	2331	O
be	2332	2334	O
used	2335	2339	O
to	2340	2342	O
label	2343	2348	O
both	2349	2353	O
receptors	2354	2363	O
.	2363	2364	O

Because	2365	2372	O
the	2373	2376	O
ciliary	2377	2384	B-Tissue
epithelium	2385	2395	I-Tissue
of	2396	2398	O
the	2399	2402	O
pars	2403	2407	B-Multi-tissue_structure
plicata	2408	2415	I-Multi-tissue_structure
is	2416	2418	O
responsible	2419	2430	O
for	2431	2434	O
the	2435	2438	O
secretion	2439	2448	O
of	2449	2451	O
aqueous	2452	2459	O
humor	2460	2465	O
,	2465	2466	O
an	2467	2469	O
obvious	2470	2477	O
function	2478	2486	O
for	2487	2490	O
these	2491	2496	O
two	2497	2500	O
receptors	2501	2510	O
would	2511	2516	O
be	2517	2519	O
an	2520	2522	O
involvement	2523	2534	O
in	2535	2537	O
the	2538	2541	O
control	2542	2549	O
of	2550	2552	O
aqueous	2553	2560	O
production	2561	2571	O
and	2572	2575	O
,	2575	2576	O
consequently	2577	2589	O
,	2589	2590	O
of	2591	2593	O
the	2594	2597	O
IOP	2598	2601	O
level	2602	2607	O
.	2607	2608	O

Further	2609	2616	O
,	2616	2617	O
the	2618	2621	O
almost	2622	2628	O
identical	2629	2638	O
distribution	2639	2651	O
of	2652	2654	O
the	2655	2658	O
5	2659	2660	O
-	2660	2661	O
HT1A	2661	2665	O
and	2666	2669	O
5	2670	2671	O
-	2671	2672	O
HT7	2672	2675	O
messengers	2676	2686	O
ribonucleic	2687	2698	O
acid	2699	2703	O
indicate	2704	2712	O
that	2713	2717	O
the	2718	2721	O
receptors	2722	2731	O
may	2732	2735	O
be	2736	2738	O
co	2739	2741	O
-	2741	2742	O
localized	2742	2751	O
in	2752	2754	O
epithelial	2755	2765	B-Cell
cells	2766	2771	I-Cell
.	2771	2772	O

The	2773	2776	O
presence	2777	2785	O
of	2786	2788	O
two	2789	2792	O
serotonin	2793	2802	O
receptors	2803	2812	O
with	2813	2817	O
opposing	2818	2826	O
effects	2827	2834	O
on	2835	2837	O
cAMP	2838	2842	O
in	2843	2845	O
the	2846	2849	O
same	2850	2854	O
cell	2855	2859	B-Cell
layer	2860	2865	O
prompts	2866	2873	O
the	2874	2877	O
suggestion	2878	2888	O
that	2889	2893	O
they	2894	2898	O
could	2899	2904	O
act	2905	2908	O
antagonistically	2909	2925	O
.	2925	2926	O

The	2927	2930	O
agonism	2931	2938	O
of	2939	2941	O
5	2942	2943	O
-	2943	2944	O
HT1A	2944	2948	O
receptors	2949	2958	O
,	2958	2959	O
negatively	2960	2970	O
coupled	2971	2978	O
to	2979	2981	O
cAMP	2982	2986	O
,	2986	2987	O
reduces	2988	2995	O
IOP	2996	2999	O
by	3000	3002	O
decreasing	3003	3013	O
the	3014	3017	O
production	3018	3028	O
of	3029	3031	O
aqueous	3032	3039	O
humor	3040	3045	O
,	3045	3046	O
like	3047	3051	O
beta	3052	3056	O
-	3056	3057	O
receptor	3057	3065	O
antagonists	3066	3077	O
which	3078	3083	O
,	3083	3084	O
diminishing	3085	3096	O
the	3097	3100	O
content	3101	3108	O
of	3109	3111	O
cAMP	3112	3116	O
at	3117	3119	O
the	3120	3123	O
postjunctional	3124	3138	O
site	3139	3143	O
,	3143	3144	O
lowers	3145	3151	O
the	3152	3155	O
aqueous	3156	3163	O
humor	3164	3169	B-Organism_substance
secretion	3170	3179	O
with	3180	3184	O
a	3185	3186	O
consequent	3187	3197	O
decrease	3198	3206	O
in	3207	3209	O
IOP	3210	3213	O
[	3214	3215	O
98	3215	3217	O
]	3217	3218	O
.	3218	3219	O

On	3220	3222	O
the	3223	3226	O
contrary	3227	3235	O
,	3235	3236	O
the	3237	3240	O
administration	3241	3255	O
of	3256	3258	O
5	3259	3260	O
-	3260	3261	O
CT	3261	3263	O
induces	3264	3271	O
a	3272	3273	O
rise	3274	3278	O
in	3279	3281	O
IOP	3282	3285	O
,	3285	3286	O
which	3287	3292	O
is	3293	3295	O
partly	3296	3302	O
or	3303	3305	O
entirely	3306	3314	O
caused	3315	3321	O
by	3322	3324	O
an	3325	3327	O
increase	3328	3336	O
in	3337	3339	O
aqueous	3340	3347	O
humor	3348	3353	B-Organism_substance
secretion	3354	3363	O
mediated	3364	3372	O
by	3373	3375	O
5	3376	3377	O
-	3377	3378	O
HT7	3378	3381	O
receptors	3382	3391	O
[	3392	3393	O
84	3393	3395	O
]	3395	3396	O
.	3396	3397	O

The	3398	3401	O
other	3402	3407	O
type	3408	3412	O
of	3413	3415	O
serotonin	3416	3425	O
receptor	3426	3434	O
present	3435	3442	O
in	3443	3445	O
the	3446	3449	O
ICB	3450	3453	B-Multi-tissue_structure
is	3454	3456	O
a	3457	3458	O
5	3459	3460	O
-	3460	3461	O
HT2	3461	3464	O
type	3465	3469	O
.	3469	3470	O

Serotonin	3471	3480	O
stimulates	3481	3491	O
the	3492	3495	O
accumulation	3496	3508	O
of	3509	3511	O
inositol	3512	3520	O
phosphates	3521	3531	O
in	3532	3534	O
the	3535	3538	O
ICB	3539	3542	B-Multi-tissue_structure
and	3543	3546	O
this	3547	3551	O
effect	3552	3558	O
is	3559	3561	O
partially	3562	3571	O
counteracted	3572	3584	O
by	3585	3587	O
the	3588	3591	O
5	3592	3593	O
-	3593	3594	O
HT2	3594	3597	O
antagonists	3598	3609	O
ketanserin	3610	3620	O
,	3620	3621	O
methysergide	3622	3634	O
and	3635	3638	O
mianserin	3639	3648	O
[	3649	3650	O
98	3650	3652	O
]	3652	3653	O
.	3653	3654	O

Studies	3655	3662	O
with	3663	3667	O
ketanserin	3668	3678	O
have	3679	3683	O
demonstrated	3684	3696	O
that	3697	3701	O
,	3701	3702	O
when	3703	3707	O
orally	3708	3714	O
or	3715	3717	O
topically	3718	3727	O
applied	3728	3735	O
,	3735	3736	O
it	3737	3739	O
lowers	3740	3746	O
IOP	3747	3750	O
in	3751	3753	O
animals	3754	3761	O
,	3761	3762	O
healthy	3763	3770	O
volunteers	3771	3781	O
and	3782	3785	O
in	3786	3788	O
glaucomatous	3789	3801	O
patients	3802	3810	O
[	3811	3812	O
26	3812	3814	O
,	3814	3815	O
34	3816	3818	O
,	3818	3819	O
37	3820	3822	O
,	3822	3823	O
64	3824	3826	O
,	3826	3827	O
75	3828	3830	O
,	3830	3831	O
88	3832	3834	O
,	3834	3835	O
113	3836	3839	O
,	3839	3840	O
126	3841	3844	O
]	3844	3845	O
.	3845	3846	O

It	3847	3849	O
has	3850	3853	O
been	3854	3858	O
emphasized	3859	3869	O
that	3870	3874	O
ketanserin	3875	3885	O
also	3886	3890	O
possesses	3891	3900	O
an	3901	3903	O
affinity	3904	3912	O
for	3913	3916	O
alpha1	3917	3923	O
-	3923	3924	O
adrenoreceptors	3924	3939	O
[	3940	3941	O
27	3941	3943	O
,	3943	3944	O
36	3945	3947	O
,	3947	3948	O
139	3949	3952	O
]	3952	3953	O
,	3953	3954	O
and	3955	3958	O
for	3959	3962	O
this	3963	3967	O
reason	3968	3974	O
the	3975	3978	O
effects	3979	3986	O
of	3987	3989	O
ketanserin	3990	4000	O
on	4001	4003	O
IOP	4004	4007	O
may	4008	4011	O
not	4012	4015	O
be	4016	4018	O
entirely	4019	4027	O
caused	4028	4034	O
by	4035	4037	O
its	4038	4041	O
action	4042	4048	O
on	4049	4051	O
5	4052	4053	O
-	4053	4054	O
HT2	4054	4057	O
receptors	4058	4067	O
.	4067	4068	O

However	4069	4076	O
,	4076	4077	O
data	4078	4082	O
from	4083	4087	O
human	4088	4093	O
studies	4094	4101	O
conducted	4102	4111	O
after	4112	4117	O
oral	4118	4122	O
or	4123	4125	O
topical	4126	4133	O
administration	4134	4148	O
of	4149	4151	O
ketanserin	4152	4162	O
,	4162	4163	O
in	4164	4166	O
which	4167	4172	O
were	4173	4177	O
determined	4178	4188	O
the	4189	4192	O
variations	4193	4203	O
of	4204	4206	O
IOP	4207	4210	O
,	4210	4211	O
total	4212	4217	O
outflow	4218	4225	O
facility	4226	4234	O
and	4235	4238	O
pupil	4239	4244	B-Multi-tissue_structure
diameter	4245	4253	O
,	4253	4254	O
demonstrated	4255	4267	O
that	4268	4272	O
the	4273	4276	O
alpha1	4277	4283	O
-	4283	4284	O
adrenoreceptor	4284	4298	O
blocking	4299	4307	O
effect	4308	4314	O
exerted	4315	4322	O
by	4323	4325	O
ketanserin	4326	4336	O
should	4337	4343	O
represent	4344	4353	O
a	4354	4355	O
further	4356	4363	O
aspect	4364	4370	O
of	4371	4373	O
its	4374	4377	O
mechanism	4378	4387	O
of	4388	4390	O
action	4391	4397	O
,	4397	4398	O
probably	4399	4407	O
due	4408	4411	O
to	4412	4414	O
a	4415	4416	O
functional	4417	4427	O
sharing	4428	4435	O
of	4436	4438	O
these	4439	4444	O
receptors	4445	4454	O
[	4455	4456	O
64	4456	4458	O
,	4458	4459	O
87	4460	4462	O
]	4462	4463	O
.	4463	4464	O

Lastly	4465	4471	O
,	4471	4472	O
already	4473	4480	O
in	4481	4483	O
1992	4484	4488	O
Martin	4489	4495	O
and	4496	4499	O
co	4500	4502	O
-	4502	4503	O
workers	4503	4510	O
showed	4511	4517	O
the	4518	4521	O
occurrence	4522	4532	O
of	4533	4535	O
a	4536	4537	O
significant	4538	4549	O
correlation	4550	4561	O
between	4562	4569	O
the	4570	4573	O
content	4574	4581	O
of	4582	4584	O
serotonin	4585	4594	O
in	4595	4597	O
the	4598	4601	O
aqueous	4602	4609	O
humor	4610	4615	B-Organism_substance
and	4616	4619	O
IOP	4620	4623	O
in	4624	4626	O
the	4627	4630	O
human	4631	4636	O
eye	4637	4640	B-Organ
[	4641	4642	O
85	4642	4644	O
]	4644	4645	O
.	4645	4646	O

In	4647	4649	O
1981	4650	4654	O
,	4654	4655	O
Moro	4656	4660	O
and	4661	4664	O
his	4665	4668	O
collaborators	4669	4682	O
found	4683	4688	O
that	4689	4693	O
intravitreal	4694	4706	O
injection	4707	4716	O
of	4717	4719	O
5	4720	4721	O
,	4721	4722	O
6	4723	4724	O
-	4724	4725	O
dihydroxytryptamine	4725	4744	O
,	4744	4745	O
a	4746	4747	O
serotonergic	4748	4760	O
neurotoxin	4761	4771	O
,	4771	4772	O
causes	4773	4779	O
miosis	4780	4786	O
[	4787	4788	O
91	4788	4790	O
]	4790	4791	O
.	4791	4792	O

The	4793	4796	O
identification	4797	4811	O
of	4812	4814	O
5	4815	4816	O
-	4816	4817	O
HT7	4817	4820	O
,	4820	4821	O
but	4822	4825	O
not	4826	4829	O
of	4830	4832	O
5	4833	4834	O
-	4834	4835	O
HT1	4835	4838	O
receptors	4839	4848	O
in	4849	4851	O
the	4852	4855	O
rabbit	4856	4862	O
iris	4863	4867	B-Multi-tissue_structure
,	4867	4868	O
suggests	4869	4877	O
that	4878	4882	O
this	4883	4887	O
population	4888	4898	O
of	4899	4901	O
serotonergic	4902	4914	O
receptors	4915	4924	O
is	4925	4927	O
involved	4928	4936	O
in	4937	4939	O
the	4940	4943	O
relaxation	4944	4954	O
of	4955	4957	O
the	4958	4961	O
sphincter	4962	4971	B-Tissue
of	4972	4974	O
the	4975	4978	O
pupil	4979	4984	B-Multi-tissue_structure
.	4984	4985	O

In	4986	4988	O
fact	4989	4993	O
,	4993	4994	O
one	4995	4998	O
of	4999	5001	O
the	5002	5005	O
function	5006	5014	O
correlate	5015	5024	O
to	5025	5027	O
5	5028	5029	O
-	5029	5030	O
HT7	5030	5033	O
receptor	5034	5042	O
activation	5043	5053	O
includes	5054	5062	O
smooth	5063	5069	B-Tissue
muscle	5070	5076	I-Tissue
relaxation	5077	5087	O
observed	5088	5096	O
in	5097	5099	O
a	5100	5101	O
variety	5102	5109	O
of	5110	5112	O
isolated	5113	5121	O
tissue	5122	5128	B-Tissue
preparations	5129	5141	O
,	5141	5142	O
in	5143	5145	O
which	5146	5151	O
elevation	5152	5161	O
of	5162	5164	O
cAMP	5165	5169	O
concentration	5170	5183	O
was	5184	5187	O
also	5188	5192	O
detected	5193	5201	O
[	5202	5203	O
3	5203	5204	O
,	5204	5205	O
44	5206	5208	O
]	5208	5209	O
.	5209	5210	O

Further	5211	5218	O
evidence	5219	5227	O
for	5228	5231	O
the	5232	5235	O
mediation	5236	5245	O
of	5246	5248	O
the	5249	5252	O
relaxant	5253	5261	O
response	5262	5270	O
via	5271	5274	O
the	5275	5278	O
5	5279	5280	O
-	5280	5281	O
HT7	5281	5284	O
receptor	5285	5293	O
is	5294	5296	O
provided	5297	5305	O
by	5306	5308	O
the	5309	5312	O
localization	5313	5325	O
of	5326	5328	O
messenger	5329	5338	O
ribonucleic	5339	5350	O
acid	5351	5355	O
transcripts	5356	5367	O
encoding	5368	5376	O
the	5377	5380	O
5	5381	5382	O
-	5382	5383	O
HT7	5383	5386	O
receptor	5387	5395	O
in	5396	5398	O
many	5399	5403	O
blood	5404	5409	B-Multi-tissue_structure
vessels	5410	5417	I-Multi-tissue_structure
[	5418	5419	O
67	5419	5421	O
]	5421	5422	O
.	5422	5423	O

This	5424	5428	O
hypothesized	5429	5441	O
mechanism	5442	5451	O
of	5452	5454	O
action	5455	5461	O
is	5462	5464	O
also	5465	5469	O
supported	5470	5479	O
by	5480	5482	O
the	5483	5486	O
fact	5487	5491	O
that	5492	5496	O
various	5497	5504	O
other	5505	5510	O
receptor	5511	5519	O
types	5520	5525	O
,	5525	5526	O
also	5527	5531	O
positively	5532	5542	O
coupled	5543	5550	O
to	5551	5553	O
cAMP	5554	5558	O
,	5558	5559	O
in	5560	5562	O
the	5563	5566	O
iris	5567	5571	B-Multi-tissue_structure
cause	5572	5577	O
relaxation	5578	5588	O
of	5589	5591	O
the	5592	5595	O
sphincter	5596	5605	B-Tissue
muscle	5606	5612	I-Tissue
[	5613	5614	O
1	5614	5615	O
,	5615	5616	O
28	5617	5619	O
]	5619	5620	O
.	5620	5621	O

Luciferase	0	10	O
Assay	11	16	O

For	17	20	O
Fig	21	24	O
.	24	25	O

1	26	27	O
,	27	28	O
10	29	31	O
ng	32	34	O
of	35	37	O
TORC1	38	43	O
,	43	44	O
5	45	46	O
ng	47	49	O
of	50	52	O
TORC2	53	58	O
,	58	59	O
and	60	63	O
15	64	66	O
ng	67	69	O
of	70	72	O
PKAalpha	73	81	O
expression	82	92	O
plasmids	93	101	B-Cellular_component
were	102	106	O
transfected	107	118	O
into	119	123	O
HEK293	124	130	B-Cell
cells	131	136	I-Cell
.	136	137	O

For	138	141	O
Fig	142	145	O
.	145	146	O

2	147	148	O
,	148	149	O
800	150	153	O
ng	154	156	O
of	157	159	O
total	160	165	O
DNA	166	169	O
consisted	170	179	O
of	180	182	O
200	183	186	O
ng	187	189	O
of	190	192	O
the	193	196	O
pMLHoxb1ARE	197	208	O
luciferase	209	219	O
reporter	220	228	O
and	229	232	O
100	233	236	O
ng	237	239	O
of	240	242	O
each	243	247	O
expression	248	258	O
plasmid	259	266	O
.	266	267	O

A	268	269	O
lacZ	270	274	O
reporter	275	283	O
was	284	287	O
co	288	290	O
-	290	291	O
transfected	291	302	O
to	303	305	O
normalize	306	315	O
transfection	316	328	O
efficiency	329	339	O
.	339	340	O

For	341	344	O
Fig	345	348	O
.	348	349	O

3A	350	352	O
,	352	353	O
the	354	357	O
amounts	358	365	O
of	366	368	O
pENTR	369	374	O
T2i	375	378	O
shRNA	379	384	O
(	385	386	O
TORC2	386	391	O
shRNA	392	397	O
)	397	398	O
are	399	402	O
given	403	408	O
within	409	415	O
the	416	419	O
panel	420	425	O
.	425	426	O

For	427	430	O
Fig	431	434	O
.	434	435	O

3B	436	438	O
,	438	439	O
25	440	442	O
,	442	443	O
000	443	446	O
cells	447	452	B-Cell
per	453	456	O
well	457	461	O
were	462	466	O
plated	467	473	O
in	474	476	O
48	477	479	O
-	479	480	O
well	480	484	O
plates	485	491	O
and	492	495	O
transfected	496	507	O
using	508	513	O
Lipofectamine	514	527	O
2000	528	532	O
with	533	537	O
the	538	541	O
following	542	551	O
vectors	552	559	O
:	559	560	O
40	561	563	O
ng	564	566	O
of	567	569	O
pML5xUAS	570	578	O
,	578	579	O
40	580	582	O
ng	583	585	O
of	586	588	O
pGAL	589	593	O
-	593	594	O
DBD	594	597	O
or	598	600	O
pGAL	601	605	O
-	605	606	O
MEIS1A	606	612	O
(	612	613	O
335	613	616	O
-	616	617	O
390	617	620	O
)	620	621	O
,	621	622	O
40	623	625	O
ng	626	628	O
of	629	631	O
pRSV	632	636	O
-	636	637	O
PBS	637	640	O
or	641	643	O
pRSV	644	648	O
-	648	649	O
PKA	649	652	O
,	652	653	O
40	654	656	O
ng	657	659	O
of	660	662	O
pENTR	663	668	O
U6	669	671	O
(	672	673	O
control	673	680	O
shRNA	681	686	O
)	686	687	O
or	688	690	O
pENTR	691	696	O
T2i	697	700	O
shRNA	701	706	O
(	707	708	O
TORC2	708	713	O
shRNA	714	719	O
)	719	720	O
,	720	721	O
and	722	725	O
100	726	729	O
ng	730	732	O
of	733	735	O
pRSV	736	740	O
-	740	741	O
beta	741	745	O
-	745	746	O
galactosidase	746	759	O
.	759	760	O

At	761	763	O
48	764	766	O
h	767	768	O
post	769	773	O
-	773	774	O
transfection	774	786	O
,	786	787	O
cell	788	792	B-Organism_substance
lysates	793	800	I-Organism_substance
were	801	805	O
prepared	806	814	O
using	815	820	O
100	821	824	O
mul	825	828	O
per	829	832	O
well	833	837	O
of	838	840	O
lysis	841	846	O
buffer	847	853	O
(	854	855	O
1	855	856	O
%	856	857	O
Triton	858	864	O
X	865	866	O
-	866	867	O
100	867	870	O
,	870	871	O
1	872	873	O
mm	874	876	O
dithiothreitol	877	891	O
,	891	892	O
92	893	895	O
.	895	896	O
8	896	897	O
mm	898	900	O
K2HPO4	901	907	O
,	907	908	O
pH	909	911	O
7	912	913	O
.	913	914	O
8	914	915	O
,	915	916	O
9	917	918	O
.	918	919	O
2	919	920	O
mm	921	923	O
KH2PO4	924	930	O
,	930	931	O
pH	932	934	O
7	935	936	O
.	936	937	O
8	937	938	O
)	938	939	O
and	940	943	O
centrifuged	944	955	O
for	956	959	O
5	960	961	O
min	962	965	O
at	966	968	O
4	969	970	O
degreesC	971	979	O
.	979	980	O

A	981	982	O
20	983	985	O
-	985	986	O
mul	986	989	O
aliquot	990	997	O
of	998	1000	O
the	1001	1004	O
supernatant	1005	1016	B-Organism_substance
was	1017	1020	O
added	1021	1026	O
to	1027	1029	O
12	1030	1032	O
.	1032	1033	O
5	1033	1034	O
mul	1035	1038	O
of	1039	1041	O
assay	1042	1047	O
buffer	1048	1054	O
(	1055	1056	O
20	1056	1058	O
mm	1059	1061	O
ATP	1062	1065	O
,	1065	1066	O
40	1067	1069	O
mm	1070	1072	O
MgCl2	1073	1078	O
,	1078	1079	O
0	1080	1081	O
.	1081	1082	O
4	1082	1083	O
m	1084	1085	O
Tris	1086	1090	O
-	1090	1091	O
Cl	1091	1093	O
,	1093	1094	O
pH	1095	1097	O
7	1098	1099	O
.	1099	1100	O
8	1100	1101	O
)	1101	1102	O
.	1102	1103	O

The	1104	1107	O
mixture	1108	1115	O
was	1116	1119	O
immediately	1120	1131	O
quantified	1132	1142	O
for	1143	1146	O
luciferase	1147	1157	O
activity	1158	1166	O
using	1167	1172	O
a	1173	1174	O
Lumat	1175	1180	O
LB	1181	1183	O
9507	1184	1188	O
luminometer	1189	1200	O
(	1201	1202	O
EG	1202	1204	O
&	1204	1205	O
G	1205	1206	O
Berthold	1207	1215	O
)	1215	1216	O
that	1217	1221	O
dispensed	1222	1231	O
100	1232	1235	O
mul	1236	1239	O
per	1240	1243	O
reaction	1244	1252	O
of	1253	1255	O
luciferin	1256	1265	O
solution	1266	1274	O
,	1274	1275	O
which	1276	1281	O
contains	1282	1290	O
1	1291	1292	O
mm	1293	1295	O
d	1296	1297	O
-	1297	1298	O
(	1298	1299	O
-	1299	1300	O
)	1300	1301	O
-	1301	1302	O
luciferin	1302	1311	O
(	1312	1313	O
catalogue	1313	1322	O
number	1323	1329	O
11626353001	1330	1341	O
,	1341	1342	O
Roche	1343	1348	O
)	1348	1349	O
and	1350	1353	O
0	1354	1355	O
.	1355	1356	O
1	1356	1357	O
m	1358	1359	O
Tris	1360	1364	O
-	1364	1365	O
Cl	1365	1367	O
,	1367	1368	O
pH	1369	1371	O
7	1372	1373	O
.	1373	1374	O
8	1374	1375	O
.	1375	1376	O

Implications	0	12	O
for	13	16	O
Psychological	17	30	O
Models	31	37	O
of	38	40	O
Interval	41	49	O
Timing	50	56	O

Several	57	64	O
models	65	71	O
have	72	76	O
been	77	81	O
previously	82	92	O
applied	93	100	O
to	101	103	O
interpret	104	113	O
data	114	118	O
obtained	119	127	O
in	128	130	O
interval	131	139	O
-	139	140	O
timing	140	146	O
experiments	147	158	O
involving	159	168	O
gaps	169	173	O
(	174	175	O
retention	175	184	O
-	184	185	O
intervals	185	194	O
)	194	195	O
.	195	196	O

A	197	198	O
switch	199	205	O
model	206	211	O
,	211	212	O
assuming	213	221	O
that	222	226	O
during	227	233	O
the	234	237	O
gap	238	241	O
time	242	246	O
fails	247	252	O
to	253	255	O
accumulate	256	266	O
due	267	270	O
to	271	273	O
the	274	277	O
opening	278	285	O
of	286	288	O
a	289	290	O
stimulus	291	299	O
-	299	300	O
controlled	300	310	O
switch	311	317	O
,	317	318	O
predicts	319	327	O
that	328	332	O
,	332	333	O
irrespective	334	346	O
of	347	349	O
gap	350	353	O
and	354	357	O
criterion	358	367	O
durations	368	377	O
,	377	378	O
subjects	379	387	O
should	388	394	O
use	395	398	O
a	399	400	O
stop	401	405	O
rule	406	410	O
[	411	412	O
14	412	414	O
]	414	415	O
,	415	416	O
[	417	418	O
15	418	420	O
]	420	421	O
,	421	422	O
[	423	424	O
30	424	426	O
]	426	427	O
,	427	428	O
[	429	430	O
31	430	432	O
]	432	433	O
.	433	434	O

In	435	437	O
contrast	438	446	O
,	446	447	O
the	448	451	O
present	452	459	O
data	460	464	O
indicate	465	473	O
that	474	478	O
rats	479	483	O
flexibly	484	492	O
change	493	499	O
their	500	505	O
behavior	506	514	O
with	515	519	O
both	520	524	O
gap	525	528	O
and	529	532	O
criterion	533	542	O
duration	543	551	O
.	551	552	O

An	553	555	O
instructional	556	569	O
-	569	570	O
ambiguity	570	579	O
model	580	585	O
proposing	586	595	O
that	596	600	O
subjects	601	609	O
perceive	610	618	O
the	619	622	O
gap	623	626	O
as	627	629	O
an	630	632	O
ambiguous	633	642	O
,	642	643	O
ITI	644	647	O
-	647	648	O
like	648	652	O
event	653	658	O
,	658	659	O
predicts	660	668	O
that	669	673	O
manipulations	674	687	O
that	688	692	O
render	693	699	O
the	700	703	O
gap	704	707	O
similar	708	715	O
to	716	718	O
the	719	722	O
ITI	723	726	O
should	727	733	O
reset	734	739	O
the	740	743	O
clock	744	749	O
,	749	750	O
while	751	756	O
manipulations	757	770	O
that	771	775	O
render	776	782	O
the	783	786	O
gap	787	790	O
dissimilar	791	801	O
from	802	806	O
the	807	810	O
ITI	811	814	O
should	815	821	O
stop	822	826	O
the	827	830	O
clock	831	836	O
[	837	838	O
37	838	840	O
]	840	841	O
.	841	842	O

Because	843	850	O
in	851	853	O
our	854	857	O
experiment	858	868	O
the	869	872	O
gap	873	876	O
and	877	880	O
ITI	881	884	O
were	885	889	O
identical	890	899	O
(	900	901	O
dark	901	905	O
)	905	906	O
this	907	911	O
hypothesis	912	922	O
predicts	923	931	O
the	932	935	O
use	936	939	O
of	940	942	O
the	943	946	O
same	947	951	O
rule	952	956	O
(	957	958	O
reset	958	963	O
)	963	964	O
at	965	967	O
all	968	971	O
gap	972	975	O
and	976	979	O
criteria	980	988	O
durations	989	998	O
,	998	999	O
in	1000	1002	O
contrast	1003	1011	O
to	1012	1014	O
the	1015	1018	O
current	1019	1026	O
data	1027	1031	O
showing	1032	1039	O
the	1040	1043	O
use	1044	1047	O
of	1048	1050	O
different	1051	1060	O
rules	1061	1066	O
for	1067	1070	O
different	1071	1080	O
temporal	1081	1089	O
criteria	1090	1098	O
.	1098	1099	O

To	1100	1102	O
account	1103	1110	O
for	1111	1114	O
the	1115	1118	O
flexible	1119	1127	O
use	1128	1131	O
of	1132	1134	O
the	1135	1138	O
run	1139	1142	O
/	1142	1143	O
stop	1143	1147	O
/	1147	1148	O
reset	1148	1153	O
rules	1154	1159	O
by	1160	1162	O
rats	1163	1167	O
and	1168	1171	O
pigeons	1172	1179	O
,	1179	1180	O
Cabeza	1181	1187	O
de	1188	1190	O
Vaca	1191	1195	O
et	1196	1198	O
al	1199	1201	O
.	1201	1202	O

[	1203	1204	O
38	1204	1206	O
]	1206	1207	O
proposed	1208	1216	O
a	1217	1218	O
passive	1219	1226	O
memory	1227	1233	O
-	1233	1234	O
decay	1234	1239	O
model	1240	1245	O
which	1246	1251	O
assumes	1252	1259	O
that	1260	1264	O
subjective	1265	1275	O
time	1276	1280	O
-	1280	1281	O
-	1281	1282	O
stored	1282	1288	O
in	1289	1291	O
WM	1292	1294	O
-	1294	1295	O
-	1295	1296	O
decays	1296	1302	O
passively	1303	1312	O
during	1313	1319	O
the	1320	1323	O
gap	1324	1327	O
.	1327	1328	O

This	1329	1333	O
model	1334	1339	O
predicts	1340	1348	O
that	1349	1353	O
the	1354	1357	O
effect	1358	1364	O
of	1365	1367	O
a	1368	1369	O
gap	1370	1373	O
should	1374	1380	O
depend	1381	1387	O
solely	1388	1394	O
on	1395	1397	O
absolute	1398	1406	O
gap	1407	1410	O
duration	1411	1419	O
,	1419	1420	O
but	1421	1424	O
not	1425	1428	O
on	1429	1431	O
criterion	1432	1441	O
duration	1442	1450	O
,	1450	1451	O
as	1452	1454	O
found	1455	1460	O
here	1461	1465	O
(	1466	1467	O
Fig	1467	1470	O
.	1470	1471	O
1B	1472	1474	O
-	1474	1475	O
D	1475	1476	O
)	1476	1477	O
.	1477	1478	O

These	1479	1484	O
models	1485	1491	O
can	1492	1495	O
not	1496	1499	O
account	1500	1507	O
for	1508	1511	O
the	1512	1515	O
differential	1516	1528	O
effects	1529	1536	O
of	1537	1539	O
gaps	1540	1544	O
on	1545	1547	O
multiple	1548	1556	O
intervals	1557	1566	O
.	1566	1567	O

In	1568	1570	O
contrast	1571	1579	O
to	1580	1582	O
these	1583	1588	O
alternatives	1589	1601	O
,	1601	1602	O
the	1603	1606	O
present	1607	1614	O
resource	1615	1623	O
allocation	1624	1634	O
model	1635	1640	O
assumes	1641	1648	O
that	1649	1653	O
during	1654	1660	O
the	1661	1664	O
gaps	1665	1669	O
resources	1670	1679	O
are	1680	1683	O
re	1684	1686	O
-	1686	1687	O
allocated	1687	1696	O
(	1697	1698	O
diverted	1698	1706	O
away	1707	1711	O
from	1712	1716	O
timing	1717	1723	O
)	1723	1724	O
,	1724	1725	O
each	1726	1730	O
clock	1731	1736	O
is	1737	1739	O
unable	1740	1746	O
to	1747	1749	O
maintain	1750	1758	O
its	1759	1762	O
current	1763	1770	O
subjective	1771	1781	O
time	1782	1786	O
in	1787	1789	O
WM	1790	1792	O
,	1792	1793	O
and	1794	1797	O
the	1798	1801	O
response	1802	1810	O
is	1811	1813	O
delayed	1814	1821	O
[	1822	1823	O
16	1823	1825	O
]	1825	1826	O
,	1826	1827	O
[	1828	1829	O
17	1829	1831	O
]	1831	1832	O
,	1832	1833	O
[	1834	1835	O
27	1835	1837	O
]	1837	1838	O
in	1839	1841	O
proportion	1842	1852	O
to	1853	1855	O
the	1856	1859	O
perceived	1860	1869	O
salience	1870	1878	O
of	1879	1881	O
the	1882	1885	O
distracter	1886	1896	O
relative	1897	1905	O
to	1906	1908	O
the	1909	1912	O
times	1913	1918	O
signal	1919	1925	O
[	1926	1927	O
34	1927	1929	O
]	1929	1930	O
,	1930	1931	O
[	1932	1933	O
35	1933	1935	O
]	1935	1936	O
.	1936	1937	O

Indeed	1938	1944	O
,	1944	1945	O
the	1946	1949	O
effect	1950	1956	O
of	1957	1959	O
a	1960	1961	O
gap	1962	1965	O
is	1966	1968	O
affected	1969	1977	O
by	1978	1980	O
the	1981	1984	O
contrast	1985	1993	O
in	1994	1996	O
intensity	1997	2006	O
between	2007	2014	O
the	2015	2018	O
gap	2019	2022	O
and	2023	2026	O
the	2027	2030	O
timed	2031	2036	O
signal	2037	2043	O
[	2044	2045	O
27	2045	2047	O
]	2047	2048	O
,	2048	2049	O
[	2050	2051	O
34	2051	2053	O
]	2053	2054	O
,	2054	2055	O
[	2056	2057	O
39	2057	2059	O
]	2059	2060	O
and	2061	2064	O
by	2065	2067	O
the	2068	2071	O
perceptual	2072	2082	O
acuity	2083	2089	O
of	2090	2092	O
the	2093	2096	O
subjects	2097	2105	O
[	2106	2107	O
27	2107	2109	O
]	2109	2110	O
.	2110	2111	O

Importantly	2112	2123	O
,	2123	2124	O
the	2125	2128	O
predictions	2129	2140	O
of	2141	2143	O
this	2144	2148	O
resource	2149	2157	O
re	2158	2160	O
-	2160	2161	O
allocation	2161	2171	O
model	2172	2177	O
are	2178	2181	O
not	2182	2185	O
restricted	2186	2196	O
to	2197	2199	O
retention	2200	2209	O
-	2209	2210	O
intervals	2210	2219	O
(	2220	2221	O
i	2221	2222	O
.	2222	2223	O
e	2223	2224	O
.	2224	2225	O
,	2225	2226	O
gaps	2227	2231	O
)	2231	2232	O
,	2232	2233	O
but	2234	2237	O
extend	2238	2244	O
to	2245	2247	O
distracters	2248	2259	O
presented	2260	2269	O
during	2270	2276	O
the	2277	2280	O
continuous	2281	2291	O
presentation	2292	2304	O
of	2305	2307	O
a	2308	2309	O
timed	2310	2315	O
signal	2316	2322	O
.	2322	2323	O

Previous	2324	2332	O
data	2333	2337	O
were	2338	2342	O
quantitatively	2343	2357	O
accounted	2358	2367	O
for	2368	2371	O
by	2372	2374	O
assuming	2375	2383	O
that	2384	2388	O
during	2389	2395	O
a	2396	2397	O
gap	2398	2401	O
and	2402	2405	O
/	2405	2406	O
or	2406	2408	O
distracter	2409	2419	O
the	2420	2423	O
accumulated	2424	2435	O
time	2436	2440	O
decays	2441	2447	O
at	2448	2450	O
a	2451	2452	O
rate	2453	2457	O
that	2458	2462	O
varies	2463	2469	O
with	2470	2474	O
the	2475	2478	O
relative	2479	2487	O
salience	2488	2496	O
of	2497	2499	O
the	2500	2503	O
distracter	2504	2514	O
to	2515	2517	O
the	2518	2521	O
timed	2522	2527	O
signal	2528	2534	O
[	2535	2536	O
25	2536	2538	O
]	2538	2539	O
,	2539	2540	O
[	2541	2542	O
26	2542	2544	O
]	2544	2545	O
,	2545	2546	O
[	2547	2548	O
35	2548	2550	O
]	2550	2551	O
.	2551	2552	O

Here	2553	2557	O
we	2558	2560	O
found	2561	2566	O
that	2567	2571	O
the	2572	2575	O
comparison	2576	2586	O
between	2587	2594	O
the	2595	2598	O
gap	2599	2602	O
and	2603	2606	O
the	2607	2610	O
(	2611	2612	O
multiple	2612	2620	O
)	2620	2621	O
timed	2622	2627	O
signal	2628	2634	O
(	2634	2635	O
s	2635	2636	O
)	2636	2637	O
extends	2638	2645	O
to	2646	2648	O
the	2649	2652	O
temporal	2653	2661	O
domain	2662	2668	O
.	2668	2669	O

Simulations	2670	2681	O
indicate	2682	2690	O
that	2691	2695	O
both	2696	2700	O
the	2701	2704	O
differential	2705	2717	O
effect	2718	2724	O
of	2725	2727	O
the	2728	2731	O
gap	2732	2735	O
on	2736	2738	O
multiple	2739	2747	O
durations	2748	2757	O
,	2757	2758	O
and	2759	2762	O
the	2763	2766	O
gradual	2767	2774	O
hierarchical	2775	2787	O
reset	2788	2793	O
due	2794	2797	O
to	2798	2800	O
increasing	2801	2811	O
gap	2812	2815	O
duration	2816	2824	O
can	2825	2828	O
be	2829	2831	O
quantitatively	2832	2846	O
accounted	2847	2856	O
for	2857	2860	O
assuming	2861	2869	O
that	2870	2874	O
the	2875	2878	O
three	2879	2884	O
clocks	2885	2891	O
have	2892	2896	O
separate	2897	2905	O
resources	2906	2915	O
re	2916	2918	O
-	2918	2919	O
allocated	2919	2928	O
independently	2929	2942	O
during	2943	2949	O
a	2950	2951	O
gap	2952	2955	O
at	2956	2958	O
a	2959	2960	O
rate	2961	2965	O
proportional	2966	2978	O
to	2979	2981	O
the	2982	2985	O
ratio	2986	2991	O
g	2992	2993	O
/	2993	2994	O
Tk	2994	2996	O
between	2997	3004	O
the	3005	3008	O
duration	3009	3017	O
of	3018	3020	O
the	3021	3024	O
gap	3025	3028	O
and	3029	3032	O
each	3033	3037	O
criterion	3038	3047	O
duration	3048	3056	O
(	3057	3058	O
Fig	3058	3061	O
.	3061	3062	O
2A	3063	3065	O
:	3065	3066	O
D	3066	3067	O
-	3067	3068	O
Model	3068	3073	O
)	3073	3074	O
.	3074	3075	O

SUMMARY	0	7	O

This	8	12	O
is	13	15	O
a	16	17	O
prospective	18	29	O
study	30	35	O
carried	36	43	O
out	44	47	O
to	48	50	O
determine	51	60	O
the	61	64	O
outcome	65	72	O
of	73	75	O
patients	76	84	O
who	85	88	O
refuse	89	95	O
cystectomy	96	106	O
after	107	112	O
receiving	113	122	O
neoadjuvant	123	134	O
chemotherapy	135	147	O
for	148	151	O
muscle	152	158	B-Pathological_formation
-	158	159	I-Pathological_formation
invasive	159	167	I-Pathological_formation
bladder	168	175	I-Pathological_formation
cancer	176	182	I-Pathological_formation
.	182	183	O

Sixty	184	189	O
-	189	190	O
three	190	195	O
patients	196	204	O
were	205	209	O
evaluated	210	219	O
between	220	227	O
1995	228	232	O
and	233	236	O
2001	237	241	O
who	242	245	O
declined	246	254	O
to	255	257	O
undergo	258	265	O
a	266	267	O
planned	268	275	O
cystectomy	276	286	O
because	287	294	O
they	295	299	O
achieved	300	308	O
a	309	310	O
complete	311	319	O
clinical	320	328	O
response	329	337	O
to	338	340	O
neoadjuvant	341	352	O
cisplatin	353	362	O
-	362	363	O
based	363	368	O
chemotherapy	369	381	O
.	381	382	O

Herr	383	387	O
assessed	388	396	O
patient	397	404	O
,	404	405	O
tumor	406	411	B-Pathological_formation
and	412	415	O
treatment	416	425	O
features	426	434	O
for	435	438	O
a	439	440	O
median	441	447	O
follow	448	454	O
-	454	455	O
up	456	458	O
of	459	461	O
86	462	464	O
months	465	471	O
,	471	472	O
all	473	476	O
patients	477	485	O
being	486	491	O
followed	492	500	O
-	500	501	O
up	501	503	O
for	504	507	O
more	508	512	O
than	513	517	O
5	518	519	O
years	520	525	O
.	525	526	O

Forty	527	532	O
patients	533	541	O
(	542	543	O
64	543	545	O
%	545	546	O
)	546	547	O
survived	548	556	O
,	556	557	O
with	558	562	O
54	563	565	O
%	565	566	O
of	567	569	O
them	570	574	O
having	575	581	O
an	582	584	O
intact	585	591	O
functioning	592	603	O
bladder	604	611	B-Organ
.	611	612	O

The	613	616	O
number	617	623	O
and	624	627	O
size	628	632	O
of	633	635	O
invasive	636	644	O
tumors	645	651	B-Pathological_formation
were	652	656	O
strongly	657	665	O
associated	666	676	O
with	677	681	O
the	682	685	O
overall	686	693	O
survival	694	702	O
.	702	703	O

The	704	707	O
most	708	712	O
significant	713	724	O
treatment	725	734	O
variable	735	743	O
predicting	744	754	O
better	755	761	O
survival	762	770	O
was	771	774	O
complete	775	783	O
resection	784	793	O
of	794	796	O
the	797	800	O
invasive	801	809	O
tumor	810	815	B-Pathological_formation
on	816	818	O
restaging	819	828	O
transurethral	829	842	O
resection	843	852	O
(	853	854	O
TUR	854	857	O
)	857	858	O
before	859	865	O
starting	866	874	O
chemotherapy	875	887	O
.	887	888	O

Of	889	891	O
23	892	894	O
patients	895	903	O
(	904	905	O
36	905	907	O
%	907	908	O
)	908	909	O
who	910	913	O
subsequently	914	926	O
died	927	931	O
of	932	934	O
disease	935	942	O
,	942	943	O
19	944	946	O
(	947	948	O
30	948	950	O
%	950	951	O
)	951	952	O
relapsed	953	961	O
with	962	966	O
invasive	967	975	O
cancer	976	982	B-Pathological_formation
in	983	985	O
the	986	989	O
bladder	990	997	B-Organ
.	997	998	O

Over	999	1003	O
90	1004	1006	O
%	1006	1007	O
of	1008	1010	O
the	1011	1014	O
surviving	1015	1024	O
patients	1025	1033	O
had	1034	1037	O
solitary	1038	1046	O
,	1046	1047	O
small	1048	1053	O
and	1054	1057	O
low	1058	1061	O
-	1061	1062	O
stage	1062	1067	O
invasive	1068	1076	O
tumors	1077	1083	B-Pathological_formation
completely	1084	1094	O
resected	1095	1103	O
and	1104	1107	O
83	1108	1110	O
%	1110	1111	O
survived	1112	1120	O
without	1121	1128	O
relapses	1129	1137	O
in	1138	1140	O
the	1141	1144	O
bladder	1145	1152	B-Organ
.	1152	1153	O
[	1153	1154	O
1	1154	1155	O
]	1155	1156	O

COMMENTS	0	8	O

Recurrent	9	18	O
anterior	19	27	B-Multi-tissue_structure
vaginal	28	35	I-Multi-tissue_structure
wall	36	40	I-Multi-tissue_structure
prolapse	41	49	O
can	50	53	O
develop	54	61	O
in	62	64	O
more	65	69	O
than	70	74	O
20	75	77	O
%	77	78	O
of	79	81	O
patients	82	90	O
undergoing	91	101	O
traditional	102	113	O
anterior	114	122	O
colporrhaphy	123	135	O
.	135	136	O

In	137	139	O
light	140	145	O
of	146	148	O
this	149	153	O
high	154	158	O
recurrence	159	169	O
rate	170	174	O
many	175	179	O
surgeons	180	188	O
have	189	193	O
been	194	198	O
incorporating	199	212	O
synthetic	213	222	O
or	223	225	O
allograft	226	235	O
mesh	236	240	O
to	241	243	O
augment	244	251	O
the	252	255	O
repair	256	262	O
.	262	263	O

In	264	266	O
this	267	271	O
study	272	277	O
there	278	283	O
are	284	287	O
some	288	292	O
shortcomings	293	305	O
,	305	306	O
including	307	316	O
retrospective	317	330	O
design	331	337	O
,	337	338	O
short	339	344	O
follow	345	351	O
-	351	352	O
up	352	354	O
for	355	358	O
a	359	360	O
study	361	366	O
spanning	367	375	O
almost	376	382	O
six	383	386	O
years	387	392	O
and	393	396	O
a	397	398	O
lack	399	403	O
of	404	406	O
validated	407	416	O
questionnaires	417	431	O
.	431	432	O

Authors	433	440	O
report	441	447	O
a	448	449	O
negative	450	458	O
experience	459	469	O
with	470	474	O
porcine	475	482	O
dermis	483	489	B-Multi-tissue_structure
,	489	490	O
both	491	495	O
in	496	498	O
terms	499	504	O
of	505	507	O
success	508	515	O
and	516	519	O
extrusion	520	529	O
rate	530	534	O
.	534	535	O

However	536	543	O
,	543	544	O
others	545	551	O
have	552	556	O
reported	557	565	O
better	566	572	O
outcome	573	580	O
[	580	581	O
1	581	582	O
]	582	583	O
which	584	589	O
may	590	593	O
be	594	596	O
due	597	600	O
to	601	603	O
different	604	613	O
follow	614	620	O
-	620	621	O
up	621	623	O
times	624	629	O
and	630	633	O
outcome	634	641	O
measures	642	650	O
.	650	651	O

Apart	652	657	O
from	658	662	O
this	663	667	O
,	667	668	O
biological	669	679	O
grafts	680	686	O
are	687	690	O
also	691	695	O
associated	696	706	O
with	707	711	O
allergic	712	720	O
reactions	721	730	O
and	731	734	O
disease	735	742	O
transmission	743	755	O
.	755	756	O

There	757	762	O
is	763	765	O
paucity	766	773	O
of	774	776	O
data	777	781	O
regarding	782	791	O
prospective	792	803	O
randomized	804	814	O
trials	815	821	O
on	822	824	O
the	825	828	O
use	829	832	O
of	833	835	O
these	836	841	O
biomaterials	842	854	O
prior	855	860	O
to	861	863	O
their	864	869	O
widespread	870	880	O
human	881	886	O
need	887	891	O
which	892	897	O
might	898	903	O
help	904	908	O
in	909	911	O
reducing	912	920	O
such	921	925	O
type	926	930	O
of	931	933	O
experiences	934	945	O
.	945	946	O

Unless	947	953	O
such	954	958	O
data	959	963	O
are	964	967	O
available	968	977	O
surgeons	978	986	O
should	987	993	O
give	994	998	O
serious	999	1006	O
thought	1007	1014	O
prior	1015	1020	O
to	1021	1023	O
embarking	1024	1033	O
on	1034	1036	O
the	1037	1040	O
use	1041	1044	O
of	1045	1047	O
such	1048	1052	O
biological	1053	1063	O
materials	1064	1073	O
.	1073	1074	O
[	1074	1075	O
2	1075	1076	O
]	1076	1077	O

Background	0	10	O

Opioid	11	17	O
analgesics	18	28	O
are	29	32	O
generally	33	42	O
used	43	47	O
to	48	50	O
combat	51	57	O
the	58	61	O
pain	62	66	O
associated	67	77	O
with	78	82	O
cancerous	83	92	B-Pathological_formation
conditions	93	103	O
.	103	104	O

These	105	110	O
agents	111	117	O
not	118	121	O
only	122	126	O
inhibit	127	134	O
respiratory	135	146	B-Anatomical_system
function	147	155	O
and	156	159	O
cause	160	165	O
constipation	166	178	O
,	178	179	O
but	180	183	O
also	184	188	O
induce	189	195	O
other	196	201	O
significant	202	213	O
side	214	218	O
effects	219	226	O
such	227	231	O
as	232	234	O
addiction	235	244	O
and	245	248	O
tolerance	249	258	O
,	258	259	O
all	260	263	O
of	264	266	O
which	267	272	O
further	273	280	O
contribute	281	291	O
to	292	294	O
a	295	296	O
reduced	297	304	O
quality	305	312	O
of	313	315	O
life	316	320	O
for	321	324	O
cancer	325	331	B-Pathological_formation
patients	332	340	O
.	340	341	O

Thus	342	346	O
,	346	347	O
in	348	350	O
the	351	354	O
present	355	362	O
study	363	368	O
,	368	369	O
the	370	373	O
effects	374	381	O
of	382	384	O
electro	385	392	O
-	392	393	O
acupuncture	393	404	O
treatment	405	414	O
(	415	416	O
EA	416	418	O
)	418	419	O
on	420	422	O
mechanical	423	433	O
allodynia	434	443	O
were	444	448	O
examined	449	457	O
in	458	460	O
a	461	462	O
cancer	463	469	B-Pathological_formation
pain	470	474	O
mouse	475	480	O
model	481	486	O
.	486	487	O

2	0	1	O
.	1	2	O
1	2	3	O
.	3	4	O

Biological	5	15	O
samples	16	23	O

Placental	24	33	B-Tissue
tissues	34	41	I-Tissue
from	42	46	O
the	47	50	O
first	51	56	O
trimester	57	66	O
legally	67	74	O
induced	75	82	O
abortions	83	92	O
(	93	94	O
8	94	95	O
-	95	96	O
12	96	98	O
weeks	99	104	O
of	105	107	O
gestation	108	117	O
)	117	118	O
were	119	123	O
obtained	124	132	O
from	133	137	O
the	138	141	O
Department	142	152	O
of	153	155	O
Obstetrics	156	166	O
and	167	170	O
Gynecology	171	181	O
at	182	184	O
the	185	188	O
Broussais	189	198	O
,	198	199	O
Saint	200	205	O
Vincent	206	213	O
de	214	216	O
Paul	217	221	O
and	222	225	O
Cochin	226	232	O
Hospitals	233	242	O
.	242	243	O

Second	244	250	O
trimester	251	260	O
placental	261	270	B-Tissue
tissues	271	278	I-Tissue
were	279	283	O
collected	284	293	O
at	294	296	O
the	297	300	O
time	301	305	O
of	306	308	O
termination	309	320	O
of	321	323	O
pregnancy	324	333	O
at	334	336	O
15	337	339	O
and	340	343	O
25	344	346	O
weeks	347	352	O
of	353	355	O
gestation	356	365	O
(	366	367	O
in	367	369	O
weeks	370	375	O
of	376	378	O
amenorrhea	379	389	O
)	389	390	O
in	391	393	O
trisomy	394	401	O
21	402	404	O
-	404	405	O
affected	405	413	O
pregnancies	414	425	O
.	425	426	O

Fetal	427	432	B-Developing_anatomical_structure
Down	433	437	O
syndrome	438	446	O
was	447	450	O
diagnosed	451	460	O
by	461	463	O
karyotyping	464	475	O
of	476	478	O
amniotic	479	487	B-Cell
fluid	488	493	I-Cell
cells	494	499	I-Cell
.	499	500	O

The	501	504	O
indication	505	515	O
of	516	518	O
amniocentesis	519	532	O
was	533	536	O
the	537	540	O
maternal	541	549	O
age	550	553	O
.	553	554	O

Term	555	559	O
placentas	560	569	B-Organ
were	570	574	O
obtained	575	583	O
after	584	589	O
elective	590	598	O
cesarean	599	607	O
section	608	615	O
from	616	620	O
healthy	621	628	O
mothers	629	636	O
near	637	641	O
term	642	646	O
with	647	651	O
uncomplicated	652	665	O
pregnancies	666	677	O
.	677	678	O

With	679	683	O
written	684	691	O
informed	692	700	O
consent	701	708	O
of	709	711	O
the	712	715	O
pregnant	716	724	O
woman	725	730	O
,	730	731	O
the	732	735	O
following	736	745	O
samples	746	753	O
were	754	758	O
collected	759	768	O
at	769	771	O
term	772	776	O
:	776	777	O
a	778	779	O
fragment	780	788	B-Organ
of	789	791	O
the	792	795	O
placenta	796	804	B-Organ
,	804	805	O
umbilical	806	815	B-Organism_substance
cord	816	820	I-Organism_substance
fetal	821	826	I-Organism_substance
blood	827	832	I-Organism_substance
and	833	836	O
maternal	837	845	O
blood	846	851	B-Organism_substance
.	851	852	O

The	853	856	O
placenta	857	865	B-Organ
biopsy	866	872	I-Organ
sample	873	879	I-Organ
was	880	883	O
collected	884	893	O
at	894	896	O
a	897	898	O
depth	899	904	O
of	905	907	O
1	908	909	O
cm	910	912	O
and	913	916	O
at	917	919	O
a	920	921	O
distance	922	930	O
of	931	933	O
8	934	935	O
cm	936	938	O
from	939	943	O
the	944	947	O
edge	948	952	O
of	953	955	O
the	956	959	O
placenta	960	968	B-Organ
,	968	969	O
with	970	974	O
the	975	978	O
maternal	979	987	O
side	988	992	O
facing	993	999	O
upward	1000	1006	O
.	1006	1007	O

The	1008	1011	O
use	1012	1015	O
of	1016	1018	O
these	1019	1024	O
biological	1025	1035	O
samples	1036	1043	O
was	1044	1047	O
approved	1048	1056	O
by	1057	1059	O
local	1060	1065	O
ethical	1066	1073	O
committee	1074	1083	O
.	1083	1084	O

Villous	1085	1092	B-Cell
cytotrophoblastic	1093	1110	I-Cell
cells	1111	1116	I-Cell
were	1117	1121	O
isolated	1122	1130	O
by	1131	1133	O
sequential	1134	1144	O
enzymatic	1145	1154	O
digestion	1155	1164	O
of	1165	1167	O
chorionic	1168	1177	B-Multi-tissue_structure
villi	1178	1183	I-Multi-tissue_structure
from	1184	1188	O
the	1189	1192	O
first	1193	1198	O
trimester	1199	1208	O
,	1208	1209	O
second	1210	1216	O
trimester	1217	1226	O
and	1227	1230	O
term	1231	1235	O
placenta	1236	1244	B-Organ
and	1245	1248	O
purified	1249	1257	O
on	1258	1260	O
a	1261	1262	O
discontinuous	1263	1276	O
percoll	1277	1284	O
gradient	1285	1293	O
,	1293	1294	O
as	1295	1297	O
described	1298	1307	O
previously	1308	1318	O
.	1318	1319	O
47	1319	1321	O
-	1321	1322	O
49	1322	1324	O
These	1325	1330	O
cells	1331	1336	B-Cell
were	1337	1341	O
positively	1342	1352	O
stained	1353	1360	O
for	1361	1364	O
cytokeratin	1365	1376	O
7	1377	1378	O
at	1379	1381	O
95	1382	1384	O
%	1384	1385	O
,	1385	1386	O
indicating	1387	1397	O
the	1398	1401	O
cytotrophoblastic	1402	1419	O
origin	1420	1426	O
of	1427	1429	O
the	1430	1433	O
cells	1434	1439	B-Cell
.	1439	1440	O

Placental	1441	1450	B-Cell
fibroblasts	1451	1462	I-Cell
were	1463	1467	O
isolated	1468	1476	O
by	1477	1479	O
prolonged	1480	1489	O
enzymatic	1490	1499	O
digestion	1500	1509	O
from	1510	1514	O
first	1515	1520	O
trimester	1521	1530	O
chorionic	1531	1540	B-Multi-tissue_structure
villi	1541	1546	I-Multi-tissue_structure
as	1547	1549	O
in	1550	1552	O
Malassine	1553	1562	O
et	1563	1565	O
al	1566	1568	O
.	1568	1569	O
50	1569	1571	O
Fibroblastic	1572	1584	B-Cell
cells	1585	1590	I-Cell
(	1591	1592	O
1	1592	1593	O
.	1593	1594	O
25	1594	1596	O
x	1597	1598	O
105	1599	1602	O
cells	1603	1608	O
/	1608	1609	O
mL	1609	1611	O
)	1611	1612	O
were	1613	1617	O
plated	1618	1624	O
on	1625	1627	O
35	1628	1630	O
-	1630	1631	O
mm	1631	1633	O
plastic	1634	1641	O
dishes	1642	1648	O
(	1649	1650	O
TPP	1650	1653	O
,	1653	1654	O
Switzerland	1655	1666	O
)	1666	1667	O
and	1668	1671	O
cultured	1672	1680	O
for	1681	1684	O
48	1685	1687	O
h	1688	1689	O
,	1689	1690	O
and	1691	1694	O
the	1695	1698	O
culture	1699	1706	O
medium	1707	1713	O
was	1714	1717	O
changed	1718	1725	O
daily	1726	1731	O
.	1731	1732	O

These	1733	1738	O
cultured	1739	1747	O
fibroblasts	1748	1759	B-Cell
were	1760	1764	O
characterized	1765	1778	O
using	1779	1784	O
immunocytochemistry	1785	1804	O
.	1804	1805	O

It	1806	1808	O
was	1809	1812	O
found	1813	1818	O
that	1819	1823	O
98	1824	1826	O
%	1826	1827	O
of	1828	1830	O
the	1831	1834	O
cells	1835	1840	B-Cell
were	1841	1845	O
vimentin	1846	1854	O
positive	1855	1863	O
and	1864	1867	O
also	1868	1872	O
positive	1873	1881	O
for	1882	1885	O
a	1886	1887	O
monoclonal	1888	1898	O
antibody	1899	1907	O
against	1908	1915	O
specific	1916	1924	O
fibroblast	1925	1935	B-Cell
antigen	1936	1943	O
(	1944	1945	O
clone	1945	1950	O
ASO2	1951	1955	O
,	1955	1956	O
Dianova	1957	1964	O
,	1964	1965	O
Hamburg	1966	1973	O
,	1973	1974	O
Germany	1975	1982	O
)	1982	1983	O
.	1983	1984	O

Owing	1985	1990	O
to	1991	1993	O
the	1994	1997	O
limited	1998	2005	O
amount	2006	2012	O
of	2013	2015	O
cells	2016	2021	B-Cell
,	2021	2022	O
only	2023	2027	O
DNA	2028	2031	O
was	2032	2035	O
extracted	2036	2045	O
.	2045	2046	O

Methods	0	7	O

Therefore	8	17	O
,	17	18	O
we	19	21	O
developed	22	31	O
a	32	33	O
reciprocal	34	44	O
system	45	51	O
of	52	54	O
a	55	56	O
full	57	61	B-Cell
-	61	62	I-Cell
length	62	68	I-Cell
HIV	69	72	I-Cell
packaging	73	82	I-Cell
cell	83	87	I-Cell
line	88	92	I-Cell
and	93	96	O
a	97	98	O
shortened	99	108	O
HI	109	111	O
-	111	112	O
viral	112	117	O
shuttle	118	125	O
vector	126	132	O
.	132	133	O

The	134	137	O
Tat	138	141	O
-	141	142	O
deficient	142	151	O
packaging	152	161	O
construct	162	171	O
is	172	174	O
stably	175	181	O
integrated	182	192	O
in	193	195	O
a	196	197	O
VSVG	198	202	B-Cell
-	202	203	I-Cell
pseudotyped	203	214	I-Cell
cell	215	219	I-Cell
line	220	224	I-Cell
and	225	228	O
transactivated	229	243	O
by	244	246	O
the	247	250	O
shuttle	251	258	O
vector	259	265	O
by	266	268	O
expression	269	279	O
of	280	282	O
TATGFP	283	289	O
from	290	294	O
a	295	296	O
heterologous	297	309	O
promoter	310	318	O
which	319	324	O
also	325	329	O
indicates	330	339	O
positive	340	348	O
cells	349	354	B-Cell
.	354	355	O

Expression	356	366	O
of	367	369	O
the	370	373	O
HI	374	376	O
-	376	377	O
viral	377	382	O
structure	383	392	O
proteins	393	401	O
is	402	404	O
driven	405	411	O
by	412	414	O
a	415	416	O
natural	417	424	O
5	425	426	O
'	426	427	O
LTR	428	431	O
promoter	432	440	O
and	441	444	O
a	445	446	O
3	447	448	O
'	448	449	O
polyadenylation	450	465	O
signal	466	472	O
,	472	473	O
whereas	474	481	O
the	482	485	O
envelope	486	494	B-Cellular_component
expression	495	505	O
out	506	509	O
of	510	512	O
the	513	516	O
shuttle	517	524	O
vector	525	531	O
is	532	534	O
achieved	535	543	O
by	544	546	O
an	547	549	O
IRES	550	554	O
.	554	555	O

This	556	560	O
system	561	567	O
of	568	570	O
two	571	574	O
vectors	575	582	O
is	583	585	O
tightly	586	593	O
controllable	594	606	O
and	607	610	O
bypasses	611	619	O
the	620	623	O
problem	624	631	O
of	632	634	O
limited	635	642	O
packaging	643	652	O
capacity	653	661	O
into	662	666	O
HIV	667	670	O
-	670	671	O
1	671	672	O
virions	673	680	O
.	680	681	O

Percutaneous	0	12	O
coronary	13	21	B-Multi-tissue_structure
intervention	22	34	O
for	35	38	O
the	39	42	O
very	43	47	O
late	48	52	O
stent	53	58	O
thrombosis	59	69	O
in	70	72	O
right	73	78	B-Multi-tissue_structure
coronary	79	87	I-Multi-tissue_structure
artery	88	94	I-Multi-tissue_structure
.	94	95	O

A	96	97	O
:	97	98	O
a	99	100	O
balloon	101	108	O
angioplasty	109	120	O
was	121	124	O
performed	125	134	O
to	135	137	O
treat	138	143	O
total	144	149	O
occlusion	150	159	O
of	160	162	O
the	163	166	O
stented	167	174	O
right	175	180	B-Multi-tissue_structure
coronary	181	189	I-Multi-tissue_structure
artery	190	196	I-Multi-tissue_structure
.	196	197	O

B	198	199	O
:	199	200	O
final	201	206	O
coronary	207	215	B-Multi-tissue_structure
angiogram	216	225	O
showed	226	232	O
good	233	237	O
distal	238	244	O
flow	245	249	O
without	250	257	O
residual	258	266	O
stenosis	267	275	O
.	275	276	O

All	0	3	O
-	3	4	O
cause	4	9	O
mortality	10	19	O
in	20	22	O
RALES	23	28	O
and	29	32	O
EPHESUS	33	40	O
(	41	42	O
adapted	42	49	O
from	50	54	O
[	55	56	O
4	56	57	O
]	57	58	O
and	59	62	O
[	63	64	O
5	64	65	O
]	65	66	O
)	66	67	O
.	67	68	O

Mean	69	73	O
follow	74	80	O
-	80	81	O
up	81	83	O
period	84	90	O
is	91	93	O
24	94	96	O
months	97	103	O
in	104	106	O
RALES	107	112	O
and	113	116	O
16	117	119	O
months	120	126	O
in	127	129	O
EPHESUS	130	137	O

Pre	0	3	O
-	3	4	O
publication	4	15	O
history	16	23	O

The	24	27	O
pre	28	31	O
-	31	32	O
publication	32	43	O
history	44	51	O
for	52	55	O
this	56	60	O
paper	61	66	O
can	67	70	O
be	71	73	O
accessed	74	82	O
here	83	87	O
:	87	88	O

http	89	93	O
:	93	94	O
/	94	95	O
/	95	96	O
www	96	99	O
.	99	100	O
biomedcentral	100	113	O
.	113	114	O
com	114	117	O
/	117	118	O
1471	118	122	O
-	122	123	O
2377	123	127	O
/	127	128	O
9	128	129	O
/	129	130	O
57	130	132	O
/	132	133	O
prepub	133	139	O

Magnetic	0	8	O
resonance	9	18	O
imaging	19	26	O
of	27	29	O
axial	30	35	O
plan	36	40	O
with	41	45	O
intravenous	46	57	B-Multi-tissue_structure
contrast	58	66	O
gadolinium	67	77	O
-	77	78	O
BOPTA	78	83	O
demonstrating	84	97	O
a	98	99	O
mass	100	104	O
adherent	105	113	O
to	114	116	O
the	117	120	O
right	121	126	O
ventricular	127	138	B-Multi-tissue_structure
wall	139	143	I-Multi-tissue_structure
.	143	144	O

Additional	0	10	O
file	11	15	O
3	16	17	O

Primers	18	25	O
used	26	30	O
in	31	33	O
this	34	38	O
study	39	44	O
.	44	45	O

All	46	49	O
of	50	52	O
the	53	56	O
primers	57	64	O
used	65	69	O
for	70	73	O
generating	74	84	O
PCR	85	88	O
products	89	97	O
for	98	101	O
microinjection	102	116	O
and	117	120	O
site	121	125	O
-	125	126	O
direct	126	132	O
mutagenesis	133	144	O
are	145	148	O
listed	149	155	O
.	155	156	O

2	0	1	O
.	1	2	O

Methods	3	10	O

We	11	13	O
conducted	14	23	O
a	24	25	O
systematic	26	36	O
study	37	42	O
of	43	45	O
patients	46	54	O
hospitalized	55	67	O
from	68	72	O
August	73	79	O
2006	80	84	O
until	85	90	O
September	91	100	O
2007	101	105	O
at	106	108	O
the	109	112	O
Yerevan	113	120	O
City	121	125	O
and	126	129	O
the	130	133	O
Republican	134	144	O
Dispensaries	145	157	O
,	157	158	O
the	159	162	O
two	163	166	O
reference	167	176	O
TB	177	179	O
hospitals	180	189	O
in	190	192	O
Armenia	193	200	O
.	200	201	O

Following	202	211	O
focus	212	217	O
group	218	223	O
discussions	224	235	O
and	236	239	O
pilot	240	245	O
testing	246	253	O
to	254	256	O
refine	257	263	O
the	264	267	O
survey	268	274	O
instrument	275	285	O
,	285	286	O
patient	287	294	O
interviews	295	305	O
began	306	311	O
in	312	314	O
the	315	318	O
fall	319	323	O
of	324	326	O
2006	327	331	O
and	332	335	O
were	336	340	O
conducted	341	350	O
by	351	353	O
trained	354	361	O
students	362	370	O
in	371	373	O
the	374	377	O
public	378	384	O
health	385	391	O
program	392	399	O
of	400	402	O
the	403	406	O
American	407	415	O
University	416	426	O
of	427	429	O
Armenia	430	437	O
.	437	438	O

Students	439	447	O
received	448	456	O
training	457	465	O
by	466	468	O
the	469	472	O
study	473	478	O
designer	479	487	O
(	488	489	O
SO	489	491	O
)	491	492	O
on	493	495	O
principles	496	506	O
of	507	509	O
interview	510	519	O
ethics	520	526	O
and	527	530	O
interviewing	531	543	O
processes	544	553	O
.	553	554	O

Most	555	559	O
patient	560	567	O
interviews	568	578	O
were	579	583	O
conducted	584	593	O
at	594	596	O
the	597	600	O
Republican	601	611	O
Dispensary	612	622	O
in	623	625	O
Abovian	626	633	O
Marz	634	638	O
,	638	639	O
the	640	643	O
national	644	652	O
TB	653	655	O
diagnostic	656	666	O
and	667	670	O
treatment	671	680	O
facility	681	689	O
to	690	692	O
which	693	698	O
all	699	702	O
suspected	703	712	O
cases	713	718	O
throughout	719	729	O
the	730	733	O
country	734	741	O
are	742	745	O
referred	746	754	O
for	755	758	O
diagnostic	759	769	O
confirmation	770	782	O
.	782	783	O

In	784	786	O
the	787	790	O
past	791	795	O
several	796	803	O
years	804	809	O
,	809	810	O
strong	811	817	O
financial	818	827	O
support	828	835	O
has	836	839	O
been	840	844	O
provided	845	853	O
to	854	856	O
Armenia	857	864	O
by	865	867	O
a	868	869	O
number	870	876	O
of	877	879	O
international	880	893	O
organizations	894	907	O
,	907	908	O
such	909	913	O
as	914	916	O
the	917	920	O
German	921	927	O
Gesellschaft	928	940	O
fur	941	944	O
Technische	945	955	O
Zusammenarbeit	956	970	O
(	971	972	O
GTZ	972	975	O
)	975	976	O
,	976	977	O
the	978	981	O
Global	982	988	O
Fund	989	993	O
to	994	996	O
Fight	997	1002	O
AIDS	1003	1007	O
,	1007	1008	O
Tuberculosis	1009	1021	O
and	1022	1025	O
Malaria	1026	1033	O
,	1033	1034	O
and	1035	1038	O
the	1039	1042	O
Red	1043	1046	O
Cross	1047	1052	O
,	1052	1053	O
which	1054	1059	O
has	1060	1063	O
enabled	1064	1071	O
both	1072	1076	O
microscopic	1077	1088	O
and	1089	1092	O
culture	1093	1100	O
examinations	1101	1113	O
for	1114	1117	O
each	1118	1122	O
TB	1123	1125	O
case	1126	1130	O
to	1131	1133	O
be	1134	1136	O
performed	1137	1146	O
at	1147	1149	O
the	1150	1153	O
National	1154	1162	O
Reference	1163	1172	O
Laboratory	1173	1183	O
located	1184	1191	O
at	1192	1194	O
the	1195	1198	O
Republican	1199	1209	O
TB	1210	1212	O
Dispensary	1213	1223	O
.	1223	1224	O

All	1225	1228	O
culture	1229	1236	O
-	1236	1237	O
confirmed	1237	1246	O
TB	1247	1249	O
cases	1250	1255	O
are	1256	1259	O
admitted	1260	1268	O
as	1269	1271	O
in	1272	1274	O
-	1274	1275	O
patients	1275	1283	O
while	1284	1289	O
undergoing	1290	1300	O
the	1301	1304	O
initial	1305	1312	O
phase	1313	1318	O
of	1319	1321	O
therapy	1322	1329	O
.	1329	1330	O

Because	1331	1338	O
all	1339	1342	O
confirmed	1343	1352	O
TB	1353	1355	O
patients	1356	1364	O
in	1365	1367	O
Armenia	1368	1375	O
are	1376	1379	O
referred	1380	1388	O
to	1389	1391	O
one	1392	1395	O
of	1396	1398	O
these	1399	1404	O
dispensaries	1405	1417	O
for	1418	1421	O
treatment	1422	1431	O
,	1431	1432	O
this	1433	1437	O
population	1438	1448	O
represents	1449	1459	O
all	1460	1463	O
known	1464	1469	O
TB	1470	1472	O
cases	1473	1478	O
in	1479	1481	O
the	1482	1485	O
country	1486	1493	O
.	1493	1494	O

Therefore	1495	1504	O
,	1504	1505	O
all	1506	1509	O
culture	1510	1517	O
-	1517	1518	O
confirmed	1518	1527	O
TB	1528	1530	O
in	1531	1533	O
-	1533	1534	O
patients	1534	1542	O
present	1543	1550	O
at	1551	1553	O
the	1554	1557	O
time	1558	1562	O
of	1563	1565	O
the	1566	1569	O
interviewer	1570	1581	O
visits	1582	1588	O
were	1589	1593	O
eligible	1594	1602	O
for	1603	1606	O
inclusion	1607	1616	O
in	1617	1619	O
the	1620	1623	O
study	1624	1629	O
(	1630	1631	O
the	1631	1634	O
study	1635	1640	O
group	1641	1646	O
included	1647	1655	O
both	1656	1660	O
new	1661	1664	O
and	1665	1668	O
relapsed	1669	1677	O
patients	1678	1686	O
)	1686	1687	O
.	1687	1688	O

Our	1689	1692	O
systematic	1693	1703	O
sample	1704	1710	O
of	1711	1713	O
the	1714	1717	O
inpatient	1718	1727	O
TB	1728	1730	O
population	1731	1741	O
-	1741	1742	O
-	1742	1743	O
in	1743	1745	O
which	1746	1751	O
interviewers	1752	1764	O
visited	1765	1772	O
every	1773	1778	O
hospital	1779	1787	O
room	1788	1792	O
to	1793	1795	O
identify	1796	1804	O
patients	1805	1813	O
willing	1814	1821	O
to	1822	1824	O
participate	1825	1836	O
-	1836	1837	O
-	1837	1838	O
yielded	1838	1845	O
a	1846	1847	O
participation	1848	1861	O
rate	1862	1866	O
of	1867	1869	O
approximately	1870	1883	O
80	1884	1886	O
%	1886	1887	O
(	1888	1889	O
a	1889	1890	O
total	1891	1896	O
of	1897	1899	O
240	1900	1903	O
patients	1904	1912	O
)	1912	1913	O
.	1913	1914	O

Interviewers	1915	1927	O
collected	1928	1937	O
demographic	1938	1949	O
information	1950	1961	O
and	1962	1965	O
asked	1966	1971	O
each	1972	1976	O
patient	1977	1984	O
to	1985	1987	O
recall	1988	1994	O
when	1995	1999	O
they	2000	2004	O
first	2005	2010	O
began	2011	2016	O
to	2017	2019	O
feel	2020	2024	O
ill	2025	2028	O
,	2028	2029	O
what	2030	2034	O
symptoms	2035	2043	O
they	2044	2048	O
experienced	2049	2060	O
,	2060	2061	O
how	2062	2065	O
long	2066	2070	O
after	2071	2076	O
symptom	2077	2084	O
onset	2085	2090	O
they	2091	2095	O
waited	2096	2102	O
to	2103	2105	O
see	2106	2109	O
a	2110	2111	O
doctor	2112	2118	O
,	2118	2119	O
their	2120	2125	O
reasons	2126	2133	O
for	2134	2137	O
delaying	2138	2146	O
medical	2147	2154	O
evaluation	2155	2165	O
,	2165	2166	O
the	2167	2170	O
type	2171	2175	O
of	2176	2178	O
facility	2179	2187	O
at	2188	2190	O
which	2191	2196	O
they	2197	2201	O
first	2202	2207	O
sought	2208	2214	O
care	2215	2219	O
,	2219	2220	O
the	2221	2224	O
initial	2225	2232	O
diagnosis	2233	2242	O
,	2242	2243	O
if	2244	2246	O
they	2247	2251	O
had	2252	2255	O
been	2256	2260	O
referred	2261	2269	O
for	2270	2273	O
further	2274	2281	O
evaluation	2282	2292	O
,	2292	2293	O
and	2294	2297	O
their	2298	2303	O
adherence	2304	2313	O
to	2314	2316	O
treatment	2317	2326	O
once	2327	2331	O
diagnosed	2332	2341	O
with	2342	2346	O
TB	2347	2349	O
.	2349	2350	O

In	2351	2353	O
2006	2354	2358	O
,	2358	2359	O
129	2360	2363	O
of	2364	2366	O
the	2367	2370	O
planned	2371	2378	O
250	2379	2382	O
surveys	2383	2390	O
were	2391	2395	O
completed	2396	2405	O
.	2405	2406	O

Data	2407	2411	O
collection	2412	2422	O
resumed	2423	2430	O
in	2431	2433	O
the	2434	2437	O
fall	2438	2442	O
of	2443	2445	O
2007	2446	2450	O
and	2451	2454	O
a	2455	2456	O
total	2457	2462	O
of	2463	2465	O
240	2466	2469	O
interviews	2470	2480	O
were	2481	2485	O
conducted	2486	2495	O
.	2495	2496	O

Summary	0	7	O

Kindt	8	13	O
et	14	16	O
al	17	19	O
.	19	20	O
1	20	21	O
published	22	31	O
a	32	33	O
report	34	40	O
entitled	41	49	O
"	50	51	O
Intestinal	51	61	B-Multi-tissue_structure
immune	62	68	O
activation	69	79	O
in	80	82	O
presumed	83	91	O
post	92	96	O
-	96	97	O
infectious	97	107	O
functional	108	118	O
syspepsia	119	128	O
"	128	129	O
in	130	132	O
the	133	136	O
August	137	143	O
issue	144	149	O
of	150	152	O
Neurogastroenterology	153	174	O
and	175	178	O
Motility	179	187	O
in	188	190	O
2009	191	195	O
.	195	196	O

By	197	199	O
comparing	200	209	O
the	210	213	O
signs	214	219	O
of	220	222	O
inflammation	223	235	O
and	236	239	O
the	240	243	O
degree	244	250	O
of	251	253	O
hyperplasia	254	265	O
of	266	268	O
the	269	272	O
enterochromaffin	273	289	B-Cell
cells	290	295	I-Cell
(	296	297	O
EC	297	299	B-Cell
)	299	300	O
in	301	303	O
duodenal	304	312	O
biopsies	313	321	O
obtained	322	330	O
from	331	335	O
patients	336	344	O
with	345	349	O
presumed	350	358	O
post	359	363	O
-	363	364	O
infectious	364	374	O
functional	375	385	O
dyspepsia	386	395	O
(	396	397	O
PI	397	399	O
-	399	400	O
FD	400	402	O
)	402	403	O
and	404	407	O
unspecified	408	419	O
-	419	420	O
onset	420	425	O
functional	426	436	O
dyspepsia	437	446	O
(	447	448	O
U	448	449	O
-	449	450	O
FD	450	452	O
)	452	453	O
,	453	454	O
they	455	459	O
showed	460	466	O
that	467	471	O
PI	472	474	O
-	474	475	O
FD	475	477	O
is	478	480	O
associated	481	491	O
with	492	496	O
persistence	497	508	O
of	509	511	O
focal	512	517	O
T	518	519	B-Cell
-	519	520	I-Cell
cell	520	524	I-Cell
aggregates	525	535	O
,	535	536	O
decrease	537	545	O
in	546	548	O
CD4	549	552	B-Cell
+	552	553	I-Cell
cells	554	559	I-Cell
and	560	563	O
increased	564	573	O
macrophage	574	584	B-Cell
counts	585	591	O
surrounding	592	603	O
the	604	607	O
crypts	608	614	B-Multi-tissue_structure
,	614	615	O
without	616	623	O
any	624	627	O
significant	628	639	O
differences	640	651	O
in	652	654	O
the	655	658	O
numbers	659	666	O
of	667	669	O
EC	670	672	B-Cell
or	673	675	O
chromogranin	676	688	B-Cell
A	689	690	I-Cell
(	691	692	I-Cell
CA	692	694	I-Cell
)	694	695	I-Cell
-	695	696	I-Cell
positive	696	704	I-Cell
cells	705	710	I-Cell
(	711	712	O
mast	712	716	B-Cell
cells	717	722	I-Cell
)	722	723	O
.	723	724	O

This	725	729	O
finding	730	737	O
may	738	741	O
indicate	742	750	O
impaired	751	759	O
ability	760	767	O
of	768	770	O
the	771	774	O
immune	775	781	B-Anatomical_system
system	782	788	I-Anatomical_system
in	789	791	O
these	792	797	O
cases	798	803	O
to	804	806	O
terminate	807	816	O
the	817	820	O
inflammatory	821	833	O
response	834	842	O
after	843	848	O
an	849	851	O
acute	852	857	O
insult	858	864	O
.	864	865	O

Temporary	0	9	O
migration	10	19	O
module	20	26	O

A	27	28	O
temporary	29	38	O
migration	39	48	O
census	49	55	O
module	56	62	O
was	63	66	O
conducted	67	76	O
in	77	79	O
2002	80	84	O
and	85	88	O
2007	89	93	O
.	93	94	O

People	95	101	O
who	102	105	O
were	106	110	O
identified	111	121	O
as	122	124	O
temporary	125	134	O
migrants	135	143	O
were	144	148	O
entered	149	156	O
into	157	161	O
the	162	165	O
module	166	172	O
,	172	173	O
and	174	177	O
a	178	179	O
household	180	189	O
respondent	190	200	O
answered	201	209	O
questions	210	219	O
about	220	225	O
the	226	229	O
migration	230	239	O
.	239	240	O

Key	241	244	O
areas	245	250	O
included	251	259	O
the	260	263	O
duration	264	272	O
of	273	275	O
migration	276	285	O
,	285	286	O
destination	287	298	O
,	298	299	O
reasons	300	307	O
for	308	311	O
migration	312	321	O
,	321	322	O
return	323	329	O
pattern	330	337	O
,	337	338	O
communication	339	352	O
pattern	353	360	O
,	360	361	O
remittances	362	373	O
,	373	374	O
linked	375	381	O
moves	382	387	O
and	388	391	O
child	392	397	O
care	398	402	O
arrangements	403	415	O
.	415	416	O

MOR1K	0	5	O
expression	6	16	O
and	17	20	O
binding	21	28	O
pattern	29	36	O
.	36	37	O

(	38	39	O
A	39	40	O
)	40	41	O
The	42	45	O
schematic	46	55	O
diagram	56	63	O
illustrates	64	75	O
the	76	79	O
exonic	80	86	O
composition	87	98	O
and	99	102	O
relative	103	111	O
positions	112	121	O
of	122	124	O
PCR	125	128	O
primers	129	136	O
designed	137	145	O
to	146	148	O
amplify	149	156	O
the	157	160	O
major	161	166	O
MOR1	167	171	O
isoform	172	179	O
and	180	183	O
the	184	187	O
newly	188	193	O
identified	194	204	O
alternative	205	216	O
MOR1K	217	222	O
isoform	223	230	O
.	230	231	O

The	232	235	O
relative	236	244	O
positions	245	254	O
of	255	257	O
translation	258	269	O
initiation	270	280	O
start	281	286	O
and	287	290	O
stop	291	295	O
codons	296	302	O
are	303	306	O
designated	307	317	O
by	318	320	O
ATG	321	324	O
and	325	328	O
TGA	329	332	O
,	332	333	O
respectively	334	346	O
.	346	347	O

The	348	351	O
predicted	352	361	O
protein	362	369	O
structure	370	379	O
of	380	382	O
MOR1	383	387	O
and	388	391	O
MOR1K	392	397	O
isoforms	398	406	O
is	407	409	O
schematically	410	423	O
presented	424	433	O
.	433	434	O

Translation	435	446	O
of	447	449	O
the	450	453	O
MOR1K	454	459	O
variant	460	467	O
results	468	475	O
in	476	478	O
a	479	480	O
6TM	481	484	O
receptor	485	493	O
,	493	494	O
truncated	495	504	O
at	505	507	O
the	508	511	O
N	512	513	O
-	513	514	O
terminus	514	522	O
.	522	523	O

(	524	525	O
B	525	526	O
)	526	527	O
Real	528	532	O
-	532	533	O
time	533	537	O
PCR	538	541	O
was	542	545	O
performed	546	555	O
on	556	558	O
total	559	564	O
RNA	565	568	O
samples	569	576	O
from	577	581	O
the	582	585	O
human	586	591	O
brain	592	597	B-Organ
regions	598	605	O
known	606	611	O
to	612	614	O
express	615	622	O
MOR1	623	627	O
.	627	628	O

Primers	629	636	O
specific	637	645	O
for	646	649	O
exons	650	655	O
1	656	657	O
and	658	661	O
2	662	663	O
were	664	668	O
used	669	673	O
to	674	676	O
measure	677	684	O
MOR1	685	689	O
and	690	693	O
primers	694	701	O
specific	702	710	O
for	711	714	O
exons	715	720	O
13	721	723	O
and	724	727	O
exon	728	732	O
2	733	734	O
were	735	739	O
used	740	744	O
to	745	747	O
measure	748	755	O
MOR1K	756	761	O
[	761	762	O
32	762	764	O
]	764	765	O
.	765	766	O

GAP3DH	767	773	O
was	774	777	O
used	778	782	O
as	783	785	O
a	786	787	O
control	788	795	O
for	796	799	O
cDNA	800	804	O
loading	805	812	O
and	813	816	O
PCR	817	820	O
efficiency	821	831	O
.	831	832	O

(	833	834	O
C	834	835	O
)	835	836	O
Confocal	837	845	O
images	846	852	O
of	853	855	O
C	856	857	O
-	857	858	O
terminally	858	868	O
MYC	869	872	O
-	872	873	O
tagged	873	879	O
MOR1	880	884	O
or	885	887	O
FLAG	888	892	O
-	892	893	O
tagged	893	899	O
MOR1K	900	905	O
overexpressed	906	919	O
in	920	922	O
HEK293	923	929	B-Cell
cells	930	935	I-Cell
and	936	939	O
stained	940	947	O
with	948	952	O
either	953	959	O
Anti	960	964	O
-	964	965	O
MYC	965	968	O
-	968	969	O
Tag	969	972	O
Antibody	973	981	O
(	982	983	O
Alexa	983	988	O
Fluor	989	994	O
647	995	998	O
Conjugate	999	1008	O
)	1008	1009	O
or	1010	1012	O
Anti	1013	1017	O
-	1017	1018	O
DYKDDDDK	1018	1026	O
Tag	1027	1030	O
Antibody	1031	1039	O
(	1040	1041	O
Alexa	1041	1046	O
Fluor	1047	1052	O
555	1053	1056	O
conjugate	1057	1066	O
)	1066	1067	O
.	1067	1068	O

Cells	1069	1074	B-Cell
transfected	1075	1086	O
with	1087	1091	O
MOR1	1092	1096	O
showed	1097	1103	O
membrane	1104	1112	B-Cellular_component
expression	1113	1123	O
of	1124	1126	O
receptor	1127	1135	O
,	1135	1136	O
while	1137	1142	O
cell	1143	1147	B-Cell
transfected	1148	1159	O
with	1160	1164	O
MOR1K	1165	1170	O
express	1171	1178	O
receptor	1179	1187	O
only	1188	1192	O
intracellular	1193	1206	B-Immaterial_anatomical_entity
.	1206	1207	O

(	1208	1209	O
D	1209	1210	O
)	1210	1211	O
Confocal	1212	1220	O
images	1221	1227	O
of	1228	1230	O
C	1231	1232	O
-	1232	1233	O
terminally	1233	1243	O
FLAG	1244	1248	O
-	1248	1249	O
tagged	1249	1255	O
MOR1K	1256	1261	O
overexpressed	1262	1275	O
in	1276	1278	O
Be2C	1279	1283	B-Cell
cells	1284	1289	I-Cell
and	1290	1293	O
stained	1294	1301	O
with	1302	1306	O
either	1307	1313	O
Anti	1314	1318	O
-	1318	1319	O
FLAG	1319	1323	O
M2	1324	1326	O
Antibody	1327	1335	O
Alexa	1336	1341	O
Fluor	1342	1347	O
Conjugate	1348	1357	O
or	1358	1360	O
fluorescent	1361	1372	O
-	1372	1373	O
labeled	1373	1380	O
naloxone	1381	1389	O
(	1390	1391	O
FNAL	1391	1395	O
)	1395	1396	O
.	1396	1397	O

Cells	1398	1403	B-Cell
transfected	1404	1415	O
with	1416	1420	O
MOR1K	1421	1426	O
showed	1427	1433	O
intracellular	1434	1447	B-Immaterial_anatomical_entity
retention	1448	1457	O
of	1458	1460	O
FNAL	1461	1465	O
that	1466	1470	O
co	1471	1473	O
-	1473	1474	O
localized	1474	1483	O
with	1484	1488	O
antibody	1489	1497	O
-	1497	1498	O
labeled	1498	1505	O
receptor	1506	1514	O
.	1514	1515	O

(	1516	1517	O
E	1517	1518	O
)	1518	1519	O
The	1520	1523	O
binding	1524	1531	O
of	1532	1534	O
naloxone	1535	1543	O
to	1544	1546	O
MOR1K	1547	1552	O
was	1553	1556	O
assessed	1557	1565	O
using	1566	1571	O
flow	1572	1576	O
cytometry	1577	1586	O
to	1587	1589	O
measure	1590	1597	O
FNAL	1598	1602	O
retention	1603	1612	O
.	1612	1613	O

Be2C	1614	1618	B-Cell
cells	1619	1624	I-Cell
transfected	1625	1636	O
with	1637	1641	O
either	1642	1648	O
MOR1	1649	1653	O
or	1654	1656	O
MOR1K	1657	1662	O
isoforms	1663	1671	O
showed	1672	1678	O
increased	1679	1688	O
retention	1689	1698	O
of	1699	1701	O
FNAL	1702	1706	O
at	1707	1709	O
concentrations	1710	1724	O
of	1725	1727	O
0	1728	1729	O
.	1729	1730	O
1	1730	1731	O
and	1732	1735	O
1	1736	1737	O
muM	1738	1741	O
.	1741	1742	O

FNAL	1743	1747	O
retention	1748	1757	O
was	1758	1761	O
abolished	1762	1771	O
in	1772	1774	O
the	1775	1778	O
presence	1779	1787	O
of	1788	1790	O
10	1791	1793	O
muM	1794	1797	O
unlabelled	1798	1808	O
naloxone	1809	1817	O
(	1818	1819	O
Nal	1819	1822	O
)	1822	1823	O
.	1823	1824	O

In	1825	1827	O
panel	1828	1833	O
E	1834	1835	O
,	1835	1836	O
data	1837	1841	O
are	1842	1845	O
presented	1846	1855	O
as	1856	1858	O
mean	1859	1863	O
+	1864	1865	O
SEM	1866	1869	O
.	1869	1870	O

*	1871	1872	O
P	1872	1873	O
<	1874	1875	O
0	1876	1877	O
.	1877	1878	O
05	1878	1880	O
different	1881	1890	O
from	1891	1895	O
controls	1896	1904	O
)	1904	1905	O
.	1905	1906	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

MBH	23	26	O
made	27	31	O
the	32	35	O
pathological	36	48	O
diagnosis	49	58	O
and	59	62	O
was	63	66	O
responsible	67	78	O
for	79	82	O
conception	83	93	O
and	94	97	O
final	98	103	O
approval	104	112	O
of	113	115	O
the	116	119	O
manuscript	120	130	O
.	130	131	O

MB	132	134	O
carried	135	142	O
out	143	146	O
the	147	150	O
literature	151	161	O
search	162	168	O
and	169	172	O
drafted	173	180	O
the	181	184	O
manuscript	185	195	O
.	195	196	O

IC	197	199	O
carried	200	207	O
out	208	211	O
the	212	215	O
surgical	216	224	O
procedure	225	234	O
and	235	238	O
reviewed	239	247	O
the	248	251	O
manuscript	252	262	O
.	262	263	O

RM	264	266	O
carried	267	274	O
out	275	278	O
the	279	282	O
surgical	283	291	O
procedure	292	301	O
,	301	302	O
provided	303	311	O
clinical	312	320	O
details	321	328	O
,	328	329	O
followed	330	338	O
up	339	341	O
our	342	345	O
patient	346	353	O
and	354	357	O
obtained	358	366	O
her	367	370	O
consent	371	378	O
to	379	381	O
publish	382	389	O
this	390	394	O
case	395	399	O
report	400	406	O
.	406	407	O

All	408	411	O
authors	412	419	O
read	420	424	O
and	425	428	O
approved	429	437	O
the	438	441	O
final	442	447	O
manuscript	448	458	O
.	458	459	O

Breast	0	6	B-Pathological_formation
cancer	7	13	I-Pathological_formation

The	14	17	O
incidence	18	27	O
of	28	30	O
breast	31	37	B-Pathological_formation
cancer	38	44	I-Pathological_formation
is	45	47	O
no	48	50	O
higher	51	57	O
than	58	62	O
in	63	65	O
the	66	69	O
rest	70	74	O
of	75	77	O
the	78	81	O
population	82	92	O
.	92	93	O

Tamoxifen	94	103	O
should	104	110	O
not	111	114	O
be	115	117	O
used	118	122	O
as	123	125	O
it	126	128	O
may	129	132	O
worsen	133	139	O
symptoms	140	148	O
[	149	150	O
43	150	152	O
]	152	153	O
.	153	154	O

Women	155	160	O
need	161	165	O
also	166	170	O
specific	171	179	O
management	180	190	O
for	191	194	O
treatment	195	204	O
of	205	207	O
HAE	208	211	O
.	211	212	O

Short	213	218	O
term	219	223	O
prophylaxis	224	235	O
:	235	236	O
three	237	242	O
options	243	250	O
are	251	254	O
available	255	264	O
:	264	265	O
attenuated	266	276	O
androgens	277	286	O
,	286	287	O
tranexamic	288	298	O
acid	299	303	O
or	304	306	O
C1Inh	307	312	O
concentrate	313	324	O
.	324	325	O

There	326	331	O
is	332	334	O
no	335	337	O
specific	338	346	O
problem	347	354	O
for	355	358	O
the	359	362	O
use	363	366	O
of	367	369	O
theses	370	376	O
drugs	377	382	O
for	383	386	O
short	387	392	O
course	393	399	O
in	400	402	O
female	403	409	O
patients	410	418	O
.	418	419	O

In	420	422	O
case	423	427	O
of	428	430	O
short	431	436	O
term	437	441	O
prophylaxis	442	453	O
with	454	458	O
attenuated	459	469	O
androgens	470	479	O
,	479	480	O
no	481	483	O
virilisation	484	496	O
has	497	500	O
been	501	505	O
observed	506	514	O
[	515	516	O
44	516	518	O
,	518	519	O
45	519	521	O
]	521	522	O
.	522	523	O

Acute	524	529	O
attack	530	536	O
treatment	537	546	O
:	546	547	O
there	548	553	O
is	554	556	O
no	557	559	O
specific	560	568	O
problem	569	576	O
for	577	580	O
the	581	584	O
use	585	588	O
of	589	591	O
C1inh	592	597	O
concentrate	598	609	O
,	609	610	O
tranexamic	611	621	O
acid	622	626	O
,	626	627	O
icatibant	628	637	O
;	637	638	O
or	639	641	O
ecallantide	642	653	O
in	654	656	O
female	657	663	O
patients	664	672	O
.	672	673	O

RNA	0	3	O
extraction	4	14	O
and	15	18	O
reverse	19	26	O
transcription	27	40	O

Total	41	46	O
RNA	47	50	O
were	51	55	O
extracted	56	65	O
from	66	70	O
cells	71	76	B-Cell
using	77	82	O
either	83	89	O
Trizol	90	96	O
reagent	97	104	O
(	105	106	O
Invitrogen	106	116	O
)	116	117	O
or	118	120	O
RNeasy	121	127	O
kit	128	131	O
(	132	133	O
Qiagen	133	139	O
)	139	140	O
and	141	144	O
treated	145	152	O
with	153	157	O
DNaseI	158	164	O
reagent	165	172	O
(	173	174	O
Macherey	174	182	O
-	182	183	O
Nagel	183	188	O
)	188	189	O
for	190	193	O
30	194	196	O
min	197	200	O
at	201	203	O
room	204	208	O
temperature	209	220	O
.	220	221	O

Reverse	222	229	O
transcriptions	230	244	O
were	245	249	O
performed	250	259	O
using	260	265	O
1microg	266	273	O
total	274	279	O
RNA	280	283	O
and	284	287	O
the	288	291	O
High	292	296	O
capacity	297	305	O
cDNA	306	310	O
reverse	311	318	O
transcription	319	332	O
kit	333	336	O
with	337	341	O
RNase	342	347	O
Inhibitor	348	357	O
(	358	359	O
Applied	359	366	O
Biosystems	367	377	O
)	377	378	O
.	378	379	O

Statistical	0	11	O
results	12	19	O
showing	20	27	O
significant	28	39	O
differences	40	51	O
between	52	59	O
habitats	60	68	O
.	68	69	O

Definition	0	10	O
of	11	13	O
pathogens	14	23	O

It	24	26	O
remains	27	34	O
difficult	35	44	O
to	45	47	O
determine	48	57	O
whether	58	65	O
the	66	69	O
organisms	70	79	O
detected	80	88	O
by	89	91	O
the	92	95	O
DNA	96	99	O
Detection	100	109	O
Kit	110	113	O
are	114	117	O
true	118	122	O
pathogens	123	132	O
.	132	133	O

This	134	138	O
also	139	143	O
applies	144	151	O
,	151	152	O
although	153	161	O
to	162	164	O
a	165	166	O
much	167	171	O
lesser	172	178	O
degree	179	185	O
,	185	186	O
to	187	189	O
conventional	190	202	O
blood	203	208	B-Organism_substance
culture	209	216	O
analysis	217	225	O
.	225	226	O

However	227	234	O
,	234	235	O
detected	236	244	O
organisms	245	254	O
were	255	259	O
considered	260	270	O
to	271	273	O
be	274	276	O
pathogens	277	286	O
if	287	289	O
the	290	293	O
results	294	301	O
of	302	304	O
culture	305	312	O
tests	313	318	O
from	319	323	O
samples	324	331	O
of	332	334	O
the	335	338	O
suspected	339	348	O
infectious	349	359	O
sites	360	365	O
coincided	366	375	O
with	376	380	O
the	381	384	O
results	385	392	O
of	393	395	O
DNA	396	399	O
Detection	400	409	O
Kit	410	413	O
or	414	416	O
blood	417	422	B-Organism_substance
culture	423	430	O
analysis	431	439	O
.	439	440	O

The	441	444	O
culture	445	452	O
data	453	457	O
of	458	460	O
sputum	461	467	B-Organism_substance
,	467	468	O
urine	469	474	B-Organism_substance
,	474	475	O
pus	476	479	B-Organism_substance
and	480	483	O
drainage	484	492	O
fluid	493	498	B-Organism_substance
were	499	503	O
used	504	508	O
to	509	511	O
define	512	518	O
the	519	522	O
pathogens	523	532	O
.	532	533	O

A	534	535	O
decision	536	544	O
as	545	547	O
to	548	550	O
whether	551	558	O
an	559	561	O
identified	562	572	O
organism	573	581	O
was	582	585	O
a	586	587	O
pathogen	588	596	O
was	597	600	O
taken	601	606	O
based	607	612	O
on	613	615	O
the	616	619	O
decision	620	628	O
tree	629	633	O
shown	634	639	O
in	640	642	O
Figure	643	649	O
1	650	651	O
.	651	652	O

Thus	653	657	O
,	657	658	O
when	659	663	O
the	664	667	O
same	668	672	O
organism	673	681	O
was	682	685	O
detected	686	694	O
by	695	697	O
both	698	702	O
DNA	703	706	O
Detection	707	716	O
Kit	717	720	O
and	721	724	O
blood	725	730	B-Organism_substance
culture	731	738	O
analysis	739	747	O
,	747	748	O
the	749	752	O
detected	753	761	O
organism	762	770	O
was	771	774	O
considered	775	785	O
an	786	788	O
infectious	789	799	O
pathogen	800	808	O
.	808	809	O

If	810	812	O
there	813	818	O
was	819	822	O
a	823	824	O
discrepancy	825	836	O
between	837	844	O
the	845	848	O
organism	849	857	O
that	858	862	O
was	863	866	O
detected	867	875	O
by	876	878	O
SeptiFast	879	888	O
analysis	889	897	O
and	898	901	O
that	902	906	O
detected	907	915	O
by	916	918	O
blood	919	924	B-Organism_substance
culture	925	932	O
analysis	933	941	O
,	941	942	O
or	943	945	O
if	946	948	O
an	949	951	O
organism	952	960	O
was	961	964	O
only	965	969	O
detected	970	978	O
in	979	981	O
one	982	985	O
of	986	988	O
these	989	994	O
tests	995	1000	O
,	1000	1001	O
then	1002	1006	O
other	1007	1012	O
samples	1013	1020	O
taken	1021	1026	O
from	1027	1031	O
the	1032	1035	O
infection	1036	1045	O
site	1046	1050	O
were	1051	1055	O
analyzed	1056	1064	O
.	1064	1065	O

If	1066	1068	O
this	1069	1073	O
second	1074	1080	O
culture	1081	1088	O
test	1089	1093	O
of	1094	1096	O
the	1097	1100	O
suspected	1101	1110	O
infectious	1111	1121	O
site	1122	1126	O
revealed	1127	1135	O
the	1136	1139	O
presence	1140	1148	O
of	1149	1151	O
the	1152	1155	O
same	1156	1160	O
organism	1161	1169	O
,	1169	1170	O
this	1171	1175	O
organism	1176	1184	O
was	1185	1188	O
considered	1189	1199	O
to	1200	1202	O
be	1203	1205	O
a	1206	1207	O
pathogen	1208	1216	O
.	1216	1217	O

If	1218	1220	O
the	1221	1224	O
microbial	1225	1234	O
strain	1235	1241	O
was	1242	1245	O
only	1246	1250	O
detected	1251	1259	O
once	1260	1264	O
for	1265	1268	O
a	1269	1270	O
sample	1271	1277	O
,	1277	1278	O
we	1279	1281	O
then	1282	1286	O
checked	1287	1294	O
the	1295	1298	O
second	1299	1305	O
culture	1306	1313	O
results	1314	1321	O
in	1322	1324	O
the	1325	1328	O
suspected	1329	1338	O
infectious	1339	1349	O
sites	1350	1355	O
.	1355	1356	O

If	1357	1359	O
this	1360	1364	O
result	1365	1371	O
identified	1372	1382	O
the	1383	1386	O
same	1387	1391	O
strain	1392	1398	O
as	1399	1401	O
that	1402	1406	O
identified	1407	1417	O
by	1418	1420	O
SeptiFast	1421	1430	O
analysis	1431	1439	O
then	1440	1444	O
it	1445	1447	O
was	1448	1451	O
decided	1452	1459	O
that	1460	1464	O
this	1465	1469	O
strain	1470	1476	O
was	1477	1480	O
a	1481	1482	O
pathogen	1483	1491	O
.	1491	1492	O

However	1493	1500	O
,	1500	1501	O
if	1502	1504	O
the	1505	1508	O
strain	1509	1515	O
was	1516	1519	O
still	1520	1525	O
only	1526	1530	O
detected	1531	1539	O
in	1540	1542	O
some	1543	1547	O
of	1548	1550	O
the	1551	1554	O
assays	1555	1561	O
,	1561	1562	O
we	1563	1565	O
next	1566	1570	O
determined	1571	1581	O
if	1582	1584	O
the	1585	1588	O
patient	1589	1596	O
involved	1597	1605	O
suffered	1606	1614	O
from	1615	1619	O
sepsis	1620	1626	O
.	1626	1627	O

Sepsis	1628	1634	O
is	1635	1637	O
defined	1638	1645	O
as	1646	1648	O
SIRS	1649	1653	O
caused	1654	1660	O
by	1661	1663	O
infection	1664	1673	O
.	1673	1674	O

The	1675	1678	O
definition	1679	1689	O
of	1690	1692	O
sepsis	1693	1699	O
that	1700	1704	O
we	1705	1707	O
used	1708	1712	O
was	1713	1716	O
based	1717	1722	O
on	1723	1725	O
the	1726	1729	O
International	1730	1743	O
Sepsis	1744	1750	O
Forum	1751	1756	O
Definition	1757	1767	O
of	1768	1770	O
Infection	1771	1780	O
at	1781	1783	O
the	1784	1787	O
ICU	1788	1791	O
Consensus	1792	1801	O
Conference	1802	1812	O
[	1813	1814	O
7	1814	1815	O
]	1815	1816	O
.	1816	1817	O

However	1818	1825	O
,	1825	1826	O
if	1827	1829	O
the	1830	1833	O
underlying	1834	1844	O
disease	1845	1852	O
is	1853	1855	O
acute	1856	1861	O
lymphoma	1862	1870	O
leukemia	1871	1879	O
(	1880	1881	O
ALL	1881	1884	O
)	1884	1885	O
,	1885	1886	O
malignant	1887	1896	B-Pathological_formation
lymphoma	1897	1905	I-Pathological_formation
(	1906	1907	O
ML	1907	1909	B-Pathological_formation
)	1909	1910	O
,	1910	1911	O
or	1912	1914	O
acute	1915	1920	O
myelogenous	1921	1932	O
leukemia	1933	1941	O
(	1942	1943	O
AML	1943	1946	O
)	1946	1947	O
,	1947	1948	O
the	1949	1952	O
definition	1953	1963	O
of	1964	1966	O
infection	1967	1976	O
is	1977	1979	O
defined	1980	1987	O
as	1988	1990	O
the	1991	1994	O
ability	1995	2002	O
to	2003	2005	O
detect	2006	2012	O
infectious	2013	2023	O
organisms	2024	2033	O
by	2034	2036	O
blood	2037	2042	B-Organism_substance
culture	2043	2050	O
analysis	2051	2059	O
.	2059	2060	O

If	2061	2063	O
the	2064	2067	O
patient	2068	2075	O
was	2076	2079	O
not	2080	2083	O
defined	2084	2091	O
as	2092	2094	O
having	2095	2101	O
sepsis	2102	2108	O
when	2109	2113	O
whole	2114	2119	B-Organism_substance
blood	2120	2125	I-Organism_substance
was	2126	2129	O
administered	2130	2142	O
to	2143	2145	O
the	2146	2149	O
patient	2150	2157	O
,	2157	2158	O
we	2159	2161	O
decided	2162	2169	O
that	2170	2174	O
the	2175	2178	O
strain	2179	2185	O
detected	2186	2194	O
by	2195	2197	O
subsequent	2198	2208	O
DNA	2209	2212	O
Detection	2213	2222	O
Kit	2223	2226	O
or	2227	2229	O
blood	2230	2235	B-Organism_substance
culture	2236	2243	O
analysis	2244	2252	O
was	2253	2256	O
not	2257	2260	O
a	2261	2262	O
pathogen	2263	2271	O
.	2271	2272	O

Figure	2273	2279	O
1	2280	2281	O

Flowchart	2282	2291	O
for	2292	2295	O
pathogen	2296	2304	O
decision	2305	2313	O
.	2313	2314	O

Samples	2315	2322	O
were	2323	2327	O
defined	2328	2335	O
as	2336	2338	O
negative	2339	2347	O
for	2348	2351	O
pathogens	2352	2361	O
if	2362	2364	O
a	2365	2366	O
pathogen	2367	2375	O
could	2376	2381	O
not	2382	2385	O
be	2386	2388	O
detected	2389	2397	O
by	2398	2400	O
any	2401	2404	O
method	2405	2411	O
of	2412	2414	O
analysis	2415	2423	O
within	2424	2430	O
seven	2431	2436	O
days	2437	2441	O
,	2441	2442	O
and	2443	2446	O
if	2447	2449	O
another	2450	2457	O
type	2458	2462	O
of	2463	2465	O
culture	2466	2473	O
test	2474	2478	O
did	2479	2482	O
not	2483	2486	O
detect	2487	2493	O
this	2494	2498	O
pathogen	2499	2507	O
but	2508	2511	O
could	2512	2517	O
detect	2518	2524	O
other	2525	2530	O
organisms	2531	2540	O
.	2540	2541	O

CoNS	2542	2546	O
bacteria	2547	2555	O
,	2555	2556	O
which	2557	2562	O
are	2563	2566	O
represented	2567	2578	O
by	2579	2581	O
the	2582	2585	O
Staphylococcus	2586	2600	O
epidermidis	2601	2612	O
(	2613	2614	O
S	2614	2615	O
.	2615	2616	O
epidermidis	2617	2628	O
)	2628	2629	O
and	2630	2633	O
Streptococcus	2634	2647	O
spp	2648	2651	O
.	2651	2652	O
are	2653	2656	O
indigenous	2657	2667	O
bacteria	2668	2676	O
and	2677	2680	O
often	2681	2686	O
cause	2687	2692	O
contamination	2693	2706	O
in	2707	2709	O
assays	2710	2716	O
of	2717	2719	O
pathogens	2720	2729	O
.	2729	2730	O

Therefore	2731	2740	O
,	2740	2741	O
when	2742	2746	O
CoNS	2747	2751	O
or	2752	2754	O
Streptococcus	2755	2768	O
spp	2769	2772	O
.	2772	2773	O
were	2774	2778	O
detected	2779	2787	O
by	2788	2790	O
blood	2791	2796	B-Organism_substance
culture	2797	2804	O
and	2805	2808	O
SeptiFast	2809	2818	O
analysis	2819	2827	O
,	2827	2828	O
the	2829	2832	O
following	2833	2842	O
criteria	2843	2851	O
were	2852	2856	O
applied	2857	2864	O
to	2865	2867	O
define	2868	2874	O
whether	2875	2882	O
these	2883	2888	O
strains	2889	2896	O
represented	2897	2908	O
a	2909	2910	O
pathogenic	2911	2921	O
infection	2922	2931	O
:	2931	2932	O
(	2933	2934	O
1	2934	2935	O
)	2935	2936	O
Tests	2937	2942	O
were	2943	2947	O
performed	2948	2957	O
at	2958	2960	O
least	2961	2966	O
twice	2967	2972	O
within	2973	2979	O
48	2980	2982	O
hours	2983	2988	O
before	2989	2995	O
and	2996	2999	O
after	3000	3005	O
CoNS	3006	3010	O
were	3011	3015	O
detected	3016	3024	O
by	3025	3027	O
blood	3028	3033	B-Organism_substance
culture	3034	3041	O
or	3042	3044	O
SeptiFast	3045	3054	O
analysis	3055	3063	O
;	3063	3064	O
(	3065	3066	O
2	3066	3067	O
)	3067	3068	O
CoNS	3069	3073	O
or	3074	3076	O
Streptococcus	3077	3090	O
spp	3091	3094	O
.	3094	3095	O
were	3096	3100	O
detected	3101	3109	O
in	3110	3112	O
two	3113	3116	O
different	3117	3126	O
blood	3127	3132	B-Organism_substance
culture	3133	3140	O
tests	3141	3146	O
that	3147	3151	O
were	3152	3156	O
separately	3157	3167	O
performed	3168	3177	O
twice	3178	3183	O
within	3184	3190	O
48	3191	3193	O
hours	3194	3199	O
;	3199	3200	O
and	3201	3204	O
,	3204	3205	O
(	3206	3207	O
3	3207	3208	O
)	3208	3209	O
CoNS	3210	3214	O
or	3215	3217	O
Streptococcus	3218	3231	O
spp	3232	3235	O
.	3235	3236	O
were	3237	3241	O
detected	3242	3250	O
twice	3251	3256	O
or	3257	3259	O
more	3260	3264	O
in	3265	3267	O
tests	3268	3273	O
that	3274	3278	O
were	3279	3283	O
performed	3284	3293	O
three	3294	3299	O
times	3300	3305	O
[	3306	3307	O
11	3307	3309	O
-	3309	3310	O
15	3310	3312	O
]	3312	3313	O
.	3313	3314	O

If	3315	3317	O
a	3318	3319	O
sample	3320	3326	O
'	3326	3327	O
s	3327	3328	O
results	3329	3336	O
met	3337	3340	O
any	3341	3344	O
of	3345	3347	O
these	3348	3353	O
three	3354	3359	O
criteria	3360	3368	O
,	3368	3369	O
then	3370	3374	O
the	3375	3378	O
sample	3379	3385	B-Organism_substance
was	3386	3389	O
evaluated	3390	3399	O
as	3400	3402	O
a	3403	3404	O
pathogen	3405	3413	O
.	3413	3414	O

The	3415	3418	O
distinction	3419	3430	O
between	3431	3438	O
pathogen	3439	3447	O
and	3448	3451	O
contamination	3452	3465	O
was	3466	3469	O
also	3470	3474	O
determined	3475	3485	O
for	3486	3489	O
CoNS	3490	3494	O
or	3495	3497	O
Streptococcus	3498	3511	O
spp	3512	3515	O
.	3515	3516	O
from	3517	3521	O
the	3522	3525	O
crossing	3526	3534	O
point	3535	3540	O
(	3541	3542	O
Cp	3542	3544	O
)	3544	3545	O
obtained	3546	3554	O
using	3555	3560	O
the	3561	3564	O
LightCycler	3565	3576	O
analysis	3577	3585	O
software	3586	3594	O
v4	3595	3597	O
.	3597	3598	O
05	3598	3600	O
.	3600	3601	O

The	3602	3605	O
Cp	3606	3608	O
represents	3609	3619	O
the	3620	3623	O
point	3624	3629	O
in	3630	3632	O
the	3633	3636	O
amplification	3637	3650	O
cycle	3651	3656	O
where	3657	3662	O
the	3663	3666	O
amplification	3667	3680	O
curve	3681	3686	O
crosses	3687	3694	O
the	3695	3698	O
detection	3699	3708	O
threshold	3709	3718	O
.	3718	3719	O

When	3720	3724	O
CoNS	3725	3729	O
or	3730	3732	O
Streptococcus	3733	3746	O
spp	3747	3750	O
.	3750	3751	O
were	3752	3756	O
detected	3757	3765	O
using	3766	3771	O
the	3772	3775	O
LightCycler	3776	3787	O
analysis	3788	3796	O
software	3797	3805	O
v4	3806	3808	O
.	3808	3809	O
05	3809	3811	O
,	3811	3812	O
a	3813	3814	O
Cp	3815	3817	O
of	3818	3820	O
less	3821	3825	O
than	3826	3830	O
20	3831	3833	O
was	3834	3837	O
defined	3838	3845	O
as	3846	3848	O
indicating	3849	3859	O
a	3860	3861	O
pathogen	3862	3870	O
and	3871	3874	O
a	3875	3876	O
Cp	3877	3879	O
of	3880	3882	O
over	3883	3887	O
20	3888	3890	O
was	3891	3894	O
defined	3895	3902	O
as	3903	3905	O
contamination	3906	3919	O
by	3920	3922	O
checking	3923	3931	O
the	3932	3935	O
amplification	3936	3949	O
curve	3950	3955	O
.	3955	3956	O

Conclusion	0	10	O
:	10	11	O

This	12	16	O
study	17	22	O
demonstrates	23	35	O
that	36	40	O
surgery	41	48	O
plus	49	53	O
chemotherapy	54	66	O
and	67	70	O
radiation	71	80	O
therapy	81	88	O
is	89	91	O
helpful	92	99	O
for	100	103	O
treating	104	112	O
patients	113	121	O
with	122	126	O
pelvic	127	133	B-Pathological_formation
Ewing	134	139	I-Pathological_formation
'	139	140	I-Pathological_formation
s	140	141	I-Pathological_formation
sarcoma	142	149	I-Pathological_formation
,	149	150	O
particularly	151	163	O
in	164	166	O
achieving	167	176	O
local	177	182	O
control	183	190	O
.	190	191	O

Fractional	0	10	O
atomic	11	17	O
coordinates	18	29	O
and	30	33	O
isotropic	34	43	O
or	44	46	O
equivalent	47	57	O
isotropic	58	67	O
displacement	68	80	O
parameters	81	91	O
(	92	93	O
A2	93	95	O
)	95	96	O

x	97	98	O
y	99	100	O
z	101	102	O
Uiso	103	107	O
*	107	108	O
/	108	109	O
Ueq	109	112	O

C1	113	115	O
0	116	117	O
.	117	118	O
3043	118	122	O
(	123	124	O
3	124	125	O
)	125	126	O
0	127	128	O
.	128	129	O
1779	129	133	O
(	134	135	O
4	135	136	O
)	136	137	O
0	138	139	O
.	139	140	O
79280	140	145	O
(	146	147	O
13	147	149	O
)	149	150	O
0	151	152	O
.	152	153	O
0445	153	157	O
(	158	159	O
6	159	160	O
)	160	161	O

C2	162	164	O
0	165	166	O
.	166	167	O
4358	167	171	O
(	172	173	O
4	173	174	O
)	174	175	O
0	176	177	O
.	177	178	O
1697	178	182	O
(	183	184	O
5	184	185	O
)	185	186	O
0	187	188	O
.	188	189	O
84058	189	194	O
(	195	196	O
17	196	198	O
)	198	199	O
0	200	201	O
.	201	202	O
0604	202	206	O
(	207	208	O
8	208	209	O
)	209	210	O

H2	211	213	O
0	214	215	O
.	215	216	O
4201	216	220	O
0	221	222	O
.	222	223	O
1476	223	227	O
0	228	229	O
.	229	230	O
8809	230	234	O
0	235	236	O
.	236	237	O
072	237	240	O
*	240	241	O

C3	242	244	O
0	245	246	O
.	246	247	O
5911	247	251	O
(	252	253	O
4	253	254	O
)	254	255	O
0	256	257	O
.	257	258	O
1953	258	262	O
(	263	264	O
6	264	265	O
)	265	266	O
0	267	268	O
.	268	269	O
8269	269	273	O
(	274	275	O
2	275	276	O
)	276	277	O
0	278	279	O
.	279	280	O
0783	280	284	O
(	285	286	O
12	286	288	O
)	288	289	O

H3	290	292	O
0	293	294	O
.	294	295	O
6811	295	299	O
0	300	301	O
.	301	302	O
1914	302	306	O
0	307	308	O
.	308	309	O
8584	309	313	O
0	314	315	O
.	315	316	O
094	316	319	O
*	319	320	O

C4	321	323	O
0	324	325	O
.	325	326	O
6130	326	330	O
(	331	332	O
4	332	333	O
)	333	334	O
0	335	336	O
.	336	337	O
2267	337	341	O
(	342	343	O
6	343	344	O
)	344	345	O
0	346	347	O
.	347	348	O
7670	348	352	O
(	353	354	O
2	354	355	O
)	355	356	O
0	357	358	O
.	358	359	O
0773	359	363	O
(	364	365	O
11	365	367	O
)	367	368	O

H4	369	371	O
0	372	373	O
.	373	374	O
7180	374	378	O
0	379	380	O
.	380	381	O
2427	381	385	O
0	386	387	O
.	387	388	O
7582	388	392	O
0	393	394	O
.	394	395	O
093	395	398	O
*	398	399	O

C5	400	402	O
0	403	404	O
.	404	405	O
4818	405	409	O
(	410	411	O
5	411	412	O
)	412	413	O
0	414	415	O
.	415	416	O
2344	416	420	O
(	421	422	O
5	422	423	O
)	423	424	O
0	425	426	O
.	426	427	O
7202	427	431	O
(	432	433	O
2	433	434	O
)	434	435	O
0	436	437	O
.	437	438	O
0746	438	442	O
(	443	444	O
10	444	446	O
)	446	447	O

H5	448	450	O
0	451	452	O
.	452	453	O
4980	453	457	O
0	458	459	O
.	459	460	O
2547	460	464	O
0	465	466	O
.	466	467	O
6798	467	471	O
0	472	473	O
.	473	474	O
090	474	477	O
*	477	478	O

C6	479	481	O
0	482	483	O
.	483	484	O
3257	484	488	O
(	489	490	O
4	490	491	O
)	491	492	O
0	493	494	O
.	494	495	O
2121	495	499	O
(	500	501	O
4	501	502	O
)	502	503	O
0	504	505	O
.	505	506	O
73293	506	511	O
(	512	513	O
15	513	515	O
)	515	516	O
0	517	518	O
.	518	519	O
0562	519	523	O
(	524	525	O
7	525	526	O
)	526	527	O

H6	528	530	O
0	531	532	O
.	532	533	O
2360	533	537	O
0	538	539	O
.	539	540	O
2200	540	544	O
0	545	546	O
.	546	547	O
7015	547	551	O
0	552	553	O
.	553	554	O
067	554	557	O
*	557	558	O

C7	559	561	O
0	562	563	O
.	563	564	O
1252	564	568	O
(	569	570	O
3	570	571	O
)	571	572	O
0	573	574	O
.	574	575	O
3838	575	579	O
(	580	581	O
4	581	582	O
)	582	583	O
0	584	585	O
.	585	586	O
90059	586	591	O
(	592	593	O
11	593	595	O
)	595	596	O
0	597	598	O
.	598	599	O
0400	599	603	O
(	604	605	O
6	605	606	O
)	606	607	O

C8	608	610	O
0	611	612	O
.	612	613	O
2051	613	617	O
(	618	619	O
4	619	620	O
)	620	621	O
0	622	623	O
.	623	624	O
5522	624	628	O
(	629	630	O
4	630	631	O
)	631	632	O
0	633	634	O
.	634	635	O
90920	635	640	O
(	641	642	O
13	642	644	O
)	644	645	O
0	646	647	O
.	647	648	O
0484	648	652	O
(	653	654	O
6	654	655	O
)	655	656	O

H8	657	659	O
0	660	661	O
.	661	662	O
2132	662	666	O
0	667	668	O
.	668	669	O
6288	669	673	O
0	674	675	O
.	675	676	O
8758	676	680	O
0	681	682	O
.	682	683	O
058	683	686	O
*	686	687	O

C9	688	690	O
0	691	692	O
.	692	693	O
2725	693	697	O
(	698	699	O
4	699	700	O
)	700	701	O
0	702	703	O
.	703	704	O
6041	704	708	O
(	709	710	O
4	710	711	O
)	711	712	O
0	713	714	O
.	714	715	O
96827	715	720	O
(	721	722	O
15	722	724	O
)	724	725	O
0	726	727	O
.	727	728	O
0558	728	732	O
(	733	734	O
7	734	735	O
)	735	736	O

C10	737	740	O
0	741	742	O
.	742	743	O
2645	743	747	O
(	748	749	O
4	749	750	O
)	750	751	O
0	752	753	O
.	753	754	O
4935	754	758	O
(	759	760	O
4	760	761	O
)	761	762	O
1	763	764	O
.	764	765	O
01861	765	770	O
(	771	772	O
14	772	774	O
)	774	775	O
0	776	777	O
.	777	778	O
0590	778	782	O
(	783	784	O
8	784	785	O
)	785	786	O

H10	787	790	O
0	791	792	O
.	792	793	O
3122	793	797	O
0	798	799	O
.	799	800	O
5293	800	804	O
1	805	806	O
.	806	807	O
0582	807	811	O
0	812	813	O
.	813	814	O
071	814	817	O
*	817	818	O

C11	819	822	O
0	823	824	O
.	824	825	O
1830	825	829	O
(	830	831	O
4	831	832	O
)	832	833	O
0	834	835	O
.	835	836	O
3278	836	840	O
(	841	842	O
4	842	843	O
)	843	844	O
1	845	846	O
.	846	847	O
00819	847	852	O
(	853	854	O
13	854	856	O
)	856	857	O
0	858	859	O
.	859	860	O
0534	860	864	O
(	865	866	O
7	866	867	O
)	867	868	O

C12	869	872	O
0	873	874	O
.	874	875	O
1118	875	879	O
(	880	881	O
3	881	882	O
)	882	883	O
0	884	885	O
.	885	886	O
2699	886	890	O
(	891	892	O
4	892	893	O
)	893	894	O
0	895	896	O
.	896	897	O
95062	897	902	O
(	903	904	O
12	904	906	O
)	906	907	O
0	908	909	O
.	909	910	O
0480	910	914	O
(	915	916	O
6	916	917	O
)	917	918	O

H12	919	922	O
0	923	924	O
.	924	925	O
0561	925	929	O
0	930	931	O
.	931	932	O
1577	932	936	O
0	937	938	O
.	938	939	O
9451	939	943	O
0	944	945	O
.	945	946	O
058	946	949	O
*	949	950	O

N1	951	953	O
0	954	955	O
.	955	956	O
0494	956	960	O
(	961	962	O
3	962	963	O
)	963	964	O
0	965	966	O
.	966	967	O
3297	967	971	O
(	972	973	O
3	973	974	O
)	974	975	O
0	976	977	O
.	977	978	O
84009	978	983	O
(	984	985	O
10	985	987	O
)	987	988	O
0	989	990	O
.	990	991	O
0441	991	995	O
(	996	997	O
5	997	998	O
)	998	999	O

H1N	1000	1003	O
0	1004	1005	O
.	1005	1006	O
038	1006	1009	O
(	1010	1011	O
4	1011	1012	O
)	1012	1013	O
0	1014	1015	O
.	1015	1016	O
418	1016	1019	O
(	1020	1021	O
3	1021	1022	O
)	1022	1023	O
0	1024	1025	O
.	1025	1026	O
8138	1026	1030	O
(	1031	1032	O
12	1032	1034	O
)	1034	1035	O
0	1036	1037	O
.	1037	1038	O
053	1038	1041	O
*	1041	1042	O

O1	1043	1045	O
-	1046	1047	O
0	1047	1048	O
.	1048	1049	O
0021	1049	1053	O
(	1054	1055	O
3	1055	1056	O
)	1056	1057	O
0	1058	1059	O
.	1059	1060	O
1298	1060	1064	O
(	1065	1066	O
3	1066	1067	O
)	1067	1068	O
0	1069	1070	O
.	1070	1071	O
74998	1071	1076	O
(	1077	1078	O
9	1078	1079	O
)	1079	1080	O
0	1081	1082	O
.	1082	1083	O
0527	1083	1087	O
(	1088	1089	O
5	1089	1090	O
)	1090	1091	O

O2	1092	1094	O
0	1095	1096	O
.	1096	1097	O
1112	1097	1101	O
(	1102	1103	O
3	1103	1104	O
)	1104	1105	O
-	1106	1107	O
0	1107	1108	O
.	1108	1109	O
0066	1109	1113	O
(	1114	1115	O
3	1115	1116	O
)	1116	1117	O
0	1118	1119	O
.	1119	1120	O
85135	1120	1125	O
(	1126	1127	O
10	1127	1129	O
)	1129	1130	O
0	1131	1132	O
.	1132	1133	O
0574	1133	1137	O
(	1138	1139	O
6	1139	1140	O
)	1140	1141	O

Cl1	1142	1145	O
0	1146	1147	O
.	1147	1148	O
37237	1148	1153	O
(	1154	1155	O
16	1155	1157	O
)	1157	1158	O
0	1159	1160	O
.	1160	1161	O
81541	1161	1166	O
(	1167	1168	O
13	1168	1170	O
)	1170	1171	O
0	1172	1173	O
.	1173	1174	O
97944	1174	1179	O
(	1180	1181	O
5	1181	1182	O
)	1182	1183	O
0	1184	1185	O
.	1185	1186	O
0927	1186	1190	O
(	1191	1192	O
4	1192	1193	O
)	1193	1194	O

Cl2	1195	1198	O
0	1199	1200	O
.	1200	1201	O
16462	1201	1206	O
(	1207	1208	O
15	1208	1210	O
)	1210	1211	O
0	1212	1213	O
.	1213	1214	O
18752	1214	1219	O
(	1220	1221	O
15	1221	1223	O
)	1223	1224	O
1	1225	1226	O
.	1226	1227	O
07089	1227	1232	O
(	1233	1234	O
4	1234	1235	O
)	1235	1236	O
0	1237	1238	O
.	1238	1239	O
0834	1239	1243	O
(	1244	1245	O
4	1245	1246	O
)	1246	1247	O

S1	1248	1250	O
0	1251	1252	O
.	1252	1253	O
10584	1253	1258	O
(	1259	1260	O
7	1260	1261	O
)	1261	1262	O
0	1263	1264	O
.	1264	1265	O
14095	1265	1270	O
(	1271	1272	O
9	1272	1273	O
)	1273	1274	O
0	1275	1276	O
.	1276	1277	O
80800	1277	1282	O
(	1283	1284	O
3	1284	1285	O
)	1285	1286	O
0	1287	1288	O
.	1288	1289	O
0412	1289	1293	O
(	1294	1295	O
3	1295	1296	O
)	1296	1297	O

Crystal	0	7	O
data	8	12	O

C16H20N4	13	21	O

M	22	23	O
r	24	25	O
=	26	27	O
268	28	31	O
.	31	32	O
36	32	34	O

Monoclinic	35	45	O
,	45	46	O

a	48	49	O
=	50	51	O
12	52	54	O
.	54	55	O
819	55	58	O
(	59	60	O
4	60	61	O
)	61	62	O
A	63	64	O

b	65	66	O
=	67	68	O
8	69	70	O
.	70	71	O
441	71	74	O
(	75	76	O
3	76	77	O
)	77	78	O
A	79	80	O

c	81	82	O
=	83	84	O
13	85	87	O
.	87	88	O
310	88	91	O
(	92	93	O
4	93	94	O
)	94	95	O
A	96	97	O

beta	98	102	O
=	103	104	O
95	105	107	O
.	107	108	O
462	108	111	O
(	112	113	O
5	113	114	O
)	114	115	O
degrees	115	122	O

V	123	124	O
=	125	126	O
1433	127	131	O
.	131	132	O
7	132	133	O
(	134	135	O
8	135	136	O
)	136	137	O
A3	138	140	O

Z	141	142	O
=	143	144	O
4	145	146	O

Mo	147	149	O
Kalpha	150	156	O
radiation	157	166	O

mu	167	169	O
=	170	171	O
0	172	173	O
.	173	174	O
08	174	176	O
mm	177	179	O
-	179	180	O
1	180	181	O

T	182	183	O
=	184	185	O
298	186	189	O
(	190	191	O
2	191	192	O
)	192	193	O
K	194	195	O

0	196	197	O
.	197	198	O
33	198	200	O
x	201	202	O
0	203	204	O
.	204	205	O
28	205	207	O
x	208	209	O
0	210	211	O
.	211	212	O
21	212	214	O
mm	215	217	O

Crystal	0	7	O
data	8	12	O

C15H12ClN3O2S2	13	27	O
F	28	29	O
(	29	30	O
000	30	33	O
)	33	34	O
=	35	36	O
752	37	40	O

Mr	41	43	O
=	44	45	O
365	46	49	O
.	49	50	O
85	50	52	O
Dx	53	55	O
=	56	57	O
1	58	59	O
.	59	60	O
507	60	63	O
Mg	64	66	O
m	67	68	O
-	68	69	O
3	69	70	O

Monoclinic	71	81	O
,	81	82	O
P21	83	86	O
/	86	87	O
n	87	88	O
Mo	89	91	O
Kalpha	92	98	O
radiation	99	108	O
,	108	109	O
lambda	110	116	O
=	117	118	O
0	119	120	O
.	120	121	O
71073	121	126	O
A	127	128	O

Hall	129	133	O
symbol	134	140	O
:	140	141	O
-	142	143	O
P	143	144	O
2yn	145	148	O
Cell	149	153	B-Cell
parameters	154	164	O
from	165	169	O
25	170	172	O
reflections	173	184	O

a	185	186	O
=	187	188	O
10	189	191	O
.	191	192	O
175	192	195	O
(	196	197	O
2	197	198	O
)	198	199	O
A	200	201	O
theta	202	207	O
=	208	209	O
9	210	211	O
-	211	212	O
12degrees	212	221	O

b	222	223	O
=	224	225	O
8	226	227	O
.	227	228	O
4958	228	232	O
(	233	234	O
17	234	236	O
)	236	237	O
A	238	239	O
micro	240	245	O
=	246	247	O
0	248	249	O
.	249	250	O
51	250	252	O
mm	253	255	O
-	255	256	O
1	256	257	O

c	258	259	O
=	260	261	O
19	262	264	O
.	264	265	O
318	265	268	O
(	269	270	O
4	270	271	O
)	271	272	O
A	273	274	O
T	275	276	O
=	277	278	O
293	279	282	O
K	283	284	O

beta	285	289	O
=	290	291	O
105	292	295	O
.	295	296	O
01	296	298	O
(	299	300	O
3	300	301	O
)	301	302	O
degrees	302	309	O
Block	310	315	O
,	315	316	O
yellow	317	323	O

V	324	325	O
=	326	327	O
1613	328	332	O
.	332	333	O
0	333	334	O
(	335	336	O
6	336	337	O
)	337	338	O
A3	339	341	O
0	342	343	O
.	343	344	O
25	344	346	O
x	347	348	O
0	349	350	O
.	350	351	O
15	351	353	O
x	354	355	O
0	356	357	O
.	357	358	O
15	358	360	O
mm	361	363	O

Z	364	365	O
=	366	367	O
4	368	369	O

Results	0	7	O
and	8	11	O
Discussion	12	22	O

Figure	23	29	O
4	30	31	O
shows	32	37	O
the	38	41	O
frequency	42	51	O
response	52	60	O
of	61	63	O
the	64	67	O
device	68	74	O
before	75	81	O
and	82	85	O
after	86	91	O
plating	92	99	O
cells	100	105	B-Cell
.	105	106	O

In	107	109	O
the	110	113	O
frequency	114	123	O
range	124	129	O
measured	130	138	O
(	139	140	O
4	140	141	O
-	141	142	O
600	142	145	O
Hz	146	148	O
)	148	149	O
,	149	150	O
only	151	155	O
two	156	159	O
clear	160	165	O
peaks	166	171	O
can	172	175	O
be	176	178	O
seen	179	183	O
in	184	186	O
the	187	190	O
bare	191	195	O
device	196	202	O
.	202	203	O

After	204	209	O
cells	210	215	B-Cell
had	216	219	O
adhered	220	227	O
to	228	230	O
the	231	234	O
surface	235	242	O
,	242	243	O
there	244	249	O
is	250	252	O
a	253	254	O
shift	255	260	O
in	261	263	O
both	264	268	O
the	269	272	O
resonant	273	281	O
frequency	282	291	O
and	292	295	O
the	296	299	O
height	300	306	O
of	307	309	O
these	310	315	O
peaks	316	321	O
.	321	322	O

Table	323	328	O
1	329	330	O
shows	331	336	O
the	337	340	O
results	341	348	O
for	349	352	O
this	353	357	O
trial	358	363	O
and	364	367	O
a	368	369	O
second	370	376	O
trial	377	382	O
where	383	388	O
the	389	392	O
experiment	393	403	O
was	404	407	O
repeated	408	416	O
to	417	419	O
confirm	420	427	O
the	428	431	O
initial	432	439	O
results	440	447	O
.	447	448	O

At	449	451	O
a	452	453	O
plating	454	461	O
density	462	469	O
of	470	472	O
1300	473	477	O
cells	478	483	B-Cell
/	483	484	O
mm2	484	487	O
,	487	488	O
there	489	494	O
were	495	499	O
approximately	500	513	O
140	514	517	O
cells	518	523	B-Cell
on	524	526	O
the	527	530	O
portion	531	538	O
of	539	541	O
the	542	545	O
cantilever	546	556	O
free	557	561	O
to	562	564	O
vibrate	565	572	O
(	573	574	O
dimensions	574	584	O
shown	585	590	O
in	591	593	O
Figure	594	600	O
1	601	602	O
)	602	603	O
.	603	604	O

Table	605	610	O
1	611	612	O

Cantilever	613	623	O
response	624	632	O
data	633	637	O
from	638	642	O
two	643	646	O
trials	647	653	O

Experiment	654	664	O
#	665	666	O
1	666	667	O
Experiment	668	678	O
#	679	680	O
2	680	681	O

Freq	682	686	O
.	686	687	O

1	688	689	O
(	690	691	O
kHz	691	694	O
)	694	695	O
Amp	696	699	O
.	699	700	O

1	701	702	O
(	703	704	O
deg	704	707	O
)	707	708	O
Freq	709	713	O
.	713	714	O

2	715	716	O
(	717	718	O
kHz	718	721	O
)	721	722	O
Amp	723	726	O
.	726	727	O

2	728	729	O
(	730	731	O
deg	731	734	O
)	734	735	O
Freq	736	740	O
.	740	741	O

1	742	743	O
(	744	745	O
kHz	745	748	O
)	748	749	O
Amp	750	753	O
.	753	754	O

1	755	756	O
(	757	758	O
deg	758	761	O
)	761	762	O
Freq	763	767	O
.	767	768	O

2	769	770	O
(	771	772	O
kHz	772	775	O
)	775	776	O
Amp	777	780	O
.	780	781	O

2	782	783	O
(	784	785	O
deg	785	788	O
)	788	789	O

Initial	790	797	O
313	798	801	O
.	801	802	O
0	802	803	O
.	804	805	O
086	805	808	O
375	809	812	O
.	812	813	O
5	813	814	O
.	815	816	O
055	816	819	O
313	820	823	O
.	823	824	O
9	824	825	O
.	826	827	O
091	827	830	O
376	831	834	O
.	834	835	O
5	835	836	O
.	837	838	O
071	838	841	O

With	842	846	O
cells	847	852	B-Cell
307	853	856	O
.	856	857	O
5	857	858	O
.	859	860	O
031	860	863	O
371	864	867	O
.	867	868	O
0	868	869	O
.	870	871	O
018	871	874	O
308	875	878	O
.	879	880	O
052	880	883	O
370	884	887	O
.	887	888	O
5	888	889	O
.	890	891	O
043	891	894	O

Change	895	901	O
5	902	903	O
.	903	904	O
5	904	905	O
.	906	907	O
055	907	910	O
4	911	912	O
.	912	913	O
5	913	914	O
.	915	916	O
037	916	919	O
5	920	921	O
.	921	922	O
9	922	923	O
.	924	925	O
039	925	928	O
6	929	930	O
.	930	931	O
0	931	932	O
.	933	934	O
028	934	937	O

Figure	938	944	O
4	945	946	O

Phase	947	952	O
angle	953	958	O
vs	959	961	O
.	961	962	O
frequency	963	972	O
.	972	973	O

(	974	975	O
left	975	979	O
)	979	980	O
Phase	981	986	O
angle	987	992	O
of	993	995	O
impedance	996	1005	O
with	1006	1010	O
linear	1011	1017	O
regression	1018	1028	O
line	1029	1033	O
.	1033	1034	O

(	1035	1036	O
right	1036	1041	O
)	1041	1042	O
To	1043	1045	O
provide	1046	1053	O
an	1054	1056	O
easier	1057	1063	O
comparison	1064	1074	O
,	1074	1075	O
phase	1076	1081	O
angles	1082	1088	O
have	1089	1093	O
been	1094	1098	O
levelled	1099	1107	O
with	1108	1112	O
respect	1113	1120	O
to	1121	1123	O
the	1124	1127	O
linear	1128	1134	O
regression	1135	1145	O
line	1146	1150	O
that	1151	1155	O
passes	1156	1162	O
through	1163	1170	O
each	1171	1175	O
set	1176	1179	O
of	1180	1182	O
data	1183	1187	O
.	1187	1188	O

The	1189	1192	O
addition	1193	1201	O
of	1202	1204	O
cells	1205	1210	B-Cell
causes	1211	1217	O
the	1218	1221	O
peaks	1222	1227	O
to	1228	1230	O
shift	1231	1236	O
to	1237	1239	O
lower	1240	1245	O
frequencies	1246	1257	O
and	1258	1261	O
decrease	1262	1270	O
in	1271	1273	O
amplitude	1274	1283	O
.	1283	1284	O

The	1285	1288	O
two	1289	1292	O
peaks	1293	1298	O
shown	1299	1304	O
were	1305	1309	O
the	1310	1313	O
only	1314	1318	O
detectable	1319	1329	O
resonances	1330	1340	O
despite	1341	1348	O
the	1349	1352	O
relatively	1353	1363	O
wide	1364	1368	O
frequency	1369	1378	O
range	1379	1384	O
measured	1385	1393	O
.	1393	1394	O

The	1395	1398	O
electrical	1399	1409	O
detection	1410	1419	O
of	1420	1422	O
resonances	1423	1433	O
is	1434	1436	O
critically	1437	1447	O
compromised	1448	1459	O
by	1460	1462	O
the	1463	1466	O
strong	1467	1473	O
damping	1474	1481	O
imposed	1482	1489	O
by	1490	1492	O
the	1493	1496	O
cell	1497	1501	B-Cell
media	1502	1507	O
,	1507	1508	O
making	1509	1515	O
these	1516	1521	O
measurements	1522	1534	O
more	1535	1539	O
challenging	1540	1551	O
than	1552	1556	O
those	1557	1562	O
carried	1563	1570	O
out	1571	1574	O
in	1575	1577	O
air	1578	1581	O
or	1582	1584	O
in	1585	1587	O
a	1588	1589	O
vacuum	1590	1596	O
where	1597	1602	O
resonance	1603	1612	O
peaks	1613	1618	O
show	1619	1623	O
much	1624	1628	O
larger	1629	1635	O
amplitude	1636	1645	O
[	1646	1647	O
18	1647	1649	O
]	1649	1650	O
.	1650	1651	O

In	1652	1654	O
the	1655	1658	O
desired	1659	1666	O
in	1667	1669	O
vivo	1670	1674	O
application	1675	1686	O
for	1687	1690	O
this	1691	1695	O
work	1696	1700	O
,	1700	1701	O
as	1702	1704	O
a	1705	1706	O
sensor	1707	1713	O
for	1714	1717	O
stent	1718	1723	O
healing	1724	1731	O
,	1731	1732	O
it	1733	1735	O
can	1736	1739	O
be	1740	1742	O
expected	1743	1751	O
that	1752	1756	O
in	1757	1759	O
the	1760	1763	O
course	1764	1770	O
of	1771	1773	O
normal	1774	1780	O
healing	1781	1788	O
the	1789	1792	O
stent	1793	1798	O
will	1799	1803	O
be	1804	1806	O
fully	1807	1812	O
populated	1813	1822	O
with	1823	1827	O
a	1828	1829	O
significantly	1830	1843	O
thicker	1844	1851	O
layer	1852	1857	O
of	1858	1860	O
endothelial	1861	1872	B-Cell
cells	1873	1878	I-Cell
.	1878	1879	O

In	1880	1882	O
the	1883	1886	O
case	1887	1891	O
of	1892	1894	O
restenosis	1895	1905	O
,	1905	1906	O
this	1907	1911	O
lining	1912	1918	O
would	1919	1924	O
be	1925	1927	O
even	1928	1932	O
thicker	1933	1940	O
.	1940	1941	O

This	1942	1946	O
may	1947	1950	O
hamper	1951	1957	O
any	1958	1961	O
movement	1962	1970	O
of	1971	1973	O
the	1974	1977	O
cantilever	1978	1988	O
and	1989	1992	O
cause	1993	1998	O
the	1999	2002	O
peaks	2003	2008	O
to	2009	2011	O
eventually	2012	2022	O
become	2023	2029	O
undetectable	2030	2042	O
.	2042	2043	O

Frequent	2044	2052	O
measurements	2053	2065	O
of	2066	2068	O
the	2069	2072	O
resonant	2073	2081	O
frequencies	2082	2093	O
will	2094	2098	O
differentiate	2099	2112	O
this	2113	2117	O
end	2118	2121	O
state	2122	2127	O
with	2128	2132	O
the	2133	2136	O
possibility	2137	2148	O
of	2149	2151	O
device	2152	2158	O
failure	2159	2166	O
.	2166	2167	O

The	2168	2171	O
noninvasive	2172	2183	O
nature	2184	2190	O
of	2191	2193	O
these	2194	2199	O
measurements	2200	2212	O
that	2213	2217	O
can	2218	2221	O
be	2222	2224	O
transmitted	2225	2236	O
wirelessly	2237	2247	O
to	2248	2250	O
an	2251	2253	O
external	2254	2262	O
device	2263	2269	O
make	2270	2274	O
this	2275	2279	O
an	2280	2282	O
attractive	2283	2293	O
and	2294	2297	O
low	2298	2301	O
risk	2302	2306	O
option	2307	2313	O
for	2314	2317	O
monitoring	2318	2328	O
healing	2329	2336	O
.	2336	2337	O

2	0	1	O
.	1	2	O
1	2	3	O
.	3	4	O

Genome	5	11	O
sequencing	12	22	O
,	22	23	O
assembly	24	32	O
and	33	36	O
validation	37	47	O

DNA	48	51	O
shotgun	52	59	O
libraries	60	69	O
with	70	74	O
average	75	82	O
insert	83	89	O
sizes	90	95	O
of	96	98	O
1	99	100	O
.	100	101	O
6	101	102	O
and	103	106	O
6	107	108	O
.	108	109	O
5	109	110	O
kb	111	113	O
were	114	118	O
constructed	119	130	O
in	131	133	O
pUC118	134	140	O
(	141	142	O
TaKaRa	142	148	O
)	148	149	O
,	149	150	O
whereas	151	158	O
a	159	160	O
fosmid	161	167	O
library	168	175	O
with	176	180	O
average	181	188	O
insert	189	195	O
size	196	200	O
of	201	203	O
37	204	206	O
kb	207	209	O
was	210	213	O
constructed	214	225	O
in	226	228	O
pCC1FOS	229	236	O
(	237	238	O
EPICENTRE	238	247	O
)	247	248	O
as	249	251	O
described	252	261	O
previously	262	272	O
.	272	273	O
18	273	275	O
,	275	276	O
19	276	278	O
A	279	280	O
total	281	286	O
of	287	289	O
50	290	292	O
400	293	296	O
clones	297	303	O
(	304	305	O
34	305	307	O
560	308	311	O
,	311	312	O
10	313	315	O
752	316	319	O
and	320	323	O
5088	324	328	O
clones	329	335	O
from	336	340	O
libraries	341	350	O
with	351	355	O
1	356	357	O
.	357	358	O
6	358	359	O
,	359	360	O
6	361	362	O
.	362	363	O
5	363	364	O
and	365	368	O
37	369	371	O
kb	372	374	O
inserts	375	382	O
,	382	383	O
respectively	384	396	O
)	396	397	O
were	398	402	O
subjected	403	412	O
to	413	415	O
sequencing	416	426	O
from	427	431	O
both	432	436	O
ends	437	441	O
of	442	444	O
the	445	448	O
inserts	449	456	O
on	457	459	O
either	460	466	O
ABI	467	470	O
3730xl	471	477	O
DNA	478	481	O
Analyzer	482	490	O
(	491	492	O
Applied	492	499	O
Biosystems	500	510	O
)	510	511	O
or	512	514	O
Base	515	519	O
Station	520	527	O
DNA	528	531	O
Fragment	532	540	O
Analyzer	541	549	O
BST	550	553	O
-	553	554	O
0100	554	558	O
(	559	560	O
MJ	560	562	O
Research	563	571	O
,	571	572	O
Inc	573	576	O
.	576	577	O
)	577	578	O
.	578	579	O

Sequence	580	588	O
reads	589	594	O
were	595	599	O
trimmed	600	607	O
at	608	610	O
a	611	612	O
threshold	613	622	O
quality	623	630	O
value	631	636	O
of	637	639	O
20	640	642	O
by	643	645	O
Phred	646	651	O
and	652	655	O
assembled	656	665	O
by	666	668	O
Phrap	669	674	O
and	675	678	O
CONSED	679	685	O
assembly	686	694	O
tools	695	700	O
.	700	701	O
20	701	703	O
,	703	704	O
21	704	706	O
For	707	710	O
alignment	711	720	O
and	721	724	O
validation	725	735	O
of	736	738	O
contigs	739	746	O
,	746	747	O
Optical	748	755	O
Mapping	756	763	O
(	764	765	O
OpGen	765	770	O
)	770	771	O
was	772	775	O
used	776	780	O
.	780	781	O

Gaps	782	786	O
between	787	794	O
contigs	795	802	O
were	803	807	O
closed	808	814	O
by	815	817	O
sequencing	818	828	O
PCR	829	832	O
products	833	841	O
,	841	842	O
which	843	848	O
bridge	849	855	O
two	856	859	O
neighboring	860	871	O
contigs	872	879	O
.	879	880	O

Finally	881	888	O
,	888	889	O
each	890	894	O
base	895	899	O
of	900	902	O
K	903	904	O
.	904	905	O
setae	906	911	O
NBRC	912	916	O
14216T	917	923	O
genome	924	930	O
was	931	934	O
ensured	935	942	O
to	943	945	O
be	946	948	O
sequenced	949	958	O
from	959	963	O
multiple	964	972	O
clones	973	979	O
and	980	983	O
from	984	988	O
both	989	993	O
directions	994	1004	O
with	1005	1009	O
Phrap	1010	1015	O
quality	1016	1023	O
score	1024	1029	O
>	1030	1031	O
=	1031	1032	O
70	1032	1034	O
or	1035	1037	O
from	1038	1042	O
one	1043	1046	O
direction	1047	1056	O
with	1057	1061	O
Phrap	1062	1067	O
quality	1068	1075	O
score	1076	1081	O
>	1082	1083	O
=	1083	1084	O
40	1084	1086	O
.	1086	1087	O

Chromosomal	1088	1099	O
terminus	1100	1108	O
was	1109	1112	O
determined	1113	1123	O
after	1124	1129	O
attaching	1130	1139	O
adenine	1140	1147	O
and	1148	1151	O
thymine	1152	1159	O
homopolymers	1160	1172	O
to	1173	1175	O
the	1176	1179	O
naked	1180	1185	O
3	1186	1187	O
'	1187	1188	O
ends	1189	1193	O
of	1194	1196	O
the	1197	1200	O
chromosome	1201	1211	B-Cellular_component
as	1212	1214	O
described	1215	1224	O
previously	1225	1235	O
.	1235	1236	O
5	1236	1237	O

Correlation	0	11	O
matrix	12	18	O
for	19	22	O
ear	23	26	O
(	27	28	O
E	28	29	O
)	29	30	O
traits	31	37	O
in	38	40	O
2006	41	45	O
;	45	46	O
data	47	51	O
from	52	56	O
water	57	62	O
stress	63	69	O
plots	70	75	O
(	76	77	O
lower	77	82	O
left	83	87	O
)	87	88	O
and	89	92	O
well	93	97	O
-	97	98	O
watered	98	105	O
plots	106	111	O
(	112	113	O
upper	113	118	O
right	119	124	O
)	124	125	O
of	126	128	O
350	129	132	O
maize	133	138	O
inbreds	139	146	O

FUNDING	0	7	O

National	8	16	O
Institutes	17	27	O
of	28	30	O
Health	31	37	O
grants	38	44	O
,	44	45	O
National	46	54	O
Institute	55	64	O
of	65	67	O
Environmental	68	81	O
Health	82	88	O
Sciences	89	97	O
and	98	101	O
the	102	105	O
National	106	114	O
Library	115	122	O
of	123	125	O
Medicine	126	134	O
(	135	136	O
R01	136	139	O
ES014065	140	148	O
and	149	152	O
R01	153	156	O
ES014065	157	165	O
-	165	166	O
04S1	166	170	O
to	171	173	O
CTD	174	177	O
)	177	178	O
;	178	179	O
INBRE	180	185	O
program	186	193	O
of	194	196	O
the	197	200	O
National	201	209	O
Center	210	216	O
for	217	220	O
Research	221	229	O
Resources	230	239	O
(	240	241	O
P20	241	244	O
RR016463	245	253	O
)	253	254	O
.	254	255	O

Funding	256	263	O
for	264	267	O
open	268	272	O
access	273	279	O
charge	280	286	O
:	286	287	O
NIEHS	288	293	O
grant	294	299	O
(	300	301	O
R01	301	304	O
ES014065	305	313	O
)	313	314	O
.	314	315	O

Conflict	316	324	O
of	325	327	O
interest	328	336	O
statement	337	346	O
.	346	347	O

None	348	352	O
declared	353	361	O
.	361	362	O

Tarsoconjunctival	0	17	B-Multi-tissue_structure
flap	18	22	I-Multi-tissue_structure
after	23	28	O
division	29	37	O

MoClo	0	5	O
cloning	6	13	O
protocol	14	22	O

Restriction	23	34	O
-	34	35	O
ligations	35	44	O
were	45	49	O
set	50	53	O
up	54	56	O
by	57	59	O
pipetting	60	69	O
in	70	72	O
one	73	76	O
tube	77	81	O
approximately	82	95	O
40	96	98	O
fmol	99	103	O
(	104	105	O
~	105	106	O
100	106	109	O
ng	110	112	O
of	113	115	O
DNA	116	119	O
for	120	123	O
a	124	125	O
4	126	127	O
kb	128	130	O
plasmid	131	138	O
)	138	139	O
of	140	142	O
each	143	147	O
DNA	148	151	O
component	152	161	O
(	162	163	O
PCR	163	166	O
product	167	174	O
or	175	177	O
plasmid	178	185	O
)	185	186	O
,	186	187	O
10	188	190	O
U	191	192	O
of	193	195	O
the	196	199	O
required	200	208	O
restriction	209	220	O
enzyme	221	227	O
(	228	229	O
BsaI	229	233	O
or	234	236	O
BpiI	237	241	O
)	241	242	O
and	243	246	O
10	247	249	O
U	250	251	O
T4	252	254	O
DNA	255	258	O
ligase	259	265	O
(	266	267	O
using	267	272	O
high	273	277	O
concentration	278	291	O
ligase	292	298	O
,	298	299	O
20	300	302	O
U	303	304	O
/	304	305	O
microl	305	311	O
)	311	312	O
in	313	315	O
Promega	316	323	O
ligation	324	332	O
buffer	333	339	O
in	340	342	O
a	343	344	O
final	345	350	O
reaction	351	359	O
volume	360	366	O
of	367	369	O
20	370	372	O
microl	373	379	O
.	379	380	O

The	381	384	O
reaction	385	393	O
was	394	397	O
incubated	398	407	O
in	408	410	O
a	411	412	O
thermocycler	413	425	O
for	426	429	O
5	430	431	O
hours	432	437	O
at	438	440	O
37degreesC	441	451	O
,	451	452	O
5	453	454	O
min	455	458	O
at	459	461	O
50degreesC	462	472	O
and	473	476	O
10	477	479	O
min	480	483	O
at	484	486	O
80degreesC	487	497	O
.	497	498	O

The	499	502	O
reaction	503	511	O
mix	512	515	O
was	516	519	O
then	520	524	O
added	525	530	O
to	531	533	O
100	534	537	O
microl	538	544	O
chemically	545	555	O
competent	556	565	O
DH10b	566	571	B-Cell
cells	572	577	I-Cell
,	577	578	O
incubated	579	588	O
for	589	592	O
15	593	595	O
-	595	596	O
30	596	598	O
min	599	602	O
on	603	605	O
ice	606	609	O
and	610	613	O
transformed	614	625	O
by	626	628	O
heat	629	633	O
shock	634	639	O
.	639	640	O

800	641	644	O
microl	645	651	O
of	652	654	O
liquid	655	661	O
LB	662	664	O
was	665	668	O
then	669	673	O
added	674	679	O
to	680	682	O
the	683	686	O
transformation	687	701	O
,	701	702	O
and	703	706	O
the	707	710	O
cells	711	716	B-Cell
were	717	721	O
let	722	725	O
to	726	728	O
recover	729	736	O
45	737	739	O
min	740	743	O
at	744	746	O
37degreesC	747	757	O
.	757	758	O

Different	759	768	O
aliquots	769	777	O
of	778	780	O
the	781	784	O
transformation	785	799	O
were	800	804	O
plated	805	811	O
on	812	814	O
LB	815	817	O
plates	818	824	O
containing	825	835	O
the	836	839	O
appropriate	840	851	O
antibiotic	852	862	O
.	862	863	O

The	864	867	O
number	868	874	O
of	875	877	O
colonies	878	886	O
was	887	890	O
counted	891	898	O
for	899	902	O
one	903	906	O
or	907	909	O
two	910	913	O
selected	914	922	O
plates	923	929	O
(	930	931	O
containing	931	941	O
countable	942	951	O
number	952	958	O
of	959	961	O
colonies	962	970	O
)	970	971	O
,	971	972	O
or	973	975	O
from	976	980	O
a	981	982	O
section	983	990	O
of	991	993	O
the	994	997	O
plates	998	1004	O
when	1005	1009	O
very	1010	1014	O
high	1015	1019	O
number	1020	1026	O
of	1027	1029	O
colonies	1030	1038	O
were	1039	1043	O
obtained	1044	1052	O
even	1053	1057	O
for	1058	1061	O
the	1062	1065	O
lowest	1066	1072	O
volume	1073	1079	O
plated	1080	1086	O
.	1086	1087	O

The	1088	1091	O
number	1092	1098	O
of	1099	1101	O
colonies	1102	1110	O
was	1111	1114	O
then	1115	1119	O
extrapolated	1120	1132	O
for	1133	1136	O
the	1137	1140	O
entire	1141	1147	O
transformation	1148	1162	O
.	1162	1163	O

For	1164	1167	O
level	1168	1173	O
2	1174	1175	O
-	1175	1176	O
2	1176	1177	O
cloning	1178	1185	O
,	1185	1186	O
two	1187	1190	O
type	1191	1195	O
IIS	1196	1199	O
enzymes	1200	1207	O
were	1208	1212	O
required	1213	1221	O
,	1221	1222	O
BpiI	1223	1227	O
and	1228	1231	O
BsaI	1232	1236	O
.	1236	1237	O

The	1238	1241	O
same	1242	1246	O
protocol	1247	1255	O
was	1256	1259	O
used	1260	1264	O
as	1265	1267	O
described	1268	1277	O
above	1278	1283	O
except	1284	1290	O
that	1291	1295	O
10	1296	1298	O
U	1299	1300	O
and	1301	1304	O
2	1305	1306	O
.	1306	1307	O
5	1307	1308	O
U	1309	1310	O
were	1311	1315	O
used	1316	1320	O
for	1321	1324	O
the	1325	1328	O
enzymes	1329	1336	O
BpiI	1337	1341	O
and	1342	1345	O
BsaI	1346	1350	O
,	1350	1351	O
respectively	1352	1364	O
.	1364	1365	O

To	1366	1368	O
optimize	1369	1377	O
efficiency	1378	1388	O
of	1389	1391	O
the	1392	1395	O
restriction	1396	1407	O
-	1407	1408	O
ligation	1408	1416	O
for	1417	1420	O
the	1421	1424	O
final	1425	1430	O
construct	1431	1440	O
containing	1441	1451	O
11	1452	1454	O
transcription	1455	1468	O
units	1469	1474	O
(	1475	1476	O
cL2	1476	1479	O
-	1479	1480	O
13	1480	1482	O
*	1482	1483	O
)	1483	1484	O
,	1484	1485	O
a	1486	1487	O
variation	1488	1497	O
of	1498	1500	O
this	1501	1505	O
protocol	1506	1514	O
was	1515	1518	O
used	1519	1523	O
as	1524	1526	O
follows	1527	1534	O
.	1534	1535	O

The	1536	1539	O
reaction	1540	1548	O
mix	1549	1552	O
was	1553	1556	O
set	1557	1560	O
up	1561	1563	O
containing	1564	1574	O
20	1575	1577	O
U	1578	1579	O
ligase	1580	1586	O
,	1586	1587	O
5	1588	1589	O
U	1590	1591	O
BpiI	1592	1596	O
and	1597	1600	O
5	1601	1602	O
U	1603	1604	O
BsaI	1605	1609	O
,	1609	1610	O
in	1611	1613	O
a	1614	1615	O
total	1616	1621	O
reaction	1622	1630	O
volume	1631	1637	O
of	1638	1640	O
20	1641	1643	O
microl	1644	1650	O
.	1650	1651	O

The	1652	1655	O
mix	1656	1659	O
was	1660	1663	O
incubated	1664	1673	O
in	1674	1676	O
a	1677	1678	O
thermocycler	1679	1691	O
with	1692	1696	O
the	1697	1700	O
following	1701	1710	O
parameters	1711	1721	O
:	1721	1722	O
incubation	1723	1733	O
for	1734	1737	O
2	1738	1739	O
minutes	1740	1747	O
at	1748	1750	O
37degreesC	1751	1761	O
,	1761	1762	O
5	1763	1764	O
minutes	1765	1772	O
at	1773	1775	O
16degreesC	1776	1786	O
,	1786	1787	O
both	1788	1792	O
steps	1793	1798	O
repeated	1799	1807	O
45	1808	1810	O
times	1811	1816	O
,	1816	1817	O
followed	1818	1826	O
by	1827	1829	O
incubation	1830	1840	O
for	1841	1844	O
5	1845	1846	O
minutes	1847	1854	O
at	1855	1857	O
50degreesC	1858	1868	O
and	1869	1872	O
10	1873	1875	O
minutes	1876	1883	O
at	1884	1886	O
80degreesC	1887	1897	O
.	1897	1898	O

The	1899	1902	O
reaction	1903	1911	O
mix	1912	1915	O
was	1916	1919	O
transformed	1920	1931	O
in	1932	1934	O
E	1935	1936	O
.	1936	1937	O
coli	1938	1942	O
chemically	1943	1953	O
competent	1954	1963	B-Cell
cells	1964	1969	I-Cell
as	1970	1972	O
described	1973	1982	O
above	1983	1988	O
.	1988	1989	O

Observed	0	8	O
type	9	13	O
I	14	15	O
error	16	21	O
for	22	25	O
datasets	26	34	O
simulated	35	44	O
under	45	50	O
the	51	54	O
null	55	59	O
hypothesis	60	70	O

DNA	0	3	O
isolation	4	13	O

All	14	17	O
solutions	18	27	O
used	28	32	O
for	33	36	O
DNA	37	40	O
isolation	41	50	O
are	51	54	O
purged	55	61	O
with	62	66	O
nitrogen	67	75	O
(	76	77	O
immediately	77	88	O
prior	89	94	O
to	95	97	O
use	98	101	O
)	101	102	O
and	103	106	O
supplemented	107	119	O
with	120	124	O
50	125	127	O
muM	128	131	O
phenyl	132	138	O
-	138	139	O
tert	139	143	O
-	143	144	O
butyl	144	149	O
nitrone	150	157	O
to	158	160	O
minimise	161	169	O
oxidative	170	179	O
damage	180	186	O
to	187	189	O
DNA	190	193	O
[	193	194	O
31	194	196	O
]	196	197	O
.	197	198	O

Qiagen	199	205	O
DNAeasy	206	213	O
Kit	214	217	O
(	218	219	O
#	219	220	O
69506	220	225	O
)	225	226	O

includes	227	235	O
:	235	236	O
Proteinase	237	247	O
K	248	249	O
,	249	250	O
AW1	251	254	O
,	254	255	O
AW2	256	259	O
,	259	260	O
AE	261	263	O
and	264	267	O
Spin	268	272	O
-	272	273	O
columns	273	280	O

Dithiothreitol	281	295	O
(	296	297	O
DTT	297	300	O
;	300	301	O
Sigma	302	307	O
)	307	308	O

Ethanol	309	316	O
(	317	318	O
Ajax	318	322	O
Finechem	323	331	O
#	332	333	O
214	333	336	O
-	336	337	O
2	337	338	O
.	338	339	O
5L	339	341	O
)	341	342	O

Nitrogen	343	351	O
(	352	353	O
for	353	356	O
purging	357	364	O
of	365	367	O
buffers	368	375	O
)	375	376	O

Genes	0	5	O
related	6	13	O
to	14	16	O
signal	17	23	O
transduction	24	36	O

On	37	39	O
day	40	43	O
7	44	45	O
,	45	46	O
the	47	50	O
up	51	53	O
-	53	54	O
regulated	54	63	O
genes	64	69	O
related	70	77	O
to	78	80	O
signal	81	87	O
transduction	88	100	O
were	101	105	O
PDE1A	106	111	O
,	111	112	O
MYO10	113	118	O
,	118	119	O
APOB	120	124	O
,	124	125	O
and	126	129	O
so	130	132	O
on	133	135	O
,	135	136	O
and	137	140	O
down	141	145	O
-	145	146	O
regulated	146	155	O
genes	156	161	O
were	162	166	O
CYTL1	167	172	O
and	173	176	O
IL6	177	180	O
.	180	181	O

On	182	184	O
day	185	188	O
14	189	191	O
,	191	192	O
the	193	196	O
up	197	199	O
-	199	200	O
regulated	200	209	O
genes	210	215	O
were	216	220	O
ANGPTL4	221	228	O
,	228	229	O
EPHA3	230	235	O
,	235	236	O
RASL10B	237	244	O
,	244	245	O
etc	246	249	O
.	249	250	O
,	250	251	O
and	252	255	O
the	256	259	O
down	260	264	O
-	264	265	O
regulated	265	274	O
genes	275	280	O
were	281	285	O
CXCL12	286	292	O
,	292	293	O
CCL8	294	298	O
and	299	302	O
VLDLR	303	308	O
.	308	309	O

The	310	313	O
genes	314	319	O
up	320	322	O
-	322	323	O
regulated	323	332	O
on	333	335	O
both	336	340	O
days	341	345	O
were	346	350	O
LEP	351	354	O
,	354	355	O
RAC3	356	360	O
,	360	361	O
and	362	365	O
RASL11B	366	373	O
,	373	374	O
and	375	378	O
those	379	384	O
down	385	389	O
-	389	390	O
regulated	390	399	O
both	400	404	O
days	405	409	O
were	410	414	O
MX1	415	418	O
and	419	422	O
WISP2	423	428	O
.	428	429	O

Notably	430	437	O
,	437	438	O
up	439	441	O
-	441	442	O
and	443	446	O
down	447	451	O
-	451	452	O
regulated	452	461	O
genes	462	467	O
PDE1A	468	473	O
,	473	474	O
APOB	475	479	O
,	479	480	O
ALCAM	481	486	O
,	486	487	O
PSCD4	488	493	O
,	493	494	O
CYTL1	495	500	O
,	500	501	O
and	502	505	O
IL6	506	509	O
were	510	514	O
more	515	519	O
strongly	520	528	O
expressed	529	538	O
on	539	541	O
day	542	545	O
7	546	547	O
than	548	552	O
on	553	555	O
day	556	559	O
14	560	562	O
,	562	563	O
while	564	569	O
ANGPTL4	570	577	O
,	577	578	O
EPHA3	579	584	O
,	584	585	O
RAB12	586	591	O
,	591	592	O
CXCL12	593	599	O
,	599	600	O
CCL8	601	605	O
,	605	606	O
and	607	610	O
VLDLR	611	616	O
were	617	621	O
more	622	626	O
strongly	627	635	O
expressed	636	645	O
on	646	648	O
day	649	652	O
14	653	655	O
than	656	660	O
on	661	663	O
day	664	667	O
7	668	669	O
.	669	670	O

SUMMARY	0	7	O

Both	8	12	O
the	13	16	O
innate	17	23	O
and	24	27	O
adaptive	28	36	O
immune	37	43	B-Anatomical_system
subsystems	44	54	I-Anatomical_system
are	55	58	O
necessary	59	68	O
to	69	71	O
provide	72	79	O
an	80	82	O
effective	83	92	O
immune	93	99	O
response	100	108	O
whether	109	116	O
to	117	119	O
an	120	122	O
actual	123	129	O
pathogenic	130	140	O
agent	141	146	O
or	147	149	O
to	150	152	O
an	153	155	O
immunization	156	168	O
.	168	169	O

Further	170	177	O
,	177	178	O
effective	179	188	O
immunizations	189	202	O
must	203	207	O
induce	208	214	O
long	215	219	O
-	219	220	O
term	220	224	O
stimulation	225	236	O
of	237	239	O
both	240	244	O
the	245	248	O
humoral	249	256	O
and	257	260	O
cell	261	265	B-Cell
-	265	266	O
mediated	266	274	O
arms	275	279	O
of	280	282	O
the	283	286	O
adaptive	287	295	O
system	296	302	O
by	303	305	O
the	306	309	O
production	310	320	O
of	321	323	O
effector	324	332	B-Cell
cells	333	338	I-Cell
for	339	342	O
the	343	346	O
current	347	354	O
infection	355	364	O
and	365	368	O
memory	369	375	B-Cell
cells	376	381	I-Cell
for	382	385	O
future	386	392	O
infections	393	403	O
with	404	408	O
the	409	412	O
pathogenic	413	423	O
agent	424	429	O
.	429	430	O

At	431	433	O
least	434	439	O
seven	440	445	O
different	446	455	O
types	456	461	O
of	462	464	O
vaccines	465	473	O
are	474	477	O
currently	478	487	O
in	488	490	O
use	491	494	O
or	495	497	O
in	498	500	O
development	501	512	O
that	513	517	O
produce	518	525	O
this	526	530	O
effective	531	540	O
immunity	541	549	O
and	550	553	O
have	554	558	O
contributed	559	570	O
greatly	571	578	O
to	579	581	O
the	582	585	O
prevention	586	596	O
of	597	599	O
infectious	600	610	O
disease	611	618	O
around	619	625	O
the	626	629	O
world	630	635	O
.	635	636	O

Encoding	0	8	O
methods	9	16	O
of	17	19	O
SOLiDzipper	20	31	O
.	31	32	O

Notes	33	38	O
:	38	39	O
A	40	41	O
)	41	42	O
The	43	46	O
quality	47	54	O
value	55	60	O
in	61	63	O
QV	64	66	O
files	67	72	O
from	73	77	O
ABI	78	81	O
SOLiD	82	87	O
system	88	94	O
ranges	95	101	O
from	102	106	O
-	107	108	O
1	108	109	O
to	110	112	O
40	113	115	O
,	115	116	O
which	117	122	O
requires	123	131	O
6	132	133	O
bit	134	137	O
space	138	143	O
.	143	144	O

The	145	148	O
remaining	149	158	O
2	159	160	O
bit	161	164	O
space	165	170	O
out	171	174	O
of	175	177	O
1	178	179	O
byte	180	184	O
can	185	188	O
be	189	191	O
used	192	196	O
for	197	200	O
storing	201	208	O
another	209	216	O
quality	217	224	O
value	225	230	O
in	231	233	O
part	234	238	O
.	238	239	O

B	240	241	O
)	241	242	O
Csfasta	243	250	O
files	251	256	O
contain	257	264	O
the	265	268	O
sequence	269	277	O
information	278	289	O
in	290	292	O
four	293	297	O
digits	298	304	O
,	304	305	O
'	306	307	O
0123	307	311	O
'	311	312	O
,	312	313	O
which	314	319	O
require	320	327	O
2	328	329	O
bit	330	333	O
space	334	339	O
.	339	340	O

Provided	341	349	O
that	350	354	O
'	355	356	O
0	356	357	O
'	357	358	O
,	358	359	O
1	360	361	O
byte	362	366	O
character	367	376	O
in	377	379	O
csfasta	380	387	O
files	388	393	O
,	393	394	O
is	395	397	O
mapped	398	404	O
as	405	407	O
binary	408	414	O
data	415	419	O
'	420	421	O
00	421	423	O
'	423	424	O
,	424	425	O
'	426	427	O
1	427	428	O
'	428	429	O
as	430	432	O
'	433	434	O
01	434	436	O
'	436	437	O
,	437	438	O
'	439	440	O
2	440	441	O
'	441	442	O
as	442	444	O
'	445	446	O
10	446	448	O
'	448	449	O
,	449	450	O
'	451	452	O
3	452	453	O
'	453	454	O
as	455	457	O
'	458	459	O
11	459	461	O
'	461	462	O
,	462	463	O
4	464	465	O
byte	466	470	O
data	471	475	O
'	476	477	O
0113	477	481	O
'	481	482	O
can	483	486	O
be	487	489	O
encoded	490	497	O
into	498	502	O
1	503	504	O
byte	505	509	O
character	510	519	O
0x17	520	524	O
(	524	525	O
00010111	525	533	O
)	533	534	O
through	535	542	O
shift	543	548	O
operation	549	558	O
.	558	559	O

C	560	561	O
)	561	562	O
Sequence	563	571	O
IDs	572	575	O
are	576	579	O
extracted	580	589	O
from	590	594	O
QV	595	597	O
and	598	601	O
csfasta	602	609	O
files	610	615	O
,	615	616	O
combined	617	625	O
,	625	626	O
and	627	630	O
compressed	631	641	O
using	642	647	O
the	648	651	O
general	652	659	O
purpose	660	667	O
compression	668	679	O
methods	680	687	O
.	687	688	O

D	689	690	O
)	690	691	O
Encoded	692	699	O
data	700	704	O
are	705	708	O
stored	709	715	O
as	716	718	O
data	719	723	O
blocks	724	730	O
of	731	733	O
fixed	734	739	O
size	740	744	O
.	744	745	O

This	746	750	O
allows	751	757	O
for	758	761	O
selective	762	771	O
decoding	772	780	O
.	780	781	O

CONCLUSION	0	10	O

Intra	11	16	O
-	16	17	O
operative	17	26	O
monitoring	27	37	O
of	38	40	O
partial	41	48	O
pressure	49	57	O
of	58	60	O
tissue	61	67	B-Tissue
oxygen	68	74	O
(	75	76	O
PtiO2	76	81	O
)	82	83	O
is	84	86	O
a	87	88	O
very	89	93	O
sensitive	94	103	O
method	104	110	O
of	111	113	O
detecting	114	123	O
the	124	127	O
decrease	128	136	O
of	137	139	O
oxygen	140	146	O
for	147	150	O
cell	151	155	B-Cell
utilization	156	167	O
,	167	168	O
due	169	172	O
to	173	175	O
decreased	176	185	O
blood	186	191	B-Organism_substance
flow	192	196	O
,	196	197	O
during	198	204	O
temporary	205	214	O
clipping	215	223	O
and	224	227	O
after	228	233	O
definitive	234	244	O
clipping	245	253	O
,	253	254	O
in	255	257	O
middle	258	264	O
cerebral	265	273	B-Multi-tissue_structure
artery	274	280	I-Multi-tissue_structure
incidental	281	291	O
unruptured	292	302	O
aneurysm	303	311	B-Pathological_formation
surgery	312	319	O
.	319	320	O

"	321	322	O
Basal	322	327	O
values	328	334	O
"	334	335	O
,	335	336	O
obtained	337	345	O
without	346	353	O
the	354	357	O
influence	358	367	O
of	368	370	O
subarachnoid	371	383	B-Organism_substance
blood	384	389	I-Organism_substance
,	389	390	O
were	391	395	O
lower	396	401	O
than	402	406	O
expected	407	415	O
in	416	418	O
"	419	420	O
uninjured	420	429	O
"	429	430	O
brain	431	436	B-Organ
,	436	437	O
and	438	441	O
this	442	446	O
fact	447	451	O
,	451	452	O
although	453	461	O
unexplained	462	473	O
,	473	474	O
should	475	481	O
be	482	484	O
kept	485	489	O
in	490	492	O
mind	493	497	O
in	498	500	O
future	501	507	O
investigation	508	521	O
in	522	524	O
this	525	529	O
field	530	535	O
.	535	536	O

Although	537	545	O
values	546	552	O
that	553	557	O
could	558	563	O
be	564	566	O
predictive	567	577	O
of	578	580	O
brain	581	586	B-Organ
ischemia	587	595	O
could	596	601	O
not	602	605	O
be	606	608	O
established	609	620	O
,	620	621	O
an	622	624	O
incomplete	625	635	O
recovery	636	644	O
or	645	647	O
continuous	648	658	O
decrease	659	667	O
in	668	670	O
PtiO2	671	676	O
values	677	683	O
after	684	689	O
definitive	690	700	O
clipping	701	709	O
should	710	716	O
be	717	719	O
considered	720	730	O
an	731	733	O
indicator	734	743	O
of	744	746	O
high	747	751	O
risk	752	756	O
for	757	760	O
the	761	764	O
development	765	776	O
of	777	779	O
post	780	784	O
-	784	785	O
operative	785	794	O
brain	795	800	B-Organ
infarction	801	811	O
,	811	812	O
and	813	816	O
,	816	817	O
therefore	818	827	O
,	827	828	O
an	829	831	O
indication	832	842	O
for	843	846	O
verification	847	859	O
of	860	862	O
the	863	866	O
position	867	875	O
of	876	878	O
the	879	882	O
clip	883	887	O
.	887	888	O

View	0	4	O
of	5	7	O
the	8	11	O
structure	12	21	O
of	22	24	O
the	25	28	O
title	29	34	O
compound	35	43	O
along	44	49	O
the	50	53	O
a	54	55	O
axis	56	60	O
displaying	61	71	O
chains	72	78	O
alternating	79	90	O
with	91	95	O
amine	96	101	O
groups	102	108	O
.	108	109	O

Results	0	7	O

(	0	1	O
a	1	2	O
)	2	3	O
Sequence	4	12	O
alignment	13	22	O
of	23	25	O
PY	26	28	O
-	28	29	O
NLSs	29	33	O
.	33	34	O

The	35	38	O
homologous	39	49	O
regions	50	57	O
of	58	60	O
C	61	62	O
-	62	63	O
NLS	63	66	O
of	67	69	O
the	70	73	O
EWS	74	77	O
protein	78	85	O
,	85	86	O
NLS	87	90	O
of	91	93	O
Sam68	94	99	O
and	100	103	O
FUS	104	107	O
/	107	108	O
TLS	108	111	O
protein	112	119	O
and	120	123	O
M9	124	126	O
NLS	127	130	O
of	131	133	O
hnRNP	134	139	O
A1	140	142	O
and	143	146	O
hnRNP	147	152	O
M	153	154	O
,	154	155	O
classified	156	166	O
as	167	169	O
PY	170	172	O
-	172	173	O
NLS	173	176	O
are	177	180	O
in	181	183	O
yellow	184	190	O
boxes	191	196	O
.	196	197	O

Phosphorylated	198	212	O
Y656	213	217	O
of	218	220	O
the	221	224	O
EWS	225	228	O
protein	229	236	O
and	237	240	O
Y440	241	245	O
of	246	248	O
Sam68	249	254	O
are	255	258	O
indicated	259	268	O
(	269	270	O
in	270	272	O
red	273	276	O
)	276	277	O
.	277	278	O

Positions	279	288	O
of	289	291	O
identical	292	301	O
residues	302	310	O
in	311	313	O
SAM68	314	319	O
and	320	323	O
EWS	324	327	O
C	328	329	O
-	329	330	O
NLS	330	333	O
are	334	337	O
indicated	338	347	O
in	348	350	O
bold	351	355	O
and	356	359	O
residues	360	368	O
with	369	373	O
identical	374	383	O
charges	384	391	O
are	392	395	O
underlined	396	406	O
.	406	407	O

Known	408	413	O
positions	414	423	O
of	424	426	O
the	427	430	O
FUS	431	434	O
/	434	435	O
TLS	435	438	O
mutations	439	448	O
in	449	451	O
ALS	452	455	O
are	456	459	O
in	460	462	O
bold	463	467	O
.	467	468	O

(	469	470	O
b	470	471	O
)	471	472	O
Subcellular	473	484	B-Cellular_component
localization	485	497	O
of	498	500	O
YFP	501	504	O
,	504	505	O
the	506	509	O
C	510	511	O
-	511	512	O
terminally	512	522	O
tagged	523	529	O
EWS	530	533	O
-	533	534	O
YFP	534	537	O
,	537	538	O
EWS	539	542	O
(	542	543	O
Y656A	543	548	O
)	548	549	O
-	549	550	O
YFP	550	553	O
,	553	554	O
EWS	555	558	O
(	558	559	O
Y656F	559	564	O
)	564	565	O
-	565	566	O
YFP	566	569	O
,	569	570	O
and	571	574	O
EWS	575	578	O
(	578	579	O
Y656D	579	584	O
)	584	585	O
-	585	586	O
YFP	586	589	O
(	590	591	O
in	591	593	O
green	594	599	O
)	599	600	O
.	600	601	O

Nuclei	602	608	B-Cellular_component
are	609	612	O
shown	613	618	O
by	619	621	O
DAPI	622	626	O
staining	627	635	O
(	636	637	O
in	637	639	O
blue	640	644	O
)	644	645	O
.	645	646	O

Bars	647	651	O
,	651	652	O
15	653	655	O
mum	656	659	O
.	659	660	O

Conclusions	0	11	O

Myocardial	12	22	B-Multi-tissue_structure
ischaemia	23	32	O
during	33	39	O
DCMR	40	44	O
is	45	47	O
independently	48	61	O
predictive	62	72	O
of	73	75	O
cardiac	76	83	B-Organ
events	84	90	O
among	91	96	O
patients	97	105	O
with	106	110	O
previous	111	119	O
myocardial	120	130	B-Multi-tissue_structure
revascularisation	131	148	O
.	148	149	O

Importing	0	9	O
citations	10	19	O
in	20	22	O
different	23	32	O
formats	33	40	O
using	41	46	O
Google	47	53	O
Scholar	54	61	O

Subject	0	7	O
disposition	8	19	O
.	19	20	O

Data	21	25	O
from	26	30	O
110	31	34	O
enrolled	35	43	O
subjects	44	52	O
were	53	57	O
eligible	58	66	O
for	67	70	O
analysis	71	79	O
.	79	80	O

The	81	84	O
demographics	85	97	O
of	98	100	O
the	101	104	O
study	105	110	O
subjects	111	119	O
,	119	120	O
by	121	123	O
site	124	128	O
,	128	129	O
are	130	133	O
recorded	134	142	O
in	143	145	O
Table	146	151	O
1	152	153	O
.	153	154	O

The	155	158	O
population	159	169	O
studied	170	177	O
was	178	181	O
predominantly	182	195	O
not	196	199	O
HIV	200	203	O
infected	204	212	O
(	213	214	O
92	214	216	O
%	216	217	O
)	217	218	O
,	218	219	O
and	220	223	O
by	224	226	O
the	227	230	O
study	231	236	O
entry	237	242	O
criteria	243	251	O
,	251	252	O
their	253	258	O
probability	259	270	O
of	271	273	O
infection	274	283	O
was	284	287	O
considered	288	298	O
to	299	301	O
be	302	304	O
low	305	308	O
.	308	309	O

The	310	313	O
risk	314	318	O
categories	319	329	O
assigned	330	338	O
at	339	341	O
the	342	345	O
time	346	350	O
of	351	353	O
study	354	359	O
entry	360	365	O
were	366	370	O
combined	371	379	O
into	380	384	O
groups	385	391	O
for	392	395	O
analysis	396	404	O
,	404	405	O
based	406	411	O
on	412	414	O
the	415	418	O
predisposition	419	433	O
for	434	437	O
PCP	438	441	O
.	441	442	O

The	443	446	O
analysis	447	455	O
groups	456	462	O
were	463	467	O
as	468	470	O
follows	471	478	O
:	478	479	O
(	480	481	O
i	481	482	O
)	482	483	O
HIV	484	487	O
/	487	488	O
AIDS	488	492	O
,	492	493	O
(	494	495	O
ii	495	497	O
)	497	498	O
lung	499	503	B-Organ
transplant	504	514	O
(	515	516	O
one	516	519	O
subject	520	527	O
with	528	532	O
a	533	534	O
dual	535	539	O
organ	540	545	B-Organ
transplant	546	556	O
[	557	558	O
lung	558	562	B-Organ
/	562	563	O
kidney	563	569	B-Organ
]	569	570	O
was	571	574	O
included	575	583	O
in	584	586	O
this	587	591	O
category	592	600	O
)	600	601	O
,	601	602	O
(	603	604	O
iii	604	607	O
)	607	608	O
all	609	612	O
other	613	618	O
organ	619	624	B-Organ
transplants	625	636	O
and	637	640	O
allogeneic	641	651	B-Cell
hematopoietic	652	665	I-Cell
stem	666	670	I-Cell
cell	671	675	I-Cell
transplants	676	687	O
(	688	689	O
HSCT	689	693	O
)	693	694	O
,	694	695	O
(	696	697	O
iv	697	699	O
)	699	700	O
leukemia	701	709	O
,	709	710	O
other	711	716	O
hematological	717	730	O
disorders	731	740	O
,	740	741	O
and	742	745	O
autologous	746	756	O
HSCT	757	761	O
,	761	762	O
(	763	764	O
v	764	765	O
)	765	766	O
other	767	772	O
solid	773	778	B-Pathological_formation
tumors	779	785	I-Pathological_formation
,	785	786	O
and	787	790	O
(	791	792	O
vi	792	794	O
)	794	795	O
other	796	801	O
nonmalignant	802	814	O
conditions	815	825	O
.	825	826	O

Table	827	832	O
1	833	834	O
.	834	835	O

Subject	836	843	O
enrollment	844	854	O
,	854	855	O
disposition	856	867	O
,	867	868	O
and	869	872	O
demographics	873	885	O
by	886	888	O
sitea	889	894	O

Characteristic	895	909	O
Valueb	910	916	O

Site	917	921	O
1	922	923	O
Site	924	928	O
2	929	930	O
Site	931	935	O
3	936	937	O
Site	938	942	O
4	943	944	O

Enrollment	945	955	O

Unique	956	962	O
subjects	963	971	O
18	972	974	O
29	975	977	O
22	978	980	O
62	981	983	O

Subjects	984	992	O
entering	993	1001	O
into	1002	1006	O
primary	1007	1014	O
analysisc	1015	1024	O
18	1025	1027	O
22	1028	1030	O
22	1031	1033	O
48	1034	1036	O

Subjects	1037	1045	O
with	1046	1050	O
repeat	1051	1057	O
visits	1058	1064	O
0	1065	1066	O
0	1067	1068	O
0	1069	1070	O
16	1071	1073	O

No	1074	1076	O
.	1076	1077	O
of	1078	1080	O
samples	1081	1088	O
assayed	1089	1096	O
18	1097	1099	O
22	1100	1102	O
22	1103	1105	O
70	1106	1108	O

Gender	1109	1115	O

Male	1116	1120	O
7	1121	1122	O
10	1123	1125	O
13	1126	1128	O
29	1129	1131	O

Female	1132	1138	O
11	1139	1141	O
12	1142	1144	O
9	1145	1146	O
19	1147	1149	O

Race	1150	1154	O

Caucasian	1155	1164	O
12	1165	1167	O
4	1168	1169	O
0	1170	1171	O
48	1172	1174	O

Black	1175	1180	O
6	1181	1182	O
13	1183	1185	O
0	1186	1187	O
0	1188	1189	O

Other	1190	1195	O
(	1196	1197	O
nonwhite	1197	1205	O
)	1205	1206	O
0	1207	1208	O
5	1209	1210	O
0	1211	1212	O
0	1213	1214	O

No	1215	1217	O
data	1218	1222	O
0	1223	1224	O
0	1225	1226	O
22	1227	1229	O
0	1230	1231	O

Mean	1232	1236	O
(	1237	1238	O
range	1238	1243	O
)	1243	1244	O
age	1245	1248	O
(	1249	1250	O
yr	1250	1252	O
)	1252	1253	O
57	1254	1256	O
(	1257	1258	O
26	1258	1260	O
-	1260	1261	O
78	1261	1263	O
)	1263	1264	O
54	1265	1267	O
(	1268	1269	O
21	1269	1271	O
-	1271	1272	O
75	1272	1274	O
)	1274	1275	O
52	1276	1278	O
(	1279	1280	O
26	1280	1282	O
-	1282	1283	O
74	1283	1285	O
)	1285	1286	O
56	1287	1289	O
(	1290	1291	O
23	1291	1293	O
-	1293	1294	O
73	1294	1296	O
)	1296	1297	O

Pretest	1298	1305	O
probability	1306	1317	O
of	1318	1320	O
PCP	1321	1324	O

Moderate	1325	1333	O
0	1334	1335	O
3	1336	1337	O
4	1338	1339	O
0	1340	1341	O

Low	1342	1345	O
18	1346	1348	O
19	1349	1351	O
18	1352	1354	O
48	1355	1357	O

Sample	1358	1364	O
type	1365	1369	O

BAL	1370	1373	O
18	1374	1376	O
20	1377	1379	O
20	1380	1382	O
43	1383	1385	O

Sputum	1386	1392	B-Organism_substance
0	1393	1394	O
1	1395	1396	O
1	1397	1398	O
0	1399	1400	O

Other	1401	1406	O
LRT	1407	1410	O
0	1411	1412	O
1	1413	1414	O
1	1415	1416	O
5	1417	1418	O

At	1419	1421	O
-	1421	1422	O
risk	1422	1426	O
group	1427	1432	O

HIV	1433	1436	O
/	1436	1437	O
AIDS	1437	1441	O
0	1442	1443	O
3	1444	1445	O
6	1446	1447	O
0	1448	1449	O

Lung	1450	1454	B-Organ
transplant	1455	1465	O
8	1466	1467	O
0	1468	1469	O
1	1470	1471	O
31	1472	1474	O

Other	1475	1480	O
transplants	1481	1492	O
1	1493	1494	O
7	1495	1496	O
3	1497	1498	O
0	1499	1500	O

Leukemia	1501	1509	O
1	1510	1511	O
1	1512	1513	O
7	1514	1515	O
0	1516	1517	O

Other	1518	1523	O
solid	1524	1529	B-Pathological_formation
tumors	1530	1536	I-Pathological_formation
2	1537	1538	O
1	1539	1540	O
1	1541	1542	O
7	1543	1544	O

Other	1545	1550	O
nonmalignant	1551	1563	O
conditions	1564	1574	O
6	1575	1576	O
10	1577	1579	O
4	1580	1581	O
10	1582	1584	O

a	1585	1586	O

The	1587	1590	O
testing	1591	1598	O
and	1599	1602	O
enrollment	1603	1613	O
sites	1614	1619	O
for	1620	1623	O
the	1624	1627	O
study	1628	1633	O
were	1634	1638	O
Duke	1639	1643	O
University	1644	1654	O
School	1655	1661	O
of	1662	1664	O
Medicine	1665	1673	O
,	1673	1674	O
Durham	1675	1681	O
,	1681	1682	O
NC	1683	1685	O
;	1685	1686	O
Albert	1687	1693	O
Einstein	1694	1702	O
College	1703	1710	O
of	1711	1713	O
Medicine	1714	1722	O
and	1723	1726	O
Montefiore	1727	1737	O
Medical	1738	1745	O
Center	1746	1752	O
,	1752	1753	O
Bronx	1754	1759	O
,	1759	1760	O
NY	1761	1763	O
;	1763	1764	O
Centre	1765	1771	O
Hospitalier	1772	1783	O
Universitaire	1784	1797	O
Vaudois	1798	1805	O
and	1806	1809	O
University	1810	1820	O
of	1821	1823	O
Lausanne	1824	1832	O
,	1832	1833	O
Lausanne	1834	1842	O
,	1842	1843	O
Switzerland	1844	1855	O
;	1855	1856	O
and	1857	1860	O
Medizinische	1861	1873	O
Universitat	1874	1885	O
and	1886	1889	O
Landeskrankenhaus	1890	1907	O
Natters	1908	1915	O
,	1915	1916	O
Innsbruck	1917	1926	O
,	1926	1927	O
Austria	1928	1935	O
.	1935	1936	O

b	1937	1938	O

Except	1939	1945	O
where	1946	1951	O
otherwise	1952	1961	O
indicated	1962	1971	O
,	1971	1972	O
values	1973	1979	O
are	1980	1983	O
numbers	1984	1991	O
of	1992	1994	O
patients	1995	2003	O
.	2003	2004	O

c	2005	2006	O

Subjects	2007	2015	O
were	2016	2020	O
excluded	2021	2029	O
from	2030	2034	O
analysis	2035	2043	O
if	2044	2046	O
they	2047	2051	O
withdrew	2052	2060	O
consent	2061	2068	O
or	2069	2071	O
if	2072	2074	O
there	2075	2080	O
was	2081	2084	O
inadequate	2085	2095	O
sample	2096	2102	O
left	2103	2107	O
for	2108	2111	O
PCR	2112	2115	O
testing	2116	2123	O
.	2123	2124	O

Acknowledgments	0	15	O
and	16	19	O
Funding	20	27	O

The	28	31	O
authors	32	39	O
thank	40	45	O
CRB	46	49	O
GADIE	50	55	O
(	56	57	O
Diane	57	62	O
Esquerre	63	71	O
)	71	72	O
for	73	76	O
BAC	77	80	O
clones	81	87	O
handling	88	96	O
and	97	100	O
Brian	101	106	O
Smith	107	112	O
,	112	113	O
Renee	114	119	O
Fincham	120	127	O
and	128	131	O
Kristy	132	138	O
Shewbridge	139	149	O
for	150	153	O
microsatellites	154	169	O
genotyping	170	180	O
.	180	181	O

We	182	184	O
are	185	188	O
grateful	189	197	O
to	198	200	O
Yann	201	205	O
Guiguen	206	213	O
for	214	217	O
help	218	222	O
and	223	226	O
precious	227	235	O
contribution	236	248	O
to	249	251	O
fund	252	256	O
raising	257	264	O
for	265	268	O
this	269	273	O
study	274	279	O
.	279	280	O

This	281	285	O
work	286	290	O
was	291	294	O
made	295	299	O
possible	300	308	O
by	309	311	O
financial	312	321	O
support	322	329	O
of	330	332	O
Genoscope	333	342	O
.	342	343	O

We	344	346	O
acknowledge	347	358	O
Rene	359	363	O
Guyomard	364	372	O
for	373	376	O
his	377	380	O
initial	381	388	O
contribution	389	401	O
in	402	404	O
BAC	405	408	O
library	409	416	O
procurement	417	428	O
.	428	429	O

The	430	433	O
microsatellites	434	449	O
genotyping	450	460	O
was	461	464	O
supported	465	474	O
by	475	477	O
NRI	478	481	O
Grant	482	487	O
No	488	490	O
.	490	491	O
2007	492	496	O
-	496	497	O
35616	497	502	O
-	502	503	O
17875	503	508	O
from	509	513	O
the	514	517	O
USDA	518	522	O
National	523	531	O
Institute	532	541	O
of	542	544	O
Food	545	549	O
and	550	553	O
Agriculture	554	565	O
.	565	566	O

Confocal	0	8	O
and	9	12	O
scanning	13	21	O
microscopic	22	33	O
images	34	40	O
of	41	43	O
mammoth	44	51	O
'	51	52	O
s	52	53	O
and	54	57	O
human	58	63	O
hair	64	68	B-Multi-tissue_structure
.	68	69	O

Taphonomic	70	80	O
changes	81	88	O
,	88	89	O
indicated	90	99	O
by	100	102	O
arrow	103	108	O
-	108	109	O
heads	109	114	O
and	115	118	O
straight	119	127	O
white	128	133	O
arrow	134	139	O
in	140	142	O
the	143	146	O
confocal	147	155	O
image	156	161	O
.	161	162	O

Bacterial	163	172	O
-	172	173	O
fungal	173	179	O
colonies	180	188	O
are	189	192	O
shown	193	198	O
by	199	201	O
broken	202	208	O
arrows	209	215	O
.	215	216	O

Red	217	220	O
arrow	221	226	O
indicates	227	236	O
space	237	242	O
between	243	250	O
cuticle	251	258	O
and	259	262	O
hair	263	267	B-Multi-tissue_structure
shaft	268	273	I-Multi-tissue_structure
due	274	277	O
to	278	280	O
shrinkage	281	290	O
.	290	291	O

Extensive	292	301	O
taphonomic	302	312	O
changes	313	320	O
in	321	323	O
YUK	324	327	O
are	328	331	O
evident	332	339	O
.	339	340	O

Note	341	345	O
the	346	349	O
preservation	350	362	O
of	363	365	O
the	366	369	O
cuticle	370	377	O
in	378	380	O
the	381	384	O
human	385	390	O
hair	391	395	B-Multi-tissue_structure
in	396	398	O
contrast	399	407	O
to	408	410	O
the	411	414	O
craters	415	422	O
in	423	425	O
the	426	429	O
cuticles	430	438	O
of	439	441	O
the	442	445	O
mammoth	446	453	O
'	453	454	O
s	454	455	O
hair	456	460	B-Multi-tissue_structure
.	460	461	O

Bacterial	462	471	O
biofilms	472	480	O
are	481	484	O
a	485	486	O
feature	487	494	O
of	495	497	O
human	498	503	O
hair	504	508	B-Multi-tissue_structure
;	508	509	O
mammoth	510	517	O
'	517	518	O
s	518	519	O
hair	520	524	B-Multi-tissue_structure
was	525	528	O
protected	529	538	O
from	539	543	O
bacterial	544	553	O
invasion	554	562	O
in	563	565	O
permafrost	566	576	O
.	576	577	O

Calculation	0	11	O
of	12	14	O
male	15	19	O
mating	20	26	O
success	27	34	O

In	35	37	O
order	38	43	O
to	44	46	O
compare	47	54	O
whether	55	62	O
males	63	68	O
'	68	69	O
access	70	76	O
to	77	79	O
receptive	80	89	O
females	90	97	O
followed	98	106	O
the	107	110	O
predictions	111	122	O
of	123	125	O
the	126	129	O
PoA	130	133	O
model	134	139	O
,	139	140	O
we	141	143	O
calculated	144	154	O
mating	155	161	O
success	162	169	O
as	170	172	O
follows	173	180	O
.	180	181	O

For	182	185	O
all	186	189	O
the	190	193	O
mating	194	200	O
partners	201	209	O
a	210	211	O
female	212	218	O
had	219	222	O
during	223	229	O
the	230	233	O
receptive	234	243	O
period	244	250	O
of	251	253	O
her	254	257	O
conceptive	258	268	O
cycle	269	274	O
,	274	275	O
mating	276	282	O
success	283	290	O
of	291	293	O
each	294	298	O
mating	299	305	O
partner	306	313	O
was	314	317	O
calculated	318	328	O
as	329	331	O
the	332	335	O
number	336	342	O
of	343	345	O
mating	346	352	O
series	353	359	O
a	360	361	O
male	362	366	O
was	367	370	O
involved	371	379	O
in	380	382	O
divided	383	390	O
by	391	393	O
the	394	397	O
total	398	403	O
number	404	410	O
of	411	413	O
mating	414	420	O
series	421	427	O
the	428	431	O
female	432	438	O
was	439	442	O
involved	443	451	O
in	452	454	O
.	454	455	O

Overall	456	463	O
mating	464	470	O
success	471	478	O
of	479	481	O
each	482	486	O
male	487	491	O
was	492	495	O
calculated	496	506	O
as	507	509	O
the	510	513	O
sum	514	517	O
of	518	520	O
all	521	524	O
mating	525	531	O
successes	532	541	O
calculated	542	552	O
for	553	556	O
this	557	561	O
male	562	566	O
as	567	569	O
described	570	579	O
above	580	585	O
.	585	586	O

Tail	0	4	O
flick	5	10	O
test	11	15	O

CSLE	16	20	O
did	21	24	O
not	25	28	O
show	29	33	O
any	34	37	O
difference	38	48	O
compared	49	57	O
with	58	62	O
control	63	70	O
,	70	71	O
at	72	74	O
all	75	78	O
the	79	82	O
tested	83	89	O
doses	90	95	O
[	96	97	O
Figure	97	103	O
4	104	105	O
]	105	106	O
.	106	107	O

Morphine	108	116	O
showed	117	123	O
a	124	125	O
significant	126	137	O
increase	138	146	O
of	147	149	O
latency	150	157	O
time	158	162	O
at	163	165	O
45	166	168	O
,	168	169	O
60	170	172	O
and	173	176	O
75	177	179	O
min	180	183	O
.	183	184	O

Figure	185	191	O
4	192	193	O

Effect	194	200	O
of	201	203	O
CSLE	204	208	O
(	209	210	O
100	210	213	O
,	213	214	O
200	215	218	O
and	219	222	O
500	223	226	O
mg	227	229	O
/	229	230	O
kg	230	232	O
)	232	233	O
and	234	237	O
morphine	238	246	O
on	247	249	O
the	250	253	O
latency	254	261	O
response	262	270	O
of	271	273	O
mice	274	278	O
in	279	281	O
the	282	285	O
tail	286	290	B-Organism_subdivision
flick	291	296	O
test	297	301	O
.	301	302	O

Values	303	309	O
are	310	313	O
presented	314	323	O
as	324	326	O
the	327	330	O
mean	331	335	O
+	336	337	O
/	337	338	O
-	338	339	O
SEM	340	343	O
(	344	345	O
n	345	346	O
=	347	348	O
5	349	350	O
)	350	351	O
*	352	353	O
P	353	354	O
<	355	356	O
0	357	358	O
.	358	359	O
05	359	361	O
,	361	362	O
significant	363	374	O
increase	375	383	O
from	384	388	O
control	389	396	O

Details	0	7	O
of	8	10	O
treatment	11	20	O
programs	21	29	O
A	30	31	O
and	32	35	O
B	36	37	O
in	38	40	O
respect	41	48	O
to	49	51	O
visits	52	58	O
to	59	61	O
different	62	71	O
health	72	78	O
care	79	83	O
professionals	84	97	O
and	98	101	O
treatment	102	111	O
activities	112	122	O

Genes	0	5	O
associated	6	16	O
with	17	21	O
nonsegmental	22	34	O
vitiligo	35	43	O
.	43	44	O

a	0	1	O
,	1	2	O
b	3	4	O
Radiographs	5	16	O
of	17	19	O
the	20	23	O
left	24	28	O
elbow	29	34	B-Organism_subdivision
and	35	38	O
forearm	39	46	B-Organism_subdivision
5	47	48	O
months	49	55	O
after	56	61	O
the	62	65	O
surgery	66	73	O

Discussion	0	10	O

The	11	14	O
two	15	18	O
most	19	23	O
important	24	33	O
factors	34	41	O
leading	42	49	O
to	50	52	O
the	53	56	O
development	57	68	O
of	69	71	O
hypoxia	72	79	O
are	80	83	O
biological	84	94	O
processes	95	104	O
that	105	109	O
determine	110	119	O
the	120	123	O
amount	124	130	O
of	131	133	O
organic	134	141	O
matter	142	148	O
available	149	158	O
to	159	161	O
be	162	164	O
degraded	165	173	O
and	174	177	O
physical	178	186	O
factors	187	194	O
creating	195	203	O
stratification	204	218	O
.	218	219	O

Stratification	220	234	O
in	235	237	O
most	238	242	O
areas	243	248	O
of	249	251	O
the	252	255	O
coastal	256	263	O
zone	264	268	O
of	269	271	O
the	272	275	O
Baltic	276	282	O
Sea	283	286	O
is	287	289	O
due	290	293	O
to	294	296	O
seasonal	297	305	O
temperature	306	317	O
changes	318	325	O
,	325	326	O
although	327	335	O
stratification	336	350	O
by	351	353	O
occasional	354	364	O
inflowing	365	374	O
saltier	375	382	O
water	383	388	O
does	389	393	O
occur	394	399	O
in	400	402	O
some	403	407	O
estuaries	408	417	O
.	417	418	O
(	418	419	O
14	419	421	O
)	421	422	O
Hypoxia	423	430	O
is	431	433	O
common	434	440	O
in	441	443	O
estuaries	444	453	O
located	454	461	O
in	462	464	O
the	465	468	O
Danish	469	475	O
Straits	476	483	O
due	484	487	O
to	488	490	O
the	491	494	O
large	495	500	O
load	501	505	O
of	506	508	O
nutrients	509	518	O
sustaining	519	529	O
algal	530	535	O
production	536	546	O
and	547	550	O
the	551	554	O
strong	555	561	O
stratification	562	576	O
caused	577	583	O
by	584	586	O
large	587	592	O
differences	593	604	O
in	605	607	O
surface	608	615	O
and	616	619	O
bottom	620	626	O
water	627	632	O
salinity	633	641	O
.	641	642	O
(	642	643	O
5	643	644	O
)	644	645	O
Hypoxia	646	653	O
in	654	656	O
the	657	660	O
Swedish	661	668	O
and	669	672	O
Finnish	673	680	O
archipelagos	681	693	O
are	694	697	O
influenced	698	708	O
by	709	711	O
phytoplankton	712	725	O
growth	726	732	O
stimulated	733	743	O
by	744	746	O
nutrient	747	755	O
loads	756	761	O
from	762	766	O
urban	767	772	O
and	773	776	O
agricultural	777	789	O
sources	790	797	O
,	797	798	O
but	799	802	O
also	803	807	O
by	808	810	O
restricted	811	821	O
water	822	827	O
circulation	828	839	O
.	839	840	O

The	841	844	O
Finnish	845	852	O
Archipelago	853	864	O
Sea	865	868	O
is	869	871	O
impacted	872	880	O
by	881	883	O
drifting	884	892	O
algal	893	898	O
mats	899	903	O
that	904	908	O
consume	909	916	O
oxygen	917	923	O
during	924	930	O
their	931	936	O
decomposition	937	950	O
when	951	955	O
they	956	960	O
sink	961	965	O
to	966	968	O
the	969	972	O
bottom	973	979	O
.	979	980	O
(	980	981	O
15	981	983	O
)	983	984	O
By	985	987	O
contrast	988	996	O
,	996	997	O
hypoxia	998	1005	O
is	1006	1008	O
rare	1009	1013	O
in	1014	1016	O
the	1017	1020	O
northern	1021	1029	O
Baltic	1030	1036	O
Sea	1037	1040	O
estuaries	1041	1050	O
located	1051	1058	O
in	1059	1061	O
the	1062	1065	O
Bothnian	1066	1074	O
Sea	1075	1078	O
coastal	1079	1086	O
zone	1087	1091	O
where	1092	1097	O
nutrient	1098	1106	O
loads	1107	1112	O
are	1113	1116	O
lower	1117	1122	O
.	1122	1123	O

Hypoxia	1124	1131	O
is	1132	1134	O
uncommon	1135	1143	O
along	1144	1149	O
the	1150	1153	O
eastern	1154	1161	O
shore	1162	1167	O
from	1168	1172	O
Estonia	1173	1180	O
to	1181	1183	O
Poland	1184	1190	O
due	1191	1194	O
to	1195	1197	O
enhanced	1198	1206	O
circulation	1207	1218	O
of	1219	1221	O
water	1222	1227	O
in	1228	1230	O
open	1231	1235	O
areas	1236	1241	O
along	1242	1247	O
the	1248	1251	O
coastline	1252	1261	O
(	1262	1263	O
Figure	1263	1269	O
1	1270	1271	O
)	1271	1272	O
.	1272	1273	O

There	1274	1279	O
are	1280	1283	O
very	1284	1288	O
limited	1289	1296	O
data	1297	1301	O
available	1302	1311	O
to	1312	1314	O
examine	1315	1322	O
how	1323	1326	O
far	1327	1330	O
back	1331	1335	O
in	1336	1338	O
time	1339	1343	O
hypoxia	1344	1351	O
has	1352	1355	O
occurred	1356	1364	O
.	1364	1365	O

A	1366	1367	O
key	1368	1371	O
question	1372	1380	O
in	1381	1383	O
this	1384	1388	O
ecosystem	1389	1398	O
affected	1399	1407	O
daily	1408	1413	O
by	1414	1416	O
over	1417	1421	O
85	1422	1424	O
million	1425	1432	O
people	1433	1439	O
could	1440	1445	O
be	1446	1448	O
"	1449	1450	O
Is	1450	1452	O
hypoxia	1453	1460	O
a	1461	1462	O
natural	1463	1470	O
phenomenon	1471	1481	O
?	1481	1482	O
"	1482	1483	O
.	1483	1484	O
(	1484	1485	O
16	1485	1487	O
)	1487	1488	O
The	1489	1492	O
large	1493	1498	O
numbers	1499	1506	O
of	1507	1509	O
enclosed	1510	1518	O
areas	1519	1524	O
,	1524	1525	O
in	1526	1528	O
many	1529	1533	O
cases	1534	1539	O
with	1540	1544	O
shallow	1545	1552	O
sills	1553	1558	O
that	1559	1563	O
restrict	1564	1572	O
the	1573	1576	O
exchange	1577	1585	O
of	1586	1588	O
bottom	1589	1595	O
water	1596	1601	O
and	1602	1605	O
often	1606	1611	O
in	1612	1614	O
combination	1615	1626	O
with	1627	1631	O
large	1632	1637	O
irregular	1638	1647	O
changes	1648	1655	O
in	1656	1658	O
salinity	1659	1667	O
,	1667	1668	O
might	1669	1674	O
mean	1675	1679	O
that	1680	1684	O
hypoxia	1685	1692	O
has	1693	1696	O
always	1697	1703	O
been	1704	1708	O
present	1709	1716	O
in	1717	1719	O
the	1720	1723	O
coastal	1724	1731	O
zone	1732	1736	O
.	1736	1737	O

However	1738	1745	O
,	1745	1746	O
sediment	1747	1755	O
laminations	1756	1767	O
from	1768	1772	O
Stockholm	1773	1782	O
Archipelago	1783	1794	O
,	1794	1795	O
an	1796	1798	O
indicator	1799	1808	O
of	1809	1811	O
past	1812	1816	O
hypoxia	1817	1824	O
,	1824	1825	O
(	1825	1826	O
17	1826	1828	O
)	1828	1829	O
have	1830	1834	O
been	1835	1839	O
shown	1840	1845	O
to	1846	1848	O
be	1849	1851	O
a	1852	1853	O
recent	1854	1860	O
phenomenon	1861	1871	O
with	1872	1876	O
very	1877	1881	O
few	1882	1885	O
areas	1886	1891	O
with	1892	1896	O
laminated	1897	1906	O
sediments	1907	1916	O
prior	1917	1922	O
to	1923	1925	O
1900	1926	1930	O
.	1930	1931	O
17	1931	1933	O
,	1933	1934	O
18	1934	1936	O
The	1937	1940	O
long	1941	1945	O
-	1945	1946	O
term	1946	1950	O
millennial	1951	1961	O
trends	1962	1968	O
in	1969	1971	O
coastal	1972	1979	O
hypoxia	1980	1987	O
remain	1988	1994	O
unknown	1995	2002	O
,	2002	2003	O
although	2004	2012	O
hypoxia	2013	2020	O
has	2021	2024	O
occurred	2025	2033	O
intermittently	2034	2048	O
throughout	2049	2059	O
the	2060	2063	O
last	2064	2068	O
8000	2069	2073	O
years	2074	2079	O
in	2080	2082	O
offshore	2083	2091	O
deep	2092	2096	O
waters	2097	2103	O
of	2104	2106	O
the	2107	2110	O
Baltic	2111	2117	O
Sea	2118	2121	O
.	2121	2122	O
(	2122	2123	O
10	2123	2125	O
)	2125	2126	O
Further	2127	2134	O
sediment	2135	2143	O
studies	2144	2151	O
are	2152	2155	O
necessary	2156	2165	O
,	2165	2166	O
similar	2167	2174	O
to	2175	2177	O
those	2178	2183	O
carried	2184	2191	O
out	2192	2195	O
in	2196	2198	O
the	2199	2202	O
open	2203	2207	O
Baltic	2208	2214	O
Sea	2215	2218	O
,	2218	2219	O
(	2219	2220	O
10	2220	2222	O
)	2222	2223	O
to	2224	2226	O
ascertain	2227	2236	O
how	2237	2240	O
far	2241	2244	O
back	2245	2249	O
in	2250	2252	O
time	2253	2257	O
hypoxia	2258	2265	O
was	2266	2269	O
observed	2270	2278	O
in	2279	2281	O
the	2282	2285	O
coastal	2286	2293	O
zone	2294	2298	O
.	2298	2299	O

Key	2300	2303	O
uncertainties	2304	2317	O
remain	2318	2324	O
including	2325	2334	O
how	2335	2338	O
have	2339	2343	O
the	2344	2347	O
driving	2348	2355	O
forces	2356	2362	O
for	2363	2366	O
hypoxia	2367	2374	O
,	2374	2375	O
e	2376	2377	O
.	2377	2378	O
g	2378	2379	O
.	2379	2380	O
,	2380	2381	O
climate	2382	2389	O
(	2389	2390	O
19	2390	2392	O
)	2392	2393	O
and	2394	2397	O
nutrient	2398	2406	O
loading	2407	2414	O
,	2414	2415	O
changed	2416	2423	O
through	2424	2431	O
time	2432	2436	O
in	2437	2439	O
the	2440	2443	O
Baltic	2444	2450	O
Sea	2451	2454	O
coastal	2455	2462	O
zone	2463	2467	O
,	2467	2468	O
and	2469	2472	O
do	2473	2475	O
they	2476	2480	O
vary	2481	2485	O
during	2486	2492	O
the	2493	2496	O
same	2497	2501	O
time	2502	2506	O
periods	2507	2514	O
that	2515	2519	O
hypoxia	2520	2527	O
varies	2528	2534	O
in	2535	2537	O
the	2538	2541	O
open	2542	2546	O
waters	2547	2553	O
?	2553	2554	O
(	2554	2555	O
16	2555	2557	O
)	2557	2558	O

An	2559	2561	O
important	2562	2571	O
consideration	2572	2585	O
in	2586	2588	O
determining	2589	2600	O
the	2601	2604	O
number	2605	2611	O
of	2612	2614	O
ecosystems	2615	2625	O
experiencing	2626	2638	O
hypoxia	2639	2646	O
is	2647	2649	O
the	2650	2653	O
size	2654	2658	O
of	2659	2661	O
the	2662	2665	O
assessment	2666	2676	O
unit	2677	2681	O
.	2681	2682	O

We	2683	2685	O
combined	2686	2694	O
numerous	2695	2703	O
monitoring	2704	2714	O
points	2715	2721	O
and	2722	2725	O
sites	2726	2731	O
to	2732	2734	O
form	2735	2739	O
a	2740	2741	O
coherent	2742	2750	O
coastal	2751	2758	O
unit	2759	2763	O
when	2764	2768	O
bottom	2769	2775	O
waters	2776	2782	O
were	2783	2787	O
physically	2788	2798	O
connected	2799	2808	O
to	2809	2811	O
each	2812	2816	O
other	2817	2822	O
.	2822	2823	O

This	2824	2828	O
means	2829	2834	O
that	2835	2839	O
assessment	2840	2850	O
units	2851	2856	O
considered	2857	2867	O
hypoxic	2868	2875	O
might	2876	2881	O
occur	2882	2887	O
in	2888	2890	O
the	2891	2894	O
same	2895	2899	O
geographical	2900	2912	O
region	2913	2919	O
and	2920	2923	O
could	2924	2929	O
be	2930	2932	O
in	2933	2935	O
close	2936	2941	O
proximately	2942	2953	O
to	2954	2956	O
each	2957	2961	O
other	2962	2967	O
,	2967	2968	O
if	2969	2971	O
their	2972	2977	O
bottom	2978	2984	O
waters	2985	2991	O
were	2992	2996	O
physically	2997	3007	O
disconnected	3008	3020	O
.	3020	3021	O

The	3022	3025	O
Baltic	3026	3032	O
Sea	3033	3036	O
archipelagos	3037	3049	O
have	3050	3054	O
a	3055	3056	O
complex	3057	3064	O
topography	3065	3075	O
with	3076	3080	O
many	3081	3085	O
basins	3086	3092	O
disjoined	3093	3102	O
by	3103	3105	O
shallow	3106	3113	O
sills	3114	3119	O
resulting	3120	3129	O
in	3130	3132	O
many	3133	3137	O
distinct	3138	3146	O
sites	3147	3152	O
,	3152	3153	O
although	3154	3162	O
they	3163	3167	O
are	3168	3171	O
all	3172	3175	O
affected	3176	3184	O
by	3185	3187	O
similar	3188	3195	O
mechanisms	3196	3206	O
.	3206	3207	O

In	3208	3210	O
fact	3211	3215	O
,	3215	3216	O
the	3217	3220	O
Stockholm	3221	3230	O
and	3231	3234	O
Finnish	3235	3242	O
archipelagos	3243	3255	O
contributed	3256	3267	O
21	3268	3270	O
%	3270	3271	O
of	3272	3274	O
the	3275	3278	O
total	3279	3284	O
assessment	3285	3295	O
units	3296	3301	O
,	3301	3302	O
a	3303	3304	O
relatively	3305	3315	O
large	3316	3321	O
share	3322	3327	O
compared	3328	3336	O
to	3337	3339	O
the	3340	3343	O
total	3344	3349	O
Baltic	3350	3356	O
Sea	3357	3360	O
coastal	3361	3368	O
zone	3369	3373	O
,	3373	3374	O
but	3375	3378	O
>	3379	3380	O
40	3380	3382	O
%	3382	3383	O
of	3384	3386	O
the	3387	3390	O
hypoxic	3391	3398	O
sites	3399	3404	O
.	3404	3405	O

The	3406	3409	O
coastal	3410	3417	O
stretches	3418	3427	O
of	3428	3430	O
the	3431	3434	O
Western	3435	3442	O
Gotland	3443	3450	O
Basin	3451	3456	O
and	3457	3460	O
Gulf	3461	3465	O
of	3466	3468	O
Finland	3469	3476	O
that	3477	3481	O
have	3482	3486	O
a	3487	3488	O
substantial	3489	3500	O
number	3501	3507	O
of	3508	3510	O
hypoxic	3511	3518	O
sites	3519	3524	O
are	3525	3528	O
also	3529	3533	O
archipelagos	3534	3546	O
,	3546	3547	O
which	3548	3553	O
are	3554	3557	O
more	3558	3562	O
prone	3563	3568	O
to	3569	3571	O
hypoxia	3572	3579	O
because	3580	3587	O
of	3588	3590	O
the	3591	3594	O
complex	3595	3602	O
topography	3603	3613	O
,	3613	3614	O
proximity	3615	3624	O
to	3625	3627	O
development	3628	3639	O
,	3639	3640	O
and	3641	3644	O
consequently	3645	3657	O
more	3658	3662	O
sensitive	3663	3672	O
to	3673	3675	O
enhanced	3676	3684	O
nutrient	3685	3693	O
inputs	3694	3700	O
from	3701	3705	O
land	3706	3710	O
.	3710	3711	O

Surprisingly	3712	3724	O
only	3725	3729	O
4	3730	3731	O
.	3731	3732	O
0	3732	3733	O
%	3733	3734	O
of	3735	3737	O
all	3738	3741	O
sites	3742	3747	O
were	3748	3752	O
classified	3753	3763	O
as	3764	3766	O
seasonally	3767	3777	O
hypoxic	3778	3785	O
according	3786	3795	O
to	3796	3798	O
our	3799	3802	O
definition	3803	3813	O
when	3814	3818	O
>	3819	3820	O
50	3820	3822	O
%	3822	3823	O
and	3824	3827	O
<	3828	3829	O
80	3829	3831	O
%	3831	3832	O
of	3833	3835	O
profiles	3836	3844	O
during	3845	3851	O
the	3852	3855	O
stratified	3856	3866	O
period	3867	3873	O
have	3874	3878	O
oxygen	3879	3885	O
concentrations	3886	3900	O
less	3901	3905	O
than	3906	3910	O
2	3911	3912	O
mg	3913	3915	O
L	3916	3917	O
-	3917	3918	O
1	3918	3919	O
.	3919	3920	O

A	3921	3922	O
statistically	3923	3936	O
rigorous	3937	3945	O
definition	3946	3956	O
of	3957	3959	O
what	3960	3964	O
constitutes	3965	3976	O
seasonal	3977	3985	O
hypoxia	3986	3993	O
does	3994	3998	O
not	3999	4002	O
currently	4003	4012	O
exist	4013	4018	O
and	4019	4022	O
in	4023	4025	O
fact	4026	4030	O
should	4031	4037	O
be	4038	4040	O
linked	4041	4047	O
to	4048	4050	O
ecological	4051	4061	O
consequences	4062	4074	O
for	4075	4078	O
it	4079	4081	O
to	4082	4084	O
be	4085	4087	O
ecologically	4088	4100	O
relevant	4101	4109	O
and	4110	4113	O
not	4114	4117	O
just	4118	4122	O
connected	4123	4132	O
to	4133	4135	O
absolute	4136	4144	O
concentrations	4145	4159	O
.	4159	4160	O
(	4160	4161	O
3	4161	4162	O
)	4162	4163	O
Currently	4164	4173	O
coastal	4174	4181	O
marine	4182	4188	O
ecosystems	4189	4199	O
that	4200	4204	O
experience	4205	4215	O
hypoxia	4216	4223	O
for	4224	4227	O
a	4228	4229	O
period	4230	4236	O
of	4237	4239	O
days	4240	4244	O
to	4245	4247	O
months	4248	4254	O
every	4255	4260	O
year	4261	4265	O
are	4266	4269	O
often	4270	4275	O
considered	4276	4286	O
to	4287	4289	O
be	4290	4292	O
seasonally	4293	4303	O
hypoxic	4304	4311	O
,	4311	4312	O
although	4313	4321	O
we	4322	4324	O
have	4325	4329	O
categorized	4330	4341	O
them	4342	4346	O
here	4347	4351	O
as	4352	4354	O
being	4355	4360	O
episodic	4361	4369	O
,	4369	4370	O
because	4371	4378	O
we	4379	4381	O
required	4382	4390	O
the	4391	4394	O
monitoring	4395	4405	O
units	4406	4411	O
to	4412	4414	O
be	4415	4417	O
hypoxic	4418	4425	O
for	4426	4429	O
most	4430	4434	O
of	4435	4437	O
the	4438	4441	O
stratified	4442	4452	O
period	4453	4459	O
.	4459	4460	O

However	4461	4468	O
,	4468	4469	O
in	4470	4472	O
Limfjorden	4473	4483	O
,	4483	4484	O
Denmark	4485	4492	O
,	4492	4493	O
bottom	4494	4500	O
water	4501	4506	O
oxygen	4507	4513	O
concentrations	4514	4528	O
can	4529	4532	O
vary	4533	4537	O
greatly	4538	4545	O
between	4546	4553	O
weekly	4554	4560	O
samplings	4561	4570	O
(	4571	4572	O
SI	4572	4574	O
Figure	4575	4581	O
S6	4582	4584	O
)	4584	4585	O
,	4585	4586	O
although	4587	4595	O
nearly	4596	4602	O
every	4603	4608	O
year	4609	4613	O
hypoxic	4614	4621	O
conditions	4622	4632	O
are	4633	4636	O
observed	4637	4645	O
somewhere	4646	4655	O
in	4656	4658	O
the	4659	4662	O
Limfjorden	4663	4673	O
.	4673	4674	O

Our	4675	4678	O
statistical	4679	4690	O
estimation	4691	4701	O
is	4702	4704	O
that	4705	4709	O
Limfjorden	4710	4720	O
is	4721	4723	O
episodically	4724	4736	O
hypoxic	4737	4744	O
.	4744	4745	O

Diaz	4746	4750	O
and	4751	4754	O
Rosenberg	4755	4764	O
(	4764	4765	O
1	4765	4766	O
)	4766	4767	O
would	4768	4773	O
classify	4774	4782	O
Limfjorden	4783	4793	O
as	4794	4796	O
periodically	4797	4809	O
hypoxic	4810	4817	O
,	4817	4818	O
although	4819	4827	O
we	4828	4830	O
have	4831	4835	O
found	4836	4841	O
it	4842	4844	O
difficult	4845	4854	O
to	4855	4857	O
create	4858	4864	O
a	4865	4866	O
statistically	4867	4880	O
robust	4881	4887	O
indicator	4888	4897	O
that	4898	4902	O
would	4903	4908	O
classify	4909	4917	O
systems	4918	4925	O
as	4926	4928	O
periodically	4929	4941	O
hypoxic	4942	4949	O
.	4949	4950	O

Periodic	4951	4959	O
hypoxia	4960	4967	O
is	4968	4970	O
problematic	4971	4982	O
because	4983	4990	O
it	4991	4993	O
never	4994	4999	O
allows	5000	5006	O
for	5007	5010	O
re	5011	5013	O
-	5013	5014	O
establishment	5014	5027	O
of	5028	5030	O
benthic	5031	5038	O
communities	5039	5050	O
.	5050	5051	O
(	5051	5052	O
20	5052	5054	O
)	5054	5055	O

Currently	5056	5065	O
,	5065	5066	O
there	5067	5072	O
are	5073	5076	O
416	5077	5080	O
areas	5081	5086	O
in	5087	5089	O
the	5090	5093	O
world	5094	5099	O
with	5100	5104	O
reported	5105	5113	O
coastal	5114	5121	O
hypoxia	5122	5129	O
with	5130	5134	O
about	5135	5140	O
30	5141	5143	O
previously	5144	5154	O
reported	5155	5163	O
sites	5164	5169	O
in	5170	5172	O
the	5173	5176	O
Baltic	5177	5183	O
Sea	5184	5187	O
region	5188	5194	O
,	5194	5195	O
which	5196	5201	O
includes	5202	5210	O
both	5211	5215	O
coastal	5216	5223	O
zone	5224	5228	O
hypoxia	5229	5236	O
and	5237	5240	O
deep	5241	5245	O
water	5246	5251	O
sites	5252	5257	O
in	5258	5260	O
the	5261	5264	O
Baltic	5265	5271	O
Sea	5272	5275	O
.	5275	5276	O
(	5276	5277	O
1	5277	5278	O
)	5278	5279	O
We	5280	5282	O
have	5283	5287	O
identified	5288	5298	O
an	5299	5301	O
additional	5302	5312	O
96	5313	5315	O
sites	5316	5321	O
that	5322	5326	O
have	5327	5331	O
experienced	5332	5343	O
hypoxia	5344	5351	O
,	5351	5352	O
increasing	5353	5363	O
the	5364	5367	O
global	5368	5374	O
total	5375	5380	O
to	5381	5383	O
nearly	5384	5390	O
500	5391	5394	O
sites	5395	5400	O
.	5400	5401	O

Of	5402	5404	O
all	5405	5408	O
the	5409	5412	O
known	5413	5418	O
sites	5419	5424	O
around	5425	5431	O
the	5432	5435	O
world	5436	5441	O
,	5441	5442	O
around	5443	5449	O
20	5450	5452	O
%	5452	5453	O
of	5454	5456	O
the	5457	5460	O
sites	5461	5466	O
are	5467	5470	O
found	5471	5476	O
in	5477	5479	O
the	5480	5483	O
Baltic	5484	5490	O
Sea	5491	5494	O
region	5495	5501	O
.	5501	5502	O

Most	5503	5507	O
sites	5508	5513	O
experienced	5514	5525	O
episodic	5526	5534	O
hypoxia	5535	5542	O
,	5542	5543	O
which	5544	5549	O
is	5550	5552	O
a	5553	5554	O
precursor	5555	5564	O
to	5565	5567	O
development	5568	5579	O
of	5580	5582	O
seasonal	5583	5591	O
hypoxia	5592	5599	O
.	5599	5600	O
(	5600	5601	O
20	5601	5603	O
)	5603	5604	O
The	5605	5608	O
large	5609	5614	O
number	5615	5621	O
of	5622	5624	O
sites	5625	5630	O
partially	5631	5640	O
reflects	5641	5649	O
the	5650	5653	O
fact	5654	5658	O
that	5659	5663	O
the	5664	5667	O
Baltic	5668	5674	O
Sea	5675	5678	O
is	5679	5681	O
one	5682	5685	O
of	5686	5688	O
the	5689	5692	O
most	5693	5697	O
data	5698	5702	O
rich	5703	5707	O
regions	5708	5715	O
of	5716	5718	O
the	5719	5722	O
world	5723	5728	O
with	5729	5733	O
no	5734	5736	O
tidal	5737	5742	O
mixing	5743	5749	O
and	5750	5753	O
complex	5754	5761	O
bottom	5762	5768	O
topography	5769	5779	O
creating	5780	5788	O
conditions	5789	5799	O
favorable	5800	5809	O
for	5810	5813	O
hypoxia	5814	5821	O
,	5821	5822	O
although	5823	5831	O
these	5832	5837	O
are	5838	5841	O
only	5842	5846	O
the	5847	5850	O
"	5851	5852	O
monitored	5852	5861	O
areas	5862	5867	O
"	5867	5868	O
and	5869	5872	O
many	5873	5877	O
more	5878	5882	O
hypoxic	5883	5890	O
sites	5891	5896	O
probably	5897	5905	O
exist	5906	5911	O
in	5912	5914	O
the	5915	5918	O
Baltic	5919	5925	O
Sea	5926	5929	O
coastal	5930	5937	O
zone	5938	5942	O
.	5942	5943	O

In	5944	5946	O
contrast	5947	5955	O
,	5955	5956	O
there	5957	5962	O
was	5963	5966	O
no	5967	5969	O
evidence	5970	5978	O
of	5979	5981	O
hypoxia	5982	5989	O
at	5990	5992	O
95	5993	5995	O
stations	5996	6004	O
in	6005	6007	O
estuarine	6008	6017	O
and	6018	6021	O
coastal	6022	6029	O
waters	6030	6036	O
around	6037	6043	O
Ireland	6044	6051	O
due	6052	6055	O
to	6056	6058	O
sufficient	6059	6069	O
tidal	6070	6075	O
mixing	6076	6082	O
.	6082	6083	O
(	6083	6084	O
21	6084	6086	O
)	6086	6087	O
If	6088	6090	O
such	6091	6095	O
detailed	6096	6104	O
data	6105	6109	O
existed	6110	6117	O
for	6118	6121	O
other	6122	6127	O
coastal	6128	6135	O
regions	6136	6143	O
around	6144	6150	O
the	6151	6154	O
world	6155	6160	O
,	6160	6161	O
it	6162	6164	O
is	6165	6167	O
likely	6168	6174	O
that	6175	6179	O
the	6180	6183	O
number	6184	6190	O
of	6191	6193	O
areas	6194	6199	O
would	6200	6205	O
increase	6206	6214	O
globally	6215	6223	O
.	6223	6224	O

Oxygen	6225	6231	O
is	6232	6234	O
an	6235	6237	O
important	6238	6247	O
parameter	6248	6257	O
in	6258	6260	O
water	6261	6266	O
quality	6267	6274	O
assessments	6275	6286	O
since	6287	6292	O
sufficient	6293	6303	O
oxygen	6304	6310	O
is	6311	6313	O
essential	6314	6323	O
to	6324	6326	O
aquatic	6327	6334	O
life	6335	6339	O
and	6340	6343	O
is	6344	6346	O
necessary	6347	6356	O
to	6357	6359	O
support	6360	6367	O
healthy	6368	6375	O
biological	6376	6386	O
communities	6387	6398	O
.	6398	6399	O
(	6399	6400	O
3	6400	6401	O
)	6401	6402	O
For	6403	6406	O
example	6407	6414	O
,	6414	6415	O
oxygen	6416	6422	O
concentration	6423	6436	O
is	6437	6439	O
a	6440	6441	O
supporting	6442	6452	O
element	6453	6460	O
to	6461	6463	O
the	6464	6467	O
biological	6468	6478	O
quality	6479	6486	O
elements	6487	6495	O
in	6496	6498	O
the	6499	6502	O
European	6503	6511	O
Water	6512	6517	O
Framework	6518	6527	O
Directive	6528	6537	O
,	6537	6538	O
(	6538	6539	O
21	6539	6541	O
)	6541	6542	O
is	6543	6545	O
one	6546	6549	O
of	6550	6552	O
the	6553	6556	O
ecological	6557	6567	O
objectives	6568	6578	O
in	6579	6581	O
the	6582	6585	O
Helsinki	6586	6594	O
Commission	6595	6605	O
'	6605	6606	O
s	6606	6607	O
(	6608	6609	O
HELCOM	6609	6615	O
)	6615	6616	O
eutrophication	6617	6631	O
assessment	6632	6642	O
of	6643	6645	O
the	6646	6649	O
Baltic	6650	6656	O
Sea	6657	6660	O
,	6660	6661	O
and	6662	6665	O
is	6666	6668	O
included	6669	6677	O
in	6678	6680	O
the	6681	6684	O
European	6685	6693	O
Marine	6694	6700	O
Strategy	6701	6709	O
Framework	6710	6719	O
Directive	6720	6729	O
as	6730	6732	O
an	6733	6735	O
effect	6736	6742	O
parameter	6743	6752	O
of	6753	6755	O
eutrophication	6756	6770	O
.	6770	6771	O

Accurate	6772	6780	O
data	6781	6785	O
for	6786	6789	O
the	6790	6793	O
concentration	6794	6807	O
of	6808	6810	O
dissolved	6811	6820	O
oxygen	6821	6827	O
are	6828	6831	O
essential	6832	6841	O
for	6842	6845	O
documenting	6846	6857	O
environmental	6858	6871	O
changes	6872	6879	O
in	6880	6882	O
water	6883	6888	O
resources	6889	6898	O
resulting	6899	6908	O
from	6909	6913	O
natural	6914	6921	O
phenomena	6922	6931	O
and	6932	6935	O
human	6936	6941	O
activities	6942	6952	O
.	6952	6953	O

Reports	6954	6961	O
of	6962	6964	O
hypoxia	6965	6972	O
globally	6973	6981	O
are	6982	6985	O
increasing1	6986	6997	O
,	6997	6998	O
22	6998	7000	O
both	7001	7005	O
due	7006	7009	O
to	7010	7012	O
the	7013	7016	O
recognition	7017	7028	O
of	7029	7031	O
the	7032	7035	O
seriousness	7036	7047	O
of	7048	7050	O
hypoxia	7051	7058	O
on	7059	7061	O
ecosystem	7062	7071	O
functioning	7072	7083	O
and	7084	7087	O
as	7088	7090	O
decades	7091	7098	O
-	7098	7099	O
long	7099	7103	O
monitoring	7104	7114	O
records	7115	7122	O
become	7123	7129	O
available	7130	7139	O
in	7140	7142	O
databases	7143	7152	O
.	7152	7153	O

How	7154	7157	O
the	7158	7161	O
large	7162	7167	O
number	7168	7174	O
of	7175	7177	O
newly	7178	7183	O
identified	7184	7194	O
hypoxic	7195	7202	O
areas	7203	7208	O
influences	7209	7219	O
nutrient	7220	7228	O
biogeochemical	7229	7243	O
cycles	7244	7250	O
and	7251	7254	O
ecosystem	7255	7264	O
services	7265	7273	O
in	7274	7276	O
the	7277	7280	O
coastal	7281	7288	O
zone	7289	7293	O
in	7294	7296	O
the	7297	7300	O
Baltic	7301	7307	O
Sea	7308	7311	O
is	7312	7314	O
currently	7315	7324	O
unknown	7325	7332	O
,	7332	7333	O
although	7334	7342	O
the	7343	7346	O
functioning	7347	7358	O
of	7359	7361	O
the	7362	7365	O
coastal	7366	7373	O
filter	7374	7380	O
certainly	7381	7390	O
plays	7391	7396	O
an	7397	7399	O
important	7400	7409	O
role	7410	7414	O
in	7415	7417	O
how	7418	7421	O
adjacent	7422	7430	O
marine	7431	7437	O
systems	7438	7445	O
respond	7446	7453	O
to	7454	7456	O
changes	7457	7464	O
in	7465	7467	O
nutrient	7468	7476	O
loading	7477	7484	O
.	7484	7485	O

Presently	7486	7495	O
about	7496	7501	O
40	7502	7504	O
%	7504	7505	O
of	7506	7508	O
the	7509	7512	O
world	7513	7518	O
'	7518	7519	O
s	7519	7520	O
population	7521	7531	O
lives	7532	7537	O
within	7538	7544	O
100	7545	7548	O
km	7549	7551	O
of	7552	7554	O
the	7555	7558	O
coastal	7559	7566	O
zone	7567	7571	O
strongly	7572	7580	O
impacting	7581	7590	O
ocean	7591	7596	O
health	7597	7603	O
,	7603	7604	O
(	7604	7605	O
24	7605	7607	O
)	7607	7608	O
including	7609	7618	O
increasing	7619	7629	O
the	7630	7633	O
occurrence	7634	7644	O
of	7645	7647	O
hypoxic	7648	7655	O
areas	7656	7661	O
.	7661	7662	O
1	7662	7663	O
,	7663	7664	O
2	7664	7665	O
What	7666	7670	O
is	7671	7673	O
currently	7674	7683	O
lacking	7684	7691	O
is	7692	7694	O
the	7695	7698	O
link	7699	7703	O
to	7704	7706	O
the	7707	7710	O
driving	7711	7718	O
factors	7719	7726	O
of	7727	7729	O
hypoxia	7730	7737	O
including	7738	7747	O
nutrient	7748	7756	O
enrichment	7757	7767	O
,	7767	7768	O
organic	7769	7776	O
carbon	7777	7783	O
loading	7784	7791	O
and	7792	7795	O
climate	7796	7803	O
change	7804	7810	O
,	7810	7811	O
(	7811	7812	O
25	7812	7814	O
)	7814	7815	O
and	7816	7819	O
a	7820	7821	O
determination	7822	7835	O
of	7836	7838	O
appropriate	7839	7850	O
nutrient	7851	7859	O
loading	7860	7867	O
targets	7868	7875	O
for	7876	7879	O
guidance	7880	7888	O
to	7889	7891	O
managers	7892	7900	O
to	7901	7903	O
ameliorate	7904	7914	O
the	7915	7918	O
devastating	7919	7930	O
impact	7931	7937	O
of	7938	7940	O
hypoxia	7941	7948	O
.	7948	7949	O
(	7949	7950	O
24	7950	7952	O
)	7952	7953	O

Pharmacokinetic	0	15	O
-	15	16	O
pharmacodynamic	16	31	O
analysis	32	40	O
.	40	41	O

The	42	45	O
mean	46	50	O
(	51	52	O
90	52	54	O
%	54	55	O
CI	56	58	O
)	58	59	O
slope	60	65	O
estimate	66	74	O
from	75	79	O
the	80	83	O
linezolid	84	93	O
concentration	94	107	O
-	107	108	O
R	108	109	O
-	109	110	O
R	110	111	O
interval	112	120	O
analysis	121	129	O
was	130	133	O
-	134	135	O
0	135	136	O
.	136	137	O
0017	137	141	O
(	142	143	O
-	143	144	O
0	144	145	O
.	145	146	O
0022	146	150	O
to	151	153	O
-	154	155	O
0	155	156	O
.	156	157	O
0011	157	161	O
)	161	162	O
ms	163	165	O
/	165	166	O
ng	166	168	O
/	168	169	O
ml	169	171	O
.	171	172	O

This	173	177	O
translates	178	188	O
to	189	191	O
mean	192	196	O
(	197	198	O
90	198	200	O
%	200	201	O
CI	202	204	O
)	204	205	O
predicted	206	215	O
decreases	216	225	O
in	226	228	O
heart	229	234	B-Organ
rate	235	239	O
of	240	242	O
approximately	243	256	O
1	257	258	O
.	258	259	O
5	259	260	O
(	261	262	O
1	262	263	O
.	263	264	O
0	264	265	O
to	266	268	O
2	269	270	O
.	270	271	O
0	271	272	O
)	272	273	O
and	274	277	O
3	278	279	O
.	279	280	O
0	280	281	O
(	282	283	O
2	283	284	O
.	284	285	O
1	285	286	O
to	287	289	O
4	290	291	O
.	291	292	O
1	292	293	O
)	293	294	O
beats	295	300	O
/	300	301	O
min	301	304	O
at	305	307	O
the	308	311	O
mean	312	316	O
Cmax	317	321	O
following	322	331	O
the	332	335	O
administration	336	350	O
of	351	353	O
600	354	357	O
-	357	358	O
and	359	362	O
1	363	364	O
,	364	365	O
200	365	368	O
-	368	369	O
mg	369	371	O
linezolid	372	381	O
doses	382	387	O
,	387	388	O
respectively	389	401	O
.	401	402	O

The	403	406	O
study	407	412	O
-	412	413	O
specific	413	421	O
mean	422	426	O
correction	427	437	O
factor	438	444	O
estimated	445	454	O
from	455	459	O
baseline	460	468	O
data	469	473	O
was	474	477	O
0	478	479	O
.	479	480	O
278	480	483	O
,	483	484	O
which	485	490	O
is	491	493	O
slightly	494	502	O
less	503	507	O
than	508	512	O
Fridericia	513	523	O
'	523	524	O
s	524	525	O
correction	526	536	O
(	537	538	O
0	538	539	O
.	539	540	O
333	540	543	O
)	543	544	O
.	544	545	O

Evaluation	546	556	O
of	557	559	O
the	560	563	O
various	564	571	O
correction	572	582	O
factors	583	590	O
showed	591	597	O
that	598	602	O
QTcF	603	607	O
most	608	612	O
appropriately	613	626	O
resolves	627	635	O
the	636	639	O
relationship	640	652	O
between	653	660	O
the	661	664	O
QT	665	667	O
interval	668	676	O
and	677	680	O
the	681	684	O
heart	685	690	B-Organ
rate	691	695	O
in	696	698	O
the	699	702	O
baseline	703	711	O
data	712	716	O
from	717	721	O
the	722	725	O
present	726	733	O
study	734	739	O
.	739	740	O

This	741	745	O
is	746	748	O
evident	749	756	O
upon	757	761	O
inspection	762	772	O
of	773	775	O
Fig	776	779	O
.	779	780	O

4	781	782	O
,	782	783	O
since	784	789	O
the	790	793	O
slope	794	799	O
between	800	807	O
the	808	811	O
QTcF	812	816	O
interval	817	825	O
and	826	829	O
the	830	833	O
R	834	835	O
-	835	836	O
R	836	837	O
interval	838	846	O
is	847	849	O
closest	850	857	O
to	858	860	O
zero	861	865	O
when	866	870	O
this	871	875	O
correction	876	886	O
is	887	889	O
applied	890	897	O
.	897	898	O

Fig	899	902	O
.	902	903	O

4	904	905	O
.	905	906	O

Evaluation	907	917	O
of	918	920	O
various	921	928	O
heart	929	934	B-Organ
rate	935	939	O
correction	940	950	O
factors	951	958	O
for	959	962	O
the	963	966	O
QT	967	969	O
interval	970	978	O
versus	979	985	O
the	986	989	O
R	990	991	O
-	991	992	O
R	992	993	O
interval	994	1002	O
.	1002	1003	O

The	1004	1007	O
predicted	1008	1017	O
line	1018	1022	O
in	1023	1025	O
each	1026	1030	O
figure	1031	1037	O
represents	1038	1048	O
the	1049	1052	O
fit	1053	1056	O
from	1057	1061	O
a	1062	1063	O
linear	1064	1070	O
mixed	1071	1076	O
-	1076	1077	O
effect	1077	1083	O
model	1084	1089	O
with	1090	1094	O
R	1095	1096	O
-	1096	1097	O
R	1097	1098	O
interval	1099	1107	O
as	1108	1110	O
a	1111	1112	O
fixed	1113	1118	O
effect	1119	1125	O
and	1126	1129	O
subject	1130	1137	O
-	1137	1138	O
specific	1138	1146	O
random	1147	1153	O
effects	1154	1161	O
for	1162	1165	O
intercept	1166	1175	O
and	1176	1179	O
slope	1180	1185	O
.	1185	1186	O

The	1187	1190	O
results	1191	1198	O
from	1199	1203	O
the	1204	1207	O
concentration	1208	1221	O
-	1221	1222	O
QTcF	1222	1226	O
analysis	1227	1235	O
are	1236	1239	O
graphically	1240	1251	O
depicted	1252	1260	O
in	1261	1263	O
Fig	1264	1267	O
.	1267	1268	O

5	1269	1270	O
.	1270	1271	O

The	1272	1275	O
mean	1276	1280	O
(	1281	1282	O
90	1282	1284	O
%	1284	1285	O
CI	1286	1288	O
)	1288	1289	O
slope	1290	1295	O
estimate	1296	1304	O
from	1305	1309	O
the	1310	1313	O
linezolid	1314	1323	O
concentration	1324	1337	O
-	1337	1338	O
QTcF	1338	1342	O
analysis	1343	1351	O
was	1352	1355	O
-	1356	1357	O
0	1357	1358	O
.	1358	1359	O
0145	1359	1363	O
(	1364	1365	O
-	1365	1366	O
0	1366	1367	O
.	1367	1368	O
0768	1368	1372	O
to	1373	1375	O
0	1376	1377	O
.	1377	1378	O
0477	1378	1382	O
)	1382	1383	O
ms	1384	1386	O
/	1386	1387	O
mug	1387	1390	O
/	1390	1391	O
ml	1391	1393	O
.	1393	1394	O

At	1395	1397	O
the	1398	1401	O
geometric	1402	1411	O
mean	1412	1416	O
Cmax	1417	1421	O
following	1422	1431	O
the	1432	1435	O
infusion	1436	1444	O
of	1445	1447	O
linezolid	1448	1457	O
at	1458	1460	O
600	1461	1464	O
mg	1465	1467	O
(	1468	1469	O
14	1469	1471	O
.	1471	1472	O
9	1472	1473	O
mug	1474	1477	O
/	1477	1478	O
ml	1478	1480	O
)	1480	1481	O
and	1482	1485	O
1	1486	1487	O
,	1487	1488	O
200	1488	1491	O
mg	1492	1494	O
(	1495	1496	O
30	1496	1498	O
.	1498	1499	O
5	1499	1500	O
mug	1501	1504	O
/	1504	1505	O
ml	1505	1507	O
)	1507	1508	O
,	1508	1509	O
the	1510	1513	O
mean	1514	1518	O
(	1519	1520	O
90	1520	1522	O
%	1522	1523	O
CI	1524	1526	O
)	1526	1527	O
predicted	1528	1537	O
placebo	1538	1545	O
-	1545	1546	O
adjusted	1546	1554	O
changes	1555	1562	O
from	1563	1567	O
the	1568	1571	O
baseline	1572	1580	O
QTcF	1581	1585	O
were	1586	1590	O
-	1591	1592	O
0	1592	1593	O
.	1593	1594	O
217	1594	1597	O
(	1598	1599	O
-	1599	1600	O
1	1600	1601	O
.	1601	1602	O
14	1602	1604	O
to	1605	1607	O
0	1608	1609	O
.	1609	1610	O
710	1610	1613	O
)	1613	1614	O
and	1615	1618	O
-	1619	1620	O
0	1620	1621	O
.	1621	1622	O
444	1622	1625	O
(	1626	1627	O
-	1627	1628	O
2	1628	1629	O
.	1629	1630	O
34	1630	1632	O
to	1633	1635	O
1	1636	1637	O
.	1637	1638	O
45	1638	1640	O
)	1640	1641	O
ms	1642	1644	O
,	1644	1645	O
respectively	1646	1658	O
,	1658	1659	O
thus	1660	1664	O
confirming	1665	1675	O
a	1676	1677	O
lack	1678	1682	O
of	1683	1685	O
a	1686	1687	O
relationship	1688	1700	O
between	1701	1708	O
linezolid	1709	1718	O
concentrations	1719	1733	O
and	1734	1737	O
QTc	1738	1741	O
interval	1742	1750	O
.	1750	1751	O

Fig	1752	1755	O
.	1755	1756	O

5	1757	1758	O
.	1758	1759	O

QTcF	1760	1764	O
interval	1765	1773	O
versus	1774	1780	O
plasma	1781	1787	B-Organism_substance
linezolid	1788	1797	O
concentrations	1798	1812	O
.	1812	1813	O

Results	0	7	O

primary	8	15	O
pancreatic	16	26	B-Pathological_formation
sarcomas	27	35	I-Pathological_formation
are	36	39	O
extremely	40	49	O
rare	50	54	O
.	54	55	O

Pancreatic	56	66	B-Pathological_formation
sarcomas	67	75	I-Pathological_formation
are	76	79	O
more	80	84	O
aggressive	85	95	O
than	96	100	O
other	101	106	O
pancreatic	107	117	B-Pathological_formation
neoplasms	118	127	I-Pathological_formation
.	127	128	O

Introduction	0	12	O

Hip	13	16	B-Organism_subdivision
fractures	17	26	O
in	27	29	O
the	30	33	O
aged	34	38	O
constitute	39	49	O
a	50	51	O
major	52	57	O
health	58	64	O
problem	65	72	O
with	73	77	O
substantial	78	89	O
morbidity	90	99	O
[	100	101	O
1	101	102	O
]	102	103	O
,	103	104	O
mortality	105	114	O
[	115	116	O
2	116	117	O
,	117	118	O
3	119	120	O
]	120	121	O
,	121	122	O
and	123	126	O
,	126	127	O
as	128	130	O
the	131	134	O
ageing	135	141	O
population	142	152	O
increases	153	162	O
,	162	163	O
an	164	166	O
increasing	167	177	O
burden	178	184	O
on	185	187	O
the	188	191	O
health	192	198	O
care	199	203	O
system	204	210	O
[	211	212	O
4	212	213	O
]	213	214	O
.	214	215	O

Fracture	216	224	O
risk	225	229	O
varies	230	236	O
markedly	237	245	O
between	246	253	O
countries	254	263	O
[	264	265	O
5	265	266	O
]	266	267	O
.	267	268	O

In	269	271	O
a	272	273	O
study	274	279	O
by	280	282	O
Kanis	283	288	O
et	289	291	O
al	292	294	O
.	294	295	O

[	296	297	O
6	297	298	O
]	298	299	O
,	299	300	O
comparing	301	310	O
10	311	313	O
-	313	314	O
year	314	318	O
probability	319	330	O
of	331	333	O
hip	334	337	B-Organism_subdivision
fracture	338	346	O
,	346	347	O
all	348	351	O
countries	352	361	O
except	362	368	O
Norway	369	375	O
had	376	379	O
lower	380	385	O
risk	386	390	O
than	391	395	O
Sweden	396	402	O
.	402	403	O

Other	404	409	O
countries	410	419	O
categorized	420	431	O
at	432	434	O
very	435	439	O
high	440	444	O
risk	445	449	O
(	450	451	O
>	451	452	O
75	452	454	O
%	454	455	O
of	456	458	O
the	459	462	O
risk	463	467	O
of	468	470	O
Sweden	471	477	O
)	477	478	O
were	479	483	O
Iceland	484	491	O
,	491	492	O
Denmark	493	500	O
and	501	504	O
the	505	508	O
US	509	511	O
.	511	512	O

At	513	515	O
the	516	519	O
age	520	523	O
of	524	526	O
80	527	529	O
,	529	530	O
the	531	534	O
estimated	535	544	O
probability	545	556	O
of	557	559	O
sustaining	560	570	O
a	571	572	O
hip	573	576	B-Organism_subdivision
fracture	577	585	O
the	586	589	O
next	590	594	O
10	595	597	O
years	598	603	O
is	604	606	O
8	607	608	O
.	608	609	O
6	609	610	O
%	610	611	O
and	612	615	O
17	616	618	O
.	618	619	O
7	619	620	O
%	620	621	O
in	622	624	O
Norwegian	625	634	O
men	635	638	O
and	639	642	O
women	643	648	O
,	648	649	O
respectively	650	662	O
[	663	664	O
7	664	665	O
]	665	666	O
,	666	667	O
and	668	671	O
a	672	673	O
report	674	680	O
from	681	685	O
the	686	689	O
Norwegian	690	699	O
capital	700	707	O
Oslo	708	712	O
calculated	713	723	O
an	724	726	O
overall	727	734	O
annual	735	741	O
fracture	742	750	O
rate	751	755	O
of	756	758	O
118	759	762	O
.	762	763	O
0	763	764	O
in	765	767	O
women	768	773	O
and	774	777	O
44	778	780	O
.	780	781	O
0	781	782	O
in	783	785	O
men	786	789	O
per	790	793	O
10	794	796	O
,	796	797	O
000	797	800	O
[	801	802	O
8	802	803	O
]	803	804	O
.	804	805	O

Several	806	813	O
recent	814	820	O
studies	821	828	O
are	829	832	O
reporting	833	842	O
declining	843	852	O
fracture	853	861	O
incidence	862	871	O
[	872	873	O
9	873	874	O
-	874	875	O
14	875	877	O
]	877	878	O
.	878	879	O

Although	880	888	O
the	889	892	O
Norwegian	893	902	O
hip	903	906	B-Organism_subdivision
fracture	907	915	O
rates	916	921	O
remain	922	928	O
the	929	932	O
highest	933	940	O
reported	941	949	O
in	950	952	O
the	953	956	O
world	957	962	O
,	962	963	O
data	964	968	O
from	969	973	O
Oslo	974	978	O
in	979	981	O
1996	982	986	O
-	986	987	O
1997	987	991	O
indicated	992	1001	O
no	1002	1004	O
increasing	1005	1015	O
incidence	1016	1025	O
rates	1026	1031	O
compared	1032	1040	O
to	1041	1043	O
the	1044	1047	O
1988	1048	1052	O
-	1052	1053	O
1989	1053	1057	O
[	1058	1059	O
8	1059	1060	O
]	1060	1061	O
.	1061	1062	O
Within	1062	1068	O
Norway	1069	1075	O
,	1075	1076	O
considerable	1077	1089	O
geographic	1090	1100	O
differences	1101	1112	O
have	1113	1117	O
been	1118	1122	O
reported	1123	1131	O
,	1131	1132	O
with	1133	1137	O
substantially	1138	1151	O
lower	1152	1157	O
rates	1158	1163	O
in	1164	1166	O
smaller	1167	1174	O
cities	1175	1181	O
and	1182	1185	O
rural	1186	1191	O
areas	1192	1197	O
compared	1198	1206	O
to	1207	1209	O
Oslo	1210	1214	O
[	1215	1216	O
7	1216	1217	O
,	1217	1218	O
15	1219	1221	O
]	1221	1222	O
.	1222	1223	O

However	1224	1231	O
,	1231	1232	O
these	1233	1238	O
are	1239	1242	O
reports	1243	1250	O
based	1251	1256	O
on	1257	1259	O
sporadic	1260	1268	O
studies	1269	1276	O
in	1277	1279	O
few	1280	1283	O
regions	1284	1291	O
and	1292	1295	O
in	1296	1298	O
limited	1299	1306	O
time	1307	1311	O
periods	1312	1319	O
[	1320	1321	O
16	1321	1323	O
,	1323	1324	O
17	1325	1327	O
]	1327	1328	O
.	1328	1329	O

From	1330	1334	O
1985	1335	1339	O
to	1340	1342	O
2003	1343	1347	O
,	1347	1348	O
the	1349	1352	O
Norwegian	1353	1362	O
Institute	1363	1372	O
of	1373	1375	O
Public	1376	1382	O
Health	1383	1389	O
commissioned	1390	1402	O
four	1403	1407	O
Norwegian	1408	1417	O
hospitals	1418	1427	O
,	1427	1428	O
representing	1429	1441	O
10	1442	1444	O
%	1444	1445	O
of	1446	1448	O
the	1449	1452	O
population	1453	1463	O
,	1463	1464	O
to	1465	1467	O
run	1468	1471	O
a	1472	1473	O
national	1474	1482	O
injury	1483	1489	O
registry	1490	1498	O
[	1499	1500	O
18	1500	1502	O
]	1502	1503	O
.	1503	1504	O

The	1505	1508	O
registry	1509	1517	O
collected	1518	1527	O
a	1528	1529	O
variety	1530	1537	O
of	1538	1540	O
data	1541	1545	O
connected	1546	1555	O
to	1556	1558	O
the	1559	1562	O
actual	1563	1569	O
injury	1570	1576	O
itself	1577	1583	O
and	1584	1587	O
the	1588	1591	O
event	1592	1597	O
leading	1598	1605	O
to	1606	1608	O
the	1609	1612	O
injury	1613	1619	O
.	1619	1620	O

In	1621	1623	O
the	1624	1627	O
city	1628	1632	O
of	1633	1635	O
Harstad	1636	1643	O
in	1644	1646	O
Northern	1647	1655	O
Norway	1656	1662	O
,	1662	1663	O
the	1664	1667	O
registration	1668	1680	O
continued	1681	1690	O
and	1691	1694	O
has	1695	1698	O
been	1699	1703	O
running	1704	1711	O
for	1712	1715	O
more	1716	1720	O
than	1721	1725	O
23	1726	1728	O
years	1729	1734	O
.	1734	1735	O

Throughout	1736	1746	O
the	1747	1750	O
years	1751	1756	O
of	1757	1759	O
the	1760	1763	O
National	1764	1772	O
Injury	1773	1779	O
Registry	1780	1788	O
,	1788	1789	O
the	1790	1793	O
injury	1794	1800	O
rates	1801	1806	O
in	1807	1809	O
Harstad	1810	1817	O
closely	1818	1825	O
resembled	1826	1835	O
the	1836	1839	O
rates	1840	1845	O
of	1846	1848	O
the	1849	1852	O
national	1853	1861	O
registry	1862	1870	O
[	1871	1872	O
18	1872	1874	O
]	1874	1875	O
.	1875	1876	O

With	1877	1881	O
reference	1882	1891	O
to	1892	1894	O
the	1895	1898	O
recent	1899	1905	O
reports	1906	1913	O
suggesting	1914	1924	O
stabilizing	1925	1936	O
hip	1937	1940	B-Organism_subdivision
fracture	1941	1949	O
incidence	1950	1959	O
internationally	1960	1975	O
as	1976	1978	O
well	1979	1983	O
as	1984	1986	O
nationally	1987	1997	O
,	1997	1998	O
and	1999	2002	O
regional	2003	2011	O
differences	2012	2023	O
within	2024	2030	O
Norway	2031	2037	O
,	2037	2038	O
we	2039	2041	O
have	2042	2046	O
used	2047	2051	O
the	2052	2055	O
hip	2056	2059	B-Organism_subdivision
fracture	2060	2068	O
data	2069	2073	O
in	2074	2076	O
the	2077	2080	O
Harstad	2081	2088	O
Injury	2089	2095	O
Registry	2096	2104	O
to	2105	2107	O
:	2107	2108	O

Describe	2110	2118	O
age	2119	2122	O
-	2122	2123	O
and	2124	2127	O
sex	2128	2131	O
-	2131	2132	O
specific	2132	2140	O
incidence	2141	2150	O
of	2151	2153	O
hip	2154	2157	B-Organism_subdivision
fractures	2158	2167	O
in	2168	2170	O
Harstad	2171	2178	O
,	2178	2179	O
Northern	2180	2188	O
Norway	2189	2195	O
and	2196	2199	O
make	2200	2204	O
comparison	2205	2215	O
with	2216	2220	O
rates	2221	2226	O
from	2227	2231	O
the	2232	2235	O
Norwegian	2236	2245	O
capital	2246	2253	O
Oslo	2254	2258	O

Describe	2259	2267	O
time	2268	2272	O
trends	2273	2279	O
in	2280	2282	O
hip	2283	2286	B-Organism_subdivision
fracture	2287	2295	O
incidence	2296	2305	O
in	2306	2308	O
Harstad	2309	2316	O
from	2317	2321	O
1994	2322	2326	O
to	2327	2329	O
2008	2330	2334	O

Describe	2335	2343	O
place	2344	2349	O
of	2350	2352	O
injury	2353	2359	O
and	2360	2363	O
seasonal	2364	2372	O
variations	2373	2383	O
in	2384	2386	O
hip	2387	2390	B-Organism_subdivision
fracture	2391	2399	O
incidence	2400	2409	O
in	2410	2412	O
Harstad	2413	2420	O

Compare	2421	2428	O
3	2429	2430	O
-	2430	2431	O
month	2431	2436	O
,	2436	2437	O
6	2438	2439	O
-	2439	2440	O
month	2440	2445	O
,	2445	2446	O
and	2447	2450	O
1	2451	2452	O
-	2452	2453	O
year	2453	2457	O
mortality	2458	2467	O
after	2468	2473	O
hip	2474	2477	B-Organism_subdivision
fracture	2478	2486	O
between	2487	2494	O
women	2495	2500	O
and	2501	2504	O
men	2505	2508	O
in	2509	2511	O
Harstad	2512	2519	O

(	0	1	O
a	1	2	O
)	2	3	O
The	4	7	O
Tn6087	8	14	O
target	15	21	O
site	22	26	O
within	27	33	O
S	34	35	O
.	35	36	O
oralis	37	43	O
F	44	45	O
.	45	46	O
MI	46	48	O
.	48	49	O
5	49	50	O
.	50	51	O

(	52	53	O
b	53	54	O
)	54	55	O
The	56	59	O
left	60	64	O
end	65	68	O
and	69	72	O
(	73	74	O
c	74	75	O
)	75	76	O
right	77	82	O
end	83	86	O
of	87	89	O
Tn6087	90	96	O
are	97	100	O
shown	101	106	O
in	107	109	O
bold	110	114	O
.	114	115	O

(	116	117	O
d	117	118	O
)	118	119	O
The	120	123	O
joint	124	129	O
of	130	132	O
the	133	136	O
circular	137	145	O
intermediate	146	158	O
of	159	161	O
Tn6087	162	168	O
is	169	171	O
shown	172	177	O
.	177	178	O

The	179	182	O
transposon	183	193	O
'	193	194	O
s	194	195	O
coupling	196	204	O
sequences	205	214	O
are	215	218	O
shown	219	224	O
in	225	227	O
bold	228	232	O
italics	233	240	O
.	240	241	O

As	242	244	O
can	245	248	O
be	249	251	O
seen	252	256	O
in	257	259	O
(	260	261	O
d	261	262	O
)	262	263	O
,	263	264	O
the	265	268	O
coupling	269	277	O
sequence	278	286	O
at	287	289	O
the	290	293	O
joint	294	299	O
of	300	302	O
the	303	306	O
circular	307	315	O
form	316	320	O
is	321	323	O
a	324	325	O
heteroduplex	326	338	O
.	338	339	O

Breeding	0	8	O
of	9	11	O
p53	12	15	O
mice	16	20	O
with	21	25	O
BCCIP	26	31	O
conditional	32	43	O
knockdown	44	53	O
mice	54	58	O

The	59	62	O
heterozygous	63	75	O
p53	76	79	O
knockout	80	88	O
mice	89	93	O
[	94	95	O
36	95	97	O
]	97	98	O
were	99	103	O
crossed	104	111	O
with	112	116	O
LoxPshBCCIP	117	128	O
+	128	129	O
/	129	130	O
+	130	131	O
-	131	132	O
4	132	133	O
mouse	134	139	O
and	140	143	O
EIIaCre	144	151	O
+	151	152	O
/	152	153	O
+	153	154	O
mouse	155	160	O
respectively	161	173	O
to	174	176	O
generate	177	185	O
p53	186	189	O
+	189	190	O
/	190	191	O
-	191	192	O
;	192	193	O
LoxPshBCCIP	193	204	O
+	204	205	O
/	205	206	O
-	206	207	O
,	207	208	O
and	209	212	O
p53	213	216	O
+	216	217	O
/	217	218	O
-	218	219	O
;	219	220	O
EIIaCre	220	227	O
+	227	228	O
/	228	229	O
-	229	230	O
mice	231	235	O
.	235	236	O

The	237	240	O
PCR	241	244	O
primers	245	252	O
used	253	257	O
to	258	260	O
genotype	261	269	O
p53	270	273	O
are	274	277	O
:	277	278	O
p53ex6F	279	286	O
:	286	287	O
5	288	289	O
'	289	290	O
-	290	291	O
GTATCCCGAGTATCTGGAAGACAG	291	315	O
-	315	316	O
3	316	317	O
'	317	318	O
,	318	319	O
p53neoF	320	327	O
:	327	328	O
5	329	330	O
'	330	331	O
-	331	332	O
GCCTTCTATCGCCTTCTTGACG	332	354	O
-	354	355	O
3	355	356	O
'	356	357	O
,	357	358	O
p53ex7RN	359	367	O
:	367	368	O
5	369	370	O
'	370	371	O
-	371	372	O
AAGGATAGGTCGGCGGTTCATGC	372	395	O
-	395	396	O
3	396	397	O
'	397	398	O
.	398	399	O

The	400	403	O
same	404	408	O
PCR	409	412	O
primer	413	419	O
pairs	420	425	O
as	426	428	O
described	429	438	O
earlier	439	446	O
in	447	449	O
this	450	454	O
report	455	461	O
were	462	466	O
used	467	471	O
for	472	475	O
BCCIPshRNA	476	486	O
and	487	490	O
EIIaCre	491	498	O
genotyping	499	509	O
.	509	510	O

The	511	514	O
p53	515	518	O
+	518	519	O
/	519	520	O
-	520	521	O
;	521	522	O
LoxPshBCCIP	522	533	O
+	533	534	O
/	534	535	O
+	535	536	O
mice	537	541	O
were	542	546	O
obtained	547	555	O
by	556	558	O
crossing	559	567	O
p53	568	571	O
+	571	572	O
/	572	573	O
-	573	574	O
;	574	575	O
LoxPshBCCIP	575	586	O
+	586	587	O
/	587	588	O
-	588	589	O
females	590	597	O
with	598	602	O
p53	603	606	O
+	606	607	O
/	607	608	O
-	608	609	O
;	609	610	O
LoxPshBCCIP	610	621	O
+	621	622	O
/	622	623	O
-	623	624	O
males	625	630	O
.	630	631	O

The	632	635	O
p53	636	639	O
+	639	640	O
/	640	641	O
-	641	642	O
;	642	643	O
LoxPshBCCIP	643	654	O
+	654	655	O
/	655	656	O
+	656	657	O
or	658	660	O
p53	661	664	O
+	664	665	O
/	665	666	O
-	666	667	O
;	667	668	O
LoxPshBCCIP	668	679	O
+	679	680	O
/	680	681	O
-	681	682	O
mice	683	687	O
were	688	692	O
crossed	693	700	O
with	701	705	O
p53	706	709	O
+	709	710	O
/	710	711	O
-	711	712	O
;	712	713	O
EIIaCre	713	720	O
+	720	721	O
/	721	722	O
-	722	723	O
mice	724	728	O
respectively	729	741	O
.	741	742	O

Biochemical	0	11	O
traits	12	18	O

ERK	0	3	O
signaling	4	13	O
is	14	16	O
involved	17	25	O
in	26	28	O
decreasing	29	39	O
BDNF	40	44	O
-	44	45	O
induced	45	52	O
gene	53	57	O
activity	58	66	O
via	67	70	O
Eph	71	74	O
receptors	75	84	O

Data	85	89	O
provided	90	98	O
so	99	101	O
far	102	105	O
suggest	106	113	O
that	114	118	O
ephrin	119	125	O
-	125	126	O
A5	126	128	O
might	129	134	O
counteract	135	145	O
BDNF	146	150	O
-	150	151	O
mediated	151	159	O
gene	160	164	O
expression	165	175	O
and	176	179	O
growth	180	186	B-Cellular_component
cone	187	191	I-Cellular_component
responses	192	201	O
via	202	205	O
decreasing	206	216	O
ERK	217	220	O
activity	221	229	O
and	230	233	O
nuclear	234	241	B-Cellular_component
localization	242	254	O
(	255	256	O
Figs	256	260	O
.	260	261	O
2	262	263	O
and	264	267	O
3	268	269	O
)	269	270	O
.	270	271	O

To	272	274	O
test	275	279	O
this	280	284	O
hypothesis	285	295	O
more	296	300	O
directly	301	309	O
,	309	310	O
we	311	313	O
analyzed	314	322	O
whether	323	330	O
Eph	331	334	O
forward	335	342	O
signaling	343	352	O
can	353	356	O
still	357	362	O
suppress	363	371	O
BDNF	372	376	O
-	376	377	O
stimulated	377	387	O
IEG	388	391	O
induction	392	401	O
and	402	405	O
growth	406	412	B-Cellular_component
cone	413	417	I-Cellular_component
collapse	418	426	O
when	427	431	O
ERK	432	435	O
kinase	436	442	O
activity	443	451	O
was	452	455	O
experimentally	456	470	O
raised	471	477	O
.	477	478	O

For	479	482	O
this	483	487	O
,	487	488	O
ERK	489	492	O
activity	493	501	O
was	502	505	O
elevated	506	514	O
by	515	517	O
expressing	518	528	O
constitutively	529	543	O
-	543	544	O
active	544	550	O
MEK1	551	555	O
(	556	557	O
CA	557	559	O
-	559	560	O
MEK1	560	564	O
)	564	565	O
,	565	566	O
an	567	569	O
ERK	570	573	O
upstream	574	582	O
activator	583	592	O
,	592	593	O
in	594	596	O
cortical	597	605	B-Cell
neurons	606	613	I-Cell
(	614	615	O
Fig	615	618	O
.	618	619	O
S3	620	622	O
)	622	623	O
.	623	624	O

Subsequently	625	637	O
,	637	638	O
neurons	639	646	B-Cell
were	647	651	O
subjected	652	661	O
to	662	664	O
either	665	671	O
an	672	674	O
ephrin	675	681	O
-	681	682	O
A5	682	684	O
mediated	685	693	O
growth	694	700	B-Cellular_component
cone	701	705	I-Cellular_component
collapse	706	714	O
assay	715	720	O
(	721	722	O
Fig	722	725	O
.	725	726	O
5	727	728	O
)	728	729	O
or	730	732	O
stimulated	733	743	O
with	744	748	O
guidance	749	757	O
cues	758	762	O
for	763	766	O
20	767	769	O
minutes	770	777	O
and	778	781	O
IEG	782	785	O
mRNA	786	790	O
levels	791	797	O
were	798	802	O
quantified	803	813	O
via	814	817	O
qRT	818	821	O
-	821	822	O
PCR	822	825	O
(	826	827	O
Fig	827	830	O
.	830	831	O
6	832	833	O
)	833	834	O
.	834	835	O

10	836	838	O
.	838	839	O
1371	839	843	O
/	843	844	O
journal	844	851	O
.	851	852	O
pone	852	856	O
.	856	857	O
0026089	857	864	O
.	864	865	O
g005	865	869	O
Figure	870	876	O
5	877	878	O

Constitutively	879	893	O
-	893	894	O
active	894	900	O
MEK1	901	905	O
blocks	906	912	O
ephrin	913	919	O
-	919	920	O
A5	920	922	O
mediated	923	931	O
growth	932	938	B-Cellular_component
cone	939	943	I-Cellular_component
collapse	944	952	O
.	952	953	O

Wild	954	958	O
-	958	959	O
type	959	963	O
neurons	964	971	B-Cell
were	972	976	O
electroporated	977	991	O
with	992	996	O
vectors	997	1004	O
expressing	1005	1015	O
GFP	1016	1019	O
(	1020	1021	O
control	1021	1028	O
;	1028	1029	O
A	1030	1031	O
,	1031	1032	O
C	1033	1034	O
,	1034	1035	O
E	1036	1037	O
)	1037	1038	O
or	1039	1041	O
expressing	1042	1052	O
a	1053	1054	O
FLAG	1055	1059	O
-	1059	1060	O
tagged	1060	1066	O
constitutively	1067	1081	O
-	1081	1082	O
active	1082	1088	O
MEK1	1089	1093	O
(	1094	1095	O
CA	1095	1097	O
-	1097	1098	O
MEK1	1098	1102	O
;	1102	1103	O
B	1104	1105	O
,	1105	1106	O
D	1107	1108	O
,	1108	1109	O
F	1110	1111	O
)	1111	1112	O
.	1112	1113	O

Neurons	1114	1121	B-Cell
were	1122	1126	O
treated	1127	1134	O
with	1135	1139	O
ephrin	1140	1146	O
-	1146	1147	O
A5	1147	1149	O
-	1149	1150	O
Fc	1150	1152	O
for	1153	1156	O
30	1157	1159	O
min	1160	1163	O
followed	1164	1172	O
by	1173	1175	O
visualization	1176	1189	O
of	1190	1192	O
GFP	1193	1196	O
(	1197	1198	O
A	1198	1199	O
,	1199	1200	O
C	1201	1202	O
,	1202	1203	O
E	1204	1205	O
)	1205	1206	O
or	1207	1209	O
CA	1210	1212	O
-	1212	1213	O
MEK	1213	1216	O
-	1216	1217	O
1	1217	1218	O
(	1219	1220	O
green	1220	1225	O
in	1226	1228	O
B	1229	1230	O
,	1230	1231	O
D	1232	1233	O
,	1233	1234	O
F	1235	1236	O
)	1236	1237	O
,	1237	1238	O
F	1239	1240	O
-	1240	1241	O
actin	1241	1246	O
and	1247	1250	O
betaIII	1251	1258	O
tubulin	1259	1266	O
.	1266	1267	O

(	1268	1269	O
A	1269	1270	O
,	1270	1271	O
B	1272	1273	O
)	1273	1274	O
Overexpression	1275	1289	O
of	1290	1292	O
CA	1293	1295	O
-	1295	1296	O
MEK1	1296	1300	O
(	1301	1302	O
B	1302	1303	O
)	1303	1304	O
reduces	1305	1312	O
mean	1313	1317	O
neurite	1318	1325	B-Cellular_component
length	1326	1332	O
compared	1333	1341	O
to	1342	1344	O
a	1345	1346	O
control	1347	1354	O
GFP	1355	1358	O
-	1358	1359	O
expressing	1359	1369	O
neuron	1370	1376	B-Cell
(	1377	1378	O
A	1378	1379	O
)	1379	1380	O
.	1380	1381	O

(	1382	1383	O
C	1383	1384	O
-	1384	1385	O
F	1385	1386	O
)	1386	1387	O
A	1388	1389	O
control	1390	1397	O
growth	1398	1404	B-Cellular_component
cone	1405	1409	I-Cellular_component
without	1410	1417	O
ephrin	1418	1424	O
-	1424	1425	O
A5	1425	1427	O
application	1428	1439	O
(	1440	1441	O
C	1441	1442	O
)	1442	1443	O
typically	1444	1453	O
protrudes	1454	1463	O
multiple	1464	1472	O
filopodia	1473	1482	B-Cellular_component
(	1483	1484	O
arrow	1484	1489	O
)	1489	1490	O
.	1490	1491	O

CA	1492	1494	O
-	1494	1495	O
MEK	1495	1498	O
-	1498	1499	O
1	1499	1500	O
expressing	1501	1511	O
growth	1512	1518	B-Cellular_component
cones	1519	1524	I-Cellular_component
(	1525	1526	O
D	1526	1527	O
)	1527	1528	O
were	1529	1533	O
indistinguishable	1534	1551	O
from	1552	1556	O
a	1557	1558	O
GFP	1559	1562	O
-	1562	1563	O
expressing	1563	1573	O
growth	1574	1580	B-Cellular_component
cone	1581	1585	I-Cellular_component
.	1585	1586	O

Note	1587	1591	O
that	1592	1596	O
CA	1597	1599	O
-	1599	1600	O
MEK1	1600	1604	O
was	1605	1608	O
expressed	1609	1618	O
in	1619	1621	O
a	1622	1623	O
dot	1624	1627	O
-	1627	1628	O
like	1628	1632	O
pattern	1633	1640	O
in	1641	1643	O
the	1644	1647	O
growth	1648	1654	B-Cellular_component
cone	1655	1659	I-Cellular_component
(	1660	1661	O
arrowheads	1661	1671	O
in	1672	1674	O
D	1675	1676	O
and	1677	1680	O
F	1681	1682	O
)	1682	1683	O
.	1683	1684	O

Upon	1685	1689	O
ephrin	1690	1696	O
-	1696	1697	O
A5	1697	1699	O
application	1700	1711	O
,	1711	1712	O
a	1713	1714	O
control	1715	1722	O
growth	1723	1729	B-Cellular_component
cone	1730	1734	I-Cellular_component
(	1735	1736	O
E	1736	1737	O
)	1737	1738	O
collapsed	1739	1748	O
resulting	1749	1758	O
in	1759	1761	O
only	1762	1766	O
few	1767	1770	O
filopodia	1771	1780	B-Cellular_component
.	1780	1781	O

In	1782	1784	O
contrast	1785	1793	O
,	1793	1794	O
a	1795	1796	O
CA	1797	1799	O
-	1799	1800	O
MEK1	1800	1804	O
expressing	1805	1815	O
growth	1816	1822	B-Cellular_component
cone	1823	1827	I-Cellular_component
(	1828	1829	O
F	1829	1830	O
)	1830	1831	O
was	1832	1835	O
only	1836	1840	O
partially	1841	1850	O
collapsed	1851	1860	O
and	1861	1864	O
many	1865	1869	O
filopodia	1870	1879	B-Cellular_component
structures	1880	1890	O
were	1891	1895	O
preserved	1896	1905	O
after	1906	1911	O
ephrin	1912	1918	O
-	1918	1919	O
A5	1919	1921	O
induction	1922	1931	O
.	1931	1932	O

(	1933	1934	O
G	1934	1935	O
)	1935	1936	O
Quantification	1937	1951	O
of	1952	1954	O
average	1955	1962	O
neurite	1963	1970	B-Cellular_component
length	1971	1977	O
.	1977	1978	O

(	1979	1980	O
H	1980	1981	O
,	1981	1982	O
I	1983	1984	O
)	1984	1985	O
Quantification	1986	2000	O
of	2001	2003	O
growth	2004	2010	B-Cellular_component
cone	2011	2015	I-Cellular_component
area	2016	2020	O
(	2021	2022	O
H	2022	2023	O
)	2023	2024	O
and	2025	2028	O
filopodia	2029	2038	B-Cellular_component
number	2039	2045	O
/	2045	2046	O
growth	2046	2052	B-Cellular_component
cone	2053	2057	I-Cellular_component
(	2058	2059	O
I	2059	2060	O
)	2060	2061	O
in	2062	2064	O
the	2065	2068	O
four	2069	2073	O
conditions	2074	2084	O
.	2084	2085	O

Ephrin	2086	2092	O
-	2092	2093	O
A5	2093	2095	O
induces	2096	2103	O
a	2104	2105	O
growth	2106	2112	B-Cellular_component
cone	2113	2117	I-Cellular_component
collapse	2118	2126	O
,	2126	2127	O
resulting	2128	2137	O
in	2138	2140	O
reduced	2141	2148	O
growth	2149	2155	B-Cellular_component
cone	2156	2160	I-Cellular_component
area	2161	2165	O
and	2166	2169	O
filopodia	2170	2179	B-Cellular_component
number	2180	2186	O
in	2187	2189	O
GFP	2190	2193	O
but	2194	2197	O
not	2198	2201	O
CA	2202	2204	O
-	2204	2205	O
MEK1	2205	2209	O
expressing	2210	2220	O
neurons	2221	2228	B-Cell
.	2228	2229	O

Scale	2230	2235	O
-	2235	2236	O
bar	2236	2239	O
(	2240	2241	O
A	2241	2242	O
,	2242	2243	O
B	2244	2245	O
)	2245	2246	O
=	2247	2248	O
10	2249	2251	O
microm	2252	2258	O
;	2258	2259	O
(	2260	2261	O
C	2261	2262	O
-	2262	2263	O
F	2263	2264	O
)	2264	2265	O
=	2266	2267	O
2	2268	2269	O
microm	2270	2276	O
.	2276	2277	O

10	2278	2280	O
.	2280	2281	O
1371	2281	2285	O
/	2285	2286	O
journal	2286	2293	O
.	2293	2294	O
pone	2294	2298	O
.	2298	2299	O
0026089	2299	2306	O
.	2306	2307	O
g006	2307	2311	O
Figure	2312	2318	O
6	2319	2320	O

Ephrin	2321	2327	O
-	2327	2328	O
A5	2328	2330	O
suppresses	2331	2341	O
BDNF	2342	2346	O
-	2346	2347	O
induced	2347	2354	O
IEG	2355	2358	O
responses	2359	2368	O
via	2369	2372	O
MAP	2373	2376	O
kinase	2377	2383	O
signaling	2384	2393	O
.	2393	2394	O

Wild	2395	2399	O
-	2399	2400	O
type	2400	2404	O
cortical	2405	2413	B-Cell
neurons	2414	2421	I-Cell
,	2421	2422	O
mock	2423	2427	O
-	2427	2428	O
electroporated	2428	2442	O
(	2443	2444	O
black	2444	2449	O
bars	2450	2454	O
)	2454	2455	O
or	2456	2458	O
with	2459	2463	O
a	2464	2465	O
vector	2466	2472	O
expressing	2473	2483	O
constitutively	2484	2498	O
-	2498	2499	O
active	2499	2505	O
MEK1	2506	2510	O
(	2511	2512	O
white	2512	2517	O
bars	2518	2522	O
)	2522	2523	O
,	2523	2524	O
were	2525	2529	O
treated	2530	2537	O
with	2538	2542	O
guidance	2543	2551	O
cues	2552	2556	O
for	2557	2560	O
20	2561	2563	O
minutes	2564	2571	O
as	2572	2574	O
depicted	2575	2583	O
,	2583	2584	O
followed	2585	2593	O
by	2594	2596	O
mRNA	2597	2601	O
quantification	2602	2616	O
.	2616	2617	O

In	2618	2620	O
mock	2621	2625	O
-	2625	2626	O
electroporated	2626	2640	O
neurons	2641	2648	B-Cell
,	2648	2649	O
BDNF	2650	2654	O
induced	2655	2662	O
an	2663	2665	O
IEG	2666	2669	O
response	2670	2678	O
of	2679	2681	O
c	2682	2683	O
-	2683	2684	O
fos	2684	2687	O
(	2688	2689	O
A	2689	2690	O
)	2690	2691	O
,	2691	2692	O
Egr1	2693	2697	O
(	2698	2699	O
B	2699	2700	O
)	2700	2701	O
,	2701	2702	O
Egr2	2703	2707	O
(	2708	2709	O
C	2709	2710	O
)	2710	2711	O
and	2712	2715	O
Arc	2716	2719	O
(	2720	2721	O
D	2721	2722	O
)	2722	2723	O
.	2723	2724	O

Co	2725	2727	O
-	2727	2728	O
application	2728	2739	O
of	2740	2742	O
ephrin	2743	2749	O
-	2749	2750	O
A5	2750	2752	O
and	2753	2756	O
BDNF	2757	2761	O
reduced	2762	2769	O
mRNA	2770	2774	O
levels	2775	2781	O
of	2782	2784	O
all	2785	2788	O
four	2789	2793	O
IEGs	2794	2798	O
in	2799	2801	O
mock	2802	2806	O
-	2806	2807	O
electroporated	2807	2821	O
neurons	2822	2829	B-Cell
(	2830	2831	O
A	2831	2832	O
-	2832	2833	O
D	2833	2834	O
)	2834	2835	O
.	2835	2836	O

In	2837	2839	O
contrast	2840	2848	O
,	2848	2849	O
expression	2850	2860	O
of	2861	2863	O
constitutively	2864	2878	O
-	2878	2879	O
active	2879	2885	O
MEK1	2886	2890	O
prevented	2891	2900	O
Eph	2901	2904	O
forward	2905	2912	O
signaling	2913	2922	O
from	2923	2927	O
suppressing	2928	2939	O
BDNF	2940	2944	O
-	2944	2945	O
evoked	2945	2951	O
IEG	2952	2955	O
responses	2956	2965	O
.	2965	2966	O

This	2967	2971	O
was	2972	2975	O
most	2976	2980	O
evident	2981	2988	O
for	2989	2992	O
the	2993	2996	O
IEGs	2997	3001	O
Egr1	3002	3006	O
(	3007	3008	O
B	3008	3009	O
)	3009	3010	O
and	3011	3014	O
Egr2	3015	3019	O
(	3020	3021	O
C	3021	3022	O
)	3022	3023	O
.	3023	3024	O

First	3025	3030	O
of	3031	3033	O
all	3034	3037	O
,	3037	3038	O
we	3039	3041	O
analyzed	3042	3050	O
the	3051	3054	O
impact	3055	3061	O
of	3062	3064	O
CA	3065	3067	O
-	3067	3068	O
MEK1	3068	3072	O
on	3073	3075	O
neurite	3076	3083	B-Cellular_component
outgrowth	3084	3093	O
and	3094	3097	O
ephrin	3098	3104	O
-	3104	3105	O
A5	3105	3107	O
mediated	3108	3116	O
growth	3117	3123	B-Cellular_component
cone	3124	3128	I-Cellular_component
responses	3129	3138	O
(	3139	3140	O
Fig	3140	3143	O
.	3143	3144	O
5	3145	3146	O
)	3146	3147	O
.	3147	3148	O

The	3149	3152	O
average	3153	3160	O
neurite	3161	3168	B-Cellular_component
length	3169	3175	O
of	3176	3178	O
neurons	3179	3186	B-Cell
overexpressing	3187	3201	O
CA	3202	3204	O
-	3204	3205	O
MEK1	3205	3209	O
(	3210	3211	O
Fig	3211	3214	O
.	3214	3215	O
5B	3216	3218	O
)	3218	3219	O
was	3220	3223	O
clearly	3224	3231	O
reduced	3232	3239	O
compared	3240	3248	O
to	3249	3251	O
control	3252	3259	O
GFP	3260	3263	O
expressing	3264	3274	O
neurons	3275	3282	B-Cell
(	3283	3284	O
Fig	3284	3287	O
.	3287	3288	O
5A	3289	3291	O
;	3291	3292	O
see	3293	3296	O
quantification	3297	3311	O
in	3312	3314	O
(	3315	3316	O
G	3316	3317	O
)	3317	3318	O
)	3318	3319	O
.	3319	3320	O

Growth	3321	3327	B-Cellular_component
cones	3328	3333	I-Cellular_component
of	3334	3336	O
GFP	3337	3340	O
(	3341	3342	O
C	3342	3343	O
)	3343	3344	O
and	3345	3348	O
CA	3349	3351	O
-	3351	3352	O
MEK1	3352	3356	O
expressing	3357	3367	O
neurons	3368	3375	B-Cell
were	3376	3380	O
similar	3381	3388	O
and	3389	3392	O
protruded	3393	3402	O
many	3403	3407	O
filopodia	3408	3417	B-Cellular_component
(	3418	3419	O
arrows	3419	3425	O
in	3426	3428	O
Fig	3429	3432	O
.	3432	3433	O
5C	3434	3436	O
-	3436	3437	O
F	3437	3438	O
)	3438	3439	O
.	3439	3440	O

CA	3441	3443	O
-	3443	3444	O
MEK1	3444	3448	O
expression	3449	3459	O
in	3460	3462	O
growth	3463	3469	B-Cellular_component
cones	3470	3475	I-Cellular_component
was	3476	3479	O
confined	3480	3488	O
to	3489	3491	O
individual	3492	3502	O
dot	3503	3506	O
-	3506	3507	O
like	3507	3511	O
structures	3512	3522	O
(	3523	3524	O
arrowheads	3524	3534	O
in	3535	3537	O
Fig	3538	3541	O
.	3541	3542	O
5D	3543	3545	O
,	3545	3546	O
F	3547	3548	O
)	3548	3549	O
.	3549	3550	O

Ephrin	3551	3557	O
-	3557	3558	O
A5	3558	3560	O
application	3561	3572	O
on	3573	3575	O
a	3576	3577	O
GFP	3578	3581	O
expressing	3582	3592	O
control	3593	3600	O
growth	3601	3607	B-Cellular_component
cone	3608	3612	I-Cellular_component
(	3613	3614	O
Fig	3614	3617	O
.	3617	3618	O
5E	3619	3621	O
)	3621	3622	O
resulted	3623	3631	O
in	3632	3634	O
a	3635	3636	O
growth	3637	3643	B-Cellular_component
cone	3644	3648	I-Cellular_component
collapse	3649	3657	O
as	3658	3660	O
revealed	3661	3669	O
by	3670	3672	O
reduced	3673	3680	O
overall	3681	3688	O
growth	3689	3695	B-Cellular_component
cone	3696	3700	I-Cellular_component
area	3701	3705	O
and	3706	3709	O
filopodia	3710	3719	B-Cellular_component
number	3720	3726	O
(	3727	3728	O
quantified	3728	3738	O
in	3739	3741	O
Fig	3742	3745	O
.	3745	3746	O
5H	3747	3749	O
,	3749	3750	O
I	3751	3752	O
)	3752	3753	O
.	3753	3754	O

In	3755	3757	O
contrast	3758	3766	O
,	3766	3767	O
in	3768	3770	O
neurons	3771	3778	B-Cell
overexpressing	3779	3793	O
CA	3794	3796	O
-	3796	3797	O
MEK1	3797	3801	O
(	3802	3803	O
Fig	3803	3806	O
.	3806	3807	O
5F	3808	3810	O
)	3810	3811	O
,	3811	3812	O
ephrin	3813	3819	O
-	3819	3820	O
A5	3820	3822	O
induced	3823	3830	O
only	3831	3835	O
a	3836	3837	O
partial	3838	3845	O
growth	3846	3852	B-Cellular_component
cone	3853	3857	I-Cellular_component
collapse	3858	3866	O
.	3866	3867	O

Thus	3868	3872	O
,	3872	3873	O
growth	3874	3880	B-Cellular_component
cone	3881	3885	I-Cellular_component
area	3886	3890	O
and	3891	3894	O
filopodia	3895	3904	B-Cellular_component
number	3905	3911	O
were	3912	3916	O
not	3917	3920	O
reduced	3921	3928	O
(	3929	3930	O
see	3930	3933	O
Fig	3934	3937	O
.	3937	3938	O
5H	3939	3941	O
,	3941	3942	O
I	3943	3944	O
)	3944	3945	O
.	3945	3946	O

This	3947	3951	O
result	3952	3958	O
suggests	3959	3967	O
that	3968	3972	O
an	3973	3975	O
ephrin	3976	3982	O
-	3982	3983	O
A5	3983	3985	O
induced	3986	3993	O
signaling	3994	4003	O
cascade	4004	4011	O
targets	4012	4019	O
MAP	4020	4023	O
kinase	4024	4030	O
signaling	4031	4040	O
to	4041	4043	O
exert	4044	4049	O
a	4050	4051	O
full	4052	4056	O
growth	4057	4063	B-Cellular_component
cone	4064	4068	I-Cellular_component
collapse	4069	4077	O
.	4077	4078	O

This	4079	4083	O
result	4084	4090	O
is	4091	4093	O
in	4094	4096	O
contrast	4097	4105	O
to	4106	4108	O
a	4109	4110	O
recent	4111	4117	O
report	4118	4124	O
[	4125	4126	O
46	4126	4128	O
]	4128	4129	O
which	4130	4135	O
excluded	4136	4144	O
ERK	4145	4148	O
signaling	4149	4158	O
downstream	4159	4169	O
of	4170	4172	O
an	4173	4175	O
ephrin	4176	4182	O
-	4182	4183	O
A5	4183	4185	O
mediated	4186	4194	O
growth	4195	4201	B-Cellular_component
cone	4202	4206	I-Cellular_component
collapse	4207	4215	O
.	4215	4216	O

Next	4217	4221	O
,	4221	4222	O
we	4223	4225	O
tested	4226	4232	O
whether	4233	4240	O
ephrin	4241	4247	O
-	4247	4248	O
A5	4248	4250	O
signaling	4251	4260	O
suppresses	4261	4271	O
ERK	4272	4275	O
kinase	4276	4282	O
signaling	4283	4292	O
also	4293	4297	O
to	4298	4300	O
interfere	4301	4310	O
with	4311	4315	O
BDNF	4316	4320	O
-	4320	4321	O
mediated	4321	4329	O
gene	4330	4334	O
expression	4335	4345	O
(	4346	4347	O
Fig	4347	4350	O
.	4350	4351	O
6	4352	4353	O
)	4353	4354	O
.	4354	4355	O

In	4356	4358	O
agreement	4359	4368	O
with	4369	4373	O
previous	4374	4382	O
results	4383	4390	O
(	4391	4392	O
Fig	4392	4395	O
.	4395	4396	O
4	4397	4398	O
)	4398	4399	O
,	4399	4400	O
in	4401	4403	O
mock	4404	4408	O
-	4408	4409	O
electroporated	4409	4423	O
neurons	4424	4431	B-Cell
,	4431	4432	O
ephrin	4433	4439	O
-	4439	4440	O
A5	4440	4442	O
incubation	4443	4453	O
reduced	4454	4461	O
the	4462	4465	O
BDNF	4466	4470	O
-	4470	4471	O
mediated	4471	4479	O
up	4480	4482	O
-	4482	4483	O
regulation	4483	4493	O
of	4494	4496	O
c	4497	4498	O
-	4498	4499	O
fos	4499	4502	O
(	4503	4504	O
Fig	4504	4507	O
.	4507	4508	O
6A	4509	4511	O
)	4511	4512	O
,	4512	4513	O
Egr1	4514	4518	O
(	4519	4520	O
Fig	4520	4523	O
.	4523	4524	O
6B	4525	4527	O
)	4527	4528	O
,	4528	4529	O
Egr2	4530	4534	O
(	4535	4536	O
Fig	4536	4539	O
.	4539	4540	O
6C	4541	4543	O
)	4543	4544	O
and	4545	4548	O
Arc	4549	4552	O
(	4553	4554	O
Fig	4554	4557	O
.	4557	4558	O
6D	4559	4561	O
)	4561	4562	O
mRNA	4563	4567	O
.	4567	4568	O

In	4569	4571	O
contrast	4572	4580	O
,	4580	4581	O
in	4582	4584	O
neurons	4585	4592	B-Cell
over	4593	4597	O
-	4597	4598	O
expressing	4598	4608	O
CA	4609	4611	O
-	4611	4612	O
MEK1	4612	4616	O
,	4616	4617	O
ephrin	4618	4624	O
-	4624	4625	O
A5	4625	4627	O
could	4628	4633	O
not	4634	4637	O
suppress	4638	4646	O
BDNF	4647	4651	O
-	4651	4652	O
induced	4652	4659	O
IEG	4660	4663	O
responses	4664	4673	O
to	4674	4676	O
the	4677	4680	O
same	4681	4685	O
degree	4686	4692	O
.	4692	4693	O

Particularly	4694	4706	O
Egr1	4707	4711	O
(	4712	4713	O
Fig	4713	4716	O
.	4716	4717	O
6B	4718	4720	O
)	4720	4721	O
and	4722	4725	O
Egr2	4726	4730	O
(	4731	4732	O
Fig	4732	4735	O
.	4735	4736	O
6C	4737	4739	O
)	4739	4740	O
mRNA	4741	4745	O
levels	4746	4752	O
were	4753	4757	O
almost	4758	4764	O
identical	4765	4774	O
when	4775	4779	O
comparing	4780	4789	O
neurons	4790	4797	B-Cell
treated	4798	4805	O
with	4806	4810	O
BDNF	4811	4815	O
alone	4816	4821	O
and	4822	4825	O
neurons	4826	4833	B-Cell
with	4834	4838	O
BDNF	4839	4843	O
and	4844	4847	O
ephrin	4848	4854	O
-	4854	4855	O
A5	4855	4857	O
together	4858	4866	O
.	4866	4867	O

Thus	4868	4872	O
,	4872	4873	O
ephrin	4874	4880	O
-	4880	4881	O
A5	4881	4883	O
represses	4884	4893	O
gene	4894	4898	O
activity	4899	4907	O
elicited	4908	4916	O
by	4917	4919	O
BDNF	4920	4924	O
at	4925	4927	O
least	4928	4933	O
in	4934	4936	O
part	4937	4941	O
via	4942	4945	O
MAP	4946	4949	O
kinases	4950	4957	O
.	4957	4958	O

Besides	4959	4966	O
IEGs	4967	4971	O
,	4971	4972	O
we	4973	4975	O
inspected	4976	4985	O
the	4986	4989	O
influence	4990	4999	O
of	5000	5002	O
both	5003	5007	O
guidance	5008	5016	O
cues	5017	5021	O
on	5022	5024	O
cytoskeletal	5025	5037	B-Cellular_component
genes	5038	5043	O
,	5043	5044	O
whose	5045	5050	O
gene	5051	5055	O
products	5056	5064	O
might	5065	5070	O
modulate	5071	5079	O
cytoskeletal	5080	5092	B-Cellular_component
dynamics	5093	5101	O
evoked	5102	5108	O
by	5109	5111	O
ephrin	5112	5118	O
-	5118	5119	O
As	5119	5121	O
and	5122	5125	O
/	5125	5126	O
or	5126	5128	O
neurotrophins	5129	5142	O
(	5143	5144	O
Fig	5144	5147	O
.	5147	5148	O
S4	5149	5151	O
)	5151	5152	O
.	5152	5153	O

Therefore	5154	5163	O
,	5163	5164	O
the	5165	5168	O
filamentous	5169	5180	B-Cellular_component
actin	5181	5186	O
(	5187	5188	O
F	5188	5189	O
-	5189	5190	O
actin	5190	5195	O
)	5195	5196	O
stabilizing	5197	5208	O
tropomyosins	5209	5221	O
(	5222	5223	O
Tpm1	5223	5227	O
and	5228	5231	O
Tpm2	5232	5236	O
)	5236	5237	O
,	5237	5238	O
the	5239	5242	O
F	5243	5244	O
-	5244	5245	O
actin	5245	5250	O
cross	5251	5256	O
-	5256	5257	O
linker	5257	5263	O
alpha	5264	5269	O
-	5269	5270	O
actinin	5270	5277	O
1	5278	5279	O
(	5280	5281	O
Actn1	5281	5286	O
)	5286	5287	O
and	5288	5291	O
the	5292	5295	O
motor	5296	5301	O
protein	5302	5309	O
dynein	5310	5316	O
light	5317	5322	O
chain	5323	5328	O
1	5329	5330	O
(	5331	5332	O
Dnal1	5332	5337	O
)	5337	5338	O
were	5339	5343	O
analyzed	5344	5352	O
.	5352	5353	O

mRNA	5354	5358	O
levels	5359	5365	O
of	5366	5368	O
other	5369	5374	O
cytoskeletal	5375	5387	B-Cellular_component
genes	5388	5393	O
were	5394	5398	O
not	5399	5402	O
altered	5403	5410	O
by	5411	5413	O
any	5414	5417	O
of	5418	5420	O
the	5421	5424	O
guidance	5425	5433	O
cues	5434	5438	O
(	5439	5440	O
i	5440	5441	O
.	5441	5442	O
e	5442	5443	O
.	5443	5444	O
cofilin	5445	5452	O
,	5452	5453	O
filamin	5454	5461	O
A	5462	5463	O
,	5463	5464	O
mena	5465	5469	O
,	5469	5470	O
vinculin	5471	5479	O
and	5480	5483	O
smooth	5484	5490	B-Tissue
muscle	5491	5497	I-Tissue
actin	5498	5503	O
;	5503	5504	O
data	5505	5509	O
not	5510	5513	O
shown	5514	5519	O
)	5519	5520	O
.	5520	5521	O

Short	5522	5527	O
-	5527	5528	O
term	5528	5532	O
stimulation	5533	5544	O
with	5545	5549	O
guidance	5550	5558	O
cues	5559	5563	O
did	5564	5567	O
not	5568	5571	O
result	5572	5578	O
in	5579	5581	O
major	5582	5587	O
alterations	5588	5599	O
of	5600	5602	O
cytoskeletal	5603	5615	B-Cellular_component
mRNA	5616	5620	O
levels	5621	5627	O
except	5628	5634	O
for	5635	5638	O
upregulation	5639	5651	O
of	5652	5654	O
Tpm1	5655	5659	O
by	5660	5662	O
ephrin	5663	5669	O
-	5669	5670	O
A5	5670	5672	O
(	5673	5674	O
Fig	5674	5677	O
.	5677	5678	O
S4A	5679	5682	O
)	5682	5683	O
.	5683	5684	O

At	5685	5687	O
16h	5688	5691	O
of	5692	5694	O
incubation	5695	5705	O
,	5705	5706	O
both	5707	5711	O
tropomyosin	5712	5723	O
genes	5724	5729	O
were	5730	5734	O
induced	5735	5742	O
by	5743	5745	O
BDNF	5746	5750	O
and	5751	5754	O
ephrin	5755	5761	O
-	5761	5762	O
A5	5762	5764	O
alone	5765	5770	O
and	5771	5774	O
both	5775	5779	O
together	5780	5788	O
(	5789	5790	O
Fig	5790	5793	O
.	5793	5794	O
S4B	5795	5798	O
,	5798	5799	O
D	5800	5801	O
)	5801	5802	O
.	5802	5803	O

Actn1	5804	5809	O
levels	5810	5816	O
were	5817	5821	O
induced	5822	5829	O
by	5830	5832	O
individual	5833	5843	O
application	5844	5855	O
of	5856	5858	O
ephrin	5859	5865	O
-	5865	5866	O
A5	5866	5868	O
and	5869	5872	O
BDNF	5873	5877	O
and	5878	5881	O
by	5882	5884	O
co	5885	5887	O
-	5887	5888	O
application	5888	5899	O
of	5900	5902	O
both	5903	5907	O
(	5908	5909	O
Fig	5909	5912	O
.	5912	5913	O
S4F	5914	5917	O
)	5917	5918	O
.	5918	5919	O

A	5920	5921	O
similar	5922	5929	O
profile	5930	5937	O
was	5938	5941	O
observed	5942	5950	O
for	5951	5954	O
the	5955	5958	O
dynein	5959	5965	O
light	5966	5971	O
chain	5972	5977	O
(	5978	5979	O
Fig	5979	5982	O
.	5982	5983	O
S4H	5984	5987	O
)	5987	5988	O
.	5988	5989	O

Taken	5990	5995	O
together	5996	6004	O
,	6004	6005	O
cytoskeletal	6006	6018	B-Cellular_component
gene	6019	6023	O
expression	6024	6034	O
was	6035	6038	O
modulated	6039	6048	O
by	6049	6051	O
ephrin	6052	6058	O
-	6058	6059	O
A5	6059	6061	O
and	6062	6065	O
BDNF	6066	6070	O
.	6070	6071	O

In	6072	6074	O
contrast	6075	6083	O
to	6084	6086	O
the	6087	6090	O
antagonistic	6091	6103	O
impact	6104	6110	O
on	6111	6113	O
the	6114	6117	O
IEG	6118	6121	O
gene	6122	6126	O
response	6127	6135	O
(	6136	6137	O
Figs	6137	6141	O
.	6141	6142	O
4	6143	6144	O
and	6145	6148	O
6	6149	6150	O
)	6150	6151	O
,	6151	6152	O
ephrin	6153	6159	O
-	6159	6160	O
A5	6160	6162	O
and	6163	6166	O
BDNF	6167	6171	O
resulted	6172	6180	O
in	6181	6183	O
rather	6184	6190	O
synergistic	6191	6202	O
action	6203	6209	O
on	6210	6212	O
cytoskeletal	6213	6225	B-Cellular_component
gene	6226	6230	O
expression	6231	6241	O
.	6241	6242	O

This	6243	6247	O
difference	6248	6258	O
might	6259	6264	O
be	6265	6267	O
due	6268	6271	O
to	6272	6274	O
short	6275	6280	O
-	6280	6281	O
term	6281	6285	O
(	6286	6287	O
i	6287	6288	O
.	6288	6289	O
e	6289	6290	O
.	6290	6291	O
20	6292	6294	O
minutes	6295	6302	O
)	6302	6303	O
vs	6304	6306	O
.	6306	6307	O
long	6308	6312	O
-	6312	6313	O
term	6313	6317	O
(	6318	6319	O
i	6319	6320	O
.	6320	6321	O
e	6321	6322	O
.	6322	6323	O
16h	6324	6327	O
)	6327	6328	O
exposure	6329	6337	O
of	6338	6340	O
both	6341	6345	O
guidance	6346	6354	O
cues	6355	6359	O
in	6360	6362	O
the	6363	6366	O
IEG	6367	6370	O
and	6371	6374	O
cytoskeletal	6375	6387	B-Cellular_component
gene	6388	6392	O
response	6393	6401	O
,	6401	6402	O
respectively	6403	6415	O
.	6415	6416	O

Introduction	0	12	O

Yeast	13	18	O
infections	19	29	O
cause	30	35	O
significant	36	47	O
mortality	48	57	O
in	58	60	O
critically	61	71	O
ill	72	75	O
and	76	79	O
immunocompromised	80	97	O
patients	98	106	O
.	106	107	O

In	108	110	O
particular	111	121	O
,	121	122	O
Candida	123	130	O
species	131	138	O
are	139	142	O
the	143	146	O
4th	147	150	O
most	151	155	O
common	156	162	O
cause	163	168	O
of	169	171	O
nosocomial	172	182	O
bloodstream	183	194	B-Organism_substance
infections	195	205	O
in	206	208	O
the	209	212	O
United	213	219	O
States	220	226	O
,	226	227	O
and	228	231	O
Cryptococcus	232	244	O
neoformans	245	255	O
,	255	256	O
the	257	260	O
commonest	261	270	O
cause	271	276	O
of	277	279	O
fungal	280	286	O
meningitis	287	297	O
worldwide	298	307	O
[	308	309	O
1	309	310	O
]	310	311	O
,	311	312	O
[	313	314	O
2	314	315	O
]	315	316	O
.	316	317	O

Whilst	318	324	O
Candida	325	332	O
albicans	333	341	O
remains	342	349	O
the	350	353	O
leading	354	361	O
pathogenic	362	372	O
yeast	373	378	O
,	378	379	O
infections	380	390	O
due	391	394	O
to	395	397	O
non	398	401	O
-	401	402	O
C	402	403	O
.	403	404	O
albicans	405	413	O
species	414	421	O
such	422	426	O
as	427	429	O
Candida	430	437	O
glabrata	438	446	O
,	446	447	O
as	448	450	O
well	451	455	O
as	456	458	O
previously	459	469	O
rare	470	474	O
opportunists	475	487	O
such	488	492	O
as	493	495	O
Trichosporon	496	508	O
and	509	512	O
Geotrichum	513	523	O
species	524	531	O
,	531	532	O
are	533	536	O
increasingly	537	549	O
reported	550	558	O
[	559	560	O
1	560	561	O
]	561	562	O
,	562	563	O
[	564	565	O
3	565	566	O
]	566	567	O
-	567	568	O
[	568	569	O
6	569	570	O
]	570	571	O
.	571	572	O

Novel	573	578	O
pathogenic	579	589	O
Candida	590	597	O
species	598	605	O
such	606	610	O
as	611	613	O
Candida	614	621	O
nivariensis	622	633	O
and	634	637	O
Candida	638	645	O
bracarensis	646	657	O
have	658	662	O
also	663	667	O
been	668	672	O
described	673	682	O
[	683	684	O
7	684	685	O
]	685	686	O
.	686	687	O

Since	688	693	O
many	694	698	O
non	699	702	O
-	702	703	O
C	703	704	O
.	704	705	O
albicans	706	714	O
Candida	715	722	O
and	723	726	O
non	727	730	O
-	730	731	O
Candida	731	738	O
yeasts	739	745	O
are	746	749	O
resistant	750	759	O
or	760	762	O
less	763	767	O
susceptible	768	779	O
to	780	782	O
antifungal	783	793	O
agents	794	800	O
,	800	801	O
rapid	802	807	O
accurate	808	816	O
species	817	824	O
identification	825	839	O
is	840	842	O
central	843	850	O
to	851	853	O
timely	854	860	O
,	860	861	O
effective	862	871	O
antifungal	872	882	O
therapy	883	890	O
[	891	892	O
3	892	893	O
]	893	894	O
-	894	895	O
[	895	896	O
6	896	897	O
]	897	898	O
,	898	899	O
[	900	901	O
8	901	902	O
]	902	903	O
,	903	904	O
[	905	906	O
9	906	907	O
]	907	908	O
.	908	909	O

Conventional	910	922	O
phenotypic	923	933	O
-	933	934	O
based	934	939	O
methods	940	947	O
for	948	951	O
yeast	952	957	O
identification	958	972	O
,	972	973	O
however	974	981	O
,	981	982	O
are	983	986	O
slow	987	991	O
(	992	993	O
24	993	995	O
-	995	996	O
72	996	998	O
h	999	1000	O
)	1000	1001	O
,	1001	1002	O
insensitive	1003	1014	O
and	1015	1018	O
often	1019	1024	O
unable	1025	1031	O
to	1032	1034	O
identify	1035	1043	O
more	1044	1048	O
unusual	1049	1056	O
species	1057	1064	O
.	1064	1065	O

Various	1066	1073	O
molecular	1074	1083	O
techniques	1084	1094	O
including	1095	1104	O
real	1105	1109	O
-	1109	1110	O
time	1110	1114	O
PCR	1115	1118	O
,	1118	1119	O
DNA	1120	1123	O
sequence	1124	1132	O
analysis	1133	1141	O
,	1141	1142	O
microarray	1143	1153	O
analysis	1154	1162	O
,	1162	1163	O
and	1164	1167	O
fluorescence	1168	1180	O
in	1181	1183	O
-	1183	1184	O
situ	1184	1188	O
hybridization	1189	1202	O
provide	1203	1210	O
accurate	1211	1219	O
identification	1220	1234	O
[	1235	1236	O
10	1236	1238	O
]	1238	1239	O
,	1239	1240	O
[	1241	1242	O
11	1242	1244	O
]	1244	1245	O
but	1246	1249	O
are	1250	1253	O
expensive	1254	1263	O
,	1263	1264	O
require	1265	1272	O
substantial	1273	1284	O
specimen	1285	1293	O
processing	1294	1304	O
time	1305	1309	O
(	1310	1311	O
hours	1311	1316	O
to	1317	1319	O
a	1320	1321	O
day	1322	1325	O
)	1325	1326	O
and	1327	1330	O
are	1331	1334	O
not	1335	1338	O
easily	1339	1345	O
implemented	1346	1357	O
as	1358	1360	O
routine	1361	1368	O
techniques	1369	1379	O
in	1380	1382	O
the	1383	1386	O
clinical	1387	1395	O
laboratory	1396	1406	O
.	1406	1407	O

Matrix	1408	1414	O
-	1414	1415	O
assisted	1415	1423	O
laser	1424	1429	O
desorption	1430	1440	O
ionization	1441	1451	O
-	1451	1452	O
time	1452	1456	O
of	1457	1459	O
flight	1460	1466	O
mass	1467	1471	O
spectrometry	1472	1484	O
(	1485	1486	O
MALDI	1486	1491	O
-	1491	1492	O
TOF	1492	1495	O
MS	1496	1498	O
)	1498	1499	O
has	1500	1503	O
emerged	1504	1511	O
as	1512	1514	O
a	1515	1516	O
powerful	1517	1525	O
and	1526	1529	O
rapid	1530	1535	O
tool	1536	1540	O
for	1541	1544	O
the	1545	1548	O
identification	1549	1563	O
of	1564	1566	O
bacterial	1567	1576	O
and	1577	1580	O
yeast	1581	1586	O
pathogens	1587	1596	O
[	1597	1598	O
12	1598	1600	O
]	1600	1601	O
-	1601	1602	O
[	1602	1603	O
17	1603	1605	O
]	1605	1606	O
.	1606	1607	O

Using	1608	1613	O
MALDI	1614	1619	O
-	1619	1620	O
TOF	1620	1623	O
MS	1624	1626	O
,	1626	1627	O
the	1628	1631	O
protein	1632	1639	O
spectral	1640	1648	O
"	1649	1650	O
fingerprint	1650	1661	O
"	1661	1662	O
of	1663	1665	O
an	1666	1668	O
isolate	1669	1676	O
is	1677	1679	O
compared	1680	1688	O
to	1689	1691	O
a	1692	1693	O
reference	1694	1703	O
spectral	1704	1712	O
database	1713	1721	O
for	1722	1725	O
identification	1726	1740	O
[	1741	1742	O
18	1742	1744	O
]	1744	1745	O
.	1745	1746	O

Previous	1747	1755	O
studies	1756	1763	O
have	1764	1768	O
reported	1769	1777	O
species	1778	1785	O
identification	1786	1800	O
rates	1801	1806	O
of	1807	1809	O
92	1810	1812	O
-	1812	1813	O
99	1813	1815	O
%	1815	1816	O
amongst	1817	1824	O
collections	1825	1836	O
of	1837	1839	O
yeasts	1840	1846	O
and	1847	1850	O
yeast	1851	1856	O
-	1856	1857	O
like	1857	1861	O
organisms	1862	1871	O
[	1872	1873	O
14	1873	1875	O
]	1875	1876	O
-	1876	1877	O
[	1877	1878	O
17	1878	1880	O
]	1880	1881	O
,	1881	1882	O
[	1883	1884	O
19	1884	1886	O
]	1886	1887	O
,	1887	1888	O
[	1889	1890	O
20	1890	1892	O
]	1892	1893	O
.	1893	1894	O

However	1895	1902	O
,	1902	1903	O
taken	1904	1909	O
collectively	1910	1922	O
,	1922	1923	O
the	1924	1927	O
results	1928	1935	O
may	1936	1939	O
not	1940	1943	O
be	1944	1946	O
directly	1947	1955	O
comparable	1956	1966	O
since	1967	1972	O
these	1973	1978	O
studies	1979	1986	O
have	1987	1991	O
used	1992	1996	O
different	1997	2006	O
approaches	2007	2017	O
to	2018	2020	O
assign	2021	2027	O
species	2028	2035	O
-	2036	2037	O
from	2038	2042	O
comparing	2043	2052	O
spectra	2053	2060	O
from	2061	2065	O
test	2066	2070	O
organisms	2071	2080	O
to	2081	2083	O
reference	2084	2093	O
spectra	2094	2101	O
in	2102	2104	O
MALDI	2105	2110	O
-	2110	2111	O
TOF	2111	2114	O
MS	2115	2117	O
databases	2118	2127	O
[	2128	2129	O
16	2129	2131	O
]	2131	2132	O
,	2132	2133	O
[	2134	2135	O
20	2135	2137	O
]	2137	2138	O
,	2138	2139	O
to	2140	2142	O
enhancing	2143	2152	O
these	2153	2158	O
databases	2159	2168	O
,	2168	2169	O
and	2170	2173	O
in	2174	2176	O
some	2177	2181	O
instances	2182	2191	O
developing	2192	2202	O
study	2203	2208	O
-	2208	2209	O
specific	2209	2217	O
databases	2218	2227	O
,	2227	2228	O
with	2229	2233	O
"	2234	2235	O
in	2235	2237	O
-	2237	2238	O
house	2238	2243	O
"	2243	2244	O
spectral	2245	2253	O
signatures	2254	2264	O
[	2265	2266	O
14	2266	2268	O
]	2268	2269	O
,	2269	2270	O
[	2271	2272	O
15	2272	2274	O
]	2274	2275	O
.	2275	2276	O

There	2277	2282	O
also	2283	2287	O
is	2288	2290	O
a	2291	2292	O
continuing	2293	2303	O
need	2304	2308	O
to	2309	2311	O
extend	2312	2318	O
the	2319	2322	O
repository	2323	2333	O
of	2334	2336	O
reference	2337	2346	O
spectra	2347	2354	O
in	2355	2357	O
MALDI	2358	2363	O
-	2363	2364	O
TOF	2364	2367	O
MS	2368	2370	O
databases	2371	2380	O
.	2380	2381	O

We	2382	2384	O
therefore	2385	2394	O
undertook	2395	2404	O
the	2405	2408	O
present	2409	2416	O
study	2417	2422	O
to	2423	2425	O
evaluate	2426	2434	O
the	2435	2438	O
utility	2439	2446	O
of	2447	2449	O
the	2450	2453	O
MALDI	2454	2459	O
Biotyper	2460	2468	O
2	2469	2470	O
.	2470	2471	O
0	2471	2472	O
Microflex	2473	2482	O
LT	2483	2485	O
spectrometer	2486	2498	O
(	2499	2500	O
Bruker	2500	2506	O
Daltonik	2507	2515	O
GmbH	2516	2520	O
;	2520	2521	O
Bremen	2522	2528	O
,	2528	2529	O
Germany	2530	2537	O
)	2537	2538	O
with	2539	2543	O
its	2544	2547	O
current	2548	2555	O
spectral	2556	2564	O
database	2565	2573	O
in	2574	2576	O
comparison	2577	2587	O
with	2588	2592	O
phenotypic	2593	2603	O
-	2603	2604	O
based	2604	2609	O
methods	2610	2617	O
for	2618	2621	O
the	2622	2625	O
identification	2626	2640	O
of	2641	2643	O
a	2644	2645	O
broad	2646	2651	O
range	2652	2657	O
of	2658	2660	O
yeasts	2661	2667	O
in	2668	2670	O
a	2671	2672	O
diagnostic	2673	2683	O
laboratory	2684	2694	O
.	2694	2695	O

The	2696	2699	O
first	2700	2705	O
part	2706	2710	O
of	2711	2713	O
the	2714	2717	O
study	2718	2723	O
comprised	2724	2733	O
testing	2734	2741	O
of	2742	2744	O
reference	2745	2754	O
and	2755	2758	O
clinical	2759	2767	O
strains	2768	2775	O
from	2776	2780	O
our	2781	2784	O
culture	2785	2792	O
collection	2793	2803	O
.	2803	2804	O

The	2805	2808	O
second	2809	2815	O
was	2816	2819	O
a	2820	2821	O
blinded	2822	2829	O
prospective	2830	2841	O
analysis	2842	2850	O
of	2851	2853	O
freshly	2854	2861	O
-	2861	2862	O
collected	2862	2871	O
yeast	2872	2877	O
isolates	2878	2886	O
recovered	2887	2896	O
during	2897	2903	O
routine	2904	2911	O
laboratory	2912	2922	O
work	2923	2927	O
flow	2928	2932	O
;	2932	2933	O
discrepant	2934	2944	O
results	2945	2952	O
between	2953	2960	O
MALDI	2961	2966	O
TOF	2967	2970	O
MS	2971	2973	O
and	2974	2977	O
phenotypic	2978	2988	O
methods	2989	2996	O
were	2997	3001	O
resolved	3002	3010	O
using	3011	3016	O
sequence	3017	3025	O
analysis	3026	3034	O
of	3035	3037	O
the	3038	3041	O
fungal	3042	3048	O
internal	3049	3057	O
transcribed	3058	3069	O
spacer	3070	3076	O
(	3077	3078	O
ITS	3078	3081	O
)	3081	3082	O
regions	3083	3090	O
[	3091	3092	O
21	3092	3094	O
]	3094	3095	O
,	3095	3096	O
[	3097	3098	O
22	3098	3100	O
]	3100	3101	O
.	3101	3102	O

Results	3103	3110	O
obtained	3111	3119	O
by	3120	3122	O
preparation	3123	3134	O
of	3135	3137	O
yeasts	3138	3144	O
by	3145	3147	O
extraction	3148	3158	O
of	3159	3161	O
fungal	3162	3168	O
proteins	3169	3177	O
and	3178	3181	O
by	3182	3184	O
direct	3185	3191	O
application	3192	3203	O
of	3204	3206	O
yeast	3207	3212	O
colonies	3213	3221	O
onto	3222	3226	O
the	3227	3230	O
MALDI	3231	3236	O
TOF	3237	3240	O
MS	3241	3243	O
plate	3244	3249	O
were	3250	3254	O
also	3255	3259	O
compared	3260	3268	O
.	3268	3269	O

Classification	0	14	O
result	15	21	O
.	21	22	O

3	0	1	O
.	1	2	O
2	2	3	O
.	3	4	O

Molecular	5	14	O
Mechanisms	15	25	O
Mediating	26	35	O
the	36	39	O
Perinatal	40	49	O
Beta	50	54	B-Cell
-	54	55	I-Cell
Cell	55	59	I-Cell
Adaptive	60	68	O
Response	69	77	O
to	78	80	O
Early	81	86	O
-	86	87	O
Life	87	91	O
Stressors	92	101	O

Molecular	102	111	O
mechanisms	112	122	O
responsible	123	134	O
for	135	138	O
impaired	139	147	O
beta	148	152	B-Cell
-	152	153	I-Cell
cell	153	157	I-Cell
mass	158	162	O
formation	163	172	O
after	173	178	O
IUCR	179	183	O
or	184	186	O
IUPR	187	191	O
have	192	196	O
come	197	201	O
under	202	207	O
investigation	208	221	O
.	221	222	O

First	223	228	O
,	228	229	O
it	230	232	O
has	233	236	O
been	237	241	O
proposed	242	250	O
that	251	255	O
IUCR	256	260	O
can	261	264	O
result	265	271	O
in	272	274	O
a	275	276	O
reduction	277	286	O
of	287	289	O
the	290	293	O
embryonic	294	303	B-Cell
beta	304	308	I-Cell
-	308	309	I-Cell
cell	309	313	I-Cell
progenitor	314	324	O
pool	325	329	O
leading	330	337	O
to	338	340	O
inappropriate	341	354	O
postnatal	355	364	O
beta	365	369	B-Cell
-	369	370	I-Cell
cell	370	374	I-Cell
formation	375	384	O
.	384	385	O

Stanger	386	393	O
et	394	396	O
al	397	399	O
.	399	400	O

[	401	402	O
108	402	405	O
]	405	406	O
demonstrated	407	419	O
that	420	424	O
selective	425	434	O
genetic	435	442	O
reduction	443	452	O
in	453	455	O
the	456	459	O
size	460	464	O
of	465	467	O
PDX	468	471	O
-	471	472	O
1	472	473	O
+	473	474	O
pancreatic	475	485	B-Organ
progenitors	486	497	O
during	498	504	O
the	505	508	O
fetal	509	514	B-Developing_anatomical_structure
period	515	521	O
results	522	529	O
in	530	532	O
impaired	533	541	O
beta	542	546	B-Cell
-	546	547	I-Cell
cell	547	551	I-Cell
formation	552	561	O
during	562	568	O
the	569	572	O
postnatal	573	582	O
period	583	589	O
with	590	594	O
consequent	595	605	O
development	606	617	O
of	618	620	O
glucose	621	628	O
intolerance	629	640	O
during	641	647	O
adulthood	648	657	O
.	657	658	O

Consistent	659	669	O
with	670	674	O
this	675	679	O
,	679	680	O
maternal	681	689	O
food	690	694	O
restriction	695	706	O
leads	707	712	O
to	713	715	O
significant	716	727	O
reduction	728	737	O
in	738	740	O
PDX	741	744	O
-	744	745	O
1	745	746	O
+	746	747	O
and	748	751	O
neurogenin	752	762	O
-	762	763	O
3	763	764	O
+	764	765	O
pancreatic	766	776	B-Organ
precursors	777	787	O
during	788	794	O
embryonic	795	804	B-Developing_anatomical_structure
development	805	816	O
in	817	819	O
rats	820	824	O
,	824	825	O
diminished	826	836	O
postnatal	837	846	O
beta	847	851	B-Cell
-	851	852	I-Cell
cell	852	856	I-Cell
formation	857	866	O
,	866	867	O
and	868	871	O
inability	872	881	O
to	882	884	O
expand	885	891	O
beta	892	896	B-Cell
-	896	897	I-Cell
cell	897	901	I-Cell
mass	902	906	O
in	907	909	O
response	910	918	O
to	919	921	O
pregnancy	922	931	O
[	932	933	O
47	933	935	O
,	935	936	O
94	937	939	O
]	939	940	O
.	940	941	O

The	942	945	O
UPI	946	949	O
model	950	955	O
is	956	958	O
also	959	963	O
characterized	964	977	O
by	978	980	O
a	981	982	O
permanent	983	992	O
decrease	993	1001	O
in	1002	1004	O
islet	1005	1010	B-Multi-tissue_structure
PDX	1011	1014	O
-	1014	1015	O
1	1015	1016	O
mRNA	1017	1021	O
expression	1022	1032	O
.	1032	1033	O

This	1034	1038	O
decrease	1039	1047	O
has	1048	1051	O
recently	1052	1060	O
been	1061	1065	O
shown	1066	1071	O
to	1072	1074	O
be	1075	1077	O
due	1078	1081	O
to	1082	1084	O
progressive	1085	1096	O
epigenetic	1097	1107	O
silencing	1108	1117	O
of	1118	1120	O
the	1121	1124	O
Pdx1	1125	1129	O
gene	1130	1134	O
locus	1135	1140	O
secondary	1141	1150	O
to	1151	1153	O
proximal	1154	1162	O
promoter	1163	1171	O
methylation	1172	1183	O
[	1184	1185	O
69	1185	1187	O
,	1187	1188	O
109	1189	1192	O
]	1192	1193	O
,	1193	1194	O
and	1195	1198	O
it	1199	1201	O
may	1202	1205	O
be	1206	1208	O
responsible	1209	1220	O
for	1221	1224	O
the	1225	1228	O
decreased	1229	1238	O
rate	1239	1243	O
of	1244	1246	O
beta	1247	1251	B-Cell
-	1251	1252	I-Cell
cell	1252	1256	I-Cell
replication	1257	1268	O
and	1269	1272	O
inappropriate	1273	1286	O
postnatal	1287	1296	O
beta	1297	1301	B-Cell
-	1301	1302	I-Cell
cell	1302	1306	I-Cell
mass	1307	1311	O
development	1312	1323	O
[	1324	1325	O
69	1325	1327	O
,	1327	1328	O
110	1329	1332	O
]	1332	1333	O
.	1333	1334	O

In	1335	1337	O
the	1338	1341	O
same	1342	1346	O
way	1347	1350	O
of	1351	1353	O
thinking	1354	1362	O
,	1362	1363	O
studies	1364	1371	O
have	1372	1376	O
demonstrated	1377	1389	O
that	1390	1394	O
the	1395	1398	O
maintenance	1399	1410	O
of	1411	1413	O
methylated	1414	1424	O
histone	1425	1432	O
H3	1433	1435	O
Lys4	1436	1440	O
by	1441	1443	O
Set7	1444	1448	O
/	1448	1449	O
9	1449	1450	O
,	1450	1451	O
a	1452	1453	O
member	1454	1460	O
of	1461	1463	O
the	1464	1467	O
SET	1468	1471	O
methyltransferase	1472	1489	O
family	1490	1496	O
,	1496	1497	O
is	1498	1500	O
crucial	1501	1508	O
to	1509	1511	O
Pdx1	1512	1516	O
activity	1517	1525	O
in	1526	1528	O
beta	1529	1533	B-Cell
-	1533	1534	I-Cell
cell	1534	1538	I-Cell
lines	1539	1544	I-Cell
[	1545	1546	O
111	1546	1549	O
-	1549	1550	O
113	1550	1553	O
]	1553	1554	O
.	1554	1555	O

This	1556	1560	O
led	1561	1564	O
to	1565	1567	O
the	1568	1571	O
hypothesis	1572	1582	O
that	1583	1587	O
Set7	1588	1592	O
/	1592	1593	O
9	1593	1594	O
may	1595	1598	O
represent	1599	1608	O
a	1609	1610	O
novel	1611	1616	O
chromatin	1617	1626	O
-	1626	1627	O
modifying	1627	1636	O
protein	1637	1644	O
that	1645	1649	O
functions	1650	1659	O
in	1660	1662	O
part	1663	1667	O
through	1668	1675	O
its	1676	1679	O
recruitment	1680	1691	O
to	1692	1694	O
target	1695	1701	O
genes	1702	1707	O
by	1708	1710	O
cell	1711	1715	B-Cell
-	1715	1716	O
specific	1716	1724	O
transcription	1725	1738	O
factors	1739	1746	O
such	1747	1751	O
as	1752	1754	O
Pdx1	1755	1759	O
.	1759	1760	O

Since	1761	1766	O
then	1767	1771	O
,	1771	1772	O
a	1773	1774	O
role	1775	1779	O
of	1780	1782	O
histone	1783	1790	O
methyl	1791	1797	O
transferases	1798	1810	O
,	1810	1811	O
particularly	1812	1824	O
set7	1825	1829	O
,	1829	1830	O
has	1831	1834	O
also	1835	1839	O
been	1840	1844	O
demonstrated	1845	1857	O
in	1858	1860	O
the	1861	1864	O
sustained	1865	1874	O
deleterious	1875	1886	O
effects	1887	1894	O
of	1895	1897	O
chronic	1898	1905	O
hyperglycemia	1906	1919	O
on	1920	1922	O
human	1923	1928	O
microvascular	1929	1942	B-Cell
endothelial	1943	1954	I-Cell
cells	1955	1960	I-Cell
[	1961	1962	O
114	1962	1965	O
]	1965	1966	O
.	1966	1967	O

Such	1968	1972	O
an	1973	1975	O
epigenetic	1976	1986	O
change	1987	1993	O
could	1994	1999	O
potentially	2000	2011	O
be	2012	2014	O
involved	2015	2023	O
in	2024	2026	O
the	2027	2030	O
deleterious	2031	2042	O
effect	2043	2049	O
of	2050	2052	O
high	2053	2057	O
glucose	2058	2065	O
upon	2066	2070	O
the	2071	2074	O
fetal	2075	2080	B-Organ
pancreas	2081	2089	I-Organ
in	2090	2092	O
the	2093	2096	O
IUED	2097	2101	O
models	2102	2108	O
.	2108	2109	O

Another	2110	2117	O
mechanism	2118	2127	O
proposed	2128	2136	O
to	2137	2139	O
explain	2140	2147	O
reduced	2148	2155	O
beta	2156	2160	B-Cell
-	2160	2161	I-Cell
cell	2161	2165	I-Cell
formation	2166	2175	O
after	2176	2181	O
IUCR	2182	2186	O
is	2187	2189	O
related	2190	2197	O
to	2198	2200	O
prenatal	2201	2209	O
glucocorticoid	2210	2224	O
exposure	2225	2233	O
.	2233	2234	O

Administration	2235	2249	O
of	2250	2252	O
either	2253	2259	O
dexamethasone	2260	2273	O
or	2274	2276	O
carbenoxolone	2277	2290	O
(	2291	2292	O
to	2292	2294	O
inhibit	2295	2302	O
11	2303	2305	O
beta	2306	2310	O
-	2310	2311	O
hydroxysteroid	2311	2325	O
dehydrogenase	2326	2339	O
type	2340	2344	O
2	2345	2346	O
)	2346	2347	O
to	2348	2350	O
normal	2351	2357	O
pregnant	2358	2366	O
rats	2367	2371	O
also	2372	2376	O
causes	2377	2383	O
fetal	2384	2389	B-Developing_anatomical_structure
growth	2390	2396	O
retardation	2397	2408	O
and	2409	2412	O
the	2413	2416	O
adult	2417	2422	O
offspring	2423	2432	O
are	2433	2436	O
hypertensive	2437	2449	O
and	2450	2453	O
hyperglycemic	2454	2467	O
,	2467	2468	O
with	2469	2473	O
hyperactive	2474	2485	O
hypothalamic	2486	2498	B-Organ
-	2498	2499	O
pituitary	2499	2508	B-Organ
-	2508	2509	O
adrenal	2509	2516	B-Organ
axis	2517	2521	O
[	2522	2523	O
115	2523	2526	O
]	2526	2527	O
.	2527	2528	O

Maternal	2529	2537	O
undernutrition	2538	2552	O
significantly	2553	2566	O
increased	2567	2576	O
both	2577	2581	O
fetal	2582	2587	B-Developing_anatomical_structure
and	2588	2591	O
maternal	2592	2600	O
corticosterone	2601	2615	O
concentrations	2616	2630	O
in	2631	2633	O
rats	2634	2638	O
[	2639	2640	O
116	2640	2643	O
]	2643	2644	O
.	2644	2645	O

Subsequently	2646	2658	O
,	2658	2659	O
maternal	2660	2668	O
and	2669	2672	O
/	2672	2673	O
or	2673	2675	O
fetal	2676	2681	B-Developing_anatomical_structure
overexposure	2682	2694	O
to	2695	2697	O
glucocorticoids	2698	2713	O
(	2714	2715	O
via	2715	2718	O
administration	2719	2733	O
of	2734	2736	O
dexamethasone	2737	2750	O
)	2750	2751	O
impairs	2752	2759	O
both	2760	2764	O
fetal	2765	2770	B-Developing_anatomical_structure
and	2771	2774	O
postnatal	2775	2784	O
beta	2785	2789	B-Cell
-	2789	2790	I-Cell
cell	2790	2794	I-Cell
formation	2795	2804	O
in	2805	2807	O
rodents	2808	2815	O
and	2816	2819	O
nonhuman	2820	2828	O
primates	2829	2837	O
[	2838	2839	O
94	2839	2841	O
,	2841	2842	O
117	2843	2846	O
-	2846	2847	O
119	2847	2850	O
]	2850	2851	O
.	2851	2852	O

Seckl	2853	2858	O
et	2859	2861	O
al	2862	2864	O
.	2864	2865	O

[	2866	2867	O
115	2867	2870	O
]	2870	2871	O
have	2872	2876	O
shown	2877	2882	O
that	2883	2887	O
fetal	2888	2893	B-Developing_anatomical_structure
corticosterone	2894	2908	O
concentrations	2909	2923	O
are	2924	2927	O
inversely	2928	2937	O
correlated	2938	2948	O
with	2949	2953	O
fetal	2954	2959	B-Developing_anatomical_structure
insulin	2960	2967	O
content	2968	2975	O
and	2976	2979	O
postnatal	2980	2989	O
beta	2990	2994	B-Cell
-	2994	2995	I-Cell
cell	2995	2999	I-Cell
formation	3000	3009	O
in	3010	3012	O
rats	3013	3017	O
.	3017	3018	O

Evidence	3019	3027	O
suggests	3028	3036	O
that	3037	3041	O
glucocorticoids	3042	3057	O
can	3058	3061	O
exert	3062	3067	O
a	3068	3069	O
direct	3070	3076	O
effect	3077	3083	O
on	3084	3086	O
the	3087	3090	O
developing	3091	3101	O
fetal	3102	3107	B-Organ
pancreas	3108	3116	I-Organ
via	3117	3120	O
transcriptional	3121	3136	O
modulation	3137	3147	O
of	3148	3150	O
transcription	3151	3164	O
factors	3165	3172	O
involved	3173	3181	O
in	3182	3184	O
beta	3185	3189	B-Cell
-	3189	3190	I-Cell
cell	3190	3194	I-Cell
formation	3195	3204	O
and	3205	3208	O
differentiation	3209	3224	O
[	3225	3226	O
117	3226	3229	O
]	3229	3230	O
.	3230	3231	O

Glucocorticoid	3232	3246	O
receptors	3247	3256	O
are	3257	3260	O
present	3261	3268	O
in	3269	3271	O
the	3272	3275	O
pancreas	3276	3284	B-Organ
during	3285	3291	O
embryonic	3292	3301	B-Developing_anatomical_structure
development	3302	3313	O
of	3314	3316	O
rodents	3317	3324	O
and	3325	3328	O
humans	3329	3335	O
[	3336	3337	O
117	3337	3340	O
]	3340	3341	O
,	3341	3342	O
and	3343	3346	O
glucocorticoids	3347	3362	O
can	3363	3366	O
bind	3367	3371	O
to	3372	3374	O
the	3375	3378	O
Pdx1	3379	3383	O
promoter	3384	3392	O
and	3393	3396	O
thus	3397	3401	O
suppress	3402	3410	O
fetal	3411	3416	B-Cell
endocrine	3417	3426	I-Cell
cell	3427	3431	I-Cell
differentiation	3432	3447	O
[	3448	3449	O
117	3449	3452	O
]	3452	3453	O
.	3453	3454	O

Glucocorticoid	3455	3469	O
treatment	3470	3479	O
has	3480	3483	O
been	3484	3488	O
shown	3489	3494	O
to	3495	3497	O
significantly	3498	3511	O
reduce	3512	3518	O
fetal	3519	3524	B-Developing_anatomical_structure
expression	3525	3535	O
of	3536	3538	O
key	3539	3542	O
endocrine	3543	3552	O
transcription	3553	3566	O
factors	3567	3574	O
such	3575	3579	O
as	3580	3582	O
Pdx1	3583	3587	O
and	3588	3591	O
Pax6	3592	3596	O
but	3597	3600	O
simultaneously	3601	3615	O
increase	3616	3624	O
expression	3625	3635	O
of	3636	3638	O
transcription	3639	3652	O
factors	3653	3660	O
that	3661	3665	O
regulate	3666	3674	O
development	3675	3686	O
of	3687	3689	O
the	3690	3693	O
exocrine	3694	3702	B-Organ
pancreas	3703	3711	I-Organ
[	3712	3713	O
119	3713	3716	O
]	3716	3717	O
.	3717	3718	O

It	3719	3721	O
has	3722	3725	O
also	3726	3730	O
been	3731	3735	O
demonstrated	3736	3748	O
that	3749	3753	O
the	3754	3757	O
UPI	3758	3761	O
or	3762	3764	O
the	3765	3768	O
low	3769	3772	O
-	3772	3773	O
protein	3773	3780	O
IUPR	3781	3785	O
offspring	3786	3795	O
experience	3796	3806	O
increased	3807	3816	O
oxidative	3817	3826	O
stress	3827	3833	O
and	3834	3837	O
impaired	3838	3846	O
mitochondrial	3847	3860	B-Cellular_component
function	3861	3869	O
[	3870	3871	O
96	3871	3873	O
,	3873	3874	O
120	3875	3878	O
]	3878	3879	O
.	3879	3880	O

The	3881	3884	O
mitochondrial	3885	3898	B-Cellular_component
dysfunction	3899	3910	O
was	3911	3914	O
not	3915	3918	O
limited	3919	3926	O
to	3927	3929	O
just	3930	3934	O
the	3935	3938	O
beta	3939	3943	B-Cell
cell	3944	3948	I-Cell
,	3948	3949	O
as	3950	3952	O
mitochondria	3953	3965	B-Cellular_component
from	3966	3970	O
both	3971	3975	O
the	3976	3979	O
liver	3980	3985	B-Organ
and	3986	3989	O
skeletal	3990	3998	B-Organ
muscle	3999	4005	I-Organ
exhibit	4006	4013	O
decreased	4014	4023	O
oxidation	4024	4033	O
of	4034	4036	O
pyruvate	4037	4045	O
,	4045	4046	O
subsequently	4047	4059	O
leading	4060	4067	O
to	4068	4070	O
the	4071	4074	O
development	4075	4086	O
of	4087	4089	O
features	4090	4098	O
commonly	4099	4107	O
found	4108	4113	O
in	4114	4116	O
T2D	4117	4120	O
[	4121	4122	O
100	4122	4125	O
,	4125	4126	O
121	4127	4130	O
]	4130	4131	O
.	4131	4132	O

Also	4133	4137	O
exposure	4138	4146	O
to	4147	4149	O
a	4150	4151	O
Western	4152	4159	O
-	4159	4160	O
style	4160	4165	O
diet	4166	4170	O
before	4171	4177	O
and	4178	4181	O
during	4182	4188	O
pregnancy	4189	4198	O
(	4199	4200	O
an	4200	4202	O
IUEO	4203	4207	O
model	4208	4213	O
)	4213	4214	O
alters	4215	4221	O
the	4222	4225	O
redox	4226	4231	O
state	4232	4237	O
as	4238	4240	O
early	4241	4246	O
as	4247	4249	O
preimplantation	4250	4265	O
development	4266	4277	O
,	4277	4278	O
leading	4279	4286	O
to	4287	4289	O
mild	4290	4294	O
oxidative	4295	4304	O
stress	4305	4311	O
associated	4312	4322	O
with	4323	4327	O
inflammation	4328	4340	O
.	4340	4341	O

The	4342	4345	O
finding	4346	4353	O
that	4354	4358	O
administration	4359	4373	O
of	4374	4376	O
antioxidants	4377	4389	O
to	4390	4392	O
the	4393	4396	O
dam	4397	4400	O
reverses	4401	4409	O
oxidative	4410	4419	O
stress	4420	4426	O
and	4427	4430	O
completely	4431	4441	O
prevents	4442	4450	O
the	4451	4454	O
development	4455	4466	O
of	4467	4469	O
glucose	4470	4477	O
intolerance	4478	4489	O
and	4490	4493	O
increased	4494	4503	O
adiposity	4504	4513	O
in	4514	4516	O
the	4517	4520	O
adult	4521	4526	O
offspring	4527	4536	O
suggests	4537	4545	O
that	4546	4550	O
oxidative	4551	4560	O
stress	4561	4567	O
plays	4568	4573	O
an	4574	4576	O
important	4577	4586	O
role	4587	4591	O
in	4592	4594	O
the	4595	4598	O
development	4599	4610	O
of	4611	4613	O
adiposity	4614	4623	O
in	4624	4626	O
this	4627	4631	O
case	4632	4636	O
[	4637	4638	O
122	4638	4641	O
]	4641	4642	O
.	4642	4643	O

Some	4644	4648	O
studies	4649	4656	O
in	4657	4659	O
the	4660	4663	O
low	4664	4667	O
-	4667	4668	O
protein	4668	4675	O
IUPR	4676	4680	O
model	4681	4686	O
have	4687	4691	O
demonstrated	4692	4704	O
that	4705	4709	O
oxidative	4710	4719	O
stress	4720	4726	O
is	4727	4729	O
not	4730	4733	O
limited	4734	4741	O
to	4742	4744	O
just	4745	4749	O
mitochondrial	4750	4763	B-Cellular_component
DNA	4764	4767	O
damage	4768	4774	O
,	4774	4775	O
but	4776	4779	O
also	4780	4784	O
to	4785	4787	O
genomic	4788	4795	O
DNA	4796	4799	O
,	4799	4800	O
impacting	4801	4810	O
cell	4811	4815	B-Cell
-	4815	4816	O
cycle	4816	4821	O
regulation	4822	4832	O
and	4833	4836	O
gene	4837	4841	O
expression	4842	4852	O
[	4853	4854	O
123	4854	4857	O
]	4857	4858	O
.	4858	4859	O

While	4860	4865	O
DNA	4866	4869	O
is	4870	4872	O
being	4873	4878	O
targeted	4879	4887	O
throughout	4888	4898	O
by	4899	4901	O
ROS	4902	4905	O
,	4905	4906	O
there	4907	4912	O
are	4913	4916	O
particular	4917	4927	O
regions	4928	4935	O
that	4936	4940	O
are	4941	4944	O
known	4945	4950	O
to	4951	4953	O
be	4954	4956	O
more	4957	4961	O
sensitive	4962	4971	O
to	4972	4974	O
ROS	4975	4978	O
-	4978	4979	O
mediated	4979	4987	O
damage	4988	4994	O
,	4994	4995	O
for	4996	4999	O
example	5000	5007	O
,	5007	5008	O
telomeres	5009	5018	O
.	5018	5019	O

Telomeres	5020	5029	O
comprise	5030	5038	O
GC	5039	5041	O
-	5041	5042	O
rich	5042	5046	O
repeats	5047	5054	O
and	5055	5058	O
are	5059	5062	O
found	5063	5068	O
at	5069	5071	O
the	5072	5075	O
ends	5076	5080	O
of	5081	5083	O
each	5084	5088	O
chromosome	5089	5099	O
.	5099	5100	O

They	5101	5105	O
are	5106	5109	O
known	5110	5115	O
to	5116	5118	O
shorten	5119	5126	O
with	5127	5131	O
each	5132	5136	O
cellular	5137	5145	B-Cell
division	5146	5154	O
and	5155	5158	O
,	5158	5159	O
hence	5160	5165	O
,	5165	5166	O
can	5167	5170	O
act	5171	5174	O
as	5175	5177	O
a	5178	5179	O
mitotic	5180	5187	O
clock	5188	5193	O
,	5193	5194	O
registering	5195	5206	O
the	5207	5210	O
number	5211	5217	O
of	5218	5220	O
replicative	5221	5232	O
divisions	5233	5242	O
to	5243	5245	O
have	5246	5250	O
taken	5251	5256	O
place	5257	5262	O
within	5263	5269	O
the	5270	5273	O
cell	5274	5278	B-Cell
.	5278	5279	O

Investigations	5280	5294	O
using	5295	5300	O
an	5301	5303	O
IUPR	5304	5308	O
model	5309	5314	O
have	5315	5319	O
indeed	5320	5326	O
reported	5327	5335	O
a	5336	5337	O
decrease	5338	5346	O
in	5347	5349	O
longevity	5350	5359	O
in	5360	5362	O
the	5363	5366	O
offspring	5367	5376	O
[	5377	5378	O
123	5378	5381	O
,	5381	5382	O
124	5383	5386	O
]	5386	5387	O
accompanied	5388	5399	O
by	5400	5402	O
reduction	5403	5412	O
in	5413	5415	O
mitochondrial	5416	5429	B-Cellular_component
antioxidant	5430	5441	O
defences	5442	5450	O
[	5451	5452	O
96	5452	5454	O
,	5454	5455	O
125	5456	5459	O
]	5459	5460	O
and	5461	5464	O
telomere	5465	5473	O
length	5474	5480	O
in	5481	5483	O
islets	5484	5490	B-Multi-tissue_structure
[	5491	5492	O
125	5492	5495	O
]	5495	5496	O
.	5496	5497	O

Pancreatic	5498	5508	B-Multi-tissue_structure
islet	5509	5514	I-Multi-tissue_structure
development	5515	5526	O
has	5527	5530	O
been	5531	5535	O
shown	5536	5541	O
to	5542	5544	O
be	5545	5547	O
influenced	5548	5558	O
by	5559	5561	O
a	5562	5563	O
number	5564	5570	O
of	5571	5573	O
growth	5574	5580	O
factors	5581	5588	O
including	5589	5598	O
the	5599	5602	O
insulin	5603	5610	O
-	5610	5611	O
like	5611	5615	O
growth	5616	5622	O
factors	5623	5630	O
,	5630	5631	O
IGF	5632	5635	O
-	5635	5636	O
I	5636	5637	O
and	5638	5641	O
IGF	5642	5645	O
-	5645	5646	O
II	5646	5648	O
whose	5649	5654	O
expression	5655	5665	O
in	5666	5668	O
utero	5669	5674	O
is	5675	5677	O
regulated	5678	5687	O
by	5688	5690	O
nutrient	5691	5699	O
and	5700	5703	O
hormone	5704	5711	O
concentrations	5712	5726	O
.	5726	5727	O

IUPR	5728	5732	O
modifies	5733	5741	O
expression	5742	5752	O
of	5753	5755	O
both	5756	5760	O
IGF	5761	5764	O
genes	5765	5770	O
in	5771	5773	O
a	5774	5775	O
variety	5776	5783	O
of	5784	5786	O
fetal	5787	5792	B-Tissue
tissues	5793	5800	I-Tissue
.	5800	5801	O

In	5802	5804	O
an	5805	5807	O
IUPR	5808	5812	O
rat	5813	5816	O
model	5817	5822	O
with	5823	5827	O
a	5828	5829	O
decreased	5830	5839	O
beta	5840	5844	B-Cell
-	5844	5845	I-Cell
cell	5845	5849	I-Cell
mass	5850	5854	O
and	5855	5858	O
beta	5859	5863	B-Cell
-	5863	5864	I-Cell
cell	5864	5868	I-Cell
replication	5869	5880	O
and	5881	5884	O
an	5885	5887	O
increased	5888	5897	O
rate	5898	5902	O
of	5903	5905	O
beta	5906	5910	B-Cell
-	5910	5911	I-Cell
cell	5911	5915	I-Cell
apoptosis	5916	5925	O
,	5925	5926	O
gene	5927	5931	O
expression	5932	5942	O
for	5943	5946	O
IGF	5947	5950	O
-	5950	5951	O
II	5951	5953	O
but	5954	5957	O
not	5958	5961	O
IGF	5962	5965	O
-	5965	5966	O
I	5966	5967	O
was	5968	5971	O
found	5972	5977	O
reduced	5978	5985	O
in	5986	5988	O
the	5989	5992	O
fetal	5993	5998	B-Organ
pancreas	5999	6007	I-Organ
[	6008	6009	O
126	6009	6012	O
]	6012	6013	O
.	6013	6014	O

In	6015	6017	O
a	6018	6019	O
different	6020	6029	O
IUPR	6030	6034	O
model	6035	6040	O
with	6041	6045	O
more	6046	6050	O
severe	6051	6057	O
global	6058	6064	O
food	6065	6069	O
restriction	6070	6081	O
which	6082	6087	O
induced	6088	6095	O
hyperinsulinemia	6096	6112	O
and	6113	6116	O
an	6117	6119	O
increase	6120	6128	O
in	6129	6131	O
beta	6132	6136	B-Cell
-	6136	6137	I-Cell
cell	6137	6141	I-Cell
mass	6142	6146	O
in	6147	6149	O
their	6150	6155	O
fetuses	6156	6163	B-Developing_anatomical_structure
[	6164	6165	O
90	6165	6167	O
]	6167	6168	O
,	6168	6169	O
the	6170	6173	O
fetal	6174	6179	B-Developing_anatomical_structure
phenotype	6180	6189	O
was	6190	6193	O
unexpectedly	6194	6206	O
associated	6207	6217	O
with	6218	6222	O
an	6223	6225	O
increase	6226	6234	O
in	6235	6237	O
pancreatic	6238	6248	B-Organ
IGF	6249	6252	O
-	6252	6253	O
I	6253	6254	O
expression	6255	6265	O
,	6265	6266	O
islet	6267	6272	B-Multi-tissue_structure
IGF	6273	6276	O
-	6276	6277	O
1R	6277	6279	O
[	6280	6281	O
91	6281	6283	O
]	6283	6284	O
,	6284	6285	O
and	6286	6289	O
IRS	6290	6293	O
-	6293	6294	O
2	6294	6295	O
[	6296	6297	O
92	6297	6299	O
]	6299	6300	O
.	6300	6301	O

In	6302	6304	O
the	6305	6308	O
fetal	6309	6314	B-Developing_anatomical_structure
GK	6315	6317	O
/	6317	6318	O
Par	6318	6321	O
rat	6322	6325	O
exposed	6326	6333	O
to	6334	6336	O
mild	6337	6341	O
hyperglycemia	6342	6355	O
during	6356	6362	O
gestation	6363	6372	O
(	6373	6374	O
a	6374	6375	O
model	6376	6381	O
of	6382	6384	O
IUED	6385	6389	O
)	6389	6390	O
,	6390	6391	O
data	6392	6396	O
from	6397	6401	O
our	6402	6405	O
group	6406	6411	O
suggest	6412	6419	O
that	6420	6424	O
the	6425	6428	O
beta	6429	6433	B-Cell
-	6433	6434	I-Cell
cell	6434	6438	I-Cell
deficit	6439	6446	O
(	6447	6448	O
reduced	6448	6455	O
by	6456	6458	O
more	6459	6463	O
than	6464	6468	O
50	6469	6471	O
%	6471	6472	O
)	6472	6473	O
starts	6474	6480	O
as	6481	6483	O
early	6484	6489	O
as	6490	6492	O
fetal	6493	6498	B-Developing_anatomical_structure
age	6499	6502	O
E16	6503	6506	O
and	6507	6510	O
reflects	6511	6519	O
decreased	6520	6529	O
beta	6530	6534	B-Cell
-	6534	6535	I-Cell
cell	6535	6539	I-Cell
proliferation	6540	6553	O
,	6553	6554	O
a	6555	6556	O
limitation	6557	6567	O
of	6568	6570	O
beta	6571	6575	B-Cell
-	6575	6576	I-Cell
cell	6576	6580	I-Cell
neogenesis	6581	6591	O
from	6592	6596	O
precursors	6597	6607	O
,	6607	6608	O
and	6609	6612	O
increased	6613	6622	O
apoptosis	6623	6632	O
of	6633	6635	O
both	6636	6640	O
beta	6641	6645	B-Cell
cells	6646	6651	I-Cell
and	6652	6655	O
their	6656	6661	O
precursors	6662	6672	O
[	6673	6674	O
86	6674	6676	O
]	6676	6677	O
.	6677	6678	O

Notably	6679	6686	O
,	6686	6687	O
Pdx1	6688	6692	O
and	6693	6696	O
Neurogenin3	6697	6708	O
expression	6709	6719	O
were	6720	6724	O
decreased	6725	6734	O
on	6735	6737	O
E18	6738	6741	O
but	6742	6745	O
normally	6746	6754	O
expressed	6755	6764	O
on	6765	6767	O
E13	6768	6771	O
[	6772	6773	O
86	6773	6775	O
]	6775	6776	O
.	6776	6777	O

Defective	6778	6787	O
signalling	6788	6798	O
through	6799	6806	O
the	6807	6810	O
Igf2	6811	6815	O
/	6815	6816	O
Igf1	6816	6820	O
-	6820	6821	O
R	6821	6822	O
pathway	6823	6830	O
may	6831	6834	O
represent	6835	6844	O
the	6845	6848	O
primary	6849	6856	O
instrumental	6857	6869	O
anomaly	6870	6877	O
since	6878	6883	O
Igf2	6884	6888	O
and	6889	6892	O
Igf1	6893	6897	O
-	6897	6898	O
R	6898	6899	O
protein	6900	6907	O
expressions	6908	6919	O
are	6920	6923	O
already	6924	6931	O
decreased	6932	6941	O
within	6942	6948	O
the	6949	6952	O
GK	6953	6955	O
/	6955	6956	O
Par	6956	6959	O
pancreatic	6960	6970	B-Organ
rudiment	6971	6979	I-Organ
at	6980	6982	O
E13	6983	6986	O
,	6986	6987	O
at	6988	6990	O
a	6991	6992	O
time	6993	6997	O
when	6998	7002	O
beta	7003	7007	B-Cell
-	7007	7008	I-Cell
cell	7008	7012	I-Cell
mass	7013	7017	O
(	7018	7019	O
first	7019	7024	O
wave	7025	7029	O
of	7030	7032	O
beta	7033	7037	B-Cell
-	7037	7038	I-Cell
cell	7038	7042	I-Cell
expansion	7043	7052	O
)	7052	7053	O
is	7054	7056	O
in	7057	7059	O
fact	7060	7064	O
normal	7065	7071	O
[	7072	7073	O
31	7073	7075	O
]	7075	7076	O
.	7076	7077	O

Low	7078	7081	O
levels	7082	7088	O
of	7089	7091	O
pancreatic	7092	7102	B-Organ
Igf2	7103	7107	O
associated	7108	7118	O
with	7119	7123	O
beta	7124	7128	B-Cell
-	7128	7129	I-Cell
cell	7129	7133	I-Cell
mass	7134	7138	O
deficiency	7139	7149	O
are	7150	7153	O
maintained	7154	7164	O
thereafter	7165	7175	O
within	7176	7182	O
the	7183	7186	O
fetal	7187	7192	B-Organ
pancreas	7193	7201	I-Organ
[	7202	7203	O
87	7203	7205	O
]	7205	7206	O
.	7206	7207	O

Crossbreeding	7208	7221	O
protocols	7222	7231	O
between	7232	7239	O
nondiabetic	7240	7251	O
W	7252	7253	O
and	7254	7257	O
diabetic	7258	7266	O
GK	7267	7269	O
rats	7270	7274	O
showed	7275	7281	O
that	7282	7286	O
,	7286	7287	O
in	7288	7290	O
late	7291	7295	O
gestation	7296	7305	O
(	7306	7307	O
E18	7307	7310	O
)	7310	7311	O
,	7311	7312	O
pancreatic	7313	7323	B-Organ
Igf2	7324	7328	O
protein	7329	7336	O
expression	7337	7347	O
was	7348	7351	O
as	7352	7354	O
low	7355	7358	O
in	7359	7361	O
GKmother	7362	7370	O
/	7370	7371	O
GKfather	7371	7379	O
and	7380	7383	O
Wmother	7384	7391	O
/	7391	7392	O
GKfather	7392	7400	O
crosses	7401	7408	O
as	7409	7411	O
in	7412	7414	O
GKmother	7415	7423	O
/	7423	7424	O
GKfather	7424	7432	O
crosses	7433	7440	O
[	7441	7442	O
87	7442	7444	O
]	7444	7445	O
.	7445	7446	O

These	7447	7452	O
findings	7453	7461	O
rather	7462	7468	O
support	7469	7476	O
the	7477	7480	O
hypothesis	7481	7491	O
that	7492	7496	O
the	7497	7500	O
pancreatic	7501	7511	B-Organ
Igf2	7512	7516	O
anomaly	7517	7524	O
in	7525	7527	O
the	7528	7531	O
GK	7532	7534	O
diabetic	7535	7543	O
model	7544	7549	O
is	7550	7552	O
linked	7553	7559	O
to	7560	7562	O
a	7563	7564	O
genetic	7565	7572	O
determinism	7573	7584	O
.	7584	7585	O

This	7586	7590	O
view	7591	7595	O
is	7596	7598	O
also	7599	7603	O
consistent	7604	7614	O
with	7615	7619	O
the	7620	7623	O
results	7624	7631	O
of	7632	7634	O
genetic	7635	7642	O
analyses	7643	7651	O
that	7652	7656	O
linked	7657	7663	O
a	7664	7665	O
locus	7666	7671	O
containing	7672	7682	O
the	7683	7686	O
gene	7687	7691	O
encoding	7692	7700	O
Igf2	7701	7705	O
to	7706	7708	O
diabetes	7709	7717	O
in	7718	7720	O
the	7721	7724	O
GK	7725	7727	O
rat	7728	7731	O
[	7732	7733	O
127	7733	7736	O
]	7736	7737	O
.	7737	7738	O

The	7739	7742	O
Igf2	7743	7747	O
gene	7748	7752	O
is	7753	7755	O
subjected	7756	7765	O
to	7766	7768	O
paternal	7769	7777	O
genomic	7778	7785	O
imprinting	7786	7796	O
.	7796	7797	O

However	7798	7805	O
,	7805	7806	O
because	7807	7814	O
the	7815	7818	O
Igf2	7819	7823	O
expression	7824	7834	O
is	7835	7837	O
similarly	7838	7847	O
affected	7848	7856	O
in	7857	7859	O
fetuses	7860	7867	B-Developing_anatomical_structure
,	7867	7868	O
regardless	7869	7879	O
of	7880	7882	O
whether	7883	7890	O
the	7891	7894	O
father	7895	7901	O
is	7902	7904	O
W	7905	7906	O
or	7907	7909	O
GK	7910	7912	O
[	7913	7914	O
87	7914	7916	O
]	7916	7917	O
,	7917	7918	O
we	7919	7921	O
cannot	7922	7928	O
conclude	7929	7937	O
with	7938	7942	O
a	7943	7944	O
simple	7945	7951	O
change	7952	7958	O
of	7959	7961	O
Igf2	7962	7966	O
gene	7967	7971	O
imprinting	7972	7982	O
in	7983	7985	O
the	7986	7989	O
GK	7990	7992	O
rat	7993	7996	O
.	7996	7997	O

Finally	7998	8005	O
,	8005	8006	O
our	8007	8010	O
understanding	8011	8024	O
of	8025	8027	O
the	8028	8031	O
underlying	8032	8042	O
mechanisms	8043	8053	O
for	8054	8057	O
reduced	8058	8065	O
BCM	8066	8069	O
in	8070	8072	O
response	8073	8081	O
to	8082	8084	O
inappropriate	8085	8098	O
perinatal	8099	8108	O
nutrition	8109	8118	O
is	8119	8121	O
growing	8122	8129	O
rapidly	8130	8137	O
.	8137	8138	O

However	8139	8146	O
,	8146	8147	O
the	8148	8151	O
relative	8152	8160	O
contribution	8161	8173	O
of	8174	8176	O
the	8177	8180	O
many	8181	8185	O
intrinsic	8186	8195	O
and	8196	8199	O
extrinsic	8200	8209	O
factors	8210	8217	O
which	8218	8223	O
contribute	8224	8234	O
to	8235	8237	O
the	8238	8241	O
adaptive	8242	8250	O
response	8251	8259	O
of	8260	8262	O
the	8263	8266	O
developing	8267	8277	O
endocrine	8278	8287	B-Organ
pancreas	8288	8296	I-Organ
is	8297	8299	O
still	8300	8305	O
to	8306	8308	O
be	8309	8311	O
established	8312	8323	O
.	8323	8324	O

Refinement	0	10	O

R	11	12	O
[	12	13	O
F	13	14	O
2	15	16	O
>	17	18	O
2sigma	19	25	O
(	25	26	O
F	26	27	O
2	28	29	O
)	29	30	O
]	30	31	O
=	32	33	O
0	34	35	O
.	35	36	O
052	36	39	O

wR	40	42	O
(	42	43	O
F	43	44	O
2	45	46	O
)	46	47	O
=	48	49	O
0	50	51	O
.	51	52	O
132	52	55	O

S	56	57	O
=	58	59	O
1	60	61	O
.	61	62	O
02	62	64	O

3804	65	69	O
reflections	70	81	O

229	82	85	O
parameters	86	96	O

67	97	99	O
restraints	100	110	O

H	111	112	O
-	112	113	O
atom	113	117	O
parameters	118	128	O
constrained	129	140	O

Deltarhomax	141	152	O
=	153	154	O
0	155	156	O
.	156	157	O
56	157	159	O
e	160	161	O
A	162	163	O
-	163	164	O
3	164	165	O

Deltarhomin	166	177	O
=	178	179	O
-	180	181	O
0	181	182	O
.	182	183	O
38	183	185	O
e	186	187	O
A	188	189	O
-	189	190	O
3	190	191	O

Outcomes	0	8	O

The	9	12	O
primary	13	20	O
outcomes	21	29	O
of	30	32	O
this	33	37	O
study	38	43	O
are	44	47	O
smoking	48	55	O
abstinence	56	66	O
rates	67	72	O
post	73	77	O
release	78	85	O
as	86	88	O
well	89	93	O
as	94	96	O
number	97	103	O
of	104	106	O
days	107	111	O
to	112	114	O
first	115	120	O
cigarette	121	130	O
after	131	136	O
release	137	144	O
.	144	145	O

Seven	146	151	O
day	152	155	O
point	156	161	O
-	161	162	O
prevalence	162	172	O
abstinence	173	183	O
will	184	188	O
be	189	191	O
determined	192	202	O
by	203	205	O
combining	206	215	O
self	216	220	O
-	220	221	O
reported	221	229	O
tobacco	230	237	O
use	238	241	O
over	242	246	O
the	247	250	O
prior	251	256	O
seven	257	262	O
days	263	267	O
and	268	271	O
urine	272	277	B-Organism_substance
cotinine	278	286	O
assays	287	293	O
(	294	295	O
below	295	300	O
200	301	304	O
ng	305	307	O
/	307	308	O
ml	308	310	O
versus	311	317	O
200	318	321	O
or	322	324	O
above	325	330	O
)	330	331	O
.	331	332	O

Participants	333	345	O
with	346	350	O
self	351	355	O
-	355	356	O
reported	356	364	O
abstinence	365	375	O
and	376	379	O
cotinine	380	388	O
levels	389	395	O
below	396	401	O
the	402	405	O
cut	406	409	O
-	409	410	O
off	410	413	O
will	414	418	O
be	419	421	O
classified	422	432	O
as	433	435	O
abstinent	436	445	O
.	445	446	O

Participants	447	459	O
lost	460	464	O
to	465	467	O
follow	468	474	O
-	474	475	O
up	475	477	O
will	478	482	O
be	483	485	O
considered	486	496	O
non	497	500	O
-	500	501	O
abstinent	501	510	O
.	510	511	O

A	512	513	O
secondary	514	523	O
analysis	524	532	O
will	533	537	O
examine	538	545	O
the	546	549	O
effect	550	556	O
of	557	559	O
length	560	566	O
of	567	569	O
forced	570	576	O
abstinence	577	587	O
on	588	590	O
quit	591	595	O
rates	596	601	O
.	601	602	O

Abbreviations	0	13	O

ARDS	14	18	O
:	18	19	O
acute	20	25	O
respiratory	26	37	B-Anatomical_system
distress	38	46	O
syndrome	47	55	O
;	55	56	O
CMV	57	60	O
:	60	61	O
conventional	62	74	O
mechanical	75	85	O
ventilation	86	97	O
;	97	98	O
HFOV	99	103	O
:	103	104	O
high	105	109	O
-	109	110	O
frequency	110	119	O
oscillation	120	131	O
ventilation	132	143	O
;	143	144	O
LPS	145	148	O
:	148	149	O
lipopolysaccharide	150	168	O
;	168	169	O
PEEP	170	174	O
:	174	175	O
positive	176	184	O
end	185	188	O
-	188	189	O
expiratory	189	199	O
pressure	200	208	O
;	208	209	O
VILI	210	214	O
:	214	215	O
ventilator	216	226	O
-	226	227	O
induced	227	234	O
lung	235	239	B-Organ
injury	240	246	O
.	246	247	O

TxA2	1	5	O
,	5	6	O
generated	7	16	O
from	17	21	O
arachidonic	22	33	O
acid	34	38	O
by	39	41	O
cyclooxygenase	42	56	O
1	57	58	O
(	59	60	O
COX	60	63	O
-	63	64	O
1	64	65	O
)	65	66	O
and	67	70	O
Tx	71	73	O
synthase	74	82	O
,	82	83	O
further	84	91	O
amplifies	92	101	O
platelet	102	110	B-Cell
activation	111	121	O
.	121	122	O

COX	123	126	O
-	126	127	O
1	127	128	O
converts	129	137	O
arachidonic	138	149	O
acid	150	154	O
into	155	159	O
prostaglandin	160	173	O
endoperoxides	174	187	O
PGG2	188	192	O
and	193	196	O
PGH2	197	201	O
,	201	202	O
the	203	206	O
latter	207	213	O
being	214	219	O
,	219	220	O
in	221	223	O
turn	224	228	O
,	228	229	O
transformed	230	241	O
by	242	244	O
Tx	245	247	O
synthase	248	256	O
into	257	261	O
TxA2	262	266	O
,	266	267	O
a	268	269	O
potent	270	276	O
amplifier	277	286	O
of	287	289	O
platelet	290	298	B-Cell
aggregation	299	310	O
with	311	315	O
vasoconstrictive	316	332	O
properties	333	343	O
.	343	344	O

At	345	347	O
the	348	351	O
site	352	356	O
of	357	359	O
the	360	363	O
atheroma	364	372	B-Pathological_formation
rupture	373	380	O
,	380	381	O
platelet	382	390	B-Cell
-	390	391	O
released	391	399	O
TxA2	400	404	O
leads	405	410	O
to	411	413	O
downstream	414	424	O
micro	425	430	B-Tissue
-	430	431	I-Tissue
vessel	431	437	I-Tissue
contraction	438	449	O
and	450	453	O
thrombus	454	462	B-Organism_substance
propagation	463	474	O
(	475	476	O
7	476	477	O
)	477	478	O
.	478	479	O

In	480	482	O
addition	483	491	O
to	492	494	O
its	495	498	O
role	499	503	O
in	504	506	O
coagulation	507	518	O
,	518	519	O
thrombin	520	528	O
at	529	531	O
extremely	532	541	O
low	542	545	O
concentrations	546	560	O
is	561	563	O
one	564	567	O
of	568	570	O
the	571	574	O
major	575	580	O
platelet	581	589	B-Cell
activators	590	600	O
(	601	602	O
8	602	603	O
)	603	604	O
.	604	605	O

Human	606	611	O
platelets	612	621	B-Cell
express	622	629	O
two	630	633	O
cell	634	638	B-Cellular_component
surface	639	646	I-Cellular_component
G	647	648	O
-	648	649	O
protein	649	656	O
-	656	657	O
coupled	657	664	O
protease	665	673	O
-	673	674	O
activated	674	683	O
receptors	684	693	O
(	694	695	O
PARs	695	699	O
)	699	700	O
for	701	704	O
thrombin	705	713	O
:	713	714	O
PAR	715	718	O
-	718	719	O
1	719	720	O
and	721	724	O
PAR	725	728	O
-	728	729	O
4	729	730	O
.	730	731	O

By	732	734	O
binding	735	742	O
the	743	746	O
hirudin	747	754	O
-	754	755	O
like	755	759	O
extracellular	760	773	B-Immaterial_anatomical_entity
amino	774	779	O
terminal	780	788	O
domain	789	795	O
(	796	797	O
the	797	800	O
so	801	803	O
-	803	804	O
called	804	810	O
thrombin	811	819	O
receptor	820	828	O
)	828	829	O
,	829	830	O
thrombin	831	839	O
activates	840	849	O
platelets	850	859	B-Cell
and	860	863	O
smooth	864	870	B-Cell
muscle	871	877	I-Cell
cells	878	883	I-Cell
,	883	884	O
thus	885	889	O
promoting	890	899	O
platelet	900	908	B-Cell
pro	909	912	O
-	912	913	O
coagulant	913	922	O
activity	923	931	O
,	931	932	O
shape	933	938	O
change	939	945	O
,	945	946	O
secretion	947	956	O
and	957	960	O
release	961	968	O
of	969	971	O
agonists	972	980	O
(	981	982	O
ADP	982	985	O
and	986	989	O
TxA2	990	994	O
)	994	995	O
,	995	996	O
expression	997	1007	O
of	1008	1010	O
P	1011	1012	O
-	1012	1013	O
selectin	1013	1021	O
,	1021	1022	O
activation	1023	1033	O
of	1034	1036	O
the	1037	1040	O
alphaIIbbeta3	1041	1054	O
integrin	1055	1063	O
receptor	1064	1072	O
,	1072	1073	O
and	1074	1077	O
aggregation	1078	1089	O
.	1089	1090	O

Thrombin	1091	1099	O
also	1100	1104	O
binds	1105	1110	O
to	1111	1113	O
GpIbalpha	1114	1123	O
on	1124	1126	O
the	1127	1130	O
surface	1131	1138	O
of	1139	1141	O
platelets	1142	1151	B-Cell
,	1151	1152	O
thought	1153	1160	O
to	1161	1163	O
act	1164	1167	O
as	1168	1170	O
a	1171	1172	O
co	1173	1175	O
-	1175	1176	O
factor	1176	1182	O
that	1183	1187	O
localizes	1188	1197	O
the	1198	1201	O
enzyme	1202	1208	O
on	1209	1211	O
the	1212	1215	O
platelet	1216	1224	B-Cellular_component
surface	1225	1232	I-Cellular_component
and	1233	1236	O
accelerates	1237	1248	O
the	1249	1252	O
hydrolysis	1253	1263	O
of	1264	1266	O
PAR	1267	1270	O
-	1270	1271	O
1	1271	1272	O
(	1273	1274	O
9	1274	1275	O
)	1275	1276	O
.	1276	1277	O

PAR	1278	1281	O
-	1281	1282	O
1	1282	1283	O
and	1284	1287	O
P2Y12	1288	1293	O
cross	1294	1299	O
-	1299	1300	O
react	1300	1305	O
in	1306	1308	O
platelet	1309	1317	B-Cell
activation	1318	1328	O
,	1328	1329	O
and	1330	1333	O
Galphaq	1334	1341	O
and	1342	1345	O
Galphai	1346	1353	O
-	1353	1354	O
coupled	1354	1361	O
receptors	1362	1371	O
are	1372	1375	O
involved	1376	1384	O
in	1385	1387	O
this	1388	1392	O
process	1393	1400	O
.	1400	1401	O

Thrombin	1402	1410	O
-	1410	1411	O
dependent	1411	1420	O
platelet	1421	1429	B-Cell
aggregation	1430	1441	O
is	1442	1444	O
mediated	1445	1453	O
in	1454	1456	O
part	1457	1461	O
by	1462	1464	O
secreted	1465	1473	O
ADP	1474	1477	O
,	1477	1478	O
acting	1479	1485	O
on	1486	1488	O
the	1489	1492	O
Galphai	1493	1500	O
-	1500	1501	O
linked	1501	1507	O
ADP	1508	1511	O
receptor	1512	1520	O
.	1520	1521	O

By	1522	1524	O
blocking	1525	1533	O
Galphaq	1534	1541	O
via	1542	1545	O
PAR	1546	1549	O
-	1549	1550	O
1	1550	1551	O
and	1552	1555	O
Gbetai	1556	1562	O
via	1563	1566	O
P2Y12	1567	1572	O
,	1572	1573	O
combined	1574	1582	O
inhibition	1583	1593	O
of	1594	1596	O
thrombin	1597	1605	O
and	1606	1609	O
P2Y12	1610	1615	O
receptors	1616	1625	O
leads	1626	1631	O
to	1632	1634	O
a	1635	1636	O
synergistic	1637	1648	O
inhibitory	1649	1659	O
effect	1660	1666	O
on	1667	1669	O
thrombin	1670	1678	O
-	1678	1679	O
induced	1679	1686	O
platelet	1687	1695	B-Cell
aggregation	1696	1707	O
(	1708	1709	O
10	1709	1711	O
)	1711	1712	O
.	1712	1713	O

5	1714	1715	O
-	1715	1716	O
HT	1716	1718	O
is	1719	1721	O
a	1722	1723	O
vasoconstrictor	1724	1739	O
agent	1740	1745	O
that	1746	1750	O
binds	1751	1756	O
to	1757	1759	O
5HT	1760	1763	O
-	1763	1764	O
2A	1764	1766	O
receptors	1767	1776	O
and	1777	1780	O
amplifies	1781	1790	O
the	1791	1794	O
platelet	1795	1803	B-Cell
response	1804	1812	O
by	1813	1815	O
stimulating	1816	1827	O
shape	1828	1833	O
change	1834	1840	O
and	1841	1844	O
enhancing	1845	1854	O
platelet	1855	1863	B-Cell
recruitment	1864	1875	O
at	1876	1878	O
sites	1879	1884	O
of	1885	1887	O
injury	1888	1894	O
(	1895	1896	O
3	1896	1897	O
)	1897	1898	O
.	1898	1899	O

It	1900	1902	O
may	1903	1906	O
also	1907	1911	O
play	1912	1916	O
a	1917	1918	O
pro	1919	1922	O
-	1922	1923	O
coagulant	1923	1932	O
role	1933	1937	O
by	1938	1940	O
promoting	1941	1950	O
the	1951	1954	O
retention	1955	1964	O
of	1965	1967	O
fibrinogen	1968	1978	O
and	1979	1982	O
thrombospondin	1983	1997	O
on	1998	2000	O
the	2001	2004	O
platelet	2005	2013	B-Cellular_component
surface	2014	2021	I-Cellular_component
.	2021	2022	O

Intraplatelet	2023	2036	B-Cell
5	2037	2038	O
-	2038	2039	O
HT	2039	2041	O
stores	2042	2048	O
are	2049	2052	O
implicated	2053	2063	O
in	2064	2066	O
shear	2067	2072	O
-	2072	2073	O
induced	2073	2080	O
platelet	2081	2089	B-Cell
aggregation	2090	2101	O
and	2102	2105	O
thrombus	2106	2114	B-Organism_substance
propagation	2115	2126	O
(	2127	2128	O
3	2128	2129	O
)	2129	2130	O
.	2130	2131	O

Methods	0	7	O

We	8	10	O
studied	11	18	O
3	19	20	O
,	20	21	O
574	21	24	O
Canadian	25	33	O
children	34	42	O
,	42	43	O
aged	44	48	O
7	49	50	O
-	50	51	O
8	51	52	O
yr	53	55	O
,	55	56	O
enrolled	57	65	O
in	66	68	O
a	69	70	O
population	71	81	O
-	81	82	O
based	82	87	O
birth	88	93	O
cohort	94	100	O
.	100	101	O

Standardized	102	114	O
questionnaires	115	129	O
were	130	134	O
completed	135	144	O
by	145	147	O
the	148	151	O
children	152	160	O
'	160	161	O
s	161	162	O
parents	163	170	O
,	170	171	O
and	172	175	O
data	176	180	O
were	181	185	O
analyzed	186	194	O
by	195	197	O
multivariate	198	210	O
logistic	211	219	O
regression	220	230	O
.	230	231	O

(	0	1	O
iii	1	4	O
)	4	5	O
HIV	6	9	O
testing	10	17	O
response	18	26	O
rate	27	31	O
by	32	34	O
educational	35	46	O
attainment	47	57	O
and	58	61	O
gender	62	68	O
.	68	69	O

Relative	0	8	O
phage	9	14	O
haplotype	15	24	O
frequencies	25	36	O
in	37	39	O
PAO1	40	44	O
samples	45	52	O
,	52	53	O
(	54	55	O
A	55	56	O
)	56	57	O
planktonic	58	68	O
,	68	69	O
(	70	71	O
B	71	72	O
)	72	73	O
biofilm	74	81	B-Cell
4	82	83	O
days	84	88	O
,	88	89	O
(	90	91	O
C	91	92	O
)	92	93	O
biofilm	94	101	B-Cell
11	102	104	O
days	105	109	O
.	109	110	O

Collaxa	0	7	O
BPEL	8	12	O
Server	13	19	O
Screenshot	20	30	O
of	31	33	O
Collaxa	34	41	O
'	41	42	O
s	42	43	O
bpelz	44	49	O
design	50	56	O
tool	57	61	O
,	61	62	O
building	63	71	O
a	72	73	O
choreography	74	86	O
of	87	89	O
GetHAPI	90	97	O
and	98	101	O
GetUMLS	102	109	O
web	110	113	O
services	114	122	O

Abbreviations	0	13	O

Ac	14	16	O
-	16	17	O
DEVD	17	21	O
-	21	22	O
AMC	22	25	O
=	26	27	O
N	28	29	O
-	29	30	O
acetyl	30	36	O
-	36	37	O
Asp	37	40	O
-	40	41	O
Glu	41	44	O
-	44	45	O
Val	45	48	O
-	48	49	O
Asp	49	52	O
-	52	53	O
7	53	54	O
-	54	55	O
amino	55	60	O
-	60	61	O
4	61	62	O
-	62	63	O
methylcoumarin	63	77	O
;	77	78	O
Ac	79	81	O
-	81	82	O
DEVD	82	86	O
-	86	87	O
CHO	87	90	O
=	91	92	O
N	93	94	O
-	94	95	O
acetyl	95	101	O
-	101	102	O
Asp	102	105	O
-	105	106	O
Glu	106	109	O
-	109	110	O
Val	110	113	O
-	113	114	O
Asp	114	117	O
-	117	118	O
aldehyde	118	126	O
;	126	127	O
COX	128	131	O
=	132	133	O
cyclooxygenase	134	148	O
;	148	149	O
Deltapsim	150	159	O
=	160	161	O
mitochondrial	162	175	B-Cellular_component
membrane	176	184	I-Cellular_component
potential	185	194	O
;	194	195	O
DAPI	196	200	O
=	201	202	O
4	203	204	O
'	204	205	O
,	205	206	O
6	206	207	O
-	207	208	O
diamidino	208	217	O
-	217	218	O
2	218	219	O
-	219	220	O
phenylindole	220	232	O
;	232	233	O
DMEM	234	238	O
=	239	240	O
Dulbecco	241	249	O
'	249	250	O
s	250	251	O
modified	252	260	O
Eagle	261	266	O
'	266	267	O
s	267	268	O
medium	269	275	O
;	275	276	O
ELISA	277	282	O
=	283	284	O
enzyme	285	291	O
-	291	292	O
linked	292	298	O
immunosorbent	299	312	O
assay	313	318	O
;	318	319	O
FCS	320	323	O
=	324	325	O
fetal	326	331	B-Developing_anatomical_structure
calf	332	336	O
serum	337	342	B-Organism_substance
;	342	343	O
FLS	344	347	B-Cell
=	348	349	O
fibroblast	350	360	B-Cell
-	360	361	I-Cell
like	361	365	I-Cell
synoviocytes	366	378	I-Cell
;	378	379	O
IL	380	382	O
=	383	384	O
interleukin	385	396	O
;	396	397	O
JC	398	400	O
-	400	401	O
1	401	402	O
=	403	404	O
5	405	406	O
,	406	407	O
5	407	408	O
'	408	409	O
,	409	410	O
6	410	411	O
,	411	412	O
6	412	413	O
'	413	414	O
-	414	415	O
tetrachloro	415	426	O
-	426	427	O
1	427	428	O
,	428	429	O
1	429	430	O
'	430	431	O
,	431	432	O
3	432	433	O
,	433	434	O
3	434	435	O
'	435	436	O
-	436	437	O
tetraethylbenzimidazole	437	460	O
carbocyanide	461	473	O
iodide	474	480	O
;	480	481	O
MTT	482	485	O
=	486	487	O
3	488	489	O
-	489	490	O
(	490	491	O
4	491	492	O
,	492	493	O
5	493	494	O
-	494	495	O
dimethylthiazol	495	510	O
-	510	511	O
2	511	512	O
-	512	513	O
yl	513	515	O
)	515	516	O
-	516	517	O
2	517	518	O
,	518	519	O
5	519	520	O
-	520	521	O
diphenyltetrazolium	521	540	O
bromide	541	548	O
;	548	549	O
PBS	550	553	O
=	554	555	O
phosphate	556	565	O
-	565	566	O
buffered	566	574	O
saline	575	581	O
;	581	582	O
PGE2	583	587	O
=	588	589	O
prostaglandin	590	603	O
E2	604	606	O
;	606	607	O
RA	608	610	O
=	611	612	O
rheumatoid	613	623	O
arthritis	624	633	O
.	633	634	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

FR	23	25	O
initiated	26	35	O
and	36	39	O
designed	40	48	O
the	49	52	O
research	53	61	O
,	61	62	O
collected	63	72	O
and	73	76	O
analyzed	77	85	O
the	86	89	O
data	90	94	O
and	95	98	O
wrote	99	104	O
the	105	108	O
paper	109	114	O
.	114	115	O

FO	116	118	O
was	119	122	O
the	123	126	O
main	127	131	O
supervisor	132	142	O
,	142	143	O
helped	144	150	O
in	151	153	O
analysis	154	162	O
,	162	163	O
and	164	167	O
revised	168	175	O
and	176	179	O
edited	180	186	O
the	187	190	O
drafts	191	197	O
.	197	198	O

MN	199	201	O
was	202	205	O
co	206	208	O
-	208	209	O
supervisor	210	220	O
and	221	224	O
revised	225	232	O
the	233	236	O
drafts	237	243	O
.	243	244	O

Conclusion	0	10	O

Artificial	11	21	O
addition	22	30	O
of	31	33	O
siderophores	34	46	O
and	47	50	O
HSLs	51	55	O
may	56	59	O
be	60	62	O
a	63	64	O
possible	65	73	O
method	74	80	O
to	81	83	O
aid	84	87	O
in	88	90	O
the	91	94	O
identification	95	109	O
and	110	113	O
isolation	114	123	O
of	124	126	O
marine	127	133	O
bacterial	134	143	O
species	144	151	O
which	152	157	O
are	158	161	O
thought	162	169	O
to	170	172	O
be	173	175	O
unknown	176	183	O
.	183	184	O

